1	When	O
2	extracorporeal	O
3	CO2	O
4	removal	O
5	approximated	O
6	CO2	O
7	production	O
8	(	O
9	VCO2	O
10	),	O
11	alveolar	O
12	ventilation	O
13	almost	O
14	ceased	O
15	.	O
1	Intravenous	O
2	administration	O
3	(	O
4	25	O
5	mg	O
6	/	O
7	kg	O
8	)	O
9	of	O
10	carbonic	B
11	anhydrase	I
12	inhibitors	O
13	(	O
14	acetazolamide	O
15	,	O
16	methazolamide	O
17	,	O
18	dichlorphenamide	O
19	,	O
20	sulthiame	O
21	)	O
22	induced	O
23	an	O
24	early	O
25	important	O
26	rise	O
27	of	O
28	cortical	O
29	p	O
30	O2	O
31	,	O
32	which	O
33	is	O
34	not	O
35	dependent	O
36	on	O
37	increase	O
38	of	O
39	p	O
40	O2	O
41	and	O
42	p	O
43	CO2	O
44	and	O
45	decrease	O
46	of	O
47	pH	O
48	in	O
49	arterial	O
50	blood	O
51	.	O
1	The	O
2	variable	O
3	HMG	B
4	dosage	O
5	regimen	O
6	was	O
7	found	O
8	to	O
9	offer	O
10	no	O
11	advantages	O
12	when	O
13	compared	O
14	with	O
15	our	O
16	standard	O
17	daily	O
18	dosage	O
19	regimen	O
20	.	O
1	When	O
2	the	O
3	CO2	O
4	content	O
5	reached	O
6	9	O
7	Vol	O
8	%	O
9	the	O
10	animals	O
11	became	O
12	apathic	O
13	and	O
14	lost	O
15	body	O
16	weight	O
17	.	O
1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	(	O
5	GGTP	B
6	)	O
7	activity	O
8	in	O
9	the	O
10	seminal	O
11	fluid	O
1	Selective	O
2	stimulation	O
3	of	O
4	central	O
5	alpha	B
6	-	I
7	autoreceptors	I
8	following	O
9	treatment	O
10	with	O
11	alpha	O
12	-	O
13	methyldopa	O
14	and	O
15	FLA	O
16	136	O
17	.	O
1	Anti	O
2	-	O
3	anxiety	O
4	action	O
5	of	O
6	diazepam	O
7	after	O
8	intra	O
9	-	O
10	amygdaloid	O
11	application	O
12	in	O
13	the	O
14	rat	O
15	.	O
1	An	O
2	IgG	B
3	monoclonal	O
4	gammopathy	O
5	was	O
6	present	O
7	in	O
8	the	O
9	serum	O
10	of	O
11	4	O
12	patients	O
13	and	O
14	Bence	O
15	-	O
16	Joanes	O
17	proteinuria	O
18	was	O
19	found	O
20	in	O
21	1	O
22	patient	O
23	.	O
1	A	O
2	mixture	O
3	of	O
4	human	B
5	albumin	I
6	5	O
7	%	O
8	and	O
9	hydroxy	O
10	-	O
11	ethyl	O
12	-	O
13	starch	O
14	was	O
15	used	O
16	as	O
17	a	O
18	solution	O
19	for	O
20	dilution	O
21	.	O
1	In	O
2	the	O
3	matched	O
4	control	O
5	group	O
6	the	O
7	acquisition	O
8	-	O
9	rate	O
10	of	O
11	both	O
12	symptomatic	O
13	and	O
14	asymptomatic	O
15	0acteriuria	O
16	was	O
17	over	O
18	12	O
19	%,	O
20	a	O
21	figure	O
22	similar	O
23	to	O
24	the	O
25	percentage	O
26	of	O
27	women	O
28	present	O
29	in	O
30	the	O
31	practice	O
32	population	O
33	during	O
34	one	O
35	year	O
36	with	O
37	transient	O
38	,	O
39	symptomatic	O
40	,	O
41	and	O
42	persistent	O
43	A	O
44	.	O
45	B	O
46	.	O
1	A	O
2	three	O
3	-	O
4	phased	O
5	analysis	O
6	of	O
7	treatment	O
8	plans	O
9	for	O
10	45	O
11	patients	O
12	was	O
13	undertaken	O
14	.	O
1	Aspirin	O
2	intolerance	O
3	:	O
4	unaltered	O
5	susceptibility	O
6	of	O
7	platelet	B
8	cyclo	I
9	-	I
10	oxygenase	I
11	to	O
12	inhibition	O
13	by	O
14	aspirin	O
15	in	O
16	vitro	O
17	.	O
1	2	O
2	.--	O
3	concepts	O
4	of	O
5	higher	O
6	nervous	O
7	function	O
8	in	O
9	the	O
10	USSR	O
11	.	O
1	The	O
2	maintenance	O
3	of	O
4	increased	O
5	myocardial	O
6	capillary	O
7	density	O
8	required	O
9	a	O
10	similar	O
11	amount	O
12	of	O
13	exercise	O
14	,	O
15	and	O
16	at	O
17	least	O
18	1	O
19	h	O
20	of	O
21	exercise	O
22	once	O
23	a	O
24	week	O
25	was	O
26	necessary	O
27	to	O
28	maintain	O
29	the	O
30	enlargement	O
31	of	O
32	ECA	O
33	.	O
34	20	O
1	Riboflavin	O
2	did	O
3	not	O
4	affect	O
5	the	O
6	percentage	O
7	of	O
8	aflatoxin	O
9	-	O
10	treated	O
11	animals	O
12	with	O
13	abnormal	O
14	urinary	O
15	excretion	O
16	patterns	O
17	,	O
18	but	O
19	did	O
20	increase	O
21	the	O
22	magnitude	O
23	of	O
24	the	O
25	disturbances	O
26	in	O
27	elimination	O
28	of	O
29	kynurenic	O
30	and	O
31	xanthurenic	O
32	acids	O
33	.	O
1	Innervation	O
2	of	O
3	the	O
4	ventral	O
5	diaphragm	O
6	of	O
7	the	O
8	locust	O
9	(	O
10	Locusta	O
11	migratoria	O
12	).	O
1	Molecular	O
2	neurochemistry	O
3	of	O
4	addictive	O
5	drugs	O
6	.	O
1	Efforts	O
2	were	O
3	made	O
4	to	O
5	determine	O
6	the	O
7	amount	O
8	of	O
9	time	O
10	required	O
11	for	O
12	kidney	O
13	lesions	O
14	to	O
15	develop	O
16	and	O
17	,	O
18	if	O
19	possible	O
20	,	O
21	to	O
22	delineate	O
23	the	O
24	potential	O
25	site	O
26	of	O
27	action	O
28	of	O
29	PBB	O
30	.	O
1	Effect	O
2	of	O
3	succimer	O
4	on	O
5	the	O
6	intensity	O
7	of	O
8	tricarboxylic	B
9	acid	I
10	dehydrogenase	I
11	reactions	O
12	in	O
13	the	O
14	brain	O
15	of	O
16	rats	O
17	poisoned	O
18	with	O
19	mercuric	O
20	chloride	O
1	XXI	O
2	.	O
1	A	O
2	gas	O
3	-	O
4	liquid	O
5	chromatographic	O
6	method	O
7	for	O
8	the	O
9	determination	O
10	of	O
11	p	O
12	-	O
13	chlorophenoxyisobutyric	O
14	(	O
15	CPIB	O
16	)	O
17	acid	O
18	in	O
19	blood	O
20	plasma	O
21	is	O
22	described	O
23	.	O
1	V	O
2	.	O
1	Diagnosis	O
2	and	O
3	treatment	O
4	planning	O
5	in	O
6	Class	O
7	II	O
8	,	O
9	division	O
10	2	O
1	Here	O
2	the	O
3	conventional	O
4	tests	O
5	clearly	O
6	pointed	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	retrocochlear	O
12	disease	O
13	.	O
1	Use	O
2	of	O
3	radioactive	O
4	isotopes	O
5	in	O
6	the	O
7	chemistry	O
8	of	O
9	proteins	O
1	Antenatal	O
2	diagnosis	O
3	of	O
4	haematological	O
5	disorders	O
6	--'	O
7	1978	O
8	'.	O
1	Gonadal	O
2	dysfunction	O
3	in	O
4	patients	O
5	with	O
6	ataxia	O
7	telangiectasia	O
8	.	O
1	Follow	O
2	-	O
3	up	O
4	controls	O
5	of	O
6	luteinizing	B
7	hormone	I
8	(	O
9	LH	B
10	),	O
11	follicle	B
12	stimulating	I
13	hormone	I
14	(	O
15	FSH	B
16	),	O
17	prolactin	B
18	(	O
19	HPRL	B
20	),	O
21	oestradiol	O
22	(	O
23	E2	O
24	),	O
25	progesterone	O
26	(	O
27	P	O
28	)	O
29	and	O
30	testosterone	O
31	(	O
32	T	O
33	)	O
34	in	O
35	the	O
36	catabolic	O
37	and	O
38	healing	O
39	phase	O
40	of	O
41	burn	O
42	disease	O
43	.	O
1	Thus	O
2	,	O
3	the	O
4	inhibition	O
5	of	O
6	pepsin	B
7	in	O
8	human	O
9	gastric	O
10	juice	O
11	does	O
12	not	O
13	appear	O
14	to	O
15	have	O
16	a	O
17	major	O
18	influence	O
19	on	O
20	the	O
21	healing	O
22	of	O
23	duodenal	O
24	ulcer	O
25	.	O
1	Seventy	O
2	-	O
3	one	O
4	percent	O
5	of	O
6	patients	O
7	treated	O
8	with	O
9	ticarcillin	O
10	alone	O
11	responded	O
12	favorably	O
13	.	O
1	Accurate	O
2	pathologic	O
3	staging	O
4	identifies	O
5	patients	O
6	who	O
7	are	O
8	potentially	O
9	curable	O
10	with	O
11	radiotherapy	O
12	.	O
1	Changes	O
2	in	O
3	tissue	O
4	PCO2	O
5	were	O
6	less	O
7	dramatic	O
8	and	O
9	did	O
10	not	O
11	vary	O
12	significantly	O
13	from	O
14	those	O
15	recorded	O
16	in	O
17	venous	O
18	blood	O
19	.	O
1	Recognition	O
2	of	O
3	emphysema	O
4	was	O
5	poor	O
6	when	O
7	radiographs	O
8	of	O
9	inadequate	O
10	quality	O
11	were	O
12	included	O
13	(	O
14	anteroposterior	O
15	films	O
16	or	O
17	films	O
18	from	O
19	patients	O
20	with	O
21	acute	O
22	or	O
23	chronic	O
24	lung	O
25	disease	O
26	).	O
1	Pharmacokinetic	O
2	profile	O
3	of	O
4	clonazepam	O
5	in	O
6	rhesus	O
7	monkeys	O
8	.	O
1	As	O
2	authorized	O
3	by	O
4	the	O
5	World	O
6	Health	O
7	Organization	O
8	29th	O
9	Expert	O
10	Committee	O
11	on	O
12	Biological	O
13	Standardization	O
14	,	O
15	the	O
16	preparation	O
17	of	O
18	human	B
19	prolactin	I
20	in	O
21	ampoules	O
22	coded	O
23	75	O
24	/	O
25	504	O
26	has	O
27	been	O
28	established	O
29	as	O
30	the	O
31	International	O
32	Reference	O
33	Preparation	O
34	(	O
35	IRP	O
36	)	O
37	of	O
38	human	B
39	prolactin	I
40	for	O
41	immunoassay	O
42	.	O
1	Serum	O
2	ferritin	B
3	concentration	O
4	and	O
5	bone	O
6	marrow	O
7	iron	O
8	stores	O
9	.	O
1	Platelet	O
2	number	O
3	and	O
4	life	O
5	span	O
6	were	O
7	determined	O
8	in	O
9	the	O
10	last	O
11	trimester	O
12	of	O
13	pregnancy	O
14	in	O
15	22	O
16	women	O
17	who	O
18	were	O
19	delivered	O
20	of	O
21	small	O
22	-	O
23	for	O
24	-	O
25	gestational	O
26	age	O
27	(	O
28	SGA	O
29	)	O
30	infants	O
31	and	O
32	in	O
33	21	O
34	women	O
35	with	O
36	infants	O
37	having	O
38	normal	O
39	birth	O
40	weights	O
41	.	O
1	Serial	O
2	measurements	O
3	of	O
4	total	O
5	serum	O
6	IgE	B
7	appears	O
8	to	O
9	be	O
10	a	O
11	useful	O
12	index	O
13	of	O
14	disease	O
15	activity	O
16	in	O
17	ABPA	O
18	.	O
1	In	O
2	the	O
3	8	O
4	patients	O
5	the	O
6	difference	O
7	betweent	O
8	he	O
9	mean	O
10	diastolic	O
11	values	O
12	of	O
13	delta	O
14	PU	O
15	and	O
16	delta	O
17	PM	O
18	was	O
19	-	O
20	0	O
21	.	O
22	54	O
23	+/-	O
24	1	O
25	.	O
26	0	O
27	(	O
28	SD	O
29	)	O
30	mmHg	O
31	.	O
1	In	O
2	this	O
3	situation	O
4	the	O
5	convlusion	O
6	threshold	O
7	for	O
8	the	O
9	8	O
10	substances	O
11	is	O
12	as	O
13	follows	O
14	:	O
15	pethidine	O
16	20	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	I	O
23	.	O
24	V	O
25	.,	O
26	piritramide	O
27	30	O
28	,	O
29	morphine	O
30	180	O
31	,	O
32	phenoperidine	O
33	4	O
34	,	O
35	R	O
36	39	O
37	209	O
38	5	O
39	,	O
40	fentanyl	O
41	4	O
42	,	O
43	sufentanil	O
44	4	O
45	and	O
46	R	O
47	34	O
48	995	O
49	10	O
50	mg	O
51	.	O
52	kg	O
53	-	O
54	1	O
55	I	O
56	.	O
57	V	O
58	.	O
1	Effects	O
2	of	O
3	chronic	O
4	descending	O
5	tractotomy	O
6	on	O
7	the	O
8	response	O
9	patterns	O
10	of	O
11	neurons	O
12	in	O
13	the	O
14	trigeminal	O
15	nuclei	O
16	principalis	O
17	and	O
18	oralis	O
19	.	O
1	Resistance	O
2	to	O
3	the	O
4	simulated	O
5	physiologic	O
6	environment	O
7	was	O
8	tested	O
9	by	O
10	measured	O
11	retention	O
12	of	O
13	mechanical	O
14	properties	O
15	after	O
16	immersion	O
17	times	O
18	in	O
19	pseudo	O
20	-	O
21	extracellular	O
22	fluid	O
23	(	O
24	PECF	O
25	)	O
26	at	O
27	37	O
28	degrees	O
29	C	O
30	for	O
31	as	O
32	long	O
33	as	O
34	three	O
35	years	O
36	.	O
1	Their	O
2	conduction	O
3	velocity	O
4	ranged	O
5	from	O
6	0	O
7	.	O
8	23	O
9	to	O
10	0	O
11	.	O
12	98	O
13	m	O
14	/	O
15	sec	O
16	(	O
17	group	O
18	C	O
19	).	O
1	The	O
2	failures	O
3	frequently	O
4	were	O
5	related	O
6	to	O
7	patient	O
8	intolerance	O
9	or	O
10	poor	O
11	mechanical	O
12	fit	O
13	and	O
14	occurred	O
15	in	O
16	the	O
17	first	O
18	few	O
19	days	O
20	or	O
21	first	O
22	few	O
23	months	O
24	after	O
25	insertion	O
26	.	O
1	Structural	O
2	characteristics	O
3	of	O
4	the	O
5	erythrocyte	O
6	membrane	O
7	,	O
8	peroxidation	O
9	processes	O
10	and	O
11	antioxidant	O
12	function	O
13	in	O
14	children	O
15	with	O
16	diffuse	O
17	glomerulonephritis	O
1	Both	O
2	reduced	O
3	spontaneous	O
4	locomotor	O
5	activity	O
6	in	O
7	mice	O
8	,	O
9	protected	O
10	them	O
11	from	O
12	death	O
13	from	O
14	amphetamine	O
15	induced	O
16	toxicity	O
17	,	O
18	prolonged	O
19	hexobarbitone	O
20	sleeping	O
21	time	O
22	and	O
23	caused	O
24	a	O
25	depletion	O
26	of	O
27	catecholamines	O
28	from	O
29	various	O
30	organs	O
31	of	O
32	the	O
33	rat	O
34	.	O
1	On	O
2	the	O
3	role	O
4	of	O
5	transferrin	B
6	in	O
7	the	O
8	uptake	O
9	of	O
10	gallium	O
11	by	O
12	tumor	O
13	cells	O
14	.	O
1	With	O
2	certain	O
3	exceptions	O
4	the	O
5	method	O
6	was	O
7	considered	O
8	suitable	O
9	in	O
10	the	O
11	routine	O
12	intravenous	O
13	cholangiography	O
14	.	O
1	When	O
2	two	O
3	determinations	O
4	were	O
5	performed	O
6	on	O
7	12	O
8	samples	O
9	of	O
10	plasma	O
11	taken	O
12	from	O
13	normal	O
14	adults	O
15	in	O
16	October	O
17	,	O
18	the	O
19	values	O
20	were	O
21	22	O
22	.	O
23	6	O
24	+/-	O
25	4	O
26	.	O
27	8	O
28	and	O
29	21	O
30	.	O
31	0	O
32	+/-	O
33	3	O
34	.	O
35	6	O
36	(	O
37	mean	O
38	+/-	O
39	SD	O
40	)	O
41	ng	O
42	/	O
43	ml	O
44	,	O
45	respectively	O
46	.	O
1	Although	O
2	Grice	O
3	'	O
4	s	O
5	operation	O
6	has	O
7	been	O
8	used	O
9	all	O
10	over	O
11	the	O
12	world	O
13	,	O
14	no	O
15	systematic	O
16	account	O
17	of	O
18	it	O
19	has	O
20	been	O
21	found	O
22	in	O
23	the	O
24	literature	O
25	(	O
26	including	O
27	publications	O
28	dealing	O
29	with	O
30	technique	O
31	),	O
32	which	O
33	presents	O
34	it	O
35	in	O
36	terms	O
37	related	O
38	to	O
39	the	O
40	basic	O
41	""""	O
42	classical	O
43	""""	O
44	principles	O
45	on	O
46	which	O
47	the	O
48	operation	O
49	was	O
50	conceived	O
51	.	O
1	Although	O
2	it	O
3	has	O
4	been	O
5	shown	O
6	that	O
7	it	O
8	is	O
9	possible	O
10	to	O
11	use	O
12	orally	O
13	administered	O
14	testosterone	O
15	to	O
16	maintain	O
17	se	O
18	-	O
19	T	O
20	levels	O
21	in	O
22	the	O
23	normal	O
24	male	O
25	range	O
26	,	O
27	the	O
28	convenience	O
29	to	O
30	the	O
31	patient	O
32	must	O
33	be	O
34	balanced	O
35	against	O
36	the	O
37	cost	O
38	and	O
39	possible	O
40	side	O
41	effects	O
42	of	O
43	the	O
44	large	O
45	doses	O
46	required	O
47	.	O
1	Contrary	O
2	to	O
3	1	O
4	,	O
5	8	O
6	-	O
7	dihydroxy	O
8	-	O
9	9	O
10	-	O
11	anthrone	O
12	,	O
13	1	O
14	,	O
15	8	O
16	,	O
17	9	O
18	-	O
19	triacetoxyanthracene	O
20	and	O
21	1	O
22	,	O
23	8	O
24	-	O
25	diacetoxy	O
26	-	O
27	9	O
28	-	O
29	anthrone	O
30	are	O
31	effective	O
32	against	O
33	psoriatic	O
34	lesions	O
35	without	O
36	accompanying	O
37	inflammations	O
38	of	O
39	the	O
40	skin	O
41	.	O
1	Nursing	O
2	of	O
3	patients	O
4	with	O
5	gynecological	O
6	diseases	O
1	Screening	O
2	of	O
3	asthma	O
4	patients	O
5	by	O
6	determination	O
7	of	O
8	IgE	B
9	and	O
10	by	O
11	comprehension	O
12	of	O
13	spectrum	O
14	of	O
15	allergospecific	B
16	IgE	I
17	antibodies	I
1	2	O
2	cases	O
3	of	O
4	toxic	O
5	lymphomononucleosis	O
1	Such	O
2	an	O
3	hemoglobin	B
4	solution	O
5	was	O
6	shown	O
7	to	O
8	exhibit	O
9	a	O
10	high	O
11	affinity	O
12	for	O
13	oxygen	O
14	and	O
15	a	O
16	low	O
17	Bohr	O
18	effect	O
19	(	O
20	assessed	O
21	from	O
22	the	O
23	delta	O
24	log	O
25	Po2	O
26	/	O
27	delta	O
28	pH	O
29	ratio	O
30	).	O
1	A	O
2	decrease	O
3	of	O
4	the	O
5	lysozyme	B
6	activity	O
7	coincided	O
8	with	O
9	the	O
10	clinical	O
11	improvement	O
12	of	O
13	the	O
14	bacterial	O
15	meningitis	O
16	.	O
1	Stress	O
2	effects	O
3	on	O
4	affiliation	O
5	preferences	O
6	among	O
7	subjects	O
8	possessing	O
9	the	O
10	type	O
11	A	O
12	coronary	O
13	-	O
14	prone	O
15	behavior	O
16	pattern	O
17	.	O
1	These	O
2	show	O
3	that	O
4	the	O
5	collagen	B
6	in	O
7	this	O
8	tissue	O
9	is	O
10	modified	O
11	compared	O
12	with	O
13	that	O
14	in	O
15	tendon	O
16	.	O
1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	labetalol	O
25	is	O
26	explained	O
27	by	O
28	concurrent	O
29	blockade	O
30	of	O
31	alpha	B
32	-	I
33	and	I
34	beta	I
35	-	I
36	adrenoceptors	I
37	.	O
1	Diuretics	O
2	:	O
3	basic	O
4	clinical	O
5	pharmacology	O
6	and	O
7	therapeutic	O
8	use	O
9	.	O
1	Internally	O
2	oriented	O
3	patients	O
4	'	O
5	scores	O
6	on	O
7	Rotter	O
8	'	O
9	s	O
10	Internal	O
11	-	O
12	External	O
13	Locus	O
14	of	O
15	Control	O
16	Scale	O
17	remained	O
18	the	O
19	same	O
20	over	O
21	treatment	O
22	but	O
23	those	O
24	of	O
25	externally	O
26	oriented	O
27	patients	O
28	shifted	O
29	toward	O
30	greater	O
31	internal	O
32	control	O
33	.	O
1	Potency	O
2	of	O
3	enflurane	O
4	in	O
5	dogs	O
6	:	O
7	comparison	O
8	with	O
9	halothane	O
10	and	O
11	isoflurane	O
12	.	O
1	Radionuclide	O
2	angiography	O
3	and	O
4	static	O
5	whole	O
6	body	O
7	imaging	O
8	performed	O
9	with	O
10	technetium	O
11	-	O
12	99m	O
13	-	O
14	labeled	O
15	particulates	O
16	can	O
17	clearly	O
18	demonstrate	O
19	differential	O
20	shunting	O
21	in	O
22	patients	O
23	with	O
24	patent	O
25	ductus	O
26	arteriosus	O
27	(	O
28	PDA	O
29	)	O
30	with	O
31	Eisenmenger	O
32	physiology	O
33	.	O
1	Procion	O
2	yellow	O
3	dye	O
4	was	O
5	injected	O
6	intracellularly	O
7	into	O
8	large	O
9	auditory	O
10	fibers	O
11	of	O
12	goldfish	O
13	to	O
14	investigate	O
15	the	O
16	relationship	O
17	between	O
18	the	O
19	response	O
20	type	O
21	of	O
22	these	O
23	fibers	O
24	and	O
25	their	O
26	site	O
27	of	O
28	termination	O
29	in	O
30	the	O
31	saccular	O
32	macula	O
33	.	O
1	Thromboplastic	O
2	and	O
3	fibrynolytic	O
4	activity	O
5	of	O
6	the	O
7	blood	O
8	after	O
9	administration	O
10	of	O
11	intralipid	O
12	in	O
13	men	O
14	with	O
15	history	O
16	of	O
17	myocardial	O
18	infarction	O
19	up	O
20	to	O
21	45	O
22	year	O
23	of	O
24	life	O
1	Value	O
2	of	O
3	determination	O
4	of	O
5	alkaline	B
6	phosphatase	I
7	isoenzymes	I
8	for	O
9	differential	O
10	diagnosis	O
11	of	O
12	obstructive	O
13	jaundice	O
14	and	O
15	biliary	O
16	liver	O
17	cirrhosis	O
1	Orthop	O
2	.	O
1	The	O
2	data	O
3	indicate	O
4	a	O
5	three	O
6	-	O
7	phase	O
8	reaction	O
9	after	O
10	B1	O
11	injection	O
12	:	O
13	Phase	O
14	1	O
15	--	O
16	shortly	O
17	after	O
18	injection	O
19	there	O
20	is	O
21	a	O
22	drop	O
23	of	O
24	all	O
25	parameters	O
26	lasting	O
27	for	O
28	30	O
29	sec	O
30	.	O
1	We	O
2	remain	O
3	convinced	O
4	that	O
5	antilymphocyte	B
6	globulin	I
7	(	O
8	ALG	B
9	)	O
10	is	O
11	a	O
12	potent	O
13	immunosuppressive	O
14	agent	O
15	in	O
16	humans	O
17	.	O
1	Deflunia	O
2	was	O
3	well	O
4	tolerated	O
5	by	O
6	25	O
7	patients	O
8	,	O
9	very	O
10	well	O
11	tolerated	O
12	by	O
13	2	O
14	.	O
1	Also	O
2	,	O
3	except	O
4	in	O
5	one	O
6	patient	O
7	who	O
8	developed	O
9	gallstones	O
10	following	O
11	institution	O
12	of	O
13	colestipol	O
14	,	O
15	saturation	O
16	of	O
17	gallbladder	O
18	bile	O
19	with	O
20	cholesterol	O
21	was	O
22	not	O
23	markedly	O
24	increased	O
25	by	O
26	this	O
27	drug	O
28	alone	O
29	.	O
1	A	O
2	five	O
3	-	O
4	phase	O
5	experiment	O
6	was	O
7	designed	O
8	to	O
9	investigate	O
10	(	O
11	a	O
12	)	O
13	whether	O
14	contingent	O
15	music	O
16	-	O
17	listening	O
18	would	O
19	act	O
20	as	O
21	a	O
22	reinforcer	O
23	to	O
24	increase	O
25	arithmetic	O
26	performance	O
27	of	O
28	EMR	O
29	children	O
30	and	O
31	(	O
32	b	O
33	)	O
34	whether	O
35	this	O
36	contingent	O
37	reinforcement	O
38	would	O
39	affect	O
40	preference	O
41	for	O
42	that	O
43	reinforcer	O
44	.	O
1	The	O
2	elevated	O
3	Viso	O
4	V	O
5	in	O
6	the	O
7	RDS	O
8	group	O
9	suggests	O
10	an	O
11	increase	O
12	in	O
13	small	O
14	airway	O
15	resistance	O
16	secondary	O
17	to	O
18	the	O
19	disease	O
20	or	O
21	to	O
22	its	O
23	therapy	O
24	.	O
1	The	O
2	sense	O
3	of	O
4	self	O
5	.	O
1	Recurrence	O
2	of	O
3	bladder	O
4	tumors	O
5	among	O
6	the	O
7	original	O
8	9	O
9	cases	O
10	has	O
11	occurred	O
12	only	O
13	among	O
14	the	O
15	5	O
16	whose	O
17	properdin	B
18	levels	O
19	remained	O
20	below	O
21	the	O
22	median	O
23	.	O
1	Adaptation	O
2	of	O
3	taurocholate	O
4	transport	O
5	maximum	O
6	to	O
7	increased	O
8	secretory	O
9	load	O
10	in	O
11	the	O
12	rat	O
13	.	O
1	In	O
2	diethyl	O
3	ether	O
4	solution	O
5	the	O
6	main	O
7	peak	O
8	is	O
9	that	O
10	of	O
11	2	O
12	-	O
13	benzylidenamio	O
14	-	O
15	1	O
16	-	O
17	phenylpropane	O
18	,	O
19	which	O
20	has	O
21	a	O
22	retention	O
23	time	O
24	of	O
25	23	O
26	,	O
27	2	O
28	minutes	O
29	under	O
30	the	O
31	condition	O
32	delineated	O
33	.	O
1	During	O
2	activity	O
3	III	O
4	,	O
5	one	O
6	patient	O
7	developed	O
8	angina	O
9	.	O
1	Evaluation	O
2	of	O
3	the	O
4	new	O
5	Gravigard	O
6	IUCD	O
7	inserter	O
8	.	O
1	Infants	O
2	who	O
3	died	O
4	in	O
5	the	O
6	first	O
7	12	O
8	hours	O
9	from	O
10	'	O
11	IVH	O
12	only	O
13	'	O
14	had	O
15	suffered	O
16	severe	O
17	birth	O
18	asphyxia	O
19	but	O
20	in	O
21	those	O
22	who	O
23	died	O
24	later	O
25	the	O
26	main	O
27	symptom	O
28	was	O
29	recurrent	O
30	apnoea	O
31	.	O
1	Since	O
2	GAGs	O
3	are	O
4	the	O
5	components	O
6	of	O
7	cartilage	O
8	matrix	O
9	,	O
10	the	O
11	depletion	O
12	of	O
13	which	O
14	is	O
15	associated	O
16	with	O
17	osteoarthrosis	O
18	,	O
19	a	O
20	method	O
21	for	O
22	measuring	O
23	sulphated	O
24	GAG	O
25	synthesis	O
26	in	O
27	culture	O
28	has	O
29	been	O
30	investigated	O
31	.	O
1	Twenty	O
2	-	O
3	nine	O
4	days	O
5	after	O
6	injection	O
7	of	O
8	5	O
9	.	O
10	8	O
11	mCi	O
12	of	O
13	Tc	O
14	-	O
15	99m	O
16	,	O
17	which	O
18	gives	O
19	28	O
20	rads	O
21	to	O
22	the	O
23	testis	O
24	,	O
25	the	O
26	number	O
27	of	O
28	sperm	O
29	hads	O
30	decreased	O
31	to	O
32	70	O
33	%	O
34	of	O
35	control	O
36	.	O
1	Thus	O
2	analysis	O
3	indicated	O
4	no	O
5	reliable	O
6	evidence	O
7	that	O
8	conscious	O
9	presleep	O
10	suggestions	O
11	become	O
12	incorporated	O
13	into	O
14	dream	O
15	content	O
16	.	O
1	The	O
2	difficulties	O
3	to	O
4	analyse	O
5	prostaglandins	O
6	(	O
7	PG	O
8	)	O
9	by	O
10	gas	O
11	-	O
12	liquid	O
13	chromatography	O
14	are	O
15	mainly	O
16	due	O
17	to	O
18	the	O
19	lack	O
20	of	O
21	sensitivity	O
22	of	O
23	the	O
24	gas	O
25	-	O
26	chromatograph	O
27	itself	O
28	(	O
29	higher	O
30	than	O
31	200	O
32	ng	O
33	)	O
34	and	O
35	to	O
36	the	O
37	poor	O
38	resolution	O
39	of	O
40	the	O
41	packed	O
42	columns	O
43	.	O
1	After	O
2	giving	O
3	a	O
4	survey	O
5	on	O
6	the	O
7	situation	O
8	of	O
9	antibiotic	O
10	resistance	O
11	in	O
12	the	O
13	region	O
14	of	O
15	Northern	O
16	Bavaria	O
17	during	O
18	1973	O
19	/	O
20	74	O
21	and	O
22	comparing	O
23	the	O
24	activity	O
25	of	O
26	a	O
27	sulfamethoxazole	O
28	(	O
29	SMZ	O
30	)	O
31	trimethoprim	O
32	(	O
33	TMP	O
34	)	O
35	combination	O
36	to	O
37	other	O
38	commonly	O
39	used	O
40	antibiotics	O
41	and	O
42	chemotherapeutic	O
43	agents	O
44	,	O
45	the	O
46	results	O
47	of	O
48	tests	O
49	with	O
50	the	O
51	new	O
52	combination	O
53	of	O
54	N1	O
55	-(	O
56	4	O
57	,	O
58	5	O
59	-	O
60	dimethyl	O
61	-	O
62	2	O
63	-	O
64	oxazolyl	O
65	)-	O
66	sulfanilamide	O
67	)	O
68	(	O
69	sulfamoxole	O
70	)	O
71	and	O
72	2	O
73	,	O
74	4	O
75	-	O
76	diamino	O
77	-	O
78	5	O
79	-(	O
80	3	O
81	,	O
82	4	O
83	,	O
84	5	O
85	-	O
86	trimethoxy	O
87	-	O
88	benzyl	O
89	)-	O
90	pyrimidine	O
91	(	O
92	trimethoprim	O
93	)	O
94	at	O
95	a	O
96	ratio	O
97	of	O
98	5	O
99	:	O
100	1	O
101	(	O
102	CN	O
103	3123	O
104	;	O
105	Nevin	O
106	,	O
107	Supristol	O
108	)	O
109	are	O
110	compared	O
111	to	O
112	those	O
113	of	O
114	tests	O
115	with	O
116	TMP	O
117	/	O
118	SMZ	O
119	.	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	spontaneous	O
6	recovery	O
7	of	O
8	central	O
9	respiratory	O
10	function	O
11	after	O
12	intoxication	O
13	with	O
14	Soman	O
15	or	O
16	Sarin	O
17	may	O
18	not	O
19	be	O
20	related	O
21	to	O
22	the	O
23	return	O
24	of	O
25	AChE	B
26	activity	O
27	.	O
1	Haemodilution	O
2	in	O
3	cardiopulmonary	O
4	bypass	O
5	using	O
6	a	O
7	gelatine	O
8	derivative	O
9	for	O
10	priming	O
11	.	O
1	Stimulation	O
2	of	O
3	macrophage	O
4	function	O
5	by	O
6	killed	O
7	Bordetella	O
8	pertussis	O
9	cells	O
10	did	O
11	not	O
12	show	O
13	any	O
14	beneficial	O
15	effect	O
16	as	O
17	an	O
18	increased	O
19	susceptibility	O
20	became	O
21	apparent	O
22	.	O
1	Efferent	O
2	projections	O
3	of	O
4	the	O
5	ventral	O
6	portion	O
7	of	O
8	the	O
9	putamen	O
10	to	O
11	the	O
12	frontal	O
13	,	O
14	parietal	O
15	and	O
16	temporal	O
17	regions	O
18	of	O
19	the	O
20	cat	O
21	cerebral	O
22	cortex	O
1	Preflight	O
2	,	O
3	inflight	O
4	,	O
5	and	O
6	postflight	O
7	exercise	O
8	response	O
9	tests	O
10	were	O
11	conducted	O
12	on	O
13	the	O
14	astronauts	O
15	of	O
16	the	O
17	second	O
18	Skylab	O
19	mission	O
20	(	O
21	Skylab	O
22	3	O
23	)	O
24	as	O
25	part	O
26	of	O
27	an	O
28	evaluation	O
29	of	O
30	physiological	O
31	adaptation	O
32	to	O
33	long	O
34	-	O
35	term	O
36	weightlessness	O
37	.	O
1	It	O
2	was	O
3	found	O
4	that	O
5	under	O
6	the	O
7	selected	O
8	conditions	O
9	a	O
10	linear	O
11	dependence	O
12	exists	O
13	between	O
14	the	O
15	betaI	O
16	%	O
17	value	O
18	and	O
19	lgC	O
20	within	O
21	the	O
22	range	O
23	of	O
24	0	O
25	.	O
26	5	O
27	--	O
28	10	O
29	mug	O
30	ruscogenin	O
31	.	O
1	Studies	O
2	of	O
3	biochemical	O
4	and	O
5	morphological	O
6	changes	O
7	(	O
8	between	O
9	normal	O
10	and	O
11	treated	O
12	animals	O
13	)	O
14	show	O
15	that	O
16	chrysotile	O
17	induces	O
18	an	O
19	increase	O
20	in	O
21	the	O
22	lung	O
23	free	O
24	cell	O
25	population	O
26	and	O
27	pulmonary	O
28	surfactant	O
29	levels	O
30	.	O
1	Since	O
2	1968	O
3	,	O
4	a	O
5	steep	O
6	decrease	O
7	in	O
8	the	O
9	number	O
10	of	O
11	strains	O
12	resistant	O
13	to	O
14	three	O
15	or	O
16	more	O
17	antibiotics	O
18	(	O
19	multiple	O
20	-	O
21	resistant	O
22	)	O
23	and	O
24	in	O
25	strains	O
26	of	O
27	the	O
28	83A	O
29	complex	O
30	was	O
31	noticed	O
32	.	O
1	Evidence	O
2	is	O
3	presented	O
4	that	O
5	Leber	O
6	'	O
7	s	O
8	military	O
9	aneurysm	O
10	retinitis	O
11	is	O
12	not	O
13	a	O
14	separate	O
15	entity	O
16	but	O
17	a	O
18	special	O
19	form	O
20	of	O
21	Coats	O
22	'	O
23	disease	O
24	.	O
1	Fibrin	B
2	cloaking	O
3	along	O
4	the	O
5	catheter	O
6	was	O
7	found	O
8	in	O
9	20	O
10	patients	O
11	studied	O
12	by	O
13	pull	O
14	-	O
15	out	O
16	arteriography	O
17	and	O
18	was	O
19	unassociated	O
20	with	O
21	clinical	O
22	symptoms	O
23	.	O
1	As	O
2	stands	O
3	shifted	O
4	in	O
5	dominance	O
6	from	O
7	pine	O
8	to	O
9	fir	O
10	with	O
11	age	O
12	,	O
13	subalpine	O
14	fir	O
15	appeared	O
16	to	O
17	maintain	O
18	gradually	O
19	increasing	O
20	rates	O
21	of	O
22	whole	O
23	-	O
24	forest	O
25	productivity	O
26	until	O
27	stands	O
28	were	O
29	approximately	O
30	400	O
31	years	O
32	old	O
33	.	O
1	Two	O
2	patients	O
3	were	O
4	treated	O
5	with	O
6	both	O
7	regimens	O
8	.	O
1	Residual	O
2	amphotericin	O
3	B	O
4	was	O
5	detected	O
6	in	O
7	the	O
8	feces	O
9	of	O
10	the	O
11	mice	O
12	only	O
13	while	O
14	they	O
15	were	O
16	receiving	O
17	the	O
18	0	O
19	.	O
20	3	O
21	mg	O
22	/	O
23	ml	O
24	dose	O
25	level	O
26	.	O
1	Bulbar	O
2	pouches	O
3	were	O
4	perfused	O
5	with	O
6	solutions	O
7	of	O
8	0	O
9	.	O
10	9	O
11	%	O
12	Na	O
13	C1	O
14	,	O
15	0	O
16	.	O
17	1	O
18	N	O
19	HC1	O
20	,	O
21	40	O
22	%	O
23	glucose	O
24	,	O
25	40	O
26	%	O
27	NaC1	O
28	,	O
29	and	O
30	40	O
31	%	O
32	peptone	O
33	or	O
34	with	O
35	0	O
36	.	O
37	1	O
38	%	O
39	solutions	O
40	of	O
41	acetylcholine	O
42	chloride	O
43	.	O
1	Glucose	B
2	-	I
3	6	I
4	-	I
5	phosphate	I
6	dehydrogenase	I
7	(	O
8	G	B
9	-	I
10	6	I
11	-	I
12	PD	I
13	)	O
14	deficiency	O
15	in	O
16	the	O
17	newborn	O
18	.	O
1	Three	O
2	groups	O
3	of	O
4	patients	O
5	who	O
6	had	O
7	undergone	O
8	subtotal	O
9	thyroidectomy	O
10	for	O
11	Graves	O
12	'	O
13	s	O
14	disease	O
15	,	O
16	toxic	O
17	multinodular	O
18	goitre	O
19	,	O
20	or	O
21	euthyroid	O
22	multinodular	O
23	goitre	O
24	12	O
25	to	O
26	15	O
27	years	O
28	before	O
29	and	O
30	in	O
31	whom	O
32	a	O
33	normal	O
34	serum	O
35	thyroxine	O
36	(	O
37	T	O
38	-	O
39	4	O
40	)	O
41	level	O
42	was	O
43	found	O
44	were	O
45	each	O
46	divided	O
47	into	O
48	two	O
49	subgroups	O
50	on	O
51	the	O
52	basis	O
53	of	O
54	a	O
55	normal	O
56	or	O
57	a	O
58	raised	O
59	serum	O
60	thyrotrophin	B
61	concentration	O
62	.	O
1	Characteristics	O
2	of	O
3	anesthesia	O
4	and	O
5	resuscitation	O
6	in	O
7	emergency	O
8	lung	O
9	surgery	O
1	We	O
2	suggest	O
3	that	O
4	such	O
5	occlusions	O
6	occurred	O
7	at	O
8	the	O
9	time	O
10	of	O
11	the	O
12	infarction	O
13	.	O
1	Generally	O
2	,	O
3	a	O
4	correlation	O
5	was	O
6	observed	O
7	between	O
8	highest	O
9	concentrations	O
10	of	O
11	CSF	B
12	immunoglobulins	I
13	and	O
14	degree	O
15	of	O
16	meningeal	O
17	inflammatory	O
18	response	O
19	,	O
20	even	O
21	if	O
22	this	O
23	was	O
24	a	O
25	component	O
26	of	O
27	other	O
28	neurological	O
29	diseases	O
30	.	O
1	The	O
2	results	O
3	obtained	O
4	tend	O
5	to	O
6	prove	O
7	that	O
8	the	O
9	reticuloendothelial	O
10	system	O
11	mainly	O
12	participated	O
13	in	O
14	beryllium	O
15	retention	O
16	.	O
1	Total	O
2	cholesterol	O
3	was	O
4	measured	O
5	in	O
6	amniotic	O
7	fluids	O
8	collected	O
9	at	O
10	different	O
11	stages	O
12	of	O
13	gestation	O
14	.	O
1	Her	O
2	serum	O
3	FT3	O
4	concentration	O
5	was	O
6	,	O
7	however	O
8	,	O
9	much	O
10	higher	O
11	than	O
12	the	O
13	ranges	O
14	in	O
15	normal	O
16	pregnancy	O
17	or	O
18	in	O
19	GTD	O
20	patients	O
21	without	O
22	clinical	O
23	hyperthyroidism	O
24	.	O
1	A	O
2	note	O
3	on	O
4	the	O
5	phase	O
6	-	O
7	plane	O
8	technique	O
9	representation	O
10	of	O
11	cardiac	O
12	action	O
13	potentials	O
14	.	O
1	The	O
2	cochlear	O
3	compromise	O
4	.	O
1	Biohydrogenation	O
2	of	O
3	linoleic	O
4	acid	O
5	into	O
6	octadecenoic	O
7	acid	O
8	was	O
9	observed	O
10	.	O
1	Previous	O
2	studies	O
3	have	O
4	shown	O
5	[	O
6	Hisanaga	O
7	,	O
8	S	O
9	.,	O
10	Kusubata	O
11	,	O
12	M	O
13	.,	O
14	Okumura	O
15	,	O
16	E	O
17	.	O
18	&	O
19	Kishimoto	O
20	,	O
21	T	O
22	.	O
1	Rabbit	B
2	skeletal	I
3	muscle	I
4	glycogenin	I
5	.	O
1	Animals	O
2	that	O
3	received	O
4	DSP	O
5	-	O
6	4	O
7	were	O
8	significantly	O
9	retarded	O
10	in	O
11	motor	O
12	recovery	O
13	compared	O
14	with	O
15	the	O
16	saline	O
17	group	O
18	.	O
1	The	O
2	mean	O
3	(+/-	O
4	SD	O
5	)	O
6	PaO2	O
7	increased	O
8	from	O
9	80	O
10	.	O
11	8	O
12	+/-	O
13	26	O
14	.	O
15	9	O
16	mmHg	O
17	before	O
18	to	O
19	89	O
20	.	O
21	8	O
22	+/-	O
23	27	O
24	.	O
25	3	O
26	mmHg	O
27	after	O
28	the	O
29	infusion	O
30	(	O
31	P	O
32	<	O
33	0	O
34	.	O
35	05	O
36	)	O
37	and	O
38	the	O
39	PaCO2	O
40	decreased	O
41	from	O
42	42	O
43	.	O
44	4	O
45	+/-	O
46	8	O
47	.	O
48	3	O
49	to	O
50	39	O
51	.	O
52	6	O
53	+/-	O
54	7	O
55	.	O
56	9	O
57	mmHg	O
58	(	O
59	P	O
60	<	O
61	0	O
62	.	O
63	05	O
64	).	O
1	Though	O
2	hepatomegaly	O
3	and	O
4	mild	O
5	elevation	O
6	of	O
7	enzymes	O
8	can	O
9	be	O
10	observed	O
11	in	O
12	a	O
13	significant	O
14	proportion	O
15	of	O
16	patients	O
17	,	O
18	involvement	O
19	of	O
20	liver	O
21	leading	O
22	to	O
23	acute	O
24	hepatitis	O
25	or	O
26	liver	O
27	cell	O
28	necrosis	O
29	is	O
30	a	O
31	relatively	O
32	uncommon	O
33	complication	O
34	in	O
35	P	O
36	.	O
37	falciparum	O
38	malaria	O
39	.	O
1	The	O
2	method	O
3	was	O
4	adapted	O
5	for	O
6	the	O
7	determination	O
8	of	O
9	nadolol	O
10	racemate	O
11	A	O
12	by	O
13	a	O
14	change	O
15	in	O
16	mobile	O
17	phase	O
18	composition	O
19	.	O
1	In	O
2	7	O
3	of	O
4	9	O
5	cases	O
6	,	O
7	the	O
8	enhancer	O
9	is	O
10	fused	O
11	to	O
12	the	O
13	c	B
14	-	I
15	myc	I
16	bearing	I
17	sequences	I
18	of	O
19	chromosome	O
20	8	O
21	.	O
1	Nucleotide	O
2	sequence	O
3	analysis	O
4	revealed	O
5	that	O
6	TAR	B
7	-	I
8	binding	I
9	protein	I
10	is	O
11	very	O
12	similar	O
13	to	O
14	the	O
15	CREB2	B
16	protein	I
17	.	O
1	Treatment	O
2	with	O
3	MK	O
4	-	O
5	801	O
6	induced	O
7	a	O
8	burst	O
9	suppression	O
10	in	O
11	the	O
12	EEG	O
13	and	O
14	a	O
15	transient	O
16	drop	O
17	(	O
18	11	O
19	.	O
20	4	O
21	+/-	O
22	6	O
23	.	O
24	5	O
25	mm	O
26	Hg	O
27	)	O
28	in	O
29	the	O
30	mean	O
31	arterial	O
32	pressure	O
33	.	O
1	Acad	O
2	.	O
1	Both	O
2	in	O
3	vitro	O
4	-	O
5	synthesized	O
6	S2	B
7	protein	I
8	and	O
9	synthetic	O
10	peptides	O
11	corresponding	O
12	to	O
13	S2	B
14	are	O
15	shown	O
16	to	O
17	react	O
18	positively	O
19	with	O
20	sera	O
21	obtained	O
22	from	O
23	EIAV	O
24	-	O
25	infected	O
26	horses	O
27	,	O
28	providing	O
29	the	O
30	first	O
31	direct	O
32	evidence	O
33	of	O
34	expression	O
35	of	O
36	this	O
37	protein	O
38	in	O
39	infected	O
40	animals	O
41	.	O
1	Interestingly	O
2	,	O
3	the	O
4	IR5	B
5	ORF	I
6	of	O
7	EHV	O
8	-	O
9	1	O
10	possesses	O
11	a	O
12	sequence	O
13	of	O
14	13	O
15	amino	O
16	acids	O
17	(	O
18	CAYWCCLGHAFAC	O
19	)	O
20	that	O
21	is	O
22	a	O
23	perfect	O
24	match	O
25	to	O
26	the	O
27	consensus	O
28	zinc	O
29	finger	O
30	motif	O
31	(	O
32	C	O
33	-	O
34	X2	O
35	-	O
36	4	O
37	-	O
38	C	O
39	-	O
40	X2	O
41	-	O
42	15	O
43	-	O
44	C	O
45	/	O
46	H	O
47	-	O
48	X2	O
49	-	O
50	4	O
51	-	O
52	C	O
53	/	O
54	H	O
55	).	O
1	Fructokinase	B
2	activity	O
3	is	O
4	elevated	O
5	up	O
6	to	O
7	twofold	O
8	when	O
9	Z	O
10	.	O
11	mobilis	O
12	was	O
13	grown	O
14	on	O
15	fructose	O
16	instead	O
17	of	O
18	glucose	O
19	,	O
20	and	O
21	there	O
22	was	O
23	a	O
24	parallel	O
25	increase	O
26	in	O
27	frk	B
28	mRNA	I
29	levels	O
30	.	O
1	Plasma	O
2	membranes	O
3	of	O
4	cultured	O
5	cells	O
6	contain	O
7	high	O
8	affinity	O
9	receptors	O
10	for	O
11	high	B
12	density	I
13	lipoprotein	I
14	(	O
15	HDL	B
16	)	O
17	that	O
18	appear	O
19	to	O
20	mediate	O
21	removal	O
22	of	O
23	excess	O
24	intracellular	O
25	cholesterol	O
26	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	an	O
6	internal	O
7	short	O
8	element	O
9	located	O
10	at	O
11	the	O
12	very	O
13	5	O
14	'	O
15	terminal	O
16	of	O
17	L1	B
18	sequence	I
19	and	O
20	the	O
21	nuclear	O
22	factor	O
23	binding	O
24	to	O
25	the	O
26	element	O
27	play	O
28	a	O
29	crucial	O
30	role	O
31	in	O
32	the	O
33	transcription	O
34	of	O
35	human	B
36	L1	I
37	.	O
1	Antibodies	O
2	against	O
3	this	O
4	purified	O
5	protein	O
6	localize	O
7	RIM1	B
8	to	O
9	mitochondria	O
10	.	O
1	HNF	B
2	-	I
3	3	I
4	beta	I
5	amino	I
6	-	I
7	terminal	I
8	sequences	I
9	defined	O
10	by	O
11	conserved	O
12	region	O
13	IV	O
14	also	O
15	contributed	O
16	to	O
17	transactivation	O
18	,	O
19	but	O
20	region	O
21	IV	O
22	activity	O
23	required	O
24	the	O
25	participation	O
26	of	O
27	the	O
28	region	O
29	II	O
30	-	O
31	III	O
32	domain	O
33	.	O
1	Nocodazole	O
2	arrest	O
3	of	O
4	DU249	O
5	cells	O
6	was	O
7	exploited	O
8	for	O
9	the	O
10	detection	O
11	of	O
12	an	O
13	M	O
14	-	O
15	phase	O
16	-	O
17	activated	O
18	MBP	B
19	kinase	I
20	that	O
21	was	O
22	resolved	O
23	from	O
24	p41	B
25	MAP	I
26	kinase	I
27	by	O
28	phenyl	O
29	-	O
30	Superose	O
31	chromatography	O
32	.	O
1	The	O
2	319	O
3	base	O
4	pair	O
5	region	O
6	immediately	O
7	upstream	O
8	of	O
9	the	O
10	CAP	O
11	site	O
12	is	O
13	characterized	O
14	by	O
15	the	O
16	lack	O
17	of	O
18	a	O
19	proximal	O
20	TATA	O
21	box	O
22	and	O
23	the	O
24	presence	O
25	of	O
26	sequences	O
27	similar	O
28	to	O
29	GC	O
30	boxes	O
31	,	O
32	CACCC	O
33	boxes	O
34	,	O
35	CCAAT	O
36	boxes	O
37	,	O
38	activator	B
39	protein	I
40	2	I
41	(	O
42	Ap	B
43	-	I
44	2	I
45	)	O
46	sites	O
47	,	O
48	partial	O
49	glucocorticoid	O
50	response	O
51	elements	O
52	(	O
53	GREs	O
54	),	O
55	and	O
56	partial	O
57	cyclic	O
58	AMP	O
59	response	O
60	elements	O
61	(	O
62	CREs	O
63	).	O
1	In	O
2	rats	O
3	anaesthetized	O
4	with	O
5	+-	O
6	chloralose	O
7	the	O
8	changes	O
9	in	O
10	extracellular	O
11	pH	O
12	and	O
13	K	O
14	+	O
15	in	O
16	spinal	O
17	cord	O
18	dorsal	O
19	horn	O
20	were	O
21	studied	O
22	using	O
23	pH	O
24	and	O
25	K	O
26	+	O
27	ion	O
28	-	O
29	selective	O
30	electrodes	O
31	.	O
1	Truncation	O
2	variants	O
3	of	O
4	peptides	O
5	isolated	O
6	from	O
7	MHC	B
8	class	I
9	II	I
10	molecules	I
11	suggest	O
12	sequence	O
13	motifs	O
14	.	O
1	Peripheral	O
2	polyneuropathy	O
3	associated	O
4	with	O
5	multiple	O
6	myeloma	O
7	.	O
1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	COX12	B
7	,	O
8	the	O
9	nuclear	O
10	gene	O
11	for	O
12	subunit	B
13	VIb	I
14	of	O
15	Saccharomyces	B
16	cerevisiae	I
17	cytochrome	I
18	c	I
19	oxidase	I
20	.	O
1	Lastly	O
2	,	O
3	there	O
4	are	O
5	multiple	O
6	instances	O
7	in	O
8	which	O
9	short	O
10	oligonucleotide	O
11	direct	O
12	repeats	O
13	flank	O
14	a	O
15	region	O
16	absent	O
17	from	O
18	either	O
19	variola	O
20	or	O
21	vaccinia	O
22	virus	O
23	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	short	O
6	synthetic	O
7	peptides	O
8	containing	O
9	the	O
10	pRB	B
11	-	I
12	binding	I
13	sequences	I
14	of	O
15	E1A	B
16	are	O
17	sufficient	O
18	for	O
19	interaction	O
20	with	O
21	p107	B
22	,	O
23	cyclin	B
24	A	I
25	,	O
26	and	O
27	p130	B
28	.	O
1	A	O
2	major	O
3	mechanism	O
4	whereby	O
5	steroid	B
6	hydroxylase	I
7	gene	I
8	transcription	O
9	is	O
10	regulated	O
11	in	O
12	the	O
13	adrenal	O
14	cortex	O
15	requires	O
16	the	O
17	pituitary	O
18	peptide	O
19	hormone	O
20	,	O
21	ACTH	B
22	,	O
23	which	O
24	acts	O
25	via	O
26	cAMP	O
27	.	O
1	The	O
2	-	O
3	64	O
4	/-	O
5	37	O
6	region	O
7	interacted	O
8	with	O
9	purified	O
10	Sp1	B
11	and	O
12	an	O
13	unidentified	O
14	protein	O
15	(	O
16	s	O
17	),	O
18	proximal	B
19	regulatory	I
20	factor	I
21	(	I
22	s	I
23	)	I
24	I	I
25	(	O
26	PRF	B
27	-	I
28	I	I
29	).	O
1	Strategies	O
2	for	O
3	blood	O
4	screening	O
5	for	O
6	the	O
7	hepatitis	O
8	C	O
9	virus	O
10	and	O
11	for	O
12	the	O
13	human	O
14	immunodeficiency	O
15	virus	O
16	in	O
17	high	O
18	risk	O
19	groups	O
20	.	O
1	No	O
2	significant	O
3	correlations	O
4	of	O
5	peak	O
6	VO2	O
7	were	O
8	observed	O
9	between	O
10	the	O
11	3	O
12	tests	O
13	.	O
1	Some	O
2	research	O
3	studies	O
4	have	O
5	related	O
6	this	O
7	kind	O
8	of	O
9	tumors	O
10	with	O
11	prolonged	O
12	ingestion	O
13	of	O
14	H2	O
15	inhibitors	O
16	and	O
17	others	O
18	antacid	O
19	.	O
1	Mutational	O
2	studies	O
3	revealed	O
4	that	O
5	it	O
6	was	O
7	the	O
8	homeodomain	B
9	binding	I
10	site	I
11	II	I
12	sequence	I
13	that	O
14	was	O
15	required	O
16	for	O
17	this	O
18	regulation	O
19	.	O
1	This	O
2	negative	O
3	regulatory	O
4	pathway	O
5	may	O
6	be	O
7	important	O
8	for	O
9	determining	O
10	cell	O
11	fate	O
12	or	O
13	maintaining	O
14	an	O
15	inducible	O
16	state	O
17	in	O
18	the	O
19	ventroposterior	O
20	region	O
21	of	O
22	the	O
23	embryo	O
24	.	O
1	The	O
2	distal	O
3	portion	O
4	of	O
5	the	O
6	rat	B
7	insulin	I
8	I	I
9	gene	I
10	5	I
11	'-	I
12	flanking	I
13	DNA	I
14	contains	O
15	two	O
16	sequence	O
17	elements	O
18	,	O
19	the	O
20	Far	O
21	and	O
22	FLAT	O
23	elements	O
24	,	O
25	that	O
26	can	O
27	function	O
28	in	O
29	combination	O
30	,	O
31	but	O
32	not	O
33	separately	O
34	,	O
35	as	O
36	a	O
37	beta	O
38	-	O
39	cell	O
40	-	O
41	specific	O
42	transcriptional	O
43	enhancer	O
44	.	O
1	Repeated	O
2	efforts	O
3	to	O
4	isolate	O
5	recombinant	O
6	baculoviruses	O
7	containing	O
8	a	O
9	wild	O
10	-	O
11	type	O
12	kinase	O
13	failed	O
14	,	O
15	whereas	O
16	recombinants	O
17	expressing	O
18	a	O
19	nonfunctional	O
20	kinase	O
21	with	O
22	a	O
23	catalytic	O
24	domain	O
25	II	O
26	mutation	O
27	were	O
28	readily	O
29	isolated	O
30	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	21	O
6	-	O
7	mer	O
8	subrepeat	O
9	structure	O
10	is	O
11	also	O
12	present	O
13	in	O
14	each	O
15	unit	O
16	.	O
1	We	O
2	propose	O
3	that	O
4	plasmids	O
5	of	O
6	the	O
7	pLS1	O
8	family	O
9	(	O
10	pE194	O
11	,	O
12	pADB201	O
13	,	O
14	and	O
15	pLB4	O
16	)	O
17	share	O
18	functional	O
19	and	O
20	structural	O
21	characteristics	O
22	for	O
23	the	O
24	regulation	O
25	of	O
26	their	O
27	copy	O
28	numbers	O
29	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	hGCSFR	B
6	gene	I
7	was	O
8	chromosomally	O
9	localized	O
10	by	O
11	Southern	O
12	blot	O
13	analysis	O
14	of	O
15	its	O
16	segregation	O
17	pattern	O
18	in	O
19	a	O
20	panel	O
21	of	O
22	rodent	O
23	-	O
24	human	O
25	hybrid	O
26	DNAs	O
27	using	O
28	the	O
29	radiolabeled	O
30	cDNA	O
31	probe	O
32	.	O
1	Homodimers	O
2	of	O
3	the	O
4	three	O
5	proteins	O
6	specifically	O
7	recognize	O
8	the	O
9	G	O
10	-	O
11	box	O
12	motif	O
13	,	O
14	with	O
15	GBF1	B
16	and	O
17	GBF3	B
18	binding	O
19	symmetrically	O
20	to	O
21	this	O
22	palindromic	O
23	sequence	O
24	.	O
1	Neither	O
2	gene	O
3	possesses	O
4	a	O
5	distinct	O
6	transcriptional	O
7	start	O
8	site	O
9	as	O
10	shown	O
11	by	O
12	nuclease	B
13	S1	I
14	analysis	O
15	.	O
1	The	O
2	initial	O
3	translation	O
4	protein	O
5	encoded	O
6	by	O
7	the	O
8	cDNA	O
9	is	O
10	53	O
11	,	O
12	932	O
13	kDa	O
14	and	O
15	possesses	O
16	a	O
17	hydrophilic	O
18	amino	O
19	acid	O
20	composition	O
21	with	O
22	glutamic	O
23	acid	O
24	comprising	O
25	22	O
26	%	O
27	of	O
28	the	O
29	total	O
30	amino	O
31	acid	O
32	residues	O
33	.	O
1	The	O
2	carcinoma	O
3	was	O
4	restricted	O
5	within	O
6	the	O
7	epithelium	O
8	in	O
9	one	O
10	,	O
11	the	O
12	mucosal	O
13	layer	O
14	in	O
15	five	O
16	,	O
17	and	O
18	the	O
19	submucosal	O
20	layer	O
21	in	O
22	two	O
23	.	O
1	In	O
2	contrast	O
3	,	O
4	tobacco	B
5	GS	I
6	-	I
7	2	I
8	is	O
9	composed	O
10	of	O
11	subunits	O
12	of	O
13	identical	O
14	size	O
15	in	O
16	all	O
17	organs	O
18	examined	O
19	.	O
1	C	O
2	.,	O
3	Sun	O
4	,	O
5	J	O
6	.,	O
7	Hsu	O
8	,	O
9	M	O
10	.-	O
11	Y	O
12	.,	O
13	Vallejo	O
14	-	O
15	Ramirez	O
16	,	O
17	J	O
18	.,	O
19	Inouye	O
20	,	O
21	S	O
22	.,	O
23	and	O
24	Inouye	O
25	,	O
26	M	O
27	.	O
1	Thus	O
2	,	O
3	cibenzoline	O
4	is	O
5	an	O
6	effective	O
7	antiarrhythmic	O
8	agent	O
9	with	O
10	a	O
11	favourable	O
12	pharmacokinetic	O
13	profile	O
14	that	O
15	may	O
16	be	O
17	considered	O
18	with	O
19	other	O
20	class	O
21	I	O
22	drugs	O
23	in	O
24	patients	O
25	requiring	O
26	therapy	O
27	for	O
28	high	O
29	risk	O
30	arrhythmias	O
31	.	O
1	In	O
2	rats	O
3	,	O
4	we	O
5	examined	O
6	the	O
7	effect	O
8	of	O
9	an	O
10	omentum	O
11	wrapping	O
12	on	O
13	the	O
14	vascularization	O
15	of	O
16	the	O
17	trachea	O
18	and	O
19	on	O
20	regeneration	O
21	of	O
22	the	O
23	mucosal	O
24	epithelium	O
25	in	O
26	the	O
27	very	O
28	early	O
29	stage	O
30	after	O
31	free	O
32	tracheal	O
33	grafting	O
34	.	O
1	Again	O
2	residue	O
3	Glu	O
4	-	O
5	381	O
6	of	O
7	beta	O
8	was	O
9	notably	O
10	reduced	O
11	and	O
12	no	O
13	missing	O
14	residue	O
15	from	O
16	the	O
17	epsilon	O
18	peptide	O
19	could	O
20	be	O
21	identified	O
22	,	O
23	but	O
24	the	O
25	peptide	O
26	sequence	O
27	limited	O
28	the	O
29	possible	O
30	choices	O
31	to	O
32	Ser	O
33	-	O
34	106	O
35	,	O
36	Ser	O
37	-	O
38	107	O
39	,	O
40	or	O
41	Ser	O
42	-	O
43	108	O
44	.	O
1	Consequently	O
2	,	O
3	significant	O
4	differences	O
5	between	O
6	the	O
7	measured	O
8	and	O
9	calculated	O
10	methods	O
11	were	O
12	noted	O
13	in	O
14	oxygen	O
15	uptake	O
16	(	O
17	213	O
18	+/-	O
19	41	O
20	ml	O
21	/	O
22	min	O
23	vs	O
24	193	O
25	+/-	O
26	25	O
27	ml	O
28	/	O
29	min	O
30	,	O
31	p	O
32	<	O
33	0	O
34	.	O
35	001	O
36	),	O
37	oxygen	O
38	delivery	O
39	(	O
40	780	O
41	+/-	O
42	297	O
43	ml	O
44	/	O
45	min	O
46	vs	O
47	716	O
48	+/-	O
49	296	O
50	ml	O
51	/	O
52	min	O
53	,	O
54	p	O
55	<	O
56	0	O
57	.	O
58	001	O
59	),	O
60	and	O
61	cardiac	O
62	output	O
63	(	O
64	5	O
65	.	O
66	8	O
67	+/-	O
68	2	O
69	.	O
70	2	O
71	L	O
72	/	O
73	min	O
74	vs	O
75	5	O
76	.	O
77	3	O
78	+/-	O
79	1	O
80	.	O
81	8	O
82	L	O
83	/	O
84	min	O
85	,	O
86	p	O
87	<	O
88	0	O
89	.	O
90	001	O
91	).	O
1	Negatively	O
2	supercoiled	O
3	plasmid	O
4	pUC19	O
5	did	O
6	not	O
7	compete	O
8	,	O
9	whereas	O
10	an	O
11	otherwise	O
12	identical	O
13	plasmid	O
14	pUC19	O
15	(	O
16	CG	O
17	),	O
18	which	O
19	contained	O
20	a	O
21	(	O
22	dG	O
23	-	O
24	dC	O
25	)	O
26	7	O
27	segment	O
28	in	O
29	the	O
30	Z	O
31	-	O
32	form	O
33	was	O
34	an	O
35	excellent	O
36	competitor	O
37	.	O
1	Our	O
2	experiments	O
3	suggest	O
4	that	O
5	the	O
6	SCL	B
7	gene	I
8	can	O
9	be	O
10	a	O
11	target	O
12	for	O
13	the	O
14	erythroid	B
15	transcription	I
16	factor	I
17	GATA	I
18	-	I
19	1	I
20	and	O
21	that	O
22	the	O
23	SCL	B
24	gene	I
25	product	I
26	serves	O
27	as	O
28	a	O
29	positive	O
30	regulator	O
31	of	O
32	erythroid	O
33	differentiation	O
34	.	O
1	Complexes	O
2	containing	O
3	wild	O
4	-	O
5	type	O
6	and	O
7	either	O
8	his175	B
9	or	I
10	his273	I
11	mutant	I
12	p53	I
13	proteins	I
14	are	O
15	completely	O
16	unable	O
17	to	O
18	bind	O
19	to	O
20	the	O
21	RGC	B
22	DNA	I
23	sequence	I
24	.	O
1	These	O
2	temperature	O
3	-	O
4	and	O
5	cold	O
6	-	O
7	sensitive	O
8	strains	O
9	were	O
10	used	O
11	to	O
12	prepare	O
13	extracts	O
14	deficient	O
15	in	O
16	BRF1	B
17	activity	O
18	and	O
19	were	O
20	tested	O
21	for	O
22	transcriptional	O
23	activity	O
24	by	O
25	RNA	B
26	polymerases	I
27	I	I
28	,	I
29	II	I
30	,	I
31	and	I
32	III	I
33	in	O
34	vitro	O
35	.	O
1	These	O
2	results	O
3	lead	O
4	us	O
5	to	O
6	hypothesize	O
7	that	O
8	a	O
9	single	O
10	multisubunit	B
11	TFIID	I
12	protein	I
13	supports	O
14	transcriptional	O
15	stimulation	O
16	by	O
17	diverse	O
18	activation	O
19	domains	O
20	and	O
21	from	O
22	a	O
23	TATA	O
24	-	O
25	less	O
26	promoter	O
27	.	O
1	The	O
2	RNase	B
3	MRP	I
4	RNA	I
5	gene	I
6	was	O
7	deleted	O
8	by	O
9	insertional	O
10	replacement	O
11	and	O
12	found	O
13	to	O
14	be	O
15	essential	O
16	for	O
17	cellular	O
18	viability	O
19	,	O
20	indicating	O
21	a	O
22	critical	O
23	nuclear	O
24	role	O
25	for	O
26	RNase	B
27	MRP	I
28	.	O
1	From	O
2	these	O
3	results	O
4	,	O
5	CBF	B
6	-	I
7	A	I
8	is	O
9	a	O
10	novel	O
11	CArG	O
12	box	O
13	-,	O
14	ssDNA	B
15	-	I
16	and	I
17	RNA	I
18	-	I
19	binding	I
20	protein	I
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	repressive	O
27	transcriptional	O
28	factor	O
29	.	O
1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	endogenous	O
6	N	O
7	-	O
8	methylation	O
9	of	O
10	salsolinol	O
11	into	O
12	N	O
13	-	O
14	methylsalsolinol	O
15	occurs	O
16	in	O
17	the	O
18	brain	O
19	in	O
20	vivo	O
21	.	O
1	DR1	B
2	molecules	I
3	purified	O
4	from	O
5	human	O
6	lymphoblastoid	O
7	cell	O
8	lines	O
9	could	O
10	specifically	O
11	bind	O
12	to	O
13	these	O
14	peptide	O
15	sequences	O
16	expressed	O
17	on	O
18	the	O
19	phage	O
20	surface	O
21	.	O
1	Alignment	O
2	of	O
3	the	O
4	selected	O
5	sequences	O
6	allowed	O
7	us	O
8	to	O
9	predict	O
10	a	O
11	consensus	O
12	sequence	O
13	for	O
14	binding	O
15	of	O
16	the	O
17	individual	O
18	homodimeric	O
19	Rel	B
20	-	I
21	related	I
22	proteins	I
23	,	O
24	and	O
25	DNA	O
26	-	O
27	protein	O
28	binding	O
29	analysis	O
30	of	O
31	the	O
32	selected	O
33	DNA	O
34	sequences	O
35	revealed	O
36	sequence	O
37	specificity	O
38	of	O
39	the	O
40	proteins	O
41	.	O
1	To	O
2	define	O
3	transcriptional	O
4	control	O
5	elements	O
6	responsible	O
7	for	O
8	muscle	O
9	-	O
10	specific	O
11	expression	O
12	of	O
13	the	O
14	human	B
15	myoglobin	I
16	gene	I
17	,	O
18	we	O
19	performed	O
20	mutational	O
21	analysis	O
22	of	O
23	upstream	O
24	sequences	O
25	(	O
26	nucleotide	O
27	positions	O
28	-	O
29	373	O
30	to	O
31	+	O
32	7	O
33	relative	O
34	to	O
35	the	O
36	transcriptional	O
37	start	O
38	site	O
39	)	O
40	linked	O
41	to	O
42	a	O
43	firefly	B
44	luciferase	I
45	gene	I
46	.	O
1	The	O
2	technique	O
3	of	O
4	the	O
5	TEE	O
6	visualization	O
7	of	O
8	the	O
9	proximal	O
10	coronary	O
11	arteries	O
12	is	O
13	described	O
14	.	O
1	In	O
2	the	O
3	eight	O
4	patients	O
5	with	O
6	persistent	O
7	generalized	O
8	lymph	O
9	-	O
10	adenopathy	O
11	(	O
12	PGL	O
13	)	O
14	and	O
15	nontender	O
16	,	O
17	nonenlarging	O
18	nodes	O
19	,	O
20	pathologic	O
21	analysis	O
22	revealed	O
23	lymphoid	O
24	hyperplasia	O
25	.	O
1	We	O
2	found	O
3	that	O
4	both	O
5	the	O
6	E26	O
7	virus	O
8	-	O
9	encoded	O
10	v	B
11	-	I
12	ets	I
13	and	O
14	the	O
15	myeloid	B
16	/	I
17	B	I
18	-	I
19	cell	I
20	-	I
21	specific	I
22	factor	I
23	PU	I
24	.	I
25	1	I
26	bind	O
27	efficiently	O
28	to	O
29	this	O
30	site	O
31	in	O
32	vitro	O
33	.	O
1	In	O
2	8	O
3	healthy	O
4	volunteers	O
5	there	O
6	were	O
7	no	O
8	significant	O
9	differences	O
10	in	O
11	AUC	O
12	,	O
13	peak	O
14	plasma	O
15	concentrations	O
16	or	O
17	time	O
18	to	O
19	peak	O
20	concentration	O
21	when	O
22	OXC	O
23	was	O
24	administered	O
25	either	O
26	with	O
27	or	O
28	without	O
29	ERY	O
30	.	O
1	Localization	O
2	of	O
3	the	O
4	brachial	O
5	plexus	O
6	with	O
7	the	O
8	nerve	O
9	stimulator	O
10	is	O
11	equally	O
12	effective	O
13	at	O
14	the	O
15	interscalene	O
16	,	O
17	supraclavicular	O
18	,	O
19	and	O
20	axillary	O
21	sites	O
22	.	O
1	Substitution	O
2	of	O
3	either	O
4	Val33	O
5	(	O
6	by	O
7	Gly	O
8	)	O
9	or	O
10	Gly28	O
11	(	O
12	by	O
13	Ser	O
14	),	O
15	two	O
16	of	O
17	the	O
18	most	O
19	conserved	O
20	residues	O
21	in	O
22	all	O
23	protein	O
24	kinases	O
25	,	O
26	resulted	O
27	in	O
28	enzyme	O
29	with	O
30	marginally	O
31	detectable	O
32	activity	O
33	.	O
1	Significance	O
2	of	O
3	the	O
4	biopsy	O
5	site	O
6	of	O
7	the	O
8	latissimus	O
9	dorsi	O
10	muscle	O
11	for	O
12	fiber	O
13	typing	O
14	.	O
1	The	O
2	distinguishing	O
3	features	O
4	involved	O
5	eight	O
6	amino	O
7	acid	O
8	changes	O
9	,	O
10	including	O
11	a	O
12	single	O
13	lysine	O
14	deletion	O
15	relative	O
16	to	O
17	a	O
18	primate	O
19	consensus	O
20	sequence	O
21	in	O
22	the	O
23	first	O
24	complementary	O
25	-	O
26	determing	O
27	region	O
28	of	O
29	V1J1	B
30	.	O
1	4	O
2	.	O
1	The	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	catalytic	O
8	domain	O
9	of	O
10	Nmt1p	B
11	is	O
12	located	O
13	between	O
14	Ile59	O
15	-->	O
16	Phe96	O
17	and	O
18	Gly451	O
19	-->	O
20	Leu455	O
21	.	O
1	Human	O
2	neutrophil	O
3	response	O
4	to	O
5	short	O
6	-	O
7	term	O
8	exposure	O
9	to	O
10	F	O
11	-	O
12	75	O
13	cobalt	O
14	-	O
15	based	O
16	alloy	O
17	.	O
1	No	O
2	other	O
3	changes	O
4	in	O
5	hematopoietic	O
6	differentiation	O
7	status	O
8	were	O
9	observed	O
10	in	O
11	association	O
12	with	O
13	Id	B
14	-	I
15	SCL	I
16	expression	O
17	.	O
1	Respiratory	O
2	interaction	O
3	after	O
4	spinal	O
5	anesthesia	O
6	and	O
7	sedation	O
8	with	O
9	midazolam	O
10	.	O
1	For	O
2	pressure	O
3	greater	O
4	than	O
5	121	O
6	atm	O
7	abs	O
8	,	O
9	an	O
10	increased	O
11	excitability	O
12	of	O
13	the	O
14	tadpoles	O
15	made	O
16	it	O
17	difficult	O
18	to	O
19	distinguish	O
20	the	O
21	righting	O
22	reflex	O
23	from	O
24	involuntary	O
25	movements	O
26	.	O
1	These	O
2	data	O
3	indicate	O
4	that	O
5	RNK	B
6	-	I
7	Met	I
8	-	I
9	1	I
10	is	O
11	a	O
12	serine	B
13	protease	I
14	with	O
15	unique	O
16	activity	O
17	that	O
18	is	O
19	expressed	O
20	in	O
21	the	O
22	granules	O
23	of	O
24	large	O
25	granular	O
26	lymphocytes	O
27	.	O
1	Purification	O
2	and	O
3	cloning	O
4	of	O
5	a	O
6	novel	O
7	serine	B
8	protease	I
9	,	O
10	RNK	B
11	-	I
12	Met	I
13	-	I
14	1	I
15	,	O
16	from	O
17	the	O
18	granules	O
19	of	O
20	a	O
21	rat	O
22	natural	O
23	killer	O
24	cell	O
25	leukemia	O
26	.	O
1	Administration	O
2	of	O
3	growth	B
4	hormone	I
5	leads	O
6	to	O
7	faster	O
8	growth	O
9	,	O
10	but	O
11	also	O
12	faster	O
13	bone	O
14	maturation	O
15	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	utility	O
6	of	O
7	beta	B
8	2	I
9	transferrin	I
10	assay	O
11	in	O
12	the	O
13	diagnosis	O
14	of	O
15	cerebrospinal	O
16	fluid	O
17	otorrhea	O
18	is	O
19	presented	O
20	.	O
1	To	O
2	prepare	O
3	for	O
4	analyses	O
5	with	O
6	the	O
7	family	O
8	variables	O
9	,	O
10	we	O
11	next	O
12	present	O
13	descriptive	O
14	data	O
15	based	O
16	on	O
17	separate	O
18	principal	O
19	components	O
20	analysis	O
21	(	O
22	PCA	O
23	)	O
24	and	O
25	multidimensional	O
26	scaling	O
27	analysis	O
28	(	O
29	MDS	O
30	)	O
31	of	O
32	14	O
33	self	O
34	-	O
35	reported	O
36	health	O
37	scores	O
38	for	O
39	husbands	O
40	and	O
41	for	O
42	wives	O
43	.	O
1	GAL4	B
2	-	O
3	VP16	B
4	-	O
5	mediated	O
6	antirepression	O
7	required	O
8	an	O
9	auxiliary	O
10	factor	O
11	,	O
12	denoted	O
13	as	O
14	a	O
15	co	O
16	-	O
17	antirepressor	O
18	,	O
19	which	O
20	was	O
21	partially	O
22	purified	O
23	from	O
24	Drosophila	O
25	embryos	O
26	.	O
1	Four	O
2	ruminally	O
3	and	O
4	duodenally	O
5	cannulated	O
6	Hampshire	O
7	wethers	O
8	were	O
9	used	O
10	in	O
11	a	O
12	4	O
13	x	O
14	4	O
15	Latin	O
16	square	O
17	experiment	O
18	to	O
19	determine	O
20	whether	O
21	linoleoyl	O
22	methionine	O
23	and	O
24	calcium	O
25	linoleate	O
26	would	O
27	increase	O
28	duodenal	O
29	flow	O
30	of	O
31	unsaturated	O
32	fatty	O
33	acids	O
34	(	O
35	C18	O
36	:	O
37	2	O
38	+	O
39	cis	O
40	C18	O
41	:	O
42	1	O
43	).	O
1	Interestingly	O
2	,	O
3	a	O
4	portion	O
5	of	O
6	the	O
7	tail	O
8	domain	O
9	(	O
10	aa	O
11	,	O
12	1	O
13	,	O
14	094	O
15	-	O
16	1	O
17	,	O
18	830	O
19	)	O
20	shares	O
21	58	O
22	%	O
23	amino	O
24	acid	O
25	sequence	O
26	identity	O
27	with	O
28	a	O
29	723	O
30	-	O
31	aa	O
32	protein	O
33	from	O
34	mouse	O
35	brain	O
36	reported	O
37	to	O
38	be	O
39	a	O
40	glutamic	B
41	acid	I
42	decarboxylase	I
43	.	O
1	Brucellosis	O
2	--	O
3	1990	O
1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	AGA	O
6	group	O
7	,	O
8	both	O
9	fetal	O
10	and	O
11	maternal	O
12	serum	O
13	prolactin	B
14	concentration	O
15	increased	O
16	significantly	O
17	with	O
18	gestation	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	and	O
26	P	O
27	<	O
28	0	O
29	.	O
30	01	O
31	,	O
32	respectively	O
33	).	O
1	BiP670	B
2	retains	O
3	basal	O
4	and	O
5	Ca2	O
6	+	O
7	ionophore	O
8	A23187	O
9	-	O
10	inducible	O
11	activities	O
12	.	O
1	DIBA	O
2	was	O
3	more	O
4	sensitive	O
5	and	O
6	had	O
7	a	O
8	better	O
9	negative	O
10	predictive	O
11	value	O
12	and	O
13	a	O
14	lower	O
15	false	O
16	negative	O
17	percentage	O
18	than	O
19	DFAT	O
20	.	O
1	Four	O
2	short	O
3	nucleotide	O
4	sequences	O
5	(	O
6	boxes	O
7	I	O
8	to	O
9	IV	O
10	)	O
11	contribute	O
12	to	O
13	the	O
14	light	O
15	responsiveness	O
16	of	O
17	the	O
18	parsley	B
19	chalcone	I
20	synthase	I
21	promoter	I
22	.	O
1	ME1a1	B
2	,	O
3	a	O
4	16	O
5	-	O
6	base	O
7	-	O
8	pair	O
9	nuclear	O
10	factor	O
11	binding	O
12	site	O
13	residing	O
14	between	O
15	the	O
16	c	B
17	-	I
18	MYC	I
19	P1	I
20	and	I
21	P2	I
22	transcription	I
23	initiation	I
24	sites	I
25	,	O
26	is	O
27	required	O
28	for	O
29	P2	O
30	activity	O
31	.	O
1	The	O
2	next	O
3	twenty	O
4	years	O
5	of	O
6	prevention	O
7	in	O
8	Indian	O
9	country	O
10	:	O
11	visionary	O
12	,	O
13	complex	O
14	,	O
15	and	O
16	practical	O
17	.	O
1	The	O
2	first	O
3	146	O
4	consecutive	O
5	patients	O
6	treated	O
7	with	O
8	EVL	O
9	during	O
10	the	O
11	period	O
12	from	O
13	August	O
14	,	O
15	1986	O
16	to	O
17	July	O
18	,	O
19	1989	O
20	are	O
21	reported	O
22	.	O
1	Greater	O
2	rupture	O
3	force	O
4	was	O
5	required	O
6	in	O
7	the	O
8	adult	O
9	pigs	O
10	than	O
11	in	O
12	the	O
13	young	O
14	pigs	O
15	.	O
1	NE	B
2	and	O
3	PR3	B
4	assist	O
5	in	O
6	the	O
7	destruction	O
8	of	O
9	phagocytosed	O
10	microorganisms	O
11	,	O
12	cleave	O
13	the	O
14	important	O
15	connective	B
16	-	I
17	tissue	I
18	protein	I
19	elastin	I
20	,	O
21	and	O
22	generate	O
23	chemotactic	O
24	activities	O
25	by	O
26	forming	O
27	alpha	B
28	1	I
29	-	I
30	proteinase	I
31	inhibitor	I
32	complexes	I
33	and	O
34	elastin	B
35	peptides	I
36	.	O
1	Methods	O
2	included	O
3	24	O
4	-	O
5	hour	O
6	dietary	O
7	recall	O
8	,	O
9	menu	O
10	weights	O
11	,	O
12	and	O
13	recipe	O
14	analysis	O
15	.	O
1	By	O
2	contrast	O
3	,	O
4	d	B
5	(	I
6	T2AG3T	I
7	)	I
8	and	O
9	d	B
10	(	I
11	T2G4T	I
12	)	I
13	form	O
14	only	O
15	the	O
16	G	O
17	-	O
18	quadruplex	O
19	monomer	O
20	structures	O
21	independent	O
22	of	O
23	K	O
24	cation	O
25	concentration	O
26	as	O
27	reported	O
28	previously	O
29	[	O
30	Sen	O
31	,	O
32	D	O
33	.,	O
34	&	O
35	Gilbert	O
36	,	O
37	W	O
38	.	O
1	IFI	B
2	16	I
3	mRNA	I
4	was	O
5	found	O
6	to	O
7	be	O
8	constitutively	O
9	expressed	O
10	in	O
11	lymphoid	O
12	cells	O
13	and	O
14	in	O
15	cell	O
16	lines	O
17	of	O
18	both	O
19	the	O
20	T	O
21	and	O
22	B	O
23	lineages	O
24	.	O
1	Moreover	O
2	,	O
3	LD50	O
4	in	O
5	mice	O
6	of	O
7	RP	O
8	-	O
9	170	O
10	(	O
11	4	O
12	.	O
13	3	O
14	g	O
15	/	O
16	kg	O
17	on	O
18	i	O
19	.	O
20	v	O
21	.)	O
22	was	O
23	increased	O
24	to	O
25	5	O
26	.	O
27	2	O
28	g	O
29	/	O
30	kg	O
31	by	O
32	oral	O
33	administration	O
34	.	O
1	Switching	O
2	FDC	O
3	-	O
4	P1	O
5	/	O
6	MAC	O
7	cells	O
8	from	O
9	growth	O
10	in	O
11	M	B
12	-	I
13	CSF	I
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	caused	O
19	the	O
20	selective	O
21	degradation	O
22	of	O
23	c	B
24	-	I
25	fms	I
26	mRNA	I
27	within	O
28	6	O
29	h	O
30	after	O
31	factor	O
32	switching	O
33	.	O
1	Radiolabelled	O
2	palmitate	O
3	was	O
4	not	O
5	incorporated	O
6	into	O
7	the	O
8	mutated	O
9	protein	O
10	,	O
11	showing	O
12	that	O
13	lipid	O
14	modification	O
15	occurs	O
16	at	O
17	the	O
18	Cys	O
19	-	O
20	22	O
21	residue	O
22	.	O
1	Mature	B
2	tobacco	I
3	L12	I
4	protein	I
5	has	O
6	44	O
7	%	O
8	amino	O
9	acid	O
10	identity	O
11	with	O
12	ribosomal	O
13	protein	O
14	L7	B
15	/	O
16	L12	B
17	of	O
18	Escherichia	O
19	coli	O
20	.	O
1	Characterization	O
2	of	O
3	these	O
4	R	O
5	subunits	O
6	by	O
7	their	O
8	8	O
9	-	O
10	azido	O
11	-	O
12	cAMP	O
13	photoaffinity	O
14	labeling	O
15	and	O
16	immunoreactivity	O
17	,	O
18	as	O
19	well	O
20	as	O
21	by	O
22	a	O
23	phosphorylation	O
24	-	O
25	dependent	O
26	mobility	O
27	shift	O
28	on	O
29	sodium	O
30	dodecyl	O
31	sulfate	O
32	-	O
33	polyacrylamide	O
34	gel	O
35	electrophoresis	O
36	(	O
37	SDS	O
38	-	O
39	PAGE	O
40	),	O
41	indicated	O
42	subunit	O
43	sizes	O
44	of	O
45	RII	B
46	beta	I
47	(	O
48	53	O
49	kDa	O
50	)	O
51	greater	O
52	than	O
53	RII	B
54	alpha	I
55	dephosphoform	O
56	(	O
57	51	O
58	kDa	O
59	)	O
60	greater	O
61	than	O
62	RI	B
63	alpha	I
64	(	O
65	49	O
66	kDa	O
67	).	O
1	Comparison	O
2	of	O
3	the	O
4	genomic	O
5	DNA	O
6	sequence	O
7	with	O
8	that	O
9	of	O
10	the	O
11	four	O
12	different	O
13	mRNAs	O
14	indicates	O
15	that	O
16	these	O
17	transcripts	O
18	are	O
19	produced	O
20	by	O
21	alternative	O
22	splicing	O
23	of	O
24	the	O
25	murine	O
26	pre	O
27	-	O
28	mRNA	O
29	according	O
30	to	O
31	a	O
32	cassette	O
33	model	O
34	.	O
1	During	O
2	the	O
3	1980	O
4	'	O
5	s	O
6	,	O
7	quantifications	O
8	of	O
9	immunoserological	O
10	testings	O
11	,	O
12	especially	O
13	C	B
14	reactive	I
15	protein	I
16	,	O
17	rheumatoid	B
18	factor	I
19	and	O
20	antistreptolysin	B
21	O	I
22	,	O
23	progressed	O
24	rapidly	O
25	.	O
1	The	O
2	cardiac	B
3	myosin	I
4	light	I
5	chain	I
6	-	I
7	2	I
8	(	O
9	MLC	B
10	-	I
11	2	I
12	)	O
13	gene	O
14	promoter	O
15	contains	O
16	several	O
17	positive	O
18	and	O
19	negative	O
20	cis	O
21	-	O
22	acting	O
23	sequences	O
24	that	O
25	are	O
26	involved	O
27	in	O
28	the	O
29	regulation	O
30	of	O
31	its	O
32	expression	O
33	.	O
1	Disruption	O
2	mutations	O
3	have	O
4	been	O
5	constructed	O
6	in	O
7	the	O
8	SLK1	B
9	gene	I
10	.	O
11	slk1	B
12	null	I
13	mutants	I
14	cannot	O
15	grow	O
16	at	O
17	37	O
18	degrees	O
19	C	O
20	,	O
21	but	O
22	many	O
23	cells	O
24	can	O
25	grow	O
26	at	O
27	30	O
28	,	O
29	24	O
30	,	O
31	and	O
32	17	O
33	degrees	O
34	C	O
35	.	O
1	Molecular	O
2	and	O
3	genetic	O
4	analysis	O
5	of	O
6	the	O
7	yeast	B
8	early	I
9	meiotic	I
10	recombination	I
11	genes	I
12	REC102	I
13	and	O
14	REC107	B
15	/	O
16	MER2	B
17	.	O
1	These	O
2	data	O
3	support	O
4	a	O
5	possible	O
6	biological	O
7	significance	O
8	of	O
9	the	O
10	frameshift	O
11	to	O
12	occur	O
13	at	O
14	this	O
15	position	O
16	of	O
17	the	O
18	large	O
19	overlap	O
20	by	O
21	including	O
22	the	O
23	putative	O
24	RNA	O
25	template	O
26	-	O
27	binding	O
28	site	O
29	of	O
30	the	O
31	PLRV	B
32	replicase	I
33	in	O
34	the	O
35	ORF2a	B
36	/	I
37	ORF2b	I
38	transframe	I
39	protein	I
40	.	O
1	Stringent	O
2	hybridization	O
3	of	O
4	EHS	B
5	-	I
6	1	I
7	back	O
8	to	O
9	primate	O
10	genomic	O
11	DNA	O
12	indicates	O
13	two	O
14	distinct	O
15	EHS	B
16	-	I
17	1	I
18	loci	I
19	in	O
20	normal	O
21	human	O
22	DNA	O
23	,	O
24	an	O
25	identical	O
26	band	O
27	pattern	O
28	in	O
29	chimpanzee	O
30	DNA	O
31	,	O
32	and	O
33	a	O
34	single	O
35	locus	O
36	in	O
37	rhesus	O
38	monkey	O
39	DNA	O
40	.	O
1	The	O
2	MET4	B
3	gene	O
4	was	O
5	cloned	O
6	,	O
7	and	O
8	its	O
9	sequence	O
10	reveals	O
11	that	O
12	it	O
13	encodes	O
14	a	O
15	protein	O
16	related	O
17	to	O
18	the	O
19	family	O
20	of	O
21	the	O
22	bZIP	B
23	transcriptional	I
24	activators	I
25	.	O
1	It	O
2	is	O
3	believed	O
4	that	O
5	these	O
6	domains	O
7	are	O
8	important	O
9	for	O
10	directing	O
11	specific	O
12	protein	O
13	-	O
14	protein	O
15	interactions	O
16	necessary	O
17	for	O
18	the	O
19	proper	O
20	functioning	O
21	of	O
22	Src	B
23	.	O
1	Problems	O
2	remain	O
3	to	O
4	be	O
5	resolved	O
6	in	O
7	the	O
8	area	O
9	of	O
10	quantitative	O
11	risk	O
12	assessment	O
13	.	O
1	Thus	O
2	,	O
3	the	O
4	human	B
5	D1A	I
6	gene	I
7	belongs	O
8	to	O
9	the	O
10	category	O
11	of	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	regulated	O
17	genes	O
18	that	O
19	have	O
20	housekeeping	O
21	-	O
22	type	O
23	promoters	O
24	.	O
1	Lac	B
2	operators	O
3	were	O
4	introduced	O
5	into	O
6	several	O
7	positions	O
8	within	O
9	the	O
10	CAB	B
11	promoter	I
12	and	O
13	operator	O
14	-	O
15	free	O
16	plasmid	O
17	was	O
18	used	O
19	as	O
20	control	O
21	.	O
1	From	O
2	March	O
3	5	O
4	through	O
5	October	O
6	26	O
7	,	O
8	1991	O
9	,	O
10	eight	O
11	persons	O
12	were	O
13	diagnosed	O
14	with	O
15	elevated	O
16	blood	O
17	lead	O
18	levels	O
19	(	O
20	BLLs	O
21	)	O
22	at	O
23	a	O
24	local	O
25	hospital	O
26	and	O
27	were	O
28	reported	O
29	to	O
30	the	O
31	notifiable	O
32	disease	O
33	surveillance	O
34	system	O
35	maintained	O
36	by	O
37	the	O
38	Alabama	O
39	Department	O
40	of	O
41	Public	O
42	Health	O
43	(	O
44	ADPH	O
45	).	O
1	A	O
2	possible	O
3	mechanism	O
4	is	O
5	that	O
6	elevated	O
7	alveolar	O
8	pressure	O
9	and	O
10	decreased	O
11	cardiac	O
12	output	O
13	eliminate	O
14	blood	O
15	flow	O
16	from	O
17	corner	O
18	vessels	O
19	in	O
20	nondependent	O
21	high	O
22	VA	O
23	/	O
24	Q	O
25	regions	O
26	.	O
1	The	O
2	SEN1	B
3	gene	I
4	corresponds	O
5	to	O
6	a	O
7	6	O
8	,	O
9	336	O
10	-	O
11	bp	O
12	open	O
13	reading	O
14	frame	O
15	coding	O
16	for	O
17	a	O
18	2	O
19	,	O
20	112	O
21	-	O
22	amino	O
23	-	O
24	acid	O
25	protein	O
26	(	O
27	molecular	O
28	mass	O
29	,	O
30	239	O
31	kDa	O
32	).	O
1	Protein	B
2	tyrosine	I
3	kinases	I
4	(	O
5	PTKs	B
6	)	O
7	are	O
8	implicated	O
9	in	O
10	the	O
11	control	O
12	of	O
13	cell	O
14	growth	O
15	by	O
16	virtue	O
17	of	O
18	their	O
19	frequent	O
20	appearance	O
21	as	O
22	products	O
23	of	O
24	retroviral	O
25	oncogenes	O
26	,	O
27	as	O
28	intracellular	O
29	signal	O
30	transducers	O
31	,	O
32	and	O
33	as	O
34	growth	B
35	factor	I
36	receptors	I
37	or	O
38	components	O
39	thereof	O
40	.	O
1	At	O
2	the	O
3	C	O
4	-	O
5	terminus	O
6	of	O
7	the	O
8	protein	O
9	is	O
10	a	O
11	domain	O
12	that	O
13	contains	O
14	sequences	O
15	very	O
16	similar	O
17	to	O
18	those	O
19	found	O
20	in	O
21	the	O
22	breakpoint	O
23	cluster	O
24	region	O
25	gene	O
26	product	O
27	,	O
28	n	B
29	-	I
30	chimerin	I
31	,	O
32	and	O
33	rho	B
34	GAP	I
35	,	O
36	all	O
37	of	O
38	which	O
39	have	O
40	been	O
41	shown	O
42	to	O
43	possess	O
44	intrinsic	O
45	GAP	B
46	activity	O
47	on	O
48	small	B
49	GTPases	I
50	.	O
1	Dimerization	O
2	of	O
3	Myf	B
4	-	I
5	5	I
6	with	O
7	the	O
8	ubiquitously	O
9	expressed	O
10	bHLH	O
11	protein	O
12	E12	B
13	not	O
14	only	O
15	increases	O
16	the	O
17	affinity	O
18	for	O
19	DNA	O
20	but	O
21	also	O
22	stimulates	O
23	transactivation	O
24	independently	O
25	of	O
26	DNA	O
27	binding	O
28	.	O
1	The	O
2	circadian	O
3	rhythmicity	O
4	of	O
5	sleep	O
6	was	O
7	pronounced	O
8	.	O
1	Drug	O
2	-	O
3	drug	O
4	interactions	O
5	are	O
6	most	O
7	likely	O
8	to	O
9	occur	O
10	in	O
11	patients	O
12	receiving	O
13	multiple	O
14	medications	O
15	and	O
16	with	O
17	drugs	O
18	that	O
19	have	O
20	a	O
21	narrow	O
22	therapeutic	O
23	window	O
24	.	O
1	The	O
2	decay	O
3	curves	O
4	of	O
5	chlorophyll	O
6	fluorescence	O
7	showed	O
8	a	O
9	superposition	O
10	of	O
11	three	O
12	exponentially	O
13	decaying	O
14	components	O
15	with	O
16	time	O
17	constants	O
18	of	O
19	T1	O
20	=	O
21	100	O
22	-	O
23	200	O
24	ps	O
25	,	O
26	T2	O
27	=	O
28	300	O
29	-	O
30	500	O
31	ps	O
32	and	O
33	T3	O
34	=	O
35	2	O
36	.	O
37	0	O
38	-	O
39	3	O
40	.	O
41	5	O
42	ns	O
43	.	O
1	A	O
2	724	O
3	-	O
4	bp	O
5	segment	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	consisting	O
13	of	O
14	the	O
15	proximal	O
16	E	O
17	-	O
18	box	O
19	flanked	O
20	upstream	O
21	by	O
22	a	O
23	mammalian	O
24	-	O
25	specific	O
26	352	O
27	-	O
28	bp	O
29	region	O
30	was	O
31	sufficient	O
32	for	O
33	maximal	O
34	transcriptional	O
35	activation	O
36	in	O
37	postconfluent	O
38	BC3H1	O
39	myoblasts	O
40	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	baculovirus	O
6	-	O
7	expressed	O
8	TR	B
9	mediates	O
10	transcriptional	O
11	activation	O
12	and	O
13	repression	O
14	in	O
15	a	O
16	promoter	O
17	-	O
18	specific	O
19	manner	O
20	in	O
21	vitro	O
22	.	O
1	In	O
2	conclusion	O
3	,	O
4	to	O
5	study	O
6	and	O
7	overcome	O
8	TI	O
9	region	O
10	-	O
11	based	O
12	expression	O
13	problems	O
14	it	O
15	is	O
16	worthwhile	O
17	to	O
18	start	O
19	out	O
20	with	O
21	a	O
22	versatile	O
23	vector	O
24	containing	O
25	exhaustive	O
26	mutations	O
27	in	O
28	the	O
29	periShine	O
30	-	O
31	Dalgarno	O
32	sequences	O
33	;	O
34	as	O
35	a	O
36	rule	O
37	the	O
38	coding	O
39	MTI	O
40	subregion	O
41	can	O
42	be	O
43	kept	O
44	unchanged	O
45	.	O
1	Therefore	O
2	,	O
3	with	O
4	a	O
5	biopsy	O
6	from	O
7	the	O
8	stoma	O
9	site	O
10	there	O
11	is	O
12	a	O
13	risk	O
14	of	O
15	missing	O
16	early	O
17	rejection	O
18	.	O
1	In	O
2	agreement	O
3	with	O
4	this	O
5	southern	O
6	blotting	O
7	of	O
8	mouse	O
9	DNA	O
10	with	O
11	SmN	B
12	probes	O
13	reveals	O
14	bands	O
15	,	O
16	additional	O
17	to	O
18	those	O
19	derived	O
20	from	O
21	the	O
22	pseudogene	O
23	,	O
24	which	O
25	are	O
26	characteristic	O
27	of	O
28	an	O
29	intron	O
30	-	O
31	containing	O
32	SmN	B
33	gene	I
34	.	O
1	Two	O
2	cDNAs	O
3	encoding	O
4	casein	B
5	kinase	I
6	-	I
7	1	I
8	have	O
9	been	O
10	isolated	O
11	from	O
12	a	O
13	yeast	O
14	cDNA	O
15	library	O
16	and	O
17	termed	O
18	CKI1	B
19	and	O
20	CKI2	B
21	.	O
1	The	O
2	observed	O
3	sequence	O
4	variation	O
5	disrupts	O
6	the	O
7	first	O
8	ORF	O
9	in	O
10	many	O
11	Y	B
12	'	O
13	s	O
14	while	O
15	most	O
16	of	O
17	the	O
18	second	O
19	ORF	O
20	including	O
21	the	O
22	putative	O
23	helicase	B
24	region	I
25	is	O
26	unaffected	O
27	.	O
1	Lesions	O
2	were	O
3	made	O
4	by	O
5	pressure	O
6	injection	O
7	of	O
8	kainic	O
9	acid	O
10	into	O
11	the	O
12	SOC	O
13	through	O
14	a	O
15	stereotaxically	O
16	positioned	O
17	glass	O
18	micropipette	O
19	.	O
1	In	O
2	patients	O
3	with	O
4	limited	O
5	disease	O
6	,	O
7	the	O
8	survival	O
9	in	O
10	the	O
11	alternating	O
12	arm	O
13	was	O
14	significantly	O
15	superior	O
16	to	O
17	the	O
18	survival	O
19	in	O
20	the	O
21	CAV	O
22	arm	O
23	(	O
24	P	O
25	=	O
26	.	O
27	014	O
28	)	O
29	or	O
30	the	O
31	survival	O
32	in	O
33	the	O
34	PE	O
35	arm	O
36	(	O
37	P	O
38	=	O
39	.	O
40	023	O
41	).	O
1	In	O
2	contrast	O
3	to	O
4	behavioral	O
5	deviation	O
6	(	O
7	the	O
8	avoidance	O
9	conditioning	O
10	lost	O
11	),	O
12	the	O
13	haloperidol	O
14	intrastriatal	O
15	microinjections	O
16	did	O
17	not	O
18	affect	O
19	the	O
20	DA	O
21	synaptic	O
22	level	O
23	in	O
24	rostral	O
25	neostriatum	O
26	.	O
1	TPA	O
2	and	O
3	TGF	B
4	-	I
5	beta	I
6	1	I
7	did	O
8	not	O
9	markedly	O
10	affect	O
11	the	O
12	activities	O
13	of	O
14	the	O
15	72	O
16	-	O
17	kDa	O
18	enzyme	O
19	.	O
1	We	O
2	have	O
3	determined	O
4	that	O
5	the	O
6	mutants	O
7	define	O
8	two	O
9	complementation	O
10	groups	O
11	,	O
12	designated	O
13	cgs1	B
14	+	I
15	and	O
16	cgs2	B
17	+	I
18	(	O
19	continues	O
20	to	O
21	grow	O
22	in	O
23	stationary	O
24	).	O
1	The	O
2	strategy	O
3	has	O
4	been	O
5	used	O
6	to	O
7	determine	O
8	2	O
9	.	O
10	6	O
11	kilobases	O
12	of	O
13	nucleotide	O
14	sequence	O
15	in	O
16	the	O
17	Saccharomyces	B
18	cerevisiae	I
19	ADE	I
20	1	I
21	locus	I
22	.	O
1	We	O
2	report	O
3	the	O
4	isolation	O
5	of	O
6	genomic	O
7	and	O
8	cDNA	O
9	clones	O
10	of	O
11	the	O
12	light	O
13	-	O
14	independent	O
15	Sn	B
16	:	I
17	bol3	I
18	allele	I
19	.	O
1	We	O
2	enrolled	O
3	253	O
4	HIV	B
5	-	I
6	antibody	I
7	positive	O
8	heroin	O
9	addicts	O
10	without	O
11	HIV	O
12	-	O
13	related	O
14	disease	O
15	(	O
16	n	O
17	=	O
18	81	O
19	)	O
20	or	O
21	with	O
22	persistent	O
23	generalized	O
24	lymphadenopathy	O
25	(	O
26	n	O
27	=	O
28	172	O
29	)	O
30	in	O
31	a	O
32	prospective	O
33	study	O
34	to	O
35	evaluate	O
36	clinical	O
37	progression	O
38	to	O
39	AIDS	O
40	related	O
41	complex	O
42	(	O
43	ARC	O
44	)	O
45	or	O
46	AIDS	O
47	and	O
48	to	O
49	identify	O
50	factors	O
51	of	O
52	possible	O
53	prognostic	O
54	relevance	O
55	.	O
1	However	O
2	,	O
3	the	O
4	increase	O
5	in	O
6	biliary	O
7	excretion	O
8	did	O
9	not	O
10	compensate	O
11	for	O
12	the	O
13	reduced	O
14	elimination	O
15	of	O
16	bretylium	O
17	and	O
18	hexylsalicylic	O
19	acid	O
20	via	O
21	the	O
22	kidney	O
23	.	O
1	The	O
2	Drosophila	B
3	suppressor	I
4	of	I
5	sable	I
6	gene	I
7	encodes	O
8	a	O
9	polypeptide	O
10	with	O
11	regions	O
12	similar	O
13	to	O
14	those	O
15	of	O
16	RNA	O
17	-	O
18	binding	O
19	proteins	O
20	.	O
1	2	O
2	:	O
3	121	O
4	-	O
5	133	O
6	,	O
7	1988	O
8	).	O
1	The	O
2	DNA	O
3	sequence	O
4	conferring	O
5	AP	B
6	-	I
7	1	I
8	activity	O
9	was	O
10	located	O
11	in	O
12	the	O
13	proximal	O
14	promoter	O
15	region	O
16	.	O
1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	the	O
6	rat	O
7	chromosomal	O
8	gene	O
9	for	O
10	a	O
11	polypeptide	O
12	(	O
13	pS1	B
14	)	O
15	antigenically	O
16	related	O
17	to	O
18	statin	B
19	.	O
1	Heterozygous	O
2	mutation	O
3	in	O
4	the	O
5	G	O
6	+	O
7	5	O
8	position	O
9	of	O
10	intron	O
11	33	O
12	of	O
13	the	O
14	pro	B
15	-	I
16	alpha	I
17	2	I
18	(	I
19	I	I
20	)	I
21	gene	I
22	(	O
23	COL1A2	B
24	)	O
25	that	O
26	causes	O
27	aberrant	O
28	RNA	O
29	splicing	O
30	and	O
31	lethal	O
32	osteogenesis	O
33	imperfecta	O
34	.	O
1	A	O
2	second	O
3	even	O
4	more	O
5	significant	O
6	match	O
7	to	O
8	this	O
9	E	O
10	.	O
11	coli	O
12	region	O
13	was	O
14	found	O
15	in	O
16	the	O
17	retroviral	B
18	ribonuclease	I
19	H	I
20	(	O
21	RNase	B
22	H	I
23	)	O
24	domain	O
25	,	O
26	and	O
27	corresponds	O
28	precisely	O
29	to	O
30	a	O
31	region	O
32	that	O
33	has	O
34	been	O
35	aligned	O
36	by	O
37	previous	O
38	investigators	O
39	with	O
40	the	O
41	E	B
42	.	I
43	coli	I
44	RNase	I
45	H	I
46	,	O
47	suggesting	O
48	that	O
49	Pol	B
50	I	I
51	helices	O
52	O	O
53	and	O
54	P	O
55	are	O
56	homologous	O
57	to	O
58	helices	O
59	A	O
60	and	O
61	D	O
62	of	O
63	the	O
64	RNase	B
65	H	I
66	crystal	O
67	structure	O
68	,	O
69	respectively	O
70	.	O
1	They	O
2	were	O
3	checked	O
4	for	O
5	anti	B
6	-	I
7	HCV	I
8	(	O
9	anti	B
10	-	I
11	C100	I
12	-	I
13	3	I
14	)	O
15	with	O
16	HCV	O
17	EIA	O
18	kit	O
19	(	O
20	Abbott	O
21	Lab	O
22	.,	O
23	North	O
24	Chicago	O
25	,	O
26	IL	O
27	).	O
1	Zn	O
2	(	O
3	II	O
4	)	O
5	coordination	O
6	domain	O
7	mutants	O
8	of	O
9	T4	B
10	gene	I
11	32	I
12	protein	I
13	.	O
1	The	O
2	genome	O
3	of	O
4	Thogoto	O
5	virus	O
6	comprises	O
7	six	O
8	segments	O
9	of	O
10	single	O
11	-	O
12	stranded	O
13	,	O
14	negative	O
15	sense	O
16	RNA	O
17	.	O
1	Immunostaining	O
2	of	O
3	cells	O
4	transfected	O
5	with	O
6	these	O
7	constructs	O
8	revealed	O
9	that	O
10	both	O
11	the	O
12	myristoylated	O
13	and	O
14	nonmyristoylated	O
15	mutants	O
16	were	O
17	localized	O
18	in	O
19	nuclei	O
20	,	O
21	whereas	O
22	wild	B
23	-	I
24	type	I
25	PKC	I
26	alpha	I
27	was	O
28	primarily	O
29	cytoplasmic	O
30	and	O
31	perinuclear	O
32	.	O
1	We	O
2	have	O
3	partially	O
4	sequenced	O
5	the	O
6	RAP74	B
7	protein	I
8	from	O
9	purified	O
10	HeLa	O
11	cells	O
12	,	O
13	cloned	O
14	its	O
15	complementary	O
16	DNA	O
17	and	O
18	shown	O
19	that	O
20	its	O
21	translation	O
22	product	O
23	can	O
24	interact	O
25	with	O
26	RAP30	B
27	in	O
28	vitro	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vivo	O
34	.	O
1	Effects	O
2	of	O
3	thromboxane	B
4	synthetase	I
5	inhibition	O
6	on	O
7	postburn	O
8	mesenteric	O
9	vascular	O
10	resistance	O
11	and	O
12	the	O
13	rate	O
14	of	O
15	bacterial	O
16	translocation	O
17	in	O
18	a	O
19	chronic	O
20	porcine	O
21	model	O
22	.	O
1	Testosterone	O
2	,	O
3	free	O
4	testosterone	O
5	,	O
6	non	B
7	-	I
8	sex	I
9	hormone	I
10	-	I
11	binding	I
12	globulin	I
13	-	O
14	bound	O
15	testosterone	O
16	,	O
17	and	O
18	free	O
19	androgen	O
20	index	O
21	:	O
22	which	O
23	testosterone	O
24	measurement	O
25	is	O
26	most	O
27	relevant	O
28	to	O
29	reproductive	O
30	and	O
31	sexual	O
32	function	O
33	in	O
34	men	O
35	with	O
36	epilepsy	O
37	?	O
1	BACKGROUND	O
2	:	O
3	The	O
4	effectiveness	O
5	of	O
6	monoamine	B
7	oxidase	I
8	inhibitors	O
9	(	O
10	MAOIs	O
11	)	O
12	in	O
13	tricyclic	O
14	resistant	O
15	depression	O
16	has	O
17	received	O
18	surprisingly	O
19	little	O
20	systematic	O
21	study	O
22	.	O
1	Patients	O
2	with	O
3	moderate	O
4	PDDAT	O
5	were	O
6	impaired	O
7	on	O
8	all	O
9	serial	O
10	positions	O
11	for	O
12	both	O
13	spatial	O
14	order	O
15	and	O
16	spatial	O
17	recognition	O
18	memory	O
19	.	O
1	One	O
2	patients	O
3	had	O
4	plasma	B
5	C	I
6	-	I
7	peptide	I
8	greater	O
9	than	O
10	3	O
11	pM	O
12	and	O
13	was	O
14	therefore	O
15	excluded	O
16	from	O
17	analysis	O
18	.	O
1	The	O
2	constraints	O
3	of	O
4	primase	B
5	recognition	I
6	sequences	I
7	,	O
8	nucleotide	O
9	substrate	O
10	requirements	O
11	,	O
12	and	O
13	the	O
14	effects	O
15	of	O
16	additional	O
17	proteins	O
18	on	O
19	oligoribonucleotide	O
20	synthesis	O
21	by	O
22	the	O
23	63	B
24	-	I
25	kDa	I
26	gene	I
27	4	I
28	protein	I
29	have	O
30	been	O
31	examined	O
32	using	O
33	templates	O
34	of	O
35	defined	O
36	sequence	O
37	.	O
1	Airway	O
2	pressure	O
3	and	O
4	air	O
5	flow	O
6	were	O
7	measured	O
8	at	O
9	the	O
10	endotracheal	O
11	tube	O
12	in	O
13	13	O
14	children	O
15	on	O
16	a	O
17	variety	O
18	of	O
19	ventilators	O
20	.	O
1	CONCLUSION	O
2	:	O
3	Monitoring	O
4	SpO2	O
5	at	O
6	the	O
7	nasal	O
8	septum	O
9	site	O
10	is	O
11	more	O
12	reliable	O
13	than	O
14	monitoring	O
15	it	O
16	at	O
17	the	O
18	finger	O
19	site	O
20	in	O
21	hypothermic	O
22	patients	O
23	.	O
1	Diltiazem	O
2	decreased	O
3	the	O
4	total	O
5	body	O
6	clearance	O
7	from	O
8	34	O
9	.	O
10	0	O
11	+/-	O
12	8	O
13	.	O
14	0	O
15	to	O
16	28	O
17	.	O
18	6	O
19	+/-	O
20	6	O
21	.	O
22	1	O
23	mL	O
24	/	O
25	min	O
26	(	O
27	P	O
28	less	O
29	than	O
30	.	O
31	01	O
32	),	O
33	and	O
34	prolonged	O
35	the	O
36	elimination	O
37	half	O
38	-	O
39	life	O
40	from	O
41	12	O
42	.	O
43	6	O
44	+/-	O
45	3	O
46	.	O
47	0	O
48	to	O
49	14	O
50	.	O
51	3	O
52	+/-	O
53	2	O
54	.	O
55	5	O
56	hours	O
57	(	O
58	P	O
59	less	O
60	than	O
61	.	O
62	01	O
63	)	O
64	of	O
65	antipyrine	O
66	without	O
67	any	O
68	changes	O
69	in	O
70	volume	O
71	of	O
72	distribution	O
73	.	O
1	In	O
2	one	O
3	,	O
4	exploratory	O
5	behavior	O
6	(	O
7	assessed	O
8	by	O
9	hole	O
10	pokes	O
11	)	O
12	and	O
13	locomotion	O
14	were	O
15	assessed	O
16	during	O
17	a	O
18	10	O
19	-	O
20	min	O
21	test	O
22	session	O
23	.	O
1	12	O
2	-	O
3	O	O
4	-	O
5	Tetradecanoylphorbol	O
6	13	O
7	-	O
8	acetate	O
9	was	O
10	found	O
11	to	O
12	inhibit	O
13	rapidly	O
14	and	O
15	potently	O
16	the	O
17	expression	O
18	of	O
19	mRNAs	O
20	coding	O
21	for	O
22	the	O
23	myogenic	O
24	regulators	O
25	CMD1	B
26	and	O
27	myogenin	B
28	.	O
1	These	O
2	introns	O
3	belong	O
4	to	O
5	the	O
6	class	O
7	of	O
8	nuclear	O
9	pre	O
10	-	O
11	mRNA	O
12	introns	O
13	and	O
14	contain	O
15	typical	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	consensus	O
22	sequences	O
23	,	O
24	as	O
25	well	O
26	as	O
27	unique	O
28	features	O
29	.	O
1	Antibodies	O
2	specific	O
3	to	O
4	rE12	B
5	and	O
6	rNFIL	B
7	-	I
8	6	I
9	disrupt	O
10	nucleoprotein	O
11	complexes	O
12	with	O
13	these	O
14	DNA	O
15	-	O
16	binding	O
17	sites	O
18	,	O
19	confirming	O
20	the	O
21	interaction	O
22	of	O
23	native	O
24	in	O
25	vivo	O
26	factors	O
27	.	O
1	A	O
2	method	O
3	is	O
4	described	O
5	for	O
6	detecting	O
7	targeted	O
8	events	O
9	at	O
10	the	O
11	mu	B
12	heavy	I
13	chain	I
14	gene	I
15	which	O
16	relies	O
17	on	O
18	co	O
19	-	O
20	conversion	O
21	(	O
22	or	O
23	co	O
24	-	O
25	exchange	O
26	)	O
27	of	O
28	a	O
29	point	O
30	mutation	O
31	with	O
32	a	O
33	selectable	O
34	marker	O
35	contained	O
36	on	O
37	a	O
38	replacement	O
39	vector	O
40	.	O
1	This	O
2	study	O
3	was	O
4	aimed	O
5	at	O
6	assessing	O
7	whether	O
8	c	O
9	-	O
10	DDP	O
11	administration	O
12	immediately	O
13	before	O
14	radiotherapy	O
15	could	O
16	increase	O
17	frequency	O
18	and	O
19	duration	O
20	of	O
21	objective	O
22	responses	O
23	,	O
24	as	O
25	well	O
26	as	O
27	survival	O
28	,	O
29	in	O
30	patients	O
31	affected	O
32	with	O
33	locally	O
34	advanced	O
35	stages	O
36	of	O
37	squamous	O
38	carcinomas	O
39	of	O
40	the	O
41	head	O
42	and	O
43	neck	O
44	.	O
1	Two	O
2	potential	O
3	regulatory	O
4	sequences	O
5	for	O
6	DNA	O
7	binding	O
8	proteins	O
9	were	O
10	found	O
11	in	O
12	the	O
13	non	O
14	-	O
15	coding	O
16	5	O
17	'	O
18	region	O
19	:	O
20	a	O
21	HAP2	B
22	/	O
23	HAP3	B
24	consensus	O
25	recognition	O
26	sequence	O
27	at	O
28	nucleotide	O
29	-	O
30	154	O
31	and	O
32	a	O
33	BAF1	B
34	consensus	I
35	recognition	I
36	sequence	I
37	at	O
38	nucleotide	O
39	-	O
40	136	O
41	.	O
1	When	O
2	examined	O
3	as	O
4	adults	O
5	(	O
6	8	O
7	weeks	O
8	old	O
9	),	O
10	the	O
11	external	O
12	genitalia	O
13	of	O
14	TA	O
15	-	O
16	exposed	O
17	offspring	O
18	were	O
19	normal	O
20	.	O
1	The	O
2	alcoholic	O
3	patient	O
4	,	O
5	his	O
6	work	O
7	and	O
8	the	O
9	subjectivity	O
10	of	O
11	the	O
12	period	O
1	Magnetotherapy	O
2	of	O
3	hepatitis	O
4	A	O
5	and	O
6	B	O
7	in	O
8	children	O
1	Pigs	O
2	were	O
3	switched	O
4	from	O
5	the	O
6	growing	O
7	to	O
8	the	O
9	finishing	O
10	diet	O
11	at	O
12	57	O
13	and	O
14	61	O
15	kg	O
16	in	O
17	Exp	O
18	.	O
1	TPTA	O
2	produced	O
3	brain	O
4	congestion	O
5	,	O
6	and	O
7	hepatic	O
8	and	O
9	pulmonary	O
10	petechial	O
11	and	O
12	generalized	O
13	hemorrhages	O
14	.	O
1	A	O
2	two	O
3	phase	O
4	slug	O
5	flow	O
6	tubular	O
7	heat	O
8	exchanger	O
9	was	O
10	used	O
11	for	O
12	the	O
13	thermal	O
14	inactivation	O
15	of	O
16	Listeria	O
17	monocytogenes	O
18	in	O
19	natural	O
20	infected	O
21	milk	O
22	from	O
23	seven	O
24	cows	O
25	.	O
1	Regional	O
2	cerebral	O
3	blood	O
4	flow	O
5	(	O
6	rCBF	O
7	)	O
8	measurements	O
9	and	O
10	psychiatric	O
11	ratings	O
12	were	O
13	performed	O
14	on	O
15	seven	O
16	schizophrenic	O
17	patients	O
18	(	O
19	mean	O
20	age	O
21	=	O
22	41	O
23	.	O
24	4	O
25	years	O
26	)	O
27	who	O
28	had	O
29	been	O
30	examined	O
31	18	O
32	years	O
33	previously	O
34	in	O
35	a	O
36	study	O
37	that	O
38	used	O
39	similar	O
40	psychiatric	O
41	ratings	O
42	and	O
43	a	O
44	comparable	O
45	rCBF	O
46	technique	O
47	.	O
1	The	O
2	12S	B
3	E1A	I
4	product	I
5	does	O
6	not	O
7	activate	O
8	a	O
9	TRE	O
10	sequence	O
11	,	O
12	but	O
13	cotransfection	O
14	with	O
15	c	B
16	-	I
17	jun	I
18	circumvents	O
19	this	O
20	lack	O
21	of	O
22	stimulation	O
23	.	O
1	The	O
2	gene	O
3	is	O
4	1	O
5	,	O
6	139	O
7	base	O
8	pairs	O
9	(	O
10	bp	O
11	)	O
12	long	O
13	,	O
14	and	O
15	,	O
16	like	O
17	other	O
18	members	O
19	of	O
20	the	O
21	SIG	B
22	family	I
23	,	O
24	the	O
25	beta	B
26	TG	I
27	gene	I
28	is	O
29	divided	O
30	into	O
31	3	O
32	exons	O
33	.	O
1	Furthermore	O
2	,	O
3	the	O
4	UvrA	B
5	protein	I
6	interacts	O
7	with	O
8	the	O
9	UvrB	B
10	protein	I
11	to	O
12	modulate	O
13	its	O
14	activities	O
15	,	O
16	both	O
17	in	O
18	solution	O
19	and	O
20	in	O
21	association	O
22	with	O
23	DNA	O
24	,	O
25	where	O
26	the	O
27	UvrAB	B
28	complex	I
29	possesses	O
30	a	O
31	helicase	B
32	activity	O
33	.	O
1	The	O
2	ED30	O
3	values	O
4	were	O
5	2	O
6	.	O
7	4	O
8	and	O
9	2	O
10	.	O
11	2	O
12	mg	O
13	/	O
14	kg	O
15	and	O
16	similar	O
17	to	O
18	the	O
19	respective	O
20	values	O
21	of	O
22	nifedipine	O
23	(	O
24	ED	O
25	30	O
26	:	O
27	2	O
28	.	O
29	4	O
30	,	O
31	2	O
32	.	O
33	1	O
34	mg	O
35	/	O
36	kg	O
37	).	O
1	Southwestern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	that	O
6	this	O
7	phosphoprotein	O
8	can	O
9	bind	O
10	the	O
11	kappa	B
12	B	I
13	element	I
14	directly	O
15	and	O
16	specifically	O
17	.	O
1	It	O
2	is	O
3	transparent	O
4	,	O
5	cheap	O
6	to	O
7	be	O
8	made	O
9	,	O
10	and	O
11	easy	O
12	to	O
13	empty	O
14	and	O
15	was	O
16	tested	O
17	in	O
18	118	O
19	animals	O
20	for	O
21	two	O
22	and	O
23	four	O
24	weeks	O
25	.	O
1	The	O
2	Thr161Val	O
3	mutation	O
4	causes	O
5	a	O
6	lethal	O
7	phenotype	O
8	in	O
9	the	O
10	fission	O
11	yeast	O
12	Schizosaccharomyces	O
13	pombe	O
14	,	O
15	while	O
16	replacement	O
17	of	O
18	Thr161	O
19	with	O
20	glutamic	O
21	acid	O
22	,	O
23	potentially	O
24	mimicking	O
25	phosphorylation	O
26	,	O
27	causes	O
28	uncoordination	O
29	of	O
30	mitosis	O
31	and	O
32	multiple	O
33	cytokinesis	O
34	.	O
1	The	O
2	RNA	O
3	genome	O
4	of	O
5	rabbit	O
6	hemorrhagic	O
7	disease	O
8	virus	O
9	(	O
10	RHDV	O
11	)	O
12	was	O
13	molecularly	O
14	cloned	O
15	.	O
1	However	O
2	,	O
3	the	O
4	relative	O
5	positions	O
6	of	O
7	the	O
8	VV	O
9	genes	O
10	(	O
11	genus	O
12	Orthopoxvirus	O
13	)	O
14	are	O
15	different	O
16	than	O
17	those	O
18	of	O
19	the	O
20	corresponding	O
21	ORFs	O
22	in	O
23	SFV	O
24	(	O
25	genus	O
26	Leporipoxvirus	O
27	),	O
28	indicating	O
29	complex	O
30	rearrangements	O
31	of	O
32	DNA	O
33	in	O
34	the	O
35	genome	O
36	of	O
37	one	O
38	or	O
39	both	O
40	of	O
41	these	O
42	viruses	O
43	subsequent	O
44	to	O
45	their	O
46	divergence	O
47	from	O
48	a	O
49	common	O
50	ancestor	O
51	.	O
1	This	O
2	study	O
3	tested	O
4	the	O
5	hypothesis	O
6	that	O
7	sodium	O
8	channel	O
9	blocking	O
10	drugs	O
11	selectively	O
12	prolong	O
13	the	O
14	late	O
15	potential	O
16	,	O
17	or	O
18	terminal	O
19	low	O
20	amplitude	O
21	signal	O
22	,	O
23	portion	O
24	of	O
25	the	O
26	signal	O
27	-	O
28	averaged	O
29	QRS	O
30	complex	O
31	and	O
32	that	O
33	prolongation	O
34	of	O
35	the	O
36	late	O
37	potential	O
38	would	O
39	correlate	O
40	with	O
41	slowing	O
42	of	O
43	ventricular	O
44	tachycardia	O
45	.	O
1	Identification	O
2	and	O
3	nucleotide	O
4	sequence	O
5	of	O
6	Rhizobium	B
7	meliloti	I
8	insertion	I
9	sequence	I
10	ISRm3	I
11	:	O
12	similarity	O
13	between	O
14	the	O
15	putative	O
16	transposase	B
17	encoded	O
18	by	O
19	ISRm3	B
20	and	O
21	those	O
22	encoded	O
23	by	O
24	Staphylococcus	B
25	aureus	I
26	IS256	I
27	and	O
28	Thiobacillus	B
29	ferrooxidans	I
30	IST2	I
31	.	O
1	The	O
2	rad9	B
3	.	I
4	192	I
5	DNA	I
6	repair	I
7	mutant	I
8	from	I
9	the	I
10	fission	I
11	yeast	I
12	,	I
13	Schizosaccharomyces	I
14	pombe	I
15	,	O
16	is	O
17	sensitive	O
18	to	O
19	both	O
20	UV	O
21	and	O
22	ionising	O
23	radiation	O
24	.	O
1	The	O
2	human	O
3	cDNA	O
4	was	O
5	used	O
6	to	O
7	demonstrate	O
8	that	O
9	tumor	B
10	necrosis	I
11	factor	I
12	-	I
13	alpha	I
14	could	O
15	rapidly	O
16	stimulate	O
17	MARCKS	B
18	gene	I
19	transcription	O
20	in	O
21	the	O
22	human	O
23	promyelocytic	O
24	leukemia	O
25	cell	O
26	line	O
27	HL60	O
28	.	O
1	These	O
2	features	O
3	were	O
4	considered	O
5	consistent	O
6	with	O
7	a	O
8	diagnosis	O
9	of	O
10	Rothmund	O
11	-	O
12	Thomson	O
13	syndrome	O
14	.	O
1	The	O
2	primary	O
3	structure	O
4	of	O
5	each	O
6	of	O
7	the	O
8	three	O
9	proteins	O
10	has	O
11	about	O
12	70	O
13	%	O
14	homology	O
15	with	O
16	that	O
17	of	O
18	mouse	B
19	contrapsin	I
20	,	O
21	in	O
22	contrast	O
23	to	O
24	43	O
25	-	O
26	46	O
27	%	O
28	homology	O
29	with	O
30	that	O
31	of	O
32	rat	B
33	alpha	I
34	1	I
35	-	I
36	protease	I
37	inhibitor	O
38	.	O
1	Mutation	O
2	analysis	O
3	implicated	O
4	multiple	O
5	segments	O
6	of	O
7	the	O
8	5	O
9	'	O
10	untranslated	O
11	region	O
12	as	O
13	contributing	O
14	to	O
15	the	O
16	inhibitory	O
17	effect	O
18	.	O
1	The	O
2	enzymatic	O
3	response	O
4	of	O
5	neutrophils	O
6	and	O
7	monocytes	O
8	was	O
9	similar	O
10	although	O
11	the	O
12	magnitude	O
13	of	O
14	the	O
15	NADPH	B
16	oxidase	I
17	activity	O
18	was	O
19	significantly	O
20	higher	O
21	in	O
22	neutrophils	O
23	than	O
24	in	O
25	monocytes	O
26	.	O
1	All	O
2	members	O
3	are	O
4	also	O
5	capable	O
6	of	O
7	activating	O
8	in	O
9	vivo	O
10	transcription	O
11	from	O
12	promoters	O
13	that	O
14	contain	O
15	a	O
16	C	B
17	/	I
18	EBP	I
19	-	I
20	binding	I
21	site	I
22	.	O
1	PO2	O
2	measurements	O
3	using	O
4	a	O
5	double	O
6	barrelled	O
7	recess	O
8	type	O
9	microelectrodes	O
10	were	O
11	measured	O
12	in	O
13	the	O
14	optic	O
15	nerve	O
16	head	O
17	of	O
18	miniature	O
19	pigs	O
20	in	O
21	normoxia	O
22	and	O
23	hyperoxia	O
24	.	O
1	POU	B
2	-	O
3	specific	O
4	and	O
5	POU	B
6	-	O
7	homeo	O
8	domains	O
9	of	O
10	Oct3	B
11	were	O
12	produced	O
13	in	O
14	Echerichia	O
15	coli	O
16	for	O
17	characterization	O
18	of	O
19	DNA	O
20	binding	O
21	to	O
22	the	O
23	octamer	O
24	sequence	O
25	.	O
1	Toxicity	O
2	was	O
3	very	O
4	mild	O
5	with	O
6	both	O
7	regimens	O
8	,	O
9	although	O
10	sedation	O
11	was	O
12	significantly	O
13	higher	O
14	in	O
15	arm	O
16	B	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	001	O
24	).	O
1	J	O
2	.	O
1	The	O
2	currently	O
3	proposed	O
4	extended	O
5	arch	O
6	repair	O
7	should	O
8	be	O
9	reserved	O
10	for	O
11	the	O
12	small	O
13	group	O
14	of	O
15	infants	O
16	with	O
17	transverse	O
18	aortic	O
19	arch	O
20	to	O
21	ascending	O
22	aorta	O
23	diameter	O
24	ratios	O
25	(	O
26	arch	O
27	indices	O
28	)	O
29	of	O
30	less	O
31	than	O
32	0	O
33	.	O
34	25	O
35	.	O
1	Increases	O
2	in	O
3	the	O
4	perfusate	O
5	PCO2	O
6	but	O
7	not	O
8	in	O
9	the	O
10	perfusate	O
11	H	O
12	+	O
13	were	O
14	highly	O
15	correlated	O
16	with	O
17	decreases	O
18	in	O
19	both	O
20	myocardial	O
21	contractility	O
22	and	O
23	oxygen	O
24	consumption	O
25	(	O
26	r2	O
27	=	O
28	.	O
29	88	O
30	).	O
1	Analysis	O
2	of	O
3	mRNA	O
4	expression	O
5	shows	O
6	that	O
7	AT	B
8	-	I
9	BP1	I
10	and	O
11	AT	B
12	-	I
13	BP2	I
14	are	O
15	expressed	O
16	in	O
17	all	O
18	the	O
19	tissues	O
20	examined	O
21	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	human	B
16	nidogen	I
17	gene	I
18	.	O
1	Ventilatory	O
2	management	O
3	casebook	O
4	.	O
1	An	O
2	ASSEMBLER	O
3	routine	O
4	for	O
5	on	O
6	-	O
7	line	O
8	graphic	O
9	display	O
10	and	O
11	averaging	O
12	of	O
13	data	O
14	acquired	O
15	on	O
16	a	O
17	personal	O
18	microcomputer	O
19	.	O
1	Position	O
2	22	O
3	is	O
4	an	O
5	isoleucine	O
6	in	O
7	the	O
8	complete	B
9	SsoL12	I
10	protein	I
11	sequence	I
12	,	O
13	coded	O
14	by	O
15	an	O
16	AUA	O
17	codon	O
18	.	O
1	Twenty	O
2	-	O
3	four	O
4	hours	O
5	later	O
6	,	O
7	the	O
8	animals	O
9	were	O
10	randomized	O
11	to	O
12	subretinal	O
13	treatment	O
14	with	O
15	2	O
16	.	O
17	5	O
18	micrograms	O
19	of	O
20	tissue	B
21	plasminogen	I
22	activator	I
23	or	O
24	a	O
25	similar	O
26	volume	O
27	of	O
28	physiologic	O
29	saline	O
30	.	O
1	Neuro	O
2	-	O
3	otological	O
4	examinations	O
5	revealed	O
6	spontaneous	O
7	downbeat	O
8	nystagmus	O
9	,	O
10	bilateral	O
11	gaze	O
12	nystagmus	O
13	and	O
14	rebound	O
15	nystagmus	O
16	.	O
1	Equine	O
2	amnion	O
3	and	O
4	live	O
5	yeast	O
6	cell	O
7	derivative	O
8	were	O
9	evaluated	O
10	as	O
11	a	O
12	biological	O
13	dressing	O
14	and	O
15	as	O
16	a	O
17	topical	O
18	wound	O
19	medicament	O
20	respectively	O
21	,	O
22	in	O
23	the	O
24	treatment	O
25	of	O
26	granulating	O
27	wounds	O
28	of	O
29	the	O
30	distal	O
31	portion	O
32	of	O
33	the	O
34	limbs	O
35	of	O
36	horses	O
37	.	O
1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	responses	O
5	are	O
6	impaired	O
7	in	O
8	heart	O
9	failure	O
10	.	O
1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	exercise	O
5	responses	O
6	are	O
7	attenuated	O
8	in	O
9	heart	O
10	failure	O
11	.	O
1	Evaluation	O
2	of	O
3	antiepileptic	O
4	drug	O
5	effect	O
6	on	O
7	membrane	O
8	fluidity	O
9	.	O
1	This	O
2	generalization	O
3	of	O
4	MFP	O
5	involves	O
6	defining	O
7	an	O
8	appropriate	O
9	high	O
10	-	O
11	resolution	O
12	cost	O
13	function	O
14	,	O
15	parametrizing	O
16	the	O
17	search	O
18	space	O
19	of	O
20	the	O
21	environment	O
22	and	O
23	source	O
24	,	O
25	constructing	O
26	solutions	O
27	of	O
28	the	O
29	wave	O
30	equation	O
31	,	O
32	and	O
33	utilizing	O
34	a	O
35	nonlinear	O
36	optimization	O
37	method	O
38	to	O
39	search	O
40	the	O
41	parameter	O
42	landscape	O
43	for	O
44	the	O
45	global	O
46	minimum	O
47	of	O
48	the	O
49	cost	O
50	function	O
51	.	O
1	Toluene	O
2	is	O
3	the	O
4	chemical	O
5	most	O
6	frequently	O
7	present	O
8	in	O
9	cases	O
10	involving	O
11	volatile	O
12	solvents	O
13	.	O
1	Adult	O
2	H	O
3	,	O
4	but	O
5	not	O
6	R	O
7	,	O
8	manifested	O
9	the	O
10	burrowing	O
11	preference	O
12	whenever	O
13	offered	O
14	the	O
15	opportunity	O
16	.	O
1	Sci	O
2	.	O
1	This	O
2	study	O
3	suggests	O
4	that	O
5	BSPMs	O
6	are	O
7	useful	O
8	in	O
9	the	O
10	assessment	O
11	of	O
12	AMI	O
13	in	O
14	terms	O
15	of	O
16	diagnosis	O
17	,	O
18	location	O
19	and	O
20	extent	O
21	of	O
22	myocardial	O
23	infarct	O
24	.	O
1	Combined	O
2	therapy	O
3	with	O
4	MK	O
5	-	O
6	801	O
7	and	O
8	nimodipine	O
9	for	O
10	protection	O
11	of	O
12	ischemic	O
13	brain	O
14	damage	O
15	.	O
1	Cloning	O
2	,	O
3	expression	O
4	,	O
5	and	O
6	nucleotide	O
7	sequence	O
8	of	O
9	rat	B
10	liver	I
11	sterol	I
12	carrier	I
13	protein	I
14	2	I
15	cDNAs	I
16	.	O
1	We	O
2	report	O
3	here	O
4	the	O
5	identification	O
6	of	O
7	HSF	B
8	in	O
9	the	O
10	fission	O
11	yeast	O
12	Schizosaccharomyces	O
13	pombe	O
14	.	O
1	Immunophenotyping	O
2	in	O
3	four	O
4	cases	O
5	,	O
6	demonstrated	O
7	non	O
8	-	O
9	B	O
10	,	O
11	non	O
12	-	O
13	T	O
14	cell	O
15	origin	O
16	in	O
17	three	O
18	and	O
19	pre	O
20	-	O
21	B	O
22	cell	O
23	origin	O
24	in	O
25	one	O
26	.	O
1	DNA	O
2	-	O
3	protein	O
4	UV	O
5	cross	O
6	-	O
7	linking	O
8	studies	O
9	indicated	O
10	that	O
11	UHF	B
12	-	I
13	1	I
14	has	O
15	an	O
16	electrophoretic	O
17	mobility	O
18	on	O
19	sodium	O
20	dodecyl	O
21	sulfate	O
22	-	O
23	acrylamide	O
24	gels	O
25	of	O
26	approximately	O
27	85	O
28	kDa	O
29	and	O
30	suggested	O
31	that	O
32	additional	O
33	proteins	O
34	,	O
35	specific	O
36	to	O
37	each	O
38	promoter	O
39	,	O
40	bind	O
41	to	O
42	each	O
43	site	O
44	.	O
1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	Pseudomonas	B
7	putida	I
8	PpG7	I
9	salicylate	I
10	hydroxylase	I
11	gene	I
12	(	O
13	nahG	B
14	)	O
15	and	O
16	its	O
17	3	O
18	'-	O
19	flanking	O
20	region	O
21	.	O
1	In	O
2	summary	O
3	,	O
4	at	O
5	equianesthetic	O
6	concentrations	O
7	,	O
8	desflurane	O
9	and	O
10	isoflurane	O
11	produced	O
12	similar	O
13	hemodynamic	O
14	effects	O
15	;	O
16	however	O
17	,	O
18	in	O
19	the	O
20	absence	O
21	of	O
22	drugs	O
23	that	O
24	inhibit	O
25	autonomic	O
26	reflexes	O
27	,	O
28	desflurane	O
29	had	O
30	less	O
31	negative	O
32	inotropic	O
33	activity	O
34	and	O
35	produced	O
36	less	O
37	decrease	O
38	in	O
39	arterial	O
40	pressure	O
41	.	O
1	Displacement	O
2	thresholds	O
3	of	O
4	peripheral	O
5	sites	O
6	in	O
7	monocular	O
8	human	O
9	vision	O
10	were	O
11	obtained	O
12	.	O
1	No	O
2	positive	O
3	family	O
4	history	O
5	was	O
6	obtained	O
7	.	O
1	A	O
2	further	O
3	subdivision	O
4	of	O
5	Category	O
6	pN1	O
7	into	O
8	pN1a	O
9	(	O
10	metastasis	O
11	in	O
12	single	O
13	node	O
14	)	O
15	and	O
16	pN1b	O
17	(	O
18	two	O
19	or	O
20	more	O
21	nodes	O
22	)	O
23	is	O
24	recommended	O
25	.	O
1	After	O
2	6	O
3	months	O
4	,	O
5	definite	O
6	improvement	O
7	in	O
8	strength	O
9	occurred	O
10	in	O
11	4	O
12	of	O
13	7	O
14	carnitine	O
15	-	O
16	treated	O
17	patients	O
18	and	O
19	in	O
20	none	O
21	of	O
22	7	O
23	controls	O
24	.	O
1	Age	O
2	at	O
3	POI	O
4	and	O
5	asymptote	O
6	were	O
7	achieved	O
8	later	O
9	for	O
10	Line	O
11	RBC2	O
12	than	O
13	for	O
14	Line	O
15	F	O
16	.	O
1	The	O
2	CDC7	B
3	gene	I
4	has	O
5	two	O
6	in	O
7	-	O
8	frame	O
9	AUG	O
10	codons	O
11	as	O
12	possible	O
13	translation	O
14	start	O
15	sites	O
16	,	O
17	which	O
18	would	O
19	produce	O
20	58	O
21	-	O
22	and	O
23	56	O
24	-	O
25	kDa	O
26	proteins	O
27	,	O
28	respectively	O
29	.	O
1	During	O
2	the	O
3	years	O
4	1980	O
5	-	O
6	87	O
7	a	O
8	total	O
9	of	O
10	287	O
11	persons	O
12	received	O
13	disability	O
14	pensions	O
15	in	O
16	the	O
17	municipality	O
18	of	O
19	Nordreisa	O
20	in	O
21	northern	O
22	Norway	O
23	.	O
1	We	O
2	purified	O
3	a	O
4	Ca2	B
5	+/	I
6	calmodulin	I
7	(	I
8	CaM	I
9	)-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	O
14	CaM	B
15	kinase	I
16	)	O
17	from	O
18	the	O
19	yeast	O
20	Saccharomyces	O
21	cerevisiae	O
22	with	O
23	properties	O
24	similar	O
25	to	O
26	mammalian	B
27	type	I
28	II	I
29	CaM	I
30	kinases	I
31	.	O
1	The	O
2	muscles	O
3	from	O
4	the	O
5	ischemic	O
6	group	O
7	had	O
8	significantly	O
9	lower	O
10	(	O
11	P	O
12	less	O
13	than	O
14	.	O
15	05	O
16	)	O
17	values	O
18	for	O
19	capillary	O
20	density	O
21	and	O
22	capillary	O
23	to	O
24	fiber	O
25	ratio	O
26	and	O
27	significantly	O
28	higher	O
29	intercapillary	O
30	distance	O
31	than	O
32	those	O
33	from	O
34	the	O
35	normal	O
36	group	O
37	.	O
1	Most	O
2	of	O
3	the	O
4	expressed	O
5	human	B
6	E3	I
7	polypeptides	I
8	(	O
9	five	O
10	bands	O
11	)	O
12	were	O
13	found	O
14	in	O
15	the	O
16	insoluble	O
17	pellet	O
18	while	O
19	primarily	O
20	full	B
21	-	I
22	length	I
23	mature	I
24	E3	I
25	was	O
26	found	O
27	in	O
28	the	O
29	soluble	O
30	fraction	O
31	.	O
1	The	O
2	alpha	B
3	4	I
4	gene	I
5	5	O
6	'	O
7	flanking	O
8	region	O
9	acted	O
10	as	O
11	a	O
12	promoter	O
13	in	O
14	transfection	O
15	assays	O
16	.	O
1	Only	O
2	the	O
3	3	O
4	.	O
5	0	O
6	-	O
7	kb	O
8	transcript	O
9	was	O
10	detected	O
11	in	O
12	adult	O
13	tissues	O
14	,	O
15	where	O
16	its	O
17	expression	O
18	was	O
19	restricted	O
20	almost	O
21	exclusively	O
22	to	O
23	the	O
24	central	O
25	nervous	O
26	system	O
27	.	O
1	To	O
2	measure	O
3	the	O
4	enhancer	O
5	activity	O
6	of	O
7	DR60	B
8	,	O
9	a	O
10	reporter	O
11	plasmid	O
12	was	O
13	constructed	O
14	that	O
15	contained	O
16	DR60	B
17	cloned	O
18	upstream	O
19	of	O
20	the	O
21	reporter	O
22	chloramphenicol	B
23	acetyltransferase	I
24	gene	I
25	under	O
26	the	O
27	control	O
28	of	O
29	the	O
30	delayed	O
31	-	O
32	early	O
33	39K	O
34	promoter	O
35	.	O
1	To	O
2	facilitate	O
3	the	O
4	availability	O
5	of	O
6	important	O
7	new	O
8	therapeutic	O
9	agents	O
10	,	O
11	the	O
12	Food	O
13	and	O
14	Drug	O
15	Administration	O
16	(	O
17	FDA	O
18	)	O
19	in	O
20	the	O
21	mid	O
22	-	O
23	1970s	O
24	began	O
25	assigning	O
26	therapeutic	O
27	ratings	O
28	to	O
29	investigational	O
30	new	O
31	drugs	O
32	and	O
33	holding	O
34	end	O
35	-	O
36	of	O
37	-	O
38	phase	O
39	II	O
40	conferences	O
41	with	O
42	drug	O
43	sponsors	O
44	.	O
1	The	O
2	standard	O
3	principles	O
4	of	O
5	surgical	O
6	management	O
7	must	O
8	be	O
9	adhered	O
10	to	O
11	when	O
12	using	O
13	Sandostatin	O
14	to	O
15	treat	O
16	patients	O
17	with	O
18	these	O
19	disorders	O
20	.	O
1	The	O
2	sequence	O
3	of	O
4	the	O
5	pMxL1	O
6	plasmid	O
7	containing	O
8	the	O
9	invertible	O
10	region	O
11	contains	O
12	a	O
13	perfect	O
14	tandem	O
15	repeat	O
16	of	O
17	19	O
18	bp	O
19	in	O
20	the	O
21	orientation	O
22	1	O
23	nonexpressed	O
24	pilin	B
25	gene	I
26	at	O
27	the	O
28	middle	O
29	of	O
30	the	O
31	recombination	O
32	junction	O
33	site	O
34	.	O
1	Hypoxic	O
2	ventilatory	O
3	responses	O
4	were	O
5	-	O
6	1	O
7	.	O
8	99	O
9	+/-	O
10	0	O
11	.	O
12	37	O
13	L	O
14	/	O
15	min	O
16	/%	O
17	SaO2	O
18	in	O
19	the	O
20	relatives	O
21	and	O
22	-	O
23	1	O
24	.	O
25	54	O
26	+/-	O
27	0	O
28	.	O
29	25	O
30	L	O
31	/	O
32	min	O
33	/%	O
34	SaO2	O
35	in	O
36	the	O
37	control	O
38	subjects	O
39	.(	O
40	ABSTRACT	O
41	TRUNCATED	O
42	AT	O
43	250	O
44	WORDS	O
45	)	O
1	This	O
2	computerized	O
3	list	O
4	was	O
5	linked	O
6	to	O
7	the	O
8	central	O
9	files	O
10	of	O
11	the	O
12	Massachusetts	O
13	Cancer	O
14	Registry	O
15	and	O
16	cases	O
17	diagnosed	O
18	between	O
19	1982	O
20	and	O
21	1988	O
22	were	O
23	identified	O
24	.	O
1	After	O
2	hemodynamic	O
3	stabilization	O
4	,	O
5	the	O
6	goal	O
7	of	O
8	therapy	O
9	is	O
10	to	O
11	diminish	O
12	the	O
13	chance	O
14	that	O
15	an	O
16	ulcer	O
17	will	O
18	continue	O
19	to	O
20	bleed	O
21	or	O
22	will	O
23	rebleed	O
24	.	O
1	Phosphopeptide	O
2	mapping	O
3	revealed	O
4	the	O
5	same	O
6	autophosphorylation	O
7	sites	O
8	utilized	O
9	by	O
10	EGFR	B
11	-	I
12	IC	I
13	as	O
14	those	O
15	identified	O
16	in	O
17	wild	B
18	-	I
19	type	I
20	EGFR	I
21	.	O
1	Effect	O
2	of	O
3	separate	O
4	and	O
5	combined	O
6	effects	O
7	of	O
8	plutonium	O
9	-	O
10	239	O
11	,	O
12	hexachlorobutadiene	O
13	and	O
14	tributyl	O
15	phosphate	O
16	on	O
17	the	O
18	thymus	O
19	gland	O
20	of	O
21	rats	O
1	ARPIA	O
2	has	O
3	been	O
4	implemented	O
5	by	O
6	using	O
7	a	O
8	relational	O
9	DBMS	O
10	,	O
11	very	O
12	cheap	O
13	and	O
14	highly	O
15	diffused	O
16	on	O
17	personal	O
18	computers	O
19	.	O
1	Spore	O
2	inocula	O
3	(	O
4	approximately	O
5	10	O
6	(	O
7	6	O
8	)/	O
9	coupon	O
10	)	O
11	were	O
12	dried	O
13	onto	O
14	0	O
15	.	O
16	5	O
17	-	O
18	in	O
19	.	O
1	The	O
2	interindividual	O
3	variability	O
4	of	O
5	the	O
6	parameters	O
7	is	O
8	taken	O
9	into	O
10	consideration	O
11	by	O
12	interactively	O
13	determining	O
14	the	O
15	threshold	O
16	levels	O
17	.	O
1	Expression	O
2	,	O
3	nucleotide	O
4	sequence	O
5	and	O
6	mutational	O
7	analysis	O
8	of	O
9	two	O
10	open	O
11	reading	O
12	frames	O
13	in	O
14	the	O
15	nif	B
16	gene	I
17	region	I
18	of	I
19	Anabaena	I
20	sp	I
21	.	I
22	strain	I
23	PCC7120	I
24	.	O
1	We	O
2	also	O
3	discovered	O
4	a	O
5	V	B
6	lambda	I
7	pseudogene	I
8	,	O
9	called	O
10	psi	B
11	V	I
12	lambda	I
13	1	I
14	,	O
15	3	O
16	kb	O
17	upstream	O
18	of	O
19	the	O
20	U266	B
21	lambda	I
22	gene	I
23	.	O
1	But	O
2	no	O
3	influence	O
4	was	O
5	observed	O
6	at	O
7	lower	O
8	concentrations	O
9	than	O
10	1	O
11	/	O
12	4	O
13	MIC	O
14	of	O
15	AMK	O
16	.	O
1	Uses	O
2	of	O
3	orthoclone	O
4	OKT3	B
5	for	O
6	prophylaxis	O
7	of	O
8	rejection	O
9	and	O
10	induction	O
11	in	O
12	initial	O
13	nonfunction	O
14	in	O
15	kidney	O
16	transplantation	O
17	.	O
1	Five	O
2	of	O
3	10	O
4	scars	O
5	studied	O
6	decreased	O
7	at	O
8	least	O
9	50	O
10	%	O
11	in	O
12	linear	O
13	dimensions	O
14	.	O
1	Gel	O
2	-	O
3	mobility	O
4	-	O
5	shift	O
6	assays	O
7	confirmed	O
8	that	O
9	the	O
10	Raji	O
11	nuclear	O
12	proteins	O
13	that	O
14	bound	O
15	to	O
16	W	O
17	and	O
18	V	O
19	elements	O
20	were	O
21	competed	O
22	with	O
23	by	O
24	an	O
25	HLA	B
26	-	I
27	DRA	I
28	X	I
29	-	I
30	box	I
31	oligonucleotide	I
32	.	O
1	PBSX	B
2	is	O
3	induced	O
4	by	O
5	agents	O
6	which	O
7	elicit	O
8	the	O
9	SOS	O
10	response	O
11	.	O
1	In	O
2	the	O
3	controls	O
4	,	O
5	it	O
6	was	O
7	found	O
8	that	O
9	all	O
10	right	O
11	-	O
12	handed	O
13	and	O
14	10	O
15	out	O
16	of	O
17	14	O
18	left	O
19	-	O
20	handed	O
21	control	O
22	subjects	O
23	showed	O
24	a	O
25	right	O
26	VHF	O
27	(	O
28	i	O
29	.	O
30	e	O
31	.,	O
32	left	O
33	hemisphere	O
34	)	O
35	advantage	O
36	.	O
1	Although	O
2	no	O
3	Rh	B
4	-	I
5	antibodies	I
6	were	O
7	demonstrable	O
8	,	O
9	a	O
10	similar	O
11	mechanism	O
12	can	O
13	be	O
14	postulated	O
15	for	O
16	the	O
17	Rh	O
18	-	O
19	system	O
20	.	O
1	Higher	O
2	fasting	O
3	serum	O
4	gastrin	B
5	concentration	O
6	(	O
7	102	O
8	.	O
9	0	O
10	+/-	O
11	21	O
12	.	O
13	1	O
14	vs	O
15	63	O
16	.	O
17	3	O
18	+/-	O
19	8	O
20	.	O
21	3	O
22	ng	O
23	.	O
24	l	O
25	-	O
26	1	O
27	),	O
28	and	O
29	greater	O
30	postprandial	O
31	gastrin	B
32	release	O
33	(	O
34	AUC0	O
35	-	O
36	120	O
37	:	O
38	16690	O
39	+/-	O
40	2648	O
41	vs	O
42	10654	O
43	+/-	O
44	1283	O
45	ng	O
46	.	O
47	l	O
48	-	O
49	1	O
50	min	O
51	)	O
52	were	O
53	observed	O
54	after	O
55	VTP	O
56	-	O
57	HM	O
58	than	O
59	after	O
60	VTP	O
61	-	O
62	Cas	O
63	.	O
1	A	O
2	needs	O
3	assessment	O
4	of	O
5	these	O
6	families	O
7	was	O
8	also	O
9	done	O
10	.	O
1	We	O
2	have	O
3	isolated	O
4	and	O
5	sequenced	O
6	the	O
7	gene	O
8	encoding	O
9	the	O
10	human	B
11	U1	I
12	-	I
13	70K	I
14	snRNP	I
15	protein	I
16	.	O
1	Fluid	O
2	(	O
3	AVLF	O
4	)	O
5	31	O
6	.	O
1	The	O
2	nmr	B
3	gene	I
4	is	O
5	the	O
6	major	O
7	negative	O
8	regulatory	O
9	gene	O
10	in	O
11	the	O
12	nitrogen	O
13	control	O
14	circuit	O
15	of	O
16	Neurospora	O
17	crassa	O
18	,	O
19	which	O
20	,	O
21	together	O
22	with	O
23	positive	O
24	regulatory	O
25	genes	O
26	,	O
27	governs	O
28	the	O
29	expression	O
30	of	O
31	multiple	O
32	unlinked	O
33	structural	O
34	genes	O
35	of	O
36	the	O
37	circuit	O
38	.	O
1	Cutaneous	O
2	necrosis	O
3	associated	O
4	with	O
5	protein	B
6	S	I
7	deficiency	O
8	.	O
1	Mean	O
2	ROI	O
3	-	O
4	A	O
5	/	O
6	B	O
7	ratio	O
8	was	O
9	49	O
10	.	O
11	6	O
12	+/-	O
13	1	O
14	.	O
15	7	O
16	%	O
17	in	O
18	the	O
19	diabetic	O
20	group	O
21	,	O
22	significantly	O
23	lower	O
24	than	O
25	the	O
26	57	O
27	.	O
28	9	O
29	+/-	O
30	1	O
31	.	O
32	6	O
33	%	O
34	at	O
35	the	O
36	nondiabetic	O
37	group	O
38	(	O
39	p	O
40	less	O
41	than	O
42	0	O
43	.	O
44	005	O
45	).	O
1	The	O
2	PC2	B
3	protein	I
4	also	O
5	shows	O
6	great	O
7	similarity	O
8	to	O
9	the	O
10	incomplete	O
11	NH2	O
12	-	O
13	terminal	O
14	sequence	O
15	of	O
16	the	O
17	human	B
18	furin	I
19	gene	I
20	product	I
21	,	O
22	a	O
23	putative	O
24	membrane	O
25	-	O
26	inserted	O
27	receptor	O
28	-	O
29	like	O
30	molecule	O
31	.	O
1	Fragments	O
2	containing	O
3	the	O
4	21	O
5	-	O
6	base	O
7	-	O
8	pair	O
9	repeat	O
10	region	O
11	,	O
12	the	O
13	enhancer	B
14	of	I
15	simian	I
16	virus	I
17	40	I
18	or	O
19	both	O
20	strongly	O
21	stimulated	O
22	beta	B
23	-	I
24	galactosidase	I
25	synthesis	O
26	,	O
27	and	O
28	three	O
29	fragments	O
30	from	O
31	the	O
32	polyomavirus	B
33	enhancer	I
34	region	I
35	stimulated	O
36	moderate	O
37	levels	O
38	.	O
1	The	O
2	possible	O
3	benefits	O
4	of	O
5	LMW	O
6	heparin	O
7	(	O
8	reduced	O
9	frequency	O
10	of	O
11	bleeding	O
12	,	O
13	alleviation	O
14	of	O
15	hypertriglyceridemia	O
16	)	O
17	were	O
18	not	O
19	,	O
20	however	O
21	,	O
22	apparent	O
23	,	O
24	possibly	O
25	because	O
26	of	O
27	the	O
28	short	O
29	observation	O
30	period	O
31	and	O
32	the	O
33	low	O
34	incidence	O
35	of	O
36	hemorrhagic	O
37	complications	O
38	in	O
39	routine	O
40	dialyses	O
41	.	O
1	We	O
2	cloned	O
3	and	O
4	sequenced	O
5	the	O
6	cDNAs	O
7	against	O
8	genomic	O
9	RNA	O
10	and	O
11	mRNA	O
12	for	O
13	phosphoprotein	B
14	(	I
15	P	I
16	)	I
17	of	O
18	human	O
19	parainfluenza	O
20	type	O
21	2	O
22	virus	O
23	(	O
24	PIV	O
25	-	O
26	2	O
27	).	O
28	cDNA	O
29	clone	O
30	from	O
31	genomic	O
32	RNA	O
33	was	O
34	1439	O
35	nucleotides	O
36	in	O
37	length	O
38	excluding	O
39	poly	O
40	(	O
41	A	O
42	)	O
43	and	O
44	was	O
45	found	O
46	to	O
47	have	O
48	two	O
49	small	O
50	open	O
51	reading	O
52	frames	O
53	encoding	O
54	proteins	O
55	of	O
56	233	O
57	and	O
58	249	O
59	amino	O
60	acids	O
61	.	O
1	Our	O
2	studies	O
3	extend	O
4	these	O
5	findings	O
6	and	O
7	show	O
8	that	O
9	the	O
10	E2	B
11	transactivation	I
12	gene	I
13	is	O
14	expressed	O
15	from	O
16	multiple	O
17	promoters	O
18	.	O
1	Disruption	O
2	of	O
3	the	O
4	IRA2	B
5	gene	I
6	resulted	O
7	in	O
8	(	O
9	i	O
10	)	O
11	increased	O
12	sensitivity	O
13	to	O
14	heat	O
15	shock	O
16	and	O
17	nitrogen	O
18	starvation	O
19	,	O
20	(	O
21	ii	O
22	)	O
23	sporulation	O
24	defects	O
25	,	O
26	and	O
27	(	O
28	iii	O
29	)	O
30	suppression	O
31	of	O
32	the	O
33	lethality	O
34	of	O
35	the	O
36	cdc25	B
37	mutant	I
38	.	O
1	Five	O
2	healthy	O
3	male	O
4	subjects	O
5	inspired	O
6	air	O
7	for	O
8	20	O
9	min	O
10	and	O
11	then	O
12	5	O
13	%	O
14	CO2	O
15	/	O
16	95	O
17	%	O
18	O2	O
19	for	O
20	30	O
21	min	O
22	,	O
23	of	O
24	which	O
25	the	O
26	first	O
27	10	O
28	min	O
29	was	O
30	used	O
31	to	O
32	achieve	O
33	a	O
34	steady	O
35	-	O
36	state	O
37	end	O
38	-	O
39	tidal	O
40	CO2	O
41	measurement	O
42	.	O
1	Immunohistochemical	O
2	analysis	O
3	of	O
4	several	O
5	rat	O
6	organs	O
7	also	O
8	showed	O
9	staining	O
10	in	O
11	epithelial	O
12	cells	O
13	.	O
1	Both	O
2	strains	O
3	grew	O
4	very	O
5	poorly	O
6	,	O
7	or	O
8	not	O
9	at	O
10	all	O
11	,	O
12	on	O
13	nonfermentable	O
14	carbon	O
15	sources	O
16	and	O
17	exhibited	O
18	,	O
19	at	O
20	most	O
21	,	O
22	only	O
23	5	O
24	%	O
25	of	O
26	wild	B
27	-	I
28	type	I
29	ubiquinol	I
30	-	I
31	cytochrome	I
32	c	I
33	oxidoreductase	I
34	activity	O
35	.	O
1	Regulation	O
2	of	O
3	irgA	B
4	by	O
5	iron	O
6	in	O
7	V	O
8	.	O
9	cholerae	O
10	occurs	O
11	at	O
12	the	O
13	transcriptional	O
14	level	O
15	,	O
16	and	O
17	there	O
18	is	O
19	an	O
20	interrupted	O
21	dyad	O
22	symmetric	O
23	sequence	O
24	in	O
25	the	O
26	vicinity	O
27	of	O
28	the	O
29	promoter	O
30	that	O
31	is	O
32	homologous	O
33	to	O
34	Fur	B
35	binding	I
36	sites	I
37	of	O
38	E	O
39	.	O
40	coli	O
41	.	O
1	However	O
2	,	O
3	primary	O
4	transcripts	O
5	of	O
6	a	O
7	variant	B
8	tRNA	I
9	(	I
10	Val	I
11	)(	I
12	UAC	I
13	)	I
14	gene	I
15	are	O
16	processing	O
17	deficient	O
18	under	O
19	standard	O
20	growth	O
21	conditions	O
22	(	O
23	30	O
24	degrees	O
25	C	O
26	),	O
27	due	O
28	to	O
29	a	O
30	slightly	O
31	altered	O
32	5	O
33	'	O
34	flanking	O
35	region	O
36	.	O
1	Pulmonary	O
2	vascular	O
3	resistance	O
4	was	O
5	not	O
6	altered	O
7	,	O
8	ejection	O
9	fraction	O
10	remained	O
11	unchanged	O
12	and	O
13	isovolumic	O
14	relaxation	O
15	period	O
16	was	O
17	lengthened	O
18	(	O
19	119	O
20	+/-	O
21	20	O
22	.	O
23	1	O
24	to	O
25	147	O
26	.	O
27	39	O
28	+/-	O
29	21	O
30	.	O
31	15	O
32	,	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O
1	This	O
2	emancipation	O
3	of	O
4	the	O
5	ability	O
6	to	O
7	copulate	O
8	from	O
9	hormonal	O
10	influence	O
11	makes	O
12	female	O
13	sexual	O
14	motivation	O
15	the	O
16	primary	O
17	regulator	O
18	of	O
19	mating	O
20	in	O
21	primates	O
22	.	O
1	Since	O
2	general	B
3	regulatory	I
4	factor	I
5	I	I
6	(	O
7	GRFI	B
8	)/	O
9	repressor	B
10	/	I
11	activator	I
12	site	I
13	binding	I
14	protein	I
15	1	I
16	(	O
17	RAP1	B
18	)/	O
19	translation	B
20	upstream	I
21	factor	I
22	(	O
23	TUF	B
24	)	O
25	is	O
26	believed	O
27	to	O
28	be	O
29	an	O
30	activator	O
31	of	O
32	MAT	B
33	alpha	I
34	expression	O
35	,	O
36	we	O
37	examined	O
38	whether	O
39	PYK1	B
40	,	O
41	which	O
42	is	O
43	known	O
44	to	O
45	be	O
46	regulated	O
47	by	O
48	GRFI	B
49	/	O
50	RAP1	B
51	/	O
52	TUF	B
53	,	O
54	is	O
55	also	O
56	affected	O
57	by	O
58	the	O
59	gal11	B
60	mutation	I
61	.	O
1	This	O
2	gene	O
3	joins	O
4	the	O
5	group	O
6	of	O
7	genes	O
8	whose	O
9	members	O
10	are	O
11	rapidly	O
12	transcribed	O
13	in	O
14	response	O
15	to	O
16	insulin	B
17	and	O
18	other	O
19	mitogens	O
20	.	O
1	Pups	O
2	placed	O
3	into	O
4	the	O
5	novel	O
6	environment	O
7	with	O
8	their	O
9	mothers	O
10	exhibited	O
11	an	O
12	intermediate	O
13	level	O
14	of	O
15	DA	O
16	turnover	O
17	.	O
1	The	O
2	efficacy	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	novel	O
8	percutaneous	O
9	anaesthetic	O
10	preparation	O
11	based	O
12	on	O
13	amethocaine	O
14	has	O
15	been	O
16	investigated	O
17	in	O
18	the	O
19	paediatric	O
20	clinical	O
21	environment	O
22	.	O
1	The	O
2	effects	O
3	of	O
4	coenzyme	O
5	Q10	O
6	(	O
7	CoQ	O
8	)	O
9	and	O
10	captopril	O
11	on	O
12	functional	O
13	capacity	O
14	,	O
15	hemodynamics	O
16	and	O
17	survival	O
18	were	O
19	studied	O
20	in	O
21	154	O
22	rats	O
23	that	O
24	recovered	O
25	after	O
26	experimental	O
27	myocardial	O
28	infarction	O
29	.	O
1	On	O
2	an	O
3	antithrombin	B
4	unit	O
5	basis	O
6	,	O
7	CY	O
8	216	O
9	and	O
10	CY	O
11	222	O
12	were	O
13	equivalent	O
14	and	O
15	more	O
16	potent	O
17	than	O
18	UH	O
19	.	O
1	Primer	O
2	extension	O
3	analysis	O
4	and	O
5	RNA	O
6	sequencing	O
7	demonstrates	O
8	that	O
9	the	O
10	transcription	O
11	start	O
12	point	O
13	of	O
14	rat	B
15	ODC	I
16	mRNA	I
17	is	O
18	located	O
19	303	O
20	nt	O
21	upstream	O
22	from	O
23	the	O
24	A	O
25	residue	O
26	in	O
27	the	O
28	start	O
29	codon	O
30	.	O
1	Giant	O
2	pilomatrix	O
3	carcinoma	O
4	:	O
5	report	O
6	and	O
7	review	O
8	of	O
9	the	O
10	literature	O
11	.	O
1	The	O
2	protooncogene	O
3	c	B
4	-	I
5	myb	I
6	encodes	O
7	a	O
8	nuclear	O
9	transcription	O
10	factor	O
11	that	O
12	binds	O
13	to	O
14	DNA	O
15	in	O
16	a	O
17	sequence	O
18	-	O
19	specific	O
20	manner	O
21	and	O
22	transactivates	O
23	transcription	O
24	of	O
25	several	O
26	viral	O
27	and	O
28	cellular	O
29	genes	O
30	.	O
1	S6	B
2	kinase	I
3	activation	O
4	requires	O
5	displacement	O
6	of	O
7	this	O
8	inhibitory	O
9	segment	O
10	,	O
11	which	O
12	is	O
13	proposed	O
14	to	O
15	occur	O
16	consequent	O
17	to	O
18	its	O
19	multiple	O
20	phosphorylation	O
21	.	O
1	Rats	O
2	with	O
3	one	O
4	olfactory	O
5	bulb	O
6	removed	O
7	and	O
8	the	O
9	contralateral	O
10	naris	O
11	closed	O
12	can	O
13	detect	O
14	odors	O
15	.	O
1	Cerebral	O
2	flow	O
3	and	O
4	resistance	O
5	showed	O
6	minor	O
7	reductions	O
8	with	O
9	HD	O
10	.	O
1	The	O
2	SUP44	B
3	suppressor	I
4	mutation	I
5	occurs	O
6	near	O
7	a	O
8	region	O
9	of	O
10	the	O
11	protein	O
12	that	O
13	corresponds	O
14	to	O
15	the	O
16	known	O
17	positions	O
18	of	O
19	alterations	O
20	in	O
21	E	B
22	.	I
23	coli	I
24	S5	I
25	ram	I
26	mutations	I
27	.	O
1	This	O
2	,	O
3	together	O
4	with	O
5	the	O
6	data	O
7	obtained	O
8	with	O
9	haloperidol	O
10	,	O
11	suggests	O
12	that	O
13	a	O
14	minimal	O
15	increase	O
16	in	O
17	the	O
18	firing	O
19	rate	O
20	of	O
21	LC	O
22	cells	O
23	(+	O
24	140	O
25	%)	O
26	is	O
27	required	O
28	before	O
29	it	O
30	could	O
31	influence	O
32	the	O
33	turnover	O
34	of	O
35	NA	O
36	,	O
37	as	O
38	measured	O
39	by	O
40	DOPAC	O
41	changes	O
42	.	O
1	For	O
2	this	O
3	,	O
4	cDNAs	O
5	containing	O
6	the	O
7	60K	O
8	,	O
9	87K	O
10	,	O
11	110K	O
12	and	O
13	170K	O
14	protein	O
15	coding	O
16	sequences	O
17	were	O
18	each	O
19	provided	O
20	with	O
21	an	O
22	ATG	O
23	start	O
24	codon	O
25	and	O
26	the	O
27	cDNA	O
28	containing	O
29	the	O
30	60K	O
31	coding	O
32	sequence	O
33	with	O
34	a	O
35	TAA	O
36	stop	O
37	codon	O
38	immediately	O
39	downstream	O
40	of	O
41	the	O
42	coding	O
43	sequence	O
44	.	O
1	The	O
2	upstream	O
3	promoter	O
4	is	O
5	located	O
6	within	O
7	the	O
8	coding	O
9	sequence	O
10	of	O
11	a	O
12	divergent	O
13	gene	O
14	expressing	O
15	a	O
16	protein	O
17	of	O
18	Mr	O
19	39	O
20	kDa	O
21	of	O
22	unknown	O
23	function	O
24	.	O
1	The	O
2	occurrence	O
3	,	O
4	maintenance	O
5	and	O
6	possible	O
7	involvement	O
8	of	O
9	these	O
10	repeated	O
11	sequences	O
12	,	O
13	capable	O
14	of	O
15	forming	O
16	stable	O
17	secondary	O
18	structures	O
19	,	O
20	are	O
21	discussed	O
22	in	O
23	relation	O
24	to	O
25	their	O
26	location	O
27	in	O
28	the	O
29	region	O
30	of	O
31	control	O
32	signals	O
33	.	O
1	Significance	O
2	of	O
3	thin	O
4	glomerular	O
5	basement	O
6	membranes	O
7	in	O
8	hematuric	O
9	children	O
10	.	O
1	Ultrastructural	O
2	and	O
3	morphometric	O
4	study	O
5	of	O
6	the	O
7	myeloid	O
8	parenchyma	O
9	cells	O
10	of	O
11	mice	O
12	prior	O
13	and	O
14	after	O
15	X	O
16	-	O
17	ray	O
18	exposure	O
1	The	O
2	mean	O
3	change	O
4	in	O
5	HbA1	B
6	,	O
7	adjusted	O
8	for	O
9	the	O
10	initial	O
11	value	O
12	,	O
13	was	O
14	-	O
15	0	O
16	.	O
17	4	O
18	%	O
19	in	O
20	the	O
21	experimental	O
22	and	O
23	+	O
24	0	O
25	.	O
26	5	O
27	%	O
28	in	O
29	the	O
30	control	O
31	group	O
32	(	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O
1	By	O
2	introducing	O
3	a	O
4	series	O
5	of	O
6	deletions	O
7	in	O
8	the	O
9	vimentin	B
10	promoter	O
11	,	O
12	we	O
13	further	O
14	restrict	O
15	these	O
16	sequences	O
17	to	O
18	30	O
19	base	O
20	pairs	O
21	,	O
22	located	O
23	between	O
24	241	O
25	and	O
26	210	O
27	base	O
28	pairs	O
29	upstream	O
30	of	O
31	the	O
32	mRNA	O
33	cap	O
34	site	O
35	.	O
1	All	O
2	89	O
3	participating	O
4	household	O
5	members	O
6	were	O
7	anti	B
8	-	I
9	HIV	I
10	seronegative	O
11	,	O
12	and	O
13	78	O
14	who	O
15	were	O
16	tested	O
17	were	O
18	serum	B
19	p24	I
20	antigen	I
21	negative	O
22	.	O
1	The	O
2	therapeutic	O
3	protocole	O
4	used	O
5	at	O
6	the	O
7	Gustave	O
8	Roussy	O
9	Institute	O
10	for	O
11	invasive	O
12	epithelioma	O
13	of	O
14	the	O
15	uterine	O
16	cervix	O
17	rests	O
18	,	O
19	for	O
20	limited	O
21	forms	O
22	(	O
23	T1B	O
24	-	O
25	T2	O
26	proximal	O
27	),	O
28	on	O
29	combined	O
30	radiology	O
31	and	O
32	surgery	O
33	.	O
1	In	O
2	the	O
3	first	O
4	series	O
5	of	O
6	experiments	O
7	,	O
8	Sprague	O
9	-	O
10	Dawley	O
11	male	O
12	rats	O
13	were	O
14	implanted	O
15	unilaterally	O
16	with	O
17	guide	O
18	cannulas	O
19	aimed	O
20	at	O
21	the	O
22	lateral	O
23	ventricle	O
24	.	O
1	The	O
2	induction	O
3	of	O
4	RNKP	B
5	-	I
6	1	I
7	expression	O
8	in	O
9	the	O
10	Con	B
11	A	I
12	-	O
13	cultured	O
14	spleen	O
15	cells	O
16	is	O
17	accompanied	O
18	by	O
19	increases	O
20	in	O
21	both	O
22	NK	O
23	and	O
24	lymphokine	O
25	-	O
26	activated	O
27	killer	O
28	lymphocyte	O
29	activities	O
30	.	O
1	TMBr	B
2	-	I
3	1	I
4	is	O
5	identical	O
6	to	O
7	striated	B
8	muscle	I
9	alpha	I
10	-	I
11	tropomyosin	I
12	from	O
13	amino	O
14	acids	O
15	1	O
16	through	O
17	258	O
18	but	O
19	contains	O
20	a	O
21	novel	O
22	COOH	O
23	-	O
24	terminal	O
25	region	O
26	from	O
27	amino	O
28	acids	O
29	259	O
30	through	O
31	281	O
32	.	O
1	French	O
2	,	O
3	M	O
4	.	O
1	Accumulations	O
2	of	O
3	Tl	O
4	+	O
5	1	O
6	(	O
7	202Tl	O
8	label	O
9	)	O
10	were	O
11	6	O
12	times	O
13	those	O
14	for	O
15	Ga	O
16	or	O
17	In	O
18	in	O
19	the	O
20	brain	O
21	and	O
22	muscles	O
23	,	O
24	and	O
25	.	O
26	1	O
27	times	O
28	in	O
29	plasma	O
30	.	O
1	The	O
2	afferents	O
3	'	O
4	phase	O
5	of	O
6	response	O
7	was	O
8	unmodified	O
9	by	O
10	electrical	O
11	EVS	O
12	stimulation	O
13	.	O
1	In	O
2	a	O
3	stepwise	O
4	logistic	O
5	regression	O
6	analysis	O
7	of	O
8	SPT	O
9	and	O
10	RAST	O
11	data	O
12	,	O
13	the	O
14	occurrence	O
15	of	O
16	serum	B
17	IgE	I
18	antibodies	I
19	to	I
20	P	I
21	.	I
22	orbiculare	I
23	had	O
24	the	O
25	highest	O
26	explanatory	O
27	value	O
28	for	O
29	current	O
30	eczema	O
31	.	O
1	While	O
2	no	O
3	significant	O
4	differences	O
5	in	O
6	the	O
7	tensile	O
8	responses	O
9	or	O
10	failure	O
11	characteristics	O
12	were	O
13	noted	O
14	for	O
15	irradiated	O
16	and	O
17	nonirradiated	O
18	grafts	O
19	in	O
20	the	O
21	drip	O
22	,	O
23	in	O
24	the	O
25	bath	O
26	environment	O
27	the	O
28	nonirradiated	O
29	tissues	O
30	had	O
31	greater	O
32	strength	O
33	and	O
34	modulus	O
35	.	O
1	The	O
2	findings	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	iodine	O
8	deficiency	O
9	is	O
10	the	O
11	most	O
12	probable	O
13	cause	O
14	of	O
15	goiter	O
16	among	O
17	immigrants	O
18	of	O
19	the	O
20	1928	O
21	cohort	O
22	,	O
23	where	O
24	the	O
25	native	O
26	population	O
27	is	O
28	concerned	O
29	(	O
30	both	O
31	men	O
32	and	O
33	women	O
34	),	O
35	some	O
36	other	O
37	goitrogenic	O
38	factor	O
39	(	O
40	s	O
41	)	O
42	must	O
43	be	O
44	involved	O
45	.	O
1	The	O
2	transcriptional	O
3	unit	O
4	spans	O
5	a	O
6	chromosomal	O
7	region	O
8	of	O
9	about	O
10	55	O
11	kilobase	O
12	pairs	O
13	(	O
14	kbp	O
15	).	O
1	100	O
2	of	O
3	the	O
4	patients	O
5	who	O
6	would	O
7	have	O
8	died	O
9	survive	O
10	.	O
1	The	O
2	Community	O
3	Adjustment	O
4	Scale	O
5	provided	O
6	outcome	O
7	data	O
8	related	O
9	to	O
10	the	O
11	subjects	O
12	'	O
13	degree	O
14	of	O
15	productivity	O
16	,	O
17	ability	O
18	to	O
19	maintain	O
20	close	O
21	relationships	O
22	,	O
23	and	O
24	presence	O
25	/	O
26	absence	O
27	of	O
28	symptomatology	O
29	an	O
30	average	O
31	of	O
32	32	O
33	years	O
34	after	O
35	initial	O
36	admission	O
37	.	O
1	Fatal	O
2	encephalitis	O
3	in	O
4	a	O
5	patient	O
6	with	O
7	chronic	O
8	graft	O
9	-	O
10	versus	O
11	-	O
12	host	O
13	disease	O
14	.	O
1	Branch	O
2	occlusion	O
3	of	O
4	Heubner	O
5	'	O
6	s	O
7	artery	O
8	,	O
9	or	O
10	perforators	O
11	from	O
12	the	O
13	proximal	O
14	anterior	O
15	or	O
16	middle	O
17	cerebral	O
18	arteries	O
19	were	O
20	the	O
21	posited	O
22	mechanism	O
23	of	O
24	infarction	O
25	.	O
1	An	O
2	examination	O
3	of	O
4	the	O
5	properties	O
6	of	O
7	sequences	O
8	surrounding	O
9	ARS1	O
10	left	O
11	open	O
12	the	O
13	possibility	O
14	that	O
15	ABFI	B
16	enhances	O
17	the	O
18	initiation	O
19	of	O
20	DNA	O
21	replication	O
22	at	O
23	ARS1	O
24	by	O
25	transcriptional	O
26	activation	O
27	.	O
1	Role	O
2	of	O
3	superoxide	B
4	dismutase	I
5	in	O
6	cellular	O
7	oxidative	O
8	processes	O
9	and	O
10	method	O
11	of	O
12	its	O
13	determination	O
14	in	O
15	biological	O
16	materials	O
1	At	O
2	maximum	O
3	photosensitivity	O
4	the	O
5	inhibitory	O
6	amino	O
7	acids	O
8	gamma	O
9	-	O
10	aminobutyric	O
11	acid	O
12	and	O
13	taurine	O
14	were	O
15	lower	O
16	,	O
17	and	O
18	those	O
19	of	O
20	asparagine	O
21	(	O
22	metabolite	O
23	of	O
24	the	O
25	excitatory	O
26	amino	O
27	acid	O
28	aspartate	O
29	)	O
30	were	O
31	higher	O
32	,	O
33	than	O
34	when	O
35	the	O
36	animals	O
37	were	O
38	not	O
39	photosensitive	O
40	.	O
1	Lysozyme	B
2	activity	O
3	was	O
4	evidently	O
5	increased	O
6	as	O
7	well	O
8	in	O
9	undiluted	O
10	as	O
11	in	O
12	diluted	O
13	sera	O
14	in	O
15	all	O
16	our	O
17	tested	O
18	patients	O
19	.	O
1	A	O
2	5	B
3	.	I
4	8S	I
5	-	I
6	like	I
7	structure	I
8	is	O
9	present	O
10	within	O
11	the	O
12	5	O
13	'-	O
14	terminal	O
15	region	O
16	of	O
17	all	O
18	three	O
19	fungal	B
20	mitochondrial	I
21	LSU	I
22	rRNAs	I
23	;	O
24	in	O
25	contrast	O
26	,	O
27	no	O
28	4	B
29	.	I
30	5S	I
31	-	I
32	like	I
33	structure	I
34	is	O
35	evident	O
36	at	O
37	the	O
38	3	O
39	'	O
40	end	O
41	of	O
42	these	O
43	molecules	O
44	.	O
1	The	O
2	recovery	O
3	of	O
4	labelled	O
5	methoxydextrane	O
6	is	O
7	98	O
8	+/-	O
9	7	O
10	%.	O
1	Svensson	O
2	et	O
3	al	O
4	.	O
1	The	O
2	effects	O
3	of	O
4	L655	O
5	,	O
6	240	O
7	,	O
8	a	O
9	selective	O
10	thromboxane	O
11	and	O
12	prostaglandin	O
13	endoperoxide	O
14	antagonist	O
15	,	O
16	on	O
17	ischemia	O
18	-	O
19	and	O
20	reperfusion	O
21	-	O
22	induced	O
23	cardiac	O
24	arrhythmias	O
25	.	O
1	Dopamine	O
2	caused	O
3	a	O
4	prominent	O
5	potassium	O
6	efflux	O
7	measured	O
8	as	O
9	86Rb	O
10	+	O
11	efflux	O
12	from	O
13	control	O
14	glands	O
15	,	O
16	but	O
17	was	O
18	without	O
19	effect	O
20	in	O
21	denervated	O
22	glands	O
23	.	O
1	Endocrine	O
2	cells	O
3	were	O
4	studied	O
5	by	O
6	means	O
7	of	O
8	Grimelius	O
9	'	O
10	silver	O
11	staining	O
12	and	O
13	immunostaining	O
14	for	O
15	chromogranin	B
16	,	O
17	a	O
18	general	O
19	marker	O
20	of	O
21	endocrine	O
22	cells	O
23	.	O
1	During	O
2	the	O
3	program	O
4	'	O
5	s	O
6	use	O
7	at	O
8	the	O
9	RSNA	O
10	meeting	O
11	,	O
12	the	O
13	program	O
14	selected	O
15	the	O
16	correct	O
17	diagnosis	O
18	in	O
19	the	O
20	top	O
21	five	O
22	22	O
23	%	O
24	of	O
25	the	O
26	time	O
27	.	O
1	The	O
2	results	O
3	were	O
4	as	O
5	follows	O
6	:	O
7	1	O
8	)	O
9	Total	O
10	integrated	O
11	EMG	O
12	activity	O
13	of	O
14	FB	O
15	group	O
16	was	O
17	approximately	O
18	equal	O
19	in	O
20	any	O
21	occluded	O
22	position	O
23	,	O
24	whereas	O
25	that	O
26	of	O
27	CG	O
28	and	O
29	GF	O
30	group	O
31	varied	O
32	from	O
33	position	O
34	to	O
35	position	O
36	.	O
1	When	O
2	considered	O
3	with	O
4	the	O
5	known	O
6	neurotoxic	O
7	effects	O
8	on	O
9	children	O
10	of	O
11	""""	O
12	low	O
13	levels	O
14	""""	O
15	of	O
16	exposure	O
17	to	O
18	lead	O
19	,	O
20	these	O
21	results	O
22	also	O
23	suggest	O
24	that	O
25	either	O
26	an	O
27	excessively	O
28	narrow	O
29	margin	O
30	of	O
31	safety	O
32	or	O
33	insufficient	O
34	safety	O
35	is	O
36	provided	O
37	by	O
38	present	O
39	U	O
40	.	O
41	S	O
42	.	O
43	guidelines	O
44	,	O
45	which	O
46	classify	O
47	an	O
48	elevated	O
49	blood	O
50	lead	O
51	concentration	O
52	as	O
53	25	O
54	micrograms	O
55	/	O
56	dl	O
57	or	O
58	greater	O
59	.	O
1	O2	O
2	and	O
3	CO2	O
4	in	O
5	the	O
6	tracheostomy	O
7	tube	O
8	were	O
9	continuously	O
10	monitored	O
11	by	O
12	mass	O
13	spectrometry	O
14	using	O
15	a	O
16	special	O
17	sample	O
18	-	O
19	hold	O
20	phase	O
21	-	O
22	locked	O
23	sampling	O
24	technique	O
25	.	O
1	Enzyme	O
2	-	O
3	linked	O
4	immunosorbent	O
5	assay	O
6	for	O
7	screening	O
8	aflatoxin	O
9	B1	O
10	in	O
11	cottonseed	O
12	products	O
13	and	O
14	mixed	O
15	feed	O
16	:	O
17	collaborative	O
18	study	O
19	.	O
1	Functional	O
2	rearranged	O
3	antibody	O
4	genes	O
5	were	O
6	detected	O
7	with	O
8	JH	B
9	and	O
10	VH	B
11	heavy	I
12	chain	I
13	probes	O
14	and	O
15	with	O
16	Jk	B
17	and	O
18	Vk	B
19	light	I
20	chain	I
21	probes	O
22	.	O
1	Lowering	O
2	of	O
3	the	O
4	renal	O
5	blood	O
6	flow	O
7	alters	O
8	the	O
9	glomerular	O
10	and	O
11	tubular	O
12	excretion	O
13	processes	O
14	.	O
1	Growth	O
2	of	O
3	tracheal	O
4	anastomoses	O
5	in	O
6	growing	O
7	animals	O
1	Fourth	O
2	,	O
3	sometime	O
4	between	O
5	4	O
6	and	O
7	24	O
8	hours	O
9	of	O
10	recovery	O
11	is	O
12	necessary	O
13	to	O
14	reverse	O
15	the	O
16	effect	O
17	of	O
18	chronic	O
19	hypoxia	O
20	on	O
21	cerebral	O
22	blood	O
23	flow	O
24	.	O
1	The	O
2	ORF1	O
3	product	O
4	was	O
5	required	O
6	for	O
7	competence	O
8	,	O
9	while	O
10	ORF2	O
11	,	O
12	which	O
13	was	O
14	cotranscribed	O
15	with	O
16	ORF1	O
17	and	O
18	encoded	O
19	a	O
20	predicted	O
21	protein	O
22	of	O
23	126	O
24	amino	O
25	acids	O
26	,	O
27	was	O
28	not	O
29	.	O
1	Abundant	O
2	infiltration	O
3	of	O
4	lymphocytes	O
5	and	O
6	plasma	O
7	cells	O
8	was	O
9	also	O
10	wide	O
11	-	O
12	spread	O
13	beneath	O
14	the	O
15	carcinoma	O
16	in	O
17	situ	O
18	,	O
19	together	O
20	with	O
21	the	O
22	lymphoid	O
23	follicles	O
24	.	O
1	Among	O
2	100	O
3	cases	O
4	of	O
5	post	O
6	-	O
7	transfusion	O
8	hepatitis	O
9	,	O
10	10	O
11	are	O
12	due	O
13	to	O
14	the	O
15	hepatitis	O
16	B	O
17	virus	O
18	(	O
19	despite	O
20	systematic	O
21	search	O
22	for	O
23	HBs	B
24	Ag	I
25	),	O
26	89	O
27	are	O
28	due	O
29	to	O
30	one	O
31	of	O
32	the	O
33	non	O
34	-	O
35	A	O
36	non	O
37	-	O
38	B	O
39	viruses	O
40	(	O
41	not	O
42	detectable	O
43	by	O
44	specific	O
45	serological	O
46	tests	O
47	)	O
48	and	O
49	1	O
50	to	O
51	several	O
52	viruses	O
53	,	O
54	specially	O
55	CMV	O
56	.	O
1	The	O
2	other	O
3	patients	O
4	continued	O
5	the	O
6	trial	O
7	with	O
8	single	O
9	daily	O
10	doses	O
11	of	O
12	monotherapy	O
13	.	O
1	Neonatal	O
2	Chagas	O
3	disease	O
4	:	O
5	laboratory	O
6	diagnosis	O
7	during	O
8	the	O
9	first	O
10	year	O
11	of	O
12	life	O
1	An	O
2	immunologically	O
3	related	O
4	protein	O
5	was	O
6	detected	O
7	in	O
8	ribosome	O
9	and	O
10	membrane	O
11	fractions	O
12	of	O
13	mitochondria	O
14	from	O
15	Saccharomyces	O
16	cerevisiae	O
17	.	O
1	According	O
2	to	O
3	the	O
4	published	O
5	sequence	O
6	of	O
7	the	O
8	CHS1	B
9	gene	I
10	,	O
11	this	O
12	fragment	O
13	contains	O
14	four	O
15	repeats	O
16	of	O
17	a	O
18	TGAAACA	O
19	consensus	O
20	sequence	O
21	previously	O
22	identified	O
23	in	O
24	the	O
25	alpha	B
26	-	I
27	factor	I
28	-	O
29	inducible	O
30	BAR1	B
31	promoter	I
32	[	O
33	Kronstad	O
34	,	O
35	J	O
36	.	O
1	Three	O
2	missense	O
3	mutants	O
4	in	O
5	subunit	O
6	a	O
7	of	O
8	the	O
9	Escherichia	B
10	coli	I
11	F1F0	I
12	-	I
13	ATPase	I
14	were	O
15	isolated	O
16	and	O
17	characterized	O
18	after	O
19	hydroxylamine	O
20	mutagenesis	O
21	of	O
22	a	O
23	plasmid	O
24	carrying	O
25	the	O
26	uncB	B
27	(	I
28	subunit	I
29	a	I
30	)	I
31	gene	I
32	.	O
1	The	O
2	overall	O
3	prevalence	O
4	of	O
5	HBV	O
6	markers	O
7	was	O
8	higher	O
9	among	O
10	staff	O
11	members	O
12	than	O
13	in	O
14	the	O
15	blood	O
16	donors	O
17	of	O
18	our	O
19	area	O
20	.	O
1	The	O
2	adenovirus	B
3	E1A	I
4	gene	I
5	encodes	O
6	a	O
7	protein	O
8	that	O
9	transcriptionally	O
10	activates	O
11	viral	B
12	early	I
13	genes	I
14	.	O
1	We	O
2	have	O
3	determined	O
4	that	O
5	several	O
6	E1	B
7	mutants	I
8	mapping	O
9	in	O
10	both	O
11	the	O
12	M	O
13	and	O
14	R	O
15	regions	O
16	and	O
17	a	O
18	single	O
19	mutant	O
20	of	O
21	the	O
22	upstream	O
23	regulatory	O
24	region	O
25	have	O
26	a	O
27	higher	O
28	transforming	O
29	activity	O
30	on	O
31	mouse	O
32	C127	O
33	cells	O
34	than	O
35	the	O
36	wild	O
37	-	O
38	type	O
39	genome	O
40	does	O
41	.	O
1	That	O
2	of	O
3	the	O
4	T2	B
5	gene	I
6	contains	O
7	numerous	O
8	potential	O
9	sites	O
10	for	O
11	binding	O
12	the	O
13	mammalian	B
14	transcription	I
15	factor	I
16	SP1	I
17	,	O
18	but	O
19	no	O
20	TATA	O
21	or	O
22	CCAAT	O
23	sequences	O
24	are	O
25	evident	O
26	near	O
27	to	O
28	its	O
29	5	O
30	'	O
31	end	O
32	,	O
33	although	O
34	these	O
35	latter	O
36	features	O
37	are	O
38	associated	O
39	with	O
40	the	O
41	human	B
42	T1	I
43	gene	I
44	.	O
1	The	O
2	application	O
3	of	O
4	ISH	O
5	and	O
6	IHC	O
7	did	O
8	not	O
9	change	O
10	significantly	O
11	the	O
12	routine	O
13	histologic	O
14	classification	O
15	of	O
16	pneumonias	O
17	into	O
18	CMV	O
19	-	O
20	IP	O
21	and	O
22	IIP	O
23	.	O
1	The	O
2	Bacillus	B
3	subtilis	I
4	phage	I
5	phi	I
6	105	I
7	repressor	I
8	,	O
9	a	O
10	lambda	B
11	repressor	I
12	-	O
13	like	O
14	transcriptional	O
15	regulatory	O
16	protein	O
17	,	O
18	was	O
19	overproduced	O
20	in	O
21	Escherichia	O
22	coli	O
23	and	O
24	purified	O
25	to	O
26	near	O
27	homogeneity	O
28	in	O
29	order	O
30	to	O
31	examine	O
32	its	O
33	in	O
34	vitro	O
35	DNA	O
36	-	O
37	binding	O
38	properties	O
39	.	O
1	In	O
2	consequence	O
3	,	O
4	the	O
5	gpI	B
6	derived	O
7	from	O
8	cells	O
9	infected	O
10	with	O
11	mO74	O
12	showed	O
13	antigenic	O
14	characteristics	O
15	similar	O
16	to	O
17	those	O
18	of	O
19	gpI	B
20	from	O
21	VZV	O
22	-	O
23	infected	O
24	cells	O
25	as	O
26	determined	O
27	from	O
28	the	O
29	immunoprecipitation	O
30	pattern	O
31	,	O
32	although	O
33	the	O
34	molecular	O
35	weight	O
36	of	O
37	each	O
38	polypeptide	O
39	was	O
40	different	O
41	,	O
42	and	O
43	antibody	O
44	produced	O
45	in	O
46	rabbits	O
47	infected	O
48	with	O
49	recombinant	O
50	virus	O
51	had	O
52	a	O
53	high	O
54	neutralizing	O
55	activity	O
56	,	O
57	when	O
58	the	O
59	reaction	O
60	was	O
61	performed	O
62	with	O
63	complement	O
64	.	O
1	However	O
2	,	O
3	bilateral	O
4	diffuse	O
5	pulmonary	O
6	infiltrations	O
7	developed	O
8	21	O
9	days	O
10	later	O
11	.	O
1	The	O
2	data	O
3	indicate	O
4	that	O
5	calcitonin	B
6	induced	O
7	a	O
8	beta	B
9	-	I
10	endorphin	I
11	increase	O
12	independent	O
13	of	O
14	enhanced	O
15	corticotrophin	B
16	-	O
17	cortisol	O
18	release	O
19	.	O
1	Responsiveness	O
2	to	O
3	beta	O
4	-	O
5	2	O
6	agonist	O
7	therapy	O
8	was	O
9	retained	O
10	with	O
11	both	O
12	agents	O
13	(	O
14	p	O
15	less	O
16	than	O
17	0	O
18	.	O
19	05	O
20	).	O
1	In	O
2	contrast	O
3	,	O
4	the	O
5	neu	B
6	proto	I
7	-	I
8	oncogene	I
9	did	O
10	not	O
11	show	O
12	kinase	O
13	activity	O
14	or	O
15	transforming	O
16	properties	O
17	when	O
18	expressed	O
19	at	O
20	similar	O
21	levels	O
22	in	O
23	NIH	O
24	3T3	O
25	cells	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O
1	After	O
2	overtraining	O
3	on	O
4	the	O
5	original	O
6	discrimination	O
7	,	O
8	the	O
9	controls	O
10	showed	O
11	the	O
12	normal	O
13	difficulty	O
14	in	O
15	learning	O
16	the	O
17	first	O
18	reversal	O
19	.	O
1	Monitoring	O
2	of	O
3	rheumatoid	O
4	arthritis	O
5	.	O
1	When	O
2	the	O
3	first	O
4	twitch	O
5	of	O
6	TOF	O
7	spontaneously	O
8	recovered	O
9	to	O
10	10	O
11	%	O
12	of	O
13	control	O
14	value	O
15	,	O
16	neostigmine	O
17	was	O
18	injected	O
19	(	O
20	40	O
21	micrograms	O
22	/	O
23	kg	O
24	in	O
25	adults	O
26	,	O
27	30	O
28	micrograms	O
29	/	O
30	kg	O
31	in	O
32	infants	O
33	and	O
34	children	O
35	).	O
1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	multiple	O
6	oIGF	B
7	-	I
8	I	I
9	transcripts	I
10	in	O
11	a	O
12	broad	O
13	band	O
14	at	O
15	800	O
16	-	O
17	1	O
18	,	O
19	100	O
20	nucleotides	O
21	and	O
22	other	O
23	transcripts	O
24	of	O
25	higher	O
26	molecular	O
27	weight	O
28	in	O
29	liver	O
30	.	O
1	Analysis	O
2	of	O
3	the	O
4	inferred	O
5	1	B
6	,	I
7	859	I
8	-	I
9	residue	I
10	ama	I
11	-	I
12	1	I
13	product	I
14	showed	O
15	considerable	O
16	identity	O
17	with	O
18	the	O
19	largest	O
20	subunit	O
21	of	O
22	RNAP	B
23	II	I
24	from	O
25	other	O
26	organisms	O
27	,	O
28	including	O
29	the	O
30	presence	O
31	of	O
32	a	O
33	zinc	O
34	finger	O
35	motif	O
36	near	O
37	the	O
38	amino	O
39	terminus	O
40	,	O
41	and	O
42	a	O
43	carboxyl	O
44	-	O
45	terminal	O
46	domain	O
47	of	O
48	42	O
49	tandemly	O
50	reiterated	O
51	heptamers	O
52	with	O
53	the	O
54	consensus	O
55	Tyr	O
56	Ser	O
57	Pro	O
58	Thr	O
59	Ser	O
60	Pro	O
61	Ser	O
62	.	O
1	We	O
2	conclude	O
3	that	O
4	at	O
5	steady	O
6	state	O
7	the	O
8	timing	O
9	of	O
10	a	O
11	light	O
12	meal	O
13	is	O
14	unlikely	O
15	to	O
16	alter	O
17	in	O
18	any	O
19	clinically	O
20	important	O
21	manner	O
22	the	O
23	pharmacokinetics	O
24	of	O
25	nifedipine	O
26	released	O
27	from	O
28	'	O
29	biphasic	O
30	'	O
31	tablets	O
32	.	O
1	Most	O
2	of	O
3	them	O
4	were	O
5	situated	O
6	at	O
7	Sylvius	O
8	fissure	O
9	(	O
10	13	O
11	cases	O
12	).	O
1	Intracellular	O
2	activity	O
3	studies	O
4	indicated	O
5	that	O
6	,	O
7	at	O
8	ten	O
9	times	O
10	MBC	O
11	,	O
12	only	O
13	penicillin	O
14	had	O
15	any	O
16	significant	O
17	activity	O
18	against	O
19	intracellular	O
20	staphylococci	O
21	,	O
22	reducing	O
23	survival	O
24	by	O
25	28	O
26	%.	O
1	Reagent	O
2	strips	O
3	are	O
4	frequently	O
5	used	O
6	in	O
7	the	O
8	practice	O
9	of	O
10	laboratory	O
11	medicine	O
12	as	O
13	well	O
14	as	O
15	outside	O
16	the	O
17	professional	O
18	laboratories	O
19	.	O
1	The	O
2	lowest	O
3	detectable	O
4	concentration	O
5	was	O
6	1	O
7	.	O
8	0	O
9	ng	O
10	/	O
11	ml	O
12	in	O
13	the	O
14	serum	O
15	.	O
1	Although	O
2	the	O
3	fertility	O
4	decline	O
5	in	O
6	the	O
7	black	O
8	population	O
9	in	O
10	the	O
11	Mississippi	O
12	Delta	O
13	between	O
14	the	O
15	late	O
16	1870	O
17	'	O
18	s	O
19	and	O
20	early	O
21	1930	O
22	'	O
23	s	O
24	closely	O
25	paralleled	O
26	that	O
27	of	O
28	the	O
29	national	O
30	black	O
31	population	O
32	,	O
33	it	O
34	rose	O
35	much	O
36	more	O
37	dramatically	O
38	in	O
39	the	O
40	1940	O
41	'	O
42	s	O
43	and	O
44	1950	O
45	'	O
46	s	O
47	to	O
48	almost	O
49	1880	O
50	levels	O
51	.	O
1	Retrograde	O
2	filling	O
3	consists	O
4	in	O
5	sealing	O
6	endodontics	O
7	system	O
8	directly	O
9	at	O
10	the	O
11	apical	O
12	zone	O
13	after	O
14	surgical	O
15	approach	O
16	.	O
1	Collaborative	O
2	study	O
3	of	O
4	Japanese	O
5	Pharmacopoeia	O
6	Heparin	O
7	Sodium	O
8	Reference	O
9	Standard	O
1	Ischemic	O
2	heart	O
3	disease	O
4	evaluated	O
5	by	O
6	exercise	O
7	stress	O
8	thallium	O
9	-	O
10	201	O
11	myocardial	O
12	scintigraphy	O
13	:	O
14	a	O
15	comparison	O
16	of	O
17	SPECT	O
18	and	O
19	bull	O
20	'	O
21	s	O
22	eye	O
23	display	O
1	A	O
2	0	O
3	.	O
4	5	O
5	rating	O
6	was	O
7	intended	O
8	to	O
9	characterize	O
10	subjects	O
11	in	O
12	whom	O
13	mild	O
14	cognitive	O
15	impairment	O
16	due	O
17	to	O
18	senile	O
19	dementia	O
20	of	O
21	the	O
22	Alzheimer	O
23	type	O
24	was	O
25	suspected	O
26	but	O
27	was	O
28	insufficient	O
29	in	O
30	degree	O
31	to	O
32	warrant	O
33	a	O
34	diagnosis	O
35	of	O
36	definite	O
37	dementia	O
38	.	O
1	Following	O
2	the	O
3	patients	O
4	during	O
5	a	O
6	course	O
7	of	O
8	therapy	O
9	with	O
10	a	O
11	selective	O
12	vasodilator	O
13	calcium	O
14	antagonist	O
15	,	O
16	the	O
17	beta	O
18	-	O
19	adrenergic	O
20	reflex	O
21	vasodilation	O
22	became	O
23	substantially	O
24	attenuated	O
25	but	O
26	was	O
27	preserved	O
28	during	O
29	a	O
30	placebo	O
31	course	O
32	of	O
33	therapy	O
34	.	O
1	The	O
2	galactose	B
3	transporter	I
4	shows	O
5	both	O
6	sequence	O
7	and	O
8	structural	O
9	homology	O
10	with	O
11	a	O
12	superfamily	O
13	of	O
14	sugar	B
15	transporters	I
16	which	O
17	includes	O
18	the	O
19	human	B
20	HepG2	I
21	-	I
22	erythrocyte	I
23	and	I
24	fetal	I
25	muscle	I
26	glucose	I
27	transporters	I
28	,	O
29	the	O
30	rat	B
31	brain	I
32	and	I
33	liver	I
34	glucose	I
35	transporters	I
36	,	O
37	the	O
38	Escherichia	B
39	coli	I
40	xylose	I
41	and	I
42	arabinose	I
43	permeases	I
44	,	O
45	and	O
46	the	O
47	S	B
48	.	I
49	cerevisiae	I
50	glucose	I
51	,	I
52	maltose	I
53	,	I
54	and	I
55	galactose	I
56	transporters	I
57	.	O
1	Mapping	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	complementation	O
7	group	O
8	identified	O
9	by	O
10	these	O
11	mutants	O
12	is	O
13	allelic	O
14	to	O
15	the	O
16	ag	B
17	alpha	I
18	1	I
19	mutation	O
20	identified	O
21	previously	O
22	.	O
1	The	O
2	products	O
3	of	O
4	genes	O
5	ura10	B
6	and	O
7	ura3	B
8	are	O
9	proposed	O
10	to	O
11	participate	O
12	in	O
13	the	O
14	channeling	O
15	of	O
16	orotidine	O
17	monophosphate	O
18	.	O
1	The	O
2	R	B
3	.	I
4	meliloti	I
5	nifH	I
6	promoter	I
7	but	O
8	not	O
9	the	O
10	K	B
11	.	I
12	pneumoniae	I
13	nifH	I
14	promoter	I
15	showed	O
16	sigma	B
17	54	I
18	-	O
19	dependent	O
20	methylation	O
21	protection	O
22	of	O
23	guanine	O
24	residues	O
25	at	O
26	-	O
27	14	O
28	,	O
29	-	O
30	25	O
31	and	O
32	-	O
33	26	O
34	,	O
35	the	O
36	most	O
37	conserved	O
38	nucleotides	O
39	characteristic	O
40	of	O
41	sigma	B
42	54	I
43	-	I
44	dependent	I
45	promoters	I
46	.	O
1	Recently	O
2	,	O
3	an	O
4	alternatively	O
5	spliced	O
6	form	O
7	of	O
8	c	B
9	-	I
10	myb	I
11	-	I
12	encoded	I
13	mRNA	I
14	has	O
15	been	O
16	identified	O
17	in	O
18	murine	O
19	cells	O
20	containing	O
21	either	O
22	normal	O
23	or	O
24	rearranged	O
25	c	B
26	-	I
27	myb	I
28	genes	I
29	.	O
1	During	O
2	the	O
3	first	O
4	3	O
5	min	O
6	of	O
7	recovery	O
8	,	O
9	plasma	O
10	potassium	O
11	fell	O
12	rapidly	O
13	in	O
14	spite	O
15	of	O
16	nearly	O
17	unchanged	O
18	blood	O
19	acidosis	O
20	and	O
21	significantly	O
22	decreasing	O
23	bicarbonate	O
24	concentration	O
25	.	O
1	A	O
2	significant	O
3	relationship	O
4	existed	O
5	during	O
6	the	O
7	evolution	O
8	of	O
9	the	O
10	disease	O
11	between	O
12	CRS	O
13	/	O
14	BW	O
15	and	O
16	gas	O
17	exchange	O
18	parameters	O
19	(	O
20	FIO2	O
21	and	O
22	a	O
23	/	O
24	AO2	O
25	ratio	O
26	)	O
27	(	O
28	P	O
29	less	O
30	than	O
31	0	O
32	.	O
33	01	O
34	),	O
35	but	O
36	gas	O
37	exchange	O
38	improved	O
39	earlier	O
40	than	O
41	lung	O
42	mechanics	O
43	.	O
1	End	O
2	points	O
3	measured	O
4	were	O
5	perioperative	O
6	(	O
7	30	O
8	-	O
9	day	O
10	)	O
11	myocardial	O
12	infarction	O
13	(	O
14	MI	O
15	)	O
16	rate	O
17	and	O
18	death	O
19	.	O
1	An	O
2	alternative	O
3	method	O
4	of	O
5	UKM	O
6	is	O
7	proposed	O
8	based	O
9	on	O
10	collecting	O
11	a	O
12	small	O
13	fraction	O
14	of	O
15	spent	O
16	dialysate	O
17	flow	O
18	for	O
19	3	O
20	consecutive	O
21	dialyses	O
22	.	O
1	Primer	O
2	extension	O
3	experiments	O
4	indicated	O
5	that	O
6	the	O
7	transcription	O
8	initiation	O
9	site	O
10	mapped	O
11	to	O
12	a	O
13	position	O
14	on	O
15	gene	B
16	IV	I
17	that	O
18	was	O
19	analogous	O
20	to	O
21	that	O
22	reported	O
23	for	O
24	the	O
25	structurally	O
26	similar	O
27	P	B
28	-	I
29	450e	I
30	gene	I
31	.	O
1	From	O
2	day	O
3	30	O
4	after	O
5	turnout	O
6	,	O
7	the	O
8	PFB	O
9	-	O
10	group	O
11	had	O
12	significantly	O
13	lower	O
14	serum	B
15	pepsinogen	I
16	levels	O
17	,	O
18	which	O
19	reflects	O
20	the	O
21	low	O
22	degree	O
23	of	O
24	abomasal	O
25	damage	O
26	in	O
27	these	O
28	animals	O
29	.	O
1	Handgrip	O
2	dynamometry	O
3	was	O
4	also	O
5	carried	O
6	out	O
7	in	O
8	249	O
9	of	O
10	the	O
11	patients	O
12	.	O
1	Perfusion	O
2	washout	O
3	:	O
4	increasing	O
5	a	O
6	microvascular	O
7	free	O
8	flap	O
9	tolerance	O
10	to	O
11	ischemia	O
12	.	O
1	Similarly	O
2	,	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	U2	B
8	RNA	I
9	region	I
10	shown	O
11	to	O
12	be	O
13	involved	O
14	in	O
15	pre	O
16	-	O
17	mRNA	O
18	branchpoint	O
19	recognition	O
20	in	O
21	yeast	O
22	,	O
23	and	O
24	exactly	O
25	conserved	O
26	in	O
27	metazoan	B
28	U2	I
29	RNAs	I
30	,	O
31	was	O
32	totally	O
33	divergent	O
34	in	O
35	trypanosomes	O
36	.	O
1	From	O
2	the	O
3	National	O
4	Institutes	O
5	of	O
6	Health	O
7	.	O
1	In	O
2	the	O
3	final	O
4	model	O
5	,	O
6	grade	O
7	(	O
8	p	O
9	=	O
10	0	O
11	.	O
12	0002	O
13	),	O
14	peritoneal	O
15	cytologic	O
16	results	O
17	(	O
18	p	O
19	=	O
20	0	O
21	.	O
22	0002	O
23	),	O
24	progesterone	B
25	receptor	I
26	status	O
27	(	O
28	p	O
29	=	O
30	0	O
31	.	O
32	004	O
33	),	O
34	and	O
35	age	O
36	as	O
37	a	O
38	continuous	O
39	variable	O
40	(	O
41	p	O
42	=	O
43	0	O
44	.	O
45	008	O
46	)	O
47	were	O
48	most	O
49	closely	O
50	associated	O
51	with	O
52	disease	O
53	-	O
54	free	O
55	survival	O
56	.	O
1	COUP	B
2	transcription	I
3	factor	I
4	is	O
5	a	O
6	member	O
7	of	O
8	the	O
9	steroid	B
10	receptor	I
11	superfamily	I
12	.	O
1	In	O
2	Experiment	O
3	2	O
4	,	O
5	we	O
6	again	O
7	used	O
8	classification	O
9	,	O
10	but	O
11	the	O
12	fixed	O
13	standard	O
14	75	O
15	was	O
16	not	O
17	at	O
18	the	O
19	center	O
20	of	O
21	the	O
22	range	O
23	of	O
24	target	O
25	numbers	O
26	(	O
27	20	O
28	,	O
29	21	O
30	,	O
31	...	O
1	Epithelial	O
2	damage	O
3	was	O
4	not	O
5	observed	O
6	in	O
7	any	O
8	controls	O
9	but	O
10	was	O
11	in	O
12	all	O
13	tissues	O
14	exposed	O
15	to	O
16	SO2	O
17	.	O
1	The	O
2	present	O
3	study	O
4	investigates	O
5	whether	O
6	prostaglandins	O
7	""""	O
8	cytoprotect	O
9	""""	O
10	the	O
11	gastric	O
12	mucosa	O
13	against	O
14	hemorrhage	O
15	-	O
16	induced	O
17	stress	O
18	ulceration	O
19	by	O
20	assessing	O
21	the	O
22	influence	O
23	of	O
24	16	O
25	,	O
26	16	O
27	-	O
28	dimethyl	O
29	prostaglandin	O
30	E2	O
31	(	O
32	16	O
33	,	O
34	16	O
35	-	O
36	dm	O
37	PGE2	O
38	)	O
39	on	O
40	gross	O
41	and	O
42	microscopic	O
43	lesion	O
44	formation	O
45	,	O
46	intramucosal	O
47	tissue	O
48	pH	O
49	,	O
50	H	O
51	+	O
52	back	O
53	-	O
54	diffusion	O
55	,	O
56	and	O
57	mucosal	O
58	blood	O
59	flow	O
60	in	O
61	rat	O
62	gastric	O
63	mucosa	O
64	exposed	O
65	to	O
66	luminal	O
67	acid	O
68	(	O
69	100	O
70	mM	O
71	HCl	O
72	)	O
73	during	O
74	hemorrhagic	O
75	shock	O
76	(	O
77	13	O
78	ml	O
79	/	O
80	kg	O
81	for	O
82	20	O
83	min	O
84	).	O
1	Transcripts	O
2	characterized	O
3	include	O
4	(	O
5	i	O
6	)	O
7	abundant	O
8	monocistronic	O
9	L11e	B
10	and	O
11	tricistronic	O
12	L1e	B
13	-	O
14	L10e	B
15	-	O
16	L12e	B
17	transcripts	O
18	;	O
19	(	O
20	ii	O
21	)	O
22	less	O
23	abundant	O
24	bicistronic	O
25	NAB	B
26	-	O
27	L11e	B
28	and	O
29	monocistronic	O
30	NAB	B
31	transcripts	I
32	and	O
33	(	O
34	iii	O
35	)	O
36	a	O
37	very	O
38	rare	O
39	ORF	O
40	monocistronic	O
41	transcript	O
42	.	O
1	Evidence	O
2	from	O
3	the	O
4	structure	O
5	of	O
6	a	O
7	number	O
8	of	O
9	cDNA	O
10	clones	O
11	,	O
12	as	O
13	well	O
14	as	O
15	S1	B
16	nuclease	I
17	and	O
18	primer	O
19	extension	O
20	studies	O
21	supports	O
22	the	O
23	hypothesis	O
24	that	O
25	the	O
26	PTHrP	B
27	gene	I
28	contains	O
29	at	O
30	least	O
31	two	O
32	mRNA	O
33	transcription	O
34	start	O
35	points	O
36	that	O
37	define	O
38	two	O
39	putative	O
40	regulatory	O
41	domains	O
42	.	O
1	Each	O
2	individual	O
3	shot	O
4	25	O
5	bullets	O
6	in	O
7	about	O
8	5	O
9	minutes	O
10	,	O
11	at	O
12	an	O
13	intensity	O
14	level	O
15	calculated	O
16	at	O
17	163	O
18	dB	O
19	.	O
1	On	O
2	admission	O
3	to	O
4	our	O
5	department	O
6	in	O
7	September	O
8	,	O
9	1987	O
10	,	O
11	the	O
12	patient	O
13	was	O
14	alert	O
15	and	O
16	had	O
17	spastic	O
18	paraparesis	O
19	,	O
20	the	O
21	impairment	O
22	of	O
23	all	O
24	sensory	O
25	modalities	O
26	below	O
27	the	O
28	level	O
29	of	O
30	Th	O
31	10	O
32	and	O
33	urinary	O
34	disturbance	O
35	.	O
1	The	O
2	nature	O
3	of	O
4	the	O
5	process	O
6	formed	O
7	by	O
8	the	O
9	successive	O
10	occurrences	O
11	of	O
12	this	O
13	arrhythmia	O
14	was	O
15	studied	O
16	in	O
17	8	O
18	patients	O
19	with	O
20	a	O
21	history	O
22	of	O
23	symptomatic	O
24	paroxysmal	O
25	AF	O
26	.	O
1	Obesity	O
2	was	O
3	strongly	O
4	associated	O
5	with	O
6	the	O
7	proportions	O
8	of	O
9	nonprotein	O
10	-	O
11	bound	O
12	and	O
13	albumin	B
14	-	O
15	bound	O
16	estradiol	O
17	,	O
18	and	O
19	inversely	O
20	associated	O
21	with	O
22	sex	B
23	hormone	I
24	binding	I
25	globulin	I
26	(	O
27	SHBG	B
28	)	O
29	levels	O
30	and	O
31	the	O
32	proportion	O
33	of	O
34	SHBG	B
35	-	O
36	bound	O
37	estradiol	O
38	.	O
1	Brain	B
2	cholinesterase	I
3	activity	O
4	of	O
5	nestling	O
6	great	O
7	egrets	O
8	,	O
9	snowy	O
10	egrets	O
11	and	O
12	black	O
13	-	O
14	crowned	O
15	night	O
16	-	O
17	herons	O
18	.	O
19	inhibition	O
20	of	O
21	brain	B
22	cholinesterase	I
23	(	O
24	ChE	B
25	)	O
26	activity	O
27	in	O
28	birds	O
29	is	O
30	often	O
31	used	O
32	to	O
33	diagnose	O
34	exposure	O
35	or	O
36	death	O
37	from	O
38	organophosphorus	O
39	or	O
40	carbamate	O
41	pesticides	O
42	.	O
1	PULSE	O
2	is	O
3	used	O
4	to	O
5	set	O
6	such	O
7	NMR	O
8	spectroscopic	O
9	parameters	O
10	as	O
11	the	O
12	delay	O
13	and	O
14	duration	O
15	of	O
16	rf	O
17	transmit	O
18	and	O
19	receive	O
20	gates	O
21	,	O
22	rf	O
23	phase	O
24	,	O
25	sampling	O
26	times	O
27	,	O
28	and	O
29	such	O
30	imaging	O
31	parameters	O
32	as	O
33	rf	O
34	pulse	O
35	shape	O
36	and	O
37	gradient	O
38	waveforms	O
39	.	O
1	Definite	O
2	JPsA	O
3	(	O
4	24	O
5	patients	O
6	)	O
7	was	O
8	defined	O
9	as	O
10	arthritis	O
11	associated	O
12	,	O
13	but	O
14	not	O
15	necessarily	O
16	coincident	O
17	,	O
18	with	O
19	a	O
20	typical	O
21	psoriatic	O
22	rash	O
23	,	O
24	or	O
25	arthritis	O
26	plus	O
27	at	O
28	least	O
29	3	O
30	of	O
31	4	O
32	minor	O
33	criteria	O
34	:	O
35	dactylitis	O
36	,	O
37	nail	O
38	pitting	O
39	,	O
40	psoriasis	O
41	-	O
42	like	O
43	rash	O
44	,	O
45	or	O
46	family	O
47	history	O
48	of	O
49	psoriasis	O
50	.	O
1	A	O
2	hospital	O
3	-	O
4	based	O
5	study	O
6	of	O
7	the	O
8	relationship	O
9	between	O
10	retained	O
11	placenta	O
12	and	O
13	mastitis	O
14	in	O
15	dairy	O
16	cows	O
17	.	O
1	A	O
2	value	O
3	of	O
4	1	O
5	.	O
6	1	O
7	l	O
8	/	O
9	kg	O
10	was	O
11	used	O
12	for	O
13	V	O
14	in	O
15	calculating	O
16	all	O
17	single	O
18	sample	O
19	estimates	O
20	of	O
21	clearance	O
22	(	O
23	CL	O
24	),	O
25	and	O
26	a	O
27	value	O
28	of	O
29	4	O
30	.	O
31	3	O
32	l	O
33	/	O
34	kg	O
35	was	O
36	used	O
37	to	O
38	calculate	O
39	single	O
40	sample	O
41	estimates	O
42	of	O
43	clearance	O
44	of	O
45	plasma	O
46	unbound	O
47	drug	O
48	(	O
49	CLunb	O
50	).	O
1	The	O
2	values	O
3	were	O
4	consistently	O
5	lower	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	01	O
13	)	O
14	during	O
15	summer	O
16	(	O
17	3	O
18	.	O
19	79	O
20	+/-	O
21	0	O
22	.	O
23	13	O
24	micrograms	O
25	/	O
26	100	O
27	ml	O
28	),	O
29	as	O
30	compared	O
31	to	O
32	winter	O
33	(	O
34	5	O
35	.	O
36	06	O
37	+/-	O
38	0	O
39	.	O
40	27	O
41	).	O
1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	lack	O
7	of	O
8	conservation	O
9	of	O
10	the	O
11	membrane	O
12	attachment	O
13	sequence	O
14	arginine	O
15	-	O
16	glycine	O
17	-	O
18	aspartic	O
19	acid	O
20	argues	O
21	against	O
22	its	O
23	functional	O
24	importance	O
25	in	O
26	CgA	B
27	.	O
1	The	O
2	use	O
3	of	O
4	an	O
5	appropriate	O
6	solution	O
7	of	O
8	methylene	O
9	blue	O
10	(	O
11	0	O
12	.	O
13	2	O
14	%	O
15	in	O
16	0	O
17	.	O
18	9	O
19	M	O
20	NaCl	O
21	for	O
22	15	O
23	min	O
24	)	O
25	permits	O
26	the	O
27	staining	O
28	of	O
29	premalignant	O
30	areas	O
31	and	O
32	CIS	O
33	,	O
34	and	O
35	their	O
36	early	O
37	diagnosis	O
38	.	O
1	In	O
2	one	O
3	acromegalic	O
4	patient	O
5	visual	O
6	improvement	O
7	was	O
8	obtained	O
9	while	O
10	the	O
11	abnormal	O
12	GH	B
13	secretion	O
14	remained	O
15	unaltered	O
16	.	O
1	In	O
2	contrast	O
3	,	O
4	the	O
5	PPSF	O
6	+	O
7	DBP	O
8	side	O
9	showed	O
10	large	O
11	amounts	O
12	of	O
13	bone	O
14	formation	O
15	,	O
16	and	O
17	bone	O
18	almost	O
19	covered	O
20	the	O
21	implant	O
22	.	O
1	We	O
2	also	O
3	found	O
4	that	O
5	the	O
6	same	O
7	males	O
8	,	O
9	breeding	O
10	in	O
11	different	O
12	years	O
13	on	O
14	the	O
15	same	O
16	territories	O
17	,	O
18	had	O
19	significantly	O
20	larger	O
21	harems	O
22	in	O
23	the	O
24	years	O
25	they	O
26	had	O
27	familiar	O
28	neighbors	O
29	.	O
1	The	O
2	subepicardial	O
3	lymphatic	O
4	capillaries	O
5	were	O
6	ramified	O
7	and	O
8	anastomosed	O
9	with	O
10	each	O
11	other	O
12	to	O
13	form	O
14	a	O
15	relatively	O
16	dense	O
17	network	O
18	which	O
19	extended	O
20	over	O
21	the	O
22	entire	O
23	surface	O
24	of	O
25	both	O
26	ventricles	O
27	.	O
1	Low	O
2	-	O
3	grade	O
4	glioma	O
5	.	O
1	The	O
2	predicted	O
3	L	B
4	mRNA	I
5	was	O
6	6398	O
7	nucleotides	O
8	long	O
9	and	O
10	contained	O
11	a	O
12	single	O
13	open	O
14	reading	O
15	frame	O
16	corresponding	O
17	to	O
18	an	O
19	L	B
20	protein	I
21	encompassing	I
22	2109	I
23	amino	I
24	acids	I
25	with	O
26	a	O
27	MW	O
28	of	O
29	241	O
30	,	O
31	546	O
32	.	O
1	Either	O
2	two	O
3	or	O
4	more	O
5	different	O
6	sequences	O
7	can	O
8	promote	O
9	cleavage	O
10	,	O
11	or	O
12	a	O
13	single	O
14	element	O
15	exists	O
16	which	O
17	is	O
18	long	O
19	and	O
20	diffuse	O
21	.	O
1	The	O
2	levels	O
3	of	O
4	NPY	B
5	-	O
6	ir	O
7	in	O
8	the	O
9	rat	O
10	vas	O
11	deferens	O
12	were	O
13	not	O
14	affected	O
15	by	O
16	either	O
17	surgical	O
18	or	O
19	pharmacological	O
20	treatment	O
21	.	O
1	The	O
2	Nostoc	O
3	petBD	B
4	genes	I
5	are	O
6	not	O
7	closely	O
8	linked	O
9	to	O
10	the	O
11	psbB	B
12	gene	I
13	(	O
14	encoding	O
15	the	O
16	51	O
17	-	O
18	kDa	O
19	photosystem	B
20	II	I
21	polypeptide	I
22	)	O
23	and	O
24	do	O
25	not	O
26	contain	O
27	introns	O
28	as	O
29	do	O
30	the	O
31	closely	O
32	related	O
33	chloroplast	O
34	genes	O
35	.	O
1	Whereas	O
2	the	O
3	muscle	O
4	isoform	O
5	consists	O
6	of	O
7	997	O
8	amino	O
9	acids	O
10	and	O
11	terminates	O
12	with	O
13	the	O
14	sequence	O
15	Ala	O
16	-	O
17	Ile	O
18	-	O
19	Leu	O
20	-	O
21	Glu	O
22	,	O
23	the	O
24	second	O
25	isoform	O
26	is	O
27	1043	O
28	amino	O
29	acids	O
30	in	O
31	length	O
32	due	O
33	to	O
34	the	O
35	replacement	O
36	of	O
37	these	O
38	last	O
39	4	O
40	amino	O
41	acids	O
42	with	O
43	a	O
44	50	O
45	-	O
46	amino	O
47	acid	O
48	sequence	O
49	that	O
50	contains	O
51	a	O
52	potential	O
53	transmembrane	O
54	domain	O
55	followed	O
56	by	O
57	a	O
58	consensus	O
59	sequence	O
60	for	O
61	an	O
62	N	O
63	-	O
64	linked	O
65	glycosylation	O
66	site	O
67	.	O
1	The	O
2	number	O
3	of	O
4	polymerases	O
5	active	O
6	in	O
7	vitro	O
8	at	O
9	the	O
10	E	O
11	strand	O
12	promoter	O
13	was	O
14	similar	O
15	to	O
16	the	O
17	number	O
18	of	O
19	polymerases	O
20	at	O
21	the	O
22	L	O
23	strand	O
24	promoter	O
25	.	O
1	A	O
2	highly	O
3	hydrophobic	O
4	sequence	O
5	located	O
6	near	O
7	the	O
8	carboxyl	O
9	-	O
10	terminal	O
11	extremity	O
12	of	O
13	the	O
14	molecule	O
15	most	O
16	likely	O
17	constitutes	O
18	the	O
19	anchor	O
20	to	O
21	the	O
22	plasma	O
23	membrane	O
24	.	O
1	The	O
2	SV40	B
3	enhancer	I
4	augmented	O
5	replication	O
6	1	O
7	.	O
8	5	O
9	-	O
10	10	O
11	fold	O
12	.	O
1	Poor	O
2	response	O
3	when	O
4	laboratory	O
5	recommended	O
6	range	O
7	for	O
8	serum	O
9	lithium	O
10	is	O
11	changed	O
12	.	O
1	No	O
2	significant	O
3	differences	O
4	between	O
5	the	O
6	two	O
7	treatment	O
8	groups	O
9	were	O
10	found	O
11	,	O
12	but	O
13	rapid	O
14	responders	O
15	had	O
16	a	O
17	smaller	O
18	mean	O
19	initial	O
20	platelet	B
21	-	I
22	associated	I
23	IgG	I
24	index	O
25	which	O
26	returned	O
27	more	O
28	rapidly	O
29	and	O
30	more	O
31	permanently	O
32	to	O
33	normal	O
34	than	O
35	that	O
36	of	O
37	slow	O
38	responders	O
39	.	O
1	Output	O
2	of	O
3	99mTcO	O
4	-	O
5	4	O
6	by	O
7	the	O
8	parotid	O
9	gland	O
10	closely	O
11	mimicked	O
12	fluctuations	O
13	in	O
14	parotid	O
15	saliva	O
16	flow	O
17	rate	O
18	.	O
1	On	O
2	Days	O
3	1	O
4	and	O
5	14	O
6	,	O
7	most	O
8	young	O
9	and	O
10	elderly	O
11	subjects	O
12	exhibited	O
13	monoexponential	O
14	decline	O
15	in	O
16	bevantolol	O
17	plasma	O
18	concentrations	O
19	after	O
20	absorption	O
21	phase	O
22	.	O
1	Present	O
2	results	O
3	reveal	O
4	a	O
5	frequency	O
6	-	O
7	dependent	O
8	inhibition	O
9	of	O
10	ganglionic	O
11	transmission	O
12	by	O
13	diltiazem	O
14	,	O
15	and	O
16	suggest	O
17	that	O
18	diltiazem	O
19	may	O
20	depress	O
21	excessive	O
22	sympathetic	O
23	activity	O
24	without	O
25	affecting	O
26	normal	O
27	ganglionic	O
28	transmission	O
29	.	O
1	Testing	O
2	blood	O
3	donors	O
4	for	O
5	non	O
6	-	O
7	A	O
8	,	O
9	non	O
10	-	O
11	B	O
12	hepatitis	O
13	:	O
14	irrational	O
15	,	O
16	perhaps	O
17	,	O
18	but	O
19	inescapable	O
20	.	O
1	Somatostatin	B
2	-	O
3	producing	O
4	endocrine	O
5	pancreatic	O
6	tumor	O
7	in	O
8	Recklinghausen	O
9	'	O
10	s	O
11	neurofibromatosis	O
12	.	O
1	Transformed	O
2	bacterial	O
3	colonies	O
4	were	O
5	screened	O
6	for	O
7	recombinant	O
8	plasmids	O
9	containing	O
10	cDNA	O
11	coding	O
12	for	O
13	BiP	B
14	by	O
15	hybrid	O
16	-	O
17	selected	O
18	mRNA	O
19	translation	O
20	.	O
1	Like	O
2	scrotal	O
3	testes	O
4	,	O
5	undescended	O
6	testes	O
7	were	O
8	hypointense	O
9	to	O
10	fat	O
11	on	O
12	sequences	O
13	with	O
14	a	O
15	short	O
16	repetition	O
17	time	O
18	(	O
19	TR	O
20	)	O
21	and	O
22	echo	O
23	time	O
24	(	O
25	TE	O
26	)	O
27	in	O
28	all	O
29	cases	O
30	,	O
31	and	O
32	hyperintense	O
33	or	O
34	isointense	O
35	to	O
36	fat	O
37	on	O
38	long	O
39	TR	O
40	/	O
41	TE	O
42	sequences	O
43	in	O
44	all	O
45	but	O
46	two	O
47	cases	O
48	.	O
1	The	O
2	East	O
3	African	O
4	dik	O
5	-	O
6	dik	O
7	antelope	O
8	represents	O
9	a	O
10	miniature	O
11	model	O
12	ruminant	O
13	for	O
14	comparative	O
15	studies	O
16	.	O
1	By	O
2	sequence	O
3	comparison	O
4	,	O
5	42	O
6	blocks	O
7	of	O
8	homology	O
9	are	O
10	defined	O
11	in	O
12	the	O
13	5	O
14	'-	O
15	terminal	O
16	region	O
17	,	O
18	of	O
19	which	O
20	36	O
21	appear	O
22	in	O
23	the	O
24	CpG	O
25	island	O
26	and	O
27	contain	O
28	numerous	O
29	conserved	O
30	CpG	O
31	dinucleotides	O
32	.	O
1	Among	O
2	unusual	O
3	features	O
4	,	O
5	we	O
6	report	O
7	numerous	O
8	large	O
9	G	O
10	+	O
11	C	O
12	-	O
13	rich	O
14	conserved	O
15	sequences	O
16	located	O
17	in	O
18	the	O
19	first	O
20	intron	O
21	.	O
1	Efficacy	O
2	and	O
3	field	O
4	evaluation	O
5	of	O
6	Bacillus	O
7	thuringiensis	O
8	(	O
9	H	O
10	-	O
11	14	O
12	)	O
13	and	O
14	B	O
15	.	O
16	sphaericus	O
17	against	O
18	floodwater	O
19	mosquitoes	O
20	in	O
21	California	O
22	.	O
1	We	O
2	conclude	O
3	that	O
4	at	O
5	these	O
6	low	O
7	levels	O
8	studied	O
9	,	O
10	aluminum	O
11	accumulates	O
12	in	O
13	intestinal	O
14	tissue	O
15	,	O
16	and	O
17	that	O
18	this	O
19	accumulation	O
20	is	O
21	enhanced	O
22	by	O
23	citrate	O
24	ligand	O
25	.	O
1	Successful	O
2	use	O
3	of	O
4	transureteroureterostomy	O
5	to	O
6	salvage	O
7	ureterosigmoidostomy	O
8	after	O
9	anastomotic	O
10	failure	O
11	.	O
1	Partial	O
2	N	O
3	-	O
4	terminal	O
5	amino	O
6	acid	O
7	sequence	O
8	analysis	O
9	showed	O
10	that	O
11	the	O
12	43K	B
13	and	I
14	42K	I
15	T	I
16	antigens	I
17	contain	O
18	methionine	O
19	at	O
20	residues	O
21	1	O
22	and	O
23	5	O
24	,	O
25	as	O
26	predicted	O
27	from	O
28	the	O
29	DNA	O
30	sequence	O
31	,	O
32	whereas	O
33	no	O
34	methionine	O
35	was	O
36	released	O
37	from	O
38	the	O
39	39K	B
40	T	I
41	antigen	I
42	during	O
43	the	O
44	first	O
45	six	O
46	cycles	O
47	of	O
48	Edman	O
49	degradation	O
50	.	O
1	Thus	O
2	,	O
3	quantitative	O
4	analysis	O
5	of	O
6	thallium	O
7	-	O
8	201	O
9	uptake	O
10	and	O
11	washout	O
12	provided	O
13	objective	O
14	evidence	O
15	for	O
16	improved	O
17	myocardial	O
18	perfusion	O
19	after	O
20	coronary	O
21	angioplasty	O
22	.	O
1	This	O
2	study	O
3	reports	O
4	the	O
5	effects	O
6	of	O
7	a	O
8	preparation	O
9	with	O
10	50	O
11	micrograms	O
12	ethinyl	O
13	estradiol	O
14	and	O
15	2	O
16	mg	O
17	cyproterone	O
18	acetate	O
19	on	O
20	gonadotropins	B
21	,	O
22	prolactin	B
23	,	O
24	testosterone	O
25	,	O
26	sex	B
27	hormone	I
28	binding	I
29	globulin	I
30	(	O
31	SHBG	B
32	),	O
33	androstenedione	O
34	,	O
35	and	O
36	calculated	O
37	free	O
38	testosterone	O
39	index	O
40	before	O
41	and	O
42	after	O
43	six	O
44	months	O
45	of	O
46	treatment	O
47	.	O
1	Functional	O
2	flow	O
3	was	O
4	evaluated	O
5	using	O
6	laser	O
7	Doppler	O
8	flowmetry	O
9	(	O
10	LDF	O
11	),	O
12	for	O
13	which	O
14	the	O
15	output	O
16	signal	O
17	,	O
18	blood	O
19	cell	O
20	flux	O
21	(	O
22	BCF	O
23	),	O
24	is	O
25	expressed	O
26	in	O
27	terms	O
28	of	O
29	volts	O
30	.	O
1	To	O
2	investigate	O
3	the	O
4	effects	O
5	of	O
6	isotretinoin	O
7	on	O
8	HDL	B
9	,	O
10	we	O
11	measured	O
12	HDL	B
13	-	I
14	C	I
15	,	O
16	HDL	B
17	phospholipids	O
18	(	O
19	HDL	B
20	-	I
21	PL	I
22	),	O
23	apoprotein	B
24	A1	I
25	(	O
26	apo	B
27	A	I
28	-	I
29	1	I
30	),	O
31	and	O
32	HDL	B
33	-	I
34	C	I
35	subfractions	O
36	(	O
37	HDL2	B
38	-	I
39	C	I
40	and	O
41	HDL3	B
42	-	I
43	C	I
44	)	O
45	in	O
46	24	O
47	healthy	O
48	,	O
49	male	O
50	patients	O
51	receiving	O
52	a	O
53	16	O
54	-	O
55	week	O
56	course	O
57	of	O
58	isotretinoin	O
59	(	O
60	1	O
61	.	O
62	0	O
63	mg	O
64	/	O
65	kg	O
66	/	O
67	day	O
68	)	O
69	for	O
70	treatment	O
71	of	O
72	severe	O
73	acne	O
74	vulgaris	O
75	.	O
1	Preventive	O
2	effect	O
3	of	O
4	ONO	O
5	-	O
6	3708	O
7	on	O
8	thrombosis	O
9	and	O
10	vasospasms	O
11	in	O
12	vitro	O
13	and	O
14	in	O
15	vivo	O
16	.	O
1	Quantitative	O
2	analysis	O
3	of	O
4	the	O
5	coronary	O
6	stenosis	O
7	was	O
8	assessed	O
9	before	O
10	and	O
11	after	O
12	PTCA	O
13	,	O
14	and	O
15	the	O
16	dilatation	O
17	resulted	O
18	in	O
19	an	O
20	increase	O
21	in	O
22	minimal	O
23	luminal	O
24	cross	O
25	-	O
26	sectional	O
27	area	O
28	from	O
29	1	O
30	.	O
31	1	O
32	+/-	O
33	0	O
34	.	O
35	8	O
36	to	O
37	2	O
38	.	O
39	7	O
40	+/-	O
41	1	O
42	.	O
43	2	O
44	mm2	O
45	.	O
1	Atomic	O
2	absorption	O
3	spectrophotometry	O
4	applied	O
5	to	O
6	bacterially	O
7	expressed	O
8	E1A	B
9	proteins	I
10	revealed	O
11	that	O
12	the	O
13	289	O
14	-	O
15	amino	O
16	acid	O
17	protein	O
18	binds	O
19	one	O
20	zinc	O
21	ion	O
22	,	O
23	whereas	O
24	the	O
25	243	O
26	-	O
27	amino	O
28	acid	O
29	protein	O
30	binds	O
31	no	O
32	zinc	O
33	.	O
1	Organ	O
2	transplantation	O
3	in	O
4	Denmark	O
5	.	O
1	Effects	O
2	of	O
3	single	O
4	and	O
5	combined	O
6	maltose	O
7	tetrapalmitate	O
8	immunotherapy	O
9	,	O
10	cyclophosphamide	O
11	chemotherapy	O
12	and	O
13	radiotherapy	O
14	on	O
15	ethyl	O
16	carbamate	O
17	accelerated	O
18	primary	O
19	lung	O
20	cancer	O
21	in	O
22	A	O
23	/	O
24	J	O
25	mice	O
26	.	O
1	When	O
2	the	O
3	coding	O
4	segments	O
5	,	O
6	including	O
7	both	O
8	framework	O
9	and	O
10	complementarity	O
11	-	O
12	determining	O
13	regions	O
14	,	O
15	of	O
16	these	O
17	genes	O
18	and	O
19	the	O
20	murine	O
21	probe	O
22	sequences	O
23	are	O
24	compared	O
25	by	O
26	metric	O
27	analysis	O
28	,	O
29	it	O
30	is	O
31	apparent	O
32	that	O
33	the	O
34	caiman	O
35	genes	O
36	are	O
37	only	O
38	slightly	O
39	more	O
40	related	O
41	to	O
42	each	O
43	other	O
44	than	O
45	to	O
46	the	O
47	mammalian	O
48	sequence	O
49	,	O
50	consistent	O
51	with	O
52	significant	O
53	preservation	O
54	of	O
55	nucleotide	O
56	sequence	O
57	over	O
58	an	O
59	extended	O
60	period	O
61	of	O
62	phylogenetic	O
63	time	O
64	.	O
1	The	O
2	data	O
3	obtained	O
4	up	O
5	to	O
6	now	O
7	only	O
8	suggest	O
9	the	O
10	future	O
11	potentiality	O
12	of	O
13	Bestatin	O
14	treatment	O
15	for	O
16	these	O
17	types	O
18	of	O
19	malignancy	O
20	.	O
1	These	O
2	IgG	B
3	antibodies	I
4	in	O
5	the	O
6	babies	O
7	diminished	O
8	rapidly	O
9	after	O
10	delivery	O
11	,	O
12	and	O
13	were	O
14	detectable	O
15	only	O
16	in	O
17	3	O
18	cases	O
19	at	O
20	2	O
21	,	O
22	3	O
23	,	O
24	and	O
25	5	O
26	months	O
27	of	O
28	ages	O
29	out	O
30	of	O
31	38	O
32	babies	O
33	up	O
34	to	O
35	21	O
36	months	O
37	.	O
1	Those	O
2	dosages	O
3	that	O
4	inhibited	O
5	mean	O
6	NTE	B
7	activity	O
8	in	O
9	spinal	O
10	cord	O
11	greater	O
12	than	O
13	or	O
14	equal	O
15	to	O
16	72	O
17	%	O
18	and	O
19	brain	O
20	greater	O
21	than	O
22	or	O
23	equal	O
24	to	O
25	66	O
26	%	O
27	of	O
28	control	O
29	values	O
30	within	O
31	44	O
32	hr	O
33	postexposure	O
34	produced	O
35	marked	O
36	spinal	O
37	cord	O
38	pathology	O
39	14	O
40	days	O
41	postexposure	O
42	in	O
43	greater	O
44	than	O
45	or	O
46	equal	O
47	to	O
48	90	O
49	%	O
50	of	O
51	similarly	O
52	dosed	O
53	animals	O
54	.	O
1	Six	O
2	(	O
3	four	O
4	FAP	O
5	;	O
6	two	O
7	primary	O
8	amyloidosis	O
9	)	O
10	also	O
11	had	O
12	diffusely	O
13	positive	O
14	myocardial	O
15	uptakes	O
16	,	O
17	but	O
18	the	O
19	intensity	O
20	was	O
21	less	O
22	than	O
23	that	O
24	of	O
25	the	O
26	sternum	O
27	.	O
1	Alveolar	O
2	lymphocytes	O
3	were	O
4	surprisingly	O
5	increased	O
6	in	O
7	most	O
8	patients	O
9	with	O
10	AIDS	O
11	(	O
12	mean	O
13	26	O
14	.	O
15	1	O
16	+/-	O
17	21	O
18	.	O
19	9	O
20	%;	O
21	range	O
22	1	O
23	-	O
24	76	O
25	%)	O
26	and	O
27	CGL	O
28	(	O
29	mean	O
30	26	O
31	.	O
32	6	O
33	+/-	O
34	22	O
35	.	O
36	6	O
37	%;	O
38	range	O
39	3	O
40	-	O
41	76	O
42	%)	O
43	with	O
44	criteria	O
45	of	O
46	activation	O
47	contrasting	O
48	with	O
49	the	O
50	blood	O
51	lymphopenia	O
52	.	O
1	Its	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	shows	O
7	extensive	O
8	homology	O
9	to	O
10	those	O
11	of	O
12	Drosophila	B
13	hsp70	I
14	,	O
15	trout	B
16	hsp70	I
17	,	O
18	Xenopus	B
19	hsp70	I
20	,	O
21	yeast	B
22	hsp70	I
23	,	O
24	and	O
25	some	O
26	homology	O
27	to	O
28	the	O
29	heat	B
30	-	I
31	inducible	I
32	dnaK	I
33	gene	I
34	product	I
35	of	O
36	Escherichia	O
37	coli	O
38	.	O
1	Multistep	O
2	transformation	O
3	by	O
4	defined	O
5	fragments	O
6	of	O
7	herpes	O
8	simplex	O
9	virus	O
10	type	O
11	2	O
12	DNA	O
13	:	O
14	oncogenic	O
15	region	O
16	and	O
17	its	O
18	gene	O
19	product	O
20	.	O
1	Comparison	O
2	with	O
3	a	O
4	recently	O
5	described	O
6	c	B
7	-	I
8	sis	I
9	cDNA	I
10	clone	I
11	(	O
12	Collins	O
13	et	O
14	al	O
15	.,	O
16	Nature	O
17	316	O
18	,	O
19	748	O
20	-	O
21	750	O
22	(	O
23	1985	O
24	))	O
25	revealed	O
26	that	O
27	the	O
28	1	O
29	.	O
30	9	O
31	kbp	O
32	DNA	O
33	region	O
34	contained	O
35	a	O
36	large	O
37	5	B
38	'	I
39	c	I
40	-	I
41	sis	I
42	exon	I
43	of	O
44	at	O
45	least	O
46	1050	O
47	bp	O
48	.	O
1	Surprisingly	O
2	,	O
3	a	O
4	C	O
5	to	O
6	G	O
7	transversion	O
8	at	O
9	the	O
10	first	O
11	residue	O
12	of	O
13	the	O
14	CAT	B
15	pentanucleotide	I
16	,	O
17	which	O
18	severely	O
19	impairs	O
20	the	O
21	activity	O
22	of	O
23	both	O
24	promoters	O
25	,	O
26	appears	O
27	to	O
28	increase	O
29	affinity	O
30	of	O
31	the	O
32	CAT	B
33	binding	I
34	protein	I
35	.	O
1	The	O
2	5	O
3	'	O
4	and	O
5	3	O
6	'	O
7	untranslated	O
8	sequences	O
9	contain	O
10	characteristic	O
11	sequences	O
12	that	O
13	are	O
14	involved	O
15	in	O
16	the	O
17	initiation	O
18	and	O
19	termination	O
20	of	O
21	transcription	O
22	,	O
23	including	O
24	two	O
25	possible	O
26	promoters	O
27	,	O
28	one	O
29	of	O
30	which	O
31	may	O
32	contain	O
33	two	O
34	overlapping	O
35	-	O
36	10	O
37	sequences	O
38	.	O
1	The	O
2	open	O
3	reading	O
4	frames	O
5	of	O
6	rbsD	B
7	,	O
8	rbsA	B
9	,	O
10	and	O
11	rbsC	B
12	encode	O
13	proteins	O
14	of	O
15	139	O
16	,	O
17	501	O
18	,	O
19	and	O
20	321	O
21	amino	O
22	acid	O
23	residues	O
24	,	O
25	respectively	O
26	.	O
1	In	O
2	order	O
3	to	O
4	study	O
5	the	O
6	influence	O
7	of	O
8	iron	O
9	overload	O
10	on	O
11	the	O
12	polymorphonuclear	O
13	leucocyte	O
14	(	O
15	PMN	O
16	)	O
17	metabolism	O
18	of	O
19	patients	O
20	on	O
21	chronic	O
22	hemodialysis	O
23	,	O
24	generation	O
25	of	O
26	superoxide	O
27	anion	O
28	(	O
29	O2	O
30	-)	O
31	by	O
32	PMN	O
33	in	O
34	whole	O
35	blood	O
36	was	O
37	compared	O
38	in	O
39	two	O
40	groups	O
41	of	O
42	hemodialyzed	O
43	patients	O
44	:	O
45	group	O
46	A	O
47	consisted	O
48	of	O
49	twenty	O
50	-	O
51	one	O
52	individuals	O
53	with	O
54	serum	O
55	ferritin	B
56	levels	O
57	above	O
58	1000	O
59	ng	O
60	/	O
61	ml	O
62	and	O
63	group	O
64	B	O
65	of	O
66	nineteen	O
67	individuals	O
68	with	O
69	serum	O
70	ferritin	B
71	levels	O
72	below	O
73	1000	O
74	ng	O
75	/	O
76	ml	O
77	.	O
1	The	O
2	coding	O
3	region	O
4	of	O
5	2385	O
6	nucleotides	O
7	corresponds	O
8	to	O
9	a	O
10	polypeptide	O
11	chain	O
12	of	O
13	795	O
14	amino	O
15	acids	O
16	,	O
17	giving	O
18	a	O
19	molecular	O
20	weight	O
21	of	O
22	91	O
23	,	O
24	555	O
25	for	O
26	the	O
27	hsp108	B
28	protein	I
29	.	O
1	The	O
2	second	O
3	group	O
4	of	O
5	homologous	O
6	elements	O
7	is	O
8	present	O
9	in	O
10	the	O
11	upstream	O
12	region	O
13	of	O
14	both	O
15	genes	O
16	.	O
1	A	O
2	centromere	O
3	in	O
4	S	O
5	.	O
6	cerevisiae	O
7	consists	O
8	of	O
9	a	O
10	region	O
11	of	O
12	DNA	O
13	,	O
14	approximately	O
15	150	O
16	bp	O
17	in	O
18	length	O
19	,	O
20	containing	O
21	three	O
22	important	O
23	sequence	O
24	elements	O
25	,	O
26	which	O
27	are	O
28	folded	O
29	with	O
30	proteins	O
31	into	O
32	a	O
33	specific	O
34	conformation	O
35	in	O
36	the	O
37	chromatin	O
38	(	O
39	the	O
40	yeast	O
41	kinetochore	O
42	).	O
1	Influence	O
2	of	O
3	cyclo	B
4	-	I
5	oxygenase	I
6	inhibition	O
7	and	O
8	of	O
9	leukotriene	B
10	receptor	I
11	blockade	O
12	on	O
13	pulmonary	O
14	vascular	O
15	pressure	O
16	/	O
17	cardiac	O
18	index	O
19	relationships	O
20	in	O
21	hyperoxic	O
22	and	O
23	in	O
24	hypoxic	O
25	dogs	O
26	.	O
1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	upstream	O
7	promoter	O
8	element	O
9	of	O
10	the	O
11	yeast	B
12	RP39A	I
13	gene	I
14	consists	O
15	of	O
16	these	O
17	identical	O
18	sequence	O
19	motifs	O
20	.	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	mammalian	O
6	erythroid	O
7	alpha	B
8	-	I
9	spectrin	I
10	evolved	O
11	by	O
12	duplication	O
13	and	O
14	rapid	O
15	divergence	O
16	from	O
17	an	O
18	ancestral	O
19	alpha	B
20	-	I
21	fodrin	I
22	-	I
23	like	I
24	gene	I
25	.	O
1	Northern	O
2	analyses	O
3	of	O
4	RNAs	O
5	from	O
6	mouse	O
7	tissues	O
8	and	O
9	cell	O
10	lines	O
11	indicated	O
12	that	O
13	p11	B
14	mRNA	I
15	levels	O
16	vary	O
17	widely	O
18	.	O
1	It	O
2	is	O
3	concluded	O
4	that	O
5	suppression	O
6	of	O
7	elevated	O
8	prolactin	B
9	levels	O
10	in	O
11	progressive	O
12	metastatic	O
13	breast	O
14	cancer	O
15	patients	O
16	is	O
17	not	O
18	effective	O
19	in	O
20	restoring	O
21	tumor	O
22	sensitivity	O
23	to	O
24	chemotherapy	O
25	.	O
1	These	O
2	results	O
3	imply	O
4	that	O
5	the	O
6	GCN3	B
7	product	I
8	can	O
9	promote	O
10	either	O
11	repression	O
12	or	O
13	activation	O
14	of	O
15	GCN4	B
16	expression	O
17	depending	O
18	on	O
19	amino	O
20	acid	O
21	availability	O
22	.	O
1	The	O
2	efficacy	O
3	of	O
4	these	O
5	immunosuppressive	O
6	drugs	O
7	is	O
8	clinical	O
9	proven	O
10	.	O
1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	of	O
6	the	O
7	S	O
8	.	O
9	aureus	O
10	peptide	O
11	carrying	O
12	the	O
13	phosphoryl	O
14	group	O
15	was	O
16	found	O
17	to	O
18	be	O
19	Gln	O
20	-	O
21	Val	O
22	-	O
23	Val	O
24	-	O
25	Ser	O
26	-	O
27	Thr	O
28	-	O
29	Phe	O
30	-	O
31	Met	O
32	-	O
33	Gly	O
34	-	O
35	Asn	O
36	-	O
37	Gly	O
38	-	O
39	Leu	O
40	-	O
41	Ala	O
42	-	O
43	Ile	O
44	-	O
45	Pro	O
46	-	O
47	His	O
48	-	O
49	Gly	O
50	-	O
51	Thr	O
52	-	O
53	Asp	O
54	-	O
55	Asp	O
56	.	O
1	The	O
2	rci	B
3	gene	I
4	was	O
5	fused	O
6	with	O
7	lacZ	B
8	and	O
9	its	O
10	gene	O
11	product	O
12	was	O
13	identified	O
14	by	O
15	Western	O
16	blot	O
17	analysis	O
18	.	O
1	Amounts	O
2	of	O
3	glucose	O
4	infused	O
5	during	O
6	the	O
7	last	O
8	20	O
9	min	O
10	of	O
11	each	O
12	2	O
13	hour	O
14	insulin	B
15	infusion	O
16	were	O
17	(	O
18	at	O
19	1	O
20	and	O
21	10	O
22	m	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	respectively	O
28	):	O
29	before	O
30	treatment	O
31	(	O
32	K	O
33	+	O
34	=	O
35	2	O
36	.	O
37	7	O
38	mmol	O
39	/	O
40	l	O
41	):	O
42	2	O
43	.	O
44	4	O
45	and	O
46	8	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	kg	O
52	/	O
53	min	O
54	;	O
55	after	O
56	spironolactone	O
57	(	O
58	K	O
59	+	O
60	=	O
61	3	O
62	.	O
63	9	O
64	mmol	O
65	/	O
66	l	O
67	):	O
68	3	O
69	.	O
70	3	O
71	and	O
72	15	O
73	.	O
74	4	O
75	mg	O
76	/	O
77	kg	O
78	/	O
79	min	O
80	;	O
81	after	O
82	indomethacine	O
83	(	O
84	K	O
85	+	O
86	=	O
87	3	O
88	.	O
89	7	O
90	mmol	O
91	/	O
92	l	O
93	):	O
94	5	O
95	and	O
96	19	O
97	mg	O
98	/	O
99	kg	O
100	/	O
101	min	O
102	after	O
103	stopping	O
104	drugs	O
105	(	O
106	K	O
107	+	O
108	=	O
109	2	O
110	.	O
111	9	O
112	mmol	O
113	/	O
114	l	O
115	):	O
116	2	O
117	.	O
118	5	O
119	and	O
120	5	O
121	.	O
122	3	O
123	mg	O
124	/	O
125	kg	O
126	/	O
127	min	O
128	.	O
1	The	O
2	bile	O
3	acid	O
4	sequestrants	O
5	(	O
6	cholestyramine	O
7	and	O
8	colestipol	O
9	),	O
10	nicotinic	O
11	acid	O
12	,	O
13	fenofibrate	O
14	and	O
15	inhibitors	O
16	of	O
17	hydroxymethylglutaryl	B
18	coenzyme	I
19	A	I
20	(	I
21	HMG	I
22	CoA	I
23	)	I
24	reductase	I
25	(	O
26	e	O
27	.	O
28	g	O
29	.	O
30	lovastatin	O
31	or	O
32	simvastatin	O
33	)	O
34	are	O
35	the	O
36	most	O
37	effective	O
38	drugs	O
39	for	O
40	use	O
41	in	O
42	patients	O
43	with	O
44	primary	O
45	hypercholesterolaemia	O
46	;	O
47	these	O
48	agents	O
49	reduce	O
50	plasma	O
51	concentrations	O
52	of	O
53	total	O
54	and	O
55	LDL	B
56	-	I
57	cholesterol	I
58	by	O
59	15	O
60	to	O
61	45	O
62	%.	O
1	The	O
2	effects	O
3	of	O
4	glutaraldehyde	O
5	on	O
6	dimensions	O
7	and	O
8	ultrastructure	O
9	of	O
10	microvascular	O
11	beds	O
12	in	O
13	rat	O
14	mesentery	O
15	were	O
16	studied	O
17	in	O
18	two	O
19	kinds	O
20	of	O
21	experiment	O
22	,	O
23	administering	O
24	the	O
25	fixative	O
26	by	O
27	intra	O
28	-	O
29	arterial	O
30	perfusion	O
31	at	O
32	a	O
33	pressure	O
34	of	O
35	80	O
36	mm	O
37	Hg	O
38	and	O
39	by	O
40	superfusion	O
41	of	O
42	the	O
43	exteriorized	O
44	mesenteric	O
45	membrane	O
46	.	O
1	Within	O
2	Stage	O
3	IA	O
4	,	O
5	141	O
6	patients	O
7	had	O
8	well	O
9	differentiated	O
10	tumor	O
11	(	O
12	G1	O
13	),	O
14	20	O
15	had	O
16	moderately	O
17	well	O
18	differentiated	O
19	tumor	O
20	(	O
21	G2	O
22	),	O
23	and	O
24	12	O
25	patients	O
26	had	O
27	poorly	O
28	differentiated	O
29	(	O
30	G3	O
31	).	O
1	After	O
2	age	O
3	30	O
4	,	O
5	mean	O
6	hemoglobin	B
7	levels	O
8	for	O
9	men	O
10	gradually	O
11	declined	O
12	,	O
13	while	O
14	those	O
15	in	O
16	women	O
17	rose	O
18	,	O
19	so	O
20	that	O
21	the	O
22	sex	O
23	difference	O
24	diminished	O
25	after	O
26	60	O
27	years	O
28	of	O
29	age	O
30	.	O
1	40	O
2	.	O
3	3	O
4	+/-	O
5	10	O
6	.	O
7	1	O
8	mg	O
9	/	O
10	l	O
11	(	O
12	SD	O
13	)	O
14	vs	O
15	31	O
16	.	O
17	2	O
18	+/-	O
19	8	O
20	.	O
21	0	O
22	,	O
23	P	O
24	less	O
25	than	O
26	0	O
27	.	O
28	01	O
29	).	O
30	beta	B
31	2m	I
32	was	O
33	not	O
34	significantly	O
35	higher	O
36	in	O
37	patients	O
38	with	O
39	bone	O
40	cysts	O
41	(	O
42	37	O
43	.	O
44	7	O
45	+/-	O
46	11	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	l	O
52	vs	O
53	37	O
54	.	O
55	0	O
56	+/-	O
57	10	O
58	.	O
59	0	O
60	),	O
61	but	O
62	median	O
63	duration	O
64	of	O
65	dialysis	O
66	was	O
67	significantly	O
68	(	O
69	P	O
70	less	O
71	than	O
72	0	O
73	.	O
74	01	O
75	)	O
76	longer	O
77	in	O
78	patients	O
79	with	O
80	bone	O
81	cysts	O
82	(	O
83	90	O
84	vs	O
85	57	O
86	months	O
87	).	O
88	beta	B
89	2m	I
90	was	O
91	lower	O
92	in	O
93	patients	O
94	maintained	O
95	on	O
96	dialysis	O
97	for	O
98	less	O
99	than	O
100	1	O
101	year	O
102	and	O
103	whose	O
104	residual	O
105	urine	O
106	volume	O
107	was	O
108	greater	O
109	than	O
110	0	O
111	.	O
112	1	O
113	litre	O
114	per	O
115	day	O
116	.	O
1	No	O
2	effect	O
3	was	O
4	found	O
5	on	O
6	grooming	O
7	behavior	O
8	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	wild	O
6	-	O
7	type	O
8	strain	O
9	containing	O
10	a	O
11	temperature	B
12	-	I
13	sensitive	I
14	threonyl	I
15	-	I
16	tRNA	I
17	synthetase	I
18	mutation	I
19	showed	O
20	increased	O
21	thr	B
22	operon	I
23	expression	O
24	at	O
25	the	O
26	non	O
27	-	O
28	permissive	O
29	temperature	O
30	,	O
31	whereas	O
32	none	O
33	of	O
34	the	O
35	mutants	O
36	showed	O
37	any	O
38	change	O
39	.	O
1	The	O
2	mean	O
3	weight	O
4	and	O
5	height	O
6	velocities	O
7	were	O
8	148	O
9	%	O
10	and	O
11	122	O
12	%	O
13	of	O
14	the	O
15	standard	O
16	,	O
17	respectively	O
18	.	O
1	A	O
2	complementary	O
3	study	O
4	,	O
5	showing	O
6	a	O
7	good	O
8	agreement	O
9	between	O
10	surface	O
11	and	O
12	oesophageal	O
13	EMGd	O
14	seems	O
15	to	O
16	confirm	O
17	that	O
18	surface	O
19	EMGd	O
20	is	O
21	a	O
22	useful	O
23	and	O
24	promising	O
25	tool	O
26	for	O
27	clinical	O
28	investigation	O
29	.	O
1	The	O
2	DNA	O
3	sequence	O
4	encodes	O
5	a	O
6	protein	O
7	of	O
8	1520	O
9	amino	O
10	acids	O
11	with	O
12	sequence	O
13	homology	O
14	to	O
15	the	O
16	human	B
17	c	I
18	-	I
19	abl	I
20	proto	I
21	-	I
22	oncogene	I
23	product	I
24	,	O
25	beginning	O
26	at	O
27	the	O
28	amino	O
29	terminus	O
30	and	O
31	extending	O
32	656	O
33	amino	O
34	acids	O
35	through	O
36	the	O
37	region	O
38	essential	O
39	for	O
40	tyrosine	B
41	kinase	I
42	activity	O
43	.	O
1	In	O
2	64	O
3	%	O
4	a	O
5	small	O
6	cardiac	O
7	vein	O
8	does	O
9	not	O
10	exist	O
11	,	O
12	but	O
13	its	O
14	origin	O
15	,	O
16	the	O
17	right	O
18	marginal	O
19	vein	O
20	,	O
21	joins	O
22	the	O
23	system	O
24	of	O
25	anterior	O
26	cardiac	O
27	veins	O
28	.	O
1	A	O
2	randomized	O
3	,	O
4	prospective	O
5	study	O
6	was	O
7	conducted	O
8	to	O
9	compare	O
10	ovarian	O
11	stimulation	O
12	with	O
13	human	B
14	menopausal	I
15	gonadotropin	I
16	(	O
17	hMG	B
18	)	O
19	and	O
20	human	B
21	follicle	I
22	-	I
23	stimulating	I
24	hormone	I
25	(	O
26	hFSH	B
27	)	O
28	in	O
29	an	O
30	in	O
31	vitro	O
32	fertilization	O
33	and	O
34	embryo	O
35	transfer	O
36	(	O
37	IVF	O
38	-	O
39	ET	O
40	)	O
41	program	O
42	.	O
1	Our	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	mtr	B
7	product	I
8	causes	O
9	both	O
10	transcription	O
11	attenuation	O
12	and	O
13	inhibition	O
14	of	O
15	translation	O
16	of	O
17	trpE	B
18	mRNA	I
19	.	O
1	The	O
2	genetic	O
3	basis	O
4	for	O
5	the	O
6	expression	O
7	of	O
8	a	O
9	latent	O
10	VH	B
11	allotype	I
12	in	O
13	the	O
14	rabbit	O
15	was	O
16	investigated	O
17	.	O
1	Potentiation	O
2	of	O
3	the	O
4	thrombolytic	O
5	efficacy	O
6	of	O
7	single	B
8	-	I
9	chain	I
10	urokinase	I
11	(	O
12	Pro	B
13	-	I
14	urokinase	I
15	)	O
16	by	O
17	heparin	O
18	.	O
1	Symptomatic	O
2	hyperventilators	O
3	had	O
4	a	O
5	larger	O
6	number	O
7	of	O
8	sighs	O
9	and	O
10	abnormally	O
11	wide	O
12	fluctuations	O
13	in	O
14	baseline	O
15	for	O
16	inspiratory	O
17	time	O
18	,	O
19	expiratory	O
20	time	O
21	,	O
22	and	O
23	PETCO2	O
24	.	O
1	It	O
2	is	O
3	suggested	O
4	that	O
5	the	O
6	use	O
7	of	O
8	endogenous	O
9	creatinine	O
10	clearance	O
11	to	O
12	estimate	O
13	the	O
14	glomerular	O
15	filtration	O
16	rate	O
17	(	O
18	GFR	O
19	)	O
20	requires	O
21	caution	O
22	and	O
23	the	O
24	recognition	O
25	of	O
26	the	O
27	limitations	O
28	of	O
29	the	O
30	method	O
31	,	O
32	and	O
33	that	O
34	simpler	O
35	techniques	O
36	(	O
37	serum	O
38	creatinine	O
39	or	O
40	estimated	O
41	endogenous	O
42	creatinine	O
43	clearance	O
44	)	O
45	are	O
46	preferable	O
47	in	O
48	routine	O
49	practice	O
50	.	O
1	This	O
2	led	O
3	to	O
4	the	O
5	conclusion	O
6	that	O
7	the	O
8	metatarsal	O
9	artery	O
10	should	O
11	be	O
12	used	O
13	for	O
14	toe	O
15	MP	O
16	joint	O
17	grafts	O
18	,	O
19	while	O
20	the	O
21	unilateral	O
22	proper	O
23	digital	O
24	artery	O
25	is	O
26	suitable	O
27	for	O
28	toe	O
29	PIP	O
30	joint	O
31	grafts	O
32	,	O
33	together	O
34	with	O
35	concomitant	O
36	or	O
37	dorsal	O
38	cutaneous	O
39	vein	O
40	.	O
1	Esophageal	O
2	brush	O
3	cytological	O
4	screening	O
5	was	O
6	undertaken	O
7	and	O
8	blood	O
9	concentrations	O
10	of	O
11	micronutrients	O
12	(	O
13	vitamin	O
14	A	O
15	,	O
16	E	O
17	,	O
18	B12	O
19	,	O
20	folic	O
21	acid	O
22	and	O
23	methionine	O
24	)	O
25	determined	O
26	from	O
27	adults	O
28	at	O
29	risk	O
30	for	O
31	esophageal	O
32	carcinoma	O
33	(	O
34	EC	O
35	)	O
36	in	O
37	Transkei	O
38	and	O
39	Ciskei	O
40	,	O
41	Southern	O
42	Africa	O
43	.	O
1	Sequential	O
2	MR	O
3	examinations	O
4	of	O
5	the	O
6	nasal	O
7	cavity	O
8	and	O
9	paranasal	O
10	sinuses	O
11	were	O
12	performed	O
13	within	O
14	a	O
15	6	O
16	-	O
17	8	O
18	h	O
19	period	O
20	in	O
21	five	O
22	normal	O
23	volunteers	O
24	.	O
1	Comparison	O
2	was	O
3	made	O
4	with	O
5	other	O
6	neuroradiological	O
7	imaging	O
8	modalities	O
9	including	O
10	CT	O
11	,	O
12	myelography	O
13	,	O
14	CT	O
15	ventriculography	O
16	,	O
17	and	O
18	CT	O
19	myelocisternography	O
20	.	O
1	The	O
2	feed	O
3	given	O
4	to	O
5	young	O
6	broiler	O
7	chickens	O
8	was	O
9	contaminated	O
10	artificially	O
11	with	O
12	Salmonella	O
13	kedougou	O
14	,	O
15	a	O
16	serotype	O
17	associated	O
18	with	O
19	both	O
20	subclinical	O
21	infections	O
22	in	O
23	commercially	O
24	reared	O
25	chickens	O
26	and	O
27	food	O
28	poisoning	O
29	in	O
30	humans	O
31	.	O
1	Interpersonal	O
2	style	O
3	differences	O
4	among	O
5	drug	O
6	abusers	O
7	were	O
8	explored	O
9	using	O
10	Ryan	O
11	'	O
12	s	O
13	(	O
14	1977	O
15	)	O
16	typological	O
17	system	O
18	of	O
19	FIRO	O
20	-	O
21	B	O
22	interpretation	O
23	.	O
1	Sera	O
2	from	O
3	euthyroid	O
4	post	O
5	-	O
6	menopausal	O
7	or	O
8	pregnant	O
9	women	O
10	yielded	O
11	TSH	B
12	levels	O
13	within	O
14	the	O
15	normal	O
16	range	O
17	.	O
1	Existence	O
2	and	O
3	uniqueness	O
4	of	O
5	solutions	O
6	of	O
7	the	O
8	appropriate	O
9	boundary	O
10	value	O
11	problems	O
12	are	O
13	established	O
14	,	O
15	in	O
16	the	O
17	case	O
18	of	O
19	small	O
20	permeability	O
21	coefficients	O
22	and	O
23	transport	O
24	rates	O
25	,	O
26	or	O
27	large	O
28	diffusion	O
29	coefficients	O
30	and	O
31	small	O
32	resistance	O
33	to	O
34	flow	O
35	constants	O
36	.	O
1	The	O
2	results	O
3	presented	O
4	suggest	O
5	that	O
6	TIQ	O
7	reduces	O
8	the	O
9	turnover	O
10	rate	O
11	of	O
12	the	O
13	nigrostriatal	O
14	dopamine	O
15	neurons	O
16	after	O
17	repeated	O
18	administration	O
19	for	O
20	a	O
21	long	O
22	period	O
23	in	O
24	mice	O
25	.	O
1	The	O
2	median	O
3	survival	O
4	is	O
5	not	O
6	reached	O
7	with	O
8	a	O
9	median	O
10	follow	O
11	-	O
12	up	O
13	time	O
14	of	O
15	9	O
16	.	O
17	6	O
18	years	O
19	.	O
1	Critical	O
2	evaluation	O
3	of	O
4	various	O
5	methods	O
6	of	O
7	determining	O
8	markers	O
9	of	O
10	fetal	O
11	maturity	O
12	in	O
13	amniotic	O
14	fluid	O
1	Of	O
2	the	O
3	43	O
4	infants	O
5	with	O
6	a	O
7	(	O
8	probable	O
9	)	O
10	loss	O
11	18	O
12	were	O
13	examined	O
14	again	O
15	at	O
16	3	O
17	months	O
18	corrected	O
19	age	O
20	.	O
1	Variety	O
2	of	O
3	cows	O
4	and	O
5	sires	O
6	according	O
7	to	O
8	types	O
9	of	O
10	dermatoglyphics	O
11	(	O
12	patterns	O
13	)	O
14	of	O
15	the	O
16	nose	O
17	-	O
18	labial	O
19	mirror	O
20	of	O
21	cattle	O
1	Neuromyelitis	O
2	optica	O
3	(	O
4	Devic	O
5	'	O
6	s	O
7	syndrome	O
8	):	O
9	not	O
10	always	O
11	multiple	O
12	sclerosis	O
13	.	O
1	None	O
2	had	O
3	a	O
4	past	O
5	history	O
6	of	O
7	opportunistic	O
8	infections	O
9	;	O
10	neither	O
11	did	O
12	any	O
13	have	O
14	lymphopenia	O
15	.	O
1	The	O
2	temporal	O
3	and	O
4	static	O
5	plasma	O
6	concentration	O
7	-	O
8	effect	O
9	relationships	O
10	were	O
11	evaluated	O
12	by	O
13	pharmacodynamic	O
14	modeling	O
15	and	O
16	linear	O
17	regression	O
18	.	O
1	Possible	O
2	factors	O
3	for	O
4	the	O
5	development	O
6	of	O
7	psychotic	O
8	symptomatology	O
9	during	O
10	group	O
11	activities	O
12	and	O
13	the	O
14	role	O
15	of	O
16	group	O
17	dynamics	O
18	acting	O
19	as	O
20	stress	O
21	factors	O
22	precipitating	O
23	functional	O
24	psychoses	O
25	,	O
26	especially	O
27	bipolar	O
28	manifestations	O
29	,	O
30	are	O
31	discussed	O
32	.	O
1	Baseline	O
2	measurements	O
3	of	O
4	forced	O
5	expiratory	O
6	volume	O
7	in	O
8	1	O
9	s	O
10	(	O
11	FEV1	O
12	),	O
13	specific	O
14	airway	O
15	conductance	O
16	(	O
17	SGaw	O
18	)	O
19	and	O
20	the	O
21	provocative	O
22	dose	O
23	of	O
24	carbachol	O
25	causing	O
26	a	O
27	35	O
28	%	O
29	reduction	O
30	in	O
31	SGaw	O
32	(	O
33	PD35	O
34	),	O
35	and	O
36	a	O
37	20	O
38	%	O
39	reduction	O
40	in	O
41	FEV1	O
42	(	O
43	PD20	O
44	)	O
45	were	O
46	established	O
47	on	O
48	entry	O
49	while	O
50	each	O
51	subject	O
52	was	O
53	still	O
54	smoking	O
55	.	O
1	SPECT	O
2	is	O
3	an	O
4	important	O
5	aid	O
6	in	O
7	the	O
8	diagnosis	O
9	of	O
10	AIDS	O
11	dementia	O
12	complex	O
13	and	O
14	contributes	O
15	to	O
16	the	O
17	understanding	O
18	of	O
19	the	O
20	pathophysiological	O
21	mechanisms	O
22	of	O
23	this	O
24	disorder	O
25	.	O
1	The	O
2	murine	B
3	MHC	I
4	class	I
5	I	I
6	genes	I
7	,	O
8	H	B
9	-	I
10	2Dq	I
11	and	O
12	H	B
13	-	I
14	2Lq	I
15	,	O
16	are	O
17	strikingly	O
18	homologous	O
19	to	O
20	each	O
21	other	O
22	,	O
23	H	B
24	-	I
25	2Ld	I
26	,	O
27	and	O
28	two	O
29	genes	O
30	reported	O
31	to	O
32	encode	O
33	tumor	O
34	-	O
35	specific	O
36	antigens	O
37	.	O
1	We	O
2	concluded	O
3	that	O
4	Ga	O
5	-	O
6	fbg	O
7	scintigraphy	O
8	is	O
9	a	O
10	very	O
11	simple	O
12	method	O
13	and	O
14	sufficiently	O
15	useful	O
16	for	O
17	detecting	O
18	active	O
19	left	O
20	ventricular	O
21	thrombi	O
22	and	O
23	for	O
24	monitoring	O
25	the	O
26	effect	O
27	of	O
28	anticoagulant	O
29	therapy	O
30	.	O
1	GRFI	B
2	bound	O
3	to	O
4	sequences	O
5	at	O
6	the	O
7	negative	O
8	regulatory	O
9	elements	O
10	(	O
11	silencers	O
12	)	O
13	of	O
14	the	O
15	silent	B
16	mating	I
17	type	I
18	loci	I
19	HML	I
20	E	I
21	and	O
22	HMR	B
23	E	I
24	and	O
25	to	O
26	the	O
27	upstream	O
28	activating	O
29	sequence	O
30	(	O
31	UAS	O
32	)	O
33	required	O
34	for	O
35	transcription	O
36	of	O
37	the	O
38	MAT	B
39	alpha	I
40	genes	I
41	.	O
1	Mutations	O
2	at	O
3	the	O
4	suf12	B
5	locus	I
6	were	O
7	isolated	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	as	O
12	extragenic	O
13	suppressors	O
14	of	O
15	+	O
16	1	O
17	frameshift	O
18	mutations	O
19	in	O
20	glycine	O
21	(	O
22	GGX	O
23	)	O
24	and	O
25	proline	O
26	(	O
27	CCX	O
28	)	O
29	codons	O
30	,	O
31	as	O
32	well	O
33	as	O
34	UGA	O
35	and	O
36	UAG	O
37	nonsense	O
38	mutations	O
39	.	O
1	Time	O
2	delay	O
3	effects	O
4	on	O
5	the	O
6	tensile	O
7	bond	O
8	strength	O
9	developed	O
10	by	O
11	the	O
12	Silicoater	O
13	.	O
1	The	O
2	future	O
3	of	O
4	research	O
5	with	O
6	interferon	B
7	may	O
8	be	O
9	divided	O
10	into	O
11	three	O
12	areas	O
13	:	O
14	Efforts	O
15	must	O
16	be	O
17	made	O
18	to	O
19	determine	O
20	how	O
21	best	O
22	to	O
23	translate	O
24	the	O
25	in	O
26	vitro	O
27	synergy	O
28	into	O
29	clinically	O
30	meaningful	O
31	terms	O
32	;	O
33	in	O
34	order	O
35	to	O
36	exploit	O
37	the	O
38	fullest	O
39	potential	O
40	of	O
41	IFN	B
42	,	O
43	research	O
44	is	O
45	moving	O
46	toward	O
47	using	O
48	this	O
49	agent	O
50	earlier	O
51	in	O
52	disease	O
53	either	O
54	as	O
55	an	O
56	adjuvant	O
57	after	O
58	tumor	O
59	debulking	O
60	or	O
61	after	O
62	initial	O
63	diagnosis	O
64	;	O
65	the	O
66	medical	O
67	community	O
68	must	O
69	rethink	O
70	the	O
71	natural	O
72	history	O
73	of	O
74	some	O
75	diseases	O
76	,	O
77	because	O
78	the	O
79	fullest	O
80	potential	O
81	of	O
82	the	O
83	biologic	O
84	agents	O
85	will	O
86	most	O
87	likely	O
88	manifest	O
89	itself	O
90	when	O
91	these	O
92	agents	O
93	are	O
94	used	O
95	together	O
96	.	O
1	Contrary	O
2	to	O
3	the	O
4	observation	O
5	made	O
6	with	O
7	other	O
8	S	O
9	.	O
10	pombe	O
11	genes	O
12	transcribed	O
13	in	O
14	the	O
15	budding	O
16	yeast	O
17	,	O
18	the	O
19	heterologous	O
20	actin	B
21	gene	I
22	transcript	I
23	is	O
24	initiated	O
25	39	O
26	nucleotides	O
27	upstream	O
28	of	O
29	the	O
30	initiation	O
31	start	O
32	site	O
33	used	O
34	in	O
35	the	O
36	homologous	O
37	yeast	O
38	.	O
1	In	O
2	contrast	O
3	to	O
4	this	O
5	mRNA	O
6	,	O
7	90	O
8	%	O
9	of	O
10	alpha	B
11	and	I
12	beta	I
13	actin	I
14	mRNAs	I
15	were	O
16	translated	O
17	in	O
18	both	O
19	myoblasts	O
20	and	O
21	myotubes	O
22	.	O
1	Cephradine	O
2	250	O
3	mg	O
4	at	O
5	night	O
6	for	O
7	12	O
8	months	O
9	was	O
10	given	O
11	as	O
12	a	O
13	prophylactic	O
14	measure	O
15	to	O
16	33	O
17	female	O
18	patients	O
19	of	O
20	mean	O
21	age	O
22	41	O
23	.	O
24	6	O
25	years	O
26	,	O
27	who	O
28	had	O
29	a	O
30	history	O
31	in	O
32	the	O
33	preceding	O
34	12	O
35	months	O
36	of	O
37	between	O
38	three	O
39	and	O
40	24	O
41	(	O
42	median	O
43	=	O
44	7	O
45	)	O
46	episodes	O
47	of	O
48	frequency	O
49	and	O
50	/	O
51	or	O
52	dysuria	O
53	.	O
1	The	O
2	size	O
3	of	O
4	the	O
5	group	O
6	allocated	O
7	to	O
8	the	O
9	good	O
10	compliance	O
11	category	O
12	by	O
13	the	O
14	use	O
15	of	O
16	the	O
17	digoxin	O
18	marker	O
19	was	O
20	equivalent	O
21	in	O
22	size	O
23	to	O
24	a	O
25	group	O
26	of	O
27	patients	O
28	who	O
29	had	O
30	returned	O
31	less	O
32	than	O
33	15	O
34	%	O
35	of	O
36	their	O
37	prescribed	O
38	dose	O
39	or	O
40	reported	O
41	a	O
42	deviation	O
43	of	O
44	less	O
45	than	O
46	6	O
47	%	O
48	from	O
49	their	O
50	prescription	O
51	.	O
1	The	O
2	correlation	O
3	between	O
4	PaCO2	O
5	and	O
6	PtcO2	O
7	in	O
8	RDS	O
9	was	O
10	insufficient	O
11	to	O
12	make	O
13	clinical	O
14	judgement	O
15	.	O
1	UK	O
2	'	O
3	s	O
4	biotechnology	O
5	lacking	O
6	specialists	O
7	.	O
1	To	O
2	evaluate	O
3	the	O
4	effect	O
5	of	O
6	altitude	O
7	on	O
8	adolescent	O
9	growth	O
10	and	O
11	development	O
12	,	O
13	three	O
14	groups	O
15	of	O
16	healthy	O
17	,	O
18	well	O
19	-	O
20	nourished	O
21	youth	O
22	of	O
23	similar	O
24	socioeconomic	O
25	status	O
26	and	O
27	ethnic	O
28	grouping	O
29	who	O
30	resided	O
31	at	O
32	sea	O
33	level	O
34	(	O
35	n	O
36	=	O
37	1262	O
38	subjects	O
39	),	O
40	mid	O
41	-	O
42	altitude	O
43	(	O
44	n	O
45	=	O
46	1743	O
47	subjects	O
48	),	O
49	and	O
50	high	O
51	altitude	O
52	(	O
53	n	O
54	=	O
55	1137	O
56	subjects	O
57	)	O
58	were	O
59	studied	O
60	.	O
1	We	O
2	have	O
3	improved	O
4	our	O
5	system	O
6	for	O
7	nuclear	O
8	contour	O
9	digitization	O
10	and	O
11	determined	O
12	its	O
13	theoretical	O
14	limitations	O
15	by	O
16	digitizing	O
17	standardized	O
18	objects	O
19	.	O
1	Rapid	O
2	detection	O
3	of	O
4	radioisotopically	O
5	contaminated	O
6	test	O
7	serum	O
8	before	O
9	radioassay	O
10	of	O
11	vitamin	O
12	B12	O
13	.	O
1	Psychological	O
2	disturbance	O
3	was	O
4	greater	O
5	in	O
6	the	O
7	high	O
8	life	O
9	stress	O
10	group	O
11	as	O
12	indicated	O
13	by	O
14	significant	O
15	elevations	O
16	on	O
17	the	O
18	global	O
19	severity	O
20	index	O
21	of	O
22	the	O
23	Symptom	O
24	Checklist	O
25	-	O
26	90	O
27	and	O
28	elevations	O
29	on	O
30	somatization	O
31	,	O
32	obsessive	O
33	compulsive	O
34	,	O
35	interpersonal	O
36	sensitivity	O
37	,	O
38	depression	O
39	,	O
40	anxiety	O
41	and	O
42	psychoticism	O
43	subscales	O
44	.	O
1	Histopathological	O
2	examination	O
3	revealed	O
4	dose	O
5	-	O
6	related	O
7	proliferation	O
8	of	O
9	type	O
10	II	O
11	pneumocytes	O
12	in	O
13	dams	O
14	and	O
15	proliferation	O
16	of	O
17	interstitial	O
18	cells	O
19	and	O
20	delayed	O
21	septal	O
22	/	O
23	capillary	O
24	development	O
25	in	O
26	neonates	O
27	.(	O
28	ABSTRACT	O
29	TRUNCATED	O
30	AT	O
31	250	O
32	WORDS	O
33	)	O
1	The	O
2	effects	O
3	of	O
4	anabolic	O
5	implants	O
6	on	O
7	rate	O
8	,	O
9	composition	O
10	and	O
11	energetic	O
12	efficiency	O
13	of	O
14	growth	O
15	were	O
16	determined	O
17	in	O
18	steers	O
19	fed	O
20	diets	O
21	varying	O
22	in	O
23	forage	O
24	and	O
25	grain	O
26	content	O
27	.	O
1	The	O
2	interaction	O
3	of	O
4	radiation	O
5	and	O
6	hyperthermia	O
7	was	O
8	systematically	O
9	studied	O
10	in	O
11	the	O
12	Dunning	O
13	R3327G	O
14	prostatic	O
15	adenocarcinoma	O
16	,	O
17	the	O
18	preeminent	O
19	animal	O
20	model	O
21	for	O
22	human	O
23	prostatic	O
24	cancer	O
25	.	O
1	Nuclear	B
2	factor	I
3	III	I
4	(	O
5	NFIII	B
6	)	O
7	is	O
8	a	O
9	protein	O
10	from	O
11	HeLa	O
12	cells	O
13	that	O
14	stimulates	O
15	the	O
16	initiation	O
17	of	O
18	adenovirus	O
19	type	O
20	2	O
21	(	O
22	Ad2	O
23	)	O
24	DNA	O
25	replication	O
26	by	O
27	binding	O
28	to	O
29	a	O
30	specific	O
31	nucleotide	O
32	sequence	O
33	in	O
34	the	O
35	origin	O
36	,	O
37	adjacent	O
38	to	O
39	the	O
40	nuclear	B
41	factor	I
42	I	I
43	recognition	I
44	site	I
45	.	O
1	Quantitative	O
2	computed	O
3	tomography	O
4	for	O
5	measuring	O
6	vertebral	O
7	bone	O
8	mineral	O
9	content	O
10	offers	O
11	high	O
12	sensitivity	O
13	and	O
14	reproducibility	O
15	.	O
1	Kf	O
2	,	O
3	c	O
4	and	O
5	CT	O
6	(	O
7	referenced	O
8	to	O
9	the	O
10	initial	O
11	lung	O
12	mass	O
13	)	O
14	decreased	O
15	linearly	O
16	with	O
17	reductions	O
18	in	O
19	lung	O
20	mass	O
21	%	O
22	delta	O
23	Kf	O
24	,	O
25	c	O
26	=	O
27	1	O
28	.	O
29	26	O
30	-	O
31	0	O
32	.	O
33	98	O
34	%	O
35	mass	O
36	removed	O
37	(	O
38	r	O
39	=	O
40	0	O
41	.	O
42	90	O
43	,	O
44	P	O
45	less	O
46	than	O
47	0	O
48	.	O
49	01	O
50	)	O
51	and	O
52	%	O
53	delta	O
54	CT	O
55	=	O
56	-	O
57	3	O
58	.	O
59	99	O
60	-	O
61	0	O
62	.	O
63	98	O
64	%	O
65	mass	O
66	removed	O
67	(	O
68	r	O
69	=	O
70	0	O
71	.	O
72	82	O
73	,	O
74	P	O
75	less	O
76	than	O
77	0	O
78	.	O
79	01	O
80	)	O
81	relationships	O
82	that	O
83	were	O
84	not	O
85	altered	O
86	by	O
87	blocker	O
88	pretreatment	O
89	.(	O
90	ABSTRACT	O
91	TRUNCATED	O
92	AT	O
93	250	O
94	WORDS	O
95	)	O
1	Overall	O
2	least	O
3	-	O
4	squares	O
5	means	O
6	for	O
7	uncooked	O
8	and	O
9	cooked	O
10	longissimus	O
11	muscle	O
12	and	O
13	subcutaneous	O
14	fat	O
15	were	O
16	63	O
17	.	O
18	32	O
19	,	O
20	80	O
21	.	O
22	27	O
23	and	O
24	98	O
25	.	O
26	90	O
27	mg	O
28	of	O
29	cholesterol	O
30	/	O
31	100	O
32	g	O
33	of	O
34	tissue	O
35	,	O
36	respectively	O
37	.	O
1	The	O
2	role	O
3	of	O
4	supercritical	O
5	fluid	O
6	chromatography	O
7	(	O
8	SFC	O
9	)	O
10	as	O
11	a	O
12	viable	O
13	technique	O
14	for	O
15	analyzing	O
16	agricultural	O
17	products	O
18	has	O
19	been	O
20	investigated	O
21	using	O
22	packed	O
23	and	O
24	capillary	O
25	column	O
26	methodology	O
27	.	O
1	Ovarian	O
2	tumors	O
3	in	O
4	pregnancy	O
5	.	O
1	Ultrastructural	O
2	study	O
3	of	O
4	polyarteritis	O
1	Five	O
2	out	O
3	of	O
4	eight	O
5	consecutive	O
6	cases	O
7	with	O
8	initial	O
9	symptoms	O
10	of	O
11	a	O
12	'	O
13	midline	O
14	granuloma	O
15	'	O
16	were	O
17	identified	O
18	as	O
19	malignant	O
20	histiocytosis	O
21	(	O
22	histiocytic	O
23	sarcoma	O
24	)	O
25	which	O
26	within	O
27	5	O
28	months	O
29	to	O
30	4	O
31	years	O
32	led	O
33	to	O
34	generalization	O
35	and	O
36	death	O
37	.	O
1	All	O
2	patients	O
3	then	O
4	received	O
5	suxamethonium	O
6	1	O
7	.	O
8	5	O
9	mg	O
10	kg	O
11	-	O
12	1	O
13	i	O
14	.	O
15	v	O
16	.	O
1	The	O
2	highest	O
3	postoperative	O
4	CK	B
5	-	I
6	MB	I
7	level	O
8	was	O
9	less	O
10	after	O
11	BC	O
12	(	O
13	BC	O
14	,	O
15	31	O
16	+/-	O
17	17	O
18	U	O
19	/	O
20	L	O
21	;	O
22	CC	O
23	,	O
24	56	O
25	+/-	O
26	13	O
27	U	O
28	/	O
29	L	O
30	;	O
31	p	O
32	less	O
33	than	O
34	0	O
35	.	O
36	05	O
37	).	O
1	No	O
2	relevant	O
3	changes	O
4	in	O
5	heart	O
6	rate	O
7	,	O
8	body	O
9	weight	O
10	,	O
11	and	O
12	plasma	O
13	levels	O
14	of	O
15	renin	B
16	activity	O
17	and	O
18	aldosterone	O
19	concentration	O
20	were	O
21	observed	O
22	.	O
1	The	O
2	small	O
3	size	O
4	and	O
5	placement	O
6	of	O
7	the	O
8	mutagenesis	O
9	marker	O
10	(	O
11	the	O
12	supF	B
13	suppressor	I
14	tRNA	I
15	gene	I
16	from	I
17	Escherichia	I
18	coli	I
19	)	O
20	within	O
21	the	O
22	vector	O
23	substantially	O
24	reduced	O
25	the	O
26	frequency	O
27	of	O
28	spontaneous	O
29	mutations	O
30	normally	O
31	observed	O
32	after	O
33	transfection	O
34	of	O
35	mammalian	O
36	cells	O
37	with	O
38	plasmid	O
39	DNA	O
40	;	O
41	hence	O
42	,	O
43	UV	O
44	-	O
45	induced	O
46	mutations	O
47	were	O
48	easily	O
49	identified	O
50	above	O
51	the	O
52	spontaneous	O
53	background	O
54	.	O
1	Ciprofloxacin	O
2	:	O
3	an	O
4	overview	O
5	of	O
6	adverse	O
7	experiences	O
8	.	O
1	The	O
2	rho	B
3	genes	I
4	comprise	O
5	an	O
6	evolutionarily	O
7	conserved	O
8	family	O
9	with	O
10	significant	O
11	homology	O
12	to	O
13	the	O
14	ras	B
15	oncogene	I
16	family	I
17	.	O
1	Development	O
2	of	O
3	a	O
4	yeast	O
5	system	O
6	to	O
7	assay	O
8	mutational	O
9	specificity	O
10	.	O
1	A	O
2	preliminary	O
3	study	O
4	on	O
5	pyogenic	O
6	arthritis	O
7	.	O
1	As	O
2	a	O
3	last	O
4	resort	O
5	,	O
6	it	O
7	may	O
8	be	O
9	possible	O
10	to	O
11	maintain	O
12	a	O
13	patient	O
14	on	O
15	dialysis	O
16	in	O
17	reasonable	O
18	health	O
19	with	O
20	a	O
21	DiaTAP	O
22	button	O
23	graft	O
24	complex	O
25	infected	O
26	with	O
27	Staphylococcus	O
28	epidermidis	O
29	and	O
30	intermittent	O
31	positive	O
32	blood	O
33	cultures	O
34	using	O
35	long	O
36	term	O
37	vancomycin	O
38	therapy	O
39	.	O
1	Encompassing	O
2	tamponade	O
3	and	O
4	pericardiocentesis	O
5	data	O
6	,	O
7	left	O
8	ventricular	O
9	stroke	O
10	work	O
11	index	O
12	showed	O
13	positive	O
14	correlation	O
15	with	O
16	TMFP1	O
17	(	O
18	r	O
19	=	O
20	.	O
21	59	O
22	)	O
23	and	O
24	TMFP2	O
25	(	O
26	r	O
27	=	O
28	.	O
29	52	O
30	)	O
31	but	O
32	not	O
33	with	O
34	TMFP3	O
35	.	O
1	Due	O
2	to	O
3	its	O
4	relatively	O
5	soluble	O
6	chemical	O
7	form	O
8	,	O
9	90Sr	O
10	was	O
11	rapidly	O
12	translocated	O
13	from	O
14	lung	O
15	to	O
16	bone	O
17	where	O
18	a	O
19	substantial	O
20	portion	O
21	was	O
22	retained	O
23	for	O
24	a	O
25	long	O
26	period	O
27	of	O
28	time	O
29	.	O
1	An	O
2	epidemiological	O
3	survey	O
4	of	O
5	rheumatic	O
6	valve	O
7	disease	O
8	and	O
9	rheumatic	O
10	fever	O
11	in	O
12	primary	O
13	and	O
14	secondary	O
15	school	O
16	students	O
17	in	O
18	Jiangxi	O
19	Province	O
1	A	O
2	study	O
3	of	O
4	human	O
5	genes	O
6	coding	O
7	for	O
8	U4	B
9	small	I
10	nuclear	I
11	RNA	I
12	is	O
13	presented	O
14	.	O
1	Heat	O
2	-	O
3	labile	O
4	-	O
5	like	O
6	enterotoxin	O
7	(	O
8	LT	B
9	)	O
10	was	O
11	produced	O
12	by	O
13	26	O
14	of	O
15	42	O
16	stool	O
17	isolates	O
18	(	O
19	62	O
20	%),	O
21	while	O
22	only	O
23	1	O
24	of	O
25	the	O
26	42	O
27	isolates	O
28	(	O
29	2	O
30	%)	O
31	produced	O
32	enterotoxinlike	O
33	activity	O
34	in	O
35	suckling	O
36	mice	O
37	;	O
38	65	O
39	%	O
40	of	O
41	the	O
42	cytotoxin	O
43	-	O
44	producing	O
45	strains	O
46	also	O
47	produced	O
48	an	O
49	LT	B
50	-	I
51	like	I
52	material	O
53	.	O
1	Development	O
2	of	O
3	a	O
4	provisional	O
5	information	O
6	-	O
7	retrieval	O
8	descriptor	O
9	language	O
10	for	O
11	""""	O
12	Roentgenology	O
13	and	O
14	Medical	O
15	Radiology	O
16	""""	O
17	for	O
18	use	O
19	in	O
20	the	O
21	Medinform	O
22	system	O
1	Dorsal	O
2	foot	O
3	TcpO2	O
4	was	O
5	measured	O
6	by	O
7	using	O
8	oxygen	O
9	-	O
10	sensing	O
11	electrodes	O
12	with	O
13	surface	O
14	temperatures	O
15	of	O
16	42	O
17	degrees	O
18	C	O
19	and	O
20	45	O
21	degrees	O
22	C	O
23	;	O
24	in	O
25	theory	O
26	,	O
27	changes	O
28	in	O
29	sympathetic	O
30	activity	O
31	should	O
32	affect	O
33	vasomotor	O
34	tone	O
35	and	O
36	TcpO2	O
37	in	O
38	skin	O
39	beneath	O
40	an	O
41	electrode	O
42	at	O
43	42	O
44	degrees	O
45	C	O
46	(	O
47	submaximal	O
48	vasodilation	O
49	),	O
50	but	O
51	not	O
52	at	O
53	45	O
54	degrees	O
55	C	O
56	(	O
57	maximal	O
58	vasodilation	O
59	).	O
1	Hypoglycemic	O
2	action	O
3	of	O
4	""""	O
5	he	O
6	xiang	O
7	zhuang	O
8	qi	O
9	gong	O
10	""""	O
11	and	O
12	its	O
13	mechanism	O
14	on	O
15	diabetes	O
16	mellitus	O
1	Weaned	O
2	rats	O
3	were	O
4	fed	O
5	a	O
6	normal	O
7	diet	O
8	or	O
9	a	O
10	low	O
11	-	O
12	protein	O
13	,	O
14	low	O
15	-	O
16	energy	O
17	diet	O
18	,	O
19	and	O
20	injected	O
21	with	O
22	saline	O
23	or	O
24	thyroxine	O
25	(	O
26	5	O
27	micrograms	O
28	/	O
29	100	O
30	g	O
31	BW	O
32	)	O
33	for	O
34	22	O
35	days	O
36	.	O
1	Groups	O
2	of	O
3	male	O
4	and	O
5	female	O
6	Fischer	O
7	344	O
8	rats	O
9	,	O
10	B6C3F1	O
11	mice	O
12	,	O
13	and	O
14	Hartley	O
15	guinea	O
16	pigs	O
17	were	O
18	exposed	O
19	once	O
20	for	O
21	6	O
22	hr	O
23	to	O
24	mean	O
25	concentrations	O
26	of	O
27	10	O
28	.	O
29	5	O
30	,	O
31	5	O
32	.	O
33	4	O
34	,	O
35	2	O
36	.	O
37	4	O
38	,	O
39	1	O
40	.	O
41	0	O
42	,	O
43	or	O
44	0	O
45	(	O
46	control	O
47	)	O
48	ppm	O
49	of	O
50	methyl	O
51	isocyanate	O
52	(	O
53	MIC	O
54	)	O
55	vapor	O
56	.	O
1	Effects	O
2	of	O
3	a	O
4	low	O
5	-	O
6	energy	O
7	laser	O
8	beam	O
9	on	O
10	the	O
11	cells	O
12	of	O
13	the	O
14	newt	O
15	embryo	O
1	Comparison	O
2	of	O
3	the	O
4	amino	O
5	acid	O
6	sequence	O
7	of	O
8	the	O
9	M	B
10	RNA	I
11	product	I
12	of	I
13	Uukuniemi	I
14	virus	I
15	with	O
16	that	O
17	of	O
18	Punta	O
19	Toro	O
20	and	O
21	Rift	O
22	Valley	O
23	fever	O
24	viruses	O
25	showed	O
26	in	O
27	both	O
28	cases	O
29	a	O
30	weak	O
31	homology	O
32	that	O
33	was	O
34	more	O
35	pronounced	O
36	for	O
37	the	O
38	proteins	O
39	located	O
40	at	O
41	the	O
42	COOH	O
43	-	O
44	terminal	O
45	end	O
46	of	O
47	the	O
48	precursor	O
49	.	O
1	Thus	O
2	in	O
3	this	O
4	region	O
5	of	O
6	the	O
7	vessel	O
8	pyridinoline	O
9	represents	O
10	the	O
11	major	O
12	stabilising	O
13	crosslink	O
14	of	O
15	collagen	B
16	.	O
1	In	O
2	the	O
3	evening	O
4	,	O
5	the	O
6	amplitude	O
7	of	O
8	the	O
9	responses	O
10	to	O
11	both	O
12	O2	O
13	and	O
14	CO2	O
15	increased	O
16	but	O
17	the	O
18	increase	O
19	in	O
20	CO2	O
21	sensitivity	O
22	was	O
23	proportionally	O
24	more	O
25	important	O
26	.	O
1	These	O
2	changes	O
3	at	O
4	the	O
5	site	O
6	of	O
7	injection	O
8	consist	O
9	of	O
10	a	O
11	focal	O
12	abnormality	O
13	characterized	O
14	by	O
15	a	O
16	slight	O
17	increase	O
18	in	O
19	signal	O
20	intensity	O
21	on	O
22	T1	O
23	weighted	O
24	images	O
25	and	O
26	markedly	O
27	increased	O
28	signal	O
29	intensity	O
30	on	O
31	T2	O
32	weighted	O
33	images	O
34	.	O
1	In	O
2	calves	O
3	receiving	O
4	milk	O
5	-	O
6	substitute	O
7	diets	O
8	containing	O
9	80	O
10	-	O
11	260	O
12	g	O
13	DM	O
14	/	O
15	kg	O
16	,	O
17	milk	O
18	intakes	O
19	were	O
20	reduced	O
21	by	O
22	up	O
23	to	O
24	30	O
25	%	O
26	on	O
27	the	O
28	1st	O
29	day	O
30	that	O
31	calves	O
32	were	O
33	fed	O
34	once	O
35	daily	O
36	instead	O
37	of	O
38	twice	O
39	daily	O
40	.	O
1	Today	O
2	there	O
3	is	O
4	no	O
5	doubt	O
6	that	O
7	elevated	O
8	plasma	O
9	cholesterol	O
10	levels	O
11	should	O
12	be	O
13	lowered	O
14	first	O
15	by	O
16	dietary	O
17	modification	O
18	even	O
19	in	O
20	early	O
21	childhood	O
22	,	O
23	beginning	O
24	at	O
25	the	O
26	age	O
27	of	O
28	two	O
29	years	O
30	.	O
1	The	O
2	histologic	O
3	grade	O
4	for	O
5	the	O
6	same	O
7	anatomic	O
8	site	O
9	varied	O
10	among	O
11	hearts	O
12	and	O
13	among	O
14	different	O
15	anatomic	O
16	sites	O
17	in	O
18	the	O
19	same	O
20	heart	O
21	.	O
1	For	O
2	colostral	O
3	milk	O
4	there	O
5	was	O
6	a	O
7	significant	O
8	correlation	O
9	of	O
10	vitamin	O
11	K1	O
12	to	O
13	cholesterol	O
14	(	O
15	r	O
16	=	O
17	0	O
18	.	O
19	62	O
20	)	O
21	but	O
22	not	O
23	to	O
24	total	O
25	lipid	O
26	or	O
27	phospholipid	O
28	suggesting	O
29	a	O
30	role	O
31	for	O
32	cholesterol	O
33	in	O
34	the	O
35	secretion	O
36	of	O
37	vitamin	O
38	K1	O
39	into	O
40	colostral	O
41	milk	O
42	.	O
1	Two	O
2	of	O
3	these	O
4	six	O
5	cases	O
6	showed	O
7	mucosal	O
8	spread	O
9	without	O
10	stromal	O
11	invasion	O
12	(	O
13	type	O
14	A	O
15	);	O
16	the	O
17	remaining	O
18	four	O
19	cases	O
20	presented	O
21	a	O
22	direct	O
23	extension	O
24	(	O
25	type	O
26	B	O
27	)	O
28	from	O
29	muscle	O
30	-	O
31	invasive	O
32	carcinomas	O
33	of	O
34	the	O
35	bladder	O
36	.	O
1	The	O
2	maximum	O
3	amplitude	O
4	of	O
5	evoked	O
6	responses	O
7	in	O
8	the	O
9	cervical	O
10	sympathetic	O
11	trunk	O
12	was	O
13	obtained	O
14	when	O
15	the	O
16	T2	O
17	white	O
18	ramus	O
19	was	O
20	stimulated	O
21	and	O
22	decreased	O
23	gradually	O
24	when	O
25	followed	O
26	by	O
27	the	O
28	stimulation	O
29	of	O
30	T1	O
31	,	O
32	T3	O
33	,	O
34	T4	O
35	and	O
36	T5	O
37	white	O
38	rami	O
39	.	O
1	Infants	O
2	of	O
3	this	O
4	sample	O
5	had	O
6	monocular	O
7	PL	O
8	visual	O
9	acuities	O
10	similar	O
11	to	O
12	those	O
13	established	O
14	by	O
15	McDonald	O
16	et	O
17	al	O
18	.	O
19	in	O
20	a	O
21	laboratory	O
22	setting	O
23	.	O
1	Primary	O
2	invasive	O
3	Haemophilus	O
4	influenzae	O
5	type	O
6	b	O
7	disease	O
8	:	O
9	a	O
10	population	O
11	-	O
12	based	O
13	assessment	O
14	of	O
15	risk	O
16	factors	O
17	.	O
1	New	O
2	and	O
3	successful	O
4	steps	O
5	have	O
6	been	O
7	made	O
8	in	O
9	immunodiagnostics	O
10	,	O
11	immunotherapy	O
12	,	O
13	and	O
14	immunoprophylaxis	O
15	of	O
16	immunologically	O
17	conditioned	O
18	infertility	O
19	.	O
1	Amikacin	O
2	was	O
3	the	O
4	most	O
5	stable	O
6	and	O
7	tobramycin	O
8	was	O
9	the	O
10	least	O
11	stable	O
12	aminoglycoside	O
13	under	O
14	the	O
15	conditions	O
16	tested	O
17	.	O
1	Calcifications	O
2	in	O
3	the	O
4	thoracic	O
5	aorta	O
6	at	O
7	the	O
8	level	O
9	of	O
10	the	O
11	11th	O
12	and	O
13	the	O
14	12th	O
15	thoracic	O
16	vertebrae	O
17	in	O
18	592	O
19	men	O
20	and	O
21	333	O
22	women	O
23	were	O
24	studied	O
25	using	O
26	computed	O
27	tomography	O
28	.	O
1	Pharmacological	O
2	action	O
3	of	O
4	eptazocine	O
5	(	O
6	l	O
7	-	O
8	1	O
9	,	O
10	4	O
11	-	O
12	dimethyl	O
13	-	O
14	10	O
15	-	O
16	hydroxy	O
17	-	O
18	2	O
19	,	O
20	3	O
21	,	O
22	4	O
23	,	O
24	5	O
25	,	O
26	6	O
27	,	O
28	7	O
29	-	O
30	hexahydro	O
31	-	O
32	1	O
33	,	O
34	6	O
35	-	O
36	methano	O
37	-	O
38	1H	O
39	-	O
40	4	O
41	-	O
42	benz	O
43	azonine	O
44	).	O
1	Findings	O
2	of	O
3	positive	O
4	potentials	O
5	showed	O
6	that	O
7	N1	O
8	originated	O
9	in	O
10	the	O
11	area	O
12	of	O
13	ventral	O
14	gray	O
15	matter	O
16	through	O
17	the	O
18	ventro	O
19	-	O
20	lateral	O
21	column	O
22	and	O
23	N2	O
24	through	O
25	the	O
26	dorsal	O
27	column	O
28	.	O
1	There	O
2	have	O
3	been	O
4	five	O
5	problems	O
6	(	O
7	extravasation	O
8	2	O
9	,	O
10	suspected	O
11	sepsis	O
12	1	O
13	,	O
14	and	O
15	hematoma	O
16	2	O
17	)	O
18	during	O
19	a	O
20	total	O
21	of	O
22	2	O
23	,	O
24	927	O
25	days	O
26	of	O
27	exposure	O
28	.	O
1	Possibilities	O
2	and	O
3	outlook	O
4	for	O
5	wrist	O
6	joint	O
7	endoprosthesis	O
1	Among	O
2	them	O
3	,	O
4	26	O
5	cases	O
6	were	O
7	benign	O
8	and	O
9	34	O
10	malignant	O
11	.	O
1	Of	O
2	the	O
3	cases	O
4	with	O
5	PLD	O
6	,	O
7	50	O
8	%	O
9	had	O
10	associated	O
11	renal	O
12	cysts	O
13	and	O
14	10	O
15	%	O
16	of	O
17	the	O
18	cases	O
19	with	O
20	APCD	O
21	had	O
22	associated	O
23	liver	O
24	cysts	O
25	.	O
1	She	O
2	also	O
3	had	O
4	slight	O
5	weakness	O
6	of	O
7	the	O
8	upper	O
9	extremities	O
10	.	O
1	The	O
2	mechanism	O
3	of	O
4	action	O
5	is	O
6	explored	O
7	in	O
8	some	O
9	detail	O
10	,	O
11	specifically	O
12	as	O
13	it	O
14	relates	O
15	to	O
16	reticuloendothelial	O
17	system	O
18	(	O
19	RES	O
20	)	O
21	Fc	B
22	receptor	I
23	blockade	O
24	and	O
25	suppression	O
26	of	O
27	antiplatelet	O
28	antibody	O
29	synthesis	O
30	.	O
1	A	O
2	large	O
3	increase	O
4	of	O
5	serum	O
6	ketones	O
7	occurred	O
8	under	O
9	all	O
10	conditions	O
11	,	O
12	and	O
13	the	O
14	exercise	O
15	respiratory	O
16	quotient	O
17	suggested	O
18	some	O
19	increase	O
20	of	O
21	fat	O
22	utilization	O
23	,	O
24	WW	O
25	(	O
26	0	O
27	.	O
28	85	O
29	)	O
30	through	O
31	CW	O
32	(	O
33	0	O
34	.	O
35	84	O
36	)	O
37	to	O
38	CC	O
39	(	O
40	0	O
41	.	O
42	83	O
43	).	O
1	While	O
2	the	O
3	examiner	O
4	observed	O
5	the	O
6	interior	O
7	of	O
8	the	O
9	eye	O
10	with	O
11	indirect	O
12	ophthalmoscopy	O
13	,	O
14	the	O
15	point	O
16	source	O
17	of	O
18	light	O
19	from	O
20	the	O
21	fiberoptic	O
22	light	O
23	pipe	O
24	was	O
25	moved	O
26	along	O
27	the	O
28	margins	O
29	of	O
30	the	O
31	episcleral	O
32	plaque	O
33	.	O
1	II	O
2	.	O
1	Intensification	O
2	of	O
3	human	O
4	myocardial	O
5	contractile	O
6	activity	O
7	as	O
8	affected	O
9	by	O
10	blood	O
11	serum	O
1	The	O
2	observation	O
3	of	O
4	late	O
5	effects	O
6	after	O
7	irradiations	O
8	or	O
9	after	O
10	space	O
11	flights	O
12	show	O
13	the	O
14	difficulties	O
15	encountered	O
16	in	O
17	assessing	O
18	radiative	O
19	risks	O
20	during	O
21	long	O
22	duration	O
23	space	O
24	flights	O
25	.	O
1	In	O
2	recent	O
3	years	O
4	,	O
5	successful	O
6	physiological	O
7	models	O
8	have	O
9	been	O
10	developed	O
11	for	O
12	a	O
13	variety	O
14	of	O
15	volatile	O
16	and	O
17	nonvolatile	O
18	chemicals	O
19	,	O
20	and	O
21	their	O
22	ability	O
23	to	O
24	perform	O
25	the	O
26	extrapolations	O
27	needed	O
28	in	O
29	risk	O
30	assessment	O
31	has	O
32	been	O
33	demonstrated	O
34	.	O
1	Eleven	O
2	healthy	O
3	,	O
4	normotensive	O
5	males	O
6	undergoing	O
7	routine	O
8	restorative	O
9	dental	O
10	care	O
11	were	O
12	evaluated	O
13	during	O
14	treatment	O
15	for	O
16	possible	O
17	hemodynamic	O
18	alterations	O
19	in	O
20	response	O
21	to	O
22	potential	O
23	sympathetic	O
24	nervous	O
25	system	O
26	stimulation	O
27	.	O
1	Within	O
2	the	O
3	Strep	O
4	.	O
5	mutans	O
6	group	O
7	there	O
8	was	O
9	a	O
10	highly	O
11	-	O
12	significant	O
13	difference	O
14	between	O
15	Strep	O
16	.	O
17	mutans	O
18	/	O
19	Strep	O
20	.	O
21	cricetus	O
22	(	O
23	p	O
24	less	O
25	than	O
26	0	O
27	.	O
28	01	O
29	)	O
30	with	O
31	respect	O
32	to	O
33	mean	O
34	clump	O
35	size	O
36	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	T	O
6	.	O
7	C	O
8	.,	O
9	LDL	B
10	-	I
11	C	I
12	.,	O
13	HDL	B
14	-	I
15	C	I
16	.,	O
17	HDL2	B
18	-	I
19	C	I
20	.,	O
21	apo	B
22	B	I
23	,	O
24	apo	B
25	A	I
26	-	I
27	I	I
28	/	I
29	B	I
30	ratio	O
31	and	O
32	apo	B
33	A	I
34	-	I
35	II	I
36	/	I
37	B	I
38	ratio	O
39	are	O
40	predictive	O
41	risk	O
42	factors	O
43	of	O
44	the	O
45	coronary	O
46	heart	O
47	disease	O
48	.	O
1	MRI	O
2	disclosed	O
3	one	O
4	or	O
5	more	O
6	of	O
7	the	O
8	following	O
9	abnormalities	O
10	in	O
11	24	O
12	(	O
13	63	O
14	%)	O
15	of	O
16	38	O
17	treated	O
18	kidneys	O
19	:	O
20	(	O
21	1	O
22	)	O
23	loss	O
24	of	O
25	corticomedullary	O
26	differentiation	O
27	,	O
28	(	O
29	2	O
30	)	O
31	perirenal	O
32	fluid	O
33	,	O
34	(	O
35	3	O
36	)	O
37	subcapsular	O
38	hematoma	O
39	,	O
40	(	O
41	4	O
42	)	O
43	hemorrhage	O
44	into	O
45	a	O
46	renal	O
47	cyst	O
48	,	O
49	and	O
50	(	O
51	5	O
52	)	O
53	unexplained	O
54	abnormalities	O
55	.	O
1	A	O
2	yeast	O
3	DNA	O
4	fragment	O
5	carrying	O
6	the	O
7	gene	B
8	CP	I
9	A1	I
10	encoding	O
11	the	O
12	small	O
13	subunit	O
14	of	O
15	the	O
16	arginine	O
17	pathway	O
18	carbamoyl	B
19	-	I
20	phosphate	I
21	synthetase	I
22	has	O
23	been	O
24	sequenced	O
25	.	O
1	The	O
2	H2	B
3	receptor	I
4	antagonists	O
5	and	O
6	sucralfate	O
7	cost	O
8	about	O
9	the	O
10	same	O
11	and	O
12	have	O
13	few	O
14	side	O
15	effects	O
16	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	indoramin	O
6	may	O
7	have	O
8	Class	O
9	III	O
10	antiarrhythmic	O
11	activity	O
12	.	O
1	A	O
2	high	O
3	efficacy	O
4	of	O
5	the	O
6	combined	O
7	use	O
8	of	O
9	nontoxic	O
10	doses	O
11	of	O
12	two	O
13	pharmaceuticals	O
14	:	O
15	cystamine	O
16	(	O
17	50	O
18	mg	O
19	/	O
20	kg	O
21	)	O
22	and	O
23	mexamine	O
24	(	O
25	25	O
26	mg	O
27	/	O
28	kg	O
29	)	O
30	under	O
31	the	O
32	conditions	O
33	of	O
34	short	O
35	-	O
36	term	O
37	exogenous	O
38	hypoxia	O
39	(	O
40	7	O
41	.	O
42	5	O
43	%	O
44	O2	O
45	)	O
46	was	O
47	found	O
48	in	O
49	(	O
50	CBA	O
51	X	O
52	C57Bl	O
53	)	O
54	F1	O
55	mice	O
56	.	O
1	In	O
2	the	O
3	region	O
4	Walgau	O
5	with	O
6	mixed	O
7	industrial	O
8	-	O
9	rural	O
10	population	O
11	an	O
12	iodine	O
13	deficiency	O
14	I	O
15	was	O
16	found	O
17	in	O
18	81	O
19	%	O
20	and	O
21	an	O
22	iodine	O
23	deficiency	O
24	II	O
25	in	O
26	45	O
27	%.	O
1	The	O
2	availability	O
3	of	O
4	cryoprecipitate	O
5	and	O
6	DDAVP	O
7	offers	O
8	an	O
9	alternative	O
10	and	O
11	effective	O
12	treatment	O
13	for	O
14	the	O
15	temporary	O
16	reversal	O
17	of	O
18	uremic	O
19	bleeding	O
20	in	O
21	patients	O
22	who	O
23	require	O
24	urgent	O
25	invasive	O
26	procedures	O
27	.	O
1	Mild	O
2	orbital	O
3	discomfort	O
4	occurred	O
5	in	O
6	some	O
7	patients	O
8	.	O
1	The	O
2	overall	O
3	prevalence	O
4	of	O
5	psoriasis	O
6	was	O
7	4	O
8	.	O
9	79	O
10	%	O
11	in	O
12	men	O
13	and	O
14	4	O
15	.	O
16	85	O
17	%	O
18	in	O
19	women	O
20	.	O
1	Chronic	O
2	thyroiditis	O
3	as	O
4	a	O
5	risk	O
6	factor	O
7	of	O
8	B	O
9	-	O
10	cell	O
11	lymphoma	O
12	in	O
13	the	O
14	thyroid	O
15	gland	O
16	.	O
1	Using	O
2	this	O
3	method	O
4	,	O
5	we	O
6	measured	O
7	absorption	O
8	of	O
9	low	O
10	doses	O
11	of	O
12	vitamin	O
13	A	O
14	,	O
15	which	O
16	may	O
17	provide	O
18	a	O
19	more	O
20	physiological	O
21	approach	O
22	to	O
23	assessment	O
24	of	O
25	fat	O
26	malabsorption	O
27	.	O
1	Tissue	O
2	pressure	O
3	,	O
4	rCBF	O
5	,	O
6	and	O
7	water	O
8	content	O
9	were	O
10	measured	O
11	from	O
12	gray	O
13	matter	O
14	in	O
15	the	O
16	central	O
17	core	O
18	and	O
19	the	O
20	peripheral	O
21	margin	O
22	of	O
23	the	O
24	MCA	O
25	territory	O
26	over	O
27	6	O
28	h	O
29	after	O
30	MCAO	O
31	.	O
1	The	O
2	results	O
3	from	O
4	the	O
5	first	O
6	five	O
7	years	O
8	of	O
9	follow	O
10	up	O
11	in	O
12	1972	O
13	showed	O
14	a	O
15	4	O
16	.	O
17	7	O
18	-	O
19	fold	O
20	excess	O
21	mortality	O
22	for	O
23	ischaemic	O
24	and	O
25	other	O
26	heart	O
27	diseases	O
28	(	O
29	ICD	O
30	A83	O
31	-	O
32	A84	O
33	)	O
34	compared	O
35	with	O
36	a	O
37	comparable	O
38	reference	O
39	cohort	O
40	of	O
41	paper	O
42	mill	O
43	workers	O
44	.	O
1	Electrical	O
2	activity	O
3	was	O
4	evaluated	O
5	by	O
6	monitoring	O
7	the	O
8	general	O
9	electrocorticogram	O
10	(	O
11	ECoG	O
12	)	O
13	as	O
14	well	O
15	as	O
16	local	O
17	DC	O
18	steady	O
19	potential	O
20	(	O
21	two	O
22	sites	O
23	).	O
1	The	O
2	primary	O
3	CT	O
4	findings	O
5	were	O
6	misinterpreted	O
7	as	O
8	a	O
9	brain	O
10	infarct	O
11	or	O
12	possibly	O
13	a	O
14	tumour	O
15	.	O
1	These	O
2	findings	O
3	suggest	O
4	that	O
5	both	O
6	in	O
7	the	O
8	early	O
9	stages	O
10	(	O
11	0T	O
12	,	O
13	0N	O
14	)	O
15	and	O
16	in	O
17	more	O
18	severe	O
19	stages	O
20	of	O
21	VWF	O
22	(	O
23	stages	O
24	1	O
25	-	O
26	2	O
27	)	O
28	cold	O
29	induced	O
30	hyperreactivity	O
31	in	O
32	the	O
33	digital	O
34	vessels	O
35	and	O
36	Raynaud	O
37	'	O
38	s	O
39	syndrome	O
40	are	O
41	vascular	O
42	disorders	O
43	of	O
44	functional	O
45	origin	O
46	occurring	O
47	without	O
48	any	O
49	prethrombotic	O
50	alterations	O
51	.	O
1	Doxorubicin	O
2	,	O
3	dacarbazine	O
4	,	O
5	vincristine	O
6	,	O
7	and	O
8	cyclophosphamide	O
9	in	O
10	the	O
11	treatment	O
12	of	O
13	advanced	O
14	gastrointestinal	O
15	leiomyosarcoma	O
16	.	O
1	The	O
2	effect	O
3	of	O
4	the	O
5	opiate	O
6	antagonist	O
7	naloxone	O
8	was	O
9	evaluated	O
10	in	O
11	11	O
12	unselected	O
13	patients	O
14	with	O
15	cerebral	O
16	ischemia	O
17	.	O
1	During	O
2	a	O
3	disease	O
4	remission	O
5	there	O
6	was	O
7	an	O
8	increase	O
9	in	O
10	GAG	O
11	secretion	O
12	with	O
13	urine	O
14	,	O
15	linked	O
16	with	O
17	hyperheparinuria	O
18	(	O
19	13	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	,	O
25	P	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	).	O
1	In	O
2	metastasis	O
3	-	O
4	free	O
5	patients	O
6	,	O
7	the	O
8	best	O
9	results	O
10	were	O
11	obtained	O
12	with	O
13	tumor	O
14	diameters	O
15	under	O
16	2	O
17	cm	O
18	regardless	O
19	of	O
20	their	O
21	localization	O
22	in	O
23	lung	O
24	tissue	O
25	and	O
26	with	O
27	2	O
28	--	O
29	4	O
30	.	O
31	9	O
32	cm	O
33	tumors	O
34	embedded	O
35	in	O
36	lung	O
37	parenchyma	O
38	.	O
1	In	O
2	the	O
3	10	O
4	patients	O
5	with	O
6	a	O
7	more	O
8	severe	O
9	degree	O
10	of	O
11	steatorrhea	O
12	the	O
13	decrease	O
14	in	O
15	fat	O
16	loss	O
17	approached	O
18	20	O
19	%	O
20	and	O
21	a	O
22	close	O
23	relationship	O
24	was	O
25	found	O
26	(	O
27	r	O
28	=	O
29	0	O
30	.	O
31	84	O
32	,	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	01	O
39	)	O
40	between	O
41	the	O
42	extent	O
43	of	O
44	the	O
45	fatty	O
46	acid	O
47	loss	O
48	on	O
49	placebo	O
50	and	O
51	the	O
52	decrease	O
53	of	O
54	this	O
55	loss	O
56	on	O
57	taurine	O
58	.	O
1	Marrow	O
2	cell	O
3	necrosis	O
4	in	O
5	anorexia	O
6	nervosa	O
7	and	O
8	involuntary	O
9	starvation	O
10	.	O
1	Because	O
2	of	O
3	its	O
4	wide	O
5	spectrum	O
6	of	O
7	activity	O
8	particularly	O
9	against	O
10	ampicillin	O
11	resistant	O
12	strains	O
13	of	O
14	H	O
15	.	O
16	influenzae	O
17	and	O
18	because	O
19	of	O
20	its	O
21	good	O
22	tolerance	O
23	Cefaclor	O
24	is	O
25	very	O
26	useful	O
27	in	O
28	treatment	O
29	of	O
30	respiratory	O
31	tract	O
32	infections	O
33	in	O
34	children	O
35	.	O
1	Lower	O
2	extremity	O
3	weight	O
4	bearing	O
5	under	O
6	various	O
7	standing	O
8	conditions	O
9	in	O
10	independently	O
11	ambulatory	O
12	patients	O
13	with	O
14	hemiparesis	O
15	.	O
1	This	O
2	study	O
3	indicated	O
4	that	O
5	the	O
6	Japanese	O
7	quail	O
8	was	O
9	less	O
10	sensitive	O
11	to	O
12	particulate	O
13	Mn3O4	O
14	exposure	O
15	than	O
16	rodents	O
17	treated	O
18	comparably	O
19	.	O
1	These	O
2	results	O
3	were	O
4	compared	O
5	with	O
6	those	O
7	obtained	O
8	in	O
9	-	O
10	D	O
11	mothers	O
12	and	O
13	pups	O
14	,	O
15	after	O
16	giving	O
17	the	O
18	mothers	O
19	an	O
20	oral	O
21	supplement	O
22	(	O
23	10	O
24	i	O
25	.	O
26	u	O
27	.	O
28	vitamin	O
29	D3	O
30	/	O
31	day	O
32	)	O
33	during	O
34	the	O
35	period	O
36	of	O
37	lactation	O
38	(	O
39	20	O
40	days	O
41	).	O
1	Duration	O
2	of	O
3	remission	O
4	in	O
5	advanced	O
6	gastric	O
7	cancer	O
8	patients	O
9	responding	O
10	to	O
11	sequential	O
12	dose	O
13	of	O
14	MTX	O
15	and	O
16	5	O
17	-	O
18	FU	O
1	These	O
2	data	O
3	showed	O
4	:	O
5	that	O
6	progesterone	O
7	secretion	O
8	is	O
9	pulsatile	O
10	throughout	O
11	the	O
12	human	O
13	luteal	O
14	phase	O
15	,	O
16	with	O
17	maximum	O
18	frequency	O
19	in	O
20	the	O
21	mid	O
22	-	O
23	luteal	O
24	phase	O
25	;	O
26	that	O
27	during	O
28	the	O
29	mid	O
30	-	O
31	luteal	O
32	phase	O
33	most	O
34	subjects	O
35	had	O
36	progesterone	O
37	levels	O
38	both	O
39	above	O
40	and	O
41	below	O
42	currently	O
43	accepted	O
44	ovulatory	O
45	thresholds	O
46	;	O
47	the	O
48	use	O
49	of	O
50	a	O
51	single	O
52	measurement	O
53	of	O
54	progesterone	O
55	in	O
56	the	O
57	mid	O
58	-	O
59	luteal	O
60	phase	O
61	is	O
62	not	O
63	always	O
64	a	O
65	reliable	O
66	indicator	O
67	of	O
68	ovulation	O
69	;	O
70	a	O
71	threshold	O
72	greater	O
73	than	O
74	20	O
75	nmol	O
76	/	O
77	l	O
78	may	O
79	yield	O
80	an	O
81	unacceptable	O
82	number	O
83	of	O
84	false	O
85	negative	O
86	results	O
87	.	O
1	There	O
2	was	O
3	a	O
4	significant	O
5	but	O
6	similar	O
7	elevation	O
8	of	O
9	mean	O
10	O2	O
11	uptake	O
12	during	O
13	40	O
14	min	O
15	postexercise	O
16	by	O
17	13	O
18	.	O
19	6	O
20	%	O
21	in	O
22	both	O
23	the	O
24	fasted	O
25	(	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	)	O
33	and	O
34	fed	O
35	state	O
36	(	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O
1	National	O
2	Institutes	O
3	of	O
4	Health	O
5	Consensus	O
6	Development	O
7	Conference	O
8	Statement	O
9	.	O
1	In	O
2	controls	O
3	,	O
4	most	O
5	of	O
6	the	O
7	output	O
8	from	O
9	the	O
10	conduit	O
11	occurred	O
12	during	O
13	type	O
14	I	O
15	activity	O
16	(	O
17	73	O
18	+/-	O
19	14	O
20	%).	O
1	The	O
2	comparisons	O
3	revealed	O
4	that	O
5	female	O
6	homicide	O
7	-	O
8	suicide	O
9	perpetrators	O
10	were	O
11	more	O
12	likely	O
13	than	O
14	female	O
15	homicide	O
16	-	O
17	suicide	O
18	victims	O
19	to	O
20	live	O
21	in	O
22	mobile	O
23	homes	O
24	,	O
25	kill	O
26	their	O
27	lover	O
28	or	O
29	ex	O
30	-	O
31	lover	O
32	,	O
33	have	O
34	their	O
35	crime	O
36	accidentally	O
37	discovered	O
38	,	O
39	leave	O
40	a	O
41	suicide	O
42	note	O
43	,	O
44	kill	O
45	on	O
46	a	O
47	weekend	O
48	,	O
49	and	O
50	be	O
51	depressed	O
52	,	O
53	but	O
54	are	O
55	less	O
56	likely	O
57	than	O
58	female	O
59	homicide	O
60	-	O
61	suicide	O
62	victims	O
63	to	O
64	live	O
65	with	O
66	a	O
67	spouse	O
68	.	O
1	Germ	O
2	-	O
3	free	O
4	rabbits	O
5	given	O
6	mouse	O
7	CRF	O
8	-	O
9	flora	O
10	showed	O
11	values	O
12	quite	O
13	different	O
14	from	O
15	control	O
16	animals	O
17	for	O
18	most	O
19	parameters	O
20	,	O
21	indicating	O
22	unsuitability	O
23	of	O
24	mouse	O
25	CRF	O
26	flora	O
27	to	O
28	'	O
29	normalize	O
30	'	O
31	rabbits	O
32	.	O
1	Diagnosis	O
2	:	O
3	progressive	O
4	multifocal	O
5	leukoencephalopathy	O
6	.	O
1	Although	O
2	no	O
3	differences	O
4	were	O
5	noted	O
6	in	O
7	the	O
8	decrease	O
9	in	O
10	platelet	O
11	counts	O
12	between	O
13	the	O
14	two	O
15	groups	O
16	,	O
17	fibrinogen	B
18	levels	O
19	and	O
20	alpha	B
21	2	I
22	-	I
23	antiplasmin	I
24	levels	O
25	declined	O
26	less	O
27	drastically	O
28	in	O
29	the	O
30	antithrombin	B
31	-	O
32	treated	O
33	group	O
34	.	O
1	Clinical	O
2	aspects	O
3	and	O
4	therapy	O
1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	secretor	O
7	status	O
8	and	O
9	clinical	O
10	status	O
11	,	O
12	spirometry	O
13	measurements	O
14	,	O
15	salivary	O
16	and	O
17	serum	B
18	lysozyme	I
19	levels	O
20	or	O
21	rates	O
22	of	O
23	respiratory	O
24	tract	O
25	colonization	O
26	with	O
27	P	O
28	.	O
29	aeruginosa	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O
1	Comparative	O
2	studies	O
3	of	O
4	the	O
5	antithrombin	B
6	III	I
7	level	O
8	and	O
9	plasminogen	B
10	activator	I
11	activity	O
12	in	O
13	patients	O
14	with	O
15	thrombophlebitis	O
1	Is	O
2	desensitization	O
3	'	O
4	for	O
5	ragweed	O
6	hay	O
7	fever	O
8	immunologically	O
9	specific	O
10	?	O
1	Experiences	O
2	with	O
3	the	O
4	clinical	O
5	and	O
6	experimental	O
7	use	O
8	of	O
9	Urat	O
10	-	O
11	I	O
12	lithotriptor	O
13	.	O
1	Formation	O
2	of	O
3	hyphae	O
4	and	O
5	chlamydospores	O
6	by	O
7	Cryptococcus	O
8	laurentii	O
9	.	O
1	HL	B
2	-	I
3	A	I
4	antibodies	I
5	in	O
6	polytransfused	O
7	patients	O
1	Relaxation	O
2	of	O
3	catch	O
4	in	O
5	a	O
6	molluscan	O
7	smooth	O
8	muscle	O
9	.	O
1	Studies	O
2	on	O
3	alcoholic	O
4	liver	O
5	injury	O
6	.	O
1	Hypothalamic	O
2	control	O
3	of	O
4	coronary	O
5	circulation	O
6	in	O
7	the	O
8	dog	O
9	.	O
1	Serotonin	O
2	levels	O
3	in	O
4	infant	O
5	hypothyroidism	O
6	.	O
1	A	O
2	medical	O
3	-	O
4	geographical	O
5	review	O
1	Androgens	O
2	and	O
3	growth	O
4	.	O
1	Serodiagnosis	O
2	of	O
3	ectromelia	O
4	in	O
5	laboratory	O
6	mice	O
1	Ultrasound	O
2	effect	O
3	on	O
4	the	O
5	cytochrome	B
6	oxidase	I
7	activity	O
1	Conditions	O
2	influencing	O
3	inhibitors	O
4	of	O
5	the	O
6	colony	B
7	-	I
8	stimulating	I
9	factor	I
10	(	O
11	CSF	B
12	).	O
1	A	O
2	study	O
3	in	O
4	vivo	O
5	of	O
6	adrenergic	B
7	receptors	I
8	in	O
9	the	O
10	rectum	O
11	and	O
12	in	O
13	the	O
14	internal	O
15	and	O
16	sphincter	O
17	of	O
18	the	O
19	cat	O
20	.	O
1	Copper	O
2	and	O
3	ceruloplasmin	B
4	content	O
5	in	O
6	pregnant	O
7	women	O
8	and	O
9	in	O
10	women	O
11	with	O
12	certain	O
13	gynecological	O
14	diseases	O
1	On	O
2	the	O
3	transport	O
4	of	O
5	mucus	O
6	and	O
7	its	O
8	rheologic	O
9	simulants	O
10	in	O
11	ciliated	O
12	systems	O
13	.	O
1	Junctions	O
2	between	O
3	cells	O
4	of	O
5	the	O
6	human	O
7	enamel	O
8	organ	O
9	.	O
1	Intracellular	O
2	pH	O
3	,	O
4	H	O
5	ion	O
6	flux	O
7	and	O
8	H	O
9	ion	O
10	permeability	O
11	coefficient	O
12	in	O
13	bullfrog	O
14	toe	O
15	muscle	O
16	.	O
1	Teratological	O
2	studies	O
3	on	O
4	SF	O
5	-	O
6	837	O
7	.	O
1	Proceedings	O
2	:	O
3	Reversible	O
4	complete	O
5	heart	O
6	block	O
7	following	O
8	surgery	O
9	of	O
10	congenital	O
11	heart	O
12	defects	O
1	Method	O
2	of	O
3	synthesis	O
4	of	O
5	the	O
6	rheumatoid	B
7	factor	I
8	in	O
9	clinico	O
10	-	O
11	immunological	O
12	studies	O
1	State	O
2	-	O
3	approved	O
4	schools	O
5	of	O
6	nursing	O
7	--	O
8	R	O
9	.	O
10	N	O
11	.,	O
12	1972	O
13	.	O
1	Further	O
2	investigation	O
3	on	O
4	the	O
5	chemotactic	O
6	influence	O
7	of	O
8	thymic	B
9	hormone	I
10	on	O
11	lymphocytes	O
1	Letter	O
2	:	O
3	Salmonella	O
4	detection	O
1	Morphology	O
2	of	O
3	bacteriophages	O
4	of	O
5	Klebsiella	O
6	bacilli	O
7	.	O
1	Resistance	O
2	pattern	O
3	of	O
4	Mycobacterium	O
5	tuberculosis	O
6	(	O
7	H	O
8	37	O
9	Rv	O
10	)	O
11	to	O
12	a	O
13	new	O
14	antibiotic	O
15	,	O
16	lividomycin	O
1	Role	O
2	of	O
3	histoclinical	O
4	studies	O
5	in	O
6	the	O
7	prophylaxis	O
8	of	O
9	spontaneous	O
10	abortions	O
1	Chemical	O
2	constituents	O
3	of	O
4	the	O
5	gentianaceae	O
6	V	O
7	:	O
8	tetraoxygenated	O
9	xanthones	O
10	of	O
11	Swertia	O
12	chirata	O
13	Buch	O
14	.-	O
15	Ham	O
16	.	O
1	Estimation	O
2	of	O
3	renin	B
4	secretion	O
5	rate	O
6	and	O
7	renal	O
8	plasma	O
9	flow	O
10	from	O
11	peripheral	O
12	and	O
13	renal	B
14	vein	I
15	renin	I
16	levels	O
17	.	O
1	9	O
2	,	O
3	11	O
4	-	O
5	Seco	O
6	steroids	O
7	derived	O
8	from	O
9	estradiol	O
10	3	O
11	-	O
12	methyl	O
13	ether	O
14	.	O
1	Possibilities	O
2	of	O
3	needleless	O
4	administration	O
5	of	O
6	various	O
7	substances	O
8	to	O
9	animals	O
1	Letter	O
2	:	O
3	Aryl	B
4	hydrocarbon	I
5	hydroxylase	I
6	and	O
7	smoking	O
8	.	O
1	Observations	O
2	on	O
3	saccules	O
4	of	O
5	rats	O
6	exposed	O
7	to	O
8	long	O
9	-	O
10	term	O
11	hypergravity	O
12	.	O
1	The	O
2	metabolism	O
3	and	O
4	pharmacology	O
5	of	O
6	5	O
7	-	O
8	fluorouracil	O
9	.	O
1	Human	O
2	synovial	O
3	fluid	O
4	:	O
5	detection	O
6	of	O
7	a	O
8	new	O
9	component	O
10	.	O
1	Analysis	O
2	of	O
3	corticosteroids	O
4	.	O
1	Reactivities	O
2	to	O
3	horse	B
4	anti	I
5	-	I
6	lymphocyte	I
7	globulin	I
8	.	O
1	Immunogenicity	O
2	of	O
3	various	O
4	mycobacteria	O
5	and	O
6	the	O
7	corresponding	O
8	levels	O
9	of	O
10	cross	O
11	-	O
12	protection	O
13	developed	O
14	between	O
15	species	O
16	.	O
1	Ten	O
2	-	O
3	year	O
4	experience	O
5	with	O
6	one	O
7	-	O
8	stage	O
9	proctocolectomy	O
10	and	O
11	anal	O
12	ileostomy	O
13	.	O
1	Serum	O
2	lipid	O
3	changes	O
4	during	O
5	pregnancy	O
6	due	O
7	to	O
8	oral	O
9	calcium	O
10	administration	O
1	Successful	O
2	treatment	O
3	of	O
4	candidiasis	O
5	with	O
6	transfer	B
7	factor	I
8	.	O
1	A	O
2	possible	O
3	role	O
4	for	O
5	the	O
6	mixed	O
7	function	O
8	oxidase	B
9	enzyme	O
10	system	O
11	in	O
12	the	O
13	requirement	O
14	for	O
15	selenium	O
16	in	O
17	the	O
18	rat	O
19	.	O
1	Oscilloscope	O
2	triggering	O
3	circuit	O
4	for	O
5	recording	O
6	long	O
7	transients	O
8	at	O
9	fast	O
10	sweep	O
11	speeds	O
12	.	O
1	Coronary	O
2	arteries	O
3	--	O
4	old	O
5	and	O
6	new	O
7	.	O
1	A	O
2	case	O
3	of	O
4	M	O
5	hemoglobinosis	O
1	Sinusoidal	O
2	oscillations	O
3	of	O
4	a	O
5	gas	O
6	dilution	O
7	indicator	O
1	The	O
2	non	O
3	-	O
4	role	O
5	of	O
6	fluoride	O
7	in	O
8	the	O
9	control	O
10	of	O
11	plasma	O
12	calcium	O
13	in	O
14	the	O
15	parathyroidectomized	O
16	rat	O
17	.	O
1	Second	O
2	report	O
3	of	O
4	the	O
5	Norwegian	O
6	Cancer	O
7	Society	O
8	.	O
1	BIM	O
2	130	O
3	.	O
1	Homograft	O
2	response	O
3	and	O
4	hemagglutinin	B
5	production	O
6	by	O
7	sensitized	O
8	thymectomized	O
9	irradiated	O
10	adult	O
11	mice	O
12	.	O
1	Comparative	O
2	study	O
3	on	O
4	acute	O
5	oral	O
6	overload	O
7	using	O
8	tolbutamide	O
9	and	O
10	tolazamide	O
11	in	O
12	normal	O
13	and	O
14	diabetic	O
15	subjects	O
16	.	O
1	Pitfalls	O
2	in	O
3	the	O
4	use	O
5	of	O
6	chromosome	O
7	aberration	O
8	analysis	O
9	for	O
10	biological	O
11	radiation	O
12	dosimetry	O
13	.	O
1	Renin	B
2	secretion	O
3	in	O
4	essential	O
5	and	O
6	accelerated	O
7	hypertension	O
8	.	O
1	Genitography	O
2	in	O
3	intersexual	O
4	states	O
5	.	O
1	Early	O
2	disagnosis	O
3	of	O
4	cancer	O
5	--	O
6	50	O
7	per	O
8	cent	O
9	of	O
10	all	O
11	patients	O
12	could	O
13	be	O
14	cured	O
1	Mae	O
2	West	O
3	and	O
4	the	O
5	doctor	O
6	shortage	O
7	.	O
1	A	O
2	new	O
3	hemagglutination	O
4	test	O
5	for	O
6	the	O
7	on	O
8	-	O
9	slide	O
10	assay	O
11	of	O
12	rheumatoid	B
13	factor	I
1	The	O
2	biology	O
3	of	O
4	Hyostrongylus	O
5	ruidus	O
6	.	O
1	V	O
2	.	O
1	18F	O
2	and	O
3	85Sr	O
4	scintimetry	O
5	in	O
6	the	O
7	study	O
8	of	O
9	primary	O
10	arthropathies	O
11	.	O
1	Health	O
2	:	O
3	an	O
4	integrative	O
5	reticulum	O
6	.	O
1	Sensitivities	O
2	of	O
3	thromboplastins	B
4	to	O
5	factor	B
6	VII	I
7	deficiency	O
8	.	O
1	Changing	O
2	and	O
3	predicting	O
4	doses	O
5	of	O
6	Cs137	O
7	irradiation	O
1	Positive	O
2	shifts	O
3	of	O
4	basal	O
5	skin	O
6	potentials	O
7	during	O
8	human	O
9	sleep	O
10	.	O
1	Histological	O
2	observations	O
3	on	O
4	the	O
5	decidua	O
6	in	O
7	the	O
8	second	O
9	half	O
10	of	O
11	pregnancy	O
1	Studies	O
2	carried	O
3	out	O
4	with	O
5	the	O
6	Glossina	O
7	morsitans	O
8	colony	O
9	of	O
10	Lisbon	O
11	.	O
1	Relations	O
2	between	O
3	adrenergic	O
4	mechanisms	O
5	and	O
6	analgesic	O
7	effects	O
1	Estrus	O
2	and	O
3	copulative	O
4	abilities	O
5	of	O
6	androgen	O
7	-	O
8	sterilized	O
9	rats	O
1	The	O
2	bearing	O
3	of	O
4	season	O
5	and	O
6	sequence	O
7	of	O
8	calving	O
9	on	O
10	frequency	O
11	of	O
12	male	O
13	,	O
14	female	O
15	and	O
16	total	O
17	calvings	O
18	in	O
19	Hariana	O
20	cows	O
21	.	O
1	Phosphate	B
2	glucose	I
3	dehydrogenase	I
4	deficiency	O
5	causing	O
6	hyperbilirubinemia	O
7	in	O
8	the	O
9	newborn	O
1	Variation	O
2	in	O
3	the	O
4	temporal	O
5	-	O
6	spatial	O
7	distribution	O
8	of	O
9	228Ra	O
10	and	O
11	224Ra	O
12	in	O
13	the	O
14	RES	O
15	and	O
16	marrow	O
17	-	O
18	free	O
19	skeleton	O
20	after	O
21	incorporation	O
22	of	O
23	colloidal	O
24	ThO2	O
1	Mining	O
2	the	O
3	diagnostic	O
4	iron	O
5	ore	O
6	.	O
1	On	O
2	the	O
3	character	O
4	of	O
5	changes	O
6	in	O
7	the	O
8	enzyme	O
9	activity	O
10	in	O
11	the	O
12	brain	O
13	tissue	O
14	during	O
15	reflex	O
16	epilepsy	O
1	Functional	O
2	disorders	O
3	of	O
4	the	O
5	ureter	O
6	following	O
7	gynecologic	O
8	surgery	O
1	Chemical	O
2	histologic	O
3	and	O
4	immunologic	O
5	responses	O
6	in	O
7	rats	O
8	to	O
9	CC1	O
10	-	O
11	4	O
12	by	O
13	different	O
14	routes	O
15	of	O
16	administration	O
17	.	O
1	On	O
2	the	O
3	diagnosis	O
4	of	O
5	bovine	O
6	leucosis	O
7	and	O
8	its	O
9	control	O
10	in	O
11	southern	O
12	Lower	O
13	Saxony	O
1	Experience	O
2	with	O
3	the	O
4	restoration	O
5	of	O
6	agglutination	O
7	properties	O
8	of	O
9	non	O
10	-	O
11	agglutinating	O
12	dysenterial	O
13	cultures	O
14	with	O
15	the	O
16	use	O
17	of	O
18	Rzhaninov	O
19	'	O
20	s	O
21	method	O
1	Naphthalene	O
2	and	O
3	paradichlorobenzene	O
4	in	O
5	clinical	O
6	toxicology	O
1	IV	O
2	.	O
1	Pigmentary	O
2	rhythms	O
3	as	O
4	indicators	O
5	of	O
6	neurosecretion	O
7	.	O
1	When	O
2	the	O
3	cervical	O
4	Pap	O
5	smear	O
6	is	O
7	positive	O
8	.	O
1	I	O
2	.	O
1	Persistence	O
2	of	O
3	toxaphene	O
4	in	O
5	treated	O
6	lakes	O
7	.	O
1	Studies	O
2	on	O
3	Coxsackie	O
4	B	O
5	Type	O
6	5	O
7	virus	O
8	infections	O
9	.	O
1	Study	O
2	on	O
3	the	O
4	evagination	O
5	of	O
6	Cysticercus	O
7	pisiformis	O
8	.	O
1	The	O
2	pathogenicity	O
3	of	O
4	Achromobacter	O
5	puntatum	O
6	for	O
7	cold	O
8	blooded	O
9	and	O
10	warm	O
11	blooded	O
12	animals	O
1	(	O
2	3	O
3	).	O
1	Electrophoretic	O
2	characteriaztion	O
3	of	O
4	virus	O
5	-	O
6	induced	O
7	interferon	B
8	of	O
9	the	O
10	blood	O
11	and	O
12	urine	O
13	in	O
14	rabbits	O
1	Iron	O
2	and	O
3	folate	O
4	deficiency	O
5	in	O
6	pregnancy	O
1	Two	O
2	hundred	O
3	forty	O
4	-	O
5	three	O
6	patients	O
7	have	O
8	received	O
9	WR	O
10	-	O
11	2721	O
12	in	O
13	Phase	O
14	I	O
15	-	O
16	II	O
17	studies	O
18	.	O
1	Hepatitis	O
2	B	O
3	virus	O
4	and	O
5	hepatoma	O
6	.	O
1	Eight	O
2	recombinant	O
3	DNA	O
4	clones	O
5	of	O
6	endogenous	O
7	murine	O
8	leukemia	O
9	virus	O
10	(	O
11	MuLV	O
12	)-	O
13	related	O
14	DNA	O
15	sequences	O
16	have	O
17	been	O
18	isolated	O
19	from	O
20	a	O
21	lambdaphage	O
22	genomic	O
23	library	O
24	of	O
25	Balb	O
26	/	O
27	c	O
28	mouse	O
29	DNA	O
30	.	O
1	It	O
2	is	O
3	concluded	O
4	that	O
5	haloperidol	O
6	selectively	O
7	reduced	O
8	the	O
9	animal	O
10	'	O
11	s	O
12	capacity	O
13	to	O
14	'	O
15	programme	O
16	non	O
17	-	O
18	stimulus	O
19	directed	O
20	motor	O
21	behaviour	O
22	'.	O
1	Neither	O
2	side	O
3	effect	O
4	nor	O
5	abnormal	O
6	laboratory	O
7	findings	O
8	due	O
9	to	O
10	this	O
11	drug	O
12	were	O
13	observed	O
14	.	O
1	Glutamic	O
2	acid	O
3	in	O
4	a	O
5	dose	O
6	of	O
7	1	O
8	/	O
9	100	O
10	of	O
11	the	O
12	LD50	O
13	was	O
14	injected	O
15	in	O
16	the	O
17	form	O
18	of	O
19	sodium	O
20	salt	O
21	into	O
22	male	O
23	and	O
24	female	O
25	Wistar	O
26	rats	O
27	for	O
28	7	O
29	days	O
30	after	O
31	8	O
32	-	O
33	and	O
34	12	O
35	-	O
36	day	O
37	injections	O
38	of	O
39	dexazone	O
40	.	O
1	In	O
2	several	O
3	cases	O
4	of	O
5	definite	O
6	SjS	O
7	,	O
8	labial	O
9	salivary	O
10	gland	O
11	examinations	O
12	after	O
13	more	O
14	than	O
15	a	O
16	one	O
17	year	O
18	interval	O
19	were	O
20	performed	O
21	on	O
22	two	O
23	occasions	O
24	,	O
25	and	O
26	the	O
27	clinical	O
28	and	O
29	histopathological	O
30	changes	O
31	were	O
32	investigated	O
33	.	O
1	The	O
2	effect	O
3	of	O
4	echothiophate	O
5	on	O
6	the	O
7	biphasic	O
8	response	O
9	of	O
10	rabbit	O
11	ocular	O
12	pressure	O
13	to	O
14	dipivefrin	O
15	.	O
1	Bacillus	O
2	cereus	O
3	cross	O
4	-	O
5	infection	O
6	in	O
7	a	O
8	maternity	O
9	-	O
10	unit	O
11	.	O
1	A	O
2	polypeptide	O
3	chain	O
4	of	O
5	34	O
6	residues	O
7	of	O
8	the	O
9	deduced	O
10	yeast	O
11	amino	O
12	acid	O
13	sequence	O
14	closely	O
15	resembles	O
16	a	O
17	peptide	O
18	sequence	O
19	at	O
20	the	O
21	ADP	O
22	binding	O
23	site	O
24	of	O
25	bovine	B
26	muscle	I
27	pyruvate	I
28	kinase	I
29	.	O
1	Products	O
2	of	O
3	immune	O
4	cells	O
5	such	O
6	as	O
7	transfer	B
8	factor	I
9	and	O
10	lymphokines	O
11	form	O
12	the	O
13	third	O
14	and	O
15	possibly	O
16	most	O
17	important	O
18	group	O
19	of	O
20	immune	O
21	-	O
22	stimulating	O
23	agents	O
24	.	O
1	Immunochemotherapy	O
2	with	O
3	schizophyllan	O
4	(	O
5	SPG	O
6	)	O
7	combined	O
8	with	O
9	chemotherapeutic	O
10	agents	O
11	was	O
12	evaluated	O
13	in	O
14	two	O
15	syngeneic	O
16	tumor	O
17	-	O
18	C3H	O
19	/	O
20	He	O
21	mouse	O
22	systems	O
23	.	O
1	Ventricular	O
2	volume	O
3	stiffness	O
4	vs	O
5	.	O
6	the	O
7	mean	O
8	wall	O
9	stress	O
10	relationship	O
11	of	O
12	LVH	O
13	shifted	O
14	upward	O
15	,	O
16	whereas	O
17	the	O
18	normalized	O
19	wall	O
20	muscle	O
21	stiffness	O
22	vs	O
23	.	O
24	the	O
25	mean	O
26	wall	O
27	stress	O
28	relationship	O
29	of	O
30	LVH	O
31	showed	O
32	a	O
33	smaller	O
34	slope	O
35	.	O
1	Synthesis	O
2	of	O
3	(+)-	O
4	lysergic	O
5	acid	O
6	diethylamide	O
7	tartrate	O
1	Among	O
2	six	O
3	different	O
4	library	O
5	isolates	O
6	containing	O
7	6	B
8	.	I
9	5	I
10	-	I
11	to	I
12	7	I
13	-	I
14	kb	I
15	IAP	I
16	units	I
17	,	O
18	some	O
19	restriction	O
20	sites	O
21	were	O
22	highly	O
23	conserved	O
24	whereas	O
25	others	O
26	varied	O
27	in	O
28	both	O
29	occurrence	O
30	and	O
31	position	O
32	.	O
1	Catecholamines	O
2	and	O
3	aversive	O
4	learning	O
5	:	O
6	a	O
7	review	O
8	.	O
1	A	O
2	haemolytic	O
3	enterotoxigenic	O
4	strain	O
5	of	O
6	E	O
7	.	O
8	coli	O
9	(	O
10	O149	O
11	:	O
12	K88	O
13	:	O
14	H10	O
15	)	O
16	was	O
17	regularly	O
18	recovered	O
19	from	O
20	piglets	O
21	with	O
22	PWD	O
23	while	O
24	rotavirus	O
25	was	O
26	demonstrated	O
27	on	O
28	a	O
29	number	O
30	of	O
31	occasions	O
32	.	O
1	Because	O
2	RNase	B
3	III	I
4	host	I
5	mutants	I
6	are	O
7	defective	O
8	in	O
9	sib	B
10	regulation	O
11	,	O
12	processing	O
13	of	O
14	the	O
15	PL	B
16	mRNA	I
17	at	O
18	sib	B
19	by	O
20	this	O
21	endoribonuclease	O
22	may	O
23	cause	O
24	int	B
25	mRNA	I
26	decay	O
27	and	O
28	decrease	O
29	int	B
30	synthesis	O
31	.	O
1	The	O
2	strong	O
3	conservation	O
4	of	O
5	the	O
6	inverted	O
7	terminal	O
8	repeat	O
9	sequence	O
10	may	O
11	reflect	O
12	a	O
13	common	O
14	integration	O
15	mechanism	O
16	for	O
17	VL30	B
18	elements	I
19	and	O
20	MuLV	O
21	proviruses	O
22	.	O
1	Hybridization	O
2	of	O
3	plasmid	O
4	-	O
5	transformed	O
6	Escherichia	O
7	coli	O
8	RR1	O
9	colonies	O
10	with	O
11	32P	O
12	-	O
13	labeled	O
14	viral	O
15	genome	O
16	RNAs	O
17	demonstrated	O
18	the	O
19	presence	O
20	of	O
21	DNA	O
22	clones	O
23	representative	O
24	of	O
25	each	O
26	of	O
27	the	O
28	10	O
29	reovirus	O
30	RNAs	O
31	and	O
32	10	O
33	of	O
34	the	O
35	11	O
36	constituent	O
37	segments	O
38	of	O
39	the	O
40	rotavirus	O
41	genome	O
42	.	O
1	Plasmids	O
2	for	O
3	the	O
4	cloning	O
5	and	O
6	expression	O
7	of	O
8	full	O
9	-	O
10	length	O
11	double	O
12	-	O
13	stranded	O
14	cDNAs	O
15	under	O
16	control	O
17	of	O
18	the	O
19	SV40	B
20	early	I
21	or	O
22	late	B
23	gene	I
24	promoter	O
25	.	O
1	Surgical	O
2	treatment	O
3	of	O
4	pulmonary	O
5	metastases	O
6	.	O
1	A	O
2	promoter	O
3	sequence	O
4	(	O
5	Goldberg	O
6	-	O
7	Hogness	O
8	or	O
9	TATA	O
10	box	O
11	)	O
12	is	O
13	situated	O
14	28	O
15	base	O
16	pairs	O
17	upstream	O
18	from	O
19	the	O
20	point	O
21	of	O
22	initiation	O
23	of	O
24	transcription	O
25	which	O
26	was	O
27	found	O
28	by	O
29	S1	B
30	nuclease	I
31	mapping	O
32	and	O
33	by	O
34	oligonucleotide	O
35	-	O
36	primed	O
37	reverse	O
38	transcription	O
39	of	O
40	rat	B
41	PTH	I
42	mRNA	I
43	.	O
1	No	O
2	significant	O
3	correlation	O
4	was	O
5	found	O
6	between	O
7	LVM	O
8	or	O
9	wall	O
10	thickness	O
11	and	O
12	body	O
13	surface	O
14	area	O
15	,	O
16	age	O
17	,	O
18	blood	O
19	pressure	O
20	,	O
21	heart	O
22	rate	O
23	,	O
24	cardiac	O
25	output	O
26	,	O
27	total	O
28	peripheral	O
29	resistance	O
30	and	O
31	left	O
32	ventricular	O
33	systolic	O
34	wall	O
35	stress	O
36	,	O
37	whereas	O
38	CD25	O
39	was	O
40	correlated	O
41	with	O
42	urinary	O
43	catecholamines	O
44	only	O
45	in	O
46	hypertensive	O
47	patients	O
48	(	O
49	r	O
50	=	O
51	0	O
52	.	O
53	606	O
54	,	O
55	p	O
56	less	O
57	than	O
58	0	O
59	.	O
60	001	O
61	).	O
1	An	O
2	immunologic	O
3	test	O
4	using	O
5	stomach	O
6	and	O
7	tumor	O
8	antigens	O
9	for	O
10	screening	O
11	of	O
12	those	O
13	at	O
14	high	O
15	risk	O
16	for	O
17	stomach	O
18	cancer	O
19	is	O
20	suggested	O
21	.	O
1	Tiaprofenic	O
2	acid	O
3	overdose	O
4	.	O
1	Blood	O
2	glucose	O
3	and	O
4	plasma	O
5	insulin	B
6	were	O
7	measured	O
8	at	O
9	zero	O
10	time	O
11	and	O
12	then	O
13	at	O
14	15	O
15	,	O
16	30	O
17	,	O
18	60	O
19	,	O
20	90	O
21	and	O
22	120	O
23	min	O
24	after	O
25	ingestion	O
26	of	O
27	25	O
28	g	O
29	glucose	O
30	,	O
31	fructose	O
32	or	O
33	lactose	O
34	,	O
35	or	O
36	30	O
37	g	O
38	honey	O
39	,	O
40	50	O
41	g	O
42	white	O
43	bread	O
44	,	O
45	125	O
46	g	O
47	white	O
48	rice	O
49	or	O
50	potatoes	O
51	,	O
52	150	O
53	g	O
54	apples	O
55	or	O
56	260	O
57	g	O
58	carrots	O
59	.	O
1	Clinical	O
2	use	O
3	of	O
4	absorbable	O
5	polyglycolic	O
6	acid	O
7	suture	O
8	in	O
9	Blalock	O
10	-	O
11	Taussig	O
12	'	O
13	s	O
14	operation	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	naturally	O
7	acquired	O
8	and	O
9	passive	O
10	(	O
11	modified	O
12	immune	B
13	serum	I
14	globulin	I
15	)	O
16	antibodies	O
17	to	O
18	type	B
19	III	I
20	group	I
21	B	I
22	Streptococcus	I
23	antigen	I
24	are	O
25	partially	O
26	protective	O
27	against	O
28	intra	O
29	-	O
30	amniotic	O
31	infection	O
32	.	O
1	In	O
2	the	O
3	posthospital	O
4	phase	O
5	of	O
6	AMI	O
7	,	O
8	as	O
9	well	O
10	as	O
11	in	O
12	CCHD	O
13	,	O
14	the	O
15	occurrence	O
16	of	O
17	high	O
18	-	O
19	grade	O
20	VPBs	O
21	usually	O
22	indicates	O
23	more	O
24	advanced	O
25	degrees	O
26	of	O
27	both	O
28	coronary	O
29	and	O
30	left	O
31	ventricular	O
32	disease	O
33	as	O
34	well	O
35	as	O
36	the	O
37	possibility	O
38	of	O
39	cardiac	O
40	and	O
41	/	O
42	or	O
43	sudden	O
44	death	O
45	.	O
1	The	O
2	enzymic	O
3	hydrolysis	O
4	of	O
5	urea	O
6	produces	O
7	ammonia	O
8	which	O
9	causes	O
10	a	O
11	vivid	O
12	yellow	O
13	to	O
14	purple	O
15	colour	O
16	change	O
17	in	O
18	the	O
19	pH	O
20	indicator	O
21	.	O
1	Analysis	O
2	of	O
3	proteins	O
4	synthesized	O
5	by	O
6	plasmids	O
7	containing	O
8	deleted	O
9	forms	O
10	of	O
11	the	O
12	trfA	B
13	region	I
14	indicates	O
15	that	O
16	the	O
17	A2	B
18	protein	I
19	is	O
20	the	O
21	essential	O
22	trfA	B
23	-	I
24	encoded	I
25	replication	I
26	protein	I
27	of	O
28	plasmid	O
29	RK2	O
30	.	O
1	Renal	O
2	response	O
3	to	O
4	captopril	O
5	in	O
6	severe	O
7	heart	O
8	failure	O
9	:	O
10	role	O
11	of	O
12	furosemide	O
13	in	O
14	natriuresis	O
15	and	O
16	reversal	O
17	of	O
18	hyponatremia	O
19	.	O
1	Lauciello	O
2	describes	O
3	a	O
4	technique	O
5	for	O
6	the	O
7	placement	O
8	of	O
9	functionally	O
10	generated	O
11	amalgam	O
12	stops	O
13	as	O
14	restorations	O
15	within	O
16	mandibular	O
17	acrylic	O
18	teeth	O
19	.	O
1	Climatic	O
2	treatment	O
3	of	O
4	children	O
5	with	O
6	respiratory	O
7	allergy	O
1	Hydrallazine	O
2	also	O
3	caused	O
4	a	O
5	slight	O
6	increase	O
7	in	O
8	plasma	B
9	renin	I
10	activity	O
11	and	O
12	urinary	O
13	excretion	O
14	of	O
15	noradrenaline	O
16	.	O
1	Total	O
2	cumulative	O
3	doses	O
4	of	O
5	doxorubicin	O
6	ranged	O
7	from	O
8	145	O
9	to	O
10	625	O
11	mg	O
12	./	O
13	m	O
14	.	O
15	2	O
16	.	O
1	Movement	O
2	programming	O
3	depends	O
4	on	O
5	understanding	O
6	of	O
7	behavioral	O
8	requirements	O
9	.	O
1	Transitory	O
2	subclinical	O
3	and	O
4	permanent	O
5	hypothyroidism	O
6	in	O
7	the	O
8	course	O
9	of	O
10	subacute	O
11	thyroiditis	O
12	(	O
13	de	O
14	Quervain	O
15	).	O
1	Each	O
2	patient	O
3	had	O
4	measurable	O
5	LH	B
6	and	O
7	FSH	B
8	levels	O
9	,	O
10	with	O
11	pulsed	O
12	nocturnal	O
13	secretion	O
14	,	O
15	and	O
16	pubertal	O
17	LH	B
18	and	O
19	FSH	B
20	responses	O
21	to	O
22	LRH	B
23	.	O
1	It	O
2	is	O
3	concluded	O
4	that	O
5	axillo	O
6	-	O
7	axillary	O
8	by	O
9	-	O
10	pass	O
11	is	O
12	a	O
13	simple	O
14	solution	O
15	for	O
16	a	O
17	complex	O
18	haemodynamic	O
19	,	O
20	clinical	O
21	and	O
22	therapeutic	O
23	problem	O
24	.	O
1	The	O
2	development	O
3	and	O
4	histostructural	O
5	organization	O
6	of	O
7	intrahepatic	O
8	biliary	O
9	ducts	O
10	were	O
11	studied	O
12	on	O
13	a	O
14	human	O
15	embryofetal	O
16	material	O
17	6	O
18	to	O
19	32	O
20	weeks	O
21	old	O
22	.	O
1	Cardiovascular	O
2	and	O
3	adrenal	O
4	medullo	O
5	-	O
6	sympathetic	O
7	reactions	O
8	to	O
9	acute	O
10	tobacco	O
11	poisoning	O
1	There	O
2	was	O
3	a	O
4	close	O
5	correlation	O
6	between	O
7	plasma	O
8	clearance	O
9	of	O
10	NT	O
11	by	O
12	10	O
13	-	O
14	hydroxylation	O
15	and	O
16	the	O
17	D	O
18	metabolic	O
19	ratio	O
20	(	O
21	D	O
22	/	O
23	4	O
24	-	O
25	OH	O
26	-	O
27	D	O
28	in	O
29	urine	O
30	)	O
31	in	O
32	the	O
33	Ghanaians	O
34	(	O
35	rs	O
36	=	O
37	-	O
38	0	O
39	.	O
40	95	O
41	;	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	01	O
48	)	O
49	and	O
50	Swedes	O
51	(	O
52	rs	O
53	=	O
54	-	O
55	0	O
56	.	O
57	84	O
58	;	O
59	P	O
60	less	O
61	than	O
62	0	O
63	.	O
64	01	O
65	).	O
1	Significant	O
2	clinical	O
3	differences	O
4	between	O
5	the	O
6	patients	O
7	treated	O
8	with	O
9	and	O
10	without	O
11	AMB	O
12	were	O
13	longer	O
14	survival	O
15	time	O
16	following	O
17	diagnosis	O
18	of	O
19	illness	O
20	(	O
21	P	O
22	less	O
23	than	O
24	0	O
25	.	O
26	05	O
27	)	O
28	and	O
29	more	O
30	frequent	O
31	cranial	O
32	nerve	O
33	signs	O
34	in	O
35	the	O
36	treated	O
37	patients	O
38	(	O
39	P	O
40	=	O
41	0	O
42	.	O
43	089	O
44	).	O
1	Salivary	O
2	estradiol	O
3	17	O
4	beta	O
5	(	O
6	E2	O
7	-	O
8	17	O
9	beta	O
10	)	O
11	and	O
12	progesterone	O
13	(	O
14	P	O
15	)	O
16	were	O
17	determined	O
18	by	O
19	using	O
20	radioimmunoassay	O
21	techniques	O
22	in	O
23	30	O
24	pregnant	O
25	females	O
26	in	O
27	the	O
28	first	O
29	,	O
30	second	O
31	and	O
32	third	O
33	trimesters	O
34	as	O
35	well	O
36	as	O
37	in	O
38	10	O
39	non	O
40	-	O
41	pregnant	O
42	controls	O
43	during	O
44	the	O
45	luteal	O
46	phase	O
47	of	O
48	the	O
49	menstrual	O
50	cycle	O
51	.	O
1	According	O
2	to	O
3	the	O
4	biochemical	O
5	tests	O
6	,	O
7	high	O
8	activity	O
9	(	O
10	over	O
11	200	O
12	U	O
13	/	O
14	l	O
15	)	O
16	of	O
17	alkaline	B
18	phosphatase	I
19	was	O
20	recorded	O
21	exclusively	O
22	in	O
23	patients	O
24	with	O
25	the	O
26	lymphogranulomatosis	O
27	-	O
28	induced	O
29	liver	O
30	damage	O
31	.	O
1	Reaction	O
2	of	O
3	human	O
4	organism	O
5	to	O
6	exercise	O
7	.	O
1	HA	O
2	resulted	O
3	in	O
4	decreased	O
5	(	O
6	p	O
7	less	O
8	than	O
9	0	O
10	.	O
11	05	O
12	)	O
13	Tre	O
14	(	O
15	0	O
16	.	O
17	4	O
18	degrees	O
19	C	O
20	)	O
21	and	O
22	HR	O
23	(	O
24	17	O
25	b	O
26	X	O
27	min	O
28	-	O
29	1	O
30	),	O
31	and	O
32	increased	O
33	(	O
34	p	O
35	less	O
36	than	O
37	0	O
38	.	O
39	05	O
40	)	O
41	Msw	O
42	(	O
43	16	O
44	g	O
45	X	O
46	m	O
47	-	O
48	2	O
49	X	O
50	h	O
51	-	O
52	1	O
53	)	O
54	during	O
55	the	O
56	saline	O
57	experiments	O
58	.	O
1	Scientific	O
2	cooperation	O
3	of	O
4	CMEA	O
5	member	O
6	countries	O
7	has	O
8	been	O
9	carried	O
10	out	O
11	since	O
12	1974	O
13	under	O
14	the	O
15	sponsorship	O
16	of	O
17	the	O
18	Cancer	O
19	Research	O
20	Institute	O
21	,	O
22	Slovak	O
23	Academy	O
24	of	O
25	Sciences	O
26	(	O
27	Czechoslovakia	O
28	)	O
29	within	O
30	the	O
31	framework	O
32	of	O
33	CMEA	O
34	.	O
1	In	O
2	the	O
3	Arithmetic	O
4	subtest	O
5	one	O
6	of	O
7	the	O
8	items	O
9	would	O
10	not	O
11	meet	O
12	the	O
13	difficulty	O
14	grading	O
15	shown	O
16	while	O
17	the	O
18	last	O
19	two	O
20	items	O
21	offer	O
22	very	O
23	little	O
24	possibility	O
25	of	O
26	success	O
27	for	O
28	all	O
29	subjects	O
30	.(	O
31	ABSTRACT	O
32	TRUNCATED	O
33	AT	O
34	250	O
35	WORDS	O
36	)	O
1	Ammonia	O
2	concentration	O
3	dropped	O
4	significantly	O
5	in	O
6	all	O
7	treatments	O
8	,	O
9	a	O
10	finding	O
11	which	O
12	suggests	O
13	a	O
14	protective	O
15	effect	O
16	on	O
17	protein	O
18	nitrogen	O
19	degradation	O
20	to	O
21	non	O
22	-	O
23	protein	O
24	nitrogen	O
25	(	O
26	NH3	O
27	).	O
1	Brainstem	O
2	auditory	O
3	evoked	O
4	responses	O
5	(	O
6	BAERs	O
7	)	O
8	and	O
9	quantitative	O
10	saccadic	O
11	eye	O
12	movement	O
13	studies	O
14	provide	O
15	information	O
16	on	O
17	the	O
18	integrity	O
19	of	O
20	pathways	O
21	traversing	O
22	the	O
23	brainstem	O
24	.	O
1	Effects	O
2	of	O
3	ketamine	O
4	on	O
5	the	O
6	circulatory	O
7	functions	O
8	and	O
9	body	O
10	tissue	O
11	oxygenation	O
12	in	O
13	dogs	O
14	under	O
15	normal	O
16	and	O
17	hypovolemic	O
18	conditions	O
19	.	O
1	Three	O
2	radiologists	O
3	without	O
4	knowledge	O
5	of	O
6	patients	O
7	'	O
8	data	O
9	and	O
10	treatment	O
11	analyzed	O
12	30	O
13	angiograms	O
14	with	O
15	and	O
16	30	O
17	examinations	O
18	without	O
19	PGF	O
20	.	O
1	The	O
2	rational	O
3	for	O
4	the	O
5	prophylactic	O
6	treatment	O
7	,	O
8	the	O
9	therapy	O
10	of	O
11	the	O
12	meningopathy	O
13	and	O
14	AIL	O
15	-	O
16	AIEOP	O
17	protocols	O
18	are	O
19	exposed	O
20	.	O
1	Hepatitis	O
2	B	O
3	vaccine	O
1	The	O
2	invasive	O
3	pattern	O
4	of	O
5	squamous	O
6	cell	O
7	carcinoma	O
8	in	O
9	the	O
10	mandibular	O
11	gingiva	O
1	However	O
2	,	O
3	the	O
4	history	O
5	of	O
6	acute	O
7	severe	O
8	complications	O
9	from	O
10	otitis	O
11	media	O
12	revealed	O
13	a	O
14	higher	O
15	frequency	O
16	in	O
17	those	O
18	individuals	O
19	with	O
20	alpha	B
21	1	I
22	-	I
23	antitrypsin	I
24	deficiency	O
25	as	O
26	compared	O
27	to	O
28	normals	O
29	.	O
1	Refractory	O
2	periods	O
3	of	O
4	the	O
5	AV	O
6	junction	O
7	were	O
8	altered	O
9	in	O
10	a	O
11	comparable	O
12	fashion	O
13	to	O
14	conduction	O
15	through	O
16	the	O
17	AV	O
18	node	O
19	.	O
1	While	O
2	these	O
3	findings	O
4	may	O
5	reflect	O
6	the	O
7	sensitivity	O
8	of	O
9	a	O
10	thick	O
11	myocardial	O
12	wall	O
13	to	O
14	ischaemia	O
15	during	O
16	surgery	O
17	,	O
18	the	O
19	postoperative	O
20	recovery	O
21	was	O
22	not	O
23	related	O
24	to	O
25	the	O
26	serum	B
27	CK	I
28	-	I
29	MB	I
30	level	O
31	.	O
1	Amikacin	O
2	concentrations	O
3	in	O
4	serum	O
5	and	O
6	blister	O
7	fluid	O
8	in	O
9	healthy	O
10	volunteers	O
11	and	O
12	in	O
13	patients	O
14	with	O
15	renal	O
16	impairment	O
17	.	O
1	Urinary	B
2	N	I
3	-	I
4	acetylglucosaminidase	I
5	activity	O
6	per	O
7	mg	O
8	creatinine	O
9	did	O
10	not	O
11	differ	O
12	significantly	O
13	between	O
14	groups	O
15	.	O
1	The	O
2	concentrations	O
3	of	O
4	C4	B
5	and	O
6	C1	B
7	-	I
8	INH	I
9	increased	O
10	with	O
11	advancing	O
12	stage	O
13	of	O
14	disease	O
15	and	O
16	were	O
17	above	O
18	normal	O
19	mean	O
20	values	O
21	in	O
22	all	O
23	stages	O
24	.	O
1	Less	O
2	antibacterial	O
3	activity	O
4	was	O
5	shown	O
6	toward	O
7	the	O
8	Gram	O
9	-	O
10	negative	O
11	bacilli	O
12	,	O
13	i	O
14	.	O
15	e	O
16	.,	O
17	Pseudomonas	O
18	,	O
19	Klebsiella	O
20	-	O
21	Enterobacter	O
22	,	O
23	Shigella	O
24	,	O
25	Escherichia	O
26	coli	O
27	,	O
28	Serratia	O
29	marcescens	O
30	and	O
31	Proteus	O
32	.	O
1	A	O
2	stable	O
3	interface	O
4	depends	O
5	on	O
6	overall	O
7	stress	O
8	and	O
9	microstress	O
10	distribution	O
11	on	O
12	the	O
13	bone	O
14	,	O
15	particularly	O
16	trabecular	O
17	bone	O
18	.	O
1	All	O
2	samples	O
3	exhibited	O
4	a	O
5	decline	O
6	in	O
7	ethanol	O
8	concentration	O
9	,	O
10	with	O
11	most	O
12	losses	O
13	falling	O
14	within	O
15	the	O
16	expected	O
17	20	O
18	to	O
19	40	O
20	mg	O
21	%	O
22	range	O
23	.	O
1	Adult	O
2	Amblyomma	O
3	lepidum	O
4	ticks	O
5	fed	O
6	as	O
7	nymphs	O
8	on	O
9	this	O
10	goat	O
11	transmitted	O
12	heartwater	O
13	to	O
14	a	O
15	Friesian	O
16	(	O
17	Bos	O
18	taurus	O
19	)	O
20	calf	O
21	.	O
1	Morphine	O
2	injected	O
3	into	O
4	the	O
5	lateral	O
6	ventricle	O
7	of	O
8	the	O
9	rat	O
10	produced	O
11	unilateral	O
12	analgesia	O
13	in	O
14	the	O
15	formalin	O
16	test	O
17	,	O
18	which	O
19	involves	O
20	continuous	O
21	,	O
22	moderate	O
23	pain	O
24	.	O
1	Mutations	O
2	in	O
3	seven	O
4	other	O
5	lts	B
6	genes	I
7	do	O
8	not	O
9	result	O
10	in	O
11	the	O
12	mak	B
13	-	I
14	phenotype	I
15	.	O
1	Single	O
2	tooth	O
3	replacement	O
4	with	O
5	the	O
6	aid	O
7	of	O
8	the	O
9	ITI	O
10	(	O
11	International	O
12	Team	O
13	fur	O
14	Implantologie	O
15	)	O
16	type	O
17	F	O
18	hollow	O
19	-	O
20	cylinder	O
21	implant	O
1	Colorimetric	O
2	determination	O
3	of	O
4	urinary	O
5	iron	O
6	,	O
7	chelated	O
8	with	O
9	deferoxamine	O
10	B	O
11	,	O
12	using	O
13	a	O
14	single	O
15	reagent	O
1	A	O
2	convenient	O
3	measure	O
4	of	O
5	this	O
6	impairment	O
7	may	O
8	be	O
9	obtained	O
10	using	O
11	the	O
12	ratio	O
13	of	O
14	urine	O
15	volume	O
16	(	O
17	V	O
18	)	O
19	divided	O
20	by	O
21	lithium	O
22	clearance	O
23	(	O
24	CLi	O
25	).	O
1	Nitrogen	O
2	balance	O
3	was	O
4	compared	O
5	,	O
6	and	O
7	metabolic	O
8	complications	O
9	were	O
10	monitored	O
11	by	O
12	evaluating	O
13	BUN	O
14	,	O
15	serum	O
16	creatinine	O
17	,	O
18	creatinine	O
19	clearance	O
20	,	O
21	serum	O
22	CO2	O
23	,	O
24	SGOT	B
25	,	O
26	SGPT	B
27	,	O
28	serum	B
29	LDH	I
30	,	O
31	and	O
32	serum	B
33	alkaline	I
34	phosphatase	I
35	.	O
1	Production	O
2	of	O
3	C	B
4	mu	I
5	RNAs	I
6	,	O
7	unlike	O
8	mu	B
9	mRNAs	I
10	,	O
11	does	O
12	not	O
13	require	O
14	recombination	O
15	with	O
16	the	O
17	joining	B
18	region	I
19	(	O
20	JH	B
21	)	O
22	locus	O
23	.	O
1	All	O
2	62	O
3	isolates	O
4	were	O
5	resistant	O
6	to	O
7	lincomycin	O
8	,	O
9	colistin	O
10	,	O
11	nystatin	O
12	,	O
13	amphotericin	O
14	B	O
15	,	O
16	trimethoprim	O
17	lactate	O
18	,	O
19	polymyxin	O
20	B	O
21	,	O
22	and	O
23	anisomycin	O
24	.	O
1	Morphine	O
2	-	O
3	dependent	O
4	and	O
5	control	O
6	rats	O
7	in	O
8	an	O
9	oral	O
10	free	O
11	-	O
12	choice	O
13	protocol	O
14	were	O
15	treated	O
16	with	O
17	gamma	O
18	-	O
19	vinyl	O
20	GABA	O
21	(	O
22	GVG	O
23	),	O
24	60	O
25	,	O
26	120	O
27	and	O
28	240	O
29	mg	O
30	/	O
31	kg	O
32	IP	O
33	,	O
34	for	O
35	3	O
36	days	O
37	over	O
38	three	O
39	successive	O
40	periods	O
41	.	O
1	Significance	O
2	of	O
3	the	O
4	pulmonary	O
5	gas	O
6	exchange	O
7	reaction	O
8	to	O
9	physical	O
10	loading	O
11	in	O
12	evaluating	O
13	the	O
14	effectiveness	O
15	of	O
16	mitral	O
17	commissurotomy	O
1	Thyreoliberin	B
2	VUFB	O
3	in	O
4	thyroid	O
5	gammagraphy	O
1	LCBF	O
2	in	O
3	normal	O
4	and	O
5	hypoxic	O
6	puppies	O
7	was	O
8	correlated	O
9	with	O
10	local	O
11	cerebral	O
12	glucose	O
13	utilization	O
14	(	O
15	LCGU	O
16	)	O
17	obtained	O
18	under	O
19	the	O
20	same	O
21	experimental	O
22	conditions	O
23	(	O
24	Duffy	O
25	et	O
26	al	O
27	,	O
28	1982	O
29	).	O
1	Apo	B
2	A	I
3	-	I
4	I	I
5	level	O
6	was	O
7	unrelated	O
8	to	O
9	age	O
10	,	O
11	but	O
12	increased	O
13	with	O
14	ethanol	O
15	consumption	O
16	and	O
17	decreased	O
18	with	O
19	adiposity	O
20	.	O
1	During	O
2	the	O
3	last	O
4	6	O
5	months	O
6	of	O
7	the	O
8	study	O
9	a	O
10	striking	O
11	change	O
12	in	O
13	epidemiology	O
14	concerning	O
15	hepatitis	O
16	A	O
17	was	O
18	seen	O
19	,	O
20	apparently	O
21	caused	O
22	by	O
23	a	O
24	steep	O
25	increase	O
26	in	O
27	the	O
28	incidence	O
29	of	O
30	this	O
31	type	O
32	of	O
33	hepatitis	O
34	among	O
35	drug	O
36	addicts	O
37	.	O
1	Time	O
2	shifts	O
3	increase	O
4	growth	B
5	hormone	I
6	release	O
7	.	O
1	Determination	O
2	of	O
3	20	O
4	alpha	O
5	-	O
6	hydroxy	O
7	-	O
8	9	O
9	beta	O
10	,	O
11	10	O
12	alpha	O
13	-	O
14	pregna	O
15	-	O
16	4	O
17	,	O
18	6	O
19	-	O
20	dien	O
21	-	O
22	3	O
23	-	O
24	one	O
25	in	O
26	plasma	O
27	by	O
28	selected	O
29	ion	O
30	monitoring	O
31	.	O
1	On	O
2	the	O
3	basis	O
4	of	O
5	histopathological	O
6	findings	O
7	,	O
8	the	O
9	origin	O
10	of	O
11	amyloid	O
12	appeared	O
13	to	O
14	be	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	fibroblasts	O
20	.	O
1	In	O
2	visible	O
3	tumours	O
4	the	O
5	best	O
6	results	O
7	were	O
8	obtained	O
9	with	O
10	FB	O
11	(	O
12	85	O
13	%)	O
14	while	O
15	TBN	O
16	was	O
17	positive	O
18	in	O
19	65	O
20	%.	O
1	Terbutaline	O
2	;	O
3	a	O
4	beta2	O
5	-	O
6	adrenergic	O
7	agonist	O
8	,	O
9	and	O
10	aminophyllin	O
11	,	O
12	a	O
13	phosphodiesterase	O
14	inhibitor	O
15	,	O
16	were	O
17	given	O
18	separately	O
19	,	O
20	or	O
21	in	O
22	combination	O
23	,	O
24	to	O
25	rabbit	O
26	fetuses	O
27	on	O
28	the	O
29	28th	O
30	day	O
31	of	O
32	gestation	O
33	.	O
1	The	O
2	hyperacute	O
3	phase	O
4	of	O
5	posterolateral	O
6	myocardial	O
7	infarction	O
8	.	O
1	Similar	O
2	clinical	O
3	evaluation	O
4	of	O
5	an	O
6	obligate	O
7	carrier	O
8	revealed	O
9	no	O
10	ocular	O
11	abnormalities	O
12	.	O
1	The	O
2	daily	O
3	administration	O
4	of	O
5	betamethasone	O
6	for	O
7	three	O
8	weeks	O
9	markedly	O
10	reduced	O
11	the	O
12	absorption	O
13	of	O
14	calcium	O
15	and	O
16	phosphate	O
17	as	O
18	well	O
19	as	O
20	the	O
21	growth	O
22	rate	O
23	.	O
1	At	O
2	necropsy	O
3	28	O
4	days	O
5	post	O
6	-	O
7	inoculation	O
8	,	O
9	F344	O
10	rats	O
11	had	O
12	no	O
13	gross	O
14	lung	O
15	lesions	O
16	,	O
17	even	O
18	those	O
19	given	O
20	the	O
21	maximum	O
22	dose	O
23	of	O
24	1	O
25	.	O
26	4	O
27	X	O
28	10	O
29	(	O
30	9	O
31	)	O
32	colony	O
33	-	O
34	forming	O
35	units	O
36	of	O
37	M	O
38	.	O
39	pulmonis	O
40	.	O
1	Aneurysmectomy	O
2	and	O
3	the	O
4	performance	O
5	of	O
6	CABG	O
7	were	O
8	not	O
9	significantly	O
10	associated	O
11	with	O
12	postoperative	O
13	ECG	O
14	changes	O
15	,	O
16	but	O
17	more	O
18	bypass	O
19	grafts	O
20	per	O
21	patient	O
22	grafted	O
23	appeared	O
24	in	O
25	the	O
26	group	O
27	with	O
28	postoperative	O
29	ECG	O
30	changes	O
31	,	O
32	suggesting	O
33	that	O
34	coronary	O
35	artery	O
36	disease	O
37	may	O
38	be	O
39	more	O
40	severe	O
41	in	O
42	that	O
43	group	O
44	.	O
1	The	O
2	extraction	O
3	measurements	O
4	were	O
5	used	O
6	to	O
7	test	O
8	for	O
9	extracerebral	O
10	contamination	O
11	of	O
12	venous	O
13	outflow	O
14	.	O
1	Contractile	O
2	responses	O
3	to	O
4	norepinephrine	O
5	,	O
6	serotonin	O
7	and	O
8	potassium	O
9	(	O
10	K	O
11	+)	O
12	and	O
13	relaxant	O
14	responses	O
15	to	O
16	isoproterenol	O
17	and	O
18	papaverine	O
19	were	O
20	studied	O
21	in	O
22	vitro	O
23	with	O
24	spirally	O
25	cut	O
26	thoracic	O
27	aortic	O
28	strips	O
29	from	O
30	aortic	O
31	coarcted	O
32	hypertensive	O
33	rats	O
34	(	O
35	AHR	O
36	)	O
37	2	O
38	,	O
39	6	O
40	,	O
41	14	O
42	and	O
43	28	O
44	days	O
45	postoperatively	O
46	and	O
47	compared	O
48	to	O
49	time	O
50	-	O
51	matched	O
52	,	O
53	sham	O
54	-	O
55	operated	O
56	normotensive	O
57	controls	O
58	.	O
1	Fifty	O
2	-	O
3	eight	O
4	RMI	O
5	'	O
6	s	O
7	occurred	O
8	in	O
9	the	O
10	placebo	O
11	group	O
12	as	O
13	compared	O
14	to	O
15	only	O
16	twenty	O
17	in	O
18	the	O
19	AC	O
20	group	O
21	(	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	).	O
1	Commonly	O
2	observed	O
3	systemic	O
4	toxic	O
5	effects	O
6	(	O
7	bone	O
8	marrow	O
9	,	O
10	gastrointestinal	O
11	tract	O
12	,	O
13	and	O
14	heart	O
15	)	O
16	were	O
17	not	O
18	seen	O
19	in	O
20	this	O
21	study	O
22	.	O
1	Diagnosis	O
2	of	O
3	phenylalanine	B
4	hydroxylase	I
5	deficiency	O
6	(	O
7	phenylketonuria	O
8	).	O
1	A	O
2	note	O
3	on	O
4	some	O
5	consequences	O
6	of	O
7	UV	O
8	vision	O
9	in	O
10	birds	O
11	.	O
1	Conjugated	O
2	and	O
3	unconjugated	O
4	phenylacetic	O
5	acid	O
6	and	O
7	m	O
8	-	O
9	and	O
10	p	O
11	-	O
12	hydroxyphenylacetic	O
13	acid	O
14	have	O
15	been	O
16	determined	O
17	in	O
18	the	O
19	plasma	O
20	of	O
21	normal	O
22	,	O
23	healthy	O
24	subjects	O
25	after	O
26	fasting	O
27	,	O
28	consumption	O
29	of	O
30	a	O
31	meal	O
32	and	O
33	ingestion	O
34	of	O
35	deuterium	O
36	labelled	O
37	amine	O
38	precursors	O
39	,	O
40	by	O
41	high	O
42	-	O
43	resolution	O
44	gas	O
45	chromatography	O
46	--	O
47	high	O
48	resolution	O
49	mass	O
50	spectrometry	O
51	with	O
52	selected	O
53	ion	O
54	monitoring	O
55	of	O
56	their	O
57	trifluoroethyl	O
58	-	O
59	pentafluoropropionyl	O
60	derivatives	O
61	.	O
1	Histamine	O
2	reactivity	O
3	had	O
4	returned	O
5	to	O
6	normal	O
7	in	O
8	half	O
9	the	O
10	workers	O
11	who	O
12	had	O
13	left	O
14	their	O
15	original	O
16	factories	O
17	,	O
18	but	O
19	in	O
20	only	O
21	one	O
22	worker	O
23	who	O
24	had	O
25	moved	O
26	within	O
27	her	O
28	original	O
29	factory	O
30	.	O
1	Ficat	O
2	and	O
3	Bizou	O
4	'	O
5	s	O
6	condylar	O
7	depth	O
8	index	O
9	and	O
10	the	O
11	condylar	O
12	-	O
13	joint	O
14	surface	O
15	angle	O
16	of	O
17	Brattstrom	O
18	are	O
19	recommended	O
20	as	O
21	especially	O
22	suitable	O
23	methods	O
24	of	O
25	measurement	O
26	.	O
1	The	O
2	COP	O
3	-	O
4	PAWP	O
5	gradient	O
6	was	O
7	markedly	O
8	decreased	O
9	in	O
10	both	O
11	shock	O
12	and	O
13	non	O
14	-	O
15	shock	O
16	patients	O
17	with	O
18	pulmonary	O
19	edema	O
20	.	O
1	Cramps	O
2	in	O
3	extrapyramidal	O
4	disorders	O
5	.	O
1	For	O
2	various	O
3	dog	O
4	vessels	O
5	in	O
6	vivo	O
7	,	O
8	Q	O
9	/	O
10	Dk	O
11	ranged	O
12	from	O
13	0	O
14	.	O
15	15	O
16	to	O
17	47	O
18	X	O
19	10	O
20	(	O
21	5	O
22	)	O
23	Torr	O
24	/	O
25	cm2	O
26	.	O
1	The	O
2	favourable	O
3	effect	O
4	of	O
5	thymic	O
6	shielding	O
7	was	O
8	also	O
9	reflected	O
10	in	O
11	a	O
12	significant	O
13	increase	O
14	of	O
15	LD50	O
16	/	O
17	30	O
18	,	O
19	and	O
20	the	O
21	dose	O
22	reduction	O
23	factor	O
24	was	O
25	equal	O
26	to	O
27	2	O
28	.	O
1	It	O
2	was	O
3	suggested	O
4	that	O
5	the	O
6	absence	O
7	of	O
8	pronounced	O
9	differences	O
10	between	O
11	conditions	O
12	may	O
13	have	O
14	been	O
15	due	O
16	to	O
17	the	O
18	complexity	O
19	of	O
20	the	O
21	task	O
22	or	O
23	the	O
24	type	O
25	of	O
26	prompts	O
27	employed	O
28	.	O
1	In	O
2	vitro	O
3	penetration	O
4	tests	O
5	of	O
6	human	O
7	sperm	O
8	into	O
9	cervical	O
10	mucus	O
11	were	O
12	introduced	O
13	in	O
14	order	O
15	to	O
16	study	O
17	the	O
18	interaction	O
19	between	O
20	sperm	O
21	and	O
22	cervical	O
23	mucus	O
24	.	O
1	Lacrimal	O
2	secretion	O
3	in	O
4	hyperthyroidism	O
1	Treatment	O
2	of	O
3	meat	O
4	muscle	O
5	800	O
6	V	O
7	for	O
8	45	O
9	s	O
10	reduced	O
11	weeping	O
12	but	O
13	increased	O
14	slightly	O
15	the	O
16	rate	O
17	of	O
18	autoxidation	O
19	of	O
20	lipids	O
21	.	O
1	TCZ	O
2	provides	O
3	quick	O
4	,	O
5	inexpensive	O
6	,	O
7	noninvasive	O
8	indication	O
9	of	O
10	tissue	O
11	necrosis	O
12	,	O
13	moderate	O
14	-	O
15	to	O
16	-	O
17	severe	O
18	intracranial	O
19	hemorrhage	O
20	,	O
21	and	O
22	delayed	O
23	brain	O
24	maturation	O
25	.	O
1	This	O
2	test	O
3	should	O
4	provide	O
5	another	O
6	practical	O
7	means	O
8	to	O
9	study	O
10	leprosy	O
11	.	O
1	Ulcer	O
2	appeared	O
3	on	O
4	the	O
5	angulus	O
6	of	O
7	the	O
8	stomach	O
9	at	O
10	the	O
11	28th	O
12	week	O
13	and	O
14	resulted	O
15	in	O
16	ulcer	O
17	scar	O
18	at	O
19	the	O
20	42nd	O
21	week	O
22	.	O
1	Following	O
2	extended	O
3	recovery	O
4	hippocampal	O
5	EEG	O
6	was	O
7	normal	O
8	despite	O
9	extensive	O
10	cellular	O
11	loss	O
12	in	O
13	areas	O
14	CA3	O
15	and	O
16	CA4	O
17	.	O
1	Evoked	O
2	potential	O
3	and	O
4	single	O
5	unit	O
6	responses	O
7	to	O
8	olfactory	O
9	nerve	O
10	volleys	O
11	in	O
12	the	O
13	isolated	O
14	turtle	O
15	olfactory	O
16	bulb	O
17	.	O
1	Strontium	O
2	-	O
3	90	O
4	was	O
5	inject	O
6	i	O
7	.	O
8	v	O
9	.	O
10	into	O
11	pregnant	O
12	rats	O
13	on	O
14	day	O
15	18	O
16	post	O
17	conception	O
18	(	O
19	p	O
20	.	O
21	c	O
22	.).	O
1	Eight	O
2	hr	O
3	of	O
4	acidosis	O
5	caused	O
6	a	O
7	significant	O
8	(	O
9	P	O
10	less	O
11	than	O
12	0	O
13	.	O
14	01	O
15	)	O
16	decrease	O
17	in	O
18	P50	O
19	in	O
20	vitro	O
21	which	O
22	fell	O
23	from	O
24	29	O
25	.	O
26	0	O
27	to	O
28	24	O
29	.	O
30	4	O
31	torr	O
32	.	O
1	Determination	O
2	of	O
3	aortic	O
4	distensibility	O
5	and	O
6	its	O
7	variations	O
8	in	O
9	arterial	O
10	hypertension	O
11	.	O
1	A	O
2	surgical	O
3	technique	O
4	for	O
5	correcting	O
6	this	O
7	problem	O
8	is	O
9	described	O
10	.	O
1	The	O
2	relationship	O
3	between	O
4	estrogenic	O
5	properties	O
6	of	O
7	Tamoxifen	O
8	and	O
9	breast	O
10	cancer	O
11	management	O
12	is	O
13	discussed	O
14	.	O
1	The	O
2	new	O
3	semi	O
4	-	O
5	synthetic	O
6	oral	O
7	cephalosporin	O
8	,	O
9	CGP	O
10	9	O
11	,	O
12	000	O
13	,	O
14	has	O
15	been	O
16	evaluated	O
17	in	O
18	a	O
19	large	O
20	number	O
21	of	O
22	hospitalized	O
23	patients	O
24	with	O
25	urinary	O
26	infections	O
27	.	O
1	When	O
2	pollen	O
3	allergen	O
4	from	O
5	three	O
6	grass	O
7	species	O
8	were	O
9	used	O
10	,	O
11	The	O
12	RAST	O
13	-	O
14	test	O
15	results	O
16	did	O
17	not	O
18	differ	O
19	from	O
20	duplicate	O
21	values	O
22	either	O
23	.	O
1	It	O
2	has	O
3	been	O
4	shown	O
5	in	O
6	experiments	O
7	in	O
8	vitro	O
9	that	O
10	the	O
11	hepatotrophic	O
12	organic	O
13	anions	O
14	,	O
15	the	O
16	radiographic	O
17	contrast	O
18	agent	O
19	(	O
20	RCA	O
21	)	O
22	bilignost	O
23	used	O
24	in	O
25	cholecystography	O
26	and	O
27	Bengal	O
28	pink	O
29	,	O
30	have	O
31	an	O
32	affinity	O
33	,	O
34	unlike	O
35	the	O
36	urographic	O
37	RCA	O
38	triombrin	O
39	and	O
40	renotrophic	O
41	dye	O
42	indigo	O
43	-	O
44	carmine	O
45	,	O
46	for	O
47	the	O
48	plasmatic	O
49	membranes	O
50	(	O
51	PM	O
52	)	O
53	of	O
54	liver	O
55	cells	O
56	.	O
1	Leukocyte	O
2	enzyme	O
3	activity	O
4	and	O
5	blood	O
6	lymphocyte	O
7	blast	O
8	transformation	O
9	in	O
10	chronic	O
11	bronchitis	O
1	The	O
2	known	O
3	B1	O
4	-	O
5	deficiency	O
6	reaches	O
7	excessive	O
8	high	O
9	values	O
10	with	O
11	light	O
12	exercise	O
13	.	O
1	Gastrin	B
2	secretion	O
3	during	O
4	food	O
5	stimulation	O
6	in	O
7	digestive	O
8	system	O
9	diseases	O
1	Nineteen	O
2	patients	O
3	with	O
4	non	O
5	-	O
6	visualized	O
7	gallbladder	O
8	with	O
9	OCG	O
10	subsequently	O
11	had	O
12	Tc	O
13	-	O
14	99m	O
15	-	O
16	PyG	O
17	cholescintigraphy	O
18	performed	O
19	.	O
1	Anamnestic	O
2	data	O
3	were	O
4	obtained	O
5	from	O
6	case	O
7	history	O
8	,	O
9	smoking	O
10	habits	O
11	were	O
12	not	O
13	known	O
14	in	O
15	collective	O
16	A	O
17	and	O
18	C	O
19	.	O
1	A	O
2	narrow	O
3	zone	O
4	of	O
5	myelin	O
6	-	O
7	axonal	O
8	dissociation	O
9	was	O
10	also	O
11	observed	O
12	.	O
1	Nutritional	O
2	cataracts	O
3	in	O
4	timber	O
5	wolves	O
6	.	O
1	Tests	O
2	of	O
3	the	O
4	method	O
5	indicate	O
6	(	O
7	1	O
8	)	O
9	the	O
10	Mossbauer	O
11	source	O
12	can	O
13	be	O
14	placed	O
15	on	O
16	the	O
17	basilar	O
18	membrane	O
19	without	O
20	altering	O
21	the	O
22	signal	O
23	-	O
24	transmission	O
25	properties	O
26	of	O
27	the	O
28	cochlea	O
29	,	O
30	and	O
31	(	O
32	2	O
33	)	O
34	the	O
35	source	O
36	adheres	O
37	to	O
38	the	O
39	basilar	O
40	membrane	O
41	.	O
1	Angiographic	O
2	work	O
3	-	O
4	up	O
5	in	O
6	a	O
7	patient	O
8	with	O
9	late	O
10	vaginal	O
11	metastasis	O
12	from	O
13	a	O
14	renal	O
15	carcinoma	O
16	.	O
1	Following	O
2	iv	O
3	injection	O
4	of	O
5	0	O
6	.	O
7	5	O
8	g	O
9	galactose	O
10	per	O
11	kg	O
12	body	O
13	weight	O
14	,	O
15	together	O
16	with	O
17	2	O
18	mu	O
19	Ci	O
20	generally	O
21	14C	O
22	-	O
23	labelled	O
24	galactose	O
25	,	O
26	14CO2	O
27	is	O
28	collected	O
29	in	O
30	regular	O
31	intervals	O
32	during	O
33	one	O
34	hour	O
35	.	O
1	Although	O
2	stone	O
3	-	O
4	formers	O
5	were	O
6	not	O
7	found	O
8	to	O
9	display	O
10	any	O
11	features	O
12	of	O
13	magnesium	O
14	metabolism	O
15	that	O
16	were	O
17	different	O
18	from	O
19	those	O
20	in	O
21	the	O
22	control	O
23	group	O
24	,	O
25	their	O
26	lower	O
27	urinary	O
28	excretion	O
29	of	O
30	magnesium	O
31	in	O
32	relation	O
33	to	O
34	calcium	O
35	may	O
36	be	O
37	a	O
38	factor	O
39	in	O
40	their	O
41	increased	O
42	stone	O
43	-	O
44	forming	O
45	propensity	O
46	.	O
1	A	O
2	16	O
3	-	O
4	year	O
5	follow	O
6	-	O
7	up	O
8	study	O
9	of	O
10	69	O
11	paraplegics	O
12	with	O
13	complete	O
14	lesions	O
15	from	O
16	T1	O
17	-	O
18	L3	O
19	is	O
20	presented	O
21	.	O
1	Implications	O
2	of	O
3	this	O
4	observation	O
5	for	O
6	pediatrics	O
7	are	O
8	discussed	O
9	.	O
1	Within	O
2	the	O
3	3	O
4	'	O
5	terminal	O
6	50	O
7	nucleotides	O
8	,	O
9	the	O
10	mouse	B
11	mt	I
12	12S	I
13	rRNA	I
14	contains	O
15	a	O
16	potential	O
17	10	O
18	bp	O
19	hairpin	O
20	structure	O
21	and	O
22	a	O
23	sequence	O
24	of	O
25	15	O
26	consecutive	O
27	nucleotides	O
28	common	O
29	to	O
30	the	O
31	RNA	O
32	of	O
33	the	O
34	small	O
35	ribosomal	O
36	subunit	O
37	in	O
38	all	O
39	systems	O
40	,	O
41	but	O
42	does	O
43	not	O
44	contain	O
45	the	O
46	mRNA	O
47	binding	O
48	site	O
49	(	O
50	ACCUCC	O
51	)	O
52	found	O
53	in	O
54	E	O
55	.	O
56	coli	O
57	and	O
58	corn	O
59	chloroplast	O
60	rRNAs	O
61	.	O
1	In	O
2	a	O
3	control	O
4	group	O
5	both	O
6	common	O
7	carotid	O
8	arteries	O
9	(	O
10	CCA	O
11	)	O
12	were	O
13	ligated	O
14	.	O
1	Simultaneous	O
2	right	O
3	and	O
4	left	O
5	adrenal	O
6	and	O
7	peripheral	O
8	blood	O
9	samples	O
10	were	O
11	collected	O
12	for	O
13	determination	O
14	of	O
15	oestrone	O
16	(	O
17	E1	O
18	)	O
19	and	O
20	oestradiol	O
21	(	O
22	E2	O
23	).	O
1	The	O
2	operation	O
3	recommended	O
4	is	O
5	excision	O
6	of	O
7	3	O
8	mm	O
9	of	O
10	central	O
11	slip	O
12	followed	O
13	by	O
14	end	O
15	-	O
16	to	O
17	-	O
18	end	O
19	repair	O
20	of	O
21	the	O
22	tendon	O
23	.	O
1	In	O
2	the	O
3	unclipped	O
4	group	O
5	arterial	O
6	pressure	O
7	decreased	O
8	50	O
9	mmHg	O
10	to	O
11	normal	O
12	by	O
13	24	O
14	h	O
15	and	O
16	was	O
17	associated	O
18	with	O
19	increased	O
20	diuresis	O
21	and	O
22	a	O
23	small	O
24	decrease	O
25	in	O
26	blood	O
27	volume	O
28	(	O
29	9	O
30	.	O
31	8	O
32	%).	O
1	In	O
2	11	O
3	patients	O
4	with	O
5	Horton	O
6	'	O
7	s	O
8	headache	O
9	morphological	O
10	investigations	O
11	(	O
12	differential	O
13	white	O
14	blood	O
15	cell	O
16	count	O
17	),	O
18	cytoenzymatic	O
19	determinations	O
20	(	O
21	alkaline	B
22	and	I
23	acid	I
24	phosphatase	I
25	,	O
26	non	B
27	-	I
28	specific	I
29	esterase	I
30	)	O
31	and	O
32	cytoimmunological	O
33	tests	O
34	(	O
35	IgM	B
36	and	O
37	IgG	B
38	binding	O
39	)	O
40	were	O
41	carried	O
42	out	O
43	on	O
44	capillary	O
45	blood	O
46	neutrophils	O
47	obtained	O
48	from	O
49	the	O
50	area	O
51	of	O
52	pain	O
53	,	O
54	non	O
55	-	O
56	painful	O
57	area	O
58	of	O
59	the	O
60	skin	O
61	on	O
62	the	O
63	head	O
64	on	O
65	the	O
66	contralateral	O
67	side	O
68	,	O
69	and	O
70	from	O
71	the	O
72	finger	O
73	.	O
1	A	O
2	third	O
3	series	O
4	of	O
5	mice	O
6	were	O
7	given	O
8	a	O
9	single	O
10	injection	O
11	of	O
12	5	O
13	-	O
14	OH	O
15	-	O
16	DA	O
17	,	O
18	sacrificed	O
19	,	O
20	and	O
21	prepared	O
22	for	O
23	ultrastructural	O
24	study	O
25	.	O
1	The	O
2	average	O
3	backscatter	O
4	coefficient	O
5	was	O
6	six	O
7	time	O
8	larger	O
9	in	O
10	regions	O
11	of	O
12	infarct	O
13	studied	O
14	8	O
15	--	O
16	10	O
17	weeks	O
18	after	O
19	occlusion	O
20	than	O
21	that	O
22	in	O
23	regions	O
24	of	O
25	infarct	O
26	studied	O
27	5	O
28	--	O
29	6	O
30	weeks	O
31	after	O
32	occlusion	O
33	.	O
1	Early	O
2	infection	O
3	was	O
4	detected	O
5	in	O
6	one	O
7	of	O
8	50	O
9	control	O
10	women	O
11	who	O
12	gave	O
13	birth	O
14	to	O
15	a	O
16	healthy	O
17	infant	O
18	.	O
1	The	O
2	term	O
3	osteomesopycnosis	O
4	is	O
5	proposed	O
6	for	O
7	a	O
8	sclerosing	O
9	bone	O
10	disease	O
11	with	O
12	dominant	O
13	inheritance	O
14	that	O
15	has	O
16	been	O
17	discovered	O
18	in	O
19	five	O
20	members	O
21	of	O
22	four	O
23	different	O
24	families	O
25	.	O
1	EUK	O
2	-	O
3	8	O
4	is	O
5	a	O
6	novel	O
7	,	O
8	synthetic	O
9	,	O
10	low	O
11	-	O
12	molecular	O
13	-	O
14	weight	O
15	salen	O
16	-	O
17	manganese	O
18	complex	O
19	that	O
20	exhibits	O
21	both	O
22	superoxide	B
23	dismutase	I
24	and	O
25	catalase	B
26	activities	O
27	in	O
28	vitro	O
29	.	O
1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	although	O
6	PI2	O
7	and	O
8	PI3	O
9	viruses	O
10	belong	O
11	to	O
12	the	O
13	same	O
14	parainfluenza	O
15	virus	O
16	genus	O
17	,	O
18	these	O
19	viruses	O
20	show	O
21	marked	O
22	differences	O
23	with	O
24	respect	O
25	to	O
26	functional	O
27	requirements	O
28	for	O
29	the	O
30	cytoplasmic	O
31	tail	O
32	of	O
33	the	O
34	F	B
35	glycoprotein	I
36	.	O
1	We	O
2	have	O
3	isolated	O
4	a	O
5	new	O
6	,	O
7	larger	O
8	rat	B
9	B	I
10	-	I
11	myc	I
12	genomic	I
13	clone	I
14	.	O
1	Both	O
2	classes	O
3	of	O
4	MHBst	B
5	proteins	I
6	were	O
7	found	O
8	to	O
9	form	O
10	dimers	O
11	;	O
12	an	O
13	which	O
14	is	O
15	involved	O
16	in	O
17	mediating	O
18	the	O
19	dimerization	O
20	.	O
1	She	O
2	had	O
3	been	O
4	receiving	O
5	MTX	O
6	7	O
7	.	O
8	5	O
9	mg	O
10	/	O
11	week	O
12	for	O
13	2	O
14	.	O
15	5	O
16	months	O
17	because	O
18	of	O
19	her	O
20	vasculitis	O
21	symptoms	O
22	.	O
1	These	O
2	are	O
3	two	O
4	regions	O
5	of	O
6	known	O
7	conserved	O
8	synteny	O
9	,	O
10	providing	O
11	further	O
12	evidence	O
13	that	O
14	the	O
15	human	B
16	STEP	I
17	is	O
18	a	O
19	true	O
20	homolog	O
21	of	O
22	the	O
23	murine	B
24	STEP	I
25	gene	I
26	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	the	O
5	human	O
6	homolog	O
7	of	O
8	a	O
9	striatum	B
10	-	I
11	enriched	I
12	phosphatase	I
13	(	I
14	STEP	I
15	)	I
16	gene	I
17	and	O
18	chromosomal	O
19	mapping	O
20	of	O
21	the	O
22	human	O
23	and	O
24	murine	O
25	loci	O
26	.	O
1	This	O
2	study	O
3	analyzed	O
4	whether	O
5	the	O
6	localization	O
7	of	O
8	an	O
9	accessory	O
10	pathway	O
11	could	O
12	be	O
13	predicted	O
14	by	O
15	using	O
16	the	O
17	polarity	O
18	of	O
19	the	O
20	QRS	O
21	complex	O
22	during	O
23	sinus	O
24	rhythm	O
25	on	O
26	the	O
27	surface	O
28	ECG	O
29	,	O
30	instead	O
31	of	O
32	the	O
33	delta	O
34	wave	O
35	polarity	O
36	as	O
37	used	O
38	in	O
39	many	O
40	reports	O
41	.	O
1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	tip	B
6	acts	O
7	at	O
8	an	O
9	early	O
10	stage	O
11	of	O
12	the	O
13	T	O
14	-	O
15	cell	O
16	signal	O
17	transduction	O
18	cascade	O
19	by	O
20	associating	O
21	with	O
22	Lck	B
23	and	O
24	downregulating	O
25	Lck	O
26	-	O
27	mediated	O
28	activation	O
29	.	O
1	In	O
2	contrast	O
3	with	O
4	the	O
5	previously	O
6	reported	O
7	HMGR1	B
8	mRNA	I
9	(	O
10	HMGR1S	B
11	mRNA	I
12	),	O
13	which	O
14	is	O
15	detected	O
16	at	O
17	high	O
18	levels	O
19	in	O
20	all	O
21	tissues	O
22	of	O
23	the	O
24	plant	O
25	,	O
26	HMGR1L	B
27	mRNA	I
28	is	O
29	present	O
30	at	O
31	relatively	O
32	low	O
33	levels	O
34	and	O
35	its	O
36	expression	O
37	is	O
38	restricted	O
39	mostly	O
40	to	O
41	seedlings	O
42	,	O
43	roots	O
44	and	O
45	inflorescences	O
46	.	O
1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	13	O
7	latest	O
8	BPVs	O
9	,	O
10	age	O
11	ranged	O
12	from	O
13	three	O
14	days	O
15	to	O
16	13	O
17	.	O
18	1	O
19	years	O
20	(	O
21	mean	O
22	5	O
23	.	O
24	7	O
25	+/-	O
26	SD	O
27	4	O
28	.	O
29	8	O
30	years	O
31	).	O
1	Interestingly	O
2	,	O
3	one	O
4	IRF	B
5	binding	I
6	site	I
7	was	O
8	found	O
9	within	O
10	the	O
11	IRF	B
12	-	I
13	2	I
14	promoter	I
15	,	O
16	and	O
17	expression	O
18	of	O
19	the	O
20	IRF	B
21	-	I
22	2	I
23	gene	I
24	was	O
25	affected	O
26	by	O
27	both	O
28	transient	O
29	and	O
30	stable	O
31	IRF	B
32	-	I
33	1	I
34	expression	O
35	.	O
1	There	O
2	was	O
3	also	O
4	a	O
5	highly	O
6	significant	O
7	correlation	O
8	between	O
9	total	O
10	selenium	O
11	intake	O
12	and	O
13	liver	O
14	selenium	O
15	concentration	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	99	O
22	,	O
23	p	O
24	<	O
25	0	O
26	.	O
27	01	O
28	)	O
29	after	O
30	1	O
31	mo	O
32	of	O
33	treatment	O
34	,	O
35	but	O
36	this	O
37	time	O
38	liver	O
39	selenium	O
40	did	O
41	not	O
42	change	O
43	with	O
44	time	O
45	,	O
46	and	O
47	the	O
48	correlation	O
49	remained	O
50	highly	O
51	significant	O
52	throughout	O
53	the	O
54	investigation	O
55	.	O
1	Two	O
2	promoters	O
3	were	O
4	identified	O
5	by	O
6	S1	B
7	nuclease	I
8	mapping	O
9	:	O
10	P1	O
11	,	O
12	which	O
13	lies	O
14	about	O
15	72	O
16	bp	O
17	upstream	O
18	from	O
19	the	O
20	structural	O
21	gene	O
22	;	O
23	and	O
24	P2	O
25	,	O
26	which	O
27	lies	O
28	about	O
29	35	O
30	bp	O
31	upstream	O
32	.	O
1	Interleukin	B
2	-	I
3	8	I
4	(	O
5	IL	B
6	-	I
7	8	I
8	)	O
9	is	O
10	a	O
11	potent	O
12	inflammatory	O
13	mediator	O
14	that	O
15	belongs	O
16	to	O
17	the	O
18	family	O
19	of	O
20	C	B
21	-	I
22	X	I
23	-	I
24	C	I
25	chemokines	I
26	.	O
1	We	O
2	recently	O
3	found	O
4	that	O
5	the	O
6	p72syk	B
7	protein	I
8	tyrosine	I
9	kinase	I
10	is	O
11	physically	O
12	associated	O
13	with	O
14	the	O
15	TCR	B
16	/	O
17	CD3	B
18	complex	O
19	and	O
20	is	O
21	rapidly	O
22	tyrosine	O
23	phosphorylated	O
24	and	O
25	activated	O
26	by	O
27	receptor	O
28	triggering	O
29	also	O
30	in	O
31	T	O
32	cells	O
33	lacking	O
34	p56lck	B
35	.	O
1	Organization	O
2	of	O
3	the	O
4	bovine	O
5	gene	O
6	encoding	O
7	the	O
8	endothelial	B
9	nitric	I
10	oxide	I
11	synthase	I
12	.	O
1	The	O
2	results	O
3	revealed	O
4	a	O
5	hierarchy	O
6	of	O
7	ligand	O
8	affinities	O
9	that	O
10	mirrored	O
11	their	O
12	adhesive	O
13	activity	O
14	(	O
15	rsVCAM	B
16	-	I
17	1	I
18	>	O
19	fibronectin	B
20	variants	I
21	containing	O
22	CS1	B
23	>>	O
24	other	O
25	fibronectin	B
26	variants	I
27	).	O
1	Dilutions	O
2	of	O
3	H	B
4	-	I
5	2b	I
6	or	I
7	H	I
8	-	I
9	2d	I
10	NP	I
11	peptides	I
12	indicated	O
13	that	O
14	3	O
15	-	O
16	4	O
17	logs	O
18	less	O
19	H	B
20	-	I
21	2b	I
22	NP	I
23	peptide	I
24	was	O
25	required	O
26	to	O
27	sensitize	O
28	syngeneic	O
29	target	O
30	cells	O
31	for	O
32	CTL	O
33	-	O
34	specific	O
35	lysis	O
36	,	O
37	suggesting	O
38	that	O
39	the	O
40	differing	O
41	affinities	O
42	of	O
43	H	O
44	-	O
45	2b	O
46	and	O
47	H	O
48	-	O
49	2d	O
50	major	B
51	histocompatibility	I
52	complex	I
53	molecules	I
54	for	O
55	their	O
56	peptides	O
57	likely	O
58	account	O
59	for	O
60	the	O
61	total	O
62	removal	O
63	of	O
64	NP	O
65	CTL	O
66	in	O
67	the	O
68	H	O
69	-	O
70	2b	O
71	mice	O
72	but	O
73	only	O
74	partial	O
75	removal	O
76	in	O
77	H	O
78	-	O
79	2d	O
80	mice	O
81	made	O
82	to	O
83	express	O
84	thymic	O
85	NP	O
86	.	O
1	Although	O
2	both	O
3	transfected	O
4	cell	O
5	lines	O
6	contain	O
7	FGF	B
8	-	I
9	1	I
10	cell	I
11	surface	I
12	receptors	I
13	as	O
14	judged	O
15	by	O
16	crosslinking	O
17	studies	O
18	,	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	transfectants	O
24	are	O
25	refractory	O
26	to	O
27	exogenous	O
28	FGF	B
29	-	I
30	1	I
31	,	O
32	whereas	O
33	the	O
34	mutant	O
35	transfectants	O
36	respond	O
37	normally	O
38	.(	O
39	ABSTRACT	O
40	TRUNCATED	O
41	AT	O
42	250	O
43	WORDS	O
44	)	O
1	Membrane	O
2	-	O
3	bound	O
4	Steel	B
5	factor	I
6	induces	O
7	more	O
8	persistent	O
9	tyrosine	B
10	kinase	I
11	activation	O
12	and	O
13	longer	O
14	life	O
15	span	O
16	of	O
17	c	B
18	-	I
19	kit	I
20	gene	O
21	-	O
22	encoded	O
23	protein	O
24	than	O
25	its	O
26	soluble	O
27	form	O
28	.	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	these	O
6	sequences	O
7	located	O
8	immediately	O
9	3	O
10	'	O
11	to	O
12	the	O
13	breakpoint	O
14	of	O
15	the	O
16	HPFH	B
17	-	I
18	3	I
19	deletion	I
20	,	O
21	exhibit	O
22	both	O
23	the	O
24	structure	O
25	and	O
26	the	O
27	function	O
28	of	O
29	an	O
30	enhancer	O
31	,	O
32	and	O
33	can	O
34	modify	O
35	the	O
36	developmental	O
37	specificity	O
38	of	O
39	the	O
40	fetal	B
41	gamma	I
42	-	I
43	globin	I
44	genes	I
45	,	O
46	resulting	O
47	in	O
48	their	O
49	continued	O
50	expression	O
51	during	O
52	adult	O
53	life	O
54	.	O
1	Our	O
2	results	O
3	indicate	O
4	that	O
5	interaction	O
6	between	O
7	Jak2	B
8	and	O
9	PRLR	B
10	requires	O
11	a	O
12	proline	O
13	-	O
14	rich	O
15	sequence	O
16	in	O
17	the	O
18	membrane	O
19	proximal	O
20	region	O
21	of	O
22	the	O
23	receptor	O
24	,	O
25	which	O
26	is	O
27	conserved	O
28	among	O
29	the	O
30	different	O
31	members	O
32	of	O
33	the	O
34	cytokine	B
35	receptor	I
36	superfamily	I
37	.	O
1	When	O
2	combined	O
3	with	O
4	independent	O
5	activating	O
6	mutations	O
7	in	O
8	the	O
9	c	B
10	-	I
11	abl	I
12	kinase	I
13	domain	I
14	or	O
15	NH2	O
16	-	O
17	terminus	O
18	,	O
19	the	O
20	G128R	B
21	mutation	O
22	blocked	O
23	transformation	O
24	by	O
25	the	O
26	double	O
27	mutant	O
28	,	O
29	suggesting	O
30	that	O
31	the	O
32	G128R	B
33	mutant	I
34	was	O
35	unable	O
36	to	O
37	transform	O
38	cells	O
39	for	O
40	trivial	O
41	reasons	O
42	.	O
1	Changes	O
2	induced	O
3	in	O
4	the	O
5	gills	O
6	of	O
7	milkfish	O
8	(	O
9	Chanos	O
10	chanos	O
11	Forsskal	O
12	)	O
13	fingerlings	O
14	after	O
15	acute	O
16	exposure	O
17	to	O
18	nifurpirinol	O
19	(	O
20	Furanace	O
21	;	O
22	P	O
23	-	O
24	7138	O
25	).	O
1	GCD10	B
2	was	O
3	first	O
4	identified	O
5	genetically	O
6	as	O
7	a	O
8	translational	O
9	repressor	O
10	of	O
11	GCN4	B
12	.	O
1	GCD10	B
2	binds	O
3	RNA	O
4	in	O
5	vitro	O
6	and	O
7	we	O
8	present	O
9	strong	O
10	biochemical	O
11	evidence	O
12	that	O
13	it	O
14	is	O
15	identical	O
16	to	O
17	the	O
18	RNA	O
19	-	O
20	binding	O
21	subunit	O
22	of	O
23	yeast	B
24	initiation	I
25	factor	I
26	-	I
27	3	I
28	(	O
29	eIF	B
30	-	I
31	3	I
32	).	O
33	eIF	B
34	-	I
35	3	I
36	is	O
37	a	O
38	multisubunit	O
39	complex	O
40	that	O
41	stimulates	O
42	translation	O
43	initiation	O
44	in	O
45	vitro	O
46	at	O
47	several	O
48	different	O
49	steps	O
50	.	O
1	Our	O
2	results	O
3	suggest	O
4	that	O
5	protein	O
6	binding	O
7	to	O
8	the	O
9	E2F	B
10	-	I
11	like	I
12	sequences	I
13	may	O
14	act	O
15	to	O
16	reduce	O
17	expression	O
18	.	O
1	We	O
2	showed	O
3	previously	O
4	that	O
5	a	O
6	fusion	O
7	protein	O
8	(	O
9	GAL4	B
10	-	O
11	p40	B
12	)	O
13	containing	O
14	the	O
15	DNA	O
16	-	O
17	binding	O
18	domain	O
19	of	O
20	GAL4	B
21	and	O
22	sequences	O
23	of	O
24	chicken	B
25	l	I
26	kappa	I
27	B	I
28	-	I
29	alpha	I
30	(	O
31	p40	B
32	)	O
33	inhibits	O
34	growth	O
35	in	O
36	the	O
37	yeast	O
38	Saccharomyces	O
39	cerevisiae	O
40	.	O
1	We	O
2	have	O
3	demonstrated	O
4	previously	O
5	that	O
6	two	O
7	binding	O
8	sites	O
9	in	O
10	the	O
11	-	B
12	184	I
13	HNF	I
14	-	I
15	3	I
16	beta	I
17	promoter	I
18	are	O
19	recognized	O
20	by	O
21	widely	O
22	distributed	O
23	factors	O
24	and	O
25	that	O
26	there	O
27	is	O
28	also	O
29	a	O
30	critical	O
31	autoregulatory	O
32	site	O
33	,	O
34	we	O
35	identified	O
36	a	O
37	binding	O
38	site	O
39	for	O
40	a	O
41	cell	O
42	-	O
43	specific	O
44	factor	O
45	,	O
46	LF	B
47	-	I
48	H3	I
49	beta	I
50	,	O
51	that	O
52	may	O
53	function	O
54	in	O
55	restricting	O
56	HNF	B
57	-	I
58	3	I
59	beta	I
60	gene	I
61	expression	O
62	to	O
63	hepatocytes	O
64	.	O
1	The	O
2	optimal	O
3	care	O
4	of	O
5	CHF	O
6	patient	O
7	includes	O
8	the	O
9	recognition	O
10	and	O
11	management	O
12	of	O
13	these	O
14	electrolyte	O
15	disturbances	O
16	.	O
1	Alanine	B
2	aminotransferase	I
3	(	O
4	ALT	B
5	)	O
6	levels	O
7	had	O
8	been	O
9	elevated	O
10	for	O
11	six	O
12	months	O
13	in	O
14	all	O
15	patients	O
16	and	O
17	hepatitis	O
18	B	O
19	viral	O
20	infection	O
21	was	O
22	replicative	O
23	.	O
1	In	O
2	this	O
3	study	O
4	we	O
5	have	O
6	investigated	O
7	the	O
8	role	O
9	of	O
10	C	B
11	/	I
12	EBP	I
13	beta	I
14	in	O
15	initiating	O
16	the	O
17	adipogenic	O
18	program	O
19	by	O
20	overexpressing	O
21	C	B
22	/	I
23	EBP	I
24	beta	I
25	in	O
26	multipotential	O
27	NIH	O
28	-	O
29	3T3	O
30	fibroblasts	O
31	.	O
1	However	O
2	,	O
3	division	O
4	of	O
5	the	O
6	chest	O
7	wall	O
8	muscles	O
9	,	O
10	usually	O
11	with	O
12	diathermy	O
13	,	O
14	contributes	O
15	to	O
16	prolonged	O
17	pain	O
18	and	O
19	morbidity	O
20	.	O
1	Citrate	B
2	synthase	I
3	activity	O
4	was	O
5	increased	O
6	in	O
7	the	O
8	medial	O
9	head	O
10	(	O
11	81	O
12	%,	O
13	P	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	and	O
20	the	O
21	red	O
22	long	O
23	head	O
24	(	O
25	88	O
26	%,	O
27	P	O
28	<	O
29	0	O
30	.	O
31	001	O
32	)	O
33	of	O
34	the	O
35	triceps	O
36	brachii	O
37	muscle	O
38	in	O
39	R	O
40	rats	O
41	but	O
42	not	O
43	in	O
44	the	O
45	white	O
46	long	O
47	head	O
48	(	O
49	25	O
50	%,	O
51	P	O
52	=	O
53	0	O
54	.	O
55	06	O
56	).	O
1	Although	O
2	eight	O
3	contiguous	O
4	genes	O
5	necessary	O
6	for	O
7	urease	B
8	activity	O
9	have	O
10	been	O
11	cloned	O
12	and	O
13	sequenced	O
14	,	O
15	the	O
16	transcriptional	O
17	organization	O
18	and	O
19	regulation	O
20	of	O
21	specific	O
22	genes	O
23	within	O
24	the	O
25	Proteus	B
26	gene	I
27	cluster	I
28	has	O
29	not	O
30	been	O
31	investigated	O
32	in	O
33	detail	O
34	.	O
1	Although	O
2	Micrococcus	B
3	luteus	I
4	UV	I
5	endonuclease	I
6	has	O
7	been	O
8	reported	O
9	to	O
10	be	O
11	an	O
12	18	O
13	-	O
14	kDa	O
15	enzyme	O
16	with	O
17	possible	O
18	homology	O
19	to	O
20	the	O
21	16	B
22	-	I
23	kDa	I
24	endonuclease	I
25	V	I
26	from	I
27	bacteriophage	I
28	T4	I
29	(	O
30	Gordon	O
31	,	O
32	L	O
33	.	O
1	Ras	B
2	p21Val	I
3	inhibits	O
4	myogenesis	O
5	without	O
6	altering	O
7	the	O
8	DNA	O
9	binding	O
10	or	O
11	transcriptional	O
12	activities	O
13	of	O
14	the	O
15	myogenic	B
16	basic	I
17	helix	I
18	-	I
19	loop	I
20	-	I
21	helix	I
22	factors	I
23	.	O
1	Immunofluorescence	O
2	microscopy	O
3	and	O
4	cell	O
5	fractionation	O
6	analyses	O
7	showed	O
8	that	O
9	the	O
10	110	O
11	-	O
12	kDa	O
13	protein	O
14	was	O
15	exclusively	O
16	nuclear	O
17	,	O
18	whereas	O
19	the	O
20	150	O
21	-	O
22	kDa	O
23	protein	O
24	was	O
25	present	O
26	in	O
27	both	O
28	the	O
29	cytoplasm	O
30	and	O
31	nucleus	O
32	of	O
33	human	O
34	cells	O
35	.	O
1	(	O
2	1986	O
3	)	O
4	method	O
5	of	O
6	separation	O
7	of	O
8	Cryptosporidium	O
9	spp	O
10	.	O
11	oocysts	O
12	from	O
13	feces	O
14	by	O
15	using	O
16	a	O
17	percoll	O
18	discontinuous	O
19	density	O
20	gradient	O
21	appeared	O
22	a	O
23	method	O
24	of	O
25	choice	O
26	for	O
27	obtaining	O
28	large	O
29	numbers	O
30	of	O
31	oocysts	O
32	of	O
33	C	O
34	.	O
35	parvum	O
36	free	O
37	of	O
38	fecal	O
39	contamination	O
40	.	O
1	Our	O
2	findings	O
3	also	O
4	provide	O
5	the	O
6	basis	O
7	for	O
8	the	O
9	development	O
10	of	O
11	assays	O
12	to	O
13	screen	O
14	for	O
15	the	O
16	ligands	O
17	to	O
18	testis	B
19	receptor	I
20	2	I
21	and	O
22	hERR1	B
23	.	O
1	This	O
2	action	O
3	is	O
4	dependent	O
5	on	O
6	helix	B
7	-	I
8	loop	I
9	-	I
10	helix	I
11	factors	I
12	bound	O
13	to	O
14	the	O
15	E1	B
16	element	O
17	.	O
1	However	O
2	,	O
3	a	O
4	strongly	O
5	increased	O
6	frequency	O
7	of	O
8	CpG	O
9	dinucleotides	O
10	was	O
11	found	O
12	.	O
1	In	O
2	comparison	O
3	of	O
4	cDNA	O
5	and	O
6	genomic	O
7	sequences	O
8	four	O
9	RNA	O
10	editing	O
11	events	O
12	were	O
13	found	O
14	in	O
15	both	O
16	atp9	B
17	genes	I
18	.	O
1	The	O
2	effects	O
3	of	O
4	Codonopsis	O
5	pilosula	O
6	oral	O
7	liquor	O
8	(	O
9	CPOL	O
10	)	O
11	on	O
12	tissue	B
13	-	I
14	type	I
15	plasminogen	I
16	activator	I
17	(	O
18	t	B
19	-	I
20	PA	I
21	)	O
22	and	O
23	plasminogen	B
24	activator	I
25	inhibitor	I
26	(	O
27	PAI	B
28	)	O
29	in	O
30	the	O
31	plasma	O
32	of	O
33	25	O
34	patients	O
35	of	O
36	coronary	O
37	heart	O
38	disease	O
39	with	O
40	blood	O
41	stasis	O
42	were	O
43	studied	O
44	.	O
1	Estimated	O
2	daily	O
3	intakes	O
4	(	O
5	EDIs	O
6	)	O
7	per	O
8	person	O
9	were	O
10	0	O
11	.	O
12	56	O
13	microgram	O
14	for	O
15	total	O
16	HCH	O
17	,	O
18	0	O
19	.	O
20	20	O
21	microgram	O
22	for	O
23	gamma	O
24	-	O
25	HCH	O
26	,	O
27	0	O
28	.	O
29	09	O
30	microgram	O
31	for	O
32	dieldrin	O
33	,	O
34	1	O
35	.	O
36	42	O
37	micrograms	O
38	for	O
39	total	O
40	DDT	O
41	,	O
42	and	O
43	0	O
44	.	O
45	15	O
46	microgram	O
47	for	O
48	HCB	O
49	.	O
1	HRES	O
2	has	O
3	been	O
4	found	O
5	to	O
6	be	O
7	clinically	O
8	useful	O
9	in	O
10	assessing	O
11	histologic	O
12	damage	O
13	following	O
14	pneumatic	O
15	dilatation	O
16	and	O
17	in	O
18	localizing	O
19	the	O
20	LES	O
21	during	O
22	the	O
23	administration	O
24	of	O
25	intrasphincter	O
26	botulinum	B
27	toxin	I
28	injection	O
29	in	O
30	the	O
31	treatment	O
32	of	O
33	achalasia	O
34	.	O
1	SL1	B
2	trans	O
3	-	O
4	splicing	O
5	specified	O
6	by	O
7	AU	O
8	-	O
9	rich	O
10	synthetic	O
11	RNA	O
12	inserted	O
13	at	O
14	the	O
15	5	O
16	'	O
17	end	O
18	of	O
19	Caenorhabditis	O
20	elegans	O
21	pre	O
22	-	O
23	mRNA	O
24	.	O
1	Overexpression	O
2	of	O
3	wild	B
4	-	I
5	type	I
6	p53	I
7	also	O
8	induces	O
9	apoptosis	O
10	in	O
11	an	O
12	LCL	O
13	.	O
1	We	O
2	show	O
3	that	O
4	c	B
5	-	I
6	Fos	I
7	(	O
8	the	O
9	c	B
10	-	I
11	fos	I
12	protooncogene	I
13	product	I
14	),	O
15	which	O
16	is	O
17	an	O
18	intrinsically	O
19	unstable	O
20	nuclear	O
21	protein	O
22	,	O
23	is	O
24	metabolically	O
25	highly	O
26	stabilized	O
27	,	O
28	and	O
29	greatly	O
30	enhances	O
31	the	O
32	transforming	O
33	efficiency	O
34	of	O
35	NIH	O
36	3T3	O
37	cells	O
38	,	O
39	by	O
40	Mos	B
41	.	O
1	A	O
2	2	B
3	.	I
4	4	I
5	-	I
6	kb	I
7	MAPKAPK	I
8	-	I
9	2	I
10	message	I
11	is	O
12	expressed	O
13	throughout	O
14	development	O
15	,	O
16	while	O
17	two	O
18	shorter	O
19	transcripts	O
20	of	O
21	2	O
22	.	O
23	3	O
24	and	O
25	1	O
26	.	O
27	8	O
28	kb	O
29	appear	O
30	to	O
31	be	O
32	specifically	O
33	expressed	O
34	in	O
35	the	O
36	germline	O
37	.	O
1	The	O
2	integrity	O
3	of	O
4	the	O
5	cDNA	O
6	sequence	O
7	was	O
8	confirmed	O
9	by	O
10	analysis	O
11	of	O
12	several	O
13	overlapping	O
14	genomic	O
15	clones	O
16	that	O
17	span	O
18	the	O
19	GAR1	B
20	gene	I
21	.	O
1	If	O
2	NCR	O
3	-	O
4	sensitive	O
5	gene	O
6	expression	O
7	occurs	O
8	exclusively	O
9	by	O
10	this	O
11	pathway	O
12	,	O
13	as	O
14	has	O
15	been	O
16	thought	O
17	to	O
18	be	O
19	the	O
20	case	O
21	,	O
22	then	O
23	the	O
24	NCR	O
25	sensitivity	O
26	of	O
27	a	O
28	gene	O
29	'	O
30	s	O
31	expression	O
32	should	O
33	be	O
34	abolished	O
35	by	O
36	a	O
37	ure2	B
38	delta	I
39	mutation	I
40	.	O
1	Another	O
2	common	O
3	mutation	O
4	involved	O
5	amino	O
6	acids	O
7	that	O
8	are	O
9	thought	O
10	to	O
11	make	O
12	specific	O
13	contacts	O
14	with	O
15	DNA	O
16	.	O
1	We	O
2	conclude	O
3	that	O
4	this	O
5	new	O
6	measurement	O
7	technique	O
8	provides	O
9	an	O
10	easy	O
11	and	O
12	accurate	O
13	P0	O
14	.	O
15	1	O
16	measurement	O
17	using	O
18	standard	O
19	respiratory	O
20	equipment	O
21	when	O
22	tested	O
23	in	O
24	a	O
25	lung	O
26	model	O
27	.	O
1	Subjects	O
2	with	O
3	a	O
4	short	O
5	postexposure	O
6	time	O
7	and	O
8	a	O
9	dioxin	O
10	burden	O
11	>	O
12	0	O
13	.	O
14	6	O
15	pg	O
16	/	O
17	m3	O
18	had	O
19	a	O
20	significantly	O
21	higher	O
22	risk	O
23	of	O
24	hypoergy	O
25	than	O
26	unexposed	O
27	subjects	O
28	(	O
29	hypoergy	O
30	I	O
31	:	O
32	OR	O
33	=	O
34	9	O
35	.	O
36	51	O
37	,	O
38	95	O
39	%	O
40	CI	O
41	=	O
42	1	O
43	.	O
44	96	O
45	-	O
46	42	O
47	.	O
48	02	O
49	;	O
50	hypoergy	O
51	II	O
52	:	O
53	OR	O
54	=	O
55	2	O
56	.	O
57	92	O
58	,	O
59	95	O
60	%	O
61	CI	O
62	=	O
63	1	O
64	.	O
65	14	O
66	-	O
67	7	O
68	.	O
69	5	O
70	).	O
1	The	O
2	experimental	O
3	design	O
4	represents	O
5	a	O
6	2	O
7	x	O
8	3	O
9	factorial	O
10	arrangement	O
11	of	O
12	treatments	O
13	with	O
14	three	O
15	dietary	O
16	levels	O
17	of	O
18	incorporation	O
19	of	O
20	RSB	O
21	(	O
22	0	O
23	,	O
24	50	O
25	,	O
26	and	O
27	100	O
28	%),	O
29	and	O
30	chickens	O
31	either	O
32	infected	O
33	or	O
34	uninfected	O
35	.	O
1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	is	O
7	highly	O
8	GC	O
9	rich	O
10	,	O
11	with	O
12	multiple	O
13	CpG	O
14	doublets	O
15	,	O
16	and	O
17	contains	O
18	multiple	O
19	binding	O
20	sites	O
21	for	O
22	Sp1	B
23	.	O
1	Oncological	O
2	,	O
3	clinical	O
4	and	O
5	psychological	O
6	aspects	O
7	are	O
8	evaluated	O
9	according	O
10	to	O
11	experience	O
12	accumulated	O
13	in	O
14	recent	O
15	years	O
16	,	O
17	with	O
18	immediate	O
19	and	O
20	delayed	O
21	reconstruction	O
22	,	O
23	carried	O
24	out	O
25	in	O
26	the	O
27	most	O
28	diverse	O
29	specialized	O
30	centers	O
31	.	O
1	The	O
2	cryptococcal	B
3	antigen	I
4	test	O
5	was	O
6	positive	O
7	at	O
8	1	O
9	:	O
10	125	O
11	by	O
12	latex	O
13	agglutination	O
14	.	O
1	Both	O
2	mu	B
3	and	I
4	gamma	I
5	2b	I
6	heavy	I
7	chain	I
8	genes	I
9	cause	O
10	this	O
11	feedback	O
12	inhibition	O
13	of	O
14	heavy	O
15	chain	O
16	gene	O
17	rearrangement	O
18	.	O
1	They	O
2	include	O
3	genes	O
4	encoding	O
5	three	O
6	subunits	O
7	of	O
8	the	O
9	cytochrome	B
10	oxidase	I
11	(	O
12	cox1	B
13	to	I
14	3	I
15	),	O
16	apocytochrome	B
17	b	I
18	(	O
19	cob	B
20	),	O
21	seven	O
22	subunits	O
23	of	O
24	the	O
25	NADH	B
26	dehydrogenase	I
27	complex	I
28	(	O
29	nad1	B
30	to	I
31	6	I
32	,	O
33	nad4L	B
34	),	O
35	two	O
36	ATPase	B
37	subunits	O
38	(	O
39	atp6	B
40	and	O
41	atp9	B
42	),	O
43	three	O
44	ribosomal	O
45	RNAs	O
46	(	O
47	rrn5	B
48	,	O
49	srn	B
50	and	O
51	lrn	B
52	),	O
53	23	O
54	tRNAs	O
55	and	O
56	four	O
57	ribosomal	O
58	proteins	O
59	(	O
60	rps3	B
61	,	O
62	rps11	B
63	,	O
64	rps12	B
65	and	O
66	rpl16	B
67	).	O
1	From	O
2	day	O
3	10	O
4	,	O
5	a	O
6	significant	O
7	increase	O
8	in	O
9	platelet	O
10	count	O
11	was	O
12	observed	O
13	in	O
14	eight	O
15	of	O
16	the	O
17	ten	O
18	patients	O
19	treated	O
20	with	O
21	heparin	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	),	O
29	with	O
30	return	O
31	to	O
32	the	O
33	initial	O
34	value	O
35	after	O
36	heparin	O
37	cessation	O
38	in	O
39	six	O
40	of	O
41	the	O
42	responders	O
43	.	O
1	These	O
2	""""	O
3	nucleocapsid	O
4	-	O
5	like	O
6	""""	O
7	structures	O
8	were	O
9	readily	O
10	purified	O
11	by	O
12	density	O
13	gradient	O
14	centrifugation	O
15	.	O
1	The	O
2	PEBP2	B
3	alpha	I
4	proteins	I
5	contain	O
6	a	O
7	128	O
8	-	O
9	amino	O
10	-	O
11	acid	O
12	(	O
13	aa	O
14	)	O
15	region	O
16	highly	O
17	homologous	O
18	to	O
19	the	O
20	Drosophila	B
21	melanogaster	I
22	segmentation	I
23	gene	I
24	runt	I
25	.	O
1	Histopathological	O
2	features	O
3	of	O
4	relapsed	O
5	leprosy	O
6	.	O
1	To	O
2	dissect	O
3	these	O
4	mechanisms	O
5	,	O
6	wild	O
7	-	O
8	type	O
9	and	O
10	mutant	B
11	Raf	I
12	-	I
13	1	I
14	proteins	I
15	were	O
16	studied	O
17	in	O
18	an	O
19	in	O
20	vitro	O
21	system	O
22	with	O
23	purified	O
24	plasma	O
25	membranes	O
26	from	O
27	v	B
28	-	I
29	Ras	I
30	-	O
31	and	O
32	v	B
33	-	I
34	Src	I
35	-	O
36	transformed	O
37	cells	O
38	(	O
39	transformed	O
40	membranes	O
41	).	O
1	Regulation	O
2	of	O
3	Gax	B
4	homeobox	I
5	gene	I
6	transcription	O
7	by	O
8	a	O
9	combination	O
10	of	O
11	positive	O
12	factors	O
13	including	O
14	myocyte	B
15	-	I
16	specific	I
17	enhancer	I
18	factor	I
19	2	I
20	.	O
1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	transactivation	O
6	domain	O
7	of	O
8	heat	B
9	shock	I
10	factor	I
11	1	I
12	is	O
13	negatively	O
14	regulated	O
15	and	O
16	stress	O
17	responsive	O
18	.	O
1	It	O
2	was	O
3	proposed	O
4	that	O
5	the	O
6	synthetase	O
7	-	O
8	related	O
9	sequences	O
10	of	O
11	GCN2	B
12	stimulate	O
13	the	O
14	activity	O
15	of	O
16	the	O
17	kinase	O
18	by	O
19	interacting	O
20	directly	O
21	with	O
22	uncharged	O
23	tRNA	O
24	that	O
25	accumulates	O
26	during	O
27	amino	O
28	acid	O
29	limitation	O
30	.	O
1	Hepatitis	O
2	B	O
3	vaccine	O
4	:	O
5	still	O
6	has	O
7	its	O
8	problems	O
9	.	O
1	Tumor	B
2	necrosis	I
3	factor	I
4	-	I
5	alpha	I
6	(	O
7	TNF	B
8	alpha	I
9	),	O
10	a	O
11	proinflammatory	O
12	cytokine	O
13	,	O
14	inhibits	O
15	cAMP	O
16	-	O
17	stimulated	O
18	testosterone	O
19	production	O
20	in	O
21	mouse	O
22	Leydig	O
23	cells	O
24	.	O
1	However	O
2	,	O
3	a	O
4	similar	O
5	mutation	O
6	of	O
7	a	O
8	leucine	O
9	residue	O
10	to	O
11	arginine	O
12	at	O
13	position	O
14	422	O
15	showed	O
16	no	O
17	alteration	O
18	of	O
19	heterodimerization	O
20	,	O
21	DNA	O
22	binding	O
23	,	O
24	or	O
25	transcriptional	O
26	activation	O
27	.	O
1	We	O
2	also	O
3	show	O
4	that	O
5	in	O
6	fusions	O
7	with	O
8	the	O
9	DNA	O
10	binding	O
11	domain	O
12	of	O
13	GAL4	B
14	,	O
15	full	O
16	activity	O
17	requires	O
18	the	O
19	entire	O
20	BHV	B
21	-	I
22	alpha	I
23	TIF	I
24	,	O
25	although	O
26	both	O
27	amino	O
28	and	O
29	carboxyl	O
30	termini	O
31	display	O
32	some	O
33	activity	O
34	on	O
35	their	O
36	own	O
37	.	O
1	The	O
2	C	O
3	-	O
4	terminal	O
5	peptide	O
6	sequences	O
7	of	O
8	the	O
9	human	B
10	lymphocyte	I
11	-	I
12	specific	I
13	high	I
14	mobility	I
15	group	I
16	(	I
17	HMG	I
18	)-	I
19	box	I
20	transcription	I
21	factor	I
22	TCF	I
23	-	I
24	1	I
25	are	O
26	determined	O
27	by	O
28	alternative	O
29	splice	O
30	mechanisms	O
31	affecting	O
32	the	O
33	exons	O
34	VIII	O
35	to	O
36	X	O
37	.	O
1	In	O
2	contrast	O
3	,	O
4	over	O
5	-	O
6	expression	O
7	of	O
8	RAR	B
9	beta	I
10	only	O
11	poorly	O
12	restored	O
13	differentiation	O
14	,	O
15	although	O
16	it	O
17	could	O
18	replace	O
19	RAR	B
20	gamma	I
21	for	O
22	the	O
23	activation	O
24	of	O
25	target	O
26	genes	O
27	.	O
1	Biochemical	O
2	analysis	O
3	shows	O
4	that	O
5	Ssm1p	B
6	is	O
7	a	O
8	structural	O
9	protein	O
10	that	O
11	forms	O
12	part	O
13	of	O
14	the	O
15	largest	O
16	60S	B
17	ribosomal	I
18	subunit	I
19	,	O
20	which	O
21	does	O
22	not	O
23	exist	O
24	in	O
25	a	O
26	pool	O
27	of	O
28	free	O
29	proteins	O
30	.	O
1	In	O
2	wild	O
3	-	O
4	type	O
5	cells	O
6	,	O
7	SSM1b	B
8	transcripts	I
9	accumulate	O
10	to	O
11	twice	O
12	the	O
13	level	O
14	of	O
15	SSM1a	B
16	transcripts	I
17	,	O
18	suggesting	O
19	that	O
20	SSM1b	B
21	is	O
22	responsible	O
23	for	O
24	the	O
25	majority	O
26	of	O
27	the	O
28	Ssm1p	B
29	pool	O
30	.	O
1	However	O
2	,	O
3	the	O
4	relative	O
5	binding	O
6	affinity	O
7	for	O
8	the	O
9	motifs	O
10	is	O
11	different	O
12	.	O
1	On	O
2	the	O
3	basis	O
4	of	O
5	this	O
6	anatomic	O
7	concept	O
8	,	O
9	the	O
10	brachioplasty	O
11	procedure	O
12	was	O
13	modified	O
14	to	O
15	provide	O
16	secure	O
17	anchoring	O
18	of	O
19	the	O
20	arm	O
21	flap	O
22	to	O
23	the	O
24	axillary	O
25	fascia	O
26	along	O
27	with	O
28	strong	O
29	superficial	O
30	fascial	O
31	system	O
32	repair	O
33	of	O
34	incisions	O
35	,	O
36	reducing	O
37	the	O
38	risk	O
39	of	O
40	widening	O
41	or	O
42	migration	O
43	of	O
44	scars	O
45	and	O
46	unnatural	O
47	contours	O
48	.	O
1	The	O
2	yeast	O
3	enzyme	O
4	was	O
5	6	O
6	-	O
7	fold	O
8	slower	O
9	than	O
10	the	O
11	mammalian	O
12	enzymes	O
13	,	O
14	which	O
15	made	O
16	it	O
17	amenable	O
18	to	O
19	pre	O
20	-	O
21	steady	O
22	-	O
23	state	O
24	stopped	O
25	-	O
26	flow	O
27	spectroscopic	O
28	kinetic	O
29	analysis	O
30	at	O
31	30	O
32	degrees	O
33	C	O
34	and	O
35	pH	O
36	6	O
37	.	O
38	0	O
39	.	O
1	We	O
2	used	O
3	deletion	O
4	analysis	O
5	and	O
6	transfection	O
7	assays	O
8	with	O
9	reporter	O
10	gene	O
11	constructs	O
12	to	O
13	examine	O
14	the	O
15	transcription	O
16	control	O
17	elements	O
18	in	O
19	the	O
20	5	O
21	'	O
22	flanking	O
23	region	O
24	of	O
25	the	O
26	human	B
27	EpoR	I
28	gene	I
29	.	O
1	Adrenergic	O
2	system	O
3	activation	O
4	,	O
5	indicated	O
6	by	O
7	metanephrine	O
8	/	O
9	epinephrine	O
10	ratio	O
11	,	O
12	increased	O
13	with	O
14	time	O
15	in	O
16	losing	O
17	males	O
18	,	O
19	except	O
20	that	O
21	after	O
22	one	O
23	month	O
24	of	O
25	cohabitation	O
26	,	O
27	turnover	O
28	returned	O
29	to	O
30	levels	O
31	that	O
32	equaled	O
33	those	O
34	of	O
35	control	O
36	animals	O
37	.	O
1	The	O
2	plasmin	B
3	-	I
4	derived	I
5	D	I
6	(	I
7	approximately	I
8	105	I
9	-	I
10	kDa	I
11	)	I
12	product	I
13	,	O
14	however	O
15	,	O
16	could	O
17	be	O
18	cross	O
19	-	O
20	linked	O
21	into	O
22	DD	O
23	dimers	O
24	.	O
1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	chloroplast	O
7	(	O
8	cp	O
9	)	O
10	DNA	O
11	from	O
12	maize	O
13	(	O
14	Zea	O
15	mays	O
16	)	O
17	has	O
18	been	O
19	completed	O
20	.	O
1	The	O
2	association	O
3	of	O
4	p255	B
5	with	O
6	splicing	O
7	complexes	O
8	is	O
9	suggested	O
10	by	O
11	the	O
12	finding	O
13	that	O
14	mAb	B
15	CC3	I
16	can	O
17	inhibit	O
18	in	O
19	vitro	O
20	splicing	O
21	and	O
22	immunoprecipitate	O
23	pre	O
24	-	O
25	messenger	O
26	RNA	O
27	and	O
28	splicing	O
29	products	O
30	.	O
1	Thus	O
2	,	O
3	endemic	O
4	cumlations	O
5	of	O
6	hepatitis	O
7	A	O
8	diseases	O
9	are	O
10	possible	O
11	.	O
1	This	O
2	shows	O
3	that	O
4	the	O
5	characteristically	O
6	diffuse	O
7	banding	O
8	pattern	O
9	of	O
10	plant	O
11	nuclear	O
12	proteins	O
13	interacting	O
14	with	O
15	the	O
16	G	O
17	-	O
18	box	O
19	is	O
20	also	O
21	observed	O
22	in	O
23	a	O
24	binding	O
25	assay	O
26	using	O
27	only	O
28	one	O
29	recombinant	B
30	GBF	I
31	.	O
1	Genomic	O
2	structure	O
3	and	O
4	chromosomal	O
5	location	O
6	of	O
7	the	O
8	mouse	B
9	pre	I
10	-	I
11	T	I
12	-	I
13	cell	I
14	receptor	I
15	alpha	I
16	gene	I
17	.	O
1	The	O
2	TAF	O
3	factor	O
4	appears	O
5	to	O
6	be	O
7	particularly	O
8	significant	O
9	in	O
10	OCD	O
11	.	O
1	RNase	B
2	protection	O
3	analyses	O
4	indicate	O
5	that	O
6	either	O
7	61	B
8	-	I
9	kDa	I
10	CaM	I
11	PDE	I
12	mRNA	I
13	or	O
14	structurally	O
15	related	O
16	transcripts	O
17	encoding	O
18	different	O
19	CaM	B
20	PDE	I
21	isoforms	I
22	are	O
23	expressed	O
24	in	O
25	a	O
26	tissue	O
27	-	O
28	specific	O
29	manner	O
30	.	O
1	RNA	B
2	polymerase	I
3	bound	O
4	to	O
5	the	O
6	+	O
7	10A	O
8	promoter	O
9	partially	O
10	protects	O
11	a	O
12	20	O
13	base	O
14	-	O
15	pair	O
16	sequence	O
17	from	O
18	DNase	B
19	I	I
20	digestion	O
21	upstream	O
22	of	O
23	the	O
24	start	O
25	site	O
26	.	O
1	This	O
2	agent	O
3	,	O
4	isolated	O
5	from	O
6	the	O
7	fungus	O
8	Streptomyces	O
9	tsukubaensis	O
10	,	O
11	has	O
12	a	O
13	mechanism	O
14	of	O
15	action	O
16	similar	O
17	to	O
18	that	O
19	of	O
20	cyclosporine	O
21	.	O
1	DNase	B
2	I	I
3	footprinting	O
4	of	O
5	the	O
6	proximal	O
7	promoter	O
8	revealed	O
9	four	O
10	regions	O
11	of	O
12	protection	O
13	.	O
1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	-	I
7	binding	I
8	protein	I
9	-	I
10	2	I
11	(	O
12	IGF	B
13	-	I
14	BP	I
15	-	I
16	2	I
17	)	O
18	transcription	O
19	in	O
20	rat	O
21	liver	O
22	varies	O
23	with	O
24	developmental	O
25	age	O
26	and	O
27	fasting	O
28	.	O
1	The	O
2	leader	O
3	sequence	O
4	of	O
5	the	O
6	isolated	O
7	cDNA	O
8	clone	O
9	contains	O
10	several	O
11	small	O
12	open	O
13	reading	O
14	frames	O
15	upstream	O
16	of	O
17	the	O
18	initiation	O
19	codon	O
20	of	O
21	the	O
22	largest	O
23	open	O
24	reading	O
25	frame	O
26	coding	O
27	for	O
28	the	O
29	homeodomain	B
30	protein	I
31	.	O
1	Our	O
2	data	O
3	complement	O
4	other	O
5	studies	O
6	of	O
7	circumpolar	O
8	populations	O
9	and	O
10	reinforce	O
11	the	O
12	reported	O
13	high	O
14	prevalences	O
15	of	O
16	SPA	O
17	and	O
18	HLA	B
19	-	I
20	B27	I
21	among	O
22	those	O
23	populations	O
24	.	O
1	Clinical	O
2	studies	O
3	SY5555	O
4	was	O
5	administered	O
6	to	O
7	45	O
8	patients	O
9	with	O
10	various	O
11	infectious	O
12	diseases	O
13	(	O
14	2	O
15	with	O
16	acute	O
17	pharyngitis	O
18	,	O
19	8	O
20	with	O
21	acute	O
22	tonsillitis	O
23	,	O
24	4	O
25	with	O
26	lacunar	O
27	tonsillitis	O
28	,	O
29	3	O
30	each	O
31	with	O
32	acute	O
33	bronchitis	O
34	,	O
35	pneumonia	O
36	and	O
37	pertussis	O
38	,	O
39	7	O
40	with	O
41	scarlet	O
42	fever	O
43	,	O
44	3	O
45	with	O
46	impetigo	O
47	contagiosa	O
48	,	O
49	6	O
50	with	O
51	acute	O
52	urinary	O
53	tract	O
54	infections	O
55	,	O
56	2	O
57	with	O
58	balanoposthitis	O
59	and	O
60	1	O
61	each	O
62	with	O
63	cervical	O
64	lymphadenitis	O
65	,	O
66	S	O
67	.	O
68	S	O
69	.	O
70	S	O
71	.	O
72	S	O
73	.,	O
74	vulvitis	O
75	and	O
76	acute	O
77	colitis	O
78	)	O
79	at	O
80	daily	O
81	doses	O
82	between	O
83	3	O
84	.	O
85	4	O
86	-	O
87	10	O
88	mg	O
89	/	O
90	kg	O
91	,	O
92	t	O
93	.	O
94	i	O
95	.	O
96	d	O
97	.,	O
98	for	O
99	3	O
100	-	O
101	14	O
102	days	O
103	.	O
1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	the	O
7	mouse	B
8	NMO1	I
9	cDNA	I
10	,	O
11	which	O
12	encodes	O
13	the	O
14	NAD	B
15	(	I
16	P	I
17	)	I
18	H	I
19	:	I
20	menadione	I
21	oxidoreductase	I
22	[	O
23	also	O
24	called	O
25	NAD	B
26	(	I
27	P	I
28	)	I
29	H	I
30	:(	I
31	quinone	I
32	acceptor	I
33	)	I
34	oxidoreductase	I
35	;	O
36	quinone	B
37	reductase	I
38	;	O
39	azo	B
40	dye	I
41	reductase	I
42	;	O
43	DT	B
44	diaphorase	I
45	;	O
46	EC	B
47	1	I
48	.	I
49	6	I
50	.	I
51	99	I
52	.	I
53	2	I
54	].	O
1	Such	O
2	a	O
3	mechanism	O
4	may	O
5	allow	O
6	acceleration	O
7	of	O
8	degenerative	O
9	joint	O
10	conditions	O
11	,	O
12	and	O
13	may	O
14	account	O
15	for	O
16	the	O
17	increased	O
18	prevalence	O
19	of	O
20	such	O
21	conditions	O
22	seen	O
23	with	O
24	HMS	O
25	subjects	O
26	.	O
1	Male	O
2	contraception	O
3	:	O
4	ideas	O
5	for	O
6	the	O
7	future	O
8	.	O
1	We	O
2	propose	O
3	that	O
4	Mad	B
5	and	O
6	Medea	B
7	encode	O
8	rate	O
9	-	O
10	limiting	O
11	components	O
12	integral	O
13	to	O
14	dpp	B
15	pathways	O
16	throughout	O
17	development	O
18	.	O
1	In	O
2	293	O
3	cells	O
4	,	O
5	expression	O
6	of	O
7	the	O
8	NF	B
9	-	I
10	kappa	I
11	B	I
12	inhibitor	O
13	,	O
14	I	B
15	kappa	I
16	B	I
17	-	I
18	alpha	I
19	,	O
20	reduced	O
21	the	O
22	stimulatory	O
23	activity	O
24	of	O
25	LMP	B
26	.	O
1	No	O
2	significant	O
3	differences	O
4	were	O
5	identified	O
6	between	O
7	groups	O
8	for	O
9	pH	O
10	,	O
11	PaCO2	O
12	,	O
13	intracranial	O
14	pressure	O
15	,	O
16	heart	O
17	rate	O
18	,	O
19	brain	O
20	temperature	O
21	,	O
22	or	O
23	glucose	O
24	levels	O
25	.	O
1	Primer	O
2	extension	O
3	experiments	O
4	showed	O
5	that	O
6	there	O
7	are	O
8	two	O
9	transcription	O
10	initiation	O
11	sites	O
12	16	O
13	bp	O
14	apart	O
15	in	O
16	the	O
17	mouse	B
18	type	I
19	2	I
20	receptor	I
21	gene	I
22	.	O
1	Each	O
2	dietary	O
3	treatment	O
4	was	O
5	fed	O
6	to	O
7	six	O
8	pen	O
9	replicates	O
10	of	O
11	five	O
12	chicks	O
13	per	O
14	pen	O
15	for	O
16	21	O
17	d	O
18	.	O
1	The	O
2	NarX	B
3	and	O
4	NarQ	B
5	proteins	I
6	with	O
7	amino	O
8	acid	O
9	substitutions	O
10	at	O
11	the	O
12	first	O
13	conserved	O
14	histidine	O
15	position	O
16	were	O
17	also	O
18	unable	O
19	to	O
20	dephosphorylate	O
21	NarL	B
22	-	O
23	phosphate	O
24	in	O
25	vitro	O
26	.	O
1	The	O
2	TTG	B
3	-	I
4	2	I
5	gene	I
6	has	O
7	been	O
8	identified	O
9	at	O
10	the	O
11	site	O
12	of	O
13	chromosomal	O
14	translocations	O
15	in	O
16	acute	O
17	T	O
18	-	O
19	cell	O
20	leukemia	O
21	'	O
22	s	O
23	(	O
24	T	O
25	-	O
26	ALL	O
27	).	O
1	Short	O
2	therapy	O
3	with	O
4	omeprazole	O
5	20	O
6	mg	O
7	/	O
8	b	O
9	.	O
10	i	O
11	.	O
12	d	O
13	.,	O
14	clarithromycin	O
15	500	O
16	mg	O
17	/	O
18	b	O
19	.	O
20	i	O
21	.	O
22	d	O
23	.,	O
24	and	O
25	CBS	O
26	120	O
27	mg	O
28	/	O
29	q	O
30	.	O
31	i	O
32	.	O
33	d	O
34	.	O
35	is	O
36	a	O
37	safe	O
38	,	O
39	well	O
40	tolerated	O
41	combination	O
42	that	O
43	achieves	O
44	a	O
45	80	O
46	.	O
47	6	O
48	%	O
49	eradication	O
50	rate	O
51	of	O
52	H	O
53	.	O
54	pylori	O
55	and	O
56	duodenal	O
57	ulcer	O
58	healing	O
59	rates	O
60	as	O
61	good	O
62	as	O
63	those	O
64	achieved	O
65	by	O
66	omeprazole	O
67	20	O
68	mg	O
69	/	O
70	d	O
71	when	O
72	given	O
73	for	O
74	4	O
75	wk	O
76	.	O
1	Whole	O
2	bowel	O
3	irrigation	O
4	is	O
5	a	O
6	recently	O
7	described	O
8	technique	O
9	to	O
10	enhance	O
11	the	O
12	passage	O
13	of	O
14	drugs	O
15	already	O
16	beyond	O
17	the	O
18	pylorus	O
19	.	O
1	However	O
2	,	O
3	the	O
4	mouse	O
5	has	O
6	previously	O
7	been	O
8	shown	O
9	to	O
10	possess	O
11	only	O
12	three	O
13	forms	O
14	of	O
15	ADH	B
16	.	O
1	2	O
2	.	O
1	Phylogenetic	O
2	analyses	O
3	of	O
4	19	O
5	amino	O
6	acid	O
7	sequences	O
8	of	O
9	6	O
10	related	O
11	protein	O
12	types	O
13	indicate	O
14	that	O
15	actin	B
16	-	O
17	associated	O
18	proteins	O
19	related	O
20	to	O
21	gelsolin	B
22	are	O
23	monophyletic	O
24	to	O
25	a	O
26	common	O
27	ancestor	O
28	and	O
29	include	O
30	flightless	B
31	proteins	I
32	.	O
1	By	O
2	creating	O
3	Pax	B
4	-	I
5	6	I
6	-	O
7	BSAP	B
8	fusion	O
9	proteins	O
10	,	O
11	we	O
12	were	O
13	able	O
14	to	O
15	identify	O
16	a	O
17	short	O
18	amino	O
19	acid	O
20	stretch	O
21	in	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	part	O
27	of	O
28	the	O
29	paired	B
30	domain	O
31	which	O
32	is	O
33	responsible	O
34	for	O
35	these	O
36	differences	O
37	in	O
38	DNA	O
39	-	O
40	binding	O
41	specificity	O
42	.	O
1	These	O
2	six	O
3	districts	O
4	have	O
5	an	O
6	area	O
7	of	O
8	34	O
9	,	O
10	000	O
11	km2	O
12	and	O
13	hold	O
14	a	O
15	population	O
16	of	O
17	30	O
18	million	O
19	.	O
1	According	O
2	to	O
3	symptoms	O
4	,	O
5	signs	O
6	,	O
7	imaging	O
8	features	O
9	,	O
10	operation	O
11	findings	O
12	,	O
13	the	O
14	original	O
15	places	O
16	and	O
17	the	O
18	expansive	O
19	directions	O
20	of	O
21	the	O
22	tumor	O
23	,	O
24	they	O
25	were	O
26	divided	O
27	into	O
28	four	O
29	clinical	O
30	types	O
31	:	O
32	sellar	O
33	,	O
34	clival	O
35	,	O
36	occipito	O
37	-	O
38	temporal	O
39	and	O
40	extent	O
41	.	O
1	A	O
2	triple	O
3	Ser	O
4	-->	O
5	Ala	O
6	mutant	O
7	form	O
8	of	O
9	yeast	O
10	eIF	B
11	-	I
12	2	I
13	alpha	I
14	was	O
15	found	O
16	to	O
17	be	O
18	no	O
19	longer	O
20	phosphorylated	O
21	by	O
22	either	O
23	of	O
24	the	O
25	yeast	O
26	(	O
27	or	O
28	mammalian	O
29	)	O
30	casein	B
31	kinase	I
32	activities	O
33	in	O
34	vitro	O
35	.	O
1	As	O
2	it	O
3	had	O
4	been	O
5	previously	O
6	reported	O
7	that	O
8	the	O
9	18	O
10	-	O
11	bp	O
12	palindrome	O
13	contains	O
14	sufficient	O
15	nucleotide	O
16	sequence	O
17	information	O
18	for	O
19	E1	B
20	binding	O
21	,	O
22	we	O
23	speculate	O
24	that	O
25	a	O
26	minimal	O
27	E1	B
28	recognition	O
29	motif	O
30	is	O
31	presented	O
32	in	O
33	each	O
34	half	O
35	site	O
36	.	O
1	Sequence	O
2	comparisons	O
3	of	O
4	prokaryotic	B
5	RCR	I
6	initiators	I
7	has	O
8	revealed	O
9	a	O
10	set	O
11	of	O
12	three	O
13	common	O
14	motifs	O
15	,	O
16	two	O
17	of	O
18	which	O
19	,	O
20	a	O
21	putative	O
22	metal	O
23	coordination	O
24	site	O
25	and	O
26	a	O
27	downstream	O
28	active	O
29	-	O
30	site	O
31	tyrosine	O
32	motif	O
33	,	O
34	could	O
35	be	O
36	tentatively	O
37	identified	O
38	in	O
39	parvoviral	B
40	replicator	I
41	proteins	I
42	.	O
1	The	O
2	characterized	O
3	Aplysia	B
4	Afurin2	I
5	is	O
6	a	O
7	candidate	O
8	PC	B
9	that	O
10	may	O
11	play	O
12	an	O
13	important	O
14	role	O
15	in	O
16	the	O
17	processing	O
18	of	O
19	egg	B
20	-	I
21	laying	I
22	hormone	I
23	(	O
24	ELH	B
25	)-	O
26	related	O
27	precursors	O
28	in	O
29	the	O
30	secretory	O
31	cells	O
32	of	O
33	the	O
34	atrial	O
35	gland	O
36	.	O
1	The	O
2	term	O
3	endovascular	O
4	papillary	O
5	haemangioma	O
6	is	O
7	suggested	O
8	.	O
1	In	O
2	addition	O
3	,	O
4	two	O
5	internal	O
6	promoters	O
7	,	O
8	PmiaA	B
9	and	O
10	P1hfq	B
11	were	O
12	identified	O
13	and	O
14	mapped	O
15	to	O
16	201	O
17	and	O
18	837	O
19	nucleotides	O
20	upstream	O
21	from	O
22	the	O
23	respective	O
24	translation	O
25	start	O
26	sites	O
27	.	O
1	Coronary	O
2	T1	O
3	and	O
4	T2	O
5	weighted	O
6	images	O
7	were	O
8	obtained	O
9	.	O
1	The	O
2	gene	O
3	pairs	O
4	psbB	B
5	-	O
6	psbT	B
7	and	O
8	psbH	B
9	-	O
10	psbN	B
11	are	O
12	cotranscribed	O
13	from	O
14	opposite	O
15	strands	O
16	.	O
1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	contains	O
7	regions	O
8	identical	O
9	to	O
10	the	O
11	sequences	O
12	of	O
13	peptides	O
14	derived	O
15	from	O
16	bovine	B
17	liver	I
18	eIF	I
19	-	I
20	2B	I
21	alpha	I
22	subunit	I
23	.	O
1	Expression	O
2	of	O
3	this	O
4	cDNA	O
5	in	O
6	vitro	O
7	yields	O
8	a	O
9	peptide	O
10	which	O
11	comigrates	O
12	with	O
13	natural	B
14	eIF	I
15	-	I
16	2B	I
17	alpha	I
18	in	O
19	SDS	O
20	/	O
21	polyacrylamide	O
22	gels	O
23	.	O
1	When	O
2	RNA	O
3	encoding	O
4	the	O
5	tail	O
6	domain	O
7	of	O
8	desmoglein	B
9	was	O
10	coinjected	O
11	with	O
12	plakoglobin	B
13	RNA	I
14	,	O
15	both	O
16	the	O
17	dorsalizing	O
18	effect	O
19	and	O
20	nuclear	O
21	accumulation	O
22	of	O
23	plakoglobin	B
24	were	O
25	suppressed	O
26	.	O
1	Six	O
2	of	O
3	them	O
4	,	O
5	NUC1	B
6	,	O
7	PRP21	B
8	(	O
9	also	O
10	called	O
11	SPP91	B
12	),	O
13	CDC6	B
14	,	O
15	CRY2	B
16	,	O
17	the	O
18	gene	O
19	encoding	O
20	the	O
21	ribosomal	B
22	protein	I
23	S24	I
24	and	O
25	the	O
26	gene	O
27	coding	O
28	for	O
29	a	O
30	hypothetical	O
31	protein	O
32	of	O
33	599	O
34	amino	O
35	acids	O
36	,	O
37	have	O
38	been	O
39	sequenced	O
40	previously	O
41	.	O
1	Thereafter	O
2	,	O
3	the	O
4	aggregation	O
5	rose	O
6	to	O
7	the	O
8	initial	O
9	100	O
10	%	O
11	value	O
12	4	O
13	h	O
14	after	O
15	drug	O
16	application	O
17	and	O
18	remained	O
19	at	O
20	this	O
21	level	O
22	during	O
23	the	O
24	observation	O
25	period	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O
1	The	O
2	protein	O
3	coding	O
4	region	O
5	,	O
6	1	O
7	,	O
8	696	O
9	bps	O
10	long	O
11	,	O
12	is	O
13	divided	O
14	by	O
15	an	O
16	intron	O
17	into	O
18	two	O
19	exons	O
20	.	O
1	The	O
2	UAS	O
3	of	O
4	the	O
5	AAC2	B
6	gene	I
7	contains	O
8	at	O
9	least	O
10	two	O
11	distinct	O
12	motifs	O
13	for	O
14	DNA	O
15	-	O
16	binding	O
17	transcriptional	O
18	activators	O
19	,	O
20	including	O
21	one	O
22	which	O
23	is	O
24	identical	O
25	with	O
26	the	O
27	core	O
28	HAP2	B
29	/	I
30	3	I
31	/	I
32	4	I
33	binding	I
34	motif	I
35	,	O
36	and	O
37	a	O
38	second	O
39	one	O
40	with	O
41	the	O
42	ABF1	B
43	consensus	I
44	binding	I
45	sequence	I
46	.	O
1	The	O
2	proteins	O
3	are	O
4	more	O
5	than	O
6	90	O
7	%	O
8	identical	O
9	to	O
10	each	O
11	other	O
12	within	O
13	the	O
14	protein	O
15	kinase	O
16	domain	O
17	but	O
18	only	O
19	51	O
20	-	O
21	59	O
22	%	O
23	identical	O
24	to	O
25	other	O
26	casein	B
27	kinase	I
28	I	I
29	isoforms	I
30	within	O
31	this	O
32	region	O
33	.	O
1	We	O
2	used	O
3	two	O
4	approaches	O
5	to	O
6	ascertain	O
7	whether	O
8	CDP	B
9	/	O
10	cut	B
11	serves	O
12	as	O
13	a	O
14	repressor	O
15	of	O
16	gp91	B
17	-	O
18	phox	B
19	gene	O
20	expression	O
21	.	O
1	Despite	O
2	the	O
3	activation	O
4	of	O
5	these	O
6	intracellular	O
7	signaling	O
8	molecules	O
9	,	O
10	PDGF	B
11	beta	I
12	receptor	I
13	activation	O
14	elicited	O
15	no	O
16	detectable	O
17	effect	O
18	on	O
19	cell	O
20	proliferation	O
21	or	O
22	differentiation	O
23	.	O
1	UAS1	O
2	is	O
3	the	O
4	binding	O
5	site	O
6	for	O
7	the	O
8	transcriptional	O
9	regulator	O
10	Adr1p	B
11	.	O
1	Induction	O
2	in	O
3	AP	B
4	-	I
5	1	I
6	DNA	O
7	binding	O
8	correlates	O
9	with	O
10	a	O
11	concomitant	O
12	GH	B
13	trans	O
14	-	O
15	activation	O
16	of	O
17	c	B
18	-	I
19	jun	I
20	and	O
21	c	B
22	-	I
23	fos	I
24	genes	I
25	described	O
26	previously	O
27	.	O
1	Short	O
2	-	O
3	course	O
4	amphotericin	O
5	B	O
6	therapy	O
7	for	O
8	candidemia	O
9	in	O
10	pediatric	O
11	patients	O
12	.	O
1	The	O
2	second	O
3	complex	O
4	,	O
5	when	O
6	purified	O
7	,	O
8	contained	O
9	four	O
10	protein	O
11	components	O
12	including	O
13	the	O
14	36	O
15	-	O
16	kDa	O
17	protein	O
18	.	O
1	Within	O
2	their	O
3	polypeptide	O
4	chain	O
5	,	O
6	they	O
7	all	O
8	contain	O
9	those	O
10	conserved	O
11	features	O
12	that	O
13	define	O
14	a	O
15	plant	O
16	CDPK	B
17	;	O
18	kinase	O
19	catalytic	O
20	sequences	O
21	are	O
22	linked	O
23	to	O
24	a	O
25	calmodulin	B
26	-	I
27	like	I
28	regulatory	I
29	domain	I
30	through	O
31	a	O
32	junction	O
33	region	O
34	.	O
1	Primer	O
2	extension	O
3	experiments	O
4	revealed	O
5	a	O
6	strong	O
7	transcription	O
8	initiation	O
9	site	O
10	102	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	translational	O
16	start	O
17	site	O
18	.	O
1	The	O
2	bHLH	B
3	proteins	I
4	function	O
5	as	O
6	potent	O
7	transcriptional	O
8	activators	O
9	of	O
10	tissue	O
11	-	O
12	specific	O
13	genes	O
14	by	O
15	forming	O
16	heterodimers	O
17	between	O
18	ubiquitous	O
19	and	O
20	cell	O
21	-	O
22	restricted	O
23	family	O
24	members	O
25	.	O
1	YAC	O
2	and	O
3	cosmid	O
4	contigs	O
5	spanning	O
6	the	O
7	BRCA1	B
8	region	I
9	were	O
10	used	O
11	to	O
12	select	O
13	cDNA	O
14	clones	O
15	from	O
16	pools	O
17	of	O
18	cDNAs	O
19	derived	O
20	from	O
21	human	O
22	placenta	O
23	,	O
24	HeLa	O
25	cells	O
26	,	O
27	activated	O
28	T	O
29	cells	O
30	,	O
31	and	O
32	fetal	O
33	head	O
34	.	O
1	Mutation	O
2	of	O
3	the	O
4	Sp1	B
5	element	I
6	,	O
7	which	O
8	abolishes	O
9	Sp1	B
10	binding	O
11	,	O
12	results	O
13	in	O
14	a	O
15	6	O
16	-	O
17	10	O
18	-	O
19	fold	O
20	reduction	O
21	in	O
22	reporter	O
23	activity	O
24	.	O
1	It	O
2	acts	O
3	on	O
4	Cdks	B
5	in	O
6	the	O
7	G1	O
8	and	O
9	S	O
10	phases	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	,	O
16	and	O
17	also	O
18	binds	O
19	to	O
20	proliferating	B
21	cell	I
22	nuclear	I
23	antigen	I
24	(	O
25	PCNA	B
26	),	O
27	blocking	O
28	DNA	O
29	replication	O
30	in	O
31	vitro	O
32	.	O
1	We	O
2	demonstrate	O
3	here	O
4	that	O
5	the	O
6	-	O
7	DEDDDL	O
8	sequence	O
9	stabilizes	O
10	GDP	O
11	binding	O
12	to	O
13	Ran	B
14	,	O
15	and	O
16	that	O
17	the	O
18	domain	O
19	is	O
20	required	O
21	for	O
22	high	O
23	affinity	O
24	interaction	O
25	with	O
26	a	O
27	Ran	B
28	-	I
29	binding	I
30	protein	I
31	,	O
32	HTF9A	B
33	/	O
34	RanBP1	B
35	.	O
1	Further	O
2	,	O
3	the	O
4	ORFs	O
5	of	O
6	components	O
7	3	O
8	and	O
9	5	O
10	potentially	O
11	encoded	O
12	proteins	O
13	of	O
14	about	O
15	20	O
16	kDa	O
17	,	O
18	the	O
19	size	O
20	of	O
21	the	O
22	BBTV	B
23	coat	I
24	protein	I
25	.	O
1	Transfection	O
2	of	O
3	non	O
4	-	O
5	deleted	O
6	expression	O
7	vector	O
8	into	O
9	NIH3T3	O
10	cells	O
11	results	O
12	in	O
13	acquisition	O
14	of	O
15	focus	O
16	-	O
17	forming	O
18	activity	O
19	while	O
20	a	O
21	deleted	O
22	form	O
23	of	O
24	expression	O
25	vector	O
26	fails	O
27	to	O
28	show	O
29	this	O
30	activity	O
31	even	O
32	in	O
33	the	O
34	presence	O
35	of	O
36	basic	B
37	FGF	I
38	.	O
1	The	O
2	provisional	O
3	reports	O
4	are	O
5	based	O
6	mainly	O
7	upon	O
8	macroscopic	O
9	findings	O
10	,	O
11	whereas	O
12	the	O
13	final	O
14	reports	O
15	include	O
16	the	O
17	information	O
18	provided	O
19	by	O
20	supplementary	O
21	investigations	O
22	such	O
23	as	O
24	microscopy	O
25	,	O
26	histochemistry	O
27	,	O
28	more	O
29	rarely	O
30	electron	O
31	microscopy	O
32	,	O
33	immunohistochemistry	O
34	and	O
35	/	O
36	or	O
37	microbiology	O
38	.	O
1	Circulating	O
2	thrombomodulin	B
3	:	O
4	current	O
5	knowledge	O
6	and	O
7	future	O
8	prospects	O
1	There	O
2	is	O
3	a	O
4	national	O
5	effort	O
6	to	O
7	begin	O
8	to	O
9	ask	O
10	all	O
11	female	O
12	patients	O
13	about	O
14	family	O
15	violence	O
16	.	O
1	Risks	O
2	of	O
3	chronicity	O
4	following	O
5	acute	O
6	hepatitis	O
7	B	O
8	virus	O
9	infection	O
10	:	O
11	a	O
12	review	O
13	.	O
1	A	O
2	secondary	O
3	phosphorylation	O
4	of	O
5	CREB341	B
6	at	O
7	Ser129	O
8	is	O
9	required	O
10	for	O
11	the	O
12	cAMP	O
13	-	O
14	mediated	O
15	control	O
16	of	O
17	gene	O
18	expression	O
19	.	O
1	In	O
2	contrast	O
3	,	O
4	a	O
5	Maf	B
6	-	I
7	related	I
8	protein	I
9	,	O
10	Nrl	B
11	,	O
12	completely	O
13	mimicked	O
14	c	B
15	-	I
16	Maf	I
17	actions	O
18	.	O
1	This	O
2	paper	O
3	describes	O
4	the	O
5	advantages	O
6	and	O
7	limitations	O
8	of	O
9	the	O
10	main	O
11	study	O
12	approaches	O
13	used	O
14	.	O
1	Further	O
2	studies	O
3	established	O
4	that	O
5	the	O
6	Ep	B
7	-	O
8	induced	O
9	increase	O
10	in	O
11	beta	B
12	-	I
13	globin	I
14	mRNA	I
15	could	O
16	be	O
17	inhibited	O
18	by	O
19	the	O
20	tyrosine	B
21	kinase	I
22	inhibitor	O
23	genistein	O
24	and	O
25	the	O
26	protein	B
27	kinase	I
28	C	I
29	inhibitor	O
30	Compound	O
31	3	O
32	.(	O
33	ABSTRACT	O
34	TRUNCATED	O
35	AT	O
36	250	O
37	WORDS	O
38	)	O
1	Molecular	O
2	dissection	O
3	of	O
4	the	O
5	multimeric	O
6	CD3	B
7	-	O
8	TCR	B
9	complex	O
10	revealed	O
11	that	O
12	at	O
13	least	O
14	two	O
15	associated	O
16	polypeptides	O
17	,	O
18	CD3	B
19	zeta	I
20	and	O
21	CD3	B
22	epsilon	I
23	,	O
24	autonomously	O
25	couple	O
26	antigenic	O
27	recognition	O
28	event	O
29	to	O
30	early	O
31	and	O
32	late	O
33	events	O
34	of	O
35	the	O
36	intracytoplasmic	O
37	activation	O
38	cascade	O
39	.	O
1	This	O
2	study	O
3	investigated	O
4	the	O
5	degree	O
6	to	O
7	which	O
8	racial	O
9	identity	O
10	influences	O
11	Mexican	O
12	-	O
13	Americans	O
14	'	O
15	performance	O
16	on	O
17	the	O
18	L	O
19	,	O
20	K	O
21	,	O
22	and	O
23	MF	O
24	scales	O
25	of	O
26	the	O
27	MMPI	O
28	-	O
29	2	O
30	.	O
1	A	O
2	unique	O
3	leucine	O
4	-	O
5	proline	O
6	repeat	O
7	element	O
8	found	O
9	N	O
10	-	O
11	terminal	O
12	to	O
13	the	O
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	of	O
19	EmBP	B
20	-	I
21	1	I
22	does	O
23	not	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	DNA	O
31	-	O
32	binding	O
33	or	O
34	dimerization	O
35	.	O
1	Two	O
2	related	O
3	cDNAs	O
4	were	O
5	isolated	O
6	that	O
7	encode	O
8	proteins	O
9	that	O
10	recognize	O
11	the	O
12	XMyoDa	B
13	TATA	I
14	motif	I
15	.	O
1	Inclusion	O
2	in	O
3	this	O
4	family	O
5	of	O
6	proteins	O
7	suggests	O
8	that	O
9	FliQ	B
10	and	O
11	FliR	B
12	may	O
13	participate	O
14	in	O
15	an	O
16	export	O
17	pathway	O
18	required	O
19	for	O
20	flagellum	O
21	assembly	O
22	.	O
1	We	O
2	characterized	O
3	three	O
4	Arabidopsis	O
5	thaliana	O
6	cDNA	O
7	clones	O
8	that	O
9	could	O
10	rescue	O
11	the	O
12	sterile	O
13	phenotype	O
14	of	O
15	the	O
16	Schizosaccharomyces	B
17	pombe	I
18	pde1	I
19	mutant	I
20	,	O
21	which	O
22	is	O
23	defective	O
24	in	O
25	cAMP	B
26	phosphodiesterase	I
27	.	O
1	Similarly	O
2	approximately	O
3	300	O
4	bp	O
5	of	O
6	sequence	O
7	downstream	O
8	of	O
9	the	O
10	translation	O
11	terminator	O
12	TGA	O
13	of	O
14	the	O
15	beta	B
16	-	I
17	tubulin	I
18	2	I
19	(	O
20	BTU2	B
21	)	O
22	gene	O
23	could	O
24	substitute	O
25	for	O
26	the	O
27	3	O
28	'	O
29	region	O
30	of	O
31	the	O
32	H4	B
33	-	I
34	I	I
35	gene	I
36	.	O
1	The	O
2	pre	O
3	-	O
4	and	O
5	postoperative	O
6	haemoglobin	B
7	concentrations	O
8	in	O
9	the	O
10	autologous	O
11	group	O
12	were	O
13	lower	O
14	by	O
15	15	O
16	and	O
17	10	O
18	g	O
19	/	O
20	L	O
21	,	O
22	respectively	O
23	,	O
24	after	O
25	primary	O
26	THR	O
27	and	O
28	by	O
29	10	O
30	g	O
31	/	O
32	L	O
33	in	O
34	both	O
35	instances	O
36	after	O
37	revision	O
38	THR	O
39	.	O
1	Mutagenesis	O
2	of	O
3	IM1	B
4	enhances	O
5	the	O
6	ability	O
7	of	O
8	c	B
9	-	I
10	Fos	I
11	to	O
12	activate	O
13	an	O
14	AP1	B
15	bearing	I
16	promoter	I
17	.	O
1	Binding	O
2	of	O
3	SSP	B
4	to	O
5	the	O
6	stage	B
7	selector	I
8	element	I
9	(	O
10	SSE	B
11	)	O
12	in	O
13	the	O
14	proximal	O
15	gamma	B
16	-	I
17	globin	I
18	promoter	I
19	is	O
20	integral	O
21	to	O
22	the	O
23	competitive	O
24	silencing	O
25	of	O
26	a	O
27	linked	O
28	beta	B
29	-	I
30	promoter	I
31	in	O
32	embryonic	O
33	/	O
34	fetal	O
35	stage	O
36	erythroleukemia	O
37	(	O
38	K562	O
39	)	O
40	cells	O
41	.	O
1	Mutations	O
2	that	O
3	alter	O
4	photoreceptor	O
5	cell	O
6	structure	O
7	and	O
8	development	O
9	were	O
10	isolated	O
11	that	O
12	fail	O
13	to	O
14	complement	O
15	these	O
16	deletions	O
17	.	O
1	Nucleotide	O
2	sequence	O
3	and	O
4	transcriptional	O
5	analysis	O
6	of	O
7	the	O
8	DNA	B
9	polymerase	I
10	gene	I
11	of	I
12	Bombyx	I
13	mori	I
14	nuclear	I
15	polyhedrosis	I
16	virus	I
17	.	O
1	Fraction	O
2	2	O
3	contains	O
4	1	O
5	,	O
6	25	O
7	(	O
8	OH	O
9	)	O
10	2	O
11	-	O
12	vitamin	O
13	D3	O
14	,	O
15	vitamin	O
16	D3	O
17	,	O
18	25	O
19	(	O
20	OH	O
21	)-	O
22	vitamin	O
23	D3	O
24	and	O
25	1	O
26	,	O
27	24	O
28	,	O
29	25	O
30	(	O
31	OH	O
32	)	O
33	3	O
34	-	O
35	vitamin	O
36	D3	O
37	.	O
1	A	O
2	comparison	O
3	of	O
4	the	O
5	Flavobacterium	O
6	glycosylasparaginase	B
7	with	O
8	a	O
9	mammalian	O
10	glycosylasparaginase	B
11	revealed	O
12	30	O
13	%	O
14	structural	O
15	identity	O
16	and	O
17	60	O
18	%	O
19	overall	O
20	similarity	O
21	between	O
22	the	O
23	prokaryotic	O
24	and	O
25	eukaryotic	O
26	forms	O
27	of	O
28	the	O
29	enzyme	O
30	.	O
1	Atrial	O
2	fibrillation	O
3	and	O
4	the	O
5	autonomic	O
6	nervous	O
7	system	O
1	A	O
2	reduction	O
3	of	O
4	the	O
5	aspartate	B
6	aminotransferase	I
7	activity	O
8	was	O
9	observed	O
10	from	O
11	800	O
12	mg	O
13	/	O
14	kg	O
15	b	O
16	.	O
17	w	O
18	./	O
19	d	O
20	onwards	O
21	.	O
1	The	O
2	expression	O
3	of	O
4	this	O
5	clone	O
6	in	O
7	a	O
8	wee1	B
9	/	O
10	mik1	B
11	-	O
12	deficient	O
13	mutant	O
14	causes	O
15	an	O
16	elongated	O
17	cell	O
18	phenotype	O
19	under	O
20	non	O
21	-	O
22	permissive	O
23	growth	O
24	conditions	O
25	.	O
1	The	O
2	MAP	B
3	kinase	I
4	cascade	O
5	is	O
6	highly	O
7	conserved	O
8	in	O
9	all	O
10	eukaryotes	O
11	and	O
12	involved	O
13	in	O
14	numerous	O
15	cellular	O
16	responses	O
17	.	O
1	No	O
2	serious	O
3	side	O
4	effects	O
5	were	O
6	observed	O
7	.	O
1	The	O
2	mean	O
3	jitter	O
4	and	O
5	the	O
6	fiber	O
7	density	O
8	did	O
9	not	O
10	change	O
11	significantly	O
12	from	O
13	day	O
14	0	O
15	(	O
16	30	O
17	.	O
18	1	O
19	+/-	O
20	3	O
21	.	O
22	6	O
23	microseconds	O
24	;	O
25	1	O
26	.	O
27	4	O
28	+/-	O
29	0	O
30	.	O
31	07	O
32	)	O
33	to	O
34	day	O
35	30	O
36	(	O
37	34	O
38	.	O
39	5	O
40	+/-	O
41	2	O
42	.	O
43	7	O
44	microseconds	O
45	;	O
46	1	O
47	.	O
48	6	O
49	+/-	O
50	0	O
51	.	O
52	13	O
53	).	O
1	Cloning	O
2	by	O
3	complementation	O
4	and	O
5	subsequent	O
6	physical	O
7	and	O
8	genetic	O
9	analysis	O
10	revealed	O
11	that	O
12	it	O
13	maps	O
14	to	O
15	RAF1	B
16	.	O
1	The	O
2	interleukin	B
3	2	I
4	receptor	I
5	alpha	I
6	-	I
7	chain	I
8	(	O
9	IL	B
10	-	I
11	2R	I
12	alpha	I
13	)	O
14	gene	O
15	is	O
16	rapidly	O
17	and	O
18	potently	O
19	induced	O
20	in	O
21	T	O
22	cells	O
23	in	O
24	response	O
25	to	O
26	mitogenic	O
27	stimuli	O
28	.	O
1	Similarly	O
2	,	O
3	in	O
4	mammalian	O
5	cells	O
6	PBP74	B
7	is	O
8	synthesized	O
9	as	O
10	a	O
11	pre	O
12	-	O
13	protein	O
14	that	O
15	requires	O
16	membrane	O
17	potential	O
18	-	O
19	dependent	O
20	import	O
21	into	O
22	mitochondria	O
23	for	O
24	its	O
25	maturation	O
26	.	O
1	Treatment	O
2	of	O
3	recurrent	O
4	FSGS	O
5	has	O
6	included	O
7	high	O
8	-	O
9	dose	O
10	steroids	O
11	,	O
12	high	O
13	-	O
14	dose	O
15	cyclosporine	O
16	(	O
17	CSA	O
18	),	O
19	plasmapheresis	O
20	,	O
21	and	O
22	ACE	B
23	inhibitors	O
24	with	O
25	mixed	O
26	results	O
27	.	O
1	Our	O
2	results	O
3	concluded	O
4	that	O
5	1	O
6	)	O
7	the	O
8	two	O
9	inhibin	B
10	/	O
11	activin	B
12	beta	O
13	B	O
14	-	O
15	subunit	O
16	mRNAs	O
17	were	O
18	transcribed	O
19	from	O
20	different	O
21	initiation	O
22	sites	O
23	;	O
24	2	O
25	)	O
26	both	O
27	promoters	O
28	may	O
29	be	O
30	controlled	O
31	by	O
32	up	O
33	-	O
34	stream	O
35	negative	O
36	regulatory	O
37	elements	O
38	;	O
39	and	O
40	3	O
41	)	O
42	neither	O
43	of	O
44	these	O
45	promoters	O
46	is	O
47	responsive	O
48	to	O
49	cAMP	O
50	and	O
51	/	O
52	or	O
53	phorbol	O
54	esters	O
55	under	O
56	the	O
57	conditions	O
58	employed	O
59	.	O
1	Promoter	O
2	region	O
3	of	O
4	the	O
5	transcriptional	O
6	unit	O
7	for	O
8	human	B
9	alpha	I
10	1	I
11	-	I
12	chimaerin	I
13	,	O
14	a	O
15	neuron	B
16	-	I
17	specific	I
18	GTPase	I
19	-	I
20	activating	I
21	protein	I
22	for	O
23	p21rac	B
24	.	O
25	alpha	B
26	1	I
27	-	I
28	chimaerin	I
29	is	O
30	a	O
31	neuron	B
32	-	I
33	specific	I
34	GTPase	I
35	-	I
36	activating	I
37	protein	I
38	for	O
39	p21rac	B
40	,	O
41	a	O
42	protein	O
43	involved	O
44	in	O
45	morphological	O
46	events	O
47	.	O
1	In	O
2	nucleus	O
3	ventralis	O
4	anterior	O
5	thalami	O
6	-	O
7	nucleus	O
8	ventralis	O
9	lateralis	O
10	thalami	O
11	neurons	O
12	with	O
13	an	O
14	inhibitory	O
15	input	O
16	from	O
17	nucleus	O
18	entopeduncularis	O
19	,	O
20	a	O
21	shortening	O
22	of	O
23	inhibition	O
24	from	O
25	17	O
26	.	O
27	5	O
28	+/-	O
29	3	O
30	.	O
31	6	O
32	to	O
33	9	O
34	.	O
35	1	O
36	+/-	O
37	1	O
38	.	O
39	8	O
40	ms	O
41	(	O
42	P	O
43	<	O
44	0	O
45	.	O
46	05	O
47	)	O
48	under	O
49	the	O
50	haloperidol	O
51	influence	O
52	was	O
53	evident	O
54	.	O
1	Using	O
2	this	O
3	method	O
4	,	O
5	VLPs	O
6	were	O
7	obtained	O
8	in	O
9	quantities	O
10	sufficient	O
11	for	O
12	further	O
13	characterization	O
14	.	O
1	Like	O
2	humans	O
3	,	O
4	the	O
5	PITSLRE	B
6	PK	I
7	genes	I
8	in	I
9	chickens	I
10	must	O
11	be	O
12	closely	O
13	linked	O
14	,	O
15	based	O
16	on	O
17	fluorescent	O
18	in	O
19	situ	O
20	hybridization	O
21	(	O
22	FISH	O
23	)	O
24	localization	O
25	of	O
26	these	O
27	genes	O
28	to	O
29	a	O
30	single	O
31	chicken	O
32	microchromosome	O
33	.	O
1	In	O
2	ICE	B
3	gamma	I
4	,	O
5	most	O
6	of	O
7	the	O
8	propeptide	O
9	(	O
10	amino	O
11	acids	O
12	20	O
13	-	O
14	112	O
15	)	O
16	is	O
17	deleted	O
18	,	O
19	which	O
20	suggests	O
21	that	O
22	it	O
23	may	O
24	function	O
25	as	O
26	a	O
27	catalyst	O
28	for	O
29	ICE	B
30	autoprocessing	O
31	in	O
32	vivo	O
33	.	O
1	In	O
2	addition	O
3	,	O
4	we	O
5	found	O
6	that	O
7	cell	O
8	-	O
9	specific	O
10	suppression	O
11	of	O
12	RA	O
13	-	O
14	stimulated	O
15	zif268	B
16	gene	I
17	expression	O
18	can	O
19	be	O
20	attributed	O
21	to	O
22	a	O
23	29	O
24	base	O
25	pair	O
26	nucleotide	O
27	sequence	O
28	,	O
29	located	O
30	downstream	O
31	of	O
32	the	O
33	RA	O
34	-	O
35	responsive	O
36	region	O
37	in	O
38	the	O
39	zif268	B
40	gene	I
41	.	O
1	A	O
2	DNA	O
3	fragment	O
4	encoding	O
5	the	O
6	DNA	O
7	-	O
8	binding	O
9	domain	O
10	(	O
11	amino	O
12	acids	O
13	1	O
14	-	O
15	60	O
16	)	O
17	of	O
18	the	O
19	Escherichia	B
20	coli	I
21	fru	I
22	transcriptional	I
23	regulator	I
24	was	O
25	cloned	O
26	into	O
27	the	O
28	pGEX	O
29	-	O
30	KT	O
31	vector	O
32	and	O
33	expressed	O
34	in	O
35	frame	O
36	with	O
37	the	O
38	fused	O
39	gene	O
40	encoding	O
41	glutathione	B
42	S	I
43	-	I
44	transferase	I
45	.	O
1	Several	O
2	nuclear	O
3	factors	O
4	that	O
5	interact	O
6	with	O
7	sequences	O
8	in	O
9	the	O
10	5	O
11	'	O
12	flanking	O
13	region	O
14	of	O
15	the	O
16	mouse	B
17	tyrosinase	I
18	gene	I
19	were	O
20	identified	O
21	using	O
22	band	O
23	shift	O
24	and	O
25	methylation	O
26	interference	O
27	assays	O
28	.	O
1	When	O
2	combined	O
3	with	O
4	serum	O
5	ferritin	B
6	and	O
7	hemoglobin	B
8	determinations	O
9	,	O
10	the	O
11	serum	O
12	transferrin	B
13	receptor	I
14	assay	O
15	is	O
16	a	O
17	valuable	O
18	addition	O
19	in	O
20	epidemiologic	O
21	surveys	O
22	because	O
23	it	O
24	provides	O
25	a	O
26	quantitative	O
27	measure	O
28	of	O
29	functional	O
30	iron	O
31	deficiency	O
32	and	O
33	it	O
34	distinguishes	O
35	true	O
36	IDA	O
37	from	O
38	the	O
39	anemia	O
40	of	O
41	chronic	O
42	disease	O
43	.	O
1	Expression	O
2	of	O
3	h6	O
4	.	O
5	1	O
6	in	O
7	COS	O
8	-	O
9	1	O
10	cells	O
11	led	O
12	to	O
13	the	O
14	production	O
15	of	O
16	a	O
17	typical	O
18	type	B
19	IV	I
20	PDE	I
21	activity	O
22	in	O
23	that	O
24	cAMP	O
25	,	O
26	but	O
27	not	O
28	cGMP	O
29	,	O
30	served	O
31	as	O
32	substrate	O
33	and	O
34	its	O
35	activity	O
36	was	O
37	insensitive	O
38	to	O
39	either	O
40	Ca2	O
41	+/	O
42	CaM	B
43	or	O
44	cGMP	O
45	but	O
46	was	O
47	inhibited	O
48	by	O
49	low	O
50	concentrations	O
51	of	O
52	rolipram	O
53	.(	O
54	ABSTRACT	O
55	TRUNCATED	O
56	AT	O
57	400	O
58	WORDS	O
59	)	O
1	PMEK1	B
2	displays	O
3	96	O
4	and	O
5	80	O
6	%	O
7	identity	O
8	respectively	O
9	with	O
10	the	O
11	tobacco	B
12	NTF3	I
13	and	O
14	Arabidopsis	B
15	ATMPK1	I
16	kinases	I
17	,	O
18	and	O
19	only	O
20	50	O
21	%	O
22	to	O
23	the	O
24	more	O
25	distantly	O
26	related	O
27	plant	O
28	MAP	O
29	kinase	O
30	MsERK1	B
31	from	O
32	alfalfa	O
33	.	O
1	Translation	O
2	of	O
3	the	O
4	coding	O
5	segment	O
6	,	O
7	which	O
8	was	O
9	designated	O
10	MsPRP2	B
11	,	O
12	suggested	O
13	it	O
14	encodes	O
15	a	O
16	chimeric	O
17	40	O
18	,	O
19	569	O
20	Da	O
21	cell	O
22	wall	O
23	protein	O
24	with	O
25	an	O
26	amino	O
27	-	O
28	terminal	O
29	signal	O
30	sequence	O
31	,	O
32	a	O
33	repetitive	O
34	proline	O
35	-	O
36	rich	O
37	sequence	O
38	,	O
39	and	O
40	a	O
41	cysteine	O
42	-	O
43	rich	O
44	carboxyl	O
45	-	O
46	terminal	O
47	sequence	O
48	homologous	O
49	to	O
50	nonspecific	O
51	lipid	O
52	transfer	O
53	proteins	O
54	.	O
1	The	O
2	presence	O
3	of	O
4	type	O
5	I	O
6	hypersensitivity	O
7	in	O
8	a	O
9	subgroup	O
10	of	O
11	aspergillomas	O
12	suggests	O
13	an	O
14	immunoallergic	O
15	component	O
16	to	O
17	this	O
18	disease	O
19	which	O
20	could	O
21	contribute	O
22	to	O
23	a	O
24	chronic	O
25	inflammatory	O
26	response	O
27	to	O
28	Aspergillus	O
29	in	O
30	some	O
31	aspergillomas	O
32	.	O
1	The	O
2	catenins	B
3	bind	O
4	to	O
5	APC	B
6	and	O
7	E	B
8	-	I
9	cadherin	I
10	in	O
11	a	O
12	similar	O
13	fashion	O
14	,	O
15	but	O
16	APC	B
17	and	O
18	E	B
19	-	I
20	cadherin	I
21	do	O
22	not	O
23	associate	O
24	with	O
25	each	O
26	other	O
27	either	O
28	in	O
29	the	O
30	presence	O
31	or	O
32	absence	O
33	of	O
34	catenins	B
35	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	gluconeogenic	O
6	genes	O
7	are	O
8	derepressed	O
9	upon	O
10	binding	O
11	of	O
12	Cat8p	B
13	,	O
14	whose	O
15	synthesis	O
16	depends	O
17	on	O
18	the	O
19	release	O
20	of	O
21	Cat4p	B
22	(	O
23	Mig1p	B
24	)	O
25	from	O
26	the	O
27	CAT8	B
28	promoter	I
29	.	O
1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	binding	O
7	of	O
8	C1F	B
9	in	O
10	vitro	O
11	is	O
12	sensitive	O
13	to	O
14	the	O
15	concentration	O
16	of	O
17	calcium	O
18	ions	O
19	.	O
1	Glomerular	O
2	hemodynamics	O
3	during	O
4	abortion	O
5	induced	O
6	by	O
7	RU	O
8	486	O
9	and	O
10	sepsis	O
11	in	O
12	rats	O
13	.	O
1	The	O
2	aim	O
3	of	O
4	this	O
5	retrospective	O
6	study	O
7	was	O
8	to	O
9	demonstrate	O
10	that	O
11	in	O
12	certain	O
13	cases	O
14	of	O
15	expulsive	O
16	choroidal	O
17	hemorrhage	O
18	(	O
19	ECH	O
20	)	O
21	anatomical	O
22	success	O
23	and	O
24	useful	O
25	vision	O
26	can	O
27	be	O
28	obtained	O
29	with	O
30	repeated	O
31	vitreoretinal	O
32	surgery	O
33	.	O
1	Alternatively	O
2	processed	O
3	isoforms	O
4	of	O
5	cellular	B
6	nucleic	I
7	acid	I
8	-	I
9	binding	I
10	protein	I
11	interact	O
12	with	O
13	a	O
14	suppressor	O
15	region	O
16	of	O
17	the	O
18	human	B
19	beta	I
20	-	I
21	myosin	I
22	heavy	I
23	chain	I
24	gene	I
25	.	O
1	Pregnancy	O
2	screening	O
3	by	O
4	uterine	O
5	artery	O
6	Doppler	O
7	velocimetry	O
8	--	O
9	which	O
10	criterion	O
11	performs	O
12	best	O
13	?	O
14	OBJECTIVE	O
15	:	O
16	To	O
17	test	O
18	whether	O
19	repeating	O
20	Doppler	O
21	studies	O
22	of	O
23	the	O
24	uteroplacental	O
25	circulation	O
26	late	O
27	in	O
28	gestation	O
29	will	O
30	improve	O
31	the	O
32	test	O
33	'	O
34	s	O
35	power	O
36	for	O
37	predicting	O
38	pregnancy	O
39	-	O
40	induced	O
41	hypertension	O
42	and	O
43	fetal	O
44	growth	O
45	restriction	O
46	(	O
47	FGR	O
48	),	O
49	and	O
50	whether	O
51	analysis	O
52	based	O
53	on	O
54	a	O
55	combination	O
56	of	O
57	quantitative	O
58	and	O
59	qualitative	O
60	assessments	O
61	of	O
62	the	O
63	uterine	O
64	arterial	O
65	waveforms	O
66	will	O
67	yield	O
68	better	O
69	results	O
70	than	O
71	analysis	O
72	based	O
73	on	O
74	either	O
75	alone	O
76	.	O
1	The	O
2	effect	O
3	of	O
4	the	O
5	Ca	O
6	entry	O
7	blocker	O
8	nitrendipine	O
9	,	O
10	the	O
11	antioxidant	O
12	superoxide	B
13	dismutase	I
14	(	O
15	SOD	B
16	),	O
17	and	O
18	a	O
19	combination	O
20	of	O
21	nitrendipine	O
22	and	O
23	superoxide	B
24	dismutase	I
25	on	O
26	postischemic	O
27	renal	O
28	function	O
29	was	O
30	studied	O
31	in	O
32	four	O
33	groups	O
34	(	O
35	n	O
36	=	O
37	24	O
38	)	O
39	of	O
40	rats	O
41	.	O
1	The	O
2	presence	O
3	of	O
4	an	O
5	unusual	O
6	transcript	O
7	possessing	O
8	IVS2C	B
9	beta	I
10	1	I
11	at	O
12	the	O
13	5	O
14	'	O
15	terminus	O
16	suggests	O
17	that	O
18	cleavage	O
19	of	O
20	its	O
21	splice	O
22	acceptor	O
23	is	O
24	inefficient	O
25	or	O
26	negatively	O
27	regulated	O
28	.	O
1	313	O
2	,	O
3	98	O
4	-	O
5	102	O
6	).	O
1	Gel	O
2	-	O
3	shift	O
4	assays	O
5	with	O
6	nuclear	O
7	extracts	O
8	and	O
9	oligonucleotide	O
10	sequences	O
11	spanning	O
12	the	O
13	0	O
14	.	O
15	125	O
16	-	O
17	kb	O
18	promoter	O
19	region	O
20	detected	O
21	an	O
22	ETS	B
23	-	O
24	immunoreactive	O
25	complex	O
26	,	O
27	present	O
28	most	O
29	abundantly	O
30	in	O
31	cells	O
32	overexpressing	O
33	HER2	B
34	,	O
35	whose	O
36	high	O
37	-	O
38	affinity	O
39	binding	O
40	depended	O
41	on	O
42	the	O
43	GAGGAA	O
44	response	O
45	element	O
46	.	O
1	Similar	O
2	to	O
3	the	O
4	mouse	O
5	gene	O
6	,	O
7	the	O
8	5	O
9	'	O
10	flanking	O
11	region	O
12	of	O
13	human	B
14	CD79	I
15	alpha	I
16	lacks	O
17	a	O
18	TATA	O
19	box	O
20	;	O
21	however	O
22	,	O
23	unlike	O
24	mouse	B
25	CD79	I
26	alpha	I
27	,	O
28	a	O
29	classical	O
30	octamer	O
31	motif	O
32	could	O
33	not	O
34	be	O
35	identified	O
36	in	O
37	the	O
38	human	O
39	gene	O
40	.	O
1	NOT4	B
2	interacts	O
3	with	O
4	NOT1	B
5	and	O
6	NOT3	B
7	in	O
8	the	O
9	two	O
10	-	O
11	hybrid	O
12	assay	O
13	,	O
14	and	O
15	overexpression	O
16	of	O
17	NOT3	B
18	or	O
19	NOT4	B
20	suppresses	O
21	not1	B
22	and	O
23	not2	B
24	mutations	O
25	.	O
1	Binding	O
2	site	O
3	selection	O
4	using	O
5	in	O
6	vitro	O
7	-	O
8	synthesized	O
9	proteins	O
10	reveals	O
11	that	O
12	the	O
13	ROR	B
14	alpha	I
15	1	I
16	and	O
17	ROR	B
18	alpha	I
19	2	I
20	isoforms	I
21	bind	O
22	DNA	O
23	as	O
24	monomers	O
25	to	O
26	hormone	O
27	response	O
28	elements	O
29	composed	O
30	of	O
31	a	O
32	6	O
33	-	O
34	bp	O
35	AT	O
36	-	O
37	rich	O
38	sequence	O
39	preceding	O
40	a	O
41	half	O
42	-	O
43	site	O
44	core	O
45	motif	O
46	PuGGTCA	O
47	(	O
48	RORE	B
49	).	O
1	(	O
2	1992	O
3	)	O
4	Genomics	O
5	12	O
6	,	O
7	58	O
8	-	O
9	62	O
10	).	O
1	A	O
2	comparison	O
3	of	O
4	the	O
5	predicted	O
6	polypeptide	O
7	sequence	O
8	of	O
9	the	O
10	Drosophila	O
11	protein	O
12	with	O
13	the	O
14	equivalent	O
15	subunits	O
16	from	O
17	mouse	O
18	and	O
19	yeast	O
20	suggests	O
21	that	O
22	they	O
23	are	O
24	closely	O
25	related	O
26	and	O
27	defines	O
28	three	O
29	conserved	O
30	regions	O
31	which	O
32	are	O
33	likely	O
34	to	O
35	be	O
36	important	O
37	for	O
38	enzyme	O
39	activity	O
40	.	O
1	Nine	O
2	new	O
3	naphthalene	O
4	related	O
5	compounds	O
6	(	O
7	I	O
8	,	O
9	IV	O
10	,	O
11	V	O
12	,	O
13	VII	O
14	-	O
15	XII	O
16	)	O
17	together	O
18	with	O
19	four	O
20	known	O
21	compounds	O
22	(	O
23	II	O
24	,	O
25	III	O
26	,	O
27	VI	O
28	,	O
29	XIII	O
30	)	O
31	were	O
32	isolated	O
33	from	O
34	the	O
35	root	O
36	bark	O
37	of	O
38	Oroxylum	O
39	indicum	O
40	Vent	O
41	.	O
1	Mutually	O
2	exclusive	O
3	interaction	O
4	of	O
5	the	O
6	adenovirus	B
7	E4	I
8	-	I
9	6	I
10	/	I
11	7	I
12	protein	I
13	and	O
14	the	O
15	retinoblastoma	B
16	gene	I
17	product	I
18	with	O
19	internal	O
20	domains	O
21	of	O
22	E2F	B
23	-	I
24	1	I
25	and	O
26	DP	B
27	-	I
28	1	I
29	.	O
1	As	O
2	shown	O
3	previously	O
4	,	O
5	EBNA2	B
6	transactivates	O
7	the	O
8	promoters	O
9	of	O
10	the	O
11	viral	B
12	latent	I
13	membrane	I
14	proteins	I
15	.	O
1	The	O
2	transverse	O
3	magnetization	O
4	decays	O
5	mentioned	O
6	above	O
7	exhibited	O
8	two	O
9	components	O
10	,	O
11	a	O
12	T2	O
13	fast	O
14	(	O
15	T2f	O
16	)	O
17	and	O
18	a	O
19	T2	O
20	slow	O
21	(	O
22	T2s	O
23	)	O
24	component	O
25	.	O
1	RESULTS	O
2	:	O
3	The	O
4	diagnostic	O
5	quality	O
6	of	O
7	FDG	O
8	images	O
9	was	O
10	at	O
11	least	O
12	as	O
13	good	O
14	as	O
15	that	O
16	of	O
17	their	O
18	Tl	O
19	-	O
20	201	O
21	counterparts	O
22	,	O
23	with	O
24	less	O
25	liver	O
26	background	O
27	in	O
28	all	O
29	but	O
30	one	O
31	FDG	O
32	study	O
33	.	O
1	Using	O
2	an	O
3	RNase	B
4	H	I
5	-	O
6	mediated	O
7	mapping	O
8	technique	O
9	,	O
10	we	O
11	show	O
12	that	O
13	the	O
14	64	O
15	-	O
16	kDa	O
17	subunit	O
18	of	O
19	CstF	B
20	can	O
21	be	O
22	photo	O
23	cross	O
24	-	O
25	linked	O
26	to	O
27	pre	O
28	-	O
29	mRNAs	O
30	at	O
31	U	O
32	-	O
33	rich	O
34	regions	O
35	located	O
36	downstream	O
37	of	O
38	the	O
39	cleavage	O
40	site	O
41	of	O
42	the	O
43	simian	O
44	virus	O
45	40	O
46	late	O
47	and	O
48	adenovirus	B
49	L3	I
50	pre	I
51	-	I
52	mRNAs	I
53	.	O
1	Tissue	O
2	-	O
3	specific	O
4	expression	O
5	of	O
6	the	O
7	diazepam	B
8	-	I
9	binding	I
10	inhibitor	I
11	in	O
12	Drosophila	O
13	melanogaster	O
14	:	O
15	cloning	O
16	,	O
17	structure	O
18	,	O
19	and	O
20	localization	O
21	of	O
22	the	O
23	gene	O
24	.	O
1	Activation	O
2	of	O
3	c	B
4	-	I
5	fos	I
6	gene	I
7	expression	O
8	by	O
9	a	O
10	kinase	O
11	-	O
12	deficient	O
13	epidermal	B
14	growth	I
15	factor	I
16	receptor	I
17	.	O
1	These	O
2	RZR	B
3	subtypes	O
4	represent	O
5	members	O
6	of	O
7	a	O
8	new	O
9	family	O
10	of	O
11	orphan	B
12	nuclear	I
13	receptors	I
14	that	O
15	most	O
16	likely	O
17	regulate	O
18	specific	O
19	gene	O
20	expression	O
21	.	O
1	The	O
2	parameters	O
3	of	O
4	nonspecific	O
5	humoral	O
6	immunity	O
7	--	O
8	serum	B
9	immunoglobulins	I
10	and	O
11	immune	O
12	complexes	O
13	--	O
14	were	O
15	evaluated	O
16	in	O
17	irradiated	O
18	group	O
19	of	O
20	patients	O
21	with	O
22	uterine	O
23	cervix	O
24	carcinoma	O
25	(	O
26	Stages	O
27	IIB	O
28	and	O
29	IIIB	O
30	),	O
31	during	O
32	one	O
33	year	O
34	follow	O
35	up	O
36	.	O
1	Strikingly	O
2	,	O
3	this	O
4	subdomain	O
5	is	O
6	also	O
7	present	O
8	in	O
9	the	O
10	otherwise	O
11	unrelated	O
12	N	O
13	-	O
14	terminal	O
15	activating	O
16	region	O
17	of	O
18	p58c	B
19	-	I
20	ets	I
21	-	I
22	2	I
23	and	O
24	was	O
25	thus	O
26	named	O
27	BEC	B
28	for	O
29	Ets	B
30	-	I
31	1	I
32	-	I
33	beta	I
34	/	O
35	Ets	B
36	-	I
37	2	I
38	-	I
39	Conserved	I
40	sequence	I
41	.	O
1	Using	O
2	this	O
3	method	O
4	,	O
5	we	O
6	were	O
7	able	O
8	to	O
9	select	O
10	strong	O
11	enhancer	O
12	-	O
13	type	O
14	activation	O
15	domains	O
16	from	O
17	the	O
18	immediate	B
19	early	I
20	regions	I
21	of	O
22	two	O
23	herpesviruses	O
24	,	O
25	namely	O
26	pseudorabies	O
27	virus	O
28	and	O
29	bovine	O
30	herpesvirus	O
31	1	O
32	.	O
1	These	O
2	results	O
3	provide	O
4	evidence	O
5	of	O
6	a	O
7	bypass	O
8	of	O
9	p53	B
10	-	O
11	induced	O
12	Waf1	B
13	/	O
14	Cip1	B
15	-	O
16	mediated	O
17	cell	O
18	cycle	O
19	regulatory	O
20	pathways	O
21	by	O
22	a	O
23	member	O
24	of	O
25	the	O
26	myb	B
27	oncogene	I
28	family	I
29	.	O
1	A	O
2	third	O
3	one	O
4	is	O
5	homologous	O
6	in	O
7	half	O
8	of	O
9	its	O
10	length	O
11	to	O
12	the	O
13	prokaryotic	B
14	hydantoinase	I
15	HyuA	I
16	and	O
17	in	O
18	the	O
19	other	O
20	half	O
21	to	O
22	hydatoinase	B
23	HyuB	I
24	.	O
1	It	O
2	was	O
3	shown	O
4	that	O
5	estradiol	O
6	concentrations	O
7	obtained	O
8	after	O
9	estradiol	O
10	valerate	O
11	and	O
12	micronized	O
13	estradiol	O
14	ingestion	O
15	were	O
16	dependent	O
17	on	O
18	the	O
19	patient	O
20	'	O
21	s	O
22	age	O
23	as	O
24	well	O
25	as	O
26	on	O
27	the	O
28	constitutional	O
29	type	O
30	.	O
1	In	O
2	these	O
3	vectors	O
4	the	O
5	chimeric	B
6	long	I
7	terminal	I
8	repeat	I
9	(	O
10	chLTR	B
11	)	O
12	drives	O
13	the	O
14	expression	O
15	of	O
16	the	O
17	chloramphenicol	B
18	acetyl	I
19	transferase	I
20	(	O
21	CAT	B
22	)	O
23	reporter	O
24	gene	O
25	that	O
26	is	O
27	followed	O
28	by	O
29	an	O
30	internal	O
31	SV40	B
32	virus	I
33	early	I
34	region	I
35	promoter	I
36	linked	O
37	to	O
38	the	O
39	neomycin	B
40	phosphotransferase	I
41	II	I
42	(	O
43	NEO	B
44	)	O
45	gene	O
46	.	O
1	Interestingly	O
2	,	O
3	dTFIIA	B
4	-	I
5	L	I
6	/	I
7	S	I
8	is	O
9	also	O
10	able	O
11	to	O
12	significantly	O
13	enhance	O
14	transcriptional	O
15	activation	O
16	by	O
17	upstream	O
18	transcription	O
19	factors	O
20	including	O
21	Sp1	B
22	,	O
23	VP16	B
24	,	O
25	and	O
26	NTF	B
27	-	I
28	1	I
29	.	O
1	In	O
2	particular	O
3	,	O
4	changes	O
5	in	O
6	intracellular	O
7	Ca2	O
8	+	O
9	have	O
10	the	O
11	potential	O
12	to	O
13	either	O
14	inhibit	O
15	or	O
16	augment	O
17	the	O
18	ability	O
19	of	O
20	cAMP	O
21	to	O
22	stimulate	O
23	transcription	O
24	,	O
25	depending	O
26	on	O
27	the	O
28	presence	O
29	of	O
30	specific	O
31	forms	O
32	of	O
33	Ca2	B
34	+/	I
35	calmodulin	I
36	-	I
37	dependent	I
38	protein	I
39	kinases	I
40	.	O
1	A	O
2	cDNA	O
3	for	O
4	a	O
5	newly	O
6	discovered	O
7	pseudogene	O
8	,	O
9	closely	O
10	related	O
11	to	O
12	the	O
13	mouse	B
14	mast	I
15	cell	I
16	chymases	I
17	was	O
18	isolated	O
19	by	O
20	polymerase	O
21	chain	O
22	reaction	O
23	amplification	O
24	from	O
25	a	O
26	mouse	O
27	connective	O
28	tissue	O
29	-	O
30	like	O
31	mast	O
32	cell	O
33	line	O
34	.	O
1	Therefore	O
2	,	O
3	mechanisms	O
4	that	O
5	control	O
6	activation	O
7	of	O
8	the	O
9	MAP	B
10	kinase	I
11	cascade	O
12	temporally	O
13	and	O
14	spatially	O
15	may	O
16	be	O
17	important	O
18	for	O
19	specification	O
20	of	O
21	cellular	O
22	responses	O
23	.	O
1	Elementary	O
2	visual	O
3	hallucinations	O
4	in	O
5	migraine	O
6	and	O
7	epilepsy	O
8	.	O
1	The	O
2	influence	O
3	of	O
4	patient	O
5	-	O
6	related	O
7	factors	O
8	on	O
9	inter	O
10	-	O
11	observer	O
12	variability	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	neurological	O
18	signs	O
19	was	O
20	investigated	O
21	.	O
1	The	O
2	defined	O
3	length	O
4	of	O
5	the	O
6	mRNA	O
7	,	O
8	1	O
9	,	O
10	838	O
11	nucleotides	O
12	,	O
13	was	O
14	in	O
15	agreement	O
16	with	O
17	that	O
18	of	O
19	a	O
20	1	O
21	.	O
22	9	O
23	-	O
24	kb	O
25	RNA	O
26	expressed	O
27	throughout	O
28	the	O
29	replication	O
30	cycle	O
31	,	O
32	starting	O
33	at	O
34	the	O
35	early	O
36	stages	O
37	of	O
38	infection	O
39	.	O
1	Using	O
2	in	O
3	organello	O
4	footprint	O
5	analysis	O
6	,	O
7	we	O
8	demonstrate	O
9	that	O
10	within	O
11	human	O
12	placental	O
13	mitochondria	O
14	there	O
15	is	O
16	a	O
17	high	O
18	level	O
19	of	O
20	protein	O
21	-	O
22	DNA	O
23	binding	O
24	at	O
25	regularly	O
26	phased	O
27	intervals	O
28	throughout	O
29	a	O
30	500	O
31	-	O
32	bp	O
33	region	O
34	encompassing	O
35	the	O
36	D	O
37	-	O
38	loop	O
39	DNA	O
40	origins	O
41	and	O
42	two	O
43	promoter	O
44	regions	O
45	.	O
1	Regulators	O
2	responsible	O
3	for	O
4	the	O
5	pervasive	O
6	,	O
7	nonsex	O
8	-	O
9	specific	O
10	alternative	O
11	pre	O
12	-	O
13	mRNA	O
14	splicing	O
15	characteristic	O
16	of	O
17	metazoans	O
18	are	O
19	almost	O
20	entirely	O
21	unknown	O
22	or	O
23	uncertain	O
24	.	O
1	Outflow	O
2	obstruction	O
3	of	O
4	pancreatic	O
5	juice	O
6	,	O
7	i	O
8	.	O
9	e	O
10	.,	O
11	""""	O
12	relative	O
13	stenosis	O
14	of	O
15	the	O
16	minor	O
17	papilla	O
18	","""	O
19	was	O
20	considered	O
21	to	O
22	be	O
23	present	O
24	in	O
25	the	O
26	patients	O
27	with	O
28	type	O
29	II	O
30	papilla	O
31	,	O
32	and	O
33	,	O
34	therefore	O
35	,	O
36	the	O
37	patients	O
38	with	O
39	type	O
40	II	O
41	papilla	O
42	might	O
43	suffer	O
44	from	O
45	acute	O
46	pancreatitis	O
47	resulting	O
48	from	O
49	poor	O
50	drainage	O
51	of	O
52	pancreatic	O
53	juice	O
54	and	O
55	excessive	O
56	pressure	O
57	in	O
58	the	O
59	dorsal	O
60	duct	O
61	.	O
1	Our	O
2	previous	O
3	study	O
4	suggested	O
5	that	O
6	pertussis	B
7	toxin	I
8	(	O
9	IAP	B
10	)-	O
11	sensitive	O
12	GTP	B
13	-	I
14	binding	I
15	protein	I
16	(	I
17	s	I
18	)	I
19	(	O
20	G	B
21	-	I
22	protein	I
23	)	O
24	is	O
25	involved	O
26	in	O
27	the	O
28	process	O
29	of	O
30	differentiation	O
31	by	O
32	hormones	O
33	/	O
34	IBMX	O
35	,	O
36	accompanied	O
37	by	O
38	c	B
39	-	I
40	fos	I
41	induction	O
42	.	O
1	Sequence	O
2	analysis	O
3	revealed	O
4	:	O
5	1	O
6	)	O
7	a	O
8	kinase	O
9	catalytic	O
10	domain	O
11	most	O
12	characteristic	O
13	of	O
14	serine	B
15	/	I
16	threonine	I
17	kinases	I
18	but	O
19	hybrid	O
20	between	O
21	members	O
22	of	O
23	the	O
24	family	O
25	of	O
26	microtubule	B
27	-	I
28	associated	I
29	protein	I
30	kinase	I
31	kinase	I
32	kinases	I
33	and	O
34	the	O
35	fibroblast	B
36	growth	I
37	factor	I
38	receptor	I
39	family	I
40	;	O
41	2	O
42	)	O
43	two	O
44	putative	O
45	alpha	O
46	-	O
47	helical	O
48	leucine	O
49	zipper	O
50	motifs	O
51	separated	O
52	by	O
53	a	O
54	25	O
55	-	O
56	amino	O
57	acid	O
58	charged	O
59	intermediate	O
60	segment	O
61	but	O
62	lacking	O
63	an	O
64	NH2	O
65	-	O
66	terminal	O
67	basic	O
68	domain	O
69	;	O
70	and	O
71	3	O
72	)	O
73	COOH	O
74	-	O
75	terminal	O
76	and	O
77	NH2	O
78	-	O
79	terminal	O
80	proline	O
81	-	O
82	rich	O
83	domains	O
84	suggestive	O
85	of	O
86	src	B
87	homology	I
88	3	I
89	(	O
90	SH3	B
91	)	O
92	domain	O
93	binding	O
94	regions	O
95	.	O
1	New	O
2	diagnostic	O
3	strategies	O
4	for	O
5	lupus	O
6	anticoagulants	O
7	and	O
8	antiphospholipid	O
9	antibodies	O
10	.	O
1	Propafenone	O
2	is	O
3	well	O
4	tolerated	O
5	in	O
6	the	O
7	majority	O
8	of	O
9	young	O
10	patients	O
11	.	O
1	Cumulated	O
2	maximum	O
3	lod	O
4	scores	O
5	between	O
6	FRDA	B
7	and	O
8	D9S5	B
9	and	O
10	between	O
11	FRDA	B
12	and	O
13	D9S15	B
14	are	O
15	above	O
16	36	O
17	and	O
18	61	O
19	,	O
20	respectively	O
21	,	O
22	at	O
23	a	O
24	recombination	O
25	fraction	O
26	of	O
27	0	O
28	,	O
29	indicating	O
30	that	O
31	recombination	O
32	events	O
33	needed	O
34	to	O
35	orient	O
36	the	O
37	search	O
38	of	O
39	the	O
40	gene	O
41	are	O
42	very	O
43	difficult	O
44	to	O
45	identify	O
46	and	O
47	ascertain	O
48	.	O
1	METHODS	O
2	--	O
3	16	O
4	volunteered	O
5	for	O
6	spirometry	O
7	with	O
8	methacholine	O
9	provocation	O
10	test	O
11	including	O
12	a	O
13	test	O
14	for	O
15	small	O
16	airways	O
17	function	O
18	by	O
19	volume	O
20	of	O
21	trapped	O
22	gas	O
23	(	O
24	VTG	O
25	).	O
1	Relationship	O
2	of	O
3	CDK	B
4	-	I
5	activating	I
6	kinase	I
7	and	O
8	RNA	B
9	polymerase	I
10	II	I
11	CTD	O
12	kinase	O
13	TFIIH	B
14	/	O
15	TFIIK	B
16	.	O
1	I	O
2	hypothesize	O
3	that	O
4	white	B
5	gene	I
6	expression	O
7	from	O
8	P	B
9	[	I
10	en	I
11	]	I
12	is	O
13	repressed	O
14	by	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	protein	O
20	complex	O
21	which	O
22	is	O
23	initiated	O
24	at	O
25	the	O
26	engrailed	B
27	PS	I
28	sites	I
29	and	O
30	also	O
31	requires	O
32	interactions	O
33	with	O
34	flanking	O
35	genomic	O
36	DNA	O
37	.	O
1	Standard	O
2	curve	O
3	correlation	O
4	coefficients	O
5	of	O
6	0	O
7	.	O
8	995	O
9	or	O
10	greater	O
11	were	O
12	obtained	O
13	during	O
14	validation	O
15	experiments	O
16	and	O
17	analysis	O
18	of	O
19	study	O
20	samples	O
21	.	O
1	Sample	O
2	treatment	O
3	was	O
4	optimized	O
5	in	O
6	order	O
7	to	O
8	achieve	O
9	a	O
10	complete	O
11	extraction	O
12	of	O
13	labetalol	O
14	diastereoisomers	O
15	and	O
16	to	O
17	avoid	O
18	racemization	O
19	during	O
20	extraction	O
21	.	O
1	Endotoxemia	O
2	induced	O
3	by	O
4	gram	O
5	-	O
6	negative	O
7	bacteria	O
8	leads	O
9	to	O
10	endotoxic	O
11	shock	O
12	pathogenetically	O
13	stemming	O
14	from	O
15	the	O
16	integral	O
17	component	O
18	of	O
19	the	O
20	bacterial	O
21	wall	O
22	--	O
23	lipid	O
24	A	O
25	.	O
1	The	O
2	pexB	B
3	upstream	I
4	region	I
5	contained	O
6	245	O
7	nucleotides	O
8	within	O
9	which	O
10	sequences	O
11	approximating	O
12	the	O
13	consensus	O
14	for	O
15	cyclic	B
16	AMP	I
17	receptor	I
18	protein	I
19	and	O
20	integration	B
21	host	I
22	factor	I
23	binding	O
24	sites	O
25	were	O
26	discernible	O
27	.	O
1	In	O
2	addition	O
3	,	O
4	we	O
5	sought	O
6	to	O
7	test	O
8	the	O
9	hypothesis	O
10	that	O
11	,	O
12	when	O
13	equal	O
14	volumes	O
15	are	O
16	administered	O
17	intrathecally	O
18	,	O
19	significant	O
20	differences	O
21	exist	O
22	in	O
23	the	O
24	potential	O
25	to	O
26	three	O
27	commonly	O
28	used	O
29	anesthetic	O
30	solutions	O
31	to	O
32	induce	O
33	sensory	O
34	impairment	O
35	.	O
1	In	O
2	an	O
3	in	O
4	vitro	O
5	study	O
6	,	O
7	10	O
8	/	O
9	0	O
10	nylon	O
11	was	O
12	found	O
13	to	O
14	require	O
15	a	O
16	significantly	O
17	lower	O
18	laser	O
19	energy	O
20	density	O
21	to	O
22	produce	O
23	suture	O
24	lysis	O
25	following	O
26	a	O
27	single	O
28	shot	O
29	than	O
30	either	O
31	10	O
32	/	O
33	0	O
34	Dacron	O
35	or	O
36	10	O
37	/	O
38	0	O
39	prolene	O
40	.	O
1	We	O
2	report	O
3	here	O
4	that	O
5	microinjection	O
6	of	O
7	an	O
8	anti	B
9	-	I
10	CBP	I
11	antiserum	I
12	into	O
13	fibroblasts	O
14	can	O
15	inhibit	O
16	transcription	O
17	from	O
18	a	O
19	cAMP	O
20	responsive	O
21	promoter	O
22	.	O
1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	a	O
6	class	O
7	of	O
8	proline	O
9	-	O
10	rich	O
11	activator	O
12	proteins	O
13	and	O
14	RNA	B
15	polymerase	I
16	II	I
17	possess	O
18	a	O
19	common	O
20	structural	O
21	and	O
22	functional	O
23	component	O
24	which	O
25	can	O
26	interact	O
27	with	O
28	the	O
29	same	O
30	target	O
31	in	O
32	the	O
33	general	O
34	transcription	O
35	machinery	O
36	.	O
1	CONCLUSION	O
2	:	O
3	Human	O
4	preterm	O
5	birth	O
6	is	O
7	associated	O
8	with	O
9	significantly	O
10	lower	O
11	progesterone	O
12	/	O
13	17	O
14	beta	O
15	-	O
16	estradiol	O
17	ratios	O
18	than	O
19	those	O
20	of	O
21	women	O
22	with	O
23	preterm	O
24	labor	O
25	delivered	O
26	at	O
27	term	O
28	.	O
1	In	O
2	conclusion	O
3	,	O
4	the	O
5	disposition	O
6	of	O
7	venlafaxine	O
8	and	O
9	O	O
10	-	O
11	desmethylvenlafaxine	O
12	is	O
13	markedly	O
14	altered	O
15	in	O
16	renal	O
17	disease	O
18	;	O
19	therefore	O
20	dosage	O
21	adjustment	O
22	is	O
23	warranted	O
24	for	O
25	patients	O
26	with	O
27	creatinine	O
28	clearance	O
29	values	O
30	below	O
31	30	O
32	ml	O
33	/	O
34	min	O
35	.	O
1	The	O
2	incidence	O
3	of	O
4	HSV	O
5	-	O
6	2	O
7	positive	O
8	subjects	O
9	(	O
10	HSV	B
11	-	I
12	2	I
13	/	I
14	HSV	I
15	-	I
16	1	I
17	antibody	I
18	ratio	O
19	>	O
20	or	O
21	=	O
22	1	O
23	)	O
24	was	O
25	low	O
26	in	O
27	the	O
28	Jewish	O
29	Israeli	O
30	population	O
31	,	O
32	compared	O
33	to	O
34	other	O
35	demographic	O
36	areas	O
37	.	O
1	At	O
2	least	O
3	some	O
4	of	O
5	the	O
6	difference	O
7	in	O
8	stability	O
9	of	O
10	the	O
11	two	O
12	kinds	O
13	of	O
14	complexes	O
15	was	O
16	due	O
17	to	O
18	the	O
19	fact	O
20	that	O
21	the	O
22	dissociation	O
23	rate	O
24	of	O
25	the	O
26	A	O
27	stem	O
28	substrate	O
29	from	O
30	the	O
31	protein	O
32	-	O
33	DNA	O
34	complexes	O
35	was	O
36	approximately	O
37	fourfold	O
38	faster	O
39	than	O
40	that	O
41	of	O
42	the	O
43	complete	O
44	TR	B
45	.	O
1	However	O
2	,	O
3	each	O
4	promoter	O
5	activated	O
6	by	O
7	IEP86	B
8	was	O
9	synergistically	O
10	affected	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	IEP72	B
16	.	O
1	PURPOSE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	kinetics	O
7	of	O
8	erythropoietin	B
9	(	O
10	EPO	B
11	)	O
12	production	O
13	and	O
14	address	O
15	the	O
16	pathogenesis	O
17	of	O
18	anemia	O
19	of	O
20	prematurity	O
21	,	O
22	we	O
23	measured	O
24	EPO	B
25	levels	O
26	in	O
27	infants	O
28	during	O
29	the	O
30	first	O
31	year	O
32	of	O
33	life	O
34	.	O
1	Number	O
2	and	O
3	size	O
4	of	O
5	silver	O
6	-	O
7	stained	O
8	nucleoli	O
9	(	O
10	Ag	O
11	-	O
12	NOR	O
13	clusters	O
14	)	O
15	in	O
16	canine	O
17	seminomas	O
18	:	O
19	correlation	O
20	with	O
21	histological	O
22	features	O
23	and	O
24	tumour	O
25	behaviour	O
26	.	O
1	In	O
2	earlier	O
3	studies	O
4	we	O
5	identified	O
6	several	O
7	regulatory	O
8	elements	O
9	that	O
10	control	O
11	transcriptional	O
12	activation	O
13	and	O
14	aerobic	O
15	repression	O
16	of	O
17	one	O
18	of	O
19	these	O
20	genes	O
21	,	O
22	COX5b	B
23	.	O
1	However	O
2	,	O
3	Southern	O
4	blot	O
5	and	O
6	karyotype	O
7	analyses	O
8	did	O
9	not	O
10	reveal	O
11	any	O
12	significant	O
13	changes	O
14	in	O
15	copy	O
16	number	O
17	or	O
18	gross	O
19	rearrangements	O
20	of	O
21	the	O
22	p53	B
23	gene	I
24	in	O
25	any	O
26	of	O
27	the	O
28	p53	B
29	-	I
30	cell	O
31	lines	O
32	.	O
1	HupI	B
2	showed	O
3	strong	O
4	identity	O
5	to	O
6	rubredoxin	B
7	and	O
8	rubredoxin	B
9	-	I
10	like	I
11	proteins	I
12	from	O
13	many	O
14	other	O
15	bacteria	O
16	.	O
1	However	O
2	,	O
3	regional	O
4	MVO2	O
5	increased	O
6	to	O
7	about	O
8	the	O
9	same	O
10	extent	O
11	in	O
12	the	O
13	CFX	O
14	(	O
15	from	O
16	6	O
17	.	O
18	0	O
19	+/-	O
20	0	O
21	.	O
22	7	O
23	to	O
24	12	O
25	.	O
26	4	O
27	+/-	O
28	0	O
29	.	O
30	9	O
31	ml	O
32	O2	O
33	.	O
34	min	O
35	-	O
36	1	O
37	times	O
38	100	O
39	g	O
40	-	O
41	1	O
42	)	O
43	and	O
44	the	O
45	LAD	O
46	region	O
47	(	O
48	from	O
49	7	O
50	.	O
51	0	O
52	+/-	O
53	0	O
54	.	O
55	6	O
56	to	O
57	14	O
58	.	O
59	5	O
60	+/-	O
61	1	O
62	.	O
63	3	O
64	ml	O
65	O2	O
66	.	O
67	min	O
68	-	O
69	1	O
70	times	O
71	100	O
72	g	O
73	-	O
74	1	O
75	).	O
1	Immunodepression	O
2	was	O
3	combined	O
4	with	O
5	the	O
6	increase	O
7	of	O
8	glucocorticoid	O
9	activity	O
10	of	O
11	adrenal	O
12	cortex	O
13	,	O
14	while	O
15	no	O
16	significant	O
17	changes	O
18	in	O
19	thyroid	O
20	hormones	O
21	were	O
22	registered	O
23	.	O
1	Alginate	O
2	biosynthesis	O
3	is	O
4	controlled	O
5	by	O
6	a	O
7	complex	O
8	regulatory	O
9	mechanism	O
10	.	O
1	The	O
2	sequence	O
3	upstream	O
4	of	O
5	the	O
6	rhlA	B
7	promoter	I
8	contains	O
9	two	O
10	inverted	O
11	repeats	O
12	which	O
13	define	O
14	putative	O
15	binding	O
16	sites	O
17	for	O
18	the	O
19	RhlR	B
20	regulator	I
21	.	O
1	We	O
2	have	O
3	examined	O
4	by	O
5	in	O
6	vitro	O
7	footprinting	O
8	a	O
9	region	O
10	located	O
11	downstream	O
12	of	O
13	the	O
14	human	O
15	immunodeficiency	O
16	virus	O
17	,	O
18	type	O
19	1	O
20	(	O
21	HIV	O
22	-	O
23	1	O
24	)	O
25	promoter	O
26	found	O
27	to	O
28	be	O
29	hypersensitive	O
30	to	O
31	DNase	B
32	I	I
33	digestion	O
34	in	O
35	vivo	O
36	.	O
1	The	O
2	central	O
3	globular	O
4	domain	O
5	is	O
6	highly	O
7	similar	O
8	to	O
9	those	O
10	regions	O
11	from	O
12	other	O
13	H1	B
14	molecules	I
15	,	O
16	and	O
17	the	O
18	carboxyl	O
19	-	O
20	terminal	O
21	domain	O
22	contains	O
23	a	O
24	repeating	O
25	hexapeptide	O
26	motif	O
27	,	O
28	variants	O
29	of	O
30	which	O
31	are	O
32	conserved	O
33	among	O
34	H1	B
35	molecules	I
36	.	O
1	The	O
2	two	O
3	ParA	B
4	proteins	I
5	that	O
6	are	O
7	produced	O
8	as	O
9	a	O
10	result	O
11	of	O
12	independent	O
13	translation	O
14	initiation	O
15	at	O
16	two	O
17	different	O
18	start	O
19	codons	O
20	within	O
21	the	O
22	same	O
23	open	O
24	reading	O
25	frame	O
26	were	O
27	overexpressed	O
28	in	O
29	Escherichia	O
30	coli	O
31	and	O
32	partially	O
33	purified	O
34	.	O
1	Each	O
2	expressed	O
3	domain	O
4	,	O
5	as	O
6	well	O
7	as	O
8	FKBP	B
9	-	I
10	33	I
11	itself	O
12	,	O
13	possesses	O
14	peptidyl	B
15	-	I
16	prolyl	I
17	cis	I
18	-	I
19	trans	I
20	isomerase	I
21	activity	O
22	,	O
23	though	O
24	with	O
25	much	O
26	lower	O
27	specific	O
28	activities	O
29	than	O
30	FKBP	B
31	-	I
32	12	I
33	.	O
1	The	O
2	first	O
3	85	O
4	nt	O
5	upstream	O
6	of	O
7	the	O
8	transcription	O
9	initiation	O
10	site	O
11	of	O
12	the	O
13	mouse	B
14	desmin	I
15	gene	I
16	,	O
17	which	O
18	contain	O
19	an	O
20	E	O
21	box	O
22	(	O
23	E1	O
24	),	O
25	the	O
26	binding	O
27	site	O
28	of	O
29	the	O
30	helix	B
31	-	I
32	loop	I
33	-	I
34	helix	I
35	myogenic	I
36	regulators	I
37	,	O
38	are	O
39	sufficient	O
40	to	O
41	confer	O
42	low	O
43	level	O
44	muscle	O
45	-	O
46	specific	O
47	expression	O
48	.	O
1	The	O
2	Oct	B
3	-	I
4	2	I
5	glutamine	O
6	-	O
7	rich	O
8	and	O
9	proline	O
10	-	O
11	rich	O
12	activation	O
13	domains	O
14	can	O
15	synergize	O
16	with	O
17	each	O
18	other	O
19	or	O
20	duplicates	O
21	of	O
22	themselves	O
23	to	O
24	activate	O
25	transcription	O
26	.	O
1	Ariga	O
2	,	O
3	Biochem	O
4	.	O
1	Marine	O
2	oils	O
3	and	O
4	cardiovascular	O
5	reactivity	O
6	.	O
1	We	O
2	examined	O
3	the	O
4	hypothesis	O
5	that	O
6	the	O
7	coronary	O
8	vasomotor	O
9	responses	O
10	to	O
11	etomidate	O
12	(	O
13	ETO	O
14	),	O
15	propofol	O
16	(	O
17	PRO	O
18	),	O
19	and	O
20	sodium	O
21	thiopental	O
22	(	O
23	STP	O
24	)	O
25	are	O
26	mediated	O
27	through	O
28	contrasting	O
29	effects	O
30	on	O
31	the	O
32	resting	O
33	nitric	O
34	oxide	O
35	(	O
36	NO	O
37	)-	O
38	dependent	O
39	vasodilator	O
40	tone	O
41	that	O
42	opposes	O
43	adrenergic	O
44	vasoconstrictor	O
45	activity	O
46	in	O
47	the	O
48	intact	O
49	dog	O
50	.	O
1	Surface	O
2	-	O
3	coil	O
4	experiments	O
5	on	O
6	phantoms	O
7	and	O
8	on	O
9	human	O
10	calf	O
11	muscles	O
12	in	O
13	vivo	O
14	are	O
15	presented	O
16	.	O
1	All	O
2	our	O
3	patients	O
4	had	O
5	polyps	O
6	,	O
7	23	O
8	(	O
9	54	O
10	%)	O
11	had	O
12	asthma	O
13	,	O
14	12	O
15	(	O
16	27	O
17	%)	O
18	had	O
19	aspirin	O
20	sensitivity	O
21	,	O
22	20	O
23	(	O
24	65	O
25	%)	O
26	had	O
27	eosinophilia	O
28	,	O
29	and	O
30	9	O
31	(	O
32	69	O
33	%)	O
34	had	O
35	increased	O
36	total	O
37	IgE	B
38	levels	O
39	.	O
1	c	B
2	-	I
3	Fos	I
4	transcriptional	O
5	activity	O
6	stimulated	O
7	by	O
8	H	B
9	-	I
10	Ras	I
11	-	I
12	activated	I
13	protein	I
14	kinase	I
15	distinct	O
16	from	O
17	JNK	B
18	and	O
19	ERK	B
20	.	O
1	Wild	B
2	type	I
3	and	I
4	mutant	I
5	Epo	I
6	cDNAs	I
7	were	O
8	transiently	O
9	expressed	O
10	at	O
11	high	O
12	levels	O
13	in	O
14	COS1	O
15	and	O
16	COS7	O
17	cells	O
18	.	O
1	The	O
2	bactericidal	O
3	effect	O
4	of	O
5	disinfectants	O
6	against	O
7	biofilm	O
8	cells	O
9	was	O
10	found	O
11	to	O
12	be	O
13	considerably	O
14	enhanced	O
15	by	O
16	increasing	O
17	the	O
18	concentrations	O
19	of	O
20	the	O
21	disinfectants	O
22	.	O
1	The	O
2	immune	O
3	response	O
4	of	O
5	past	O
6	-	O
7	infection	O
8	of	O
9	cytomegalovirus	O
10	in	O
11	the	O
12	patients	O
13	of	O
14	RTID	O
15	is	O
16	rather	O
17	remarkable	O
18	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	leader	O
6	-	O
7	mRNA	O
8	fusion	O
9	in	O
10	coronavirus	O
11	transcription	O
12	does	O
13	not	O
14	require	O
15	direct	O
16	RNA	O
17	-	O
18	RNA	O
19	interaction	O
20	between	O
21	complementary	O
22	sequences	O
23	.	O
1	The	O
2	consensus	O
3	gene	O
4	order	O
5	deduced	O
6	by	O
7	combining	O
8	data	O
9	from	O
10	both	O
11	crosses	O
12	is	O
13	D2Mit1	B
14	-(	O
15	Dbh	B
16	,	O
17	Notch1	B
18	)-(	O
19	Col5a1	B
20	,	O
21	Rxra	B
22	)-	O
23	Spna2	B
24	-	O
25	Ab	B
26	l	I
27	-(	O
28	Ak1	B
29	,	O
30	Fpgs	B
31	)-	O
32	(	O
33	Grp78	B
34	,	O
35	Pbx3	B
36	)-(	O
37	Epb7	B
38	.	I
39	2	I
40	,	I
41	Hc	I
42	,	I
43	Gsn	I
44	)-	O
45	Acra	B
46	.	O
1	Elimination	O
2	of	O
3	natural	O
4	antibodies	O
5	in	O
6	discordant	O
7	xenografts	O
1	Cowpox	O
2	virus	O
3	contains	O
4	two	O
5	copies	O
6	of	O
7	an	O
8	early	B
9	gene	I
10	encoding	O
11	a	O
12	soluble	O
13	secreted	O
14	form	O
15	of	O
16	the	O
17	type	B
18	II	I
19	TNF	I
20	receptor	I
21	.	O
1	Novel	O
2	8	O
3	-	O
4	base	O
5	pair	O
6	sequence	O
7	(	O
8	Drosophila	O
9	DNA	O
10	replication	O
11	-	O
12	related	O
13	element	O
14	)	O
15	and	O
16	specific	O
17	binding	O
18	factor	O
19	involved	O
20	in	O
21	the	O
22	expression	O
23	of	O
24	Drosophila	O
25	genes	O
26	for	O
27	DNA	B
28	polymerase	I
29	alpha	I
30	and	O
31	proliferating	B
32	cell	I
33	nuclear	I
34	antigen	I
35	.	O
1	Previous	O
2	studies	O
3	showed	O
4	that	O
5	mutations	O
6	in	O
7	the	O
8	6K	O
9	protein	O
10	led	O
11	to	O
12	the	O
13	slow	O
14	release	O
15	of	O
16	aberrant	O
17	,	O
18	multi	O
19	-	O
20	cored	O
21	infectious	O
22	virions	O
23	.	O
1	We	O
2	recommend	O
3	that	O
4	ovarian	O
5	stimulation	O
6	is	O
7	done	O
8	only	O
9	if	O
10	there	O
11	is	O
12	a	O
13	valid	O
14	indication	O
15	after	O
16	proper	O
17	assessment	O
18	of	O
19	the	O
20	ovaries	O
21	,	O
22	and	O
23	that	O
24	women	O
25	who	O
26	have	O
27	had	O
28	ovarian	O
29	stimulation	O
30	are	O
31	followed	O
32	for	O
33	longer	O
34	than	O
35	at	O
36	present	O
37	.	O
1	To	O
2	investigate	O
3	the	O
4	regulation	O
5	of	O
6	expression	O
7	of	O
8	the	O
9	human	B
10	mdr1	I
11	gene	I
12	,	O
13	the	O
14	response	O
15	of	O
16	the	O
17	mdr1	B
18	promoter	I
19	to	O
20	signals	O
21	involved	O
22	in	O
23	cell	O
24	proliferation	O
25	was	O
26	examined	O
27	.	O
1	Clinical	O
2	aspects	O
3	of	O
4	early	O
5	increase	O
6	in	O
7	serum	O
8	gamma	B
9	-	I
10	glutamyl	I
11	transferase	I
12	in	O
13	cerebral	O
14	infarction	O
15	.	O
1	The	O
2	results	O
3	indicate	O
4	that	O
5	hrpRS	B
6	and	O
7	hrpL	B
8	are	O
9	part	O
10	of	O
11	a	O
12	regulatory	O
13	cascade	O
14	in	O
15	which	O
16	HrpR	B
17	and	O
18	HrpS	B
19	activate	O
20	expression	O
21	of	O
22	hrpL	B
23	and	O
24	HrpL	B
25	,	O
26	a	O
27	putative	O
28	sigma	B
29	factor	I
30	,	O
31	induces	O
32	expression	O
33	of	O
34	HrpL	B
35	-	I
36	responsive	I
37	genes	I
38	.	O
1	Anti	B
2	-	I
3	B	I
4	.	I
5	burgdorferi	I
6	,	O
7	anti	B
8	-	I
9	B	I
10	.	I
11	turicatae	I
12	and	O
13	anti	B
14	-	I
15	B	I
16	.	I
17	parkeri	I
18	antibodies	I
19	,	O
20	tested	O
21	by	O
22	the	O
23	indirect	O
24	immunofluorescent	O
25	assay	O
26	(	O
27	IFA	O
28	),	O
29	were	O
30	detected	O
31	in	O
32	10	O
33	.	O
34	8	O
35	,	O
36	16	O
37	.	O
38	1	O
39	and	O
40	8	O
41	.	O
42	2	O
43	%	O
44	of	O
45	the	O
46	serum	O
47	samples	O
48	tested	O
49	,	O
50	and	O
51	confirmed	O
52	by	O
53	IFA	O
54	-	O
55	ABS	O
56	in	O
57	1	O
58	.	O
59	3	O
60	,	O
61	1	O
62	.	O
63	3	O
64	and	O
65	1	O
66	.	O
67	0	O
68	%,	O
69	respectively	O
70	.	O
1	Structural	O
2	organization	O
3	of	O
4	the	O
5	gene	O
6	encoding	O
7	the	O
8	human	B
9	lipocalin	I
10	tear	I
11	prealbumin	I
12	and	O
13	synthesis	O
14	of	O
15	the	O
16	recombinant	O
17	protein	O
18	in	O
19	Escherichia	O
20	coli	O
21	.	O
1	GATA	B
2	-	I
3	1	I
4	mRNA	I
5	was	O
6	present	O
7	in	O
8	equivalent	O
9	levels	O
10	in	O
11	both	O
12	erythroid	O
13	cell	O
14	lines	O
15	,	O
16	but	O
17	at	O
18	a	O
19	low	O
20	level	O
21	in	O
22	FDC	O
23	-	O
24	P1	O
25	cells	O
26	.	O
1	In	O
2	these	O
3	experiments	O
4	we	O
5	begin	O
6	to	O
7	study	O
8	the	O
9	potential	O
10	functions	O
11	of	O
12	the	O
13	alpha	B
14	7	I
15	cytoplasmic	I
16	domain	I
17	by	O
18	analyzing	O
19	homologies	O
20	between	O
21	the	O
22	rat	O
23	and	O
24	human	O
25	sequences	O
26	,	O
27	by	O
28	immunologic	O
29	studies	O
30	using	O
31	an	O
32	anti	O
33	-	O
34	cytoplasmic	O
35	domain	O
36	antiserum	O
37	,	O
38	and	O
39	by	O
40	identifying	O
41	two	O
42	alternate	O
43	forms	O
44	.	O
1	In	O
2	order	O
3	to	O
4	evaluate	O
5	the	O
6	function	O
7	of	O
8	the	O
9	hypothalamic	O
10	-	O
11	pituitary	O
12	-	O
13	thyroid	O
14	(	O
15	HPT	O
16	)-	O
17	axis	O
18	in	O
19	unipolar	O
20	depression	O
21	,	O
22	the	O
23	authors	O
24	measured	O
25	basal	O
26	0800h	O
27	plasma	O
28	levels	O
29	of	O
30	free	O
31	thyroxine	O
32	(	O
33	FT4	O
34	),	O
35	free	O
36	triiodothyronine	O
37	(	O
38	FT3	O
39	),	O
40	and	O
41	thyroid	B
42	stimulating	I
43	hormone	I
44	(	O
45	TSH	B
46	)	O
47	by	O
48	means	O
49	of	O
50	the	O
51	new	O
52	,	O
53	ultrasensitive	O
54	assays	O
55	(	O
56	TSH	O
57	-	O
58	IRMA	O
59	)	O
60	in	O
61	69	O
62	healthy	O
63	controls	O
64	,	O
65	62	O
66	minor	O
67	,	O
68	101	O
69	simple	O
70	major	O
71	,	O
72	and	O
73	57	O
74	melancholic	O
75	depressed	O
76	subjects	O
77	.	O
1	European	O
2	Community	O
3	Huntington	O
4	'	O
5	s	O
6	Disease	O
7	Collaborative	O
8	Study	O
9	Group	O
10	.	O
1	Varieties	O
2	of	O
3	envious	O
4	experience	O
5	.	O
1	The	O
2	3	O
3	'	O
4	UTR	O
5	has	O
6	several	O
7	stable	O
8	hairpins	O
9	that	O
10	are	O
11	flanked	O
12	by	O
13	single	O
14	-	O
15	stranded	O
16	(	O
17	A	O
18	/	O
19	U	O
20	)	O
21	UGC	O
22	sequences	O
23	.	O
1	Identical	O
2	components	O
3	of	O
4	yeast	O
5	transcription	B
6	factor	I
7	IIIB	I
8	are	O
9	required	O
10	and	O
11	sufficient	O
12	for	O
13	transcription	O
14	of	O
15	TATA	O
16	box	O
17	-	O
18	containing	O
19	and	O
20	TATA	O
21	-	O
22	less	O
23	genes	O
24	.	O
1	Rather	O
2	,	O
3	complete	O
4	skipping	O
5	of	O
6	exon	O
7	V	O
8	and	O
9	subsequent	O
10	joining	O
11	of	O
12	exon	O
13	IV	O
14	to	O
15	exon	O
16	VI	O
17	caused	O
18	a	O
19	shift	O
20	in	O
21	the	O
22	open	O
23	reading	O
24	frame	O
25	,	O
26	which	O
27	remodeled	O
28	GPHe	B
29	(	I
30	P2	I
31	)	I
32	with	O
33	an	O
34	elongated	O
35	new	O
36	hydrophobic	O
37	sequence	O
38	for	O
39	membrane	O
40	anchoring	O
41	.	O
1	Thus	O
2	our	O
3	observations	O
4	establish	O
5	a	O
6	functional	O
7	link	O
8	between	O
9	the	O
10	PKC	B
11	and	O
12	retinoid	O
13	pathways	O
14	,	O
15	which	O
16	are	O
17	generally	O
18	considered	O
19	to	O
20	have	O
21	antagonistic	O
22	activities	O
23	on	O
24	differentiation	O
25	processes	O
26	.	O
1	The	O
2	colony	B
3	-	I
4	stimulating	I
5	factors	I
6	(	O
7	CSFs	B
8	)	O
9	principally	O
10	involved	O
11	in	O
12	the	O
13	production	O
14	of	O
15	neutrophils	O
16	and	O
17	monocytes	O
18	are	O
19	granulocyte	B
20	CSF	I
21	,	O
22	granulocyte	B
23	-	I
24	macrophage	I
25	CSF	I
26	,	O
27	macrophage	B
28	CSF	I
29	,	O
30	and	O
31	interleukin	B
32	3	I
33	(	O
34	sometimes	O
35	called	O
36	multi	B
37	-	I
38	CSF	I
39	).	O
1	Insertion	O
2	of	O
3	short	O
4	oligonucleotides	O
5	encoding	O
6	the	O
7	basic	O
8	amino	O
9	acid	O
10	motifs	O
11	726	O
12	-	O
13	GRKRKSP	O
14	-	O
15	732	O
16	from	O
17	IE175	B
18	and	O
19	500	O
20	-	O
21	VRPRKRR	O
22	-	O
23	506	O
24	from	O
25	IE110	B
26	into	O
27	deleted	O
28	cytoplasmic	O
29	forms	O
30	of	O
31	the	O
32	two	O
33	proteins	O
34	restored	O
35	the	O
36	karyophilic	O
37	phenotype	O
38	and	O
39	confirmed	O
40	that	O
41	these	O
42	motifs	O
43	are	O
44	both	O
45	necessary	O
46	and	O
47	sufficient	O
48	for	O
49	proper	O
50	nuclear	O
51	localization	O
52	.	O
1	The	O
2	revertant	O
3	TATA	O
4	boxes	O
5	accelerated	O
6	the	O
7	kinetics	O
8	of	O
9	HIV	O
10	replication	O
11	when	O
12	present	O
13	in	O
14	the	O
15	context	O
16	of	O
17	an	O
18	LTR	O
19	containing	O
20	a	O
21	Sp1	B
22	mutation	O
23	(	O
24	deletion	O
25	or	O
26	site	O
27	specific	O
28	);	O
29	no	O
30	effect	O
31	was	O
32	observed	O
33	on	O
34	the	O
35	infectivity	O
36	of	O
37	wild	O
38	-	O
39	type	O
40	HIV	O
41	.	O
1	Effects	O
2	of	O
3	estradiol	O
4	on	O
5	worm	O
6	burden	O
7	and	O
8	peripheral	O
9	leukocytes	O
10	in	O
11	Parastrongylus	O
12	malaysiensis	O
13	-	O
14	infected	O
15	rats	O
16	.	O
1	These	O
2	issues	O
3	include	O
4	the	O
5	use	O
6	of	O
7	LMWHs	O
8	in	O
9	patients	O
10	with	O
11	arterial	O
12	thrombosis	O
13	or	O
14	myocardial	O
15	infarction	O
16	(	O
17	e	O
18	.	O
19	g	O
20	.	O
21	in	O
22	conjunction	O
23	with	O
24	thrombolytic	O
25	treatment	O
26	),	O
27	and	O
28	in	O
29	patients	O
30	with	O
31	pulmonary	O
32	embolism	O
33	.	O
1	Response	O
2	to	O
3	treatment	O
4	was	O
5	better	O
6	in	O
7	patients	O
8	with	O
9	less	O
10	pretreatment	O
11	(	O
12	one	O
13	-	O
14	two	O
15	prior	O
16	treatments	O
17	)	O
18	than	O
19	in	O
20	heavily	O
21	pretreated	O
22	ones	O
23	(	O
24	more	O
25	than	O
26	three	O
27	)	O
28	and	O
29	this	O
30	relation	O
31	was	O
32	found	O
33	to	O
34	be	O
35	statistically	O
36	significant	O
37	(	O
38	p	O
39	<	O
40	0	O
41	.	O
42	05	O
43	).	O
1	Therefore	O
2	,	O
3	the	O
4	amino	O
5	-	O
6	terminal	O
7	sequence	O
8	of	O
9	the	O
10	purified	O
11	carA	B
12	product	I
13	is	O
14	identical	O
15	to	O
16	that	O
17	derived	O
18	from	O
19	the	O
20	nucleotide	O
21	sequence	O
22	in	O
23	both	O
24	organisms	O
25	,	O
26	P	O
27	.	O
28	stutzeri	O
29	having	O
30	four	O
31	additional	O
32	amino	O
33	acids	O
34	.	O
1	We	O
2	have	O
3	used	O
4	these	O
5	modified	O
6	assay	O
7	conditions	O
8	to	O
9	extend	O
10	studies	O
11	on	O
12	the	O
13	transposition	O
14	pathway	O
15	.	O
1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	requirements	O
8	for	O
9	induction	O
10	of	O
11	PEPCK	B
12	by	O
13	PKA	B
14	and	O
15	inhibition	O
16	by	O
17	insulin	B
18	include	O
19	:	O
20	1	O
21	)	O
22	the	O
23	CREB	B
24	activation	I
25	domain	I
26	,	O
27	2	O
28	)	O
29	the	O
30	PEPCK	B
31	TATA	I
32	sequence	I
33	,	O
34	and	O
35	3	O
36	)	O
37	insulin	B
38	-	O
39	responsive	O
40	hepatoma	O
41	cells	O
42	.	O
1	Alternative	O
2	splicing	O
3	of	O
4	RNA	O
5	transcripts	O
6	encoded	O
7	by	O
8	the	O
9	murine	O
10	p105	B
11	NF	I
12	-	I
13	kappa	I
14	B	I
15	gene	O
16	generates	O
17	I	B
18	kappa	I
19	B	I
20	gamma	I
21	isoforms	I
22	with	O
23	different	O
24	inhibitory	O
25	activities	O
26	.	O
1	Topical	O
2	L	O
3	-	O
4	NNA	O
5	attenuated	O
6	the	O
7	hypercapnic	O
8	increase	O
9	of	O
10	CoBF	O
11	by	O
12	52	O
13	+/-	O
14	6	O
15	%	O
16	and	O
17	CeBF	O
18	by	O
19	29	O
20	+/-	O
21	5	O
22	%	O
23	after	O
24	45	O
25	-	O
26	min	O
27	exposure	O
28	.	O
1	Frequent	O
2	loss	O
3	of	O
4	heterozygosity	O
5	(	O
6	LOH	O
7	)	O
8	of	O
9	>	O
10	30	O
11	%	O
12	of	O
13	the	O
14	informative	O
15	cases	O
16	was	O
17	observed	O
18	on	O
19	chromosomes	O
20	3p	O
21	(	O
22	41	O
23	.	O
24	1	O
25	%),	O
26	5q	O
27	(	O
28	52	O
29	.	O
30	6	O
31	%),	O
32	6p	O
33	(	O
34	30	O
35	.	O
36	4	O
37	%),	O
38	8p	O
39	(	O
40	33	O
41	.	O
42	3	O
43	%),	O
44	9p	O
45	(	O
46	35	O
47	.	O
48	7	O
49	%),	O
50	9q	O
51	(	O
52	30	O
53	.	O
54	8	O
55	%),	O
56	11p	O
57	(	O
58	32	O
59	.	O
60	4	O
61	%),	O
62	13q	O
63	(	O
64	52	O
65	.	O
66	7	O
67	%),	O
68	17p	O
69	(	O
70	55	O
71	.	O
72	2	O
73	%),	O
74	17q	O
75	(	O
76	33	O
77	.	O
78	3	O
79	%),	O
80	18q	O
81	(	O
82	45	O
83	.	O
84	7	O
85	%),	O
86	and	O
87	19q	O
88	(	O
89	30	O
90	.	O
91	4	O
92	%).	O
1	Identification	O
2	of	O
3	an	O
4	immediate	B
5	-	I
6	early	I
7	gene	I
8	in	O
9	the	O
10	Marek	O
11	'	O
12	s	O
13	disease	O
14	virus	O
15	long	O
16	internal	O
17	repeat	O
18	region	O
19	which	O
20	encodes	O
21	a	O
22	unique	O
23	14	O
24	-	O
25	kilodalton	O
26	polypeptide	O
27	.	O
1	To	O
2	study	O
3	the	O
4	structure	O
5	-	O
6	function	O
7	of	O
8	the	O
9	gene	B
10	5	I
11	product	I
12	,	O
13	wild	O
14	-	O
15	type	O
16	and	O
17	mutant	O
18	forms	O
19	of	O
20	NS53	B
21	were	O
22	produced	O
23	by	O
24	using	O
25	a	O
26	recombinant	O
27	baculovirus	O
28	expression	O
29	system	O
30	and	O
31	a	O
32	recombinant	O
33	vaccinia	O
34	virus	O
35	/	O
36	T7	O
37	(	O
38	vTF7	O
39	-	O
40	3	O
41	)	O
42	expression	O
43	system	O
44	.	O
1	San	O
2	Martin	O
3	'	O
4	s	O
5	psychological	O
6	traits	O
7	coupled	O
8	to	O
9	his	O
10	work	O
11	with	O
12	masonic	O
13	lodges	O
14	that	O
15	allowed	O
16	him	O
17	to	O
18	display	O
19	his	O
20	abilities	O
21	as	O
22	strategist	O
23	and	O
24	political	O
25	ruler	O
26	.	O
1	The	O
2	7	O
3	-	O
4	day	O
5	treatment	O
6	resulted	O
7	in	O
8	a	O
9	decrease	O
10	in	O
11	mitochondrial	O
12	uptake	O
13	of	O
14	Rh123	O
15	and	O
16	an	O
17	increase	O
18	in	O
19	NAO	O
20	uptake	O
21	.	O
1	A	O
2	-	O
3	69	O
4	-	O
5	year	O
6	-	O
7	old	O
8	patient	O
9	with	O
10	postoperative	O
11	small	O
12	-	O
13	bowel	O
14	obstruction	O
15	underwent	O
16	laparotomy	O
17	three	O
18	times	O
19	.	O
1	We	O
2	conclude	O
3	that	O
4	the	O
5	SIMV	O
6	is	O
7	useful	O
8	in	O
9	weaning	O
10	neonates	O
11	from	O
12	the	O
13	ventilator	O
14	.	O
1	Simultaneous	O
2	,	O
3	bilateral	O
4	and	O
5	permanent	O
6	ventilation	O
7	with	O
8	a	O
9	diaphragm	O
10	pacing	O
11	in	O
12	childhood	O
13	:	O
14	the	O
15	implantation	O
16	technique	O
17	and	O
18	indications	O
1	A	O
2	genomic	O
3	clone	O
4	for	O
5	the	O
6	cyc07	B
7	gene	I
8	,	O
9	which	O
10	is	O
11	expressed	O
12	specifically	O
13	at	O
14	the	O
15	S	O
16	phase	O
17	during	O
18	the	O
19	cell	O
20	cycle	O
21	in	O
22	synchronous	O
23	cultures	O
24	of	O
25	periwinkle	O
26	(	O
27	Catharanthus	O
28	roseus	O
29	)	O
30	cells	O
31	,	O
32	was	O
33	isolated	O
34	.	O
1	CONCLUSIONS	O
2	:	O
3	Translocation	O
4	of	O
5	bacteria	O
6	or	O
7	endotoxin	O
8	from	O
9	the	O
10	gastrointestinal	O
11	tract	O
12	into	O
13	the	O
14	bloodstream	O
15	has	O
16	been	O
17	noted	O
18	in	O
19	animal	O
20	experiments	O
21	;	O
22	however	O
23	,	O
24	translocation	O
25	was	O
26	not	O
27	detected	O
28	in	O
29	our	O
30	patients	O
31	with	O
32	hemorrhagic	O
33	shock	O
34	.	O
1	Acylation	O
2	with	O
3	the	O
4	palmitate	O
5	analog	O
6	was	O
7	prevented	O
8	when	O
9	Gly	O
10	-	O
11	2	O
12	was	O
13	mutated	O
14	to	O
15	alanine	O
16	,	O
17	implying	O
18	that	O
19	N	O
20	-	O
21	myristylation	O
22	is	O
23	required	O
24	for	O
25	palmitylation	O
26	,	O
27	and	O
28	when	O
29	either	O
30	Cys	O
31	-	O
32	3	O
33	or	O
34	Cys	O
35	-	O
36	6	O
37	was	O
38	mutated	O
39	to	O
40	serine	O
41	.	O
1	Electrophoretic	O
2	mobility	O
3	shift	O
4	analysis	O
5	indicates	O
6	that	O
7	NF	B
8	-	I
9	IL	I
10	-	I
11	6	I
12	,	O
13	as	O
14	well	O
15	as	O
16	other	O
17	related	O
18	members	O
19	of	O
20	this	O
21	family	O
22	,	O
23	bind	O
24	specifically	O
25	to	O
26	the	O
27	NF	B
28	-	I
29	IL	I
30	-	I
31	6	I
32	site	O
33	in	O
34	the	O
35	IL	B
36	-	I
37	8	I
38	promoter	I
39	.	O
1	The	O
2	p53	B
3	tumor	I
4	suppressor	I
5	gene	I
6	product	I
7	,	O
8	a	O
9	sequence	O
10	-	O
11	specific	O
12	DNA	O
13	-	O
14	binding	O
15	protein	O
16	,	O
17	has	O
18	been	O
19	shown	O
20	to	O
21	act	O
22	as	O
23	a	O
24	transcriptional	O
25	activator	O
26	and	O
27	repressor	O
28	both	O
29	in	O
30	vitro	O
31	and	O
32	in	O
33	vivo	O
34	.	O
1	Intravenous	O
2	antibiotic	O
3	therapy	O
4	in	O
5	cystic	O
6	fibrosis	O
7	:	O
8	in	O
9	hospital	O
10	or	O
11	at	O
12	home	O
13	?	O
1	To	O
2	determine	O
3	whether	O
4	the	O
5	excess	O
6	prevalence	O
7	of	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	type	O
12	1	O
13	(	O
14	HIV	O
15	-	O
16	1	O
17	)	O
18	infection	O
19	in	O
20	US	O
21	black	O
22	and	O
23	Hispanic	O
24	homosexual	O
25	men	O
26	relative	O
27	to	O
28	white	O
29	men	O
30	can	O
31	be	O
32	explained	O
33	by	O
34	differences	O
35	in	O
36	sociodemographic	O
37	factors	O
38	,	O
39	history	O
40	of	O
41	sexually	O
42	transmitted	O
43	diseases	O
44	,	O
45	or	O
46	sexual	O
47	and	O
48	drug	O
49	-	O
50	use	O
51	behaviors	O
52	,	O
53	the	O
54	authors	O
55	conducted	O
56	a	O
57	cross	O
58	-	O
59	sectional	O
60	analysis	O
61	of	O
62	baseline	O
63	HIV	O
64	-	O
65	1	O
66	seroprevalence	O
67	and	O
68	HIV	O
69	-	O
70	1	O
71	risk	O
72	factors	O
73	among	O
74	4	O
75	,	O
76	475	O
77	non	O
78	-	O
79	Hispanic	O
80	white	O
81	,	O
82	234	O
83	Hispanic	O
84	white	O
85	,	O
86	and	O
87	194	O
88	black	O
89	homosexual	O
90	men	O
91	from	O
92	four	O
93	centers	O
94	in	O
95	the	O
96	United	O
97	States	O
98	(	O
99	Baltimore	O
100	/	O
101	Washington	O
102	,	O
103	DC	O
104	,	O
105	Pittsburgh	O
106	,	O
107	Chicago	O
108	,	O
109	and	O
110	Los	O
111	Angeles	O
112	).	O
1	The	O
2	patients	O
3	in	O
4	one	O
5	group	O
6	had	O
7	intrauterine	O
8	catheters	O
9	inserted	O
10	and	O
11	oxytocin	B
12	was	O
13	titrated	O
14	to	O
15	achieve	O
16	the	O
17	75th	O
18	percentile	O
19	of	O
20	uterine	O
21	activity	O
22	observed	O
23	in	O
24	spontaneous	O
25	normal	O
26	labour	O
27	according	O
28	to	O
29	parity	O
30	.	O
1	The	O
2	ultrastructure	O
3	of	O
4	retinal	O
5	vessels	O
6	was	O
7	examined	O
8	in	O
9	three	O
10	eyes	O
11	from	O
12	diabetic	O
13	patients	O
14	and	O
15	two	O
16	eyes	O
17	from	O
18	control	O
19	subjects	O
20	.	O
1	Acad	O
2	.	O
1	The	O
2	absence	O
3	of	O
4	H4PteGlun	O
5	bound	O
6	to	O
7	the	O
8	T	B
9	protein	I
10	in	O
11	our	O
12	experimental	O
13	conditions	O
14	demonstrates	O
15	that	O
16	H4PteGlun	O
17	is	O
18	not	O
19	covalently	O
20	linked	O
21	to	O
22	the	O
23	T	B
24	protein	I
25	.	O
1	GGS1	B
2	is	O
3	the	O
4	same	O
5	gene	O
6	as	O
7	TPS1	B
8	which	O
9	was	O
10	identified	O
11	as	O
12	encoding	O
13	a	O
14	subunit	O
15	of	O
16	the	O
17	trehalose	B
18	-	I
19	6	I
20	-	I
21	phosphate	I
22	synthase	I
23	/	I
24	phosphatase	I
25	complex	I
26	and	O
27	it	O
28	is	O
29	allelic	O
30	to	O
31	the	O
32	fdp1	B
33	,	O
34	byp1	B
35	,	O
36	glc6	B
37	and	O
38	cif1	O
39	mutations	O
40	.	O
1	[	B
2	Ala85	I
3	]	I
4	Dk	I
5	(	I
6	69	I
7	-	I
8	85	I
9	)	I
10	retains	O
11	full	O
12	biological	O
13	activity	O
14	.	O
1	A	O
2	second	O
3	important	O
4	molecule	O
5	in	O
6	TCR	B
7	signal	O
8	transduction	O
9	is	O
10	the	O
11	guanine	B
12	nucleotide	I
13	binding	I
14	protein	I
15	,	O
16	p21ras	B
17	,	O
18	which	O
19	is	O
20	coupled	O
21	to	O
22	the	O
23	TCR	B
24	by	O
25	a	O
26	protein	B
27	tyrosine	I
28	kinase	I
29	dependent	O
30	mechanism	O
31	.	O
1	A	O
2	series	O
3	of	O
4	5	O
5	'-	O
6	deletions	O
7	revealed	O
8	that	O
9	the	O
10	fragment	O
11	-	O
12	218	O
13	to	O
14	+	O
15	4	O
16	from	O
17	the	O
18	TSS	O
19	had	O
20	the	O
21	highest	O
22	promoter	O
23	activity	O
24	,	O
25	nearly	O
26	1000	O
27	-	O
28	fold	O
29	greater	O
30	than	O
31	the	O
32	promoterless	O
33	chloramphenicol	B
34	acetyltransferase	I
35	construct	I
36	.	O
1	Notice	O
2	of	O
3	retraction	O
4	.	O
1	As	O
2	regards	O
3	lipid	O
4	metabolism	O
5	,	O
6	the	O
7	mean	O
8	values	O
9	for	O
10	total	O
11	triglycerides	O
12	,	O
13	cholesterol	O
14	,	O
15	LDL	B
16	-	I
17	cholesterol	I
18	and	O
19	HDL	B
20	-	I
21	cholesterol	I
22	seen	O
23	at	O
24	the	O
25	end	O
26	of	O
27	five	O
28	years	O
29	of	O
30	Norplant	O
31	-	O
32	2	O
33	rod	O
34	use	O
35	and	O
36	six	O
37	months	O
38	postremoval	O
39	were	O
40	similar	O
41	to	O
42	the	O
43	preinsertion	O
44	mean	O
45	.	O
1	About	O
2	20	O
3	%	O
4	of	O
5	single	O
6	-	O
7	stranded	O
8	DNA	O
9	binding	O
10	was	O
11	observed	O
12	in	O
13	the	O
14	presence	O
15	of	O
16	MgdTDP	O
17	,	O
18	but	O
19	none	O
20	was	O
21	detectable	O
22	in	O
23	the	O
24	absence	O
25	of	O
26	nucleotides	O
27	.	O
1	Both	O
2	4	O
3	,	O
4	8	O
5	-	O
6	DiMeIQx	O
7	and	O
8	A	O
9	alpha	O
10	C	O
11	were	O
12	found	O
13	at	O
14	<	O
15	1	O
16	p	O
17	.	O
18	p	O
19	.	O
20	b	O
21	.	O
1	Delineating	O
2	the	O
3	molecular	O
4	basis	O
5	for	O
6	agonist	O
7	-	O
8	induced	O
9	destabilization	O
10	of	O
11	mRNA	O
12	of	O
13	G	B
14	-	I
15	protein	I
16	-	I
17	linked	I
18	receptors	I
19	that	O
20	contributes	O
21	to	O
22	receptor	O
23	down	O
24	-	O
25	regulation	O
26	is	O
27	fundamental	O
28	to	O
29	our	O
30	understanding	O
31	of	O
32	long	O
33	-	O
34	term	O
35	regulation	O
36	of	O
37	receptors	O
38	by	O
39	agonist	O
40	.	O
1	Addition	O
2	of	O
3	phalloidin	O
4	-	O
5	stabilized	O
6	F	B
7	-	I
8	actin	I
9	nuclei	O
10	and	O
11	phalloidin	O
12	restored	O
13	L266D	O
14	actin	B
15	'	O
16	s	O
17	ability	O
18	to	O
19	polymerize	O
20	at	O
21	4	O
22	degrees	O
23	C	O
24	.	O
1	Strains	O
2	bearing	O
3	the	O
4	drs2	B
5	mutation	I
6	process	O
7	the	O
8	20S	B
9	precursor	I
10	of	O
11	the	O
12	mature	B
13	18S	I
14	rRNA	I
15	slowly	O
16	and	O
17	are	O
18	deficient	O
19	in	O
20	40S	B
21	ribosomal	I
22	subunits	I
23	.	O
1	These	O
2	combined	O
3	observations	O
4	define	O
5	a	O
6	promoter	O
7	and	O
8	an	O
9	enhancer	O
10	for	O
11	the	O
12	chicken	B
13	L	I
14	-	I
15	CAM	I
16	gene	I
17	.	O
1	Rinit	O
2	reflects	O
3	the	O
4	Newtonian	O
5	resistances	O
6	and	O
7	Rdiff	O
8	represents	O
9	the	O
10	viscoelastic	O
11	/	O
12	inhomogeneous	O
13	pressure	O
14	dissipations	O
15	in	O
16	the	O
17	system	O
18	.	O
1	We	O
2	conclude	O
3	that	O
4	sequences	O
5	outside	O
6	of	O
7	the	O
8	hLEF	B
9	HMG	I
10	box	I
11	mediate	O
12	cell	O
13	-	O
14	and	O
15	context	O
16	-	O
17	specific	O
18	activation	O
19	of	O
20	the	O
21	TCR	B
22	alpha	I
23	enhancer	I
24	and	O
25	may	O
26	facilitate	O
27	interactions	O
28	between	O
29	hLEF	B
30	and	O
31	other	O
32	T	O
33	-	O
34	cell	O
35	-	O
36	specific	O
37	factors	O
38	recruited	O
39	to	O
40	the	O
41	enhancer	O
42	.	O
1	The	O
2	fourth	O
3	dose	O
4	produced	O
5	favorable	O
6	results	O
7	(	O
8	66	O
9	.	O
10	7	O
11	%)	O
12	in	O
13	individuals	O
14	with	O
15	HB	B
16	antibodies	I
17	between	O
18	10	O
19	and	O
20	100	O
21	IU	O
22	/	O
23	ml	O
24	and	O
25	unfavorable	O
26	ones	O
27	(	O
28	3	O
29	.	O
30	8	O
31	%)	O
32	where	O
33	the	O
34	HB	B
35	antibodies	I
36	were	O
37	below	O
38	10	O
39	IU	O
40	/	O
41	ml	O
42	.	O
1	This	O
2	intron	O
3	occupies	O
4	a	O
5	conserved	O
6	position	O
7	corresponding	O
8	to	O
9	that	O
10	of	O
11	intron	O
12	1	O
13	in	O
14	the	O
15	transit	O
16	peptide	O
17	region	O
18	of	O
19	chloroplast	B
20	GAPDH	I
21	genes	I
22	(	O
23	GapA	B
24	and	O
25	GapB	B
26	)	O
27	of	O
28	higher	O
29	plants	O
30	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	P	B
6	-	I
7	type	I
8	ATPase	I
9	gene	I
10	from	O
11	the	O
12	cyanobacterium	O
13	Synechocystis	O
14	sp	O
15	.	O
1	Oligonucleotide	O
2	competitors	O
3	were	O
4	used	O
5	to	O
6	evaluate	O
7	the	O
8	accessibility	O
9	of	O
10	the	O
11	TATA	O
12	-	O
13	binding	O
14	site	O
15	in	O
16	TIF	B
17	-	I
18	IB	I
19	,	O
20	TFIID	B
21	,	O
22	and	O
23	TFIIIB	B
24	.	O
1	Analysis	O
2	of	O
3	strains	O
4	harboring	O
5	an	O
6	mds1	B
7	null	I
8	mutation	I
9	demonstrates	O
10	that	O
11	MDS1	B
12	is	O
13	not	O
14	essential	O
15	during	O
16	normal	O
17	vegetative	O
18	growth	O
19	but	O
20	appears	O
21	to	O
22	be	O
23	required	O
24	for	O
25	meiosis	O
26	.	O
1	Strategic	O
2	change	O
3	in	O
4	the	O
5	NHS	O
6	.	O
1	A	O
2	much	O
3	less	O
4	expensive	O
5	solution	O
6	than	O
7	UW	O
8	,	O
9	containing	O
10	only	O
11	K	O
12	(+)-	O
13	lactobionate	O
14	,	O
15	KH2PO4	O
16	,	O
17	MgSO4	O
18	and	O
19	raffinose	O
20	,	O
21	can	O
22	be	O
23	used	O
24	successfully	O
25	for	O
26	preservation	O
27	of	O
28	rat	O
29	hepatocytes	O
30	for	O
31	24	O
32	hr	O
33	for	O
34	drug	O
35	transport	O
36	studies	O
37	.	O
1	Effect	O
2	of	O
3	single	O
4	base	O
5	substitutions	O
6	at	O
7	glycine	O
8	-	O
9	870	O
10	codon	O
11	of	O
12	gramicidin	B
13	S	I
14	synthetase	I
15	2	I
16	gene	I
17	on	O
18	proline	O
19	activation	O
20	.	O
1	The	O
2	predicted	O
3	Pay4p	B
4	sequence	I
5	contains	O
6	two	O
7	putative	O
8	ATP	O
9	-	O
10	binding	O
11	domains	O
12	and	O
13	shows	O
14	structural	O
15	relationships	O
16	to	O
17	other	O
18	potential	O
19	ATP	B
20	-	I
21	binding	I
22	proteins	I
23	involved	O
24	in	O
25	biological	O
26	processes	O
27	as	O
28	diverse	O
29	as	O
30	peroxisome	O
31	biogenesis	O
32	,	O
33	vesicle	O
34	-	O
35	mediated	O
36	protein	O
37	transport	O
38	,	O
39	cell	O
40	cycle	O
41	control	O
42	,	O
43	and	O
44	transcriptional	O
45	regulation	O
46	.	O
1	The	O
2	survival	O
3	rate	O
4	at	O
5	forty	O
6	months	O
7	in	O
8	15	O
9	patients	O
10	with	O
11	N2	O
12	disease	O
13	who	O
14	underwent	O
15	R2b	O
16	operation	O
17	was	O
18	51	O
19	%.	O
1	When	O
2	Hy	O
3	-	O
4	Vac	O
5	SPF	O
6	type	O
7	V	O
8	embryos	O
9	were	O
10	exposed	O
11	to	O
12	either	O
13	0	O
14	.	O
15	20	O
16	ml	O
17	50	O
18	%	O
19	ethanol	O
20	in	O
21	CRS	O
22	or	O
23	to	O
24	0	O
25	.	O
26	20	O
27	ml	O
28	CRS	O
29	(	O
30	controls	O
31	),	O
32	ethanol	O
33	-	O
34	treated	O
35	embryos	O
36	showed	O
37	a	O
38	VSD	O
39	incidence	O
40	of	O
41	34	O
42	.	O
43	1	O
44	%	O
45	compared	O
46	with	O
47	a	O
48	3	O
49	.	O
50	6	O
51	%	O
52	incidence	O
53	in	O
54	the	O
55	controls	O
56	(	O
57	P	O
58	=	O
59	0	O
60	.	O
61	0017	O
62	).	O
1	In	O
2	our	O
3	studies	O
4	,	O
5	we	O
6	utilized	O
7	HIV	O
8	-	O
9	1	O
10	HXB2	B
11	and	O
12	HIV	O
13	-	O
14	1	O
15	Z2Z6	B
16	core	I
17	enhancers	I
18	because	O
19	the	O
20	Z2Z6	B
21	strain	O
22	has	O
23	a	O
24	single	O
25	point	O
26	mutation	O
27	flanking	O
28	the	O
29	right	O
30	ETS	B
31	-	I
32	binding	I
33	site	I
34	.	O
1	Responses	O
2	to	O
3	the	O
4	Plowright	O
5	Rinderpest	O
6	vaccine	O
7	by	O
8	43	O
9	calves	O
10	and	O
11	70	O
12	adult	O
13	cattle	O
14	in	O
15	Uganda	O
16	in	O
17	1990	O
18	,	O
19	through	O
20	the	O
21	production	O
22	of	O
23	IgG	B
24	antibodies	I
25	,	O
26	were	O
27	monitored	O
28	for	O
29	4	O
30	weeks	O
31	using	O
32	the	O
33	ELISA	O
34	assay	O
35	.	O
1	Because	O
2	of	O
3	the	O
4	small	O
5	number	O
6	of	O
7	visceral	O
8	angiography	O
9	procedures	O
10	performed	O
11	(	O
12	38	O
13	),	O
14	no	O
15	definitive	O
16	conclusions	O
17	could	O
18	be	O
19	drawn	O
20	as	O
21	to	O
22	the	O
23	differences	O
24	between	O
25	ionic	O
26	and	O
27	nonionic	O
28	agents	O
29	regarding	O
30	grade	O
31	-	O
32	2	O
33	and	O
34	grade	O
35	-	O
36	3	O
37	adverse	O
38	events	O
39	.	O
1	Plasma	O
2	,	O
3	LDL	B
4	and	O
5	liver	O
6	cholesterol	O
7	concentrations	O
8	were	O
9	higher	O
10	in	O
11	the	O
12	hyperlipidemic	O
13	control	O
14	than	O
15	the	O
16	nonhyperlipidemic	O
17	control	O
18	and	O
19	lower	O
20	in	O
21	the	O
22	groups	O
23	fed	O
24	diets	O
25	containing	O
26	pectin	B
27	or	O
28	prune	O
29	fiber	O
30	than	O
31	in	O
32	the	O
33	hyperlipidemic	O
34	control	O
35	group	O
36	.	O
1	Using	O
2	a	O
3	polymerase	O
4	chain	O
5	reaction	O
6	-	O
7	based	O
8	approach	O
9	,	O
10	we	O
11	cloned	O
12	a	O
13	150	O
14	-	O
15	base	O
16	pair	O
17	fragment	O
18	of	O
19	a	O
20	new	O
21	sialymotif	O
22	from	O
23	human	O
24	placenta	O
25	mRNA	O
26	,	O
27	which	O
28	was	O
29	then	O
30	used	O
31	as	O
32	a	O
33	probe	O
34	to	O
35	clone	O
36	the	O
37	complete	O
38	coding	O
39	sequence	O
40	of	O
41	the	O
42	corresponding	O
43	gene	O
44	from	O
45	a	O
46	cDNA	O
47	library	O
48	.	O
1	However	O
2	,	O
3	artificially	O
4	ventilated	O
5	rats	O
6	,	O
7	pretreated	O
8	with	O
9	MK	O
10	-	O
11	801	O
12	,	O
13	were	O
14	more	O
15	sensitive	O
16	(	O
17	lethal	O
18	cocaine	O
19	dose	O
20	,	O
21	76	O
22	.	O
23	6	O
24	+/-	O
25	8	O
26	.	O
27	0	O
28	mg	O
29	/	O
30	kg	O
31	,	O
32	n	O
33	=	O
34	5	O
35	)	O
36	than	O
37	vehicle	O
38	pretreated	O
39	rats	O
40	(	O
41	129	O
42	.	O
43	4	O
44	+/-	O
45	15	O
46	.	O
47	8	O
48	mg	O
49	/	O
50	kg	O
51	,	O
52	n	O
53	=	O
54	6	O
55	),	O
56	indicating	O
57	that	O
58	MK	O
59	-	O
60	801	O
61	may	O
62	increase	O
63	both	O
64	the	O
65	respiratory	O
66	and	O
67	the	O
68	cardiac	O
69	toxicity	O
70	of	O
71	cocaine	O
72	in	O
73	urethane	O
74	anesthetized	O
75	rats	O
76	.	O
1	When	O
2	expressed	O
3	alone	O
4	in	O
5	test	O
6	cells	O
7	,	O
8	Atr	B
9	-	I
10	I	I
11	is	O
12	unable	O
13	to	O
14	bind	O
15	TGF	B
16	-	I
17	beta	I
18	,	O
19	activin	B
20	,	O
21	or	O
22	bone	B
23	morphogenetic	I
24	protein	I
25	2	I
26	.	O
1	Animal	O
2	age	O
3	and	O
4	sex	O
5	had	O
6	no	O
7	significant	O
8	effects	O
9	on	O
10	CSF	O
11	composition	O
12	,	O
13	but	O
14	serum	O
15	IgG	B
16	concentration	O
17	increased	O
18	with	O
19	age	O
20	.	O
1	Each	O
2	repeat	O
3	consists	O
4	of	O
5	12	O
6	nt	O
7	,	O
8	coding	O
9	for	O
10	the	O
11	reiterated	O
12	sequence	O
13	,	O
14	K	O
15	/	O
16	NPAG	O
17	.	O
1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	SAP	B
9	-	I
10	1	I
11	cDNA	I
12	showed	O
13	that	O
14	mature	B
15	SAP	I
16	-	I
17	1	I
18	consisted	O
19	of	O
20	1093	O
21	amino	O
22	acids	O
23	and	O
24	a	O
25	transmembrane	B
26	-	I
27	type	I
28	PTP	I
29	,	O
30	which	O
31	possessed	O
32	a	O
33	single	O
34	PTP	B
35	-	I
36	conserved	I
37	domain	I
38	in	O
39	the	O
40	cytoplasmic	O
41	region	O
42	.	O
1	Praziquantel	O
2	and	O
3	Albendazole	O
4	were	O
5	found	O
6	effective	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	neurocysticercosis	O
12	,	O
13	but	O
14	because	O
15	of	O
16	serious	O
17	side	O
18	effects	O
19	encountered	O
20	in	O
21	some	O
22	cases	O
23	,	O
24	the	O
25	drugs	O
26	should	O
27	be	O
28	used	O
29	cautiously	O
30	in	O
31	selected	O
32	cases	O
33	only	O
34	.	O
1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	traI	B
8	structural	I
9	gene	I
10	and	O
11	application	O
12	of	O
13	purified	O
14	mutant	O
15	TraI	B
16	proteins	I
17	for	O
18	in	O
19	vitro	O
20	assays	O
21	served	O
22	to	O
23	evaluate	O
24	the	O
25	functional	O
26	importance	O
27	of	O
28	conserved	O
29	amino	O
30	acid	O
31	residues	O
32	.	O
1	In	O
2	addition	O
3	,	O
4	lexical	O
5	priming	O
6	was	O
7	examined	O
8	by	O
9	presenting	O
10	an	O
11	identity	O
12	prime	O
13	earlier	O
14	in	O
15	the	O
16	text	O
17	.	O
1	IFN	B
2	alpha	I
3	and	O
4	IFN	B
5	gamma	I
6	inducibility	O
7	is	O
8	mediated	O
9	by	O
10	a	O
11	single	O
12	element	O
13	:	O
14	a	O
15	high	O
16	affinity	O
17	,	O
18	nearly	O
19	palindromic	O
20	version	O
21	of	O
22	the	O
23	IFN	B
24	gamma	I
25	activation	I
26	site	I
27	(	O
28	GAS	B
29	).	O
1	Mutations	O
2	in	O
3	the	O
4	nuclear	B
5	gene	I
6	CBP1	I
7	of	I
8	Saccharomyces	I
9	cerevisiae	I
10	result	O
11	in	O
12	degradation	O
13	of	O
14	mitochondrially	B
15	encoded	I
16	cytochrome	I
17	b	I
18	(	O
19	cob	B
20	)	O
21	RNA	O
22	;	O
23	thus	O
24	,	O
25	the	O
26	cells	O
27	are	O
28	unable	O
29	to	O
30	respire	O
31	.	O
1	We	O
2	have	O
3	investigated	O
4	the	O
5	influence	O
6	of	O
7	NaFe3	O
8	+	O
9	EDTA	O
10	,	O
11	and	O
12	of	O
13	increasing	O
14	dietary	O
15	levels	O
16	of	O
17	Na2EDTA	O
18	,	O
19	on	O
20	Zn	O
21	,	O
22	Cu	O
23	and	O
24	Ca	O
25	metabolism	O
26	in	O
27	rats	O
28	fed	O
29	on	O
30	Zn	O
31	-	O
32	sufficient	O
33	and	O
34	Zn	O
35	-	O
36	deficient	O
37	soya	O
38	-	O
39	bean	O
40	-	O
41	isolate	O
42	-	O
43	based	O
44	diets	O
45	.	O
1	Analysis	O
2	of	O
3	the	O
4	upstream	O
5	untranslated	O
6	region	O
7	of	O
8	CHL15	B
9	revealed	O
10	the	O
11	presence	O
12	of	O
13	the	O
14	hexamer	O
15	element	O
16	,	O
17	ACGCGT	O
18	(	O
19	an	O
20	MluI	B
21	restriction	I
22	site	I
23	)	O
24	controlling	O
25	both	O
26	the	O
27	periodic	O
28	expression	O
29	and	O
30	coordinate	O
31	regulation	O
32	of	O
33	the	O
34	DNA	O
35	synthesis	O
36	genes	O
37	in	O
38	budding	O
39	yeast	O
40	.	O
1	Pronounced	O
2	microangiopathy	O
3	characterized	O
4	by	O
5	avascular	O
6	fields	O
7	,	O
8	enlarged	O
9	and	O
10	tortuous	O
11	capillaries	O
12	and	O
13	increased	O
14	transcapillary	O
15	diffusion	O
16	of	O
17	sodium	O
18	fluorescein	O
19	,	O
20	was	O
21	clearly	O
22	demonstrable	O
23	in	O
24	the	O
25	area	O
26	of	O
27	the	O
28	nodules	O
29	.	O
1	Chicken	O
2	sterol	B
3	carrier	I
4	protein	I
5	2	I
6	/	O
7	sterol	B
8	carrier	I
9	protein	I
10	x	I
11	:	O
12	cDNA	O
13	cloning	O
14	reveals	O
15	evolutionary	O
16	conservation	O
17	of	O
18	structure	O
19	and	O
20	regulated	O
21	expression	O
22	.	O
1	Neither	O
2	RD19	B
3	nor	O
4	RD21	B
5	mRNA	I
6	synthesis	O
7	was	O
8	responsive	O
9	to	O
10	cold	O
11	or	O
12	to	O
13	heat	O
14	stress	O
15	.	O
1	Previous	O
2	studies	O
3	indicated	O
4	that	O
5	the	O
6	20S	B
7	proteasome	I
8	is	O
9	a	O
10	catalytic	O
11	core	O
12	of	O
13	the	O
14	26S	B
15	proteolytic	I
16	complex	I
17	that	O
18	possesses	O
19	a	O
20	latent	O
21	multicatalytic	O
22	proteinase	O
23	activity	O
24	and	O
25	catalyzes	O
26	an	O
27	ATP	O
28	-	O
29	dependent	O
30	,	O
31	selective	O
32	breakdown	O
33	of	O
34	proteins	O
35	ligated	O
36	to	O
37	ubiquitin	B
38	.	O
1	One	O
2	member	O
3	of	O
4	this	O
5	multigene	O
6	family	O
7	,	O
8	GATA	B
9	-	I
10	3	I
11	,	O
12	is	O
13	most	O
14	abundantly	O
15	expressed	O
16	in	O
17	T	O
18	lymphocytes	O
19	,	O
20	a	O
21	cellular	O
22	target	O
23	for	O
24	human	O
25	immunodeficiency	O
26	virus	O
27	type	O
28	1	O
29	(	O
30	HIV	O
31	-	O
32	1	O
33	)	O
34	infection	O
35	and	O
36	replication	O
37	.	O
1	To	O
2	begin	O
3	to	O
4	examine	O
5	the	O
6	mechanism	O
7	controlling	O
8	expression	O
9	of	O
10	this	O
11	gene	O
12	during	O
13	the	O
14	cell	O
15	-	O
16	cycle	O
17	,	O
18	a	O
19	mouse	B
20	B	I
21	-	I
22	myb	I
23	5	I
24	'	I
25	flanking	I
26	sequence	I
27	was	O
28	isolated	O
29	from	O
30	a	O
31	cosmid	O
32	library	O
33	and	O
34	shown	O
35	to	O
36	promote	O
37	efficiently	O
38	the	O
39	transcription	O
40	of	O
41	a	O
42	luciferase	B
43	reporter	I
44	gene	I
45	when	O
46	transfected	O
47	into	O
48	NIH3T3	O
49	fibroblasts	O
50	.	O
1	The	O
2	equivalent	O
3	of	O
4	the	O
5	third	O
6	ligand	O
7	,	O
8	H	O
9	-	O
10	87	O
11	,	O
12	is	O
13	T	O
14	-	O
15	47	O
16	in	O
17	the	O
18	PSTAIRE	O
19	sequence	O
20	motif	O
21	.	O
1	In	O
2	infected	O
3	mammalian	O
4	cells	O
5	,	O
6	the	O
7	ARV	B
8	G	I
9	and	O
10	GNS	B
11	genes	I
12	are	O
13	transcribed	O
14	primarily	O
15	as	O
16	a	O
17	polycistronic	O
18	mRNA	O
19	which	O
20	appears	O
21	to	O
22	extend	O
23	from	O
24	the	O
25	consensus	O
26	sequence	O
27	(	O
28	AACAG	O
29	)	O
30	at	O
31	the	O
32	start	O
33	of	O
34	the	O
35	G	B
36	gene	I
37	to	O
38	the	O
39	next	O
40	recognized	O
41	polyadenylation	O
42	signal	O
43	(	O
44	CATG	O
45	[	O
46	A	O
47	]	O
48	7	O
49	)	O
50	located	O
51	697	O
52	nucleotides	O
53	downstream	O
54	of	O
55	the	O
56	GNS	B
57	protein	I
58	termination	O
59	codon	O
60	.	O
1	PPD	B
2	-	O
3	specific	O
4	IgG	B
5	subclass	O
6	responses	O
7	were	O
8	evident	O
9	to	O
10	all	O
11	four	O
12	IgG	B
13	subclasses	O
14	.	O
1	GAP	B
2	-	I
3	N	I
4	bound	O
5	constitutively	O
6	to	O
7	p190	B
8	in	O
9	both	O
10	serum	O
11	-	O
12	deprived	O
13	and	O
14	growth	O
15	factor	O
16	-	O
17	stimulated	O
18	cells	O
19	.	O
1	The	O
2	peptide	O
3	sequence	O
4	contains	O
5	a	O
6	region	O
7	of	O
8	80	O
9	amino	O
10	acids	O
11	that	O
12	shows	O
13	similarity	O
14	to	O
15	bcl	B
16	-	I
17	2	I
18	and	O
19	to	O
20	the	O
21	recently	O
22	described	O
23	bcl	B
24	-	I
25	2	I
26	-	I
27	related	I
28	gene	I
29	,	O
30	MCL1	B
31	.	O
1	We	O
2	suggest	O
3	that	O
4	the	O
5	ER	O
6	lumenal	O
7	variable	O
8	domain	O
9	of	O
10	gp19K	B
11	has	O
12	a	O
13	specific	O
14	tertiary	O
15	structure	O
16	that	O
17	is	O
18	important	O
19	for	O
20	binding	O
21	to	O
22	the	O
23	polymorphic	O
24	alpha	O
25	1	O
26	and	O
27	alpha	O
28	2	O
29	domains	O
30	of	O
31	class	B
32	I	I
33	heavy	I
34	(	I
35	alpha	I
36	)	I
37	chains	I
38	.	O
1	Furthermore	O
2	,	O
3	a	O
4	p21X	B
5	protein	I
6	lacking	O
7	the	O
8	N	O
9	-	O
10	terminus	O
11	of	O
12	Rex1	B
13	was	O
14	expressed	O
15	at	O
16	high	O
17	levels	O
18	;	O
19	our	O
20	data	O
21	indicate	O
22	that	O
23	p21X	B
24	is	O
25	translated	O
26	from	O
27	the	O
28	1	O
29	.	O
30	6	O
31	-	O
32	kb	O
33	mRNA	O
34	which	O
35	is	O
36	derived	O
37	primarily	O
38	from	O
39	deleted	O
40	proviruses	O
41	.	O
1	When	O
2	comparing	O
3	the	O
4	barley	B
5	PSI	I
6	-	I
7	K	I
8	and	O
9	PSI	B
10	-	I
11	G	I
12	with	O
13	the	O
14	reported	O
15	PSI	B
16	-	I
17	K	I
18	sequence	I
19	from	I
20	Synechococcus	I
21	vulcanus	I
22	,	O
23	the	O
24	degree	O
25	of	O
26	similarity	O
27	is	O
28	equal	O
29	,	O
30	suggesting	O
31	that	O
32	an	O
33	ancestral	O
34	gene	O
35	has	O
36	been	O
37	duplicated	O
38	in	O
39	a	O
40	chloroplast	O
41	progenitor	O
42	but	O
43	not	O
44	in	O
45	a	O
46	cyanobacterial	O
47	.	O
1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	the	O
7	structures	O
8	of	O
9	the	O
10	b	O
11	-	O
12	Zip	O
13	domain	O
14	are	O
15	well	O
16	conserved	O
17	among	O
18	these	O
19	Maf	B
20	-	I
21	related	I
22	proteins	I
23	.	O
1	We	O
2	show	O
3	here	O
4	that	O
5	v	B
6	-	I
7	Rel	I
8	specifically	O
9	increased	O
10	expression	O
11	from	O
12	a	O
13	reporter	O
14	plasmid	O
15	containing	O
16	multiple	O
17	Sp1	B
18	binding	I
19	sites	I
20	approximately	O
21	sixfold	O
22	in	O
23	chicken	O
24	embryo	O
25	fibroblasts	O
26	(	O
27	CEFs	O
28	),	O
29	even	O
30	though	O
31	v	B
32	-	I
33	Rel	I
34	did	O
35	not	O
36	bind	O
37	directly	O
38	to	O
39	these	O
40	sites	O
41	.	O
42	v	B
43	-	I
44	Rel	I
45	also	O
46	increased	O
47	expression	O
48	from	O
49	a	O
50	reporter	O
51	plasmid	O
52	containing	O
53	a	O
54	human	B
55	immunodeficiency	I
56	virus	I
57	type	I
58	1	I
59	(	I
60	HIV	I
61	-	I
62	1	I
63	)	I
64	long	I
65	terminal	I
66	repeat	I
67	(	O
68	LTR	O
69	)	O
70	in	O
71	which	O
72	the	O
73	kappa	B
74	B	I
75	binding	I
76	sites	I
77	were	O
78	mutated	O
79	but	O
80	which	O
81	still	O
82	contained	O
83	intact	O
84	Sp1	B
85	binding	I
86	sites	I
87	.	O
1	Most	O
2	importantly	O
3	,	O
4	the	O
5	addition	O
6	of	O
7	purified	O
8	17S	B
9	U2	I
10	snRNPs	I
11	,	O
12	but	O
13	not	O
14	of	O
15	12S	B
16	U2	I
17	snRNPs	I
18	,	O
19	to	O
20	HeLa	O
21	splicing	O
22	extracts	O
23	in	O
24	which	O
25	the	O
26	endogeneous	B
27	U2	I
28	snRNPs	I
29	have	O
30	been	O
31	functionally	O
32	neutralized	O
33	with	O
34	anti	B
35	-	I
36	PRP9	I
37	antibodies	I
38	fully	O
39	restores	O
40	the	O
41	mRNA	O
42	-	O
43	splicing	O
44	activity	O
45	of	O
46	the	O
47	extracts	O
48	.	O
1	It	O
2	is	O
3	possible	O
4	that	O
5	the	O
6	patch	O
7	determines	O
8	the	O
9	proper	O
10	conformation	O
11	of	O
12	the	O
13	site	O
14	and	O
15	thereby	O
16	contributes	O
17	to	O
18	recognition	O
19	indirectly	O
20	.	O
1	The	O
2	other	O
3	transmembrane	O
4	regions	O
5	as	O
6	well	O
7	as	O
8	the	O
9	nucleoplasmic	O
10	domain	O
11	are	O
12	not	O
13	required	O
14	for	O
15	sorting	O
16	.	O
1	One	O
2	of	O
3	these	O
4	genes	O
5	,	O
6	REC114	B
7	,	O
8	is	O
9	described	O
10	here	O
11	,	O
12	and	O
13	the	O
14	data	O
15	confirm	O
16	that	O
17	REC114	B
18	is	O
19	a	O
20	meiosis	O
21	-	O
22	specific	O
23	recombination	O
24	gene	O
25	with	O
26	no	O
27	detectable	O
28	function	O
29	in	O
30	mitosis	O
31	.	O
1	Nuclear	B
2	protein	I
3	phosphatase	I
4	2A	I
5	dephosphorylates	O
6	protein	B
7	kinase	I
8	A	I
9	-	O
10	phosphorylated	O
11	CREB	B
12	and	O
13	regulates	O
14	CREB	B
15	transcriptional	O
16	stimulation	O
17	.	O
1	In	O
2	contrast	O
3	to	O
4	the	O
5	situation	O
6	in	O
7	mammalian	O
8	cells	O
9	,	O
10	prolonged	O
11	exposure	O
12	of	O
13	the	O
14	agonist	O
15	(	O
16	24	O
17	h	O
18	)	O
19	does	O
20	not	O
21	result	O
22	in	O
23	down	O
24	regulation	O
25	of	O
26	the	O
27	remaining	O
28	70	O
29	%	O
30	of	O
31	the	O
32	receptors	O
33	.	O
1	Analysis	O
2	by	O
3	cell	O
4	surface	O
5	immunofluorescence	O
6	showed	O
7	that	O
8	the	O
9	UL28	B
10	gene	I
11	is	O
12	not	O
13	required	O
14	for	O
15	expression	O
16	of	O
17	viral	O
18	glycoproteins	O
19	on	O
20	the	O
21	surface	O
22	of	O
23	infected	O
24	cells	O
25	.	O
1	Elledge	O
2	,	O
3	P	O
4	.	O
1	Two	O
2	putative	O
3	Rev	B
4	proteins	I
5	with	O
6	apparent	O
7	molecular	O
8	masses	O
9	of	O
10	18	O
11	and	O
12	16	O
13	kDa	O
14	were	O
15	expressed	O
16	by	O
17	p2	B
18	/	I
19	2	I
20	and	O
21	p176	B
22	,	O
23	while	O
24	p20	B
25	expressed	O
26	only	O
27	a	O
28	16	O
29	-	O
30	kDa	O
31	species	O
32	.	O
1	Three	O
2	group	O
3	1	O
4	patients	O
5	developed	O
6	CMV	O
7	disease	O
8	;	O
9	1	O
10	group	O
11	2	O
12	patient	O
13	developed	O
14	CMV	O
15	hepatitis	O
16	.	O
1	The	O
2	rhaB	B
3	transcription	I
4	start	I
5	site	I
6	was	O
7	mapped	O
8	to	O
9	-	O
10	24	O
11	relative	O
12	to	O
13	the	O
14	start	O
15	of	O
16	translation	O
17	.	O
1	We	O
2	linked	O
3	hypersensitivity	O
4	site	O
5	2	O
6	(	O
7	HS2	O
8	)	O
9	from	O
10	the	O
11	locus	O
12	control	O
13	region	O
14	(	O
15	LCR	O
16	)	O
17	to	O
18	a	O
19	A	B
20	gamma	I
21	-	I
22	globin	I
23	gene	O
24	(	O
25	A	O
26	gamma	O
27	*)	O
28	mutationally	O
29	marked	O
30	to	O
31	allow	O
32	its	O
33	transcript	O
34	to	O
35	be	O
36	distinguished	O
37	from	O
38	endogenous	O
39	gamma	B
40	-	I
41	globin	I
42	mRNA	O
43	.	O
1	INTERVENTIONS	O
2	--	O
3	Patients	O
4	allocated	O
5	to	O
6	treatment	O
7	with	O
8	levodopa	B
9	/	I
10	dopa	I
11	decarboxylase	I
12	inhibitor	O
13	alone	O
14	(	O
15	arm	O
16	1	O
17	),	O
18	levodopa	B
19	/	I
20	decarboxylase	I
21	inhibitor	O
22	/	O
23	selegiline	O
24	in	O
25	combination	O
26	(	O
27	arm	O
28	2	O
29	),	O
30	or	O
31	bromocriptine	O
32	(	O
33	arm	O
34	3	O
35	).	O
1	Army	O
2	veterans	O
3	given	O
4	yellow	O
5	fever	O
6	vaccine	O
7	contaminated	O
8	with	O
9	hepatitis	O
10	B	O
11	virus	O
12	in	O
13	1942	O
14	and	O
15	controls	O
16	and	O
17	(	O
18	b	O
19	)	O
20	a	O
21	case	O
22	-	O
23	control	O
24	study	O
25	comparing	O
26	veterans	O
27	with	O
28	hepatocellular	O
29	carcinoma	O
30	in	O
31	Veterans	O
32	Affairs	O
33	hospitals	O
34	with	O
35	matched	O
36	controls	O
37	with	O
38	respect	O
39	to	O
40	receipt	O
41	of	O
42	contaminated	O
43	vaccine	O
44	in	O
45	1942	O
46	.	O
1	When	O
2	introduced	O
3	into	O
4	recJ	B
5	+	I
6	strains	O
7	,	O
8	srjA	B
9	mutations	O
10	conferred	O
11	hyperrecombinational	O
12	and	O
13	hyper	B
14	-	I
15	UVr	I
16	phenotypes	O
17	.	O
1	Distinguishing	O
2	roles	O
3	of	O
4	the	O
5	membrane	O
6	-	O
7	cytoskeleton	O
8	and	O
9	cadherin	B
10	mediated	O
11	cell	O
12	-	O
13	cell	O
14	adhesion	O
15	in	O
16	generating	O
17	different	O
18	Na	B
19	+,	I
20	K	I
21	(+)-	I
22	ATPase	I
23	distributions	O
24	in	O
25	polarized	O
26	epithelia	O
27	.	O
1	Genetic	O
2	abnormalities	O
3	that	O
4	could	O
5	lead	O
6	to	O
7	mutagenesis	O
8	include	O
9	chromosomal	O
10	abnormalities	O
11	and	O
12	single	O
13	-	O
14	gene	O
15	mutations	O
16	.	O
1	A	O
2	patient	O
3	matches	O
4	a	O
5	PIC	O
6	patient	O
7	if	O
8	both	O
9	have	O
10	the	O
11	same	O
12	mechanism	O
13	of	O
14	injury	O
15	,	O
16	the	O
17	same	O
18	coding	O
19	of	O
20	Revised	O
21	Trauma	O
22	Score	O
23	variables	O
24	(	O
25	Glascow	O
26	Coma	O
27	Scale	O
28	score	O
29	,	O
30	systolic	O
31	blood	O
32	pressure	O
33	,	O
34	respiratory	O
35	rate	O
36	),	O
37	the	O
38	same	O
39	coded	O
40	age	O
41	per	O
42	A	O
43	Severity	O
44	Characterization	O
45	of	O
46	Trauma	O
47	)	O
48	(	O
49	ASCOT	O
50	),	O
51	and	O
52	if	O
53	they	O
54	differ	O
55	by	O
56	no	O
57	more	O
58	than	O
59	0	O
60	.	O
61	5	O
62	for	O
63	A	O
64	,	O
65	B	O
66	,	O
67	and	O
68	C	O
69	(	O
70	the	O
71	ASCOT	O
72	components	O
73	for	O
74	serious	O
75	injuries	O
76	).	O
1	These	O
2	CTD	B
3	kinases	I
4	,	O
5	designated	O
6	CTDK1	B
7	and	O
8	CTDK2	B
9	,	O
10	are	O
11	fractionated	O
12	by	O
13	chromatography	O
14	on	O
15	Mono	O
16	Q	O
17	.	O
1	To	O
2	characterize	O
3	the	O
4	expression	O
5	of	O
6	this	O
7	DNA	B
8	repair	I
9	enzyme	I
10	,	O
11	we	O
12	have	O
13	isolated	O
14	the	O
15	corresponding	O
16	genomic	O
17	clone	O
18	.	O
1	L	O
2	.,	O
3	Stange	O
4	,	O
5	G	O
6	.,	O
7	Markovich	O
8	,	O
9	D	O
10	.,	O
11	Biber	O
12	,	O
13	J	O
14	.,	O
15	Testar	O
16	,	O
17	X	O
18	.,	O
19	Zorzano	O
20	,	O
21	A	O
22	.,	O
23	Palacin	O
24	,	O
25	M	O
26	.,	O
27	and	O
28	Murer	O
29	,	O
30	H	O
31	.	O
1	An	O
2	extensive	O
3	inverted	O
4	repeat	O
5	is	O
6	present	O
7	3	O
8	'	O
9	of	O
10	rpeA	B
11	;	O
12	inverted	O
13	repeats	O
14	are	O
15	found	O
16	downstream	O
17	of	O
18	all	O
19	PE	B
20	operons	I
21	sequenced	O
22	to	O
23	date	O
24	,	O
25	although	O
26	the	O
27	sequence	O
28	is	O
29	not	O
30	conserved	O
31	.	O
1	One	O
2	such	O
3	mutant	O
4	also	O
5	affects	O
6	the	O
7	overlapping	O
8	-	O
9	10	O
10	hexamer	O
11	of	O
12	PR	O
13	and	O
14	results	O
15	in	O
16	reduced	O
17	occupancy	O
18	by	O
19	both	O
20	MerR	B
21	and	O
22	RNA	B
23	polymerase	I
24	,	O
25	likely	O
26	as	O
27	a	O
28	result	O
29	of	O
30	inefficient	O
31	transcriptional	O
32	initiation	O
33	of	O
34	merR	B
35	mRNA	I
36	.	O
1	This	O
2	report	O
3	describes	O
4	the	O
5	identification	O
6	of	O
7	a	O
8	gene	O
9	of	O
10	related	O
11	function	O
12	,	O
13	SMD1	B
14	,	O
15	located	O
16	immediately	O
17	3	O
18	'	O
19	to	O
20	PRP38	B
21	.	O
1	In	O
2	Experiment	O
3	2	O
4	scopolamine	O
5	hydrobromide	O
6	,	O
7	0	O
8	.	O
9	5	O
10	and	O
11	1	O
12	.	O
13	0	O
14	mg	O
15	/	O
16	kg	O
17	i	O
18	.	O
19	p	O
20	.,	O
21	was	O
22	administered	O
23	1	O
24	h	O
25	before	O
26	each	O
27	electrical	O
28	stimulation	O
29	until	O
30	each	O
31	rat	O
32	showed	O
33	the	O
34	stage	O
35	-	O
36	3	O
37	seizure	O
38	.	O
1	Therefore	O
2	,	O
3	PC	B
4	-	I
5	PLC	I
6	is	O
7	a	O
8	component	O
9	of	O
10	a	O
11	signal	O
12	transduction	O
13	pathway	O
14	leading	O
15	to	O
16	transcription	O
17	of	O
18	c	B
19	-	I
20	fos	I
21	and	O
22	junB	B
23	that	O
24	collaborates	O
25	with	O
26	c	B
27	-	I
28	myc	I
29	and	O
30	is	O
31	independent	O
32	of	O
33	PKC	B
34	-	I
35	delta	I
36	and	O
37	Ras	B
38	activation	O
39	.	O
1	The	O
2	plateau	O
3	MO2	O
4	value	O
5	was	O
6	that	O
7	predicted	O
8	by	O
9	allometric	O
10	relation	O
11	.	O
1	In	O
2	order	O
3	to	O
4	investigate	O
5	how	O
6	these	O
7	expression	O
8	patterns	O
9	are	O
10	established	O
11	,	O
12	we	O
13	fused	O
14	promoter	O
15	regions	O
16	of	O
17	an	O
18	acidic	O
19	and	O
20	a	O
21	basic	O
22	glucanase	B
23	gene	I
24	to	O
25	the	O
26	beta	B
27	-	I
28	glucuronidase	I
29	(	O
30	GUS	B
31	)	O
32	reporter	O
33	gene	O
34	and	O
35	examined	O
36	expression	O
37	of	O
38	these	O
39	constructs	O
40	in	O
41	transgenic	O
42	tobacco	O
43	plants	O
44	.	O
1	Endosonography	O
2	accurately	O
3	assessed	O
4	tumor	O
5	extension	O
6	in	O
7	two	O
8	T2	O
9	tumors	O
10	,	O
11	14	O
12	T3	O
13	tumors	O
14	,	O
15	and	O
16	seven	O
17	T4	O
18	tumors	O
19	.	O
1	Pokeweed	B
2	mitogen	I
3	(	O
4	PWM	B
5	)	O
6	or	O
7	anti	B
8	-	I
9	CD3	I
10	significantly	O
11	increases	O
12	c	B
13	-	I
14	jun	I
15	messenger	I
16	RNA	I
17	(	I
18	mRNA	I
19	)	I
20	levels	O
21	in	O
22	T	O
23	cells	O
24	.	O
1	The	O
2	region	O
3	that	O
4	imparts	O
5	inducibility	O
6	by	O
7	IL	B
8	-	I
9	1	I
10	or	O
11	TNF	B
12	(	O
13	positions	O
14	-	O
15	165	O
16	to	O
17	-	O
18	58	O
19	)	O
20	contains	O
21	potential	O
22	binding	O
23	sites	O
24	for	O
25	IRF	B
26	-	I
27	1	I
28	and	I
29	-	I
30	2	I
31	,	O
32	AP	B
33	-	I
34	1	I
35	,	O
36	and	O
37	NF	B
38	-	I
39	IL	I
40	-	I
41	6	I
42	.	O
1	It	O
2	was	O
3	shown	O
4	by	O
5	transient	O
6	expression	O
7	assay	O
8	that	O
9	HS	B
10	-	I
11	40	I
12	behaved	O
13	as	O
14	an	O
15	authentic	O
16	enhancer	O
17	for	O
18	high	O
19	-	O
20	level	O
21	zeta	B
22	2	I
23	globin	I
24	promoter	I
25	activity	O
26	in	O
27	K562	O
28	cells	O
29	,	O
30	an	O
31	erythroid	O
32	cell	O
33	line	O
34	of	O
35	embryonic	O
36	and	O
37	/	O
38	or	O
39	fetal	O
40	origin	O
41	.	O
1	Internal	O
2	amino	O
3	acid	O
4	sequence	O
5	has	O
6	now	O
7	been	O
8	obtained	O
9	from	O
10	this	O
11	protein	O
12	which	O
13	shares	O
14	50	O
15	-	O
16	100	O
17	%	O
18	sequence	O
19	identity	O
20	with	O
21	sequences	O
22	encoded	O
23	by	O
24	mammalian	B
25	G	I
26	alpha	I
27	11	I
28	and	O
29	G	B
30	alpha	I
31	q	I
32	cDNAs	I
33	.	O
1	However	O
2	,	O
3	after	O
4	repeated	O
5	infections	O
6	,	O
7	hypobiotic	O
8	larvae	O
9	were	O
10	numerous	O
11	.	O
1	Group	O
2	I	O
3	consisted	O
4	of	O
5	six	O
6	noncholestatic	O
7	patients	O
8	;	O
9	group	O
10	II	O
11	consisted	O
12	of	O
13	nine	O
14	mildly	O
15	cholestatic	O
16	patients	O
17	with	O
18	mild	O
19	hepatic	O
20	impairment	O
21	(	O
22	conjugated	O
23	bilirubin	O
24	,	O
25	47	O
26	mumol	O
27	liter	O
28	-	O
29	1	O
30	;	O
31	alkaline	B
32	phosphatase	I
33	,	O
34	280	O
35	IU	O
36	liter	O
37	-	O
38	1	O
39	;	O
40	gamma	B
41	-	I
42	glutamyltranspeptidase	I
43	,	O
44	190	O
45	IU	O
46	liter	O
47	-	O
48	1	O
49	);	O
50	group	O
51	III	O
52	consisted	O
53	of	O
54	six	O
55	benign	O
56	intrahepatic	O
57	cholestatic	O
58	patients	O
59	with	O
60	high	O
61	isolated	O
62	conjugated	O
63	hyperbilirubinemia	O
64	(	O
65	98	O
66	.	O
67	1	O
68	mumol	O
69	liter	O
70	-	O
71	1	O
72	).	O
1	Effects	O
2	of	O
3	intramammary	O
4	endotoxin	O
5	infusion	O
6	on	O
7	milking	O
8	-	O
9	induced	O
10	oxytocin	B
11	release	O
12	.	O
1	Examination	O
2	of	O
3	the	O
4	immediate	O
5	sequence	O
6	5	O
7	'	O
8	to	O
9	the	O
10	mRNA	O
11	start	O
12	site	O
13	reveals	O
14	no	O
15	TATA	O
16	box	O
17	and	O
18	multiple	O
19	known	O
20	enhancer	O
21	sequences	O
22	.	O
1	Based	O
2	on	O
3	these	O
4	results	O
5	,	O
6	a	O
7	new	O
8	model	O
9	for	O
10	the	O
11	regulation	O
12	of	O
13	nif	B
14	/	O
15	fix	B
16	gene	O
17	expression	O
18	in	O
19	A	O
20	.	O
21	caulinodans	O
22	is	O
23	proposed	O
24	.	O
1	However	O
2	,	O
3	despite	O
4	its	O
5	relationship	O
6	to	O
7	the	O
8	TR	B
9	,	O
10	Rev	B
11	-	O
12	Erb	B
13	bound	O
14	poorly	O
15	to	O
16	TR	B
17	binding	I
18	sites	I
19	.	O
1	Northern	O
2	blot	O
3	analysis	O
4	of	O
5	total	O
6	cellular	O
7	RNA	O
8	indicated	O
9	that	O
10	xylP	B
11	encodes	O
12	a	O
13	1	O
14	.	O
15	3	O
16	-	O
17	kb	O
18	transcript	O
19	which	O
20	is	O
21	induced	O
22	by	O
23	xylan	O
24	.	O
1	Although	O
2	olfactory	O
3	associative	O
4	conditioning	O
5	in	O
6	newborn	O
7	rats	O
8	produces	O
9	marked	O
10	structural	O
11	and	O
12	functional	O
13	changes	O
14	in	O
15	the	O
16	olfactory	O
17	bulb	O
18	,	O
19	recent	O
20	evidence	O
21	suggests	O
22	that	O
23	extrabulbar	O
24	circuits	O
25	must	O
26	be	O
27	involved	O
28	in	O
29	storing	O
30	these	O
31	early	O
32	memories	O
33	.	O
1	The	O
2	fission	B
3	yeast	I
4	dsk1	I
5	+	I
6	gene	I
7	,	O
8	a	O
9	multicopy	O
10	suppressor	O
11	for	O
12	cold	O
13	-	O
14	sensitive	O
15	dis1	B
16	mutants	I
17	,	O
18	encodes	O
19	a	O
20	novel	O
21	61	O
22	-	O
23	kd	O
24	protein	O
25	kinase	O
26	.	O
1	Three	O
2	patients	O
3	had	O
4	well	O
5	-,	O
6	6	O
7	patients	O
8	had	O
9	moderately	O
10	-,	O
11	and	O
12	5	O
13	patients	O
14	had	O
15	poorly	O
16	-	O
17	differentiated	O
18	adenocarcinoma	O
19	of	O
20	the	O
21	prostate	O
22	.	O
1	This	O
2	new	O
3	knowledge	O
4	has	O
5	contributed	O
6	to	O
7	the	O
8	development	O
9	of	O
10	a	O
11	successful	O
12	immunoprophylactic	O
13	strategy	O
14	for	O
15	eliminating	O
16	Hib	O
17	disease	O
18	.	O
1	The	O
2	HMG	B
3	CoA	I
4	reductase	I
5	inhibitors	O
6	are	O
7	the	O
8	most	O
9	effective	O
10	cholesterol	O
11	-	O
12	lowering	O
13	agents	O
14	currently	O
15	available	O
16	.	O
1	The	O
2	etiology	O
3	,	O
4	pathology	O
5	,	O
6	brain	O
7	CT	O
8	scan	O
9	features	O
10	,	O
11	clinical	O
12	manifestations	O
13	and	O
14	treatment	O
15	of	O
16	these	O
17	accidents	O
18	were	O
19	discussed	O
20	.	O
1	Biol	O
2	.	O
1	The	O
2	retention	O
3	of	O
4	75SeHCAT	O
5	was	O
6	low	O
7	.	O
1	Yeast	O
2	mutants	O
3	lacking	O
4	a	O
5	functional	O
6	NOP1	B
7	gene	I
8	can	O
9	be	O
10	complemented	O
11	by	O
12	human	B
13	fibrillarin	I
14	but	O
15	are	O
16	temperature	O
17	sensitive	O
18	for	O
19	growth	O
20	and	O
21	impaired	O
22	in	O
23	pre	O
24	-	O
25	rRNA	O
26	processing	O
27	.	O
1	The	O
2	first	O
3	involved	O
4	complementation	O
5	of	O
6	a	O
7	nonphotosynthetic	O
8	mutant	O
9	of	O
10	Chlamydomonas	O
11	,	O
12	CC	O
13	-	O
14	2341	O
15	(	O
16	ac	O
17	-	O
18	u	O
19	-	O
20	g	O
21	-	O
22	2	O
23	.	O
24	3	O
25	),	O
26	which	O
27	has	O
28	a	O
29	frameshift	O
30	mutation	O
31	in	O
32	the	O
33	psaB	B
34	gene	I
35	,	O
36	and	O
37	selection	O
38	of	O
39	photosynthetic	O
40	transformants	O
41	on	O
42	minimal	O
43	medium	O
44	.	O
1	Against	O
2	200	O
3	strains	O
4	of	O
5	methicillin	O
6	-	O
7	resistant	O
8	Staphylococcus	O
9	aureus	O
10	(	O
11	MRSA	O
12	)	O
13	isolated	O
14	from	O
15	1990	O
16	to	O
17	1991	O
18	,	O
19	minimum	O
20	inhibitory	O
21	concentrations	O
22	(	O
23	MICs	O
24	)	O
25	of	O
26	a	O
27	total	O
28	of	O
29	15	O
30	antibacterial	O
31	agents	O
32	including	O
33	arbekacin	O
34	(	O
35	ABK	O
36	)	O
37	were	O
38	determined	O
39	.	O
1	We	O
2	have	O
3	found	O
4	out	O
5	that	O
6	one	O
7	-	O
8	year	O
9	-	O
10	old	O
11	carps	O
12	are	O
13	extremely	O
14	sensitive	O
15	to	O
16	ichthiomycin	O
17	in	O
18	concentrations	O
19	between	O
20	25	O
21	-	O
22	125	O
23	micrograms	O
24	/	O
25	dm3	O
26	.	O
1	Both	O
2	immunophilins	B
3	may	O
4	have	O
5	important	O
6	roles	O
7	in	O
8	receptor	O
9	assembly	O
10	and	O
11	may	O
12	represent	O
13	a	O
14	new	O
15	category	O
16	of	O
17	ligand	O
18	-	O
19	and	O
20	calcium	O
21	-	O
22	dependent	O
23	modulators	O
24	of	O
25	protein	O
26	function	O
27	.	O
1	This	O
2	conclusion	O
3	is	O
4	based	O
5	on	O
6	the	O
7	observations	O
8	of	O
9	the	O
10	immunologic	O
11	changes	O
12	that	O
13	characterize	O
14	the	O
15	acute	O
16	stages	O
17	of	O
18	illness	O
19	as	O
20	well	O
21	as	O
22	on	O
23	the	O
24	demonstrated	O
25	association	O
26	with	O
27	toxin	O
28	-	O
29	producing	O
30	bacteria	O
31	in	O
32	the	O
33	pharynx	O
34	and	O
35	gastrointestinal	O
36	tract	O
37	.	O
1	Purified	O
2	PLB	B
3	showed	O
4	optimal	O
5	lyase	B
6	activity	O
7	at	O
8	pH	O
9	10	O
10	.	O
11	0	O
12	.	O
1	The	O
2	5	O
3	'	O
4	flanking	O
5	regions	O
6	of	O
7	both	O
8	pelA	B
9	and	O
10	pelB	B
11	were	O
12	translationally	O
13	fused	O
14	to	O
15	the	O
16	beta	B
17	-	I
18	glucuronidase	I
19	gene	I
20	and	O
21	introduced	O
22	into	O
23	F	O
24	.	O
25	solani	O
26	f	O
27	.	O
28	sp	O
29	.	O
30	pisi	O
31	,	O
32	and	O
33	beta	B
34	-	I
35	glucuronidase	I
36	activities	O
37	of	O
38	the	O
39	transformants	O
40	were	O
41	measured	O
42	.	O
1	Results	O
2	from	O
3	the	O
4	mechanism	O
5	study	O
6	have	O
7	revealed	O
8	that	O
9	YY1	B
10	is	O
11	able	O
12	to	O
13	inhibit	O
14	transactivation	O
15	mediated	O
16	by	O
17	either	O
18	AP1	B
19	or	O
20	the	O
21	Sp1	B
22	-	I
23	related	I
24	protein	I
25	,	O
26	and	O
27	YY1	B
28	suppressive	O
29	activity	O
30	is	O
31	DNA	O
32	binding	O
33	dependent	O
34	.	O
1	Refugees	O
2	living	O
3	in	O
4	Lund	O
5	and	O
6	repatriated	O
7	to	O
8	Chile	O
9	considered	O
10	their	O
11	health	O
12	as	O
13	bad	O
14	in	O
15	a	O
16	higher	O
17	proportion	O
18	than	O
19	their	O
20	Swedish	O
21	counterparts	O
22	,	O
23	with	O
24	an	O
25	odds	O
26	ratio	O
27	of	O
28	3	O
29	.	O
30	48	O
31	(	O
32	2	O
33	.	O
34	03	O
35	-	O
36	5	O
37	.	O
38	66	O
39	)	O
40	and	O
41	4	O
42	.	O
43	78	O
44	(	O
45	2	O
46	.	O
47	1	O
48	-	O
49	10	O
50	.	O
51	25	O
52	)	O
53	respectively	O
54	.	O
1	The	O
2	MCA	O
3	and	O
4	UA	O
5	PI	O
6	values	O
7	showed	O
8	the	O
9	greatest	O
10	deviation	O
11	for	O
12	any	O
13	single	O
14	-	O
15	vessel	O
16	parameter	O
17	.	O
1	The	O
2	human	B
3	gp39	I
4	promoter	I
5	.	O
1	Together	O
2	,	O
3	our	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	TR2	B
9	orphan	I
10	receptor	I
11	may	O
12	be	O
13	a	O
14	master	O
15	regulator	O
16	in	O
17	modulating	O
18	the	O
19	activation	O
20	of	O
21	two	O
22	key	O
23	HREs	O
24	,	O
25	RARE	O
26	beta	O
27	and	O
28	CRBPIIp	O
29	,	O
30	involved	O
31	in	O
32	the	O
33	retinoic	O
34	acid	O
35	signal	O
36	transduction	O
37	pathway	O
38	.	O
1	Unlike	O
2	ARF	B
3	,	O
4	the	O
5	ARP	B
6	immunoreactivity	O
7	was	O
8	detected	O
9	in	O
10	plasma	O
11	membranes	O
12	but	O
13	not	O
14	in	O
15	cytosol	O
16	of	O
17	fractionated	O
18	3T3	O
19	-	O
20	L1	O
21	cells	O
22	.	O
1	Competition	O
2	needs	O
3	to	O
4	be	O
5	better	O
6	studied	O
7	,	O
8	since	O
9	in	O
10	Central	O
11	America	O
12	and	O
13	Caribean	O
14	islands	O
15	this	O
16	kind	O
17	of	O
18	study	O
19	has	O
20	favored	O
21	the	O
22	biological	O
23	control	O
24	of	O
25	planorbid	O
26	species	O
27	.	O
1	The	O
2	predicted	O
3	protein	O
4	products	O
5	of	O
6	ORFs	B
7	N2417	I
8	and	O
9	N2403	B
10	present	O
11	similarities	O
12	with	O
13	domains	O
14	from	O
15	proteins	O
16	of	O
17	other	O
18	organisms	O
19	:	O
20	the	O
21	Candida	O
22	maltosa	O
23	cycloheximide	B
24	-	I
25	resistance	I
26	protein	I
27	,	O
28	the	O
29	human	O
30	interleukin	B
31	enhancer	I
32	-	I
33	binding	I
34	factor	I
35	(	O
36	ILF	B
37	-	I
38	2	I
39	).	O
1	PTP	B
2	-	I
3	S3	I
4	differs	O
5	from	O
6	PTP	B
7	-	I
8	S4	I
9	in	O
10	having	O
11	a	O
12	deletion	O
13	of	O
14	19	O
15	amino	O
16	acids	O
17	corresponding	O
18	to	O
19	exon	O
20	E1	O
21	.	O
1	All	O
2	three	O
3	NR	B
4	isoforms	O
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O
1	Interestingly	O
2	,	O
3	internal	O
4	and	O
5	5	O
6	'	O
7	deletions	O
8	revealed	O
9	tha	O
10	the	O
11	distal	O
12	promoter	O
13	was	O
14	not	O
15	required	O
16	for	O
17	full	O
18	transcriptional	O
19	activity	O
20	and	O
21	that	O
22	the	O
23	first	O
24	631	O
25	base	O
26	pairs	O
27	of	O
28	WNT	B
29	-	I
30	5A	I
31	harbored	O
32	the	O
33	strongest	O
34	promoter	O
35	activity	O
36	.	O
1	A	O
2	human	O
3	recombinant	O
4	cDNA	O
5	clone	O
6	that	O
7	encoded	O
8	253	O
9	amino	O
10	acids	O
11	residues	O
12	of	O
13	a	O
14	zinc	B
15	-	I
16	finger	I
17	protein	I
18	(	O
19	THZif	B
20	-	I
21	1	I
22	)	O
23	was	O
24	cloned	O
25	by	O
26	screening	O
27	a	O
28	cDNA	O
29	library	O
30	prepared	O
31	from	O
32	human	O
33	promyelocytic	O
34	leukemia	O
35	HL60	O
36	cells	O
37	with	O
38	synthetic	O
39	oligodeoxynucleotide	O
40	probes	O
41	that	O
42	corresponded	O
43	to	O
44	the	O
45	amino	O
46	acid	O
47	sequences	O
48	of	O
49	tryptic	O
50	peptides	O
51	derived	O
52	from	O
53	the	O
54	DNA	O
55	-	O
56	binding	O
57	protein	O
58	specific	O
59	for	O
60	the	O
61	nuclease	B
62	-	I
63	hypersensitive	I
64	element	I
65	(	O
66	NHE	B
67	)	O
68	of	O
69	the	O
70	human	B
71	c	I
72	-	I
73	myc	I
74	gene	I
75	.	O
1	CXC	O
2	chemokines	O
3	bind	O
4	to	O
5	unique	O
6	sets	O
7	of	O
8	selectivity	O
9	determinants	O
10	that	O
11	can	O
12	function	O
13	independently	O
14	and	O
15	are	O
16	broadly	O
17	distributed	O
18	on	O
19	multiple	O
20	domains	O
21	of	O
22	human	O
23	interleukin	B
24	-	I
25	8	I
26	receptor	I
27	B	I
28	.	O
1	Oligodeoxynucleotides	O
2	antisense	O
3	to	O
4	the	O
5	predicted	O
6	translation	O
7	initiation	O
8	regions	O
9	of	O
10	ICP4	B
11	and	O
12	pp38	B
13	mRNAs	I
14	inhibited	O
15	proliferation	O
16	of	O
17	MSB1	O
18	cells	O
19	but	O
20	not	O
21	MDCC	O
22	-	O
23	CU91	O
24	(	O
25	CU91	O
26	)	O
27	reticuloendotheliosis	O
28	virus	O
29	-	O
30	transformed	O
31	cells	O
32	.	O
1	We	O
2	have	O
3	identified	O
4	and	O
5	characterized	O
6	a	O
7	vitamin	O
8	D	O
9	response	O
10	element	O
11	(	O
12	VDRE	O
13	)	O
14	in	O
15	the	O
16	promoter	O
17	of	O
18	c	B
19	-	I
20	fos	I
21	.	O
1	Transgenic	O
2	tobacco	O
3	plants	O
4	(	O
5	ppa	B
6	-	I
7	1	I
8	)	O
9	constitutively	O
10	expressing	O
11	Escherichia	B
12	coli	I
13	pyrophosphatase	I
14	behind	O
15	the	O
16	35S	B
17	CaMV	I
18	promoter	I
19	accumulate	O
20	high	O
21	levels	O
22	of	O
23	soluble	O
24	sugars	O
25	in	O
26	their	O
27	leaves	O
28	[	O
29	27	O
30	].	O
1	CBT	O
2	is	O
3	discussed	O
4	in	O
5	comparison	O
6	with	O
7	the	O
8	Wisconsin	O
9	Card	O
10	Sorting	O
11	Test	O
12	as	O
13	a	O
14	potential	O
15	cognitive	O
16	activation	O
17	task	O
18	for	O
19	functional	O
20	neuroimaging	O
21	of	O
22	the	O
23	frontal	O
24	lobes	O
25	.	O
1	Strontium	O
2	chloride	O
3	Sr	O
4	89	O
5	is	O
6	costly	O
7	,	O
8	but	O
9	preliminary	O
10	analysis	O
11	indicates	O
12	that	O
13	it	O
14	may	O
15	reduce	O
16	management	O
17	expenditures	O
18	overall	O
19	.(	O
20	ABSTRACT	O
21	TRUNCATED	O
22	AT	O
23	250	O
24	WORDS	O
25	)	O
1	This	O
2	analysis	O
3	revealed	O
4	that	O
5	SAP	B
6	145	I
7	,	O
8	together	O
9	with	O
10	four	O
11	other	O
12	SF3a	B
13	/	O
14	SF3b	B
15	subunits	O
16	,	O
17	UV	O
18	cross	O
19	-	O
20	links	O
21	to	O
22	pre	O
23	-	O
24	mRNA	O
25	in	O
26	a	O
27	20	O
28	-	O
29	nucleotide	O
30	region	O
31	upstream	O
32	of	O
33	the	O
34	BPS	O
35	.	O
1	We	O
2	propose	O
3	that	O
4	CTS1	B
5	and	I
6	CTS2	I
7	of	I
8	Ci	I
9	are	O
10	members	O
11	of	O
12	two	O
13	distinct	O
14	classes	O
15	of	O
16	fungal	B
17	chitinases	I
18	,	O
19	an	O
20	observation	O
21	not	O
22	previously	O
23	reported	O
24	for	O
25	a	O
26	single	O
27	fungus	O
28	.	O
1	The	O
2	Clb5	B
3	kinase	I
4	,	O
5	which	O
6	promotes	O
7	S	O
8	phase	O
9	,	O
10	remains	O
11	active	O
12	during	O
13	the	O
14	G2	O
15	-	O
16	phase	O
17	arrest	O
18	of	O
19	cells	O
20	of	O
21	the	O
22	parental	O
23	strain	O
24	,	O
25	but	O
26	its	O
27	activity	O
28	declines	O
29	rapidly	O
30	in	O
31	sim	B
32	mutants	I
33	.	O
1	Activated	O
2	PKR	B
3	may	O
4	exist	O
5	as	O
6	a	O
7	dimer	O
8	and	O
9	phosphorylates	O
10	the	O
11	eukaryotic	B
12	translation	I
13	initiation	I
14	factor	I
15	2	I
16	alpha	I
17	subunit	I
18	(	O
19	cIF	B
20	-	I
21	2	I
22	alpha	I
23	)	O
24	to	O
25	inhibit	O
26	polypeptide	O
27	chain	O
28	initiation	O
29	.	O
1	In	O
2	a	O
3	second	O
4	series	O
5	of	O
6	experiments	O
7	,	O
8	the	O
9	efficacy	O
10	of	O
11	PDC	O
12	/	O
13	HDC	O
14	Ac	O
15	was	O
16	evaluated	O
17	in	O
18	both	O
19	single	O
20	and	O
21	multiple	O
22	dose	O
23	regiments	O
24	.	O
1	With	O
2	current	O
3	methodology	O
4	beta	B
5	-	I
6	2	I
7	transferrin	I
8	does	O
9	not	O
10	appear	O
11	to	O
12	be	O
13	a	O
14	reliable	O
15	clinical	O
16	marker	O
17	for	O
18	perilymph	O
19	in	O
20	the	O
21	operative	O
22	setting	O
23	.	O
1	Sixty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	aged	O
7	between	O
8	3	O
9	years	O
10	5	O
11	months	O
12	and	O
13	60	O
14	years	O
15	)	O
16	suffering	O
17	from	O
18	medically	O
19	resistant	O
20	temporal	O
21	lobe	O
22	epilepsy	O
23	(	O
24	TLE	O
25	)	O
26	were	O
27	operated	O
28	on	O
29	over	O
30	a	O
31	period	O
32	of	O
33	33	O
34	months	O
35	in	O
36	Bethel	O
37	Epilepsy	O
38	Center	O
39	.	O
1	A	O
2	3	O
3	-	O
4	week	O
5	regimen	O
6	of	O
7	erythropoietin	B
8	may	O
9	help	O
10	prevent	O
11	the	O
12	donor	O
13	'	O
14	s	O
15	need	O
16	to	O
17	receive	O
18	allogeneic	O
19	blood	O
20	transfusion	O
21	,	O
22	when	O
23	the	O
24	initial	O
25	Hb	B
26	levels	O
27	were	O
28	below	O
29	130	O
30	milligrams	O
31	.	O
1	QBMDs	O
2	for	O
3	a	O
4	5	O
5	%	O
6	change	O
7	in	O
8	response	O
9	(	O
10	QBMD05	O
11	)	O
12	were	O
13	6	O
14	-	O
15	fold	O
16	lower	O
17	,	O
18	on	O
19	average	O
20	,	O
21	than	O
22	the	O
23	corresponding	O
24	NOAEL	O
25	.	O
1	The	O
2	gene	O
3	encodes	O
4	an	O
5	ATP	B
6	-	I
7	binding	I
8	cassette	I
9	,	O
10	ABC	B
11	transporter	I
12	.	O
1	Molecular	O
2	analysis	O
3	of	O
4	a	O
5	novel	O
6	schizosaccharomyces	O
7	pombe	O
8	gene	O
9	containing	O
10	two	O
11	RNP	O
12	consensus	O
13	-	O
14	sequence	O
15	RNA	O
16	-	O
17	binding	O
18	domains	O
19	.	O
1	The	O
2	evidence	O
3	presented	O
4	here	O
5	suggests	O
6	that	O
7	the	O
8	p40	B
9	complex	I
10	is	O
11	a	O
12	ribonucleoprotein	O
13	complex	O
14	containing	O
15	L1Hs	B
16	RNA	I
17	(	I
18	s	I
19	)	I
20	and	O
21	that	O
22	protein	O
23	-	O
24	protein	O
25	interactions	O
26	in	O
27	which	O
28	alpha	O
29	-	O
30	helix	O
31	structures	O
32	participate	O
33	,	O
34	for	O
35	example	O
36	coiled	O
37	-	O
38	coils	O
39	,	O
40	may	O
41	occur	O
42	in	O
43	the	O
44	complex	O
45	.	O
1	Pseudomembranous	O
2	conjunctivitis	O
3	following	O
4	bone	O
5	marrow	O
6	transplantation	O
7	:	O
8	immunopathological	O
9	and	O
10	ultrastructural	O
11	study	O
12	of	O
13	one	O
14	case	O
15	.	O
1	These	O
2	animals	O
3	were	O
4	viable	O
5	and	O
6	fertile	O
7	.	O
1	Carboxy	O
2	-	O
3	terminal	O
4	Spc110p	B
5	truncations	O
6	lacking	O
7	the	O
8	calmodulin	B
9	binding	O
10	site	O
11	can	O
12	support	O
13	growth	O
14	and	O
15	are	O
16	also	O
17	phosphorylated	O
18	in	O
19	a	O
20	cell	O
21	cycle	O
22	-	O
23	specific	O
24	manner	O
25	.	O
1	SUMMARY	O
2	OF	O
3	REVIEW	O
4	:	O
5	We	O
6	discuss	O
7	the	O
8	criteria	O
9	that	O
10	make	O
11	such	O
12	studies	O
13	comparable	O
14	,	O
15	drawing	O
16	on	O
17	the	O
18	experiences	O
19	of	O
20	recent	O
21	studies	O
22	performed	O
23	around	O
24	the	O
25	world	O
26	.	O
1	Forty	O
2	-	O
3	five	O
4	patients	O
5	with	O
6	pleural	O
7	lesions	O
8	identified	O
9	on	O
10	CT	O
11	scans	O
12	were	O
13	subsequently	O
14	examined	O
15	by	O
16	MR	O
17	imaging	O
18	at	O
19	0	O
20	.	O
21	5	O
22	T	O
23	.	O
1	The	O
2	alpha	O
3	T3	O
4	-	O
5	1	O
6	cell	O
7	line	O
8	,	O
9	a	O
10	GnRH	B
11	-	O
12	responsive	O
13	gonadotroph	O
14	cell	O
15	line	O
16	developed	O
17	by	O
18	targeted	O
19	oncogenesis	O
20	in	O
21	transgenic	O
22	mice	O
23	,	O
24	was	O
25	used	O
26	to	O
27	study	O
28	regulation	O
29	of	O
30	the	O
31	glycoprotein	B
32	hormone	I
33	alpha	I
34	-	I
35	subunit	I
36	by	O
37	activin	B
38	.	O
1	TNF	B
2	Treatment	O
3	of	O
4	cell	O
5	activated	O
6	the	O
7	p38	B
8	MAP	I
9	kinase	I
10	pathway	O
11	,	O
12	as	O
13	revealed	O
14	by	O
15	increased	O
16	phosphorylation	O
17	of	O
18	p38	B
19	MAP	I
20	kinase	I
21	itself	O
22	,	O
23	activation	O
24	of	O
25	the	O
26	substrate	O
27	protein	O
28	MAPKAP	B
29	kinase	I
30	-	I
31	2	I
32	,	O
33	and	O
34	culminating	O
35	in	O
36	the	O
37	phosphorylation	O
38	of	O
39	the	O
40	heat	B
41	shock	I
42	protein	I
43	27	I
44	(	O
45	hsp27	B
46	).	O
1	However	O
2	,	O
3	while	O
4	the	O
5	sequence	O
6	similarity	O
7	between	O
8	the	O
9	membrane	O
10	exons	O
11	of	O
12	avian	B
13	mIgY	I
14	and	O
15	mammalian	B
16	mIgG	I
17	and	I
18	IgE	I
19	is	O
20	striking	O
21	,	O
22	the	O
23	overall	O
24	similarity	O
25	with	O
26	Xenopus	B
27	mIgY	I
28	is	O
29	very	O
30	low	O
31	.	O
1	DNase	B
2	I	I
3	footprinting	O
4	and	O
5	electrophoretic	O
6	mobility	O
7	shift	O
8	assays	O
9	indicate	O
10	that	O
11	PBP	B
12	binds	O
13	to	O
14	the	O
15	half	O
16	-	O
17	site	O
18	of	O
19	each	O
20	palindrome	O
21	with	O
22	the	O
23	core	O
24	recognition	O
25	sequence	O
26	TGGGAG	O
27	.	O
1	LY290181	O
2	appears	O
3	to	O
4	inhibit	O
5	uPA	B
6	promoter	I
7	activation	O
8	by	O
9	blocking	O
10	phorbol	O
11	ester	O
12	-	O
13	stimulated	O
14	binding	O
15	of	O
16	nuclear	O
17	proteins	O
18	to	O
19	the	O
20	uPA	B
21	PEA3	I
22	/	O
23	12	O
24	-	O
25	0	O
26	-	O
27	tetradecanoylphorbol	O
28	13	O
29	-	O
30	acetate	O
31	responsive	O
32	element	O
33	(	O
34	TRE	O
35	).	O
1	The	O
2	protein	O
3	folds	O
4	correctly	O
5	with	O
6	two	O
7	disulfide	O
8	bonds	O
9	and	O
10	a	O
11	free	O
12	thiol	O
13	group	O
14	at	O
15	Cys25	O
16	.	O
1	Clones	O
2	33F	O
3	and	O
4	34B	O
5	encoded	O
6	identical	O
7	aromatase	B
8	proteins	I
9	of	O
10	503	O
11	amino	O
12	acids	O
13	,	O
14	but	O
15	differed	O
16	in	O
17	size	O
18	due	O
19	to	O
20	alternative	O
21	polyadenylation	O
22	signal	O
23	usage	O
24	for	O
25	the	O
26	corresponding	O
27	mRNAs	O
28	.	O
1	Binding	O
2	specificity	O
3	and	O
4	modulation	O
5	of	O
6	the	O
7	ApoA	B
8	-	I
9	I	I
10	promoter	I
11	activity	O
12	by	O
13	homo	O
14	-	O
15	and	O
16	heterodimers	O
17	of	O
18	nuclear	O
19	receptors	O
20	.	O
1	They	O
2	were	O
3	found	O
4	to	O
5	stimulate	O
6	at	O
7	nanomolar	O
8	concentrations	O
9	the	O
10	turnover	O
11	of	O
12	biosynthetically	O
13	labeled	O
14	ceramide	O
15	,	O
16	glucosylceramide	O
17	,	O
18	and	O
19	lactosylceramide	O
20	.	O
1	Am	O
2	.	O
1	However	O
2	,	O
3	a	O
4	>	O
5	10	O
6	-	O
7	fold	O
8	increase	O
9	in	O
10	ERK3	B
11	activity	O
12	in	O
13	each	O
14	PKC	B
15	beta	I
16	transfectant	O
17	was	O
18	shown	O
19	by	O
20	immunoprecipitation	O
21	with	O
22	anti	B
23	-	I
24	ERK3	I
25	monoclonal	I
26	antibody	I
27	followed	O
28	by	O
29	either	O
30	immune	O
31	complex	O
32	kinase	O
33	assay	O
34	or	O
35	by	O
36	in	O
37	gel	O
38	kinase	O
39	assay	O
40	.	O
1	Retinoid	O
2	-	O
3	dependent	O
4	activation	O
5	of	O
6	the	O
7	tissue	B
8	transglutaminase	I
9	promoter	I
10	depends	O
11	on	O
12	both	O
13	a	O
14	proximal	O
15	regulatory	O
16	region	O
17	containing	O
18	sequences	O
19	highly	O
20	conserved	O
21	between	O
22	the	O
23	human	O
24	and	O
25	the	O
26	mouse	B
27	tissue	I
28	transglutaminase	I
29	promoters	I
30	and	O
31	a	O
32	distal	O
33	region	O
34	that	O
35	includes	O
36	a	O
37	30	O
38	-	O
39	base	O
40	pair	O
41	retinoid	O
42	response	O
43	element	O
44	(	O
45	mTGRRE1	O
46	).	O
47	mTGRRE1	O
48	contains	O
49	three	O
50	hexanucleotide	O
51	half	O
52	-	O
53	sites	O
54	(	O
55	two	O
56	canonical	O
57	and	O
58	one	O
59	non	O
60	-	O
61	canonical	O
62	)	O
63	in	O
64	a	O
65	DR7	B
66	/	O
67	DR5	B
68	motif	O
69	that	O
70	bind	O
71	both	O
72	RAR	B
73	*	O
74	RXR	B
75	heterodimers	O
76	and	O
77	RXR	B
78	homodimers	I
79	.	O
1	Significantly	O
2	,	O
3	pPKR	B
4	is	O
5	capable	O
6	of	O
7	specifically	O
8	phosphorylating	O
9	Ser51	O
10	in	O
11	a	O
12	synthetic	B
13	eIF	I
14	-	I
15	2alpha	I
16	peptide	I
17	,	O
18	a	O
19	key	O
20	characteristic	O
21	of	O
22	the	O
23	eIF	B
24	-	I
25	2alpha	I
26	kinase	I
27	family	I
28	.	O
1	ZEBRA	B
2	and	O
3	cellular	O
4	AP	B
5	-	I
6	1	I
7	bZip	I
8	activators	I
9	,	O
10	such	O
11	as	O
12	c	B
13	-	I
14	Fos	I
15	,	O
16	have	O
17	homologous	O
18	DNA	O
19	-	O
20	binding	O
21	domains	O
22	,	O
23	and	O
24	their	O
25	DNA	O
26	-	O
27	binding	O
28	specificities	O
29	overlap	O
30	.	O
1	CM	B
2	-	I
3	ACO3	I
4	is	O
5	expressed	O
6	in	O
7	flowers	O
8	and	O
9	is	O
10	not	O
11	induced	O
12	by	O
13	any	O
14	of	O
15	the	O
16	stimuli	O
17	tested	O
18	.	O
1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	increase	O
7	in	O
8	V	O
9	O2	O
10	may	O
11	have	O
12	been	O
13	a	O
14	consequence	O
15	of	O
16	the	O
17	increase	O
18	in	O
19	Q	O
20	O2	O
21	rather	O
22	than	O
23	a	O
24	response	O
25	to	O
26	the	O
27	procedure	O
28	itself	O
29	.	O
1	As	O
2	pH	O
3	and	O
4	Hb	B
5	can	O
6	also	O
7	affect	O
8	mixed	O
9	venous	O
10	CO2	O
11	content	O
12	,	O
13	the	O
14	effect	O
15	on	O
16	Q	O
17	was	O
18	also	O
19	assessed	O
20	.	O
1	The	O
2	structural	O
3	gene	O
4	for	O
5	copper	B
6	-	I
7	and	I
8	topa	I
9	quinone	I
10	-	I
11	containing	I
12	monoamine	I
13	oxidase	I
14	(	O
15	maoA	B
16	)	O
17	and	O
18	an	O
19	unknown	O
20	amine	B
21	oxidase	I
22	gene	I
23	have	O
24	been	O
25	located	O
26	at	O
27	30	O
28	.	O
29	9	O
30	min	O
31	on	O
32	the	O
33	Escherichia	O
34	coli	O
35	chromosome	O
36	.	O
1	Human	B
2	cytomegalovirus	I
3	immediate	I
4	-	I
5	early	I
6	protein	I
7	IE2	I
8	tethers	O
9	a	O
10	transcriptional	O
11	repression	O
12	domain	O
13	to	O
14	p53	B
15	.	O
1	The	O
2	frequency	O
3	of	O
4	integrations	O
5	that	O
6	led	O
7	to	O
8	transcription	O
9	of	O
10	the	O
11	lacZ	B
12	gene	I
13	was	O
14	estimated	O
15	to	O
16	be	O
17	0	O
18	.	O
19	5	O
20	%	O
21	of	O
22	all	O
23	integrations	O
24	,	O
25	of	O
26	which	O
27	14	O
28	%	O
29	were	O
30	downregulated	O
31	on	O
32	differentiation	O
33	of	O
34	32D	O
35	cells	O
36	towards	O
37	neutrophils	O
38	.	O
1	The	O
2	sequence	O
3	and	O
4	isolated	O
5	cDNAs	O
6	will	O
7	provide	O
8	useful	O
9	reagents	O
10	for	O
11	studying	O
12	the	O
13	expression	O
14	of	O
15	Brca1	B
16	in	O
17	the	O
18	mouse	O
19	,	O
20	and	O
21	for	O
22	testing	O
23	the	O
24	importance	O
25	of	O
26	the	O
27	evolutionarily	O
28	conserved	O
29	domains	O
30	.	O
1	Transcription	O
2	from	O
3	adenovirus	B
4	E2	I
5	-	I
6	early	I
7	promoter	I
8	is	O
9	controlled	O
10	by	O
11	a	O
12	unique	O
13	array	O
14	of	O
15	four	O
16	cis	O
17	-	O
18	acting	O
19	elements	O
20	which	O
21	include	O
22	an	O
23	atypical	O
24	TBP	B
25	site	I
26	,	O
27	two	O
28	E2F	B
29	sites	I
30	present	O
31	in	O
32	an	O
33	inverted	O
34	orientation	O
35	relative	O
36	to	O
37	each	O
38	other	O
39	,	O
40	and	O
41	an	O
42	ATF	B
43	site	I
44	.	O
1	A	O
2	second	O
3	peptide	O
4	(	O
5	amino	O
6	acids	O
7	58	O
8	-	O
9	77	O
10	)	O
11	also	O
12	antagonized	O
13	p21	B
14	-	O
15	activity	O
16	,	O
17	but	O
18	this	O
19	peptide	O
20	did	O
21	not	O
22	affect	O
23	the	O
24	ability	O
25	of	O
26	p21	B
27	to	O
28	interact	O
29	with	O
30	cyclin	B
31	E	I
32	/	O
33	Cdk2	B
34	.	O
1	A	O
2	p21	B
3	peptide	I
4	spanning	O
5	amino	O
6	acids	O
7	139	O
8	-	O
9	164	O
10	was	O
11	found	O
12	to	O
13	bind	O
14	PCNA	B
15	in	O
16	a	O
17	filter	O
18	binding	O
19	assay	O
20	and	O
21	this	O
22	peptide	O
23	suppressed	O
24	recombinant	O
25	p21	B
26	-	O
27	PCNA	B
28	interaction	O
29	.	O
1	Adduction	O
2	of	O
3	the	O
4	human	B
5	N	I
6	-	I
7	ras	I
8	codon	I
9	61	I
10	sequence	I
11	with	O
12	(-)-(	O
13	7S	O
14	,	O
15	8R	O
16	,	O
17	9R	O
18	,	O
19	10S	O
20	)-	O
21	7	O
22	,	O
23	8	O
24	-	O
25	dihydroxy	O
26	-	O
27	9	O
28	,	O
29	10	O
30	-	O
31	epoxy	O
32	-	O
33	7	O
34	,	O
35	8	O
36	,	O
37	9	O
38	,	O
39	10	O
40	-	O
41	tetrahydrobenzo	O
42	[	O
43	a	O
44	]	O
45	pyrene	O
46	:	O
47	structural	O
48	refinement	O
49	of	O
50	the	O
51	intercalated	O
52	SRSR	O
53	(	O
54	61	O
55	,	O
56	2	O
57	)	O
58	(-)-(	O
59	7S	O
60	,	O
61	8R	O
62	,	O
63	9S	O
64	,	O
65	10R	O
66	)-	O
67	N6	O
68	-[	O
69	10	O
70	-(	O
71	7	O
72	,	O
73	8	O
74	,	O
75	9	O
76	,	O
77	10	O
78	-	O
79	tetrahydrobenzo	O
80	[	O
81	a	O
82	]	O
83	pyrenyl	O
84	)]-	O
85	2	O
86	'-	O
87	deoxyadenosyl	O
88	adduct	O
89	from	O
90	1H	O
91	NMR	O
92	.	O
1	Isolation	O
2	by	O
3	PCR	O
4	of	O
5	a	O
6	cDNA	O
7	clone	O
8	from	O
9	pea	O
10	petals	O
11	with	O
12	similarity	O
13	to	O
14	petunia	O
15	and	O
16	wheat	B
17	zinc	I
18	finger	I
19	proteins	I
20	.	O
1	Exposure	O
2	of	O
3	peripheral	O
4	blood	O
5	T	O
6	cells	O
7	from	O
8	young	O
9	subjects	O
10	to	O
11	PHA	B
12	or	O
13	cross	O
14	-	O
15	linked	O
16	anti	B
17	-	I
18	CD3	I
19	monoclonal	I
20	antibodies	I
21	stimulated	O
22	rapid	O
23	increases	O
24	in	O
25	MAPK	B
26	and	O
27	MEK	B
28	enzymatic	O
29	activity	O
30	.	O
1	When	O
2	overexpressed	O
3	in	O
4	an	O
5	appropriate	O
6	cell	O
7	line	O
8	,	O
9	TAN	B
10	-	I
11	1C	I
12	prevented	O
13	kappa	B
14	B	I
15	-	O
16	dependent	O
17	transactivation	O
18	in	O
19	transient	O
20	reporter	O
21	gene	O
22	assays	O
23	in	O
24	a	O
25	fashion	O
26	similar	O
27	to	O
28	the	O
29	structurally	O
30	related	O
31	protein	O
32	,	O
33	Bcl	B
34	-	I
35	3	I
36	.	O
1	T	O
2	cell	O
3	leukemia	O
4	-	O
5	associated	O
6	human	O
7	Notch	B
8	/	O
9	translocation	O
10	-	O
11	associated	O
12	Notch	B
13	homologue	O
14	has	O
15	I	B
16	kappa	I
17	B	I
18	-	O
19	like	O
20	activity	O
21	and	O
22	physically	O
23	interacts	O
24	with	O
25	nuclear	B
26	factor	I
27	-	I
28	kappa	I
29	B	I
30	proteins	O
31	in	O
32	T	O
33	cells	O
34	.	O
1	Deletion	O
2	analysis	O
3	of	O
4	rOC	B
5	promoter	I
6	-	O
7	chloramphenicol	B
8	acetyltransferase	I
9	constructs	O
10	demonstrates	O
11	that	O
12	an	O
13	AML	B
14	-	I
15	1	I
16	-	I
17	binding	I
18	sequence	I
19	within	O
20	the	O
21	proximal	O
22	promoter	O
23	(-	O
24	138	O
25	to	O
26	-	O
27	130	O
28	nt	O
29	)	O
30	contributes	O
31	to	O
32	75	O
33	%	O
34	of	O
35	the	O
36	level	O
37	of	O
38	osteocalcin	B
39	gene	I
40	expression	O
41	.	O
1	Moreover	O
2	,	O
3	the	O
4	Rho	B
5	family	I
6	protein	I
7	Cdc42	I
8	,	O
9	a	O
10	conserved	O
11	morphogenetic	B
12	G	I
13	protein	I
14	,	O
15	is	O
16	also	O
17	a	O
18	potent	O
19	regulator	O
20	of	O
21	filamentous	O
22	growth	O
23	and	O
24	FG	B
25	(	O
26	TyA	B
27	)::	O
28	lacZ	B
29	expression	O
30	in	O
31	S	O
32	.	O
33	cerevisiae	O
34	.	O
1	Menstrual	O
2	-	O
3	cycle	O
4	phase	O
5	did	O
6	not	O
7	significantly	O
8	affect	O
9	personality	O
10	variables	O
11	in	O
12	either	O
13	group	O
14	.	O
1	We	O
2	report	O
3	the	O
4	isolation	O
5	of	O
6	human	O
7	cDNAs	O
8	homologous	O
9	to	O
10	the	O
11	Drosophila	B
12	dishevelled	I
13	(	O
14	dsh	B
15	)	O
16	segment	O
17	-	O
18	polarity	O
19	gene	O
20	.	O
1	Sp1	B
2	binds	O
3	two	O
4	sites	O
5	in	O
6	the	O
7	CD11c	B
8	promoter	I
9	in	O
10	vivo	O
11	specifically	O
12	in	O
13	myeloid	O
14	cells	O
15	and	O
16	cooperates	O
17	with	O
18	AP1	B
19	to	O
20	activate	O
21	transcription	O
22	.	O
1	Mesial	O
2	temporal	O
3	sclerosis	O
4	was	O
5	characterized	O
6	by	O
7	severe	O
8	neuronal	O
9	loss	O
10	accompanied	O
11	by	O
12	gliosis	O
13	occurring	O
14	in	O
15	the	O
16	CA1	O
17	/	O
18	prosubiculum	O
19	(	O
20	27	O
21	patients	O
22	,	O
23	100	O
24	%),	O
25	focally	O
26	in	O
27	the	O
28	dentate	O
29	gyrus	O
30	(	O
31	12	O
32	patients	O
33	,	O
34	44	O
35	%),	O
36	and	O
37	in	O
38	the	O
39	CA4	O
40	region	O
41	(	O
42	11	O
43	patients	O
44	,	O
45	41	O
46	%).	O
1	Therefore	O
2	,	O
3	magnetic	O
4	resonance	O
5	imaging	O
6	was	O
7	used	O
8	to	O
9	determine	O
10	liver	O
11	volume	O
12	in	O
13	pediatric	O
14	and	O
15	adolescent	O
16	patients	O
17	,	O
18	in	O
19	whom	O
20	systemic	O
21	clearance	O
22	of	O
23	three	O
24	model	O
25	substrates	O
26	[	O
27	lorazepam	O
28	(	O
29	0	O
30	.	O
31	03	O
32	mg	O
33	/	O
34	kg	O
35	),	O
36	antipyrine	O
37	(	O
38	10	O
39	mg	O
40	/	O
41	kg	O
42	),	O
43	and	O
44	indocyanine	O
45	green	O
46	(	O
47	ICG	O
48	;	O
49	0	O
50	.	O
51	5	O
52	mg	O
53	/	O
54	kg	O
55	)]	O
56	was	O
57	also	O
58	determined	O
59	.	O
1	Heme	B
2	oxygenase	I
3	1	I
4	is	O
5	an	O
6	essential	O
7	enzyme	O
8	in	O
9	heme	O
10	catabolism	O
11	that	O
12	cleaves	O
13	heme	O
14	to	O
15	form	O
16	biliverdin	O
17	,	O
18	iron	O
19	,	O
20	and	O
21	carbon	O
22	monoxide	O
23	.	O
1	In	O
2	addition	O
3	,	O
4	5	O
5	'	O
6	deletions	O
7	removing	O
8	all	O
9	but	O
10	34	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	transcription	O
16	start	O
17	point	O
18	retained	O
19	greater	O
20	than	O
21	90	O
22	%	O
23	promoter	O
24	activity	O
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	-	O
30	35	O
31	hexamer	O
32	was	O
33	not	O
34	essential	O
35	for	O
36	promoter	O
37	activity	O
38	.	O
1	Transcriptional	O
2	regulators	O
3	utilizing	O
4	the	O
5	POU	B
6	domain	I
7	DNA	I
8	-	I
9	binding	I
10	motif	I
11	have	O
12	been	O
13	shown	O
14	to	O
15	form	O
16	multi	O
17	-	O
18	protein	O
19	complexes	O
20	dependent	O
21	on	O
22	the	O
23	POU	B
24	domain	I
25	itself	O
26	and	O
27	its	O
28	flexible	O
29	recognition	O
30	of	O
31	various	O
32	octamer	O
33	sequence	O
34	elements	O
35	.	O
1	We	O
2	found	O
3	strand	O
4	selective	O
5	repair	O
6	in	O
7	DNA	O
8	fragments	O
9	within	O
10	two	O
11	active	O
12	genes	O
13	,	O
14	DHFR	B
15	and	O
16	an	O
17	unknown	O
18	gene	O
19	adjacent	O
20	to	O
21	DHFR	B
22	.	O
1	The	O
2	model	O
3	captures	O
4	the	O
5	essence	O
6	of	O
7	predator	O
8	-	O
9	prey	O
10	dynamics	O
11	to	O
12	provide	O
13	reasonable	O
14	predictions	O
15	of	O
16	population	O
17	patterns	O
18	.	O
1	The	O
2	gene	O
3	was	O
4	expressed	O
5	as	O
6	an	O
7	approximately	O
8	1	O
9	.	O
10	5	O
11	-	O
12	kb	O
13	mRNA	O
14	in	O
15	most	O
16	nonlymphoid	O
17	human	O
18	cells	O
19	/	O
20	tissues	O
21	including	O
22	prostate	O
23	,	O
24	lung	O
25	,	O
26	liver	O
27	,	O
28	and	O
29	colon	O
30	.	O
1	We	O
2	have	O
3	obtained	O
4	the	O
5	human	B
6	EP4	I
7	receptor	I
8	gene	I
9	sequence	I
10	and	O
11	determined	O
12	its	O
13	structure	O
14	relative	O
15	to	O
16	EP4R	B
17	cDNA	I
18	synthesized	O
19	from	O
20	peripheral	O
21	blood	O
22	lymphocytes	O
23	.	O
1	Receptors	O
2	for	O
3	interleukin	B
4	(	I
5	IL	I
6	)-	I
7	10	I
8	and	O
9	IL	B
10	-	I
11	6	I
12	-	I
13	type	I
14	cytokines	I
15	use	O
16	similar	O
17	signaling	O
18	mechanisms	O
19	for	O
20	inducing	O
21	transcription	O
22	through	O
23	IL	B
24	-	I
25	6	I
26	response	O
27	elements	O
28	.	O
1	A	O
2	cis	O
3	-	O
4	acting	O
5	DNA	O
6	element	O
7	located	O
8	between	O
9	TATA	O
10	box	O
11	and	O
12	transcription	O
13	initiation	O
14	site	O
15	is	O
16	critical	O
17	in	O
18	response	O
19	to	O
20	regulatory	O
21	sequences	O
22	in	O
23	human	O
24	angiotensinogen	B
25	gene	I
26	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	human	B
10	DSG3	I
11	gene	I
12	and	O
13	examined	O
14	the	O
15	transcriptional	O
16	regulation	O
17	of	O
18	its	O
19	expression	O
20	.	O
1	Clinical	O
2	evaluation	O
3	of	O
4	the	O
5	Allergan	O
6	Humphrey	O
7	500	O
8	autorefractor	O
9	and	O
10	the	O
11	Nidek	O
12	AR	O
13	-	O
14	1000	O
15	autorefractor	O
16	.	O
1	ZIOS	O
2	was	O
3	significantly	O
4	more	O
5	sensitive	O
6	than	O
7	all	O
8	subsequent	O
9	methods	O
10	,	O
11	and	O
12	Ptc	O
13	,	O
14	O2	O
15	was	O
16	significantly	O
17	more	O
18	sensitive	O
19	than	O
20	FEV1	O
21	.	O
1	The	O
2	introduction	O
3	of	O
4	hARF4	B
5	to	O
6	the	O
7	cells	O
8	maintained	O
9	the	O
10	balance	O
11	between	O
12	cytosolic	O
13	and	O
14	membrane	O
15	-	O
16	associated	O
17	Sec7p	B
18	pools	O
19	.	O
1	Our	O
2	data	O
3	demonstrate	O
4	directly	O
5	that	O
6	Rpm1r	B
7	is	O
8	transcribed	O
9	with	O
10	its	O
11	substrates	O
12	,	O
13	tRNA	B
14	met	I
15	f	I
16	and	O
17	tRNAPro	B
18	,	O
19	from	O
20	a	O
21	promoter	O
22	located	O
23	upstream	O
24	of	O
25	the	O
26	tRNA	B
27	met	I
28	f	I
29	gene	I
30	and	O
31	suggest	O
32	that	O
33	a	O
34	portion	O
35	also	O
36	originates	O
37	from	O
38	a	O
39	second	O
40	promoter	O
41	,	O
42	located	O
43	between	O
44	the	O
45	tRNA	B
46	met	I
47	f	I
48	gene	I
49	and	O
50	RPM1	B
51	.	O
1	Detailed	O
2	mutagenesis	O
3	of	O
4	the	O
5	element	O
6	'	O
7	s	O
8	rare	O
9	-	O
10	codon	O
11	/	O
12	AU	O
13	-	O
14	rich	O
15	sequence	O
16	boundary	O
17	revealed	O
18	that	O
19	the	O
20	destabilizing	O
21	activity	O
22	of	O
23	the	O
24	MATalpha1	B
25	IE	I
26	is	O
27	observed	O
28	when	O
29	the	O
30	terminal	O
31	codon	O
32	of	O
33	the	O
34	element	O
35	'	O
36	s	O
37	rare	O
38	-	O
39	codon	O
40	interval	O
41	is	O
42	translated	O
43	.	O
1	The	O
2	incidence	O
3	of	O
4	cardiac	O
5	death	O
6	(	O
7	one	O
8	per	O
9	group	O
10	),	O
11	Q	O
12	wave	O
13	MI	O
14	(	O
15	propofol	O
16	,	O
17	n	O
18	=	O
19	7	O
20	;	O
21	midazolam	O
22	,	O
23	n	O
24	=	O
25	3	O
26	;	O
27	P	O
28	=	O
29	0	O
30	.	O
31	27	O
32	),	O
33	or	O
34	non	O
35	Q	O
36	wave	O
37	MI	O
38	(	O
39	propofol	O
40	,	O
41	n	O
42	=	O
43	16	O
44	;	O
45	midazolam	O
46	,	O
47	n	O
48	=	O
49	18	O
50	;	O
51	P	O
52	=	O
53	0	O
54	.	O
55	81	O
56	)	O
57	did	O
58	not	O
59	differ	O
60	between	O
61	treatment	O
62	groups	O
63	.	O
1	Cluster	O
2	formation	O
3	of	O
4	E	B
5	-	I
6	cadherin	I
7	on	O
8	the	O
9	cell	O
10	surface	O
11	is	O
12	believed	O
13	to	O
14	be	O
15	of	O
16	major	O
17	importance	O
18	for	O
19	cell	O
20	-	O
21	cell	O
22	adhesion	O
23	.	O
1	The	O
2	factor	O
3	structure	O
4	of	O
5	""""	O
6	schizotypal	O
7	'	O
8	traits	O
9	:	O
10	a	O
11	large	O
12	replication	O
13	study	O
14	.	O
1	Outcome	O
2	of	O
3	severe	O
4	congenital	O
5	hypothyroidism	O
6	.	O
1	Mean	O
2	increase	O
3	of	O
4	milk	O
5	protein	O
6	yield	O
7	was	O
8	46	O
9	g	O
10	/	O
11	d	O
12	with	O
13	Met	O
14	plus	O
15	Lys	O
16	,	O
17	and	O
18	mean	O
19	increase	O
20	of	O
21	true	O
22	protein	O
23	content	O
24	was	O
25	1	O
26	.	O
27	1	O
28	g	O
29	/	O
30	kg	O
31	of	O
32	milk	O
33	.	O
1	The	O
2	mean	O
3	values	O
4	of	O
5	protease	O
6	activity	O
7	were	O
8	significantly	O
9	higher	O
10	in	O
11	the	O
12	test	O
13	groups	O
14	than	O
15	in	O
16	the	O
17	control	O
18	group	O
19	at	O
20	baseline	O
21	.	O
1	A	O
2	phylogenetic	O
3	tree	O
4	of	O
5	members	O
6	of	O
7	the	O
8	T2	B
9	/	I
10	S	I
11	-	I
12	RNase	I
13	superfamily	I
14	in	O
15	plants	O
16	was	O
17	obtained	O
18	.	O
1	Collectively	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	components	O
8	of	O
9	the	O
10	protein	B
11	kinase	I
12	A	I
13	signaling	O
14	pathway	O
15	are	O
16	recruited	O
17	by	O
18	mIg	B
19	to	O
20	induce	O
21	junB	B
22	transcription	O
23	.	O
1	One	O
2	complex	O
3	containing	O
4	a	O
5	70	O
6	D	O
7	protein	O
8	was	O
9	found	O
10	to	O
11	be	O
12	associated	O
13	specifically	O
14	with	O
15	transcriptionally	O
16	active	O
17	leukemia	O
18	cells	O
19	.	O
1	However	O
2	,	O
3	D8	B
4	binding	O
5	was	O
6	observed	O
7	by	O
8	nuclease	O
9	protection	O
10	with	O
11	lactotroph	B
12	-	I
13	as	I
14	well	I
15	as	I
16	somatotroph	I
17	-	I
18	like	I
19	cell	I
20	nuclear	I
21	protein	I
22	.	O
1	The	O
2	Pro	O
3	-	O
4	258	O
5	-->	O
6	Leu	O
7	(	O
8	P258L	O
9	)	O
10	mutation	O
11	caused	O
12	constitutive	O
13	receptor	O
14	signaling	O
15	that	O
16	was	O
17	equivalent	O
18	to	O
19	about	O
20	45	O
21	%	O
22	of	O
23	the	O
24	maximum	O
25	level	O
26	observed	O
27	in	O
28	wild	O
29	-	O
30	type	O
31	cells	O
32	stimulated	O
33	with	O
34	alpha	B
35	-	I
36	factor	I
37	.	O
1	CONCLUSIONS	O
2	:	O
3	Our	O
4	findings	O
5	suggest	O
6	that	O
7	pre	O
8	-	O
9	treatment	O
10	with	O
11	coenzyme	O
12	Q10	O
13	may	O
14	play	O
15	a	O
16	protective	O
17	role	O
18	during	O
19	routine	O
20	vascular	O
21	procedures	O
22	requiring	O
23	abdominal	O
24	aortic	O
25	cross	O
26	clamping	O
27	by	O
28	attenuating	O
29	the	O
30	degree	O
31	of	O
32	peroxidative	O
33	damage	O
34	.	O
1	The	O
2	mechanism	O
3	involves	O
4	Gbetagamma	B
5	subunit	O
6	-	O
7	mediated	O
8	increases	O
9	in	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	the	O
14	Shc	B
15	adapter	I
16	protein	I
17	,	O
18	Shc	B
19	*	O
20	Grb2	B
21	complex	O
22	formation	O
23	,	O
24	and	O
25	recruitment	O
26	of	O
27	Ras	B
28	guanine	I
29	nucleotide	I
30	exchange	I
31	factor	I
32	activity	O
33	.	O
1	The	O
2	small	B
3	GTPase	I
4	Rho	I
5	is	O
6	implicated	O
7	in	O
8	physiological	O
9	functions	O
10	associated	O
11	with	O
12	actin	B
13	-	O
14	myosin	B
15	filaments	O
16	such	O
17	as	O
18	cytokinesis	O
19	,	O
20	cell	O
21	motility	O
22	,	O
23	and	O
24	smooth	O
25	muscle	O
26	contraction	O
27	.	O
1	The	O
2	cis	O
3	-	O
4	acting	O
5	elements	O
6	that	O
7	control	O
8	promoter	O
9	activity	O
10	include	O
11	binding	O
12	sites	O
13	for	O
14	transcription	O
15	factors	O
16	Sp1	B
17	and	O
18	alphaCbf	B
19	,	O
20	a	O
21	60	B
22	-	I
23	kDa	I
24	CCAAT	I
25	box	I
26	-	I
27	binding	I
28	protein	I
29	.	O
1	RESULTS	O
2	:	O
3	The	O
4	LV	O
5	maximum	O
6	brightness	O
7	and	O
8	area	O
9	under	O
10	the	O
11	curve	O
12	showed	O
13	significant	O
14	negative	O
15	correlations	O
16	(	O
17	p	O
18	=	O
19	<	O
20	0	O
21	.	O
22	004	O
23	)	O
24	with	O
25	the	O
26	FIO2	O
27	,	O
28	while	O
29	the	O
30	minimum	O
31	brightness	O
32	showed	O
33	a	O
34	significant	O
35	positive	O
36	correlation	O
37	(	O
38	p	O
39	=	O
40	<	O
41	0	O
42	.	O
43	002	O
44	).	O
1	Homologous	O
2	recombination	O
3	between	O
4	the	O
5	Autographa	O
6	californica	O
7	nuclear	O
8	polyhedrosis	O
9	virus	O
10	(	O
11	AcNPV	O
12	)	O
13	genome	O
14	and	O
15	a	O
16	0	O
17	.	O
18	6	O
19	-	O
20	kbp	O
21	-	O
22	long	O
23	DNA	O
24	fragment	O
25	derived	O
26	from	O
27	the	O
28	putative	O
29	DNA	B
30	helicase	I
31	gene	I
32	of	I
33	Bombyx	I
34	mori	I
35	nuclear	I
36	polyhedrosis	I
37	virus	I
38	generates	O
39	eh2	O
40	-	O
41	AcNPV	O
42	,	O
43	an	O
44	expanded	O
45	-	O
46	host	O
47	-	O
48	range	O
49	AcNPV	O
50	mutant	O
51	(	O
52	S	O
53	.	O
1	Microcomputer	O
2	management	O
3	of	O
4	chronic	O
5	hepatitis	O
6	B	O
7	virus	O
8	asymptomatic	O
9	patients	O
1	While	O
2	fusion	O
3	to	O
4	the	O
5	N	O
6	-	O
7	terminus	O
8	required	O
9	a	O
10	linker	O
11	to	O
12	become	O
13	surface	O
14	accessible	O
15	,	O
16	both	O
17	fusion	O
18	to	O
19	the	O
20	N	O
21	-	O
22	terminus	O
23	and	O
24	to	O
25	the	O
26	C	O
27	-	O
28	terminus	O
29	was	O
30	compatible	O
31	with	O
32	particle	O
33	assembly	O
34	and	O
35	preserved	O
36	the	O
37	native	O
38	antigenicity	O
39	and	O
40	immunogenicity	O
41	of	O
42	HBcAg	B
43	.	O
1	U24	B
2	has	O
3	two	O
4	separate	O
5	12	O
6	nt	O
7	long	O
8	complementarities	O
9	to	O
10	a	O
11	highly	O
12	conserved	O
13	tract	O
14	of	O
15	28S	B
16	rRNA	I
17	.	O
1	Chromatin	O
2	repression	O
3	of	O
4	these	O
5	replacement	O
6	genes	O
7	would	O
8	be	O
9	avoided	O
10	,	O
11	consistent	O
12	with	O
13	the	O
14	high	O
15	,	O
16	constitutive	O
17	expression	O
18	of	O
19	replacement	O
20	H3	B
21	histone	I
22	genes	I
23	in	O
24	plants	O
25	.	O
1	However	O
2	,	O
3	as	O
4	determined	O
5	by	O
6	PCR	O
7	with	O
8	primers	O
9	specific	O
10	for	O
11	the	O
12	26	O
13	-	O
14	kDa	O
15	product	O
16	,	O
17	the	O
18	majority	O
19	of	O
20	cats	O
21	at	O
22	2	O
23	and	O
24	4	O
25	weeks	O
26	p	O
27	.	O
28	t	O
29	.	O
30	had	O
31	gastric	O
32	fluid	O
33	samples	O
34	which	O
35	were	O
36	positive	O
37	for	O
38	H	O
39	.	O
40	pylori	O
41	and	O
42	three	O
43	of	O
44	three	O
45	cats	O
46	at	O
47	2	O
48	weeks	O
49	p	O
50	.	O
51	t	O
52	.	O
53	had	O
54	dental	O
55	plaque	O
56	which	O
57	was	O
58	positive	O
59	for	O
60	H	O
61	.	O
62	pylori	O
63	.	O
1	Patients	O
2	who	O
3	have	O
4	undergone	O
5	thyroidectomy	O
6	for	O
7	thyroid	O
8	carcinoma	O
9	are	O
10	frequently	O
11	subjected	O
12	to	O
13	periods	O
14	of	O
15	induced	O
16	severe	O
17	hypothyroidism	O
18	in	O
19	preparation	O
20	for	O
21	131I	O
22	whole	O
23	body	O
24	scanning	O
25	and	O
26	measurement	O
27	of	O
28	serum	O
29	TG	B
30	.	O
1	Catha	O
2	edulis	O
3	,	O
4	a	O
5	plant	O
6	that	O
7	has	O
8	amphetamine	O
9	effects	O
10	.	O
1	In	O
2	3	O
3	treatments	O
4	the	O
5	diet	O
6	was	O
7	supplemented	O
8	with	O
9	0	O
10	,	O
11	100	O
12	and	O
13	150	O
14	mg	O
15	probiotic	O
16	/	O
17	kg	O
18	food	O
19	.	O
1	Protein	O
2	films	O
3	are	O
4	distinctly	O
5	different	O
6	in	O
7	mechanical	O
8	profiles	O
9	from	O
10	those	O
11	films	O
12	made	O
13	of	O
14	other	O
15	materials	O
16	.	O
1	AIMS	O
2	/	O
3	METHODS	O
4	:	O
5	Reticuloendothelial	O
6	system	O
7	function	O
8	,	O
9	as	O
10	assessed	O
11	by	O
12	clearance	O
13	of	O
14	radiolabelled	O
15	bacteria	O
16	,	O
17	was	O
18	evaluated	O
19	in	O
20	acute	O
21	liver	O
22	injury	O
23	induced	O
24	by	O
25	D	O
26	-	O
27	galactosamine	O
28	in	O
29	rats	O
30	,	O
31	and	O
32	compared	O
33	with	O
34	that	O
35	after	O
36	70	O
37	%	O
38	liver	O
39	resection	O
40	model	O
41	.	O
1	This	O
2	caused	O
3	severe	O
4	cortical	O
5	damage	O
6	and	O
7	neuronal	O
8	loss	O
9	in	O
10	hippocampus	O
11	subfields	O
12	CA1	O
13	,	O
14	CA3	O
15	,	O
16	and	O
17	hilus	O
18	.	O
1	Twelve	O
2	genomic	O
3	fragments	O
4	containing	O
5	novel	O
6	response	O
7	elements	O
8	are	O
9	described	O
10	,	O
11	and	O
12	the	O
13	transcription	O
14	unit	O
15	associated	O
16	with	O
17	one	O
18	of	O
19	them	O
20	,	O
21	NN	B
22	-	I
23	84AG	I
24	,	O
25	was	O
26	characterized	O
27	in	O
28	detail	O
29	.	O
1	Moreover	O
2	,	O
3	glucan	B
4	synthase	I
5	activity	O
6	,	O
7	which	O
8	is	O
9	activated	O
10	by	O
11	Rho1p	B
12	,	O
13	was	O
14	significantly	O
15	reduced	O
16	in	O
17	the	O
18	deltabem4	B
19	mutant	I
20	.	O
1	Thus	O
2	,	O
3	the	O
4	characterization	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	should	O
10	help	O
11	to	O
12	define	O
13	regulatory	O
14	elements	O
15	that	O
16	control	O
17	neuron	O
18	-	O
19	specific	O
20	and	O
21	developmental	O
22	expression	O
23	of	O
24	the	O
25	MAP1B	B
26	gene	I
27	.	O
1	Mutants	O
2	lacking	O
3	the	O
4	3	O
5	'	O
6	stem	O
7	-	O
8	loop	O
9	exhibited	O
10	a	O
11	75	O
12	%	O
13	reduction	O
14	in	O
15	the	O
16	level	O
17	of	O
18	psaB	B
19	mRNA	O
20	.	O
1	The	O
2	effect	O
3	of	O
4	ligustrazine	O
5	hydrochloride	O
6	(	O
7	LTH	O
8	)	O
9	on	O
10	depressing	O
11	pulmonary	O
12	artery	O
13	hypertension	O
14	has	O
15	been	O
16	proved	O
17	in	O
18	recent	O
19	studies	O
20	.	O
1	In	O
2	an	O
3	effort	O
4	to	O
5	isolate	O
6	genes	O
7	with	O
8	down	O
9	-	O
10	regulated	O
11	expression	O
12	at	O
13	the	O
14	mRNA	O
15	level	O
16	during	O
17	oncogenic	O
18	transformation	O
19	of	O
20	human	O
21	mammary	O
22	epithelial	O
23	cells	O
24	(	O
25	MECs	O
26	),	O
27	we	O
28	performed	O
29	subtractive	O
30	hybridization	O
31	between	O
32	normal	O
33	MEC	O
34	strain	O
35	76N	O
36	and	O
37	its	O
38	radiation	O
39	-	O
40	transformed	O
41	tumorigenic	O
42	derivative	O
43	76R	O
44	-	O
45	30	O
46	.	O
1	CASE	O
2	REPORT	O
3	:	O
4	Referred	O
5	because	O
6	of	O
7	a	O
8	right	O
9	corneal	O
10	perforation	O
11	with	O
12	cellular	O
13	reaction	O
14	in	O
15	anterior	O
16	chamber	O
17	,	O
18	a	O
19	patient	O
20	was	O
21	sutured	O
22	and	O
23	treated	O
24	with	O
25	a	O
26	single	O
27	intravitreal	O
28	injection	O
29	of	O
30	0	O
31	.	O
32	2	O
33	ml	O
34	(	O
35	1	O
36	mg	O
37	)	O
38	Amikacin	O
39	and	O
40	0	O
41	.	O
42	2	O
43	ml	O
44	(	O
45	1	O
46	mg	O
47	)	O
48	Vancomycin	O
49	.	O
1	The	O
2	human	B
3	MSH	I
4	-	I
5	2	I
6	gene	I
7	product	I
8	is	O
9	a	O
10	member	O
11	of	O
12	a	O
13	highly	O
14	conserved	O
15	family	O
16	of	O
17	proteins	O
18	which	O
19	are	O
20	involved	O
21	in	O
22	post	O
23	-	O
24	replication	O
25	mismatch	O
26	repair	O
27	.	O
28	hMSH	B
29	-	I
30	2	I
31	is	O
32	homologous	O
33	to	O
34	Escherichia	O
35	coli	O
36	(	O
37	E	O
38	.	O
39	coli	O
40	)	O
41	MutS	B
42	and	O
43	Sacchromyces	B
44	cerevisiae	I
45	MSH	I
46	-	I
47	1	I
48	and	O
49	MSH	B
50	-	I
51	2	I
52	proteins	I
53	,	O
54	which	O
55	recognise	O
56	heteroduplex	O
57	DNA	O
58	at	O
59	the	O
60	sites	O
61	of	O
62	all	O
63	single	O
64	base	O
65	mismatches	O
66	and	O
67	deletions	O
68	or	O
69	insertions	O
70	up	O
71	to	O
72	4	O
73	base	O
74	pairs	O
75	.	O
76	hMSH	B
77	-	I
78	2	I
79	is	O
80	one	O
81	of	O
82	the	O
83	hereditary	B
84	non	I
85	-	I
86	polyposis	I
87	colorectal	I
88	cancer	I
89	(	I
90	HNPCC	I
91	)	I
92	tumor	I
93	suppressor	I
94	genes	I
95	,	O
96	and	O
97	maps	O
98	to	O
99	human	O
100	chromosome	O
101	2p16	O
102	.	O
1	In	O
2	the	O
3	SPK	O
4	and	O
5	PTA	O
6	category	O
7	,	O
8	anti	O
9	-	O
10	T	O
11	-	O
12	cell	O
13	therapy	O
14	significantly	O
15	lowered	O
16	the	O
17	risk	O
18	of	O
19	graft	O
20	loss	O
21	.	O
1	The	O
2	partial	O
3	categories	O
4	of	O
5	the	O
6	SIP	O
7	that	O
8	were	O
9	more	O
10	affected	O
11	were	O
12	work	O
13	,	O
14	recreation	O
15	and	O
16	pastimes	O
17	,	O
18	home	O
19	management	O
20	,	O
21	and	O
22	sleep	O
23	and	O
24	rest	O
25	.	O
1	A	O
2	3	O
3	-	O
4	yr	O
5	retrospective	O
6	review	O
7	is	O
8	effective	O
9	and	O
10	detects	O
11	94	O
12	%	O
13	of	O
14	the	O
15	undercalls	O
16	.	O
1	Patients	O
2	with	O
3	low	O
4	probability	O
5	of	O
6	having	O
7	aluminum	O
8	overload	O
9	(	O
10	serum	O
11	iron	O
12	levels	O
13	<	O
14	40	O
15	micrograms	O
16	/	O
17	L	O
18	and	O
19	DAI	O
20	<	O
21	150	O
22	micrograms	O
23	/	O
24	L	O
25	)	O
26	had	O
27	significantly	O
28	higher	O
29	values	O
30	of	O
31	serum	O
32	iron	O
33	,	O
34	iron	O
35	transferrin	B
36	saturation	O
37	,	O
38	and	O
39	serum	B
40	ferritin	I
41	levels	O
42	compared	O
43	with	O
44	those	O
45	patients	O
46	with	O
47	a	O
48	high	O
49	probability	O
50	of	O
51	having	O
52	aluminum	O
53	overload	O
54	(	O
55	serum	O
56	aluminum	O
57	levels	O
58	>	O
59	40	O
60	micrograms	O
61	/	O
62	L	O
63	and	O
64	DAI	O
65	>	O
66	150	O
67	micrograms	O
68	/	O
69	L	O
70	).	O
1	A	O
2	subsequent	O
3	screen	O
4	for	O
5	the	O
6	loss	O
7	of	O
8	the	O
9	positively	O
10	selectable	O
11	target	O
12	locus	O
13	marker	O
14	detects	O
15	the	O
16	desired	O
17	replacement	O
18	at	O
19	modest	O
20	frequency	O
21	(>	O
22	2	O
23	%).	O
1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	another	O
6	cellular	O
7	protein	O
8	linked	O
9	to	O
10	BCR	B
11	/	O
12	ABL	B
13	through	O
14	the	O
15	CRKL	B
16	-	O
17	SH2	B
18	domain	O
19	is	O
20	p130	B
21	(	O
22	CAS	B
23	).	O
24	p130	B
25	(	O
26	CAS	B
27	)	O
28	was	O
29	found	O
30	to	O
31	be	O
32	tyrosine	O
33	phosphorylated	O
34	and	O
35	associated	O
36	with	O
37	CRKL	B
38	in	O
39	BCR	B
40	/	O
41	ABL	B
42	expressing	O
43	cell	O
44	lines	O
45	and	O
46	in	O
47	samples	O
48	obtained	O
49	from	O
50	CML	O
51	and	O
52	ALL	O
53	patients	O
54	,	O
55	but	O
56	not	O
57	in	O
58	samples	O
59	from	O
60	controls	O
61	.	O
1	There	O
2	are	O
3	four	O
4	polyglutamine	O
5	motifs	O
6	interspersed	O
7	with	O
8	histidine	O
9	-	O
10	rich	O
11	regions	O
12	.	O
1	The	O
2	effects	O
3	of	O
4	procedural	O
5	variations	O
6	on	O
7	lateralized	O
8	Stroop	O
9	effects	O
10	.	O
1	The	O
2	importance	O
3	of	O
4	temporal	O
5	factors	O
6	on	O
7	the	O
8	presence	O
9	and	O
10	severity	O
11	of	O
12	ethanol	O
13	withdrawal	O
14	signs	O
15	in	O
16	the	O
17	rat	O
18	was	O
19	quantified	O
20	using	O
21	rating	O
22	scale	O
23	,	O
24	tremor	O
25	,	O
26	and	O
27	acoustic	O
28	startle	O
29	paradigms	O
30	.	O
1	An	O
2	interaction	O
3	screen	O
4	with	O
5	the	O
6	repression	O
7	domain	O
8	of	O
9	the	O
10	orphan	B
11	receptor	I
12	RevErb	I
13	identified	O
14	N	B
15	-	I
16	CoR	I
17	,	O
18	the	O
19	corepressor	O
20	for	O
21	thyroid	B
22	hormone	I
23	receptor	I
24	(	O
25	TR	B
26	)	O
27	and	O
28	retinoic	B
29	acid	I
30	receptor	I
31	(	O
32	RAR	B
33	).	O
1	Almost	O
2	complete	O
3	sequence	O
4	identity	O
5	was	O
6	found	O
7	between	O
8	the	O
9	3	O
10	'	O
11	end	O
12	of	O
13	the	O
14	DXS6673E	B
15	gene	I
16	and	O
17	two	O
18	expressed	O
19	sequence	O
20	tags	O
21	(	O
22	ESTs	O
23	)	O
24	and	O
25	between	O
26	the	O
27	5	O
28	'	O
29	end	O
30	of	O
31	the	O
32	DXS6673E	B
33	gene	I
34	and	O
35	a	O
36	third	O
37	EST	O
38	.	O
1	The	O
2	limits	O
3	of	O
4	agreement	O
5	between	O
6	DBS	O
7	and	O
8	TOF	O
9	responses	O
10	were	O
11	so	O
12	wide	O
13	that	O
14	they	O
15	cannot	O
16	be	O
17	used	O
18	interchangeably	O
19	.	O
1	Despite	O
2	the	O
3	presence	O
4	of	O
5	one	O
6	additional	O
7	ribonucleotide	B
8	reductase	I
9	,	O
10	the	O
11	nrdAB	B
12	-	I
13	encoded	I
14	enzyme	I
15	is	O
16	essential	O
17	to	O
18	the	O
19	aerobic	O
20	growth	O
21	of	O
22	the	O
23	cell	O
24	because	O
25	nrdAB	B
26	-	I
27	defective	I
28	mutants	I
29	of	O
30	both	O
31	species	O
32	are	O
33	not	O
34	viable	O
35	in	O
36	the	O
37	presence	O
38	of	O
39	oxygen	O
40	.	O
1	The	O
2	fragments	O
3	are	O
4	separated	O
5	and	O
6	directly	O
7	sized	O
8	by	O
9	agarose	O
10	gel	O
11	electrophoresis	O
12	.	O
1	Several	O
2	of	O
3	the	O
4	exon	O
5	boundaries	O
6	correspond	O
7	to	O
8	the	O
9	boundaries	O
10	of	O
11	functional	O
12	domains	O
13	in	O
14	the	O
15	p55	B
16	protein	I
17	.	O
1	An	O
2	inverted	O
3	Alu	B
4	repeat	O
5	element	O
6	,	O
7	flanked	O
8	by	O
9	nonamer	O
10	direct	O
11	repeats	O
12	,	O
13	was	O
14	identified	O
15	within	O
16	the	O
17	region	O
18	-	O
19	913	O
20	/-	O
21	620	O
22	,	O
23	relative	O
24	to	O
25	the	O
26	cap	O
27	site	O
28	.	O
1	The	O
2	ewes	O
3	were	O
4	returned	O
5	to	O
6	normoxia	O
7	,	O
8	and	O
9	monitoring	O
10	was	O
11	continued	O
12	for	O
13	1	O
14	h	O
15	.	O
1	The	O
2	RPO1	B
3	of	O
4	LCDV	O
5	shows	O
6	the	O
7	highest	O
8	similarity	O
9	to	O
10	the	O
11	RPO1	B
12	of	O
13	IIV6	O
14	and	O
15	significant	O
16	lower	O
17	similarity	O
18	to	O
19	the	O
20	eukaryotic	B
21	polymerases	I
22	II	I
23	and	I
24	III	I
25	as	O
26	well	O
27	as	O
28	to	O
29	the	O
30	archaebacteral	O
31	subunit	O
32	.	O
1	Proximal	O
2	CBD	O
3	was	O
4	inversely	O
5	correlated	O
6	with	O
7	bone	B
8	alkaline	I
9	phosphatase	I
10	(	O
11	r	O
12	=	O
13	-	O
14	0	O
15	.	O
16	71	O
17	,	O
18	p	O
19	<	O
20	0	O
21	.	O
22	01	O
23	)	O
24	and	O
25	intact	O
26	PTH	B
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	59	O
34	,	O
35	p	O
36	<	O
37	0	O
38	.	O
39	05	O
40	).	O
1	Their	O
2	use	O
3	established	O
4	that	O
5	the	O
6	BrAAP	O
7	activity	O
8	catalyzed	O
9	both	O
10	a	O
11	postproline	O
12	and	O
13	a	O
14	postglutamate	O
15	cleavage	O
16	and	O
17	therefore	O
18	has	O
19	a	O
20	broader	O
21	specificity	O
22	than	O
23	previously	O
24	recognized	O
25	.	O
1	Constitutive	O
2	phosphorylation	O
3	of	O
4	the	O
5	CD30v	B
6	protein	I
7	was	O
8	demonstrated	O
9	by	O
10	in	O
11	vitro	O
12	labeling	O
13	with	O
14	[	O
15	32P	O
16	].	O
1	17	O
2	.	O
3	5	O
4	%	O
5	of	O
6	cycles	O
7	).	O
1	We	O
2	report	O
3	here	O
4	the	O
5	discovery	O
6	of	O
7	a	O
8	new	O
9	actin	B
10	-	I
11	related	I
12	gene	I
13	in	O
14	this	O
15	organism	O
16	,	O
17	which	O
18	we	O
19	have	O
20	named	O
21	ACT4	B
22	.	O
1	Here	O
2	we	O
3	localize	O
4	a	O
5	transferable	O
6	40	O
7	-	O
8	amino	O
9	acid	O
10	region	O
11	within	O
12	the	O
13	LBDs	B
14	of	O
15	RXR	B
16	,	O
17	RAR	B
18	,	O
19	TR	B
20	,	O
21	and	O
22	chicken	B
23	ovalbumin	I
24	upstream	I
25	promoter	I
26	transcription	I
27	factor	I
28	that	O
29	is	O
30	critical	O
31	for	O
32	determining	O
33	identity	O
34	in	O
35	the	O
36	heterodimeric	O
37	interaction	O
38	and	O
39	for	O
40	high	O
41	-	O
42	affinity	O
43	DNA	O
44	binding	O
45	.	O
1	In	O
2	the	O
3	absence	O
4	of	O
5	Swi4	B
6	and	O
7	Swi6	B
8	cell	O
9	viability	O
10	is	O
11	lost	O
12	,	O
13	but	O
14	can	O
15	be	O
16	regained	O
17	by	O
18	ectopic	O
19	expression	O
20	of	O
21	the	O
22	G1	B
23	cyclin	I
24	encoding	I
25	genes	I
26	,	O
27	CLN1	B
28	or	O
29	CLN2	B
30	.	O
1	The	O
2	detection	O
3	ratio	O
4	peaked	O
5	at	O
6	ages	O
7	30	O
8	to	O
9	34	O
10	and	O
11	decreased	O
12	heavily	O
13	during	O
14	the	O
15	next	O
16	15	O
17	years	O
18	of	O
19	age	O
20	.	O
1	Tonsillectomy	O
2	is	O
3	an	O
4	effective	O
5	means	O
6	of	O
7	prophylaxis	O
8	for	O
9	upper	O
10	respiratory	O
11	infection	O
12	in	O
13	habitual	O
14	angina	O
15	patients	O
16	.	O
1	This	O
2	paper	O
3	gives	O
4	an	O
5	overview	O
6	of	O
7	the	O
8	global	O
9	pattern	O
10	of	O
11	casualties	O
12	in	O
13	earthquakes	O
14	which	O
15	occurred	O
16	during	O
17	the	O
18	30	O
19	-	O
20	month	O
21	period	O
22	from	O
23	1	O
24	September	O
25	1993	O
26	to	O
27	29	O
28	February	O
29	1996	O
30	.	O
1	The	O
2	reconstituted	O
3	RNA	B
4	polymerases	I
5	containing	O
6	the	O
7	mutant	O
8	alpha	O
9	subunits	O
10	were	O
11	examined	O
12	for	O
13	their	O
14	response	O
15	to	O
16	transcription	O
17	activation	O
18	by	O
19	cAMP	B
20	-	I
21	CRP	I
22	and	O
23	the	O
24	rrnBP1	B
25	UP	I
26	element	I
27	.	O
1	Consistent	O
2	with	O
3	this	O
4	similarity	O
5	,	O
6	the	O
7	cdc28	B
8	-	O
9	P8	O
10	mutant	O
11	accumulates	O
12	unspliced	O
13	precursors	O
14	at	O
15	the	O
16	restrictive	O
17	temperature	O
18	.	O
1	Expression	O
2	of	O
3	thymidine	B
4	kinase	I
5	gene	I
6	in	O
7	normal	O
8	human	O
9	diploid	O
10	cells	O
11	is	O
12	both	O
13	cell	O
14	cycle	O
15	-	O
16	and	O
17	age	O
18	-	O
19	dependent	O
20	and	O
21	appears	O
22	to	O
23	be	O
24	transcriptionally	O
25	regulated	O
26	.	O
1	These	O
2	bacteria	O
3	produce	O
4	and	O
5	export	O
6	proteins	O
7	capable	O
8	of	O
9	specific	O
10	interactions	O
11	with	O
12	key	O
13	mammalian	O
14	cell	O
15	regulatory	O
16	molecules	O
17	in	O
18	order	O
19	to	O
20	derail	O
21	the	O
22	normal	O
23	functions	O
24	of	O
25	the	O
26	cells	O
27	.	O
1	Moreover	O
2	,	O
3	it	O
4	also	O
5	discusses	O
6	the	O
7	effects	O
8	of	O
9	antihypertensive	O
10	drugs	O
11	currently	O
12	regarded	O
13	as	O
14	first	O
15	-	O
16	choice	O
17	agents	O
18	,	O
19	i	O
20	.	O
21	e	O
22	.	O
23	calcium	O
24	antagonists	O
25	and	O
26	the	O
27	angiotensin	B
28	converting	I
29	enzyme	I
30	inhibitors	O
31	,	O
32	on	O
33	intrarenal	O
34	hemodynamics	O
35	.	O
1	It	O
2	is	O
3	suggested	O
4	that	O
5	the	O
6	observed	O
7	clinical	O
8	phenomena	O
9	in	O
10	response	O
11	to	O
12	morphine	O
13	can	O
14	be	O
15	explained	O
16	by	O
17	differences	O
18	in	O
19	expression	O
20	and	O
21	sensitivity	O
22	of	O
23	some	O
24	opioid	B
25	receptor	I
26	subtypes	O
27	in	O
28	migraine	O
29	.	O
1	The	O
2	model	O
3	also	O
4	predicts	O
5	that	O
6	blood	O
7	flow	O
8	shunt	O
9	fraction	O
10	(	O
11	Qs	O
12	/	O
13	QT	O
14	)	O
15	is	O
16	directly	O
17	related	O
18	to	O
19	the	O
20	oxygen	O
21	sine	O
22	-	O
23	wave	O
24	amplitude	O
25	perturbations	O
26	transmitted	O
27	to	O
28	end	O
29	-	O
30	expired	O
31	air	O
32	and	O
33	arterial	O
34	and	O
35	mixed	O
36	-	O
37	venous	O
38	blood	O
39	through	O
40	two	O
41	simple	O
42	equations	O
43	.	O
1	An	O
2	InlC	B
3	deletion	I
4	mutant	I
5	shows	O
6	reduced	O
7	virulence	O
8	when	O
9	tested	O
10	in	O
11	an	O
12	intravenous	O
13	mouse	O
14	model	O
15	,	O
16	but	O
17	intracellular	O
18	replication	O
19	of	O
20	the	O
21	mutant	O
22	in	O
23	Caco	O
24	-	O
25	2	O
26	and	O
27	J774	O
28	cells	O
29	appears	O
30	to	O
31	be	O
32	comparable	O
33	with	O
34	that	O
35	of	O
36	the	O
37	wild	O
38	-	O
39	type	O
40	strain	O
41	.	O
1	Interferon	B
2	stimulated	I
3	gene	I
4	factor	I
5	3	I
6	(	O
7	ISGF3	B
8	)	O
9	is	O
10	a	O
11	trimeric	O
12	transcription	O
13	factor	O
14	activated	O
15	on	O
16	treatment	O
17	of	O
18	cells	O
19	with	O
20	interferon	B
21	-	I
22	alpha	I
23	and	I
24	beta	I
25	(	O
26	type	B
27	I	I
28	IFNs	I
29	).	O
1	Three	O
2	mutants	O
3	were	O
4	isolated	O
5	from	O
6	the	O
7	widely	O
8	used	O
9	strain	O
10	,	O
11	PAO1	O
12	.	O
1	This	O
2	technique	O
3	was	O
4	employed	O
5	in	O
6	12	O
7	patients	O
8	with	O
9	a	O
10	unicameral	O
11	bone	O
12	cyst	O
13	.	O
1	Enterococcus	O
2	faecium	O
3	strains	O
4	with	O
5	vanA	O
6	-	O
7	mediated	O
8	glycopeptide	O
9	resistance	O
10	were	O
11	isolated	O
12	by	O
13	enrichment	O
14	culture	O
15	from	O
16	the	O
17	intestines	O
18	and	O
19	feces	O
20	of	O
21	several	O
22	animal	O
23	species	O
24	,	O
25	mainly	O
26	horses	O
27	and	O
28	dogs	O
29	(	O
30	8	O
31	%	O
32	positive	O
33	),	O
34	chickens	O
35	(	O
36	7	O
37	%	O
38	positive	O
39	),	O
40	and	O
41	pigs	O
42	(	O
43	6	O
44	%	O
45	positive	O
46	).	O
1	To	O
2	address	O
3	the	O
4	biological	O
5	effect	O
6	of	O
7	specific	O
8	isoform	O
9	expression	O
10	,	O
11	NIH3T3	O
12	cells	O
13	were	O
14	transfected	O
15	with	O
16	a	O
17	eukaryotic	O
18	expression	O
19	vector	O
20	containing	O
21	cDNA	O
22	for	O
23	FGF8a	B
24	,	O
25	FGF8b	B
26	,	O
27	or	O
28	FGF8e	B
29	.	O
1	When	O
2	this	O
3	DNA	O
4	fragment	O
5	was	O
6	placed	O
7	upstream	O
8	of	O
9	the	O
10	chloramphenicol	B
11	acetyltransferase	I
12	(	O
13	CAT	B
14	)	O
15	reporter	O
16	gene	O
17	and	O
18	transfected	O
19	into	O
20	a	O
21	carp	O
22	CF	O
23	cell	O
24	line	O
25	,	O
26	it	O
27	could	O
28	drive	O
29	the	O
30	synthesis	O
31	of	O
32	CAT	B
33	enzyme	I
34	16	O
35	times	O
36	more	O
37	efficiently	O
38	than	O
39	the	O
40	promoterless	O
41	pCAT	B
42	-	I
43	Basic	I
44	.	O
1	Northern	O
2	analysis	O
3	of	O
4	the	O
5	3	B
6	.	I
7	1	I
8	-	I
9	kb	I
10	PWP2H	I
11	cDNA	I
12	revealed	O
13	that	O
14	a	O
15	3	O
16	.	O
17	3	O
18	-	O
19	kb	O
20	major	O
21	transcript	O
22	is	O
23	ubiquitously	O
24	expressed	O
25	in	O
26	human	O
27	adult	O
28	tissues	O
29	.	O
1	Spliced	O
2	exons	O
3	of	O
4	adenovirus	O
5	late	O
6	RNAs	O
7	colocalize	O
8	with	O
9	snRNP	O
10	in	O
11	a	O
12	specific	O
13	nuclear	O
14	domain	O
15	.	O
1	The	O
2	PAI	B
3	-	I
4	2	I
5	gene	I
6	is	O
7	one	O
8	of	O
9	the	O
10	most	O
11	TNF	B
12	-	I
13	responsive	I
14	genes	I
15	known	O
16	and	O
17	is	O
18	also	O
19	highly	O
20	induced	O
21	by	O
22	the	O
23	phorbol	O
24	ester	O
25	phorbol	O
26	12	O
27	-	O
28	myristate	O
29	13	O
30	-	O
31	acetate	O
32	(	O
33	PMA	O
34	)	O
35	and	O
36	the	O
37	phosphatase	O
38	inhibitor	O
39	,	O
40	okadaic	O
41	acid	O
42	,	O
43	in	O
44	both	O
45	HT	O
46	-	O
47	1080	O
48	fibrosarcoma	O
49	and	O
50	U	O
51	-	O
52	937	O
53	histiocytic	O
54	cells	O
55	.	O
1	Growth	O
2	factors	O
3	induce	O
4	the	O
5	expression	O
6	of	O
7	the	O
8	immediate	B
9	early	I
10	gene	I
11	products	I
12	MAP	I
13	kinase	I
14	phosphatase	I
15	-	I
16	1	I
17	(	O
18	MKP	B
19	-	I
20	1	I
21	),	O
22	c	B
23	-	I
24	Fos	I
25	and	O
26	c	B
27	-	I
28	Jun	I
29	.	O
1	In	O
2	spite	O
3	of	O
4	much	O
5	effort	O
6	,	O
7	no	O
8	one	O
9	has	O
10	succeeded	O
11	in	O
12	isolating	O
13	and	O
14	characterizing	O
15	the	O
16	enzyme	O
17	(	O
18	s	O
19	)	O
20	responsible	O
21	for	O
22	synthesis	O
23	of	O
24	cellulose	O
25	,	O
26	the	O
27	major	O
28	cell	O
29	wall	O
30	polymer	O
31	of	O
32	plants	O
33	.	O
1	Vascular	O
2	responses	O
3	to	O
4	reactive	O
5	hyperemia	O
6	(	O
7	with	O
8	flow	O
9	increase	O
10	leading	O
11	to	O
12	endothelium	O
13	-	O
14	dependent	O
15	dilation	O
16	)	O
17	and	O
18	to	O
19	sublingual	O
20	glyceryl	O
21	trinitrate	O
22	(	O
23	GTN	O
24	;	O
25	endothelium	O
26	-	O
27	independent	O
28	dilation	O
29	)	O
30	were	O
31	recorded	O
32	.	O
1	During	O
2	this	O
3	period	O
4	,	O
5	administration	O
6	of	O
7	additional	O
8	exogenous	B
9	PRL	I
10	did	O
11	not	O
12	stimulate	O
13	further	O
14	activation	O
15	(	O
16	binding	O
17	)	O
18	of	O
19	the	O
20	Stat	B
21	factors	I
22	.	O
1	The	O
2	majority	O
3	of	O
4	the	O
5	cases	O
6	with	O
7	0	O
8	-	O
9	I	O
10	or	O
11	0	O
12	-	O
13	III	O
14	components	O
15	were	O
16	sm	O
17	.	O
18	cancer	O
19	.	O
1	These	O
2	patients	O
3	appear	O
4	to	O
5	have	O
6	slightly	O
7	better	O
8	pulmonary	O
9	function	O
10	and	O
11	nutritional	O
12	status	O
13	;	O
14	yet	O
15	,	O
16	they	O
17	seem	O
18	to	O
19	have	O
20	a	O
21	higher	O
22	degree	O
23	of	O
24	health	O
25	care	O
26	utilization	O
27	.	O
1	This	O
2	observation	O
3	calls	O
4	for	O
5	careful	O
6	monitoring	O
7	of	O
8	calcium	O
9	and	O
10	alkaline	B
11	phosphatase	I
12	values	O
13	and	O
14	possible	O
15	adjustments	O
16	of	O
17	vitamin	O
18	D	O
19	intake	O
20	when	O
21	fortifiers	O
22	are	O
23	used	O
24	for	O
25	extended	O
26	periods	O
27	.	O
1	REM	O
2	sleep	O
3	deprivation	O
4	was	O
5	performed	O
6	using	O
7	the	O
8	platform	O
9	technique	O
10	.	O
1	We	O
2	analyzed	O
3	serial	O
4	biopsy	O
5	specimens	O
6	from	O
7	eight	O
8	patients	O
9	with	O
10	FL	O
11	for	O
12	secondary	O
13	alterations	O
14	of	O
15	the	O
16	rearranged	B
17	bcl	I
18	-	I
19	2	I
20	gene	I
21	in	O
22	the	O
23	breakpoint	O
24	and	O
25	open	O
26	reading	O
27	frame	O
28	(	O
29	ORF	O
30	)	O
31	regions	O
32	.	O
1	In	O
2	all	O
3	eight	O
4	cases	O
5	,	O
6	neither	O
7	FL	O
8	nor	O
9	DLL	O
10	cells	O
11	showed	O
12	alterations	O
13	of	O
14	bcl	B
15	-	I
16	2	I
17	gene	I
18	sequences	I
19	in	O
20	the	O
21	breakpoint	O
22	region	O
23	,	O
24	suggesting	O
25	high	O
26	conservation	O
27	of	O
28	the	O
29	bcl	B
30	-	I
31	2	I
32	gene	I
33	during	O
34	both	O
35	t	O
36	(	O
37	14	O
38	;	O
39	18	O
40	)	O
41	translocation	O
42	and	O
43	morphologic	O
44	transformation	O
45	of	O
46	the	O
47	FL	O
48	cells	O
49	.	O
1	Leukemia	B
2	-	I
3	inhibitory	I
4	factor	I
5	(	O
6	LIF	B
7	)	O
8	is	O
9	a	O
10	neuropoietin	B
11	able	O
12	to	O
13	regulate	O
14	the	O
15	differentiation	O
16	and	O
17	the	O
18	survival	O
19	of	O
20	many	O
21	cell	O
22	types	O
23	,	O
24	which	O
25	include	O
26	some	O
27	neuronal	O
28	populations	O
29	.	O
1	To	O
2	analyze	O
3	the	O
4	mechanism	O
5	of	O
6	fos	B
7	/	O
8	jun	B
9	activation	O
10	by	O
11	TCDD	O
12	we	O
13	have	O
14	used	O
15	electrophoretic	O
16	mobility	O
17	shift	O
18	and	O
19	transient	O
20	expression	O
21	assays	O
22	of	O
23	reporter	O
24	gene	O
25	constructs	O
26	containing	O
27	response	O
28	elements	O
29	for	O
30	12	O
31	-	O
32	O	O
33	-	O
34	tetradecanoyl	O
35	-	O
36	phorbol	O
37	-	O
38	13	O
39	-	O
40	acetate	O
41	(	O
42	TRE	O
43	),	O
44	serum	O
45	(	O
46	SRE	O
47	),	O
48	cAMP	O
49	(	O
50	CRE	O
51	),	O
52	and	O
53	aromatic	O
54	hydrocarbons	O
55	(	O
56	AhRE	O
57	)	O
58	from	O
59	the	O
60	fos	B
61	and	O
62	jun	B
63	genes	I
64	fused	O
65	to	O
66	the	O
67	firefly	B
68	luciferase	I
69	gene	I
70	under	O
71	the	O
72	control	O
73	of	O
74	the	O
75	SV40	B
76	minimal	I
77	promoter	I
78	.	O
1	The	O
2	optimal	O
3	sequence	O
4	for	O
5	interaction	O
6	with	O
7	mu	B
8	2	I
9	and	O
10	with	O
11	AP	B
12	-	I
13	2	I
14	has	O
15	tyrosine	O
16	as	O
17	an	O
18	anchor	O
19	and	O
20	prefers	O
21	arginine	O
22	at	O
23	position	O
24	Y	O
25	+	O
26	2	O
27	and	O
28	leucine	O
29	at	O
30	position	O
31	Y	O
32	+	O
33	3	O
34	.	O
1	Kss1	B
2	binds	O
3	specifically	O
4	to	O
5	a	O
6	GST	B
7	-	O
8	Dig1	B
9	fusion	O
10	in	O
11	the	O
12	absence	O
13	of	O
14	any	O
15	other	O
16	yeast	O
17	protein	O
18	.	O
1	Analysis	O
2	of	O
3	one	O
4	cDNA	O
5	revealed	O
6	an	O
7	unusual	O
8	splicing	O
9	event	O
10	involving	O
11	EZH1	B
12	and	O
13	a	O
14	tandemly	O
15	linked	O
16	gene	O
17	GPR2	B
18	and	O
19	suggests	O
20	a	O
21	potential	O
22	mechanism	O
23	for	O
24	modifying	O
25	the	O
26	EZH1	B
27	protein	I
28	in	O
29	the	O
30	conserved	O
31	C	O
32	-	O
33	terminal	O
34	domain	O
35	.	O
1	A	O
2	given	O
3	standard	O
4	input	O
5	function	O
6	and	O
7	a	O
8	given	O
9	value	O
10	of	O
11	distribution	O
12	volume	O
13	(	O
14	Vd	O
15	)	O
16	used	O
17	for	O
18	the	O
19	rCBF	O
20	measurement	O
21	of	O
22	this	O
23	method	O
24	were	O
25	calculated	O
26	from	O
27	the	O
28	dynamic	O
29	study	O
30	by	O
31	six	O
32	normal	O
33	volunteers	O
34	.	O
1	Growth	O
2	factor	O
3	allows	O
4	effective	O
5	dose	O
6	-	O
7	intensive	O
8	regimen	O
9	in	O
10	advanced	O
11	breast	O
12	cancer	O
13	patients	O
14	.	O
1	Recombinant	B
2	erythropoietin	I
3	(	O
4	r	B
5	-	I
6	HuEPO	I
7	)	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	anemia	O
13	in	O
14	multiple	O
15	myeloma	O
1	Rat	B
2	liver	I
3	catalase	I
4	is	O
5	sorted	O
6	to	O
7	peroxisomes	O
8	by	O
9	its	O
10	C	O
11	-	O
12	terminal	O
13	tripeptide	O
14	Ala	O
15	-	O
16	Asn	O
17	-	O
18	Leu	O
19	,	O
20	not	O
21	by	O
22	the	O
23	internal	O
24	Ser	O
25	-	O
26	Lys	O
27	-	O
28	Leu	O
29	motif	O
30	.	O
1	The	O
2	mobility	O
3	shift	O
4	assay	O
5	of	O
6	the	O
7	65	O
8	bp	O
9	(-	O
10	318	O
11	/	O
12	-	O
13	254	O
14	)	O
15	fragment	O
16	with	O
17	nuclear	O
18	extract	O
19	from	O
20	the	O
21	dark	O
22	-	O
23	adapted	O
24	sample	O
25	showed	O
26	an	O
27	additional	O
28	band	O
29	,	O
30	not	O
31	seen	O
32	with	O
33	the	O
34	light	O
35	-	O
36	grown	O
37	sample	O
38	.	O
1	Furthermore	O
2	,	O
3	co	O
4	-	O
5	expression	O
6	of	O
7	both	O
8	p46	B
9	and	O
10	p54	B
11	subunits	I
12	markedly	O
13	altered	O
14	the	O
15	subcellular	O
16	distribution	O
17	of	O
18	p46	B
19	;	O
20	co	O
21	-	O
22	expressed	O
23	p46	B
24	was	O
25	transported	O
26	into	O
27	the	O
28	nucleus	O
29	as	O
30	efficiently	O
31	as	O
32	p54	B
33	.	O
1	As	O
2	the	O
3	rate	O
4	of	O
5	protein	O
6	synthesis	O
7	decreases	O
8	during	O
9	late	O
10	embryogenesis	O
11	,	O
12	levels	O
13	of	O
14	SEC	B
15	-	I
16	1	I
17	and	O
18	its	O
19	cognate	O
20	mRNA	O
21	decline	O
22	precipitously	O
23	.	O
1	Recurrent	O
2	G	O
3	-	O
4	to	O
5	-	O
6	A	O
7	substitution	O
8	in	O
9	a	O
10	single	O
11	codon	O
12	of	O
13	SREBP	B
14	cleavage	I
15	-	I
16	activating	I
17	protein	I
18	causes	O
19	sterol	O
20	resistance	O
21	in	O
22	three	O
23	mutant	O
24	Chinese	O
25	hamster	O
26	ovary	O
27	cell	O
28	lines	O
29	.	O
1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	the	O
6	promoter	O
7	and	O
8	enhancer	O
9	regions	O
10	identified	O
11	here	O
12	are	O
13	essential	O
14	for	O
15	maintaining	O
16	the	O
17	efficient	O
18	promoter	O
19	activity	O
20	of	O
21	the	O
22	human	B
23	activin	I
24	betaA	I
25	subunit	I
26	gene	I
27	.	O
1	Recombinant	O
2	,	O
3	bacterially	O
4	expressed	O
5	PIP5KIalpha	B
6	possessed	O
7	PIP5K	B
8	activity	O
9	and	O
10	was	O
11	immunoreactive	O
12	with	O
13	erythroid	B
14	PIP5KI	I
15	antibodies	I
16	.	O
1	The	O
2	0	O
3	.	O
4	22	O
5	-	O
6	kb	O
7	NheI	B
8	/	O
9	BglII	B
10	promoter	O
11	exhibited	O
12	PMA	O
13	inducibility	O
14	in	O
15	myeloid	O
16	cells	O
17	and	O
18	contained	O
19	a	O
20	PMA	O
21	-	O
22	responsive	O
23	element	O
24	recognized	O
25	by	O
26	Sp1	B
27	and	O
28	EGR	B
29	-	I
30	1	I
31	transcription	I
32	factors	I
33	.	O
1	There	O
2	were	O
3	no	O
4	significant	O
5	differences	O
6	in	O
7	graft	O
8	survival	O
9	between	O
10	groups	O
11	with	O
12	early	O
13	graft	O
14	function	O
15	(	O
16	EGF	O
17	)	O
18	and	O
19	DGF	O
20	,	O
21	either	O
22	in	O
23	first	O
24	transplantations	O
25	or	O
26	retransplantations	O
27	.	O
1	Filter	O
2	and	O
3	cytocentrifuge	O
4	preparations	O
5	of	O
6	the	O
7	urine	O
8	were	O
9	studied	O
10	and	O
11	all	O
12	cases	O
13	displayed	O
14	numerous	O
15	scattered	O
16	aggregates	O
17	or	O
18	single	O
19	tumor	O
20	cells	O
21	in	O
22	an	O
23	inflammatory	O
24	background	O
25	.	O
1	The	O
2	promoter	O
3	segment	O
4	was	O
5	inactive	O
6	when	O
7	introduced	O
8	into	O
9	the	O
10	rat	O
11	glioma	O
12	cell	O
13	line	O
14	C6B4	O
15	,	O
16	the	O
17	rat	O
18	submandibular	O
19	cell	O
20	line	O
21	RSMT	O
22	-	O
23	A5	O
24	,	O
25	and	O
26	the	O
27	rat	O
28	pancreatic	O
29	beta	O
30	cell	O
31	line	O
32	RIN	O
33	-	O
34	5AH	O
35	,	O
36	all	O
37	of	O
38	which	O
39	do	O
40	not	O
41	express	O
42	the	O
43	endogenous	O
44	alpha2c	B
45	-	I
46	AR	I
47	gene	I
48	.	O
1	Upon	O
2	serum	O
3	withdrawal	O
4	at	O
5	the	O
6	permissive	O
7	temperature	O
8	,	O
9	p53	B
10	-	O
11	mediated	O
12	apoptosis	O
13	was	O
14	induced	O
15	in	O
16	50	O
17	to	O
18	60	O
19	%	O
20	of	O
21	the	O
22	cells	O
23	.	O
1	Complementary	O
2	DNAs	O
3	encompassing	O
4	the	O
5	coat	B
6	protein	I
7	coding	O
8	and	O
9	adjacent	O
10	regions	O
11	of	O
12	Agropyron	O
13	mosaic	O
14	virus	O
15	(	O
16	AgMV	O
17	)	O
18	and	O
19	Hordeum	O
20	mosaic	O
21	virus	O
22	(	O
23	HoMV	O
24	)	O
25	were	O
26	cloned	O
27	and	O
28	sequenced	O
29	.	O
1	In	O
2	some	O
3	cases	O
4	,	O
5	factor	O
6	-	O
7	induced	O
8	Rac	B
9	activation	O
10	results	O
11	in	O
12	Rho	B
13	activation	O
14	,	O
15	and	O
16	factor	O
17	-	O
18	induced	O
19	Cdc42	B
20	activation	O
21	leads	O
22	to	O
23	Rac	B
24	activation	O
25	,	O
26	as	O
27	determined	O
28	by	O
29	specific	O
30	morphological	O
31	changes	O
32	.	O
1	Liver	O
2	injuries	O
1	The	O
2	identification	O
3	of	O
4	the	O
5	hepatitis	O
6	C	O
7	virus	O
8	as	O
9	the	O
10	major	O
11	cause	O
12	of	O
13	liver	O
14	disease	O
15	both	O
16	in	O
17	dialysis	O
18	patients	O
19	and	O
20	in	O
21	transplant	O
22	patients	O
23	has	O
24	focused	O
25	attention	O
26	on	O
27	the	O
28	epidemiology	O
29	and	O
30	the	O
31	impact	O
32	of	O
33	continuing	O
34	infection	O
35	in	O
36	these	O
37	patient	O
38	groups	O
39	.	O
1	Finally	O
2	,	O
3	the	O
4	C	O
5	-	O
6	terminal	O
7	region	O
8	of	O
9	ENBP1	B
10	shows	O
11	strong	O
12	homology	O
13	to	O
14	a	O
15	protein	O
16	from	O
17	rat	O
18	that	O
19	is	O
20	specifically	O
21	expressed	O
22	in	O
23	testis	O
24	tissue	O
25	.	O
1	Further	O
2	,	O
3	the	O
4	PIP2	O
5	content	O
6	of	O
7	the	O
8	85	O
9	-	O
10	90	O
11	kDa	O
12	protein	O
13	appeared	O
14	to	O
15	decrease	O
16	with	O
17	CSF	B
18	-	I
19	1	I
20	treatment	O
21	.	O
1	Just	O
2	before	O
3	inserting	O
4	on	O
5	the	O
6	anterior	O
7	margin	O
8	and	O
9	apex	O
10	of	O
11	the	O
12	iliac	O
13	crest	O
14	it	O
15	widens	O
16	,	O
17	assuming	O
18	the	O
19	aspect	O
20	of	O
21	a	O
22	small	O
23	cone	O
24	.	O
1	The	O
2	promoter	O
3	region	O
4	(	O
5	P1	O
6	)	O
7	corresponding	O
8	to	O
9	the	O
10	main	O
11	group	O
12	of	O
13	transcription	O
14	initiation	O
15	sites	O
16	is	O
17	devoid	O
18	of	O
19	TATA	O
20	and	O
21	CAAT	O
22	boxes	O
23	but	O
24	has	O
25	putative	O
26	binding	O
27	sites	O
28	for	O
29	the	O
30	transcription	B
31	factor	I
32	SP1	I
33	and	O
34	is	O
35	embedded	O
36	in	O
37	a	O
38	large	O
39	G	O
40	+	O
41	C	O
42	-	O
43	rich	O
44	domain	O
45	of	O
46	a	O
47	CpG	O
48	island	O
49	,	O
50	features	O
51	shared	O
52	by	O
53	the	O
54	promoters	O
55	of	O
56	constitutively	O
57	expressed	O
58	housekeeping	O
59	genes	O
60	.	O
1	The	O
2	STAT	B
3	-	I
4	1	I
5	signaling	O
6	pathway	O
7	provides	O
8	at	O
9	least	O
10	one	O
11	mechanism	O
12	for	O
13	activation	O
14	of	O
15	the	O
16	CAEV	B
17	LTR	I
18	by	O
19	IFN	B
20	-	I
21	gamma	I
22	in	O
23	monocytes	O
24	.	O
1	INTERVENTION	O
2	(	O
3	S	O
4	):	O
5	Twenty	O
6	-	O
7	six	O
8	hemostasis	O
9	parameters	O
10	evaluated	O
11	repeatedly	O
12	in	O
13	patients	O
14	undergoing	O
15	IVF	O
16	-	O
17	ET	O
18	.	O
1	Although	O
2	p48	B
3	gene	I
4	induction	O
5	is	O
6	dependent	O
7	on	O
8	STAT1	B
9	and	O
10	JAK1	B
11	,	O
12	activated	O
13	STAT1	B
14	does	O
15	not	O
16	bind	O
17	to	O
18	GATE	B
19	.	O
1	Finally	O
2	,	O
3	nonphotosynthetic	O
4	mutants	O
5	,	O
6	including	O
7	the	O
8	tscA	B
9	-	I
10	lacking	I
11	photosystem	I
12	I	I
13	mutant	I
14	,	O
15	H13	O
16	,	O
17	did	O
18	not	O
19	show	O
20	evidence	O
21	of	O
22	light	O
23	-	O
24	stimulated	O
25	RNA	O
26	processing	O
27	.	O
1	Specific	O
2	IgG	B
3	,	O
4	specific	O
5	IgE	B
6	and	O
7	total	O
8	IgE	B
9	immunoglobulins	I
10	against	O
11	Toxocara	B
12	canis	I
13	excretory	I
14	/	I
15	secretory	I
16	antigens	I
17	(	O
18	TES	B
19	)	O
20	were	O
21	detected	O
22	by	O
23	using	O
24	ELISA	O
25	technique	O
26	.	O
1	SUMMARY	O
2	BACKGROUND	O
3	DATA	O
4	:	O
5	Melanoma	O
6	care	O
7	has	O
8	not	O
9	changed	O
10	significantly	O
11	in	O
12	the	O
13	last	O
14	20	O
15	years	O
16	,	O
17	and	O
18	the	O
19	controversy	O
20	of	O
21	elective	O
22	lymph	O
23	node	O
24	dissections	O
25	in	O
26	this	O
27	disease	O
28	continues	O
29	to	O
30	be	O
31	discussed	O
32	.	O
1	Prevalence	O
2	of	O
3	sleep	O
4	-	O
5	disordered	O
6	breathing	O
7	(	O
8	SDB	O
9	)	O
10	is	O
11	reported	O
12	to	O
13	increase	O
14	in	O
15	menopausal	O
16	women	O
17	.	O
1	The	O
2	ubiquitously	O
3	expressed	O
4	E12	B
5	bHLH	I
6	protein	I
7	dimerizes	O
8	with	O
9	numerous	O
10	cell	O
11	-	O
12	specific	O
13	bHLH	B
14	factors	I
15	.	O
1	This	O
2	report	O
3	presents	O
4	the	O
5	isolation	O
6	and	O
7	characterization	O
8	of	O
9	the	O
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	(	O
15	1	O
16	.	O
17	2	O
18	kb	O
19	)	O
20	and	O
21	exon	O
22	1	O
23	of	O
24	the	O
25	human	B
26	RII	I
27	alpha	I
28	gene	I
29	.	O
1	A	O
2	cohort	O
3	of	O
4	Swedish	O
5	children	O
6	was	O
7	monitored	O
8	from	O
9	6	O
10	months	O
11	to	O
12	11	O
13	years	O
14	of	O
15	age	O
16	.	O
1	No	O
2	correlation	O
3	between	O
4	the	O
5	age	O
6	of	O
7	the	O
8	horses	O
9	and	O
10	the	O
11	antibody	O
12	level	O
13	could	O
14	be	O
15	found	O
16	.	O
1	To	O
2	characterize	O
3	the	O
4	gene	O
5	products	O
6	,	O
7	the	O
8	cvaA	B
9	gene	I
10	was	O
11	subcloned	O
12	and	O
13	expressed	O
14	under	O
15	the	O
16	control	O
17	of	O
18	T7	B
19	RNA	I
20	polymerase	I
21	promoter	I
22	.	O
1	To	O
2	investigate	O
3	the	O
4	mechanisms	O
5	involved	O
6	in	O
7	the	O
8	transcriptional	O
9	control	O
10	of	O
11	retinoid	B
12	X	I
13	receptor	I
14	(	O
15	RXR	B
16	)	O
17	gene	O
18	expression	O
19	,	O
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	region	O
25	of	O
26	the	O
27	human	B
28	RXRgamma2	I
29	isoform	I
30	was	O
31	characterized	O
32	.	O
1	JNK	B
2	and	O
3	p38	B
4	are	O
5	constitutively	O
6	present	O
7	in	O
8	the	O
9	nucleus	O
10	,	O
11	and	O
12	DNA	O
13	-	O
14	bound	O
15	c	B
16	-	I
17	JUN	I
18	and	O
19	ATF	B
20	-	I
21	2	I
22	are	O
23	stably	O
24	contacted	O
25	by	O
26	JNK	B
27	and	O
28	p38	B
29	,	O
30	respectively	O
31	.	O
1	The	O
2	effects	O
3	of	O
4	dominant	O
5	interfering	O
6	forms	O
7	of	O
8	the	O
9	JNK	B
10	/	O
11	p38	B
12	signaling	O
13	pathway	O
14	demonstrate	O
15	that	O
16	activation	O
17	of	O
18	these	O
19	kinases	O
20	is	O
21	critical	O
22	for	O
23	cytokine	O
24	-	O
25	induced	O
26	E	B
27	-	I
28	selectin	I
29	gene	I
30	expression	O
31	.	O
1	Identification	O
2	of	O
3	the	O
4	region	O
5	in	O
6	actin	B
7	-	I
8	binding	I
9	protein	I
10	that	O
11	binds	O
12	to	O
13	the	O
14	cytoplasmic	O
15	domain	O
16	of	O
17	glycoprotein	B
18	IBalpha	I
19	.	O
1	Remarkably	O
2	,	O
3	both	O
4	TTD	O
5	-	O
6	A	O
7	and	O
8	XP	O
9	-	O
10	D	O
11	defects	O
12	are	O
13	associated	O
14	with	O
15	subunits	O
16	of	O
17	TFIIH	B
18	,	O
19	a	O
20	basal	O
21	transcription	O
22	factor	O
23	with	O
24	a	O
25	second	O
26	function	O
27	in	O
28	DNA	O
29	repair	O
30	.	O
1	Phylogenetic	O
2	analysis	O
3	gave	O
4	evidence	O
5	for	O
6	a	O
7	close	O
8	evolutionary	O
9	relationship	O
10	between	O
11	PhHV	O
12	-	O
13	1	O
14	and	O
15	members	O
16	of	O
17	the	O
18	Varicellovirus	O
19	genus	O
20	of	O
21	the	O
22	alpha	O
23	-	O
24	Herpesvirinae	O
25	and	O
26	canid	O
27	herpesvirus	O
28	in	O
29	particular	O
30	.	O
1	In	O
2	this	O
3	method	O
4	,	O
5	PLP	O
6	in	O
7	plasma	O
8	can	O
9	be	O
10	determined	O
11	with	O
12	high	O
13	sensitivity	O
14	using	O
15	derivatization	O
16	with	O
17	sodium	O
18	bisulfite	O
19	in	O
20	the	O
21	mobile	O
22	phase	O
23	.	O
1	The	O
2	dnaK	B
3	operon	I
4	of	I
5	Bacillus	I
6	subtilis	I
7	is	O
8	heptacistronic	O
9	.	O
1	In	O
2	the	O
3	electrophoresis	O
4	mobility	O
5	shift	O
6	assay	O
7	using	O
8	nuclear	O
9	extracts	O
10	of	O
11	the	O
12	myogenic	O
13	cells	O
14	,	O
15	MyoD	B
16	and	O
17	myogenin	B
18	bound	O
19	to	O
20	the	O
21	right	O
22	E	O
23	-	O
24	box	O
25	in	O
26	the	O
27	enhancer	O
28	region	O
29	of	O
30	the	O
31	MCK	B
32	gene	I
33	even	O
34	in	O
35	the	O
36	presence	O
37	of	O
38	BMP	B
39	-	I
40	2	I
41	.	O
1	A	O
2	heterologous	O
3	promoter	O
4	construct	O
5	containing	O
6	three	O
7	repeats	O
8	of	O
9	a	O
10	consensus	O
11	Sp1	B
12	site	I
13	,	O
14	cloned	O
15	upstream	O
16	of	O
17	a	O
18	single	O
19	copy	O
20	of	O
21	the	O
22	ZII	B
23	(	O
24	CREB	B
25	/	I
26	AP1	I
27	)	O
28	element	O
29	from	O
30	the	O
31	BZLF1	B
32	promoter	I
33	linked	O
34	to	O
35	the	O
36	beta	B
37	-	I
38	globin	I
39	TATA	O
40	box	O
41	,	O
42	exhibited	O
43	phorbol	O
44	ester	O
45	inducibility	O
46	.	O
1	Finally	O
2	,	O
3	antibody	O
4	binding	O
5	to	O
6	site	O
7	IIIa	O
8	on	O
9	the	O
10	hCG	B
11	-	I
12	ectodomain	I
13	complex	I
14	was	O
15	also	O
16	hindered	O
17	by	O
18	an	O
19	anti	O
20	-	O
21	peptide	O
22	mAb	O
23	directed	O
24	against	O
25	a	O
26	peptide	O
27	encoded	O
28	by	O
29	the	O
30	eighth	O
31	exon	O
32	(	O
33	pE	O
34	x	O
35	8	O
36	)	O
37	of	O
38	the	O
39	LHR	B
40	.	O
1	Human	B
2	granulocyte	I
3	-	I
4	macrophage	I
5	colony	I
6	-	I
7	stimulating	I
8	factor	I
9	(	O
10	hGM	B
11	-	I
12	CSF	I
13	)	O
14	activates	O
15	a	O
16	set	O
17	of	O
18	genes	O
19	such	O
20	as	O
21	c	B
22	-	I
23	fos	I
24	,	O
25	jun	B
26	,	O
27	myc	B
28	,	O
29	and	O
30	early	B
31	growth	I
32	response	I
33	gene	I
34	1	I
35	(	O
36	egr	B
37	-	I
38	1	I
39	).	O
1	Surprisingly	O
2	,	O
3	however	O
4	,	O
5	TCR	B
6	-	O
7	mediated	O
8	tyrosine	O
9	phosphorylation	O
10	of	O
11	phospholipase	B
12	C	I
13	gamma	I
14	1	I
15	remains	O
16	intact	O
17	in	O
18	the	O
19	Jurkat	O
20	cells	O
21	expressing	O
22	the	O
23	A2	B
24	/	O
25	HCP	B
26	chimera	O
27	.	O
1	The	O
2	14	B
3	.	I
4	1	I
5	(	I
6	IGLL1	I
7	)	I
8	gene	I
9	is	O
10	expressed	O
11	in	O
12	a	O
13	lineage	O
14	-	O
15	and	O
16	stage	O
17	-	O
18	restricted	O
19	manner	O
20	.	O
1	The	O
2	interferon	B
3	(	O
4	IFN	B
5	)-	O
6	induced	O
7	double	B
8	-	I
9	stranded	I
10	RNA	I
11	(	I
12	dsRNA	I
13	)-	I
14	activated	I
15	Ser	I
16	/	I
17	Thr	I
18	protein	I
19	kinase	I
20	(	O
21	PKR	B
22	)	O
23	plays	O
24	a	O
25	role	O
26	in	O
27	the	O
28	antiviral	O
29	and	O
30	antiproliferative	O
31	effects	O
32	of	O
33	IFN	B
34	.	O
1	This	O
2	0	O
3	.	O
4	74	O
5	kb	O
6	cDNA	O
7	contains	O
8	an	O
9	open	O
10	reading	O
11	frame	O
12	(	O
13	ORF	O
14	)	O
15	of	O
16	477	O
17	bp	O
18	encoding	O
19	a	O
20	polypeptide	O
21	of	O
22	159	O
23	amino	O
24	acids	O
25	(	O
26	aa	O
27	)	O
28	which	O
29	differs	O
30	at	O
31	only	O
32	one	O
33	position	O
34	(	O
35	position	O
36	65	O
37	)	O
38	from	O
39	the	O
40	human	B
41	U1	I
42	-	I
43	C	I
44	protein	I
45	.	O
1	Studies	O
2	using	O
3	HLA	B
4	-	I
5	DR	I
6	-	O
7	B7	B
8	-	I
9	1	I
10	-	O
11	LFA	B
12	-	I
13	3	I
14	triple	O
15	transfectants	O
16	showed	O
17	that	O
18	the	O
19	LFA	B
20	-	I
21	3	I
22	-	O
23	induced	O
24	NF	B
25	-	I
26	AT	I
27	DNA	O
28	binding	O
29	activity	O
30	was	O
31	negatively	O
32	regulated	O
33	by	O
34	B7	B
35	-	I
36	1	I
37	costimulation	O
38	.	O
1	Identification	O
2	of	O
3	a	O
4	promoter	O
5	-	O
6	specific	O
7	transactivation	O
8	domain	O
9	in	O
10	the	O
11	herpes	B
12	simplex	I
13	virus	I
14	regulatory	I
15	protein	I
16	ICP4	I
17	.	O
1	The	O
2	workup	O
3	included	O
4	skin	O
5	tests	O
6	(	O
7	up	O
8	to	O
9	1	O
10	microgram	O
11	/	O
12	ml	O
13	,	O
14	Pharmacia	O
15	),	O
16	measurement	O
17	of	O
18	specific	O
19	serum	O
20	IgE	B
21	with	O
22	RAST	O
23	-	O
24	CAP	O
25	(	O
26	Pharmacia	O
27	),	O
28	and	O
29	CAST	O
30	with	O
31	three	O
32	concentrations	O
33	of	O
34	bee	O
35	(	O
36	Apis	O
37	mellifera	O
38	)	O
39	and	O
40	wasp	O
41	(	O
42	Vespula	O
43	spec	O
44	.)	O
45	venom	O
46	(	O
47	Aquagen	O
48	ALK	O
49	).	O
1	A	O
2	MEK	B
3	-	O
4	specific	O
5	inhibitor	O
6	(	O
7	PD098059	O
8	)	O
9	(	O
10	Dudley	O
11	,	O
12	D	O
13	.	O
1	The	O
2	alternative	O
3	sigma	B
4	factor	I
5	sigmaB	I
6	in	I
7	Staphylococcus	I
8	aureus	I
9	:	O
10	regulation	O
11	of	O
12	the	O
13	sigB	B
14	operon	I
15	in	O
16	response	O
17	to	O
18	growth	O
19	phase	O
20	and	O
21	heat	O
22	shock	O
1	Marinol	O
2	/	O
3	marijuana	O
4	usage	O
5	was	O
6	associated	O
7	with	O
8	depressed	O
9	CD4	B
10	+	I
11	counts	O
12	and	O
13	elevated	O
14	amylase	B
15	levels	O
16	within	O
17	the	O
18	DDI	O
19	subgroup	O
20	.	O
1	Unlike	O
2	class	O
3	II	O
4	-	O
5	and	O
6	III	O
7	-	O
8	specific	O
9	TBP	B
10	-	O
11	TAF	B
12	complexes	O
13	,	O
14	the	O
15	corresponding	O
16	murine	O
17	and	O
18	human	O
19	class	O
20	I	O
21	-	O
22	specific	O
23	transcription	O
24	initiation	O
25	factor	O
26	TIF	B
27	-	I
28	IB	I
29	/	O
30	SL1	B
31	exhibits	O
32	a	O
33	pronounced	O
34	selectivity	O
35	for	O
36	its	O
37	homologous	O
38	promoter	O
39	.	O
1	Cytohesin	B
2	-	I
3	1	I
4	,	O
5	a	O
6	protein	O
7	abundant	O
8	in	O
9	cells	O
10	of	O
11	the	O
12	immune	O
13	system	O
14	,	O
15	has	O
16	been	O
17	proposed	O
18	to	O
19	be	O
20	a	O
21	human	O
22	homolog	O
23	of	O
24	the	O
25	Saccharomyces	B
26	cerevisiae	I
27	Sec7	I
28	gene	I
29	product	I
30	,	O
31	which	O
32	is	O
33	crucial	O
34	in	O
35	protein	O
36	transport	O
37	.	O
1	Tissue	O
2	samples	O
3	were	O
4	obtained	O
5	either	O
6	from	O
7	rats	O
8	that	O
9	had	O
10	been	O
11	exposed	O
12	to	O
13	opiate	O
14	withdrawal	O
15	following	O
16	a	O
17	seven	O
18	day	O
19	morphine	O
20	infusion	O
21	or	O
22	sham	O
23	treated	O
24	control	O
25	subjects	O
26	.	O
1	Therefore	O
2	,	O
3	the	O
4	impaired	O
5	floor	O
6	plate	O
7	development	O
8	in	O
9	oep	B
10	mutants	I
11	is	O
12	not	O
13	caused	O
14	by	O
15	the	O
16	absence	O
17	of	O
18	the	O
19	floor	B
20	plate	I
21	inducer	I
22	shh	I
23	.	O
1	CONCLUSION	O
2	:	O
3	Chronic	O
4	administration	O
5	of	O
6	misoprostol	O
7	may	O
8	have	O
9	caused	O
10	a	O
11	negative	O
12	natriuretic	O
13	effect	O
14	in	O
15	cirrhotic	O
16	patients	O
17	with	O
18	ascites	O
19	.	O
1	99mTc	O
2	-	O
3	HMPAO	O
4	was	O
5	distributed	O
6	in	O
7	the	O
8	territories	O
9	of	O
10	the	O
11	ACA	O
12	and	O
13	MCA	O
14	in	O
15	the	O
16	two	O
17	patients	O
18	who	O
19	were	O
20	treated	O
21	with	O
22	intraarterial	O
23	infusion	O
24	of	O
25	papaverine	O
26	from	O
27	the	O
28	C4	O
29	segment	O
30	,	O
31	but	O
32	was	O
33	distributed	O
34	only	O
35	to	O
36	the	O
37	territory	O
38	of	O
39	the	O
40	ACA	O
41	in	O
42	four	O
43	patients	O
44	who	O
45	were	O
46	treated	O
47	with	O
48	intraarterial	O
49	infusion	O
50	of	O
51	papaverine	O
52	from	O
53	the	O
54	C1	O
55	segment	O
56	at	O
57	1	O
58	ml	O
59	/	O
60	min	O
61	.	O
1	99Tcm	O
2	-	O
3	DMP	O
4	-	O
5	HSA	O
6	showed	O
7	an	O
8	almost	O
9	identical	O
10	behaviour	O
11	to	O
12	in	O
13	vitro	O
14	labelled	O
15	red	O
16	blood	O
17	cells	O
18	(	O
19	RBCs	O
20	),	O
21	which	O
22	are	O
23	generally	O
24	considered	O
25	the	O
26	reference	O
27	standard	O
28	for	O
29	blood	O
30	pool	O
31	agents	O
32	.	O
1	We	O
2	have	O
3	thus	O
4	identified	O
5	the	O
6	first	O
7	mammalian	B
8	homolog	I
9	of	I
10	yeast	I
11	UPF1	I
12	,	O
13	a	O
14	protein	O
15	that	O
16	regulates	O
17	levels	O
18	of	O
19	nonsense	O
20	mRNA	O
21	,	O
22	and	O
23	we	O
24	tentatively	O
25	name	O
26	this	O
27	protein	O
28	human	B
29	HUPF1	I
30	(	O
31	for	O
32	human	B
33	homolog	I
34	of	I
35	UPF1	I
36	).	O
1	RESULTS	O
2	:	O
3	Nodular	O
4	opacities	O
5	,	O
6	mainly	O
7	centrilobular	O
8	in	O
9	distribution	O
10	,	O
11	were	O
12	the	O
13	most	O
14	common	O
15	finding	O
16	,	O
17	seen	O
18	in	O
19	21	O
20	(	O
21	72	O
22	%)	O
23	and	O
24	15	O
25	(	O
26	65	O
27	%)	O
28	of	O
29	patients	O
30	with	O
31	MTB	O
32	and	O
33	NTMB	O
34	,	O
35	respectively	O
36	.	O
1	The	O
2	human	B
3	CD38	I
4	gene	I
5	consists	O
6	of	O
7	8	O
8	exons	O
9	that	O
10	extend	O
11	more	O
12	than	O
13	77	O
14	kb	O
15	on	O
16	the	O
17	human	O
18	genome	O
19	.	O
1	Type	O
2	IV	O
3	splice	O
4	pattern	O
5	,	O
6	containing	O
7	exon	O
8	U3	O
9	and	O
10	S	O
11	was	O
12	found	O
13	both	O
14	in	O
15	kidney	O
16	and	O
17	ovary	O
18	.	O
1	The	O
2	reduced	O
3	NO	O
4	production	O
5	in	O
6	these	O
7	cells	O
8	was	O
9	associated	O
10	with	O
11	low	O
12	levels	O
13	of	O
14	mRNA	O
15	of	O
16	inducible	B
17	NO	I
18	synthetase	I
19	.	O
1	Grade	O
2	3	O
3	-	O
4	4	O
5	mucositis	O
6	was	O
7	present	O
8	in	O
9	13	O
10	%	O
11	of	O
12	the	O
13	cycles	O
14	.	O
1	Therefore	O
2	more	O
3	active	O
4	and	O
5	tolerable	O
6	salvage	O
7	regimens	O
8	are	O
9	needed	O
10	.	O
1	This	O
2	fragment	O
3	contained	O
4	the	O
5	C	O
6	-	O
7	terminal	O
8	47	O
9	nucleotides	O
10	of	O
11	leuB	B
12	,	O
13	encoding	O
14	3	B
15	-	I
16	isopropylmalate	I
17	dehydrogenase	I
18	;	O
19	asd	B
20	,	O
21	encoding	O
22	aspartate	B
23	-	I
24	beta	I
25	-	I
26	semialdehyde	I
27	dehydrogenase	I
28	(	O
29	Asd	B
30	);	O
31	and	O
32	orfA	O
33	,	O
34	whose	O
35	product	O
36	showed	O
37	similarity	O
38	to	O
39	the	O
40	Asd	B
41	proteins	I
42	from	I
43	Vibrio	I
44	spp	I
45	.	O
1	Hovenitin	O
2	I	O
3	and	O
4	(+)-	O
5	ampelopsin	O
6	,	O
7	both	O
8	of	O
9	which	O
10	were	O
11	principal	O
12	ingredients	O
13	of	O
14	the	O
15	active	O
16	fractions	O
17	from	O
18	this	O
19	natural	O
20	medicine	O
21	,	O
22	were	O
23	found	O
24	to	O
25	show	O
26	an	O
27	inhibitory	O
28	activity	O
29	on	O
30	the	O
31	ethanol	O
32	-	O
33	induced	O
34	muscle	O
35	relaxation	O
36	in	O
37	rats	O
38	.	O
1	Purified	B
2	P7	I
3	could	O
4	be	O
5	assembled	O
6	onto	O
7	particles	O
8	lacking	O
9	P7	B
10	and	O
11	particles	O
12	lacking	O
13	both	O
14	P2	B
15	(	O
16	RNA	B
17	polymerase	I
18	)	O
19	and	O
20	P7	B
21	.	O
1	Our	O
2	results	O
3	show	O
4	that	O
5	the	O
6	temperature	B
7	-	I
8	sensitive	I
9	rad54	I
10	-	I
11	3	I
12	allele	I
13	blocks	O
14	mitotic	O
15	recombination	O
16	between	O
17	tandemly	O
18	repeated	O
19	DYZ3	B
20	satellite	I
21	sequences	I
22	and	O
23	significantly	O
24	stabilizes	O
25	a	O
26	human	B
27	DYZ5	I
28	satellite	O
29	-	O
30	containing	O
31	YAC	O
32	clone	O
33	.	O
1	Candidate	O
2	tumor	O
3	suppressor	O
4	genes	O
5	,	O
6	Mts1	B
7	(	O
8	p16INK4a	B
9	)	O
10	and	O
11	Mts2	B
12	(	O
13	p15INK4b	B
14	),	O
15	have	O
16	been	O
17	mapped	O
18	to	O
19	this	O
20	region	O
21	,	O
22	but	O
23	by	O
24	Southern	O
25	blot	O
26	analysis	O
27	,	O
28	no	O
29	homozygous	O
30	deletions	O
31	were	O
32	detected	O
33	in	O
34	either	O
35	gene	O
36	.	O
1	Recently	O
2	,	O
3	we	O
4	have	O
5	reported	O
6	the	O
7	cloning	O
8	of	O
9	the	O
10	germ	O
11	cell	O
12	-	O
13	specific	O
14	,	O
15	nuclear	O
16	orphan	O
17	receptor	O
18	germ	B
19	cell	I
20	nuclear	I
21	factor	I
22	(	O
23	GCNF	B
24	)/	O
25	RTR	B
26	.	O
1	Based	O
2	on	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	conRTRE	B
8	,	O
9	we	O
10	located	O
11	a	O
12	putative	O
13	RTRE	B
14	,	O
15	referred	O
16	to	O
17	as	O
18	P2	B
19	-	I
20	RE	I
21	,	O
22	in	O
23	the	O
24	5	O
25	'	O
26	promoter	O
27	-	O
28	flanking	O
29	region	O
30	of	O
31	the	O
32	mouse	B
33	protamine	I
34	2	I
35	gene	I
36	,	O
37	which	O
38	is	O
39	induced	O
40	during	O
41	the	O
42	same	O
43	stage	O
44	of	O
45	spermatogenesis	O
46	as	O
47	RTR	B
48	.	O
1	Similarly	O
2	,	O
3	the	O
4	DNA	O
5	-	O
6	binding	O
7	activity	O
8	of	O
9	activator	B
10	protein	I
11	1	I
12	(	O
13	AP	B
14	-	I
15	1	I
16	)	O
17	is	O
18	modified	O
19	by	O
20	a	O
21	DNA	B
22	repair	I
23	enzyme	I
24	,	O
25	redox	B
26	factor	I
27	1	I
28	(	O
29	Ref	B
30	-	I
31	1	I
32	),	O
33	which	O
34	is	O
35	identical	O
36	to	O
37	a	O
38	DNA	B
39	repair	I
40	enzyme	I
41	,	O
42	AP	B
43	endonuclease	I
44	.	O
1	Cyclin	B
2	D1	I
3	could	O
4	not	O
5	be	O
6	displaced	O
7	from	O
8	cdk4	B
9	in	O
10	the	O
11	resistant	O
12	184A1L5R	O
13	cell	O
14	lysates	O
15	.	O
1	The	O
2	Rlm1	B
3	protein	I
4	,	O
5	a	O
6	member	O
7	of	O
8	the	O
9	MADS	B
10	box	I
11	family	I
12	of	O
13	transcription	O
14	factors	O
15	,	O
16	functions	O
17	downstream	O
18	of	O
19	Mpk1	B
20	in	O
21	the	O
22	pathway	O
23	.	O
1	In	O
2	particular	O
3	,	O
4	Western	O
5	,	O
6	supershift	O
7	,	O
8	and	O
9	promoter	O
10	deletion	O
11	analyses	O
12	suggested	O
13	a	O
14	role	O
15	for	O
16	CCAAT	B
17	/	I
18	enhancer	I
19	-	I
20	binding	I
21	protein	I
22	-	I
23	beta	I
24	(	O
25	C	B
26	/	I
27	EBP	I
28	-	I
29	beta	I
30	)	O
31	binding	O
32	site	O
33	between	O
34	-	O
35	2010	O
36	and	O
37	-	O
38	1954	O
39	in	O
40	regulating	O
41	transcription	O
42	of	O
43	collagenase	B
44	-	I
45	1	I
46	in	O
47	monocytic	O
48	cells	O
49	.	O
1	Thus	O
2	,	O
3	depending	O
4	on	O
5	their	O
6	location	O
7	,	O
8	psoralen	O
9	cross	O
10	-	O
11	links	O
12	affected	O
13	different	O
14	steps	O
15	in	O
16	the	O
17	initiation	O
18	process	O
19	.	O
1	Performance	O
2	on	O
3	two	O
4	verbal	O
5	measures	O
6	-	O
7	the	O
8	National	O
9	Adult	O
10	Reading	O
11	Test	O
12	-	O
13	Revised	O
14	(	O
15	NART	O
16	-	O
17	R	O
18	)	O
19	and	O
20	the	O
21	Vocabulary	O
22	subtest	O
23	from	O
24	the	O
25	Wechsler	O
26	Adult	O
27	Intelligence	O
28	Scale	O
29	-	O
30	Revised	O
31	(	O
32	WAIS	O
33	-	O
34	R	O
35	)-	O
36	showed	O
37	strong	O
38	correlations	O
39	with	O
40	level	O
41	of	O
42	education	O
43	.	O
1	The	O
2	different	O
3	holoenzyme	B
4	RNA	I
5	polymerases	I
6	generated	O
7	upon	O
8	reconstituting	O
9	these	O
10	mutants	O
11	independently	O
12	with	O
13	core	B
14	RNA	I
15	polymerase	I
16	(	O
17	alpha2beta	O
18	beta	O
19	')	O
20	have	O
21	shown	O
22	reduced	O
23	transcriptional	O
24	activity	O
25	in	O
26	comparison	O
27	to	O
28	the	O
29	enzyme	O
30	containing	O
31	wild	B
32	-	I
33	type	I
34	sigma	I
35	factor	I
36	.	O
1	A	O
2	role	O
3	for	O
4	the	O
5	small	B
6	GTPase	I
7	Rac	I
8	in	O
9	polyomavirus	B
10	middle	I
11	-	I
12	T	I
13	antigen	I
14	-	O
15	mediated	O
16	activation	O
17	of	O
18	the	O
19	serum	O
20	response	O
21	element	O
22	and	O
23	in	O
24	cell	O
25	transformation	O
26	.	O
1	Malonate	O
2	decarboxylation	O
3	in	O
4	Malonomonas	O
5	rubra	O
6	involves	O
7	the	O
8	formation	O
9	of	O
10	malonyl	B
11	-	I
12	S	I
13	-[	I
14	acyl	I
15	-	I
16	carrier	I
17	protein	I
18	]	I
19	from	O
20	acetyl	B
21	-	I
22	S	I
23	-[	I
24	acyl	I
25	-	I
26	carrier	I
27	protein	I
28	]	I
29	and	O
30	malonate	O
31	,	O
32	carboxyltransfer	O
33	to	O
34	a	O
35	biotin	B
36	protein	I
37	and	O
38	its	O
39	decarboxylation	O
40	that	O
41	is	O
42	coupled	O
43	to	O
44	delta	O
45	mu	O
46	Na	O
47	+	O
48	generation	O
49	.	O
1	Further	O
2	support	O
3	for	O
4	a	O
5	direct	O
6	interaction	O
7	of	O
8	Tub4p	B
9	,	O
10	Spc98p	B
11	and	O
12	Spc97p	B
13	comes	O
14	from	O
15	the	O
16	toxicity	O
17	of	O
18	strong	O
19	SPC97	B
20	overexpression	O
21	which	O
22	is	O
23	suppressed	O
24	by	O
25	co	O
26	-	O
27	overexpression	O
28	of	O
29	TUB4	B
30	or	O
31	SPC98	B
32	.	O
1	Comparison	O
2	of	O
3	the	O
4	p50	B
5	sequence	I
6	to	O
7	other	O
8	cloned	O
9	proteins	O
10	revealed	O
11	89	O
12	%	O
13	homology	O
14	with	O
15	a	O
16	glycosaminoglycan	O
17	-	O
18	binding	O
19	protein	O
20	and	O
21	54	O
22	%	O
23	homology	O
24	with	O
25	Drosophila	B
26	cell	I
27	cycle	I
28	control	I
29	protein	I
30	(	I
31	cdc	I
32	)	I
33	37	O
34	.	O
1	A	O
2	polypeptide	O
3	encoded	O
4	by	O
5	the	O
6	NTS	O
7	16	O
8	open	O
9	reading	O
10	frame	O
11	has	O
12	sequence	O
13	similarity	O
14	to	O
15	the	O
16	catalytic	O
17	domain	O
18	of	O
19	several	O
20	receptor	B
21	protein	I
22	kinases	I
23	from	I
24	plants	I
25	including	O
26	the	O
27	S	B
28	-	I
29	receptor	I
30	kinases	I
31	implicated	O
32	in	O
33	the	O
34	rejection	O
35	of	O
36	self	O
37	-	O
38	pollen	O
39	in	O
40	Brassica	O
41	species	O
42	and	O
43	the	O
44	Pto	B
45	gene	I
46	product	I
47	of	I
48	tomato	I
49	which	O
50	confers	O
51	resistance	O
52	to	O
53	a	O
54	bacterial	O
55	pathogen	O
56	.	O
1	We	O
2	report	O
3	here	O
4	that	O
5	constitutively	O
6	active	O
7	Mek1	B
8	could	O
9	activate	O
10	p96h2bk	B
11	in	O
12	the	O
13	absence	O
14	of	O
15	oncogenic	B
16	Ras	I
17	.	O
1	Glycemic	O
2	response	O
3	to	O
4	malted	O
5	,	O
6	popped	O
7	and	O
8	roller	O
9	dried	O
10	wheat	O
11	-	O
12	legume	O
13	based	O
14	foods	O
15	in	O
16	normal	O
17	subjects	O
18	.	O
1	The	O
2	results	O
3	indicate	O
4	that	O
5	DNA	O
6	methylation	O
7	,	O
8	chromatin	O
9	structure	O
10	,	O
11	and	O
12	transactivation	O
13	at	O
14	an	O
15	Sp1	B
16	site	I
17	contribute	O
18	to	O
19	the	O
20	highly	O
21	restricted	O
22	expression	O
23	of	O
24	this	O
25	myelomonocytic	O
26	lineage	O
27	specific	O
28	gene	O
29	.	O
1	Laboratory	O
2	exam	O
3	:	O
4	IDR	O
5	of	O
6	the	O
7	tuberculin	B
8	was	O
9	high	O
10	positive	O
11	,	O
12	chest	O
13	radiography	O
14	shows	O
15	hilar	O
16	bilateral	O
17	calcifications	O
18	,	O
19	ORL	O
20	exam	O
21	shows	O
22	a	O
23	tumor	O
24	at	O
25	the	O
26	foot	O
27	of	O
28	the	O
29	epiglottis	O
30	and	O
31	anatomopathological	O
32	exam	O
33	shows	O
34	low	O
35	differentiated	O
36	epidermoid	O
37	carcinoma	O
38	.	O
1	Sequence	O
2	analysis	O
3	of	O
4	cloned	O
5	PCR	O
6	products	O
7	confirmed	O
8	the	O
9	presence	O
10	of	O
11	two	O
12	different	O
13	nifV	B
14	-	I
15	like	I
16	DNA	I
17	fragments	I
18	,	O
19	which	O
20	were	O
21	subsequently	O
22	used	O
23	as	O
24	nifV	B
25	-	O
26	and	O
27	leuA	B
28	-	I
29	specific	I
30	probes	I
31	,	O
32	respectively	O
33	,	O
34	to	O
35	clone	O
36	XbaI	B
37	fragments	I
38	of	O
39	2	O
40	.	O
41	1	O
42	kbp	O
43	(	O
44	pOST4	O
45	)	O
46	and	O
47	2	O
48	.	O
49	6	O
50	kbp	O
51	(	O
52	pOST2	O
53	).	O
1	(	O
2	3	O
3	)	O
4	This	O
5	effect	O
6	occurs	O
7	without	O
8	removing	O
9	TRs	B
10	from	O
11	the	O
12	TRE	O
13	.	O
1	One	O
2	P1	O
3	genomic	O
4	clone	O
5	and	O
6	six	O
7	subsequent	O
8	plasmid	O
9	subclones	O
10	were	O
11	isolated	O
12	and	O
13	analyzed	O
14	for	O
15	the	O
16	exon	O
17	-	O
18	intron	O
19	organization	O
20	of	O
21	the	O
22	Ctpct	B
23	gene	I
24	.	O
1	The	O
2	mRNA	O
3	from	O
4	this	O
5	gene	O
6	,	O
7	termed	O
8	HES1	B
9	,	O
10	is	O
11	ubiquitously	O
12	expressed	O
13	,	O
14	but	O
15	strongly	O
16	so	O
17	in	O
18	heart	O
19	and	O
20	skeletal	O
21	muscle	O
22	.	O
1	The	O
2	husband	O
3	in	O
4	one	O
5	of	O
6	the	O
7	married	O
8	couples	O
9	was	O
10	treated	O
11	for	O
12	hepatitis	O
13	of	O
14	unidentified	O
15	etiology	O
16	in	O
17	an	O
18	Infectology	O
19	Department	O
20	four	O
21	years	O
22	ago	O
23	.	O
1	An	O
2	alternatively	O
3	spliced	O
4	MAdCAM	B
5	-	I
6	1	I
7	variant	O
8	was	O
9	identified	O
10	that	O
11	lacks	O
12	exon	O
13	4	O
14	encoding	O
15	the	O
16	mucin	B
17	domain	O
18	,	O
19	and	O
20	may	O
21	mediate	O
22	leukocyte	O
23	adhesion	O
24	to	O
25	LPAM	B
26	-	I
27	1	I
28	without	O
29	adhesion	O
30	to	O
31	the	O
32	alternate	O
33	receptor	O
34	,	O
35	L	B
36	-	I
37	selectin	I
38	.	O
1	SRE	O
2	activity	O
3	is	O
4	dependent	O
5	upon	O
6	the	O
7	activation	O
8	by	O
9	phosphorylation	O
10	of	O
11	a	O
12	ternary	O
13	complex	O
14	factor	O
15	;	O
16	included	O
17	among	O
18	the	O
19	ternary	O
20	complex	O
21	factors	O
22	is	O
23	Elk	B
24	-	I
25	1	I
26	.	O
1	METHODS	O
2	:	O
3	The	O
4	responses	O
5	of	O
6	a	O
7	31	O
8	-	O
9	year	O
10	-	O
11	old	O
12	woman	O
13	with	O
14	complex	O
15	regional	O
16	pain	O
17	syndrome	O
18	type	O
19	I	O
20	(	O
21	reflex	O
22	sympathetic	O
23	dystrophy	O
24	)	O
25	to	O
26	a	O
27	thermal	O
28	grill	O
29	were	O
30	evaluated	O
31	before	O
32	and	O
33	after	O
34	stellate	O
35	ganglion	O
36	block	O
37	.	O
1	A	O
2	xylE	B
3	transcriptional	I
4	fusion	I
5	to	O
6	the	O
7	putative	O
8	mxbD	B
9	promoter	I
10	showed	O
11	low	O
12	-	O
13	level	O
14	expression	O
15	in	O
16	wild	O
17	-	O
18	type	O
19	cells	O
20	grown	O
21	on	O
22	one	O
23	-	O
24	carbon	O
25	(	O
26	C1	O
27	)	O
28	compounds	O
29	and	O
30	no	O
31	detectable	O
32	expression	O
33	in	O
34	cells	O
35	grown	O
36	on	O
37	succinate	O
38	.	O
1	Mutation	O
2	of	O
3	nucleotides	O
4	adjacent	O
5	to	O
6	the	O
7	AP	B
8	-	I
9	1	I
10	cis	I
11	-	I
12	response	I
13	elements	I
14	had	O
15	no	O
16	effect	O
17	on	O
18	trans	O
19	-	O
20	activation	O
21	.	O
1	Cloning	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	cDNA	O
7	encoding	O
8	a	O
9	bacteriophage	B
10	-	I
11	type	I
12	RNA	I
13	polymerase	I
14	from	O
15	the	O
16	higher	O
17	plant	O
18	Chenopodium	O
19	album	O
20	.	O
1	In	O
2	ciliates	O
3	,	O
4	both	O
5	mechanisms	O
6	are	O
7	readily	O
8	observed	O
9	.	O
1	Mutational	O
2	studies	O
3	provide	O
4	evidence	O
5	to	O
6	this	O
7	end	O
8	and	O
9	indicate	O
10	that	O
11	the	O
12	side	O
13	chains	O
14	of	O
15	subdomain	O
16	4	O
17	.	O
18	2	O
19	make	O
20	specific	O
21	contacts	O
22	with	O
23	the	O
24	nucleotides	O
25	at	O
26	-	O
27	35	O
28	.	O
1	Using	O
2	PRL	B
3	-	I
4	R	I
5	tagged	O
6	both	O
7	in	O
8	the	O
9	N	O
10	-	O
11	terminal	O
12	or	O
13	C	O
14	-	O
15	terminal	O
16	regions	O
17	of	O
18	the	O
19	mature	O
20	receptor	O
21	excludes	O
22	the	O
23	possibility	O
24	of	O
25	a	O
26	cleaved	O
27	fragment	O
28	which	O
29	could	O
30	have	O
31	been	O
32	subsequently	O
33	imported	O
34	into	O
35	the	O
36	nucleus	O
37	.	O
1	Thus	O
2	,	O
3	the	O
4	B	O
5	-	O
6	S	O
7	mutant	O
8	does	O
9	not	O
10	mimic	O
11	efficiently	O
12	the	O
13	chloroplastic	B
14	GAPDHs	I
15	,	O
16	and	O
17	long	O
18	-	O
19	range	O
20	and	O
21	/	O
22	or	O
23	second	O
24	-	O
25	layer	O
26	effects	O
27	,	O
28	not	O
29	easily	O
30	predictable	O
31	from	O
32	visual	O
33	inspection	O
34	of	O
35	three	O
36	-	O
37	dimensional	O
38	structures	O
39	,	O
40	need	O
41	to	O
42	be	O
43	taken	O
44	into	O
45	account	O
46	for	O
47	designing	O
48	a	O
49	true	O
50	""""	O
51	chloroplastic	O
52	-	O
53	like	O
54	""""	O
55	mutant	O
56	of	O
57	cytosolic	B
58	GAPDH	I
59	.	O
1	The	O
2	conditions	O
3	for	O
4	obtaining	O
5	titanium	O
6	dioxide	O
7	from	O
8	the	O
9	substrates	O
10	titanium	O
11	tetrachloride	O
12	and	O
13	oxygen	O
14	and	O
15	applying	O
16	this	O
17	to	O
18	a	O
19	surgical	O
20	stainless	O
21	steel	O
22	of	O
23	the	O
24	type	O
25	316L	O
26	by	O
27	the	O
28	plasma	O
29	assisted	O
30	chemical	O
31	vapour	O
32	deposition	O
33	method	O
34	have	O
35	been	O
36	determined	O
37	.	O
1	We	O
2	have	O
3	inactivated	O
4	Krox	B
5	-	I
6	20	I
7	by	O
8	homologous	O
9	recombination	O
10	in	O
11	ES	O
12	cells	O
13	and	O
14	demonstrated	O
15	that	O
16	the	O
17	mutation	O
18	leads	O
19	to	O
20	the	O
21	deletion	O
22	of	O
23	r3	O
24	and	O
25	r5	O
26	.	O
1	The	O
2	most	O
3	important	O
4	one	O
5	among	O
6	them	O
7	is	O
8	Cyclosporin	O
9	A	O
10	,	O
11	which	O
12	is	O
13	a	O
14	selective	O
15	immunosuppressive	O
16	drug	O
17	.	O
1	This	O
2	coat	B
3	protein	I
4	consists	O
5	of	O
6	Sar1p	B
7	,	O
8	the	O
9	Sec23p	B
10	protein	I
11	complex	I
12	containing	O
13	Sec23p	B
14	and	O
15	Sec24p	B
16	,	O
17	and	O
18	the	O
19	Sec13p	B
20	protein	I
21	complex	I
22	containing	O
23	Sec13p	B
24	and	O
25	a	O
26	novel	O
27	150	B
28	-	I
29	kDa	I
30	protein	I
31	,	I
32	p150	I
33	.	O
1	Cytological	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	transgenes	O
7	associate	O
8	with	O
9	a	O
10	nucleolus	O
11	.	O
1	The	O
2	active	O
3	state	O
4	is	O
5	terminated	O
6	by	O
7	hydrolysis	O
8	of	O
9	bound	O
10	GTP	O
11	,	O
12	producing	O
13	inactive	O
14	ARF	B
15	-	I
16	GDP	I
17	.	O
1	We	O
2	suggest	O
3	that	O
4	apart	O
5	from	O
6	the	O
7	World	O
8	Summit	O
9	for	O
10	Children	O
11	'	O
12	s	O
13	under	O
14	-	O
15	five	O
16	mortality	O
17	target	O
18	for	O
19	the	O
20	year	O
21	2000	O
22	,	O
23	intraregional	O
24	targets	O
25	to	O
26	reduce	O
27	geographical	O
28	inequalities	O
29	in	O
30	under	O
31	-	O
32	five	O
33	mortality	O
34	should	O
35	be	O
36	specified	O
37	.	O
1	The	O
2	coding	O
3	region	O
4	of	O
5	mkh1	B
6	is	O
7	contained	O
8	within	O
9	a	O
10	single	O
11	exon	O
12	encoding	O
13	a	O
14	1	O
15	,	O
16	116	O
17	-	O
18	amino	O
19	-	O
20	acid	O
21	protein	O
22	.	O
1	Interdigitated	O
2	residues	O
3	within	O
4	a	O
5	small	O
6	region	O
7	of	O
8	VP16	B
9	interact	O
10	with	O
11	Oct	B
12	-	I
13	1	I
14	,	O
15	HCF	B
16	,	O
17	and	O
18	DNA	O
19	.	O
1	The	O
2	serum	O
3	levels	O
4	of	O
5	beta	B
6	-	I
7	human	I
8	chorionic	I
9	gonadotropin	I
10	(	O
11	HCG	B
12	)	O
13	and	O
14	placental	B
15	alkaline	I
16	phosphatase	I
17	(	O
18	PLAP	B
19	)	O
20	were	O
21	not	O
22	elevated	O
23	.	O
1	A	O
2	striking	O
3	feature	O
4	of	O
5	the	O
6	recombinant	B
7	H19	I
8	allele	I
9	is	O
10	the	O
11	occurrence	O
12	of	O
13	a	O
14	parental	O
15	imprint	O
16	set	O
17	on	O
18	the	O
19	neo	B
20	replacement	I
21	cassette	I
22	.	O
1	Functional	O
2	and	O
3	regulatory	O
4	analysis	O
5	of	O
6	the	O
7	two	O
8	copies	O
9	of	O
10	the	O
11	fixNOQP	B
12	operon	I
13	of	O
14	Rhizobium	O
15	leguminosarum	O
16	strain	O
17	VF39	O
18	.	O
1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	bulbospinal	O
7	micturition	O
8	reflex	O
9	evoked	O
10	by	O
11	bladder	O
12	filling	O
13	and	O
14	L	O
15	-	O
16	dopa	O
17	involves	O
18	a	O
19	descending	O
20	pathway	O
21	where	O
22	transmission	O
23	is	O
24	partly	O
25	mediated	O
26	by	O
27	spinal	B
28	alpha	I
29	1	I
30	-	I
31	adrenoceptors	I
32	.	O
1	The	O
2	products	O
3	of	O
4	the	O
5	Saccharomyces	B
6	cerevisiae	I
7	CIN1	I
8	,	O
9	CIN2	B
10	and	O
11	CIN4	B
12	genes	I
13	participate	O
14	in	O
15	a	O
16	nonessential	O
17	pathway	O
18	required	O
19	for	O
20	normal	O
21	microtubule	O
22	function	O
23	.	O
1	Vitrectomy	O
2	was	O
3	still	O
4	a	O
5	significant	O
6	risk	O
7	factor	O
8	when	O
9	macular	O
10	holes	O
11	were	O
12	excluded	O
13	.	O
1	Both	O
2	promoters	O
3	lack	O
4	a	O
5	TATA	O
6	box	O
7	,	O
8	and	O
9	Pint	B
10	belongs	O
11	to	O
12	the	O
13	MED	B
14	-	I
15	1	I
16	class	O
17	of	O
18	promoters	O
19	,	O
20	which	O
21	initiate	O
22	transcription	O
23	at	O
24	multiple	O
25	sites	O
26	.	O
1	ORF	O
2	M1	O
3	has	O
4	striking	O
5	homology	O
6	to	O
7	poxvirus	O
8	serpins	B
9	,	O
10	while	O
11	ORF	O
12	M11	O
13	encodes	O
14	a	O
15	potential	O
16	homolog	O
17	of	O
18	Bcl	B
19	-	I
20	2	I
21	-	I
22	like	I
23	molecules	I
24	encoded	O
25	by	O
26	other	O
27	gammaherpesviruses	O
28	(	O
29	gene	B
30	16	I
31	of	O
32	HVS	O
33	and	O
34	KSHV	O
35	and	O
36	the	O
37	BHRF1	B
38	gene	I
39	of	O
40	EBV	O
41	).	O
1	We	O
2	have	O
3	separated	O
4	a	O
5	dermatan	O
6	sulfate	O
7	proteoglycan	O
8	,	O
9	epiphycan	O
10	,	O
11	from	O
12	decorin	B
13	and	O
14	biglycan	O
15	by	O
16	using	O
17	dissociative	O
18	extraction	O
19	of	O
20	bovine	O
21	fetal	O
22	epiphyseal	O
23	cartilage	O
24	,	O
25	followed	O
26	by	O
27	sequential	O
28	ion	O
29	-	O
30	exchange	O
31	,	O
32	gel	O
33	permeation	O
34	,	O
35	hydrophobic	O
36	,	O
37	and	O
38	Zn2	O
39	+	O
40	chelate	O
41	chromatographic	O
42	steps	O
43	.	O
1	We	O
2	further	O
3	found	O
4	that	O
5	KmMig1p	B
6	is	O
7	fully	O
8	functional	O
9	when	O
10	expressed	O
11	in	O
12	S	O
13	.	O
14	cerevisiae	O
15	.	O
1	Second	O
2	,	O
3	plasmid	O
4	-	O
5	derived	O
6	transgenes	O
7	and	O
8	gene	O
9	targeting	O
10	of	O
11	the	O
12	endogenous	B
13	Hnf3g	I
14	gene	I
15	locus	I
16	were	O
17	used	O
18	to	O
19	demonstrate	O
20	that	O
21	the	O
22	3	O
23	'-	O
24	flanking	O
25	region	O
26	of	O
27	the	O
28	gene	O
29	is	O
30	necessary	O
31	and	O
32	sufficient	O
33	to	O
34	direct	O
35	reporter	O
36	gene	O
37	expression	O
38	in	O
39	liver	O
40	,	O
41	pancreas	O
42	,	O
43	stomach	O
44	and	O
45	small	O
46	intestine	O
47	.	O
1	This	O
2	mechanism	O
3	is	O
4	in	O
5	contrast	O
6	to	O
7	other	O
8	cases	O
9	of	O
10	splicing	O
11	regulation	O
12	by	O
13	PTB	B
14	,	O
15	in	O
16	which	O
17	the	O
18	protein	O
19	represses	O
20	the	O
21	splice	O
22	site	O
23	to	O
24	which	O
25	it	O
26	binds	O
27	.	O
1	While	O
2	important	O
3	for	O
4	ligand	O
5	-	O
6	dependent	O
7	transactivation	O
8	,	O
9	this	O
10	interaction	O
11	surface	O
12	is	O
13	not	O
14	directly	O
15	involved	O
16	in	O
17	transrepression	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	activity	O
23	.	O
1	This	O
2	night	O
3	-	O
4	day	O
5	oscillation	O
6	is	O
7	driven	O
8	by	O
9	the	O
10	endogenous	O
11	clock	O
12	(	O
13	located	O
14	in	O
15	the	O
16	suprachiasmatic	O
17	nucleus	O
18	,	O
19	SCN	O
20	).	O
1	A	O
2	consensus	O
3	sequence	O
4	indicates	O
5	a	O
6	highly	O
7	conserved	O
8	lysine	O
9	residue	O
10	,	O
11	K120	O
12	of	O
13	endonuclease	B
14	III	I
15	or	O
16	K241	O
17	of	O
18	Ogg1	B
19	,	O
20	respectively	O
21	.	O
1	Cell	O
2	49	O
3	,	O
4	753	O
5	-	O
6	761	O
7	].	O
1	For	O
2	E2	O
3	,	O
4	each	O
5	cat	O
6	was	O
7	given	O
8	either	O
9	5	O
10	(	O
11	group	O
12	[	O
13	G	O
14	]	O
15	1	O
16	)	O
17	or	O
18	10	O
19	(	O
20	G2	O
21	)	O
22	mg	O
23	of	O
24	itraconazole	O
25	/	O
26	kg	O
27	(	O
28	capsules	O
29	)	O
30	twice	O
31	daily	O
32	for	O
33	6	O
34	weeks	O
35	.	O
1	Crosstalk	O
2	among	O
3	the	O
4	pathways	O
5	may	O
6	explain	O
7	how	O
8	some	O
9	forms	O
10	of	O
11	stress	O
12	can	O
13	contribute	O
14	to	O
15	the	O
16	development	O
17	of	O
18	a	O
19	malignancy	O
20	.	O
1	Mutation	O
2	of	O
3	Enh4	B
4	,	O
5	an	O
6	essential	O
7	GT	B
8	-	I
9	IIC	I
10	-	I
11	like	I
12	enhanson	I
13	in	O
14	the	O
15	context	O
16	of	O
17	the	O
18	intact	O
19	enhancer	O
20	,	O
21	abolishes	O
22	silencer	O
23	activity	O
24	,	O
25	and	O
26	multimerized	O
27	GT	B
28	-	I
29	IIC	I
30	enhansons	I
31	mimic	O
32	the	O
33	intact	O
34	CSEn	B
35	enhancer	I
36	/	I
37	silencer	I
38	activities	O
39	in	O
40	BeWo	O
41	and	O
42	GC	O
43	cells	O
44	,	O
45	respectively	O
46	.	O
1	MR	O
2	imaging	O
3	of	O
4	traumatic	O
5	head	O
6	injuries	O
7	using	O
8	FLAIR	O
9	technique	O
1	Induction	O
2	of	O
3	B	O
4	cell	O
5	apoptosis	O
6	by	O
7	co	O
8	-	O
9	cross	O
10	-	O
11	linking	O
12	CD23	B
13	and	O
14	sIg	B
15	involves	O
16	aberrant	O
17	regulation	O
18	of	O
19	c	B
20	-	I
21	myc	I
22	and	O
23	is	O
24	inhibited	O
25	by	O
26	bcl	B
27	-	I
28	2	I
29	.	O
1	MEASUREMENTS	O
2	AND	O
3	MAIN	O
4	RESULTS	O
5	:	O
6	Lung	O
7	elastance	O
8	(	O
9	EL	O
10	)	O
11	and	O
12	resistance	O
13	(	O
14	RL	O
15	)	O
16	were	O
17	calculated	O
18	from	O
19	measurements	O
20	of	O
21	airway	O
22	pressure	O
23	,	O
24	esophageal	O
25	pressure	O
26	,	O
27	and	O
28	airway	O
29	flow	O
30	in	O
31	five	O
32	anesthetized	O
33	,	O
34	paralyzed	O
35	dogs	O
36	during	O
37	sinusoidal	O
38	forcing	O
39	at	O
40	a	O
41	constant	O
42	mean	O
43	airway	O
44	pressure	O
45	of	O
46	10	O
47	cmH2O	O
48	in	O
49	a	O
50	wide	O
51	range	O
52	of	O
53	breathing	O
54	frequencies	O
55	(	O
56	0	O
57	.	O
58	2	O
59	to	O
60	1	O
61	.	O
62	0	O
63	Hz	O
64	in	O
65	intervals	O
66	of	O
67	0	O
68	.	O
69	2	O
70	)	O
71	and	O
72	tidal	O
73	volumes	O
74	(	O
75	50	O
76	,	O
77	100	O
78	,	O
79	200	O
80	,	O
81	and	O
82	to	O
83	300	O
84	mL	O
85	).	O
1	The	O
2	dose	O
3	was	O
4	50	O
5	Gy	O
6	/	O
7	20	O
8	fractions	O
9	/	O
10	5	O
11	weeks	O
12	.	O
1	Genes	O
2	belonging	O
3	to	O
4	the	O
5	ras	B
6	superfamily	I
7	encode	O
8	low	B
9	-	I
10	molecular	I
11	-	I
12	weight	I
13	GTP	I
14	/	I
15	GDP	I
16	-	I
17	binding	I
18	proteins	I
19	that	O
20	are	O
21	highly	O
22	conserved	O
23	in	O
24	wide	O
25	variety	O
26	of	O
27	organisms	O
28	.	O
1	Ent	B
2	-	I
3	kaurene	I
4	synthase	I
5	from	I
6	the	I
7	fungus	I
8	Phaeosphaeria	I
9	sp	O
10	.	O
1	Together	O
2	,	O
3	these	O
4	data	O
5	support	O
6	a	O
7	model	O
8	in	O
9	which	O
10	Tax	B
11	anchors	O
12	CBP	B
13	to	O
14	the	O
15	HTLV	B
16	-	I
17	1	I
18	promoter	I
19	,	O
20	with	O
21	strong	O
22	transcriptional	O
23	activation	O
24	resulting	O
25	from	O
26	the	O
27	CBP	B
28	-	O
29	associated	O
30	activities	O
31	of	O
32	nucleosome	O
33	remodeling	O
34	and	O
35	recruitment	O
36	of	O
37	the	O
38	general	O
39	transcription	O
40	machinery	O
41	.	O
1	Various	O
2	assays	O
3	demonstrate	O
4	promoter	O
5	activity	O
6	in	O
7	this	O
8	sequence	O
9	that	O
10	reproduces	O
11	the	O
12	normal	O
13	control	O
14	of	O
15	E2F2	B
16	expression	O
17	during	O
18	a	O
19	growth	O
20	stimulation	O
21	.	O
1	Heterogeneous	B
2	nuclear	I
3	ribonucleoprotein	I
4	A1	I
5	binds	O
6	to	O
7	the	O
8	transcription	O
9	-	O
10	regulatory	O
11	region	O
12	of	O
13	mouse	O
14	hepatitis	O
15	virus	O
16	RNA	O
17	.	O
1	Two	O
2	experiments	O
3	(	O
4	N	O
5	=	O
6	20	O
7	each	O
8	)	O
9	were	O
10	carried	O
11	out	O
12	to	O
13	explore	O
14	the	O
15	nature	O
16	of	O
17	ERP	O
18	negativities	O
19	in	O
20	a	O
21	visuospatial	O
22	memory	O
23	task	O
24	and	O
25	in	O
26	an	O
27	auditory	O
28	spatial	O
29	memory	O
30	task	O
31	,	O
32	respectively	O
33	.	O
1	In	O
2	contrast	O
3	,	O
4	both	O
5	Sp1	B
6	and	O
7	ETS	B
8	proteins	I
9	are	O
10	required	O
11	to	O
12	bring	O
13	about	O
14	full	O
15	promoter	O
16	activity	O
17	in	O
18	the	O
19	Surf	B
20	-	I
21	1	I
22	direction	O
23	.	O
1	Area	O
2	under	O
3	the	O
4	drug	O
5	concentration	O
6	-	O
7	time	O
8	curves	O
9	(	O
10	AUC0	O
11	-	O
12	24	O
13	hr	O
14	)	O
15	for	O
16	MTX	O
17	were	O
18	2379	O
19	and	O
20	3534	O
21	ng	O
22	*	O
23	hr	O
24	/	O
25	ml	O
26	from	O
27	PG	O
28	-	O
29	2	O
30	.	O
31	5	O
32	%	O
33	Azone	O
34	and	O
35	PG	O
36	-	O
37	7	O
38	.	O
39	5	O
40	%	O
41	Azone	O
42	systems	O
43	respectively	O
44	.	O
1	The	O
2	combination	O
3	of	O
4	hydralazine	O
5	hydrochloride	O
6	and	O
7	isosorbide	O
8	dinitrate	O
9	also	O
10	improves	O
11	survival	O
12	,	O
13	but	O
14	direct	O
15	comparison	O
16	of	O
17	both	O
18	regimens	O
19	provided	O
20	evidence	O
21	for	O
22	a	O
23	less	O
24	favourable	O
25	effect	O
26	than	O
27	that	O
28	of	O
29	the	O
30	ACE	B
31	inhibitors	O
32	.	O
1	The	O
2	goal	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	identify	O
9	neuronal	O
10	cell	O
11	cultures	O
12	that	O
13	express	O
14	RC3	B
15	/	O
16	neurogranin	B
17	,	O
18	to	O
19	check	O
20	whether	O
21	they	O
22	are	O
23	sensitive	O
24	to	O
25	T3	O
26	,	O
27	and	O
28	to	O
29	examine	O
30	the	O
31	mechanism	O
32	of	O
33	regulation	O
34	.	O
1	There	O
2	were	O
3	differences	O
4	between	O
5	males	O
6	(	O
7	p	O
8	<	O
9	0	O
10	.	O
11	05	O
12	)	O
13	for	O
14	most	O
15	of	O
16	the	O
17	characteristics	O
18	studied	O
19	.	O
1	Their	O
2	circadian	O
3	responses	O
4	to	O
5	both	O
6	photic	O
7	and	O
8	non	O
9	-	O
10	photic	O
11	cues	O
12	were	O
13	then	O
14	tested	O
15	.	O
1	Plasma	B
2	leptin	I
3	concentrations	O
4	were	O
5	higher	O
6	in	O
7	women	O
8	than	O
9	men	O
10	,	O
11	even	O
12	after	O
13	the	O
14	adjustment	O
15	for	O
16	differences	O
17	in	O
18	fat	O
19	mass	O
20	(	O
21	28	O
22	+/-	O
23	3	O
24	ng	O
25	/	O
26	ml	O
27	for	O
28	women	O
29	vs	O
30	.	O
1	This	O
2	interaction	O
3	involved	O
4	the	O
5	SH3	B
6	region	I
7	of	O
8	p50	B
9	(	O
10	csk	B
11	)	O
12	and	O
13	a	O
14	proline	O
15	-	O
16	rich	O
17	region	O
18	(	O
19	PPPLPERTPESFVLADM	O
20	)	O
21	outside	O
22	the	O
23	catalytic	O
24	region	O
25	of	O
26	PTP	B
27	-	O
28	PEST	O
29	.	O
1	The	O
2	cycle	O
3	length	O
4	of	O
5	induced	O
6	VT	O
7	(	O
8	n	O
9	=	O
10	10	O
11	VTs	O
12	)	O
13	was	O
14	380	O
15	+/-	O
16	41	O
17	msec	O
18	.	O
1	These	O
2	findings	O
3	suggest	O
4	one	O
5	potential	O
6	mechanism	O
7	for	O
8	direct	O
9	recruitment	O
10	of	O
11	distal	O
12	regulatory	O
13	regions	O
14	of	O
15	the	O
16	globin	B
17	loci	I
18	to	O
19	the	O
20	individual	O
21	promoters	O
22	.	O
1	The	O
2	two	O
3	cysteine	O
4	residues	O
5	located	O
6	in	O
7	this	O
8	additional	O
9	region	O
10	may	O
11	be	O
12	involved	O
13	in	O
14	the	O
15	formation	O
16	of	O
17	a	O
18	disulfide	O
19	bridge	O
20	associated	O
21	with	O
22	the	O
23	activation	O
24	process	O
25	of	O
26	the	O
27	catalytic	O
28	activity	O
29	.	O
1	When	O
2	the	O
3	downstream	O
4	operator	O
5	was	O
6	altered	O
7	,	O
8	there	O
9	was	O
10	a	O
11	fourfold	O
12	reduction	O
13	in	O
14	reporter	O
15	enzyme	O
16	levels	O
17	.	O
1	The	O
2	ORF3	O
3	mutant	O
4	produced	O
5	reduced	O
6	levels	O
7	of	O
8	tabtoxin	B
9	,	O
10	indicating	O
11	that	O
12	ORF3	O
13	may	O
14	have	O
15	a	O
16	role	O
17	in	O
18	T	B
19	beta	I
20	L	I
21	biosynthesis	O
22	.	O
1	As	O
2	a	O
3	result	O
4	,	O
5	the	O
6	subendocardial	O
7	/	O
8	subepicardial	O
9	blood	O
10	flow	O
11	ratio	O
12	(	O
13	ENDO	O
14	/	O
15	EPI	O
16	)	O
17	increased	O
18	from	O
19	0	O
20	.	O
21	44	O
22	+/-	O
23	0	O
24	.	O
25	09	O
26	during	O
27	control	O
28	stenosis	O
29	to	O
30	0	O
31	.	O
32	85	O
33	+/-	O
34	0	O
35	.	O
36	13	O
37	after	O
38	ITF	O
39	1129	O
40	(	O
41	10	O
42	micrograms	O
43	/	O
44	kg	O
45	/	O
46	min	O
47	i	O
48	.	O
49	v	O
50	.)	O
51	and	O
52	to	O
53	0	O
54	.	O
55	81	O
56	+/-	O
57	0	O
58	.	O
59	12	O
60	after	O
61	NTG	O
62	.	O
1	In	O
2	support	O
3	of	O
4	this	O
5	interpretation	O
6	we	O
7	demonstrate	O
8	that	O
9	MQ9b	B
10	binds	O
11	strongly	O
12	5	O
13	of	O
14	17	O
15	motif	O
16	-	O
17	positive	O
18	,	O
19	pathogen	O
20	-	O
21	derived	O
22	synthetic	O
23	peptides	O
24	.	O
1	Gaucher	O
2	'	O
3	s	O
4	disease	O
5	is	O
6	a	O
7	rare	O
8	metabolic	O
9	disorder	O
10	characterized	O
11	by	O
12	the	O
13	lack	O
14	of	O
15	beta	B
16	-	I
17	glucocerebrosidase	I
18	enzyme	I
19	.	O
1	By	O
2	analyzing	O
3	the	O
4	RanGAP	B
5	activity	O
6	of	O
7	a	O
8	series	O
9	of	O
10	recombinantly	O
11	expressed	O
12	rna1p	B
13	mutant	I
14	derivatives	O
15	,	O
16	we	O
17	show	O
18	that	O
19	the	O
20	highly	O
21	acidic	O
22	sequence	O
23	in	O
24	the	O
25	C	O
26	-	O
27	terminal	O
28	domain	O
29	of	O
30	both	O
31	yeast	O
32	proteins	O
33	is	O
34	indispensable	O
35	for	O
36	activating	O
37	Ran	B
38	-	O
39	mediated	O
40	GTP	O
41	hydrolysis	O
42	.	O
1	Mnt	B
2	:	O
3	Max	B
4	complexes	O
5	also	O
6	efficiently	O
7	suppress	O
8	Myc	B
9	-	O
10	dependent	O
11	activation	O
12	from	O
13	the	O
14	same	O
15	promoter	O
16	.	O
1	Interestingly	O
2	,	O
3	the	O
4	RXRalphaF318A	B
5	constitutive	O
6	activity	O
7	generated	O
8	within	O
9	heterodimers	O
10	in	O
11	the	O
12	presence	O
13	of	O
14	BMS614	O
15	requires	O
16	the	O
17	integrity	O
18	of	O
19	both	O
20	RXR	B
21	and	O
22	RAR	B
23	AF	O
24	-	O
25	2	O
26	domains	O
27	.	O
1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	Src	B
8	homology	I
9	-	I
10	2	I
11	(	O
12	SH2	B
13	)	O
14	domain	O
15	-	O
16	containing	O
17	protein	B
18	-	I
19	tyrosine	I
20	phosphatase	I
21	,	O
22	SHP	B
23	-	I
24	2	I
25	,	O
26	associates	O
27	with	O
28	the	O
29	cytoplasmic	O
30	domain	O
31	of	O
32	PECAM	B
33	-	I
34	1	I
35	as	O
36	it	O
37	becomes	O
38	tyrosine	O
39	-	O
40	phosphorylated	O
41	during	O
42	platelet	O
43	aggregation	O
44	:	O
45	a	O
46	process	O
47	that	O
48	can	O
49	be	O
50	mimicked	O
51	in	O
52	part	O
53	by	O
54	small	O
55	synthetic	O
56	phosphopeptides	O
57	corresponding	O
58	to	O
59	the	O
60	cytoplasmic	O
61	domain	O
62	of	O
63	PECAM	B
64	-	I
65	1	I
66	encompassing	O
67	tyrosine	O
68	residues	O
69	Tyr	O
70	-	O
71	663	O
72	or	O
73	Tyr	O
74	-	O
75	686	O
76	.	O
1	Detection	O
2	of	O
3	airborne	O
4	Mycobacterium	O
5	tuberculosis	O
6	by	O
7	air	O
8	filtration	O
9	and	O
10	polymerase	O
11	chain	O
12	reaction	O
13	.	O
1	However	O
2	,	O
3	Cbf5p	B
4	was	O
5	found	O
6	to	O
7	be	O
8	nucleolar	O
9	and	O
10	is	O
11	highly	O
12	homologous	O
13	to	O
14	the	O
15	rat	B
16	nucleolar	I
17	protein	I
18	NAP57	I
19	,	O
20	which	O
21	coimmunoprecipitates	O
22	with	O
23	Nopp140	B
24	and	O
25	which	O
26	is	O
27	postulated	O
28	to	O
29	be	O
30	involved	O
31	in	O
32	nucleolar	O
33	-	O
34	cytoplasmic	O
35	shuttling	O
36	(	O
37	U	O
38	.	O
1	We	O
2	found	O
3	that	O
4	multiple	O
5	tumor	O
6	suppressor	O
7	genes	O
8	(	O
9	e	O
10	.	O
11	g	O
12	.,	O
13	p53	B
14	,	O
15	DCC	B
16	,	O
17	APC	B
18	,	O
19	MCC	B
20	,	O
21	BRCA1	B
22	,	O
23	and	O
24	WAF1	B
25	/	O
26	CIP1	B
27	)	O
28	were	O
29	inactivated	O
30	at	O
31	different	O
32	frequencies	O
33	via	O
34	various	O
35	mechanisms	O
36	[	O
37	e	O
38	.	O
39	g	O
40	.,	O
41	loss	O
42	of	O
43	heterozygosity	O
44	(	O
45	LOH	O
46	),	O
47	loss	O
48	of	O
49	expression	O
50	(	O
51	LOE	O
52	),	O
53	mutation	O
54	,	O
55	and	O
56	inactivation	O
57	by	O
58	cellular	O
59	binding	O
60	protein	O
61	].	O
1	Because	O
2	the	O
3	deletion	O
4	included	O
5	the	O
6	TK	B
7	gene	I
8	,	O
9	selection	O
10	with	O
11	gancyclovir	O
12	against	O
13	cells	O
14	not	O
15	having	O
16	undergone	O
17	recombination	O
18	was	O
19	possible	O
20	.	O
1	The	O
2	malate	B
3	synthase	I
4	gene	I
5	,	O
6	MLS1	B
7	,	O
8	of	O
9	the	O
10	yeast	O
11	Saccharomyces	O
12	cerevisiae	O
13	is	O
14	transcriptionally	O
15	regulated	O
16	by	O
17	the	O
18	carbon	O
19	source	O
20	in	O
21	the	O
22	growth	O
23	medium	O
24	.	O
1	RESULTS	O
2	:	O
3	The	O
4	standardised	O
5	mortality	O
6	ratio	O
7	(	O
8	SMR	O
9	)	O
10	for	O
11	all	O
12	malignant	O
13	neoplasms	O
14	was	O
15	94	O
16	(	O
17	95	O
18	%	O
19	CI	O
20	74	O
21	to	O
22	118	O
23	).	O
1	Sequence	O
2	analysis	O
3	of	O
4	this	O
5	region	O
6	revealed	O
7	three	O
8	eight	O
9	-	O
10	bp	O
11	repetitive	O
12	elements	O
13	,	O
14	the	O
15	deletion	O
16	of	O
17	which	O
18	restored	O
19	wild	O
20	-	O
21	type	O
22	levels	O
23	of	O
24	luciferase	B
25	activity	O
26	to	O
27	the	O
28	-	O
29	916	O
30	-	O
31	bp	O
32	reporter	O
33	plasmid	O
34	.	O
1	This	O
2	is	O
3	the	O
4	first	O
5	study	O
6	in	O
7	which	O
8	mutation	O
9	screening	O
10	has	O
11	been	O
12	performed	O
13	for	O
14	both	O
15	the	O
16	EXT1	B
17	and	O
18	EXT2	B
19	genes	I
20	prior	O
21	to	O
22	any	O
23	linkage	O
24	analysis	O
25	.	O
1	Surprisingly	O
2	,	O
3	calf	B
4	thymus	I
5	CstF	I
6	contained	O
7	an	O
8	additional	O
9	,	O
10	novel	O
11	form	O
12	of	O
13	the	O
14	64	O
15	-	O
16	kDa	O
17	subunit	O
18	with	O
19	a	O
20	molecular	O
21	mass	O
22	of	O
23	70	O
24	kDa	O
25	.	O
1	To	O
2	examine	O
3	the	O
4	basis	O
5	for	O
6	the	O
7	apparent	O
8	differences	O
9	in	O
10	postsegregational	O
11	killing	O
12	between	O
13	the	O
14	two	O
15	E	O
16	.	O
17	coli	O
18	strains	O
19	,	O
20	transformation	O
21	assays	O
22	were	O
23	carried	O
24	out	O
25	to	O
26	determine	O
27	the	O
28	relative	O
29	sensitivities	O
30	of	O
31	the	O
32	strains	O
33	to	O
34	the	O
35	ParE	B
36	toxin	I
37	protein	I
38	.	O
1	Cloning	O
2	of	O
3	a	O
4	human	B
5	phosphoinositide	I
6	3	I
7	-	I
8	kinase	I
9	with	O
10	a	O
11	C2	B
12	domain	O
13	that	O
14	displays	O
15	reduced	O
16	sensitivity	O
17	to	O
18	the	O
19	inhibitor	O
20	wortmannin	O
21	.	O
1	We	O
2	have	O
3	overexpressed	O
4	,	O
5	purified	O
6	,	O
7	characterized	O
8	,	O
9	and	O
10	crystallized	O
11	the	O
12	BTB	B
13	/	O
14	POZ	O
15	domain	O
16	from	O
17	PLZF	B
18	(	O
19	PLZF	B
20	-	O
21	BTB	B
22	/	O
23	POZ	O
24	).	O
1	Interestingly	O
2	,	O
3	segment	O
4	nesting	O
5	differentially	O
6	increases	O
7	the	O
8	copy	O
9	number	O
10	of	O
11	genes	O
12	encoded	O
13	by	O
14	segment	O
15	W	O
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	unusual	O
21	genomic	O
22	organization	O
23	of	O
24	PDVs	O
25	may	O
26	be	O
27	directly	O
28	linked	O
29	to	O
30	the	O
31	unique	O
32	functions	O
33	of	O
34	this	O
35	virus	O
36	in	O
37	its	O
38	obligate	O
39	mutualistic	O
40	association	O
41	with	O
42	parasitic	O
43	wasps	O
44	.	O
1	Furthermore	O
2	,	O
3	deletion	O
4	and	O
5	mutation	O
6	analyses	O
7	of	O
8	the	O
9	VCAM	B
10	-	I
11	1	I
12	promoter	I
13	performed	O
14	with	O
15	chloramphenicol	B
16	acetyltransferase	I
17	constructs	I
18	revealed	O
19	that	O
20	Tax	B
21	was	O
22	trans	O
23	activating	O
24	the	O
25	VCAM	B
26	-	I
27	1	I
28	promoter	I
29	via	O
30	two	O
31	NF	B
32	-	I
33	kappaB	I
34	sites	I
35	present	O
36	at	O
37	bp	O
38	-	O
39	72	O
40	and	O
41	-	O
42	57	O
43	in	O
44	the	O
45	VCAM	B
46	-	I
47	1	I
48	gene	I
49	promoter	I
50	,	O
51	with	O
52	both	O
53	of	O
54	them	O
55	being	O
56	required	O
57	for	O
58	the	O
59	Tax	B
60	-	O
61	induced	O
62	expression	O
63	of	O
64	this	O
65	adhesion	O
66	molecule	O
67	.	O
1	In	O
2	the	O
3	context	O
4	of	O
5	liver	O
6	allograft	O
7	shortage	O
8	,	O
9	our	O
10	results	O
11	suggest	O
12	that	O
13	an	O
14	ELT	O
15	should	O
16	not	O
17	be	O
18	performed	O
19	in	O
20	patients	O
21	with	O
22	cardiac	O
23	failure	O
24	,	O
25	more	O
26	than	O
27	two	O
28	OSF	O
29	,	O
30	or	O
31	an	O
32	APACHE	O
33	II	O
34	score	O
35	higher	O
36	than	O
37	30	O
38	.	O
1	Ki	B
2	-	I
3	ras4BVal	I
4	-	I
5	12	I
6	transfectant	O
7	cells	O
8	expressed	O
9	2	O
10	-	O
11	fold	O
12	elevated	O
13	protein	O
14	levels	O
15	of	O
16	the	O
17	lysosomal	B
18	cysteine	I
19	protease	I
20	cathepsin	I
21	B	I
22	but	O
23	did	O
24	not	O
25	up	O
26	-	O
27	regulate	O
28	cathepsin	B
29	B	I
30	mRNA	I
31	expression	O
32	.	O
1	Our	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	pattern	O
7	of	O
8	blood	O
9	supply	O
10	is	O
11	relevant	O
12	to	O
13	the	O
14	structural	O
15	organisation	O
16	of	O
17	mature	O
18	lamellar	O
19	bone	O
20	around	O
21	the	O
22	implant	O
23	.	O
1	It	O
2	thus	O
3	appears	O
4	that	O
5	MAPK	B
6	functions	O
7	in	O
8	meiotic	O
9	maturation	O
10	by	O
11	preventing	O
12	unfertilized	O
13	eggs	O
14	from	O
15	proceeding	O
16	into	O
17	parthenogenetic	O
18	development	O
19	.	O
1	(	O
2	ii	O
3	)	O
4	An	O
5	AF	O
6	G	B
7	-	I
8	CSF	I
9	level	O
10	>	O
11	2000	O
12	pg	O
13	/	O
14	ml	O
15	is	O
16	a	O
17	strong	O
18	positive	O
19	predictor	O
20	of	O
21	CAM	O
22	.	O
1	Furthermore	O
2	,	O
3	the	O
4	over	O
5	-	O
6	replication	O
7	phenotype	O
8	produced	O
9	by	O
10	this	O
11	mutant	B
12	p65cdc18	I
13	is	O
14	resistant	O
15	to	O
16	increased	O
17	mitotic	O
18	cyclin	B
19	/	O
20	CDK	B
21	activity	O
22	,	O
23	a	O
24	known	O
25	inhibitor	O
26	of	O
27	over	O
28	-	O
29	replication	O
30	.	O
1	In	O
2	addition	O
3	,	O
4	mutation	O
5	of	O
6	the	O
7	Sp1	B
8	site	I
9	also	O
10	significantly	O
11	reduced	O
12	promoter	O
13	activity	O
14	.	O
1	This	O
2	sequence	O
3	possessed	O
4	homology	O
5	with	O
6	a	O
7	methylation	O
8	-	O
9	sensitive	O
10	promoter	O
11	element	O
12	,	O
13	Enh2	O
14	,	O
15	present	O
16	in	O
17	the	O
18	LTR	O
19	of	O
20	mouse	O
21	intractisternal	O
22	A	O
23	-	O
24	particles	O
25	.	O
1	Codon	O
2	optimization	O
3	for	O
4	high	O
5	-	O
6	level	O
7	expression	O
8	of	O
9	human	B
10	erythropoietin	I
11	(	O
12	EPO	B
13	)	O
14	in	O
15	mammalian	O
16	cells	O
17	.	O
1	These	O
2	residues	O
3	,	O
4	Ile244	O
5	at	O
6	the	O
7	extracellular	O
8	end	O
9	of	O
10	transmembrane	O
11	helix	O
12	3	O
13	,	O
14	and	O
15	Tyr318	O
16	at	O
17	the	O
18	COOH	O
19	-	O
20	terminal	O
21	portion	O
22	of	O
23	extracellular	O
24	loop	O
25	2	O
26	,	O
27	are	O
28	replaced	O
29	by	O
30	Leu	O
31	and	O
32	Ile	O
33	in	O
34	the	O
35	PTH	B
36	-	I
37	1	I
38	receptor	I
39	,	O
40	respectively	O
41	.	O
1	Mouse	B
2	mast	I
3	cell	I
4	protease	I
5	9	I
6	,	O
7	a	O
8	novel	O
9	member	O
10	of	O
11	the	O
12	chromosome	O
13	14	O
14	family	O
15	of	O
16	serine	B
17	proteases	I
18	that	O
19	is	O
20	selectively	O
21	expressed	O
22	in	O
23	uterine	O
24	mast	O
25	cells	O
26	.	O
1	An	O
2	unusual	O
3	cysteine	O
4	triplet	O
5	conserved	O
6	in	O
7	the	O
8	sequences	O
9	of	O
10	TB	B
11	domains	I
12	is	O
13	localized	O
14	to	O
15	the	O
16	hydrophobic	O
17	core	O
18	,	O
19	at	O
20	the	O
21	C	O
22	-	O
23	terminus	O
24	of	O
25	an	O
26	alpha	O
27	-	O
28	helix	O
29	.	O
1	Xenopus	B
2	Ran	I
3	-	I
4	binding	I
5	protein	I
6	1	I
7	:	O
8	molecular	O
9	interactions	O
10	and	O
11	effects	O
12	on	O
13	nuclear	O
14	assembly	O
15	in	O
16	Xenopus	O
17	egg	O
18	extracts	O
19	.	O
1	She	O
2	improved	O
3	with	O
4	a	O
5	combination	O
6	of	O
7	benzodiazepines	O
8	and	O
9	the	O
10	acetylcholinesterase	B
11	inhibitor	O
12	physostigmine	O
13	.	O
1	The	O
2	presence	O
3	of	O
4	an	O
5	additional	O
6	sequence	O
7	of	O
8	nucleotides	O
9	145	O
10	-	O
11	165	O
12	from	O
13	the	O
14	3	O
15	'	O
16	end	O
17	of	O
18	RNA3	B
19	enhanced	O
20	template	O
21	recognition	O
22	by	O
23	RdRp	B
24	in	O
25	vitro	O
26	and	O
27	accumulation	O
28	of	O
29	RNA3	B
30	in	O
31	vivo	O
32	to	O
33	wild	O
34	-	O
35	type	O
36	levels	O
37	.	O
1	The	O
2	pen	O
3	can	O
4	heal	O
5	.	O
1	In	O
2	Arabidopsis	O
3	,	O
4	the	O
5	induction	O
6	of	O
7	a	O
8	dehydration	O
9	-	O
10	responsive	O
11	gene	O
12	,	O
13	rd22	B
14	,	O
15	is	O
16	mediated	O
17	by	O
18	abscisic	O
19	acid	O
20	(	O
21	ABA	O
22	)	O
23	and	O
24	requires	O
25	protein	O
26	biosynthesis	O
27	for	O
28	ABA	O
29	-	O
30	dependent	O
31	gene	O
32	expression	O
33	.	O
1	Electromobility	O
2	shift	O
3	and	O
4	cotransfection	O
5	assays	O
6	demonstrated	O
7	that	O
8	HNF1alpha	B
9	,	O
10	but	O
11	not	O
12	HNF4	B
13	,	O
14	bound	O
15	to	O
16	its	O
17	cognate	O
18	site	O
19	and	O
20	transactivated	O
21	G6Pase	B
22	gene	I
23	expression	O
24	.	O
1	Both	O
2	inserts	O
3	are	O
4	larger	O
5	than	O
6	their	O
7	homologues	O
8	in	O
9	eIF	B
10	-	I
11	2alpha	I
12	kinases	I
13	.	O
1	Epitopes	O
2	of	O
3	adhesion	O
4	-	O
5	perturbing	O
6	monoclonal	O
7	antibodies	O
8	map	O
9	within	O
10	a	O
11	predicted	O
12	alpha	O
13	-	O
14	helical	O
15	domain	O
16	of	O
17	the	O
18	integrin	B
19	beta	I
20	1	I
21	subunit	I
22	.	O
1	In	O
2	this	O
3	paper	O
4	,	O
5	characterization	O
6	is	O
7	given	O
8	of	O
9	clinical	O
10	and	O
11	biochemical	O
12	features	O
13	of	O
14	VH	O
15	B	O
16	course	O
17	against	O
18	the	O
19	background	O
20	of	O
21	narcomania	O
22	.	O
1	CONCLUSIONS	O
2	:	O
3	We	O
4	obtained	O
5	normal	O
6	EPO	B
7	levels	O
8	for	O
9	mothers	O
10	and	O
11	newborns	O
12	for	O
13	our	O
14	area	O
15	,	O
16	similarly	O
17	to	O
18	the	O
19	previously	O
20	described	O
21	ones	O
22	.	O
1	This	O
2	difference	O
3	may	O
4	result	O
5	from	O
6	the	O
7	lower	O
8	match	O
9	to	O
10	the	O
11	ARG	O
12	box	O
13	consensus	O
14	of	O
15	the	O
16	O	B
17	(	I
18	rocD	I
19	)	I
20	site	I
21	.	O
1	The	O
2	amplitudes	O
3	of	O
4	DPOAE	O
5	also	O
6	recovered	O
7	to	O
8	a	O
9	greater	O
10	extent	O
11	and	O
12	outer	O
13	hair	O
14	cell	O
15	losses	O
16	were	O
17	less	O
18	severe	O
19	in	O
20	the	O
21	R	O
22	-	O
23	PIA	O
24	-	O
25	treated	O
26	ears	O
27	.	O
1	In	O
2	an	O
3	effort	O
4	to	O
5	separate	O
6	domains	O
7	of	O
8	FadR	B
9	required	O
10	for	O
11	DNA	O
12	binding	O
13	,	O
14	dimerization	O
15	,	O
16	and	O
17	ligand	O
18	binding	O
19	,	O
20	chimeric	O
21	protein	O
22	fusions	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	of	O
29	LexA	B
30	and	O
31	different	O
32	regions	O
33	of	O
34	FadR	B
35	were	O
36	constructed	O
37	.	O
1	Thus	O
2	,	O
3	dpp	B
4	and	O
5	omb	B
6	promote	O
7	both	O
8	dorsal	O
9	leg	O
10	cell	O
11	fate	O
12	as	O
13	well	O
14	as	O
15	transdetermination	O
16	-	O
17	competent	O
18	leg	O
19	disc	O
20	cells	O
21	.	O
1	AIDS	O
2	-	O
3	related	O
4	disseminated	O
5	histoplasmosis	O
6	in	O
7	San	O
8	Francisco	O
9	,	O
10	California	O
11	.	O
1	Coexpression	O
2	of	O
3	mouse	O
4	PKR	B
5	(	I
6	1	I
7	-	I
8	515	I
9	)	I
10	WT	I
11	as	O
12	a	O
13	Gal4	B
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	fusion	O
19	with	O
20	either	O
21	the	O
22	catalytic	O
23	-	O
24	deficient	O
25	human	O
26	PKR	B
27	(	I
28	1	I
29	-	I
30	551	I
31	)	I
32	K296R	O
33	mutant	O
34	,	O
35	the	O
36	RNA	O
37	-	O
38	binding	O
39	-	O
40	deficient	O
41	human	O
42	PKR	B
43	(	I
44	1	I
45	-	I
46	551	I
47	)	I
48	K64E	I
49	/	I
50	K296R	I
51	double	O
52	mutant	O
53	,	O
54	or	O
55	wild	O
56	-	O
57	type	O
58	mouse	O
59	PKR	B
60	(	I
61	1	I
62	-	I
63	515	I
64	)	I
65	WT	I
66	as	O
67	full	O
68	-	O
69	length	O
70	PKR	B
71	-	O
72	Gal4	B
73	activation	O
74	domain	O
75	fusions	O
76	resulted	O
77	in	O
78	activation	O
79	of	O
80	the	O
81	HIS3	B
82	and	O
83	lacZ	B
84	reporters	O
85	.	O
1	This	O
2	binary	O
3	repeat	O
4	contains	O
5	repetitive	O
6	DNA	O
7	elements	O
8	that	O
9	include	O
10	LINES	O
11	,	O
12	SINES	O
13	,	O
14	medium	O
15	reiteration	O
16	frequency	O
17	repeats	O
18	,	O
19	and	O
20	a	O
21	transposon	O
22	-	O
23	like	O
24	element	O
25	.	O
1	As	O
2	a	O
3	sequence	O
4	-	O
5	specific	O
6	DNA	O
7	binding	O
8	transcription	O
9	factor	O
10	,	O
11	p53	B
12	specifically	O
13	binds	O
14	to	O
15	a	O
16	20	O
17	-	O
18	bp	O
19	consensus	O
20	motif	O
21	5	O
22	'-	O
23	PuPuPuC	O
24	(	O
25	A	O
26	/	O
27	T	O
28	)	O
29	(	O
30	T	O
31	/	O
32	A	O
33	)	O
34	GPyPyPyPuPuPuC	O
35	(	O
36	A	O
37	/	O
38	T	O
39	)(	O
40	T	O
41	/	O
42	A	O
43	)	O
44	GPyPyPy	O
45	-	O
46	3	O
47	'.	O
1	TSA	O
2	treatment	O
3	,	O
4	however	O
5	,	O
6	did	O
7	not	O
8	detectably	O
9	alter	O
10	enhancer	O
11	factor	O
12	binding	O
13	or	O
14	the	O
15	positioning	O
16	of	O
17	nuc	B
18	-	I
19	1	I
20	on	O
21	the	O
22	majority	O
23	of	O
24	the	O
25	chromatin	O
26	templates	O
27	indicating	O
28	that	O
29	protein	O
30	acetylation	O
31	and	O
32	chromatin	O
33	remodeling	O
34	may	O
35	be	O
36	limiting	O
37	steps	O
38	that	O
39	occur	O
40	only	O
41	on	O
42	transcriptionally	O
43	competent	O
44	templates	O
45	,	O
46	or	O
47	that	O
48	remodeling	O
49	of	O
50	nuc	B
51	-	I
52	1	I
53	requires	O
54	additional	O
55	factors	O
56	.	O
1	Upon	O
2	UV	O
3	damage	O
4	,	O
5	Crb2	B
6	is	O
7	transiently	O
8	modified	O
9	,	O
10	probably	O
11	phosphorylated	O
12	,	O
13	with	O
14	a	O
15	similar	O
16	timing	O
17	of	O
18	phosphorylation	O
19	in	O
20	Chk1	B
21	kinase	I
22	,	O
23	which	O
24	is	O
25	reported	O
26	to	O
27	restrain	O
28	Cdc2	B
29	activation	O
30	.	O
1	Stability	O
2	of	O
3	pyrimethamine	O
4	in	O
5	a	O
6	liquid	O
7	dosage	O
8	formulation	O
9	stored	O
10	for	O
11	three	O
12	months	O
13	.	O
1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	RAD30	I
5	gene	I
6	,	O
7	a	O
8	homologue	B
9	of	I
10	Escherichia	I
11	coli	I
12	dinB	I
13	and	O
14	umuC	B
15	,	O
16	is	O
17	DNA	O
18	damage	O
19	inducible	O
20	and	O
21	functions	O
22	in	O
23	a	O
24	novel	O
25	error	O
26	-	O
27	free	O
28	postreplication	O
29	repair	O
30	mechanism	O
31	.	O
1	Gel	O
2	mobility	O
3	shift	O
4	and	O
5	super	O
6	-	O
7	shift	O
8	assays	O
9	using	O
10	liver	O
11	nuclear	O
12	extracts	O
13	from	O
14	either	O
15	rat	O
16	liver	O
17	or	O
18	DDT1MF	O
19	-	O
20	2	O
21	cells	O
22	demonstrated	O
23	that	O
24	the	O
25	CRE	O
26	in	O
27	the	O
28	alpha	B
29	1B	I
30	-	I
31	AR	I
32	gene	I
33	bound	O
34	CRE	B
35	binding	I
36	protein	I
37	.	O
1	The	O
2	multidomain	O
3	structure	O
4	includes	O
5	a	O
6	cysteine	O
7	-	O
8	rich	O
9	motif	O
10	resembling	O
11	those	O
12	of	O
13	protein	B
14	kinase	I
15	C	I
16	and	O
17	n	B
18	-	I
19	chimaerin	I
20	and	O
21	a	O
22	putative	O
23	pleckstrin	B
24	homology	I
25	domain	I
26	.	O
1	271	O
2	:	O
3	31290	O
4	-	O
5	31295	O
6	,	O
7	1996	O
8	).	O
1	MpB	B
2	GroEL	I
3	has	O
4	extensive	O
5	sequence	O
6	similarity	O
7	(	O
8	92	O
9	%)	O
10	with	O
11	Escherichia	B
12	coli	I
13	GroEL	I
14	and	O
15	other	O
16	members	O
17	of	O
18	the	O
19	chaperonin	B
20	-	I
21	60	I
22	family	I
23	.	O
1	The	O
2	5	O
3	'	O
4	end	O
5	of	O
6	the	O
7	genomic	O
8	RNA	O
9	of	O
10	rubella	O
11	virus	O
12	(	O
13	RUB	O
14	)	O
15	contains	O
16	a	O
17	14	O
18	-	O
19	nucleotide	O
20	(	O
21	nt	O
22	)	O
23	single	O
24	-	O
25	stranded	O
26	leader	O
27	(	O
28	ss	O
29	-	O
30	leader	O
31	)	O
32	followed	O
33	by	O
34	a	O
35	stem	O
36	-	O
37	and	O
38	-	O
39	loop	O
40	structure	O
41	[	O
42	5	O
43	'(+)	O
44	SL	O
45	]	O
46	(	O
47	nt	O
48	15	O
49	to	O
50	65	O
51	),	O
52	the	O
53	complement	O
54	of	O
55	which	O
56	at	O
57	the	O
58	3	O
59	'	O
60	end	O
61	of	O
62	the	O
63	minus	O
64	-	O
65	strand	O
66	RNA	O
67	[	O
68	3	O
69	'(-)	O
70	SL	O
71	]	O
72	has	O
73	been	O
74	proposed	O
75	to	O
76	function	O
77	as	O
78	a	O
79	promoter	O
80	for	O
81	synthesis	O
82	of	O
83	genomic	O
84	plus	O
85	strands	O
86	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	affinities	O
6	of	O
7	CBF2	B
8	for	O
9	binding	O
10	to	O
11	the	O
12	LMP	B
13	-	I
14	1	I
15	,	O
16	LMP	B
17	-	I
18	2	I
19	,	O
20	and	O
21	CD23	B
22	promoters	I
23	were	O
24	also	O
25	measured	O
26	.	O
1	To	O
2	investigate	O
3	the	O
4	activity	O
5	of	O
6	TCF11	B
7	through	O
8	this	O
9	selected	O
10	site	O
11	,	O
12	both	O
13	alone	O
14	and	O
15	in	O
16	the	O
17	presence	O
18	of	O
19	MafG	B
20	,	O
21	we	O
22	have	O
23	used	O
24	a	O
25	transient	O
26	transfection	O
27	assay	O
28	.	O
1	Holliday	B
2	junction	I
3	resolvase	I
4	in	O
5	Schizosaccharomyces	O
6	pombe	O
7	has	O
8	identical	O
9	endonuclease	O
10	activity	O
11	to	O
12	the	O
13	CCE1	B
14	homologue	O
15	YDC2	B
16	.	O
1	The	O
2	well	O
3	-	O
4	known	O
5	Rel	B
6	/	O
7	NF	B
8	-	I
9	kappaB	I
10	family	O
11	of	O
12	vertebrate	O
13	transcription	O
14	factors	O
15	comprises	O
16	a	O
17	number	O
18	of	O
19	structurally	O
20	related	O
21	,	O
22	interacting	O
23	proteins	O
24	that	O
25	bind	O
26	DNA	O
27	as	O
28	dimers	O
29	and	O
30	whose	O
31	activity	O
32	is	O
33	regulated	O
34	by	O
35	subcellular	O
36	location	O
37	.	O
1	A	O
2	cytosolic	O
3	variant	O
4	of	O
5	the	O
6	protein	O
7	underwent	O
8	efficient	O
9	transphosphorylation	O
10	,	O
11	yet	O
12	failed	O
13	to	O
14	activate	O
15	appreciably	O
16	either	O
17	p70	B
18	(	O
19	S6k	B
20	)	O
21	or	O
22	MAP	B
23	kinase	I
24	following	O
25	treatment	O
26	with	O
27	FK1012	O
28	.	O
1	A	O
2	genomic	O
3	clone	O
4	was	O
5	isolated	O
6	that	O
7	contained	O
8	12	O
9	.	O
10	5	O
11	kb	O
12	of	O
13	the	O
14	5	O
15	'-	O
16	flanking	O
17	region	O
18	and	O
19	the	O
20	first	O
21	exon	O
22	of	O
23	the	O
24	p69	B
25	/	I
26	71	I
27	2	I
28	-	I
29	5A	I
30	synthetase	I
31	gene	I
32	.	O
1	Although	O
2	the	O
3	gene	O
4	is	O
5	substantially	O
6	smaller	O
7	than	O
8	the	O
9	human	O
10	genes	O
11	for	O
12	other	O
13	mitochondrial	O
14	enzymes	O
15	,	O
16	its	O
17	intron	O
18	/	O
19	exon	O
20	organization	O
21	is	O
22	very	O
23	similar	O
24	,	O
25	especially	O
26	to	O
27	that	O
28	of	O
29	P450scc	B
30	.	O
1	RESULTS	O
2	:	O
3	Looking	O
4	at	O
5	the	O
6	question	O
7	of	O
8	its	O
9	benefits	O
10	,	O
11	we	O
12	were	O
13	unable	O
14	to	O
15	find	O
16	any	O
17	methodologically	O
18	sound	O
19	studies	O
20	that	O
21	have	O
22	shown	O
23	efficacy	O
24	for	O
25	EMDR	O
26	in	O
27	eating	O
28	disorders	O
29	,	O
30	or	O
31	,	O
32	indeed	O
33	,	O
34	any	O
35	psychiatric	O
36	disorder	O
37	.	O
1	Furthermore	O
2	the	O
3	median	O
4	increase	O
5	in	O
6	cyclosporine	O
7	DR	O
8	/	O
9	C	O
10	(	O
11	SS	O
12	trough	O
13	)	O
14	was	O
15	18	O
16	l	O
17	h	O
18	-	O
19	1	O
20	(-	O
21	3	O
22	.	O
23	1	O
24	to	O
25	42	O
26	.	O
27	1	O
28	l	O
29	h	O
30	-	O
31	1	O
32	,	O
33	interquartile	O
34	range	O
35	).	O
1	Expression	O
2	of	O
3	PTPRO	B
4	was	O
5	also	O
6	observed	O
7	in	O
8	human	B
9	CD34	I
10	+	I
11	bone	O
12	marrow	O
13	cells	O
14	and	O
15	5	O
16	-	O
17	FU	O
18	-	O
19	treated	O
20	murine	O
21	primitive	O
22	stem	O
23	cells	O
24	.	O
1	Our	O
2	results	O
3	showed	O
4	that	O
5	compared	O
6	to	O
7	the	O
8	primary	O
9	photon	O
10	fluence	O
11	,	O
12	the	O
13	extra	O
14	-	O
15	focal	O
16	photon	O
17	fluence	O
18	from	O
19	the	O
20	primary	O
21	collimator	O
22	and	O
23	the	O
24	flattening	O
25	filter	O
26	was	O
27	11	O
28	%-	O
29	16	O
30	%	O
31	at	O
32	the	O
33	isocenter	O
34	,	O
35	among	O
36	which	O
37	70	O
38	%	O
39	was	O
40	contributed	O
41	by	O
42	the	O
43	flattening	O
44	filter	O
45	.	O
1	The	O
2	patient	O
3	underwent	O
4	two	O
5	intracytoplasmic	O
6	sperm	O
7	injection	O
8	cycles	O
9	with	O
10	thawed	O
11	epididymal	O
12	spermatozoa	O
13	,	O
14	in	O
15	which	O
16	,	O
17	due	O
18	to	O
19	a	O
20	pharmacist	O
21	'	O
22	s	O
23	mistake	O
24	,	O
25	ovarian	O
26	stimulation	O
27	was	O
28	carried	O
29	out	O
30	by	O
31	a	O
32	combination	O
33	of	O
34	long	O
35	-	O
36	acting	O
37	gonadotrophin	B
38	-	I
39	releasing	I
40	hormone	I
41	agonist	O
42	(	O
43	leuprolide	O
44	depot	O
45	)	O
46	and	O
47	gonadotrophins	B
48	.	O
1	To	O
2	examine	O
3	the	O
4	role	O
5	of	O
6	this	O
7	CE2	O
8	element	O
9	in	O
10	regulating	O
11	Hoxa1	B
12	expression	O
13	in	O
14	vivo	O
15	,	O
16	transgenic	O
17	mice	O
18	were	O
19	generated	O
20	which	O
21	express	O
22	a	O
23	Hoxa1	B
24	beta	I
25	-	I
26	galactosidase	I
27	reporter	O
28	gene	O
29	that	O
30	contains	O
31	a	O
32	mutation	O
33	in	O
34	the	O
35	CE2	O
36	element	O
37	.	O
1	Here	O
2	we	O
3	report	O
4	that	O
5	in	O
6	cultured	O
7	cells	O
8	from	O
9	Drosophila	O
10	melanogaster	O
11	human	B
12	Sp1	I
13	efficiently	O
14	activates	O
15	transcription	O
16	from	O
17	synthetic	O
18	promoters	O
19	containing	O
20	TATA	O
21	boxes	O
22	,	O
23	but	O
24	not	O
25	from	O
26	promoters	O
27	that	O
28	contain	O
29	an	O
30	initiator	O
31	instead	O
32	of	O
33	a	O
34	TATA	O
35	box	O
36	.	O
1	We	O
2	have	O
3	used	O
4	mutation	O
5	-	O
6	directed	O
7	chemical	O
8	cross	O
9	-	O
10	linking	O
11	with	O
12	bis	O
13	(	O
14	sulfosuccinimidyl	O
15	)	O
16	suberate	O
17	(	O
18	BS3	O
19	)	O
20	to	O
21	investigate	O
22	the	O
23	architecture	O
24	of	O
25	the	O
26	gp41	B
27	oligomer	I
28	.	O
1	GlcNAc	O
2	-	O
3	and	O
4	GlcNAc2	O
5	-	O
6	PP	O
7	-	O
8	Dolichol	O
9	biosynthesis	O
10	could	O
11	be	O
12	shown	O
13	with	O
14	isolated	O
15	S	O
16	.	O
17	cerevisiae	O
18	membranes	O
19	from	O
20	cells	O
21	harboring	O
22	the	O
23	recombinant	O
24	plasmid	O
25	and	O
26	grown	O
27	on	O
28	glucose	O
29	thus	O
30	suppressing	O
31	transcription	O
32	of	O
33	the	O
34	endogenous	O
35	gene	O
36	.	O
1	This	O
2	region	O
3	,	O
4	however	O
5	,	O
6	contains	O
7	a	O
8	CCAATC	O
9	box	O
10	in	O
11	the	O
12	reverse	O
13	complement	O
14	and	O
15	several	O
16	GC	O
17	boxes	O
18	that	O
19	are	O
20	recognition	O
21	sites	O
22	for	O
23	SP1	B
24	.	O
1	Training	O
2	for	O
3	audit	O
4	.	O
1	Using	O
2	himA	B
3	mutants	I
4	,	O
5	we	O
6	confirmed	O
7	that	O
8	IHF	B
9	plays	O
10	a	O
11	role	O
12	in	O
13	the	O
14	molybdate	O
15	-	O
16	dependent	O
17	regulation	O
18	of	O
19	dmsA	B
20	-	O
21	lacZ	B
22	expression	O
23	in	O
24	vivo	O
25	.	O
1	The	O
2	observation	O
3	that	O
4	beta	B
5	2m	I
6	with	O
7	covalently	O
8	attached	O
9	peptide	O
10	can	O
11	effectively	O
12	create	O
13	CTL	O
14	target	O
15	structures	O
16	in	O
17	vitro	O
18	offers	O
19	new	O
20	possibilities	O
21	for	O
22	the	O
23	in	O
24	vivo	O
25	induction	O
26	of	O
27	epitope	O
28	-	O
29	specific	O
30	CTL	O
31	responses	O
32	by	O
33	either	O
34	DNA	O
35	immunization	O
36	or	O
37	injection	O
38	of	O
39	the	O
40	purified	O
41	epitope	O
42	-	O
43	linked	O
44	beta	B
45	2m	I
46	.	O
1	Here	O
2	we	O
3	have	O
4	examined	O
5	the	O
6	ability	O
7	of	O
8	the	O
9	cellular	O
10	protein	O
11	YB	B
12	-	I
13	1	I
14	to	O
15	modulate	O
16	transcription	O
17	of	O
18	the	O
19	HIV	B
20	-	I
21	1	I
22	promoter	I
23	in	O
24	a	O
25	human	O
26	astrocytic	O
27	cell	O
28	line	O
29	(	O
30	U	O
31	-	O
32	87MG	O
33	),	O
34	a	O
35	neuronal	O
36	cell	O
37	line	O
38	(	O
39	SK	O
40	-	O
41	N	O
42	-	O
43	MC	O
44	)	O
45	and	O
46	lymphoid	O
47	cells	O
48	(	O
49	Jurkat	O
50	)	O
51	by	O
52	transfection	O
53	assay	O
54	.	O
1	Competitive	O
2	reverse	O
3	transcription	O
4	-	O
5	polymerase	O
6	chain	O
7	reaction	O
8	and	O
9	HPLC	O
10	analysis	O
11	showed	O
12	that	O
13	RUSH	B
14	-	I
15	1alpha	I
16	is	O
17	the	O
18	progesterone	O
19	-	O
20	dependent	O
21	splice	O
22	variant	O
23	.	O
1	To	O
2	elucidate	O
3	the	O
4	regulatory	O
5	mechanism	O
6	of	O
7	human	B
8	AM	I
9	gene	I
10	expression	O
11	,	O
12	functional	O
13	elements	O
14	of	O
15	5	O
16	'-	O
17	flanking	O
18	region	O
19	of	O
20	AM	B
21	gene	I
22	were	O
23	studied	O
24	in	O
25	human	O
26	aortic	O
27	endothelial	O
28	cells	O
29	(	O
30	HAEC	O
31	).	O
1	C	O
2	.	O
3	D2	O
4	-	O
5	Chr	O
6	4	O
7	congenic	O
8	strains	O
9	harboring	O
10	DBA	O
11	/	O
12	2	O
13	alleles	O
14	associated	O
15	with	O
16	the	O
17	Pctr1	B
18	locus	I
19	contained	O
20	DBA	O
21	/	O
22	2	O
23	""""	O
24	resistant	O
25	""""	O
26	alleles	O
27	of	O
28	the	O
29	CDK4	B
30	/	O
31	CDK6	B
32	inhibitors	O
33	p16	B
34	and	O
35	p15	B
36	.	O
1	When	O
2	tested	O
3	with	O
4	wild	O
5	-	O
6	type	O
7	(	O
8	DBA	O
9	/	O
10	2	O
11	)	O
12	p16	B
13	,	O
14	both	O
15	A134C	O
16	and	O
17	G232A	O
18	BALB	O
19	/	O
20	c	O
21	-	O
22	specific	O
23	variants	O
24	of	O
25	p16	B
26	were	O
27	inefficient	O
28	in	O
29	their	O
30	ability	O
31	to	O
32	inhibit	O
33	the	O
34	activity	O
35	of	O
36	cyclin	B
37	D2	I
38	/	O
39	CDK4	B
40	in	O
41	kinase	O
42	assays	O
43	with	O
44	retinoblastoma	B
45	protein	I
46	,	O
47	suggesting	O
48	this	O
49	defective	O
50	,	O
51	inherited	O
52	allele	O
53	plays	O
54	an	O
55	important	O
56	role	O
57	in	O
58	the	O
59	genetic	O
60	susceptibility	O
61	of	O
62	BALB	O
63	/	O
64	c	O
65	mice	O
66	for	O
67	plasmacytoma	O
68	induction	O
69	and	O
70	that	O
71	p16	B
72	(	O
73	INK4a	B
74	)	O
75	is	O
76	a	O
77	strong	O
78	candidate	O
79	for	O
80	the	O
81	Pctr1	B
82	locus	I
83	.	O
1	Despite	O
2	this	O
3	there	O
4	was	O
5	no	O
6	difference	O
7	in	O
8	the	O
9	intubating	O
10	conditions	O
11	at	O
12	one	O
13	minute	O
14	with	O
15	25	O
16	excellent	O
17	/	O
18	5	O
19	good	O
20	in	O
21	the	O
22	suxamethonium	O
23	group	O
24	and	O
25	27	O
26	excellent	O
27	/	O
28	3	O
29	good	O
30	in	O
31	the	O
32	rocuronium	O
33	group	O
34	.	O
1	No	O
2	difference	O
3	in	O
4	telomere	O
5	length	O
6	was	O
7	seen	O
8	in	O
9	mutants	O
10	affected	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	Cdc2	B
16	,	O
17	whereas	O
18	some	O
19	of	O
20	the	O
21	DNA	O
22	repair	O
23	mutants	O
24	examined	O
25	had	O
26	slightly	O
27	longer	O
28	telomeres	O
29	than	O
30	did	O
31	the	O
32	wild	O
33	type	O
34	.	O
1	The	O
2	ESEM	O
3	differs	O
4	from	O
5	conventional	O
6	SEM	O
7	in	O
8	that	O
9	no	O
10	sample	O
11	preparation	O
12	is	O
13	needed	O
14	,	O
15	eliminating	O
16	artifactual	O
17	changes	O
18	.	O
1	To	O
2	understand	O
3	the	O
4	regulatory	O
5	mechanism	O
6	controlling	O
7	its	O
8	expression	O
9	at	O
10	low	O
11	temperature	O
12	,	O
13	the	O
14	promoter	O
15	region	O
16	has	O
17	been	O
18	characterized	O
19	.	O
1	Its	O
2	expression	O
3	pattern	O
4	is	O
5	representative	O
6	of	O
7	many	O
8	B	O
9	cell	O
10	-	O
11	specific	O
12	proteins	O
13	,	O
14	which	O
15	are	O
16	essential	O
17	for	O
18	B	O
19	cell	O
20	development	O
21	and	O
22	activation	O
23	but	O
24	are	O
25	down	O
26	-	O
27	regulated	O
28	after	O
29	B	O
30	cells	O
31	become	O
32	terminally	O
33	differentiated	O
34	plasma	O
35	cells	O
36	.	O
1	Activation	O
2	of	O
3	the	O
4	mitogen	B
5	activated	I
6	protein	I
7	(	I
8	MAP	I
9	)	I
10	kinase	I
11	is	O
12	a	O
13	primary	O
14	consequence	O
15	of	O
16	Ras	B
17	activation	O
18	and	O
19	plays	O
20	a	O
21	key	O
22	role	O
23	in	O
24	mediating	O
25	Ras	B
26	signal	O
27	transduction	O
28	.	O
1	Histone	B
2	acetylation	O
3	levels	O
4	in	O
5	cells	O
6	result	O
7	from	O
8	a	O
9	dynamic	O
10	equilibrium	O
11	between	O
12	competing	O
13	histone	B
14	acetylases	I
15	and	I
16	deacetylases	I
17	.	O
1	RESULTS	O
2	:	O
3	Patients	O
4	in	O
5	Group	O
6	A	O
7	had	O
8	a	O
9	higher	O
10	incidence	O
11	of	O
12	posterolateral	O
13	wall	O
14	motion	O
15	abnormalities	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	on	O
24	radionuclide	O
25	ventriculography	O
26	,	O
27	a	O
28	larger	O
29	infarct	O
30	area	O
31	(	O
32	as	O
33	evidenced	O
34	by	O
35	higher	O
36	peak	O
37	creatine	B
38	kinase	I
39	levels	O
40	)	O
41	(	O
42	p	O
43	<	O
44	0	O
45	.	O
46	02	O
47	)	O
48	and	O
49	a	O
50	lower	O
51	left	O
52	ventricular	O
53	ejection	O
54	fraction	O
55	(	O
56	LVEF	O
57	)	O
58	at	O
59	hospital	O
60	discharge	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	008	O
67	)	O
68	than	O
69	those	O
70	in	O
71	Group	O
72	B	O
73	.	O
1	Although	O
2	the	O
3	expression	O
4	of	O
5	the	O
6	4E	B
7	-	I
8	BP1	I
9	gene	I
10	alone	O
11	has	O
12	not	O
13	yet	O
14	been	O
15	accomplished	O
16	,	O
17	the	O
18	gene	O
19	was	O
20	expressed	O
21	in	O
22	Escherichia	O
23	coli	O
24	[	O
25	BL21	O
26	(	O
27	DE3	O
28	)]	O
29	as	O
30	a	O
31	fusion	O
32	gene	O
33	with	O
34	the	O
35	glutathione	B
36	-	I
37	S	I
38	-	I
39	transferase	I
40	(	O
41	GST	B
42	)	O
43	gene	O
44	using	O
45	a	O
46	prokaryotic	O
47	gene	O
48	fusion	O
49	vector	O
50	(	O
51	pGEX	O
52	-	O
53	4T	O
54	-	O
55	2	O
56	),	O
57	which	O
58	contains	O
59	a	O
60	gene	O
61	sequence	O
62	coding	O
63	the	O
64	cleavage	O
65	site	O
66	for	O
67	a	O
68	specific	O
69	protease	O
70	,	O
71	alpha	B
72	-	I
73	thrombin	I
74	.	O
1	Randomised	O
2	comparison	O
3	of	O
4	addition	O
5	of	O
6	autologous	O
7	bone	O
8	-	O
9	marrow	O
10	transplantation	O
11	to	O
12	intensive	O
13	chemotherapy	O
14	for	O
15	acute	O
16	myeloid	O
17	leukaemia	O
18	in	O
19	first	O
20	remission	O
21	:	O
22	results	O
23	of	O
24	MRC	O
25	AML	O
26	10	O
27	trial	O
28	.	O
1	Human	O
2	ZFM1	B
3	protein	I
4	is	O
5	a	O
6	transcriptional	O
7	repressor	O
8	that	O
9	interacts	O
10	with	O
11	the	O
12	transcription	B
13	activation	I
14	domain	I
15	of	I
16	stage	I
17	-	I
18	specific	I
19	activator	I
20	protein	I
21	.	O
1	Surprisingly	O
2	,	O
3	the	O
4	CSF1R	B
5	/	O
6	IRDelta960	B
7	was	O
8	as	O
9	effective	O
10	as	O
11	the	O
12	CSF1R	B
13	/	O
14	IR	B
15	in	O
16	mediating	O
17	CSF	B
18	-	I
19	1	I
20	protection	O
21	of	O
22	cells	O
23	from	O
24	staurosporine	O
25	-	O
26	induced	O
27	apoptosis	O
28	.	O
1	Two	O
2	hundred	O
3	sixty	O
4	-	O
5	four	O
6	patients	O
7	scheduled	O
8	for	O
9	DCBM	O
10	were	O
11	randomized	O
12	to	O
13	receive	O
14	intravenously	O
15	geG	O
16	0	O
17	.	O
18	25	O
19	mg	O
20	(	O
21	geG	O
22	-	O
23	25	O
24	),	O
25	or	O
26	geG	O
27	0	O
28	.	O
29	5	O
30	mg	O
31	(	O
32	geG	O
33	-	O
34	50	O
35	),	O
36	or	O
37	HBB	O
38	20	O
39	mg	O
40	as	O
41	hypotonic	O
42	agent	O
43	.	O
1	Based	O
2	on	O
3	restriction	O
4	enzyme	O
5	analysis	O
6	,	O
7	Southern	O
8	blots	O
9	,	O
10	polymerase	O
11	chain	O
12	reaction	O
13	analysis	O
14	and	O
15	DNA	O
16	sequencing	O
17	,	O
18	it	O
19	was	O
20	confirmed	O
21	that	O
22	the	O
23	three	O
24	overlapping	O
25	clones	O
26	isolated	O
27	cover	O
28	the	O
29	entire	O
30	cHO	B
31	-	I
32	1	I
33	gene	I
34	,	O
35	as	O
36	well	O
37	as	O
38	approximately	O
39	10	O
40	kb	O
41	of	O
42	the	O
43	flanking	O
44	regions	O
45	on	O
46	both	O
47	ends	O
48	.	O
1	E1A	B
2	represses	O
3	apolipoprotein	B
4	AI	I
5	enhancer	I
6	activity	O
7	in	O
8	liver	O
9	cells	O
10	through	O
11	a	O
12	pRb	B
13	-	O
14	and	O
15	CBP	B
16	-	O
17	independent	O
18	pathway	O
19	.	O
1	Calcitriol	O
2	therapy	O
3	was	O
4	associated	O
5	with	O
6	a	O
7	decrease	O
8	in	O
9	serum	O
10	iPTH	B
11	levels	O
12	(	O
13	701	O
14	+/-	O
15	103	O
16	.	O
17	9	O
18	vs	O
19	.	O
1	RT	O
2	-	O
3	PCR	O
4	indicated	O
5	that	O
6	p21	B
7	mRNA	I
8	was	O
9	induced	O
10	1	O
11	.	O
12	4	O
13	-,	O
14	2	O
15	.	O
16	0	O
17	-,	O
18	and	O
19	3	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	in	O
25	the	O
26	2	O
27	-	O
28	day	O
29	neonatal	O
30	,	O
31	7	O
32	-	O
33	day	O
34	neonatal	O
35	,	O
36	and	O
37	adult	O
38	stages	O
39	,	O
40	respectively	O
41	,	O
42	compared	O
43	to	O
44	the	O
45	17	O
46	-	O
47	day	O
48	fetal	O
49	stage	O
50	.	O
1	We	O
2	have	O
3	identified	O
4	two	O
5	functional	O
6	elements	O
7	,	O
8	both	O
9	located	O
10	downstream	O
11	from	O
12	the	O
13	TATA	O
14	motif	O
15	,	O
16	that	O
17	control	O
18	Id4	B
19	promoter	I
20	activity	O
21	.	O
1	BACKGROUND	O
2	AND	O
3	OBJECTIVES	O
4	:	O
5	The	O
6	sexually	O
7	transmitted	O
8	diseases	O
9	(	O
10	STD	O
11	)	O
12	control	O
13	program	O
14	for	O
15	female	O
16	sex	O
17	workers	O
18	(	O
19	FSW	O
20	)	O
21	in	O
22	Lima	O
23	,	O
24	Peru	O
25	,	O
26	provided	O
27	periodic	O
28	serological	O
29	tests	O
30	for	O
31	syphilis	O
32	and	O
33	cervical	O
34	smears	O
35	for	O
36	gonococci	O
37	,	O
38	but	O
39	not	O
40	medication	O
41	for	O
42	STD	O
43	or	O
44	condoms	O
45	.	O
1	National	O
2	certification	O
3	:	O
4	a	O
5	vital	O
6	component	O
7	of	O
8	quality	O
9	assurance	O
10	.	O
1	Chimaeric	O
2	VP16	B
3	-	O
4	E2	B
5	molecules	O
6	suggest	O
7	that	O
8	the	O
9	epithelial	O
10	specific	O
11	transcriptional	O
12	activation	O
13	of	O
14	the	O
15	BPV	B
16	-	I
17	4	I
18	LCR	I
19	promoter	I
20	is	O
21	mediated	O
22	by	O
23	the	O
24	E2	B
25	transactivation	I
26	domain	I
27	.	O
1	In	O
2	order	O
3	to	O
4	examine	O
5	the	O
6	potential	O
7	role	O
8	of	O
9	transcriptional	O
10	silencing	O
11	during	O
12	productive	O
13	HSV	O
14	-	O
15	1	O
16	infection	O
17	,	O
18	recombinant	O
19	viruses	O
20	were	O
21	generated	O
22	in	O
23	which	O
24	wild	B
25	-	I
26	type	I
27	or	I
28	mutant	I
29	ICP34	I
30	.	I
31	5	I
32	promoters	I
33	controlling	O
34	the	O
35	expression	O
36	of	O
37	a	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	I
41	gene	I
42	were	O
43	inserted	O
44	into	O
45	the	O
46	thymidine	B
47	kinase	I
48	gene	I
49	of	O
50	the	O
51	viral	O
52	genome	O
53	.	O
1	We	O
2	also	O
3	recovered	O
4	mutations	O
5	in	O
6	the	O
7	60A	B
8	gene	I
9	which	O
10	encodes	O
11	another	O
12	TGF	B
13	-	I
14	beta	I
15	-	I
16	related	I
17	factor	I
18	in	O
19	Drosophila	O
20	.	O
1	Both	O
2	variants	O
3	display	O
4	the	O
5	seven	O
6	-	O
7	transmembrane	O
8	topology	O
9	that	O
10	is	O
11	typical	O
12	for	O
13	G	B
14	protein	I
15	-	I
16	coupled	I
17	receptors	I
18	.	O
1	This	O
2	paper	O
3	describes	O
4	the	O
5	genomic	O
6	organization	O
7	of	O
8	mouse	O
9	gC1qBP	B
10	and	O
11	the	O
12	characterization	O
13	of	O
14	its	O
15	5	O
16	'	O
17	flanking	O
18	region	O
19	.	O
1	However	O
2	,	O
3	inhibition	O
4	of	O
5	both	O
6	the	O
7	ERK	B
8	/	O
9	RSK	B
10	and	O
11	the	O
12	p38	B
13	/	O
14	MAPKAP	B
15	kinase	I
16	2	I
17	pathways	O
18	completely	O
19	abolished	O
20	NGF	B
21	-	O
22	induced	O
23	CREB	B
24	Ser	O
25	-	O
26	133	O
27	phosphorylation	O
28	.	O
1	Alternative	O
2	splicing	O
3	of	O
4	fibroblast	B
5	growth	I
6	factor	I
7	receptor	I
8	2	I
9	(	O
10	FGF	B
11	-	I
12	R2	I
13	)	O
14	is	O
15	an	O
16	example	O
17	of	O
18	highly	O
19	regulated	O
20	alternative	O
21	splicing	O
22	in	O
23	which	O
24	exons	O
25	IIIb	O
26	and	O
27	IIIc	O
28	are	O
29	utilized	O
30	in	O
31	a	O
32	mutually	O
33	exclusive	O
34	manner	O
35	in	O
36	different	O
37	cell	O
38	types	O
39	.	O
1	SNAC	O
2	or	O
3	PBS	O
4	was	O
5	infused	O
6	for	O
7	6	O
8	.	O
9	5	O
10	h	O
11	,	O
12	beginning	O
13	30	O
14	min	O
15	before	O
16	ischemia	O
17	and	O
18	continuing	O
19	throughout	O
20	the	O
21	duration	O
22	of	O
23	reperfusion	O
24	.	O
1	On	O
2	a	O
3	separate	O
4	occasion	O
5	the	O
6	T1	O
7	weighted	O
8	and	O
9	T2	O
10	weighted	O
11	sagittal	O
12	and	O
13	T2	O
14	weighted	O
15	axial	O
16	sequences	O
17	were	O
18	reported	O
19	blind	O
20	in	O
21	relation	O
22	to	O
23	the	O
24	initial	O
25	assessment	O
26	.	O
1	BRCA1	B
2	protein	I
3	contains	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	zinc	O
9	finger	O
10	motif	O
11	and	O
12	a	O
13	carboxy	O
14	-	O
15	terminal	O
16	acidic	O
17	region	O
18	.	O
1	Creatine	B
2	kinase	I
3	release	O
4	after	O
5	hepatic	O
6	artery	O
7	embolization	O
8	in	O
9	patients	O
10	with	O
11	carcinoid	O
12	tumors	O
13	.	O
1	Mutation	O
2	of	O
3	the	O
4	central	O
5	Tyr497	O
6	to	O
7	Phe	O
8	blocks	O
9	the	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	the	O
14	insulin	B
15	receptor	I
16	substrate	I
17	1	I
18	(	O
19	IRS1	B
20	)	O
21	and	O
22	diminishes	O
23	proliferation	O
24	in	O
25	response	O
26	to	O
27	IL	B
28	-	I
29	4	I
30	.	O
1	Interestingly	O
2	,	O
3	the	O
4	activated	O
5	PDGF	B
6	beta	I
7	-	I
8	receptor	I
9	was	O
10	found	O
11	not	O
12	to	O
13	bind	O
14	Crk	B
15	proteins	I
16	.	O
1	Furthermore	O
2	,	O
3	interactions	O
4	were	O
5	identified	O
6	between	O
7	endogenous	B
8	E	I
9	-	I
10	cadherin	I
11	and	O
12	the	O
13	chimera	O
14	containing	O
15	the	O
16	E	B
17	-	I
18	cadherin	I
19	extracellular	I
20	domain	I
21	and	O
22	the	O
23	desmoglein	B
24	1	I
25	intracellular	I
26	domain	I
27	providing	O
28	in	O
29	vivo	O
30	evidence	O
31	for	O
32	previously	O
33	predicted	O
34	lateral	O
35	interactions	O
36	of	O
37	E	B
38	-	I
39	cadherin	I
40	extracellular	I
41	domains	I
42	.	O
1	The	O
2	ether	O
3	phospholipid	O
4	1	O
5	-	O
6	O	O
7	-	O
8	octadecyl	O
9	-	O
10	2	O
11	-	O
12	O	O
13	-	O
14	methyl	O
15	-	O
16	rac	O
17	-	O
18	glycero	O
19	-	O
20	3	O
21	-	O
22	phosphocholine	O
23	(	O
24	ET	O
25	-	O
26	18	O
27	-	O
28	OCH3	O
29	;	O
30	edelfosine	O
31	)	O
32	is	O
33	a	O
34	potent	O
35	inducer	O
36	of	O
37	apoptosis	O
38	in	O
39	human	O
40	tumor	O
41	cells	O
42	.	O
1	Serum	O
2	levels	O
3	of	O
4	testosterone	O
5	also	O
6	showed	O
7	no	O
8	significant	O
9	changes	O
10	by	O
11	exposure	O
12	to	O
13	p	O
14	,	O
15	p	O
16	'-	O
17	DDE	O
18	under	O
19	the	O
20	conditions	O
21	of	O
22	this	O
23	study	O
24	.	O
1	One	O
2	hundred	O
3	replicate	O
4	data	O
5	sets	O
6	of	O
7	100	O
8	subjects	O
9	each	O
10	were	O
11	simulated	O
12	for	O
13	each	O
14	missing	O
15	data	O
16	scenario	O
17	.	O
1	Fluorescence	O
2	in	O
3	situ	O
4	hybridization	O
5	of	O
6	metaphase	O
7	spreads	O
8	of	O
9	chromosome	O
10	8	O
11	,	O
12	containing	O
13	hybrid	O
14	cell	O
15	line	O
16	706	O
17	-	O
18	B6	O
19	clone	O
20	17	O
21	(	O
22	CL	O
23	-	O
24	17	O
25	)	O
26	with	O
27	cosmid	O
28	c101F1	O
29	,	O
30	placed	O
31	the	O
32	9804	B
33	gene	I
34	close	O
35	to	O
36	the	O
37	telomere	O
38	at	O
39	8q24	O
40	.	O
41	3	O
42	.	O
1	Cell	O
2	survival	O
3	by	O
4	Epo	B
5	did	O
6	not	O
7	require	O
8	activation	O
9	of	O
10	other	O
11	known	O
12	signaling	O
13	pathways	O
14	including	O
15	PI	B
16	-	I
17	3	I
18	kinase	I
19	,	O
20	PLC	B
21	-	I
22	gamma	I
23	,	O
24	Ras	B
25	or	O
26	Stats	B
27	.	O
1	The	O
2	N	O
3	-	O
4	syndecan	O
5	-	O
6	dependent	O
7	neurite	O
8	outgrowth	O
9	is	O
10	inhibited	O
11	by	O
12	the	O
13	tyrosine	B
14	kinase	I
15	inhibitors	O
16	herbimycin	O
17	A	O
18	and	O
19	PP1	B
20	.	O
1	The	O
2	pharmacokinetic	O
3	patterns	O
4	of	O
5	estradiol	O
6	(	O
7	CAS	O
8	50	O
9	-	O
10	28	O
11	-	O
12	2	O
13	)	O
14	and	O
15	of	O
16	estrone	O
17	(	O
18	CAS	O
19	53	O
20	-	O
21	16	O
22	-	O
23	7	O
24	)	O
25	were	O
26	investigated	O
27	in	O
28	18	O
29	women	O
30	in	O
31	natural	O
32	or	O
33	surgical	O
34	menopause	O
35	during	O
36	the	O
37	application	O
38	of	O
39	a	O
40	new	O
41	estradiol	O
42	transdermal	O
43	patch	O
44	with	O
45	active	O
46	matrix	O
47	and	O
48	without	O
49	absorption	O
50	enhancers	O
51	designed	O
52	for	O
53	epicutaneous	O
54	applications	O
55	of	O
56	7	O
57	days	O
58	(	O
59	hereinafter	O
60	called	O
61	""""	O
62	patch	O
63	7D	O
64	""")."	O
1	A	O
2	cDNA	O
3	,	O
4	cak1At	B
5	,	O
6	was	O
7	isolated	O
8	that	O
9	suppressed	O
10	the	O
11	CAK	B
12	mutation	I
13	in	O
14	budding	O
15	yeast	O
16	,	O
17	and	O
18	it	O
19	also	O
20	complemented	O
21	a	O
22	fission	B
23	yeast	I
24	CAK	I
25	mutant	I
26	.	O
27	cak1At	B
28	encodes	O
29	a	O
30	protein	O
31	related	O
32	to	O
33	animal	B
34	CAKs	I
35	.	O
1	Decreased	O
2	levels	O
3	of	O
4	alpha2	B
5	-	I
6	antiplasmin	I
7	were	O
8	also	O
9	observed	O
10	in	O
11	the	O
12	mediastinum	O
13	(	O
14	0	O
15	.	O
16	50	O
17	versus	O
18	0	O
19	.	O
20	61	O
21	U	O
22	/	O
23	mL	O
24	;	O
25	p	O
26	<	O
27	0	O
28	.	O
29	05	O
30	).	O
1	All	O
2	three	O
3	genes	O
4	have	O
5	been	O
6	mapped	O
7	precisely	O
8	to	O
9	a	O
10	small	O
11	region	O
12	on	O
13	human	O
14	chromosome	O
15	16p12	O
16	.	O
17	1	O
18	-	O
19	p11	O
20	.	O
21	2	O
22	(	O
23	homologous	O
24	to	O
25	mouse	O
26	chromosome	O
27	7	O
28	),	O
29	using	O
30	somatic	O
31	cell	O
32	hybrids	O
33	and	O
34	cosmid	O
35	clones	O
36	.	O
1	The	O
2	general	O
3	transcription	B
4	factor	I
5	IIA	I
6	(	O
7	TFIIA	B
8	)	O
9	interacts	O
10	with	O
11	the	O
12	TATA	B
13	binding	I
14	protein	I
15	(	O
16	TBP	B
17	)	O
18	and	O
19	promoter	O
20	DNA	O
21	to	O
22	mediate	O
23	transcription	O
24	activation	O
25	in	O
26	vitro	O
27	.	O
1	Their	O
2	function	O
3	is	O
4	not	O
5	only	O
6	to	O
7	recruit	O
8	Pho2	B
9	to	O
10	the	O
11	promoter	O
12	but	O
13	to	O
14	allow	O
15	cooperative	O
16	binding	O
17	of	O
18	Pho4	B
19	together	O
20	with	O
21	Pho2	B
22	.	O
1	Fetal	O
2	growth	O
3	retardation	O
4	as	O
5	a	O
6	cause	O
7	of	O
8	impaired	O
9	ovarian	O
10	development	O
11	.	O
1	Localization	O
2	of	O
3	67	O
4	exons	O
5	on	O
6	a	O
7	YAC	O
8	contig	O
9	spanning	O
10	1	O
11	.	O
12	5	O
13	Mb	O
14	around	O
15	the	O
16	multidrug	B
17	resistance	I
18	gene	I
19	region	I
20	of	O
21	human	O
22	chromosome	O
23	7q21	O
24	.	O
25	1	O
26	.	O
1	These	O
2	two	O
3	mRNA	O
4	species	O
5	are	O
6	produced	O
7	by	O
8	differential	O
9	polyadenylation	O
10	site	O
11	usage	O
12	.	O
1	However	O
2	,	O
3	mandibular	O
4	position	O
5	(	O
6	S	O
7	-	O
8	N	O
9	-	O
10	B	O
11	and	O
12	S	O
13	-	O
14	N	O
15	-	O
16	Pog	O
17	)	O
18	was	O
19	found	O
20	to	O
21	be	O
22	significantly	O
23	more	O
24	retrusive	O
25	in	O
26	Class	O
27	II	O
28	when	O
29	compared	O
30	with	O
31	Class	O
32	I	O
33	subjects	O
34	.	O
1	Finally	O
2	,	O
3	a	O
4	role	O
5	for	O
6	NF	B
7	-	I
8	kappaB	I
9	in	O
10	preventing	O
11	apoptosis	O
12	induced	O
13	by	O
14	ER	O
15	calcium	O
16	release	O
17	was	O
18	demonstrated	O
19	by	O
20	data	O
21	showing	O
22	that	O
23	sAPPalpha	B
24	prevents	O
25	thapsigargin	O
26	-	O
27	induced	O
28	apoptosis	O
29	,	O
30	an	O
31	effect	O
32	blocked	O
33	by	O
34	kappaB	B
35	decoy	O
36	DNA	O
37	.	O
1	In	O
2	angiodysplasia	O
3	,	O
4	ectatic	O
5	vessels	O
6	in	O
7	the	O
8	mucosa	O
9	appeared	O
10	to	O
11	contain	O
12	less	O
13	collagen	B
14	type	I
15	IV	I
16	than	O
17	similarly	O
18	sized	O
19	vessels	O
20	in	O
21	the	O
22	submucosa	O
23	,	O
24	and	O
25	perforating	O
26	vessels	O
27	appeared	O
28	in	O
29	many	O
30	cases	O
31	to	O
32	lose	O
33	staining	O
34	at	O
35	the	O
36	level	O
37	of	O
38	the	O
39	muscularis	O
40	mucosae	O
41	.	O
1	The	O
2	present	O
3	results	O
4	demonstrate	O
5	that	O
6	rats	O
7	with	O
8	relatively	O
9	small	O
10	remnants	O
11	of	O
12	one	O
13	olfactory	O
14	bulb	O
15	can	O
16	perform	O
17	a	O
18	variety	O
19	of	O
20	odor	O
21	detection	O
22	and	O
23	discrimination	O
24	tasks	O
25	as	O
26	well	O
27	or	O
28	nearly	O
29	as	O
30	well	O
31	as	O
32	controls	O
33	.	O
1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	is	O
7	78	O
8	.	O
9	0	O
10	%	O
11	identical	O
12	to	O
13	the	O
14	cytoplasmic	B
15	dynein	I
16	heavy	I
17	chain	I
18	of	I
19	Neurospora	I
20	crassa	I
21	,	O
22	70	O
23	.	O
24	2	O
25	%	O
26	identical	O
27	to	O
28	that	O
29	of	O
30	Aspergillus	O
31	nidulans	O
32	and	O
33	24	O
34	.	O
35	8	O
36	%	O
37	identical	O
38	to	O
39	that	O
40	of	O
41	Saccharomyces	O
42	cerevisiae	O
43	.	O
1	Indeed	O
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	it	O
8	mediates	O
9	the	O
10	formation	O
11	of	O
12	disulfide	O
13	-	O
14	linked	O
15	homodimers	O
16	and	O
17	that	O
18	the	O
19	formation	O
20	of	O
21	homo	O
22	-	O
23	and	O
24	heterodimers	O
25	are	O
26	mutually	O
27	excluded	O
28	.	O
1	We	O
2	have	O
3	shown	O
4	previously	O
5	that	O
6	GH3	O
7	cells	O
8	transfected	O
9	with	O
10	the	O
11	rat	B
12	GnRH	I
13	receptor	I
14	cDNA	I
15	(	O
16	GGH3	O
17	-	O
18	1	O
19	'	O
20	cells	O
21	)	O
22	support	O
23	the	O
24	expression	O
25	of	O
26	a	O
27	cotransfected	O
28	fusion	O
29	gene	O
30	composed	O
31	of	O
32	797	O
33	base	O
34	pairs	O
35	of	O
36	rat	B
37	LHbeta	I
38	gene	I
39	5	I
40	'-	I
41	flanking	I
42	sequence	I
43	and	O
44	the	O
45	first	O
46	5	O
47	base	O
48	pairs	O
49	of	O
50	the	O
51	5	O
52	'-	O
53	untranslated	O
54	region	O
55	fused	O
56	to	O
57	a	O
58	luciferase	B
59	reporter	I
60	(-	I
61	797	I
62	/+	I
63	5LHbetaLUC	I
64	)	I
65	and	O
66	respond	O
67	to	O
68	a	O
69	GnRH	B
70	agonist	O
71	with	O
72	a	O
73	10	O
74	-	O
75	fold	O
76	stimulation	O
77	of	O
78	activity	O
79	.	O
1	Results	O
2	showed	O
3	that	O
4	the	O
5	mean	O
6	bond	O
7	strength	O
8	of	O
9	H	O
10	.	O
11	T	O
12	.	O
13	V	O
14	.	O
15	specimens	O
16	ranged	O
17	from	O
18	9	O
19	.	O
20	6	O
21	to	O
22	13	O
23	.	O
24	12	O
25	kg	O
26	/	O
27	cm2	O
28	,	O
29	while	O
30	the	O
31	mean	O
32	bond	O
33	strength	O
34	of	O
35	R	O
36	.	O
37	T	O
38	.	O
39	V	O
40	.	O
41	specimens	O
42	ranged	O
43	from	O
44	0	O
45	.	O
46	36	O
47	to	O
48	1	O
49	.	O
50	75	O
51	kg	O
52	/	O
53	cm2	O
54	.	O
1	OBJECTIVES	O
2	:	O
3	To	O
4	measure	O
5	coagulation	B
6	factor	I
7	VIII	I
8	:	I
9	coagulant	I
10	(	O
11	F	B
12	.	I
13	VIII	I
14	:	I
15	C	I
16	)	O
17	and	O
18	C1	B
19	-	I
20	esterase	I
21	inhibitor	I
22	(	O
23	C1	B
24	-	I
25	INH	I
26	),	O
27	hemostasis	O
28	-	O
29	associated	O
30	acute	O
31	-	O
32	phase	O
33	reactant	O
34	proteins	O
35	and	O
36	coagulation	B
37	factors	I
38	VII	I
39	(	O
40	F	B
41	.	I
42	VII	I
43	),	O
44	IX	O
45	(	O
46	F	B
47	.	I
48	IX	I
49	),	O
50	and	O
51	X	O
52	(	O
53	F	B
54	.	I
55	X	I
56	),	O
57	hemostasis	O
58	proteins	O
59	not	O
60	associated	O
61	with	O
62	an	O
63	acute	O
64	-	O
65	phase	O
66	response	O
67	,	O
68	in	O
69	a	O
70	select	O
71	population	O
72	of	O
73	horses	O
74	with	O
75	colic	O
76	and	O
77	hemostasis	O
78	abnormalities	O
79	,	O
80	and	O
81	presumed	O
82	to	O
83	have	O
84	acute	O
85	-	O
86	phase	O
87	changes	O
88	.	O
1	RESULTS	O
2	:	O
3	Horses	O
4	with	O
5	colic	O
6	had	O
7	significantly	O
8	higher	O
9	fibrinogen	B
10	concentration	O
11	,	O
12	greater	O
13	alpha	B
14	2AP	I
15	and	O
16	protein	B
17	C	I
18	activities	O
19	,	O
20	and	O
21	longer	O
22	PT	O
23	and	O
24	APTT	O
25	than	O
26	did	O
27	healthy	O
28	horses	O
29	.	O
1	None	O
2	of	O
3	the	O
4	patients	O
5	was	O
6	obese	O
7	.	O
1	Peptide	O
2	sequences	O
3	of	O
4	the	O
5	zinc	B
6	finger	I
7	protein	I
8	Ttk	I
9	and	O
10	the	O
11	transcription	B
12	factor	I
13	Adf	I
14	-	I
15	1	I
16	were	O
17	obtained	O
18	.	O
1	In	O
2	support	O
3	of	O
4	a	O
5	role	O
6	at	O
7	the	O
8	spindle	O
9	,	O
10	two	O
11	-	O
12	hybrid	O
13	library	O
14	screening	O
15	with	O
16	HEF1	B
17	identifies	O
18	the	O
19	human	O
20	homolog	O
21	of	O
22	the	O
23	G2	B
24	/	I
25	M	I
26	spindle	I
27	-	I
28	regulatory	I
29	protein	I
30	Dim1p	I
31	as	O
32	a	O
33	specific	O
34	interactor	O
35	with	O
36	a	O
37	region	O
38	of	O
39	HEF1	B
40	encompassed	O
41	in	O
42	p55	B
43	(	O
44	HEF1	B
45	).	O
1	Genetic	O
2	studies	O
3	in	O
4	Drosophila	O
5	have	O
6	led	O
7	to	O
8	the	O
9	identification	O
10	of	O
11	several	O
12	components	O
13	of	O
14	the	O
15	Notch	B
16	pathway	O
17	.	O
1	Structural	O
2	features	O
3	of	O
4	the	O
5	minimal	O
6	DNA	O
7	binding	O
8	domain	O
9	(	O
10	M98	O
11	-	O
12	F219	O
13	)	O
14	of	O
15	human	B
16	nucleotide	I
17	excision	I
18	repair	I
19	protein	I
20	XPA	I
21	.	O
1	Amongst	O
2	other	O
3	qualities	O
4	,	O
5	the	O
6	book	O
7	'	O
8	s	O
9	importance	O
10	lies	O
11	in	O
12	the	O
13	fact	O
14	that	O
15	it	O
16	associates	O
17	an	O
18	elaborate	O
19	theoretical	O
20	construction	O
21	with	O
22	the	O
23	empirical	O
24	data	O
25	,	O
26	working	O
27	within	O
28	the	O
29	possibilities	O
30	provided	O
31	by	O
32	late	O
33	19th	O
34	-	O
35	century	O
36	moral	O
37	statistics	O
38	.	O
1	Recently	O
2	,	O
3	extremely	O
4	high	O
5	levels	O
6	of	O
7	endothelin	B
8	-	I
9	1	I
10	(	O
11	ET	B
12	-	I
13	1	I
14	)	O
15	were	O
16	detected	O
17	in	O
18	the	O
19	pericardial	O
20	fluid	O
21	of	O
22	patients	O
23	undergoing	O
24	cardiac	O
25	surgery	O
26	.	O
1	We	O
2	show	O
3	that	O
4	the	O
5	surfaces	O
6	of	O
7	tracheal	O
8	cartilage	O
9	matrix	O
10	are	O
11	collagen	B
12	-	O
13	rich	O
14	and	O
15	surround	O
16	a	O
17	proteoglycan	O
18	-	O
19	rich	O
20	core	O
21	.	O
1	Identical	O
2	results	O
3	were	O
4	obtained	O
5	when	O
6	transfections	O
7	and	O
8	mobility	O
9	shift	O
10	assays	O
11	were	O
12	performed	O
13	in	O
14	primary	O
15	rat	O
16	hepatocytes	O
17	in	O
18	which	O
19	the	O
20	endogenous	O
21	ALS	B
22	gene	I
23	is	O
24	expressed	O
25	.	O
1	Examination	O
2	of	O
3	the	O
4	mitochondrial	B
5	bc1	I
6	complex	I
7	crystal	I
8	structure	I
9	[	O
10	Zhang	O
11	,	O
12	Z	O
13	.,	O
14	Huang	O
15	,	O
16	L	O
17	.,	O
18	Shulmeister	O
19	,	O
20	V	O
21	.	O
1	The	O
2	identified	O
3	isolates	O
4	of	O
5	CSF	O
6	(	O
7	20	O
8	of	O
9	29	O
10	)	O
11	were	O
12	:	O
13	ECHO	O
14	30	O
15	(	O
16	9	O
17	),	O
18	ECHO	O
19	11	O
20	(	O
21	7	O
22	),	O
23	ECHO	O
24	9	O
25	(	O
26	3	O
27	)	O
28	and	O
29	ECHO	O
30	7	O
31	(	O
32	1	O
33	).	O
1	The	O
2	ParaSight	O
3	-	O
4	F	O
5	test	O
6	alone	O
7	was	O
8	used	O
9	to	O
10	monitor	O
11	serum	O
12	antigen	O
13	levels	O
14	after	O
15	treatment	O
16	in	O
17	24	O
18	patients	O
19	.	O
1	A	O
2	deproteinization	O
3	procedure	O
4	was	O
5	coupled	O
6	with	O
7	a	O
8	reversed	O
9	-	O
10	phase	O
11	HPLC	O
12	separation	O
13	using	O
14	a	O
15	250x4	O
16	.	O
17	6	O
18	mm	O
19	I	O
20	.	O
21	D	O
22	.	O
1	At	O
2	physiological	O
3	doses	O
4	,	O
5	either	O
6	insulin	B
7	-	I
8	like	I
9	growth	I
10	factor	I
11	I	I
12	(	O
13	IGF	B
14	-	I
15	I	I
16	)	O
17	or	O
18	insulin	B
19	turned	O
20	out	O
21	to	O
22	be	O
23	as	O
24	potent	O
25	as	O
26	dibutyryl	O
27	cAMP	O
28	(	O
29	dbcAMP	O
30	)	O
31	in	O
32	increasing	O
33	UCP1	B
34	gene	I
35	transcription	O
36	rate	O
37	(	O
38	1	O
39	h	O
40	)	O
41	and	O
42	also	O
43	UCP1	B
44	mRNA	I
45	accumulation	O
46	(	O
47	3	O
48	h	O
49	),	O
50	their	O
51	maximal	O
52	effect	O
53	(	O
54	15	O
55	-	O
56	fold	O
57	increase	O
58	)	O
59	reached	O
60	upon	O
61	treatment	O
62	for	O
63	24	O
64	h	O
65	.	O
1	In	O
2	addition	O
3	,	O
4	insulin	B
5	induced	O
6	AP	B
7	-	I
8	1	I
9	DNA	O
10	binding	O
11	activity	O
12	,	O
13	this	O
14	effect	O
15	being	O
16	totally	O
17	prevented	O
18	in	O
19	the	O
20	presence	O
21	of	O
22	MEK	B
23	-	I
24	1	I
25	inhibitor	O
26	.	O
1	A	O
2	large	O
3	deletion	O
4	in	O
5	the	O
6	CTD	B
7	-	I
8	binding	I
9	motif	I
10	blocks	O
11	down	O
12	-	O
13	regulation	O
14	but	O
15	does	O
16	not	O
17	affect	O
18	the	O
19	essential	O
20	function	O
21	of	O
22	Nrd1	B
23	.	O
1	In	O
2	addition	O
3	to	O
4	the	O
5	signals	O
6	obtained	O
7	by	O
8	ligation	O
9	of	O
10	the	O
11	TCR	B
12	,	O
13	T	O
14	cells	O
15	need	O
16	additional	O
17	,	O
18	co	O
19	-	O
20	stimulatory	O
21	signals	O
22	to	O
23	be	O
24	activated	O
25	.	O
1	The	O
2	importance	O
3	of	O
4	these	O
5	sites	O
6	for	O
7	transcriptional	O
8	activation	O
9	was	O
10	studied	O
11	by	O
12	site	O
13	-	O
14	directed	O
15	mutagenesis	O
16	followed	O
17	by	O
18	promoter	O
19	function	O
20	analysis	O
21	of	O
22	the	O
23	mutants	O
24	with	O
25	a	O
26	chloramphenicol	B
27	acetyltransferase	I
28	reporter	I
29	system	O
30	.	O
1	Two	O
2	members	O
3	of	O
4	the	O
5	Cbl	B
6	family	I
7	have	O
8	since	O
9	been	O
10	defined	O
11	in	O
12	mammals	O
13	(	O
14	c	B
15	-	I
16	Cbl	I
17	and	O
18	Cbl	B
19	-	I
20	b	I
21	),	O
22	one	O
23	in	O
24	C	O
25	.	O
26	elegans	O
27	(	O
28	Sli	B
29	-	I
30	1	I
31	)	O
32	and	O
33	one	O
34	in	O
35	Drosophila	O
36	(	O
37	D	B
38	-	I
39	Cbl	I
40	).	O
1	We	O
2	have	O
3	applied	O
4	the	O
5	mRNA	O
6	differential	O
7	display	O
8	method	O
9	to	O
10	compare	O
11	and	O
12	analyze	O
13	mRNAs	O
14	prepared	O
15	from	O
16	five	O
17	normal	O
18	nasopharyngeal	O
19	epithelial	O
20	cell	O
21	cultures	O
22	and	O
23	five	O
24	nasopharyngeal	O
25	carcinoma	O
26	cell	O
27	lines	O
28	.	O
1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	patients	O
6	with	O
7	IS	O
8	,	O
9	67	O
10	%	O
11	had	O
12	significantly	O
13	greater	O
14	values	O
15	of	O
16	directional	O
17	preponderance	O
18	on	O
19	the	O
20	OVAR	O
21	test	O
22	(	O
23	a	O
24	measure	O
25	of	O
26	otolith	O
27	system	O
28	imbalance	O
29	)	O
30	compared	O
31	with	O
32	control	O
33	subjects	O
34	.	O
1	Yeast	B
2	U1	I
3	snRNP	I
4	is	O
5	considerably	O
6	more	O
7	complex	O
8	than	O
9	its	O
10	metazoan	O
11	counterpart	O
12	,	O
13	which	O
14	suggests	O
15	possible	O
16	differences	O
17	between	O
18	yeast	O
19	and	O
20	metazoa	O
21	in	O
22	early	O
23	splicing	O
24	events	O
25	.	O
1	Yeast	B
2	U1	I
3	snRNP	I
4	therefore	O
5	contains	O
6	16	O
7	different	O
8	proteins	O
9	,	O
10	including	O
11	seven	O
12	snRNP	B
13	core	I
14	proteins	I
15	,	O
16	three	O
17	homologues	O
18	of	O
19	the	O
20	metazoan	B
21	U1	I
22	snRNP	I
23	-	I
24	specific	I
25	proteins	I
26	,	O
27	and	O
28	six	O
29	yeast	B
30	-	I
31	specific	I
32	U1	I
33	snRNP	I
34	proteins	I
35	.	O
1	One	O
2	cDNA	O
3	clone	O
4	designated	O
5	NCoA	O
6	-	O
7	62	O
8	,	O
9	encoded	O
10	a	O
11	62	O
12	,	O
13	000	O
14	-	O
15	Da	O
16	protein	O
17	that	O
18	is	O
19	highly	O
20	related	O
21	to	O
22	BX42	B
23	,	O
24	a	O
25	Drosophila	O
26	melanogaster	O
27	nuclear	O
28	protein	O
29	involved	O
30	in	O
31	ecdysone	O
32	-	O
33	stimulated	O
34	gene	O
35	expression	O
36	.	O
1	Structure	O
2	of	O
3	the	O
4	gene	O
5	encoding	O
6	the	O
7	human	O
8	cyclin	B
9	-	I
10	dependent	I
11	kinase	I
12	inhibitor	O
13	p18	B
14	and	O
15	mutational	O
16	analysis	O
17	in	O
18	breast	O
19	cancer	O
20	.	O
1	Sp1	B
2	and	O
3	two	O
4	Sp3	B
5	isoforms	I
6	were	O
7	detected	O
8	as	O
9	the	O
10	primary	O
11	cellular	O
12	constituents	O
13	of	O
14	DNA	O
15	-	O
16	protein	O
17	complexes	O
18	formed	O
19	with	O
20	the	O
21	NF	B
22	-	I
23	kappaB	I
24	-	I
25	proximal	I
26	site	I
27	.	O
1	The	O
2	second	O
3	patient	O
4	had	O
5	received	O
6	pituitary	B
7	-	I
8	derived	I
9	growth	I
10	hormone	I
11	for	O
12	treatment	O
13	of	O
14	growth	B
15	hormone	I
16	deficiency	O
17	,	O
18	secondary	O
19	to	O
20	a	O
21	third	O
22	ventricle	O
23	teratoma	O
24	,	O
25	exised	O
26	13	O
27	yr	O
28	earlier	O
29	.	O
1	Osteoadherin	B
2	is	O
3	a	O
4	recently	O
5	described	O
6	bone	O
7	proteoglycan	O
8	containing	O
9	keratan	O
10	sulfate	O
11	.	O
1	Intron	O
2	8	O
3	harbored	O
4	a	O
5	strong	O
6	erythroid	O
7	-	O
8	specific	O
9	enhancer	O
10	activity	O
11	which	O
12	was	O
13	orientation	O
14	-	O
15	dependent	O
16	.	O
1	The	O
2	cleavage	O
3	of	O
4	Fak	B
5	by	O
6	caspases	B
7	may	O
8	thus	O
9	play	O
10	an	O
11	important	O
12	role	O
13	in	O
14	the	O
15	execution	O
16	of	O
17	the	O
18	suicide	O
19	program	O
20	by	O
21	disabling	O
22	the	O
23	anti	O
24	-	O
25	apoptotic	O
26	function	O
27	of	O
28	Fak	B
29	.	O
1	[	O
2	Treatment	O
3	of	O
4	early	O
5	T1	O
6	small	O
7	T2N	O
8	breast	O
9	cancers	O
10	.	O
1	In	O
2	macrophages	O
3	,	O
4	LPS	O
5	-	O
6	inducible	O
7	HIV	O
8	-	O
9	1	O
10	gene	O
11	expression	O
12	is	O
13	mediated	O
14	in	O
15	part	O
16	by	O
17	binding	O
18	of	O
19	NF	B
20	-	I
21	kappa	I
22	B	I
23	to	O
24	identical	O
25	tandem	O
26	binding	O
27	sites	O
28	located	O
29	within	O
30	the	O
31	long	O
32	terminal	O
33	repeat	O
34	(	O
35	LTR	O
36	).	O
1	Recently	O
2	,	O
3	a	O
4	human	B
5	transcription	I
6	elongation	I
7	factor	I
8	P	I
9	-	I
10	TEFb	I
11	,	O
12	consisting	O
13	of	O
14	CDK9	B
15	kinase	I
16	,	O
17	cyclin	B
18	T	I
19	and	O
20	other	O
21	associated	O
22	factors	O
23	,	O
24	has	O
25	been	O
26	shown	O
27	to	O
28	interact	O
29	with	O
30	Tat	B
31	to	O
32	restore	O
33	Tat	B
34	activation	O
35	in	O
36	HeLa	O
37	nuclear	O
38	extract	O
39	depleted	O
40	of	O
41	P	B
42	-	I
43	TEFb	I
44	.	O
1	We	O
2	have	O
3	used	O
4	the	O
5	hydrophobic	O
6	repeats	O
7	of	O
8	the	O
9	HSF1	B
10	trimerization	I
11	domain	I
12	in	O
13	the	O
14	yeast	O
15	two	O
16	-	O
17	hybrid	O
18	protein	O
19	interaction	O
20	assay	O
21	to	O
22	identify	O
23	heat	B
24	shock	I
25	factor	I
26	binding	I
27	protein	I
28	1	I
29	(	O
30	HSBP1	B
31	),	O
32	a	O
33	novel	O
34	,	O
35	conserved	O
36	,	O
37	76	O
38	-	O
39	amino	O
40	-	O
41	acid	O
42	protein	O
43	that	O
44	contains	O
45	two	O
46	extended	O
47	arrays	O
48	of	O
49	hydrophobic	O
50	repeats	O
51	that	O
52	interact	O
53	with	O
54	the	O
55	HSF1	B
56	heptad	I
57	repeats	I
58	.	O
1	The	O
2	general	O
3	recombination	O
4	at	O
5	a	O
6	polarizing	O
7	voltage	O
8	of	O
9	300	O
10	V	O
11	is	O
12	less	O
13	than	O
14	2	O
15	%	O
16	for	O
17	dose	O
18	-	O
19	rates	O
20	up	O
21	to	O
22	about	O
23	100	O
24	mGy	O
25	min	O
26	-	O
27	1	O
28	.	O
1	However	O
2	,	O
3	mutations	O
4	in	O
5	the	O
6	HNF	B
7	-	I
8	4	I
9	binding	I
10	site	I
11	on	O
12	element	B
13	CIIB	I
14	and	O
15	inhibition	O
16	of	O
17	HNF	B
18	-	I
19	4	I
20	synthesis	O
21	in	O
22	HepG2	O
23	cells	O
24	by	O
25	antisense	O
26	HNF	B
27	-	I
28	4	I
29	constructs	I
30	decreased	O
31	the	O
32	apoCII	B
33	promoter	I
34	activity	O
35	to	O
36	25	O
37	-	O
38	40	O
39	%	O
40	of	O
41	the	O
42	control	O
43	,	O
44	indicating	O
45	that	O
46	HNF	B
47	-	I
48	4	I
49	is	O
50	a	O
51	positive	O
52	regulator	O
53	of	O
54	the	O
55	apoCII	B
56	gene	I
57	.	O
1	Initially	O
2	,	O
3	we	O
4	observed	O
5	that	O
6	unmutated	O
7	p53	B
8	is	O
9	strongly	O
10	expressed	O
11	in	O
12	premalignant	O
13	mammary	O
14	glands	O
15	and	O
16	in	O
17	mammary	O
18	tumors	O
19	derived	O
20	from	O
21	the	O
22	MMTV	O
23	-	O
24	c	B
25	-	I
26	myc	I
27	strain	O
28	.	O
1	These	O
2	data	O
3	show	O
4	that	O
5	heterologous	O
6	virus	O
7	RNAs	O
8	(	O
9	BSMV	O
10	)	O
11	can	O
12	serve	O
13	as	O
14	primer	O
15	donors	O
16	for	O
17	MStV	O
18	mRNA	O
19	capped	O
20	RNA	O
21	-	O
22	primed	O
23	transcription	O
24	in	O
25	doubly	O
26	infected	O
27	plants	O
28	.	O
1	Dosage	O
2	in	O
3	both	O
4	cases	O
5	was	O
6	0	O
7	.	O
8	2	O
9	g	O
10	/	O
11	m2	O
12	.	O
1	Fowlpox	O
2	virus	O
3	encodes	O
4	nonessential	O
5	homologs	O
6	of	O
7	cellular	B
8	alpha	I
9	-	I
10	SNAP	I
11	,	O
12	PC	B
13	-	I
14	1	I
15	,	O
16	and	O
17	an	O
18	orphan	O
19	human	O
20	homolog	O
21	of	O
22	a	O
23	secreted	O
24	nematode	O
25	protein	O
26	.	O
1	Regulation	O
2	at	O
3	37	O
4	degrees	O
5	C	O
6	,	O
7	therefore	O
8	,	O
9	involves	O
10	the	O
11	action	O
12	of	O
13	three	O
14	protein	O
15	kinase	O
16	cascades	O
17	that	O
18	repress	O
19	HSF1	B
20	through	O
21	phosphorylation	O
22	of	O
23	serine	O
24	residues	O
25	303	O
26	,	O
27	307	O
28	,	O
29	and	O
30	363	O
31	and	O
32	may	O
33	promote	O
34	growth	O
35	by	O
36	suppressing	O
37	the	O
38	heat	O
39	shock	O
40	response	O
41	.	O
1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	demonstrated	O
6	specific	O
7	nuclear	O
8	protein	O
9	binding	O
10	to	O
11	-	O
12	85	O
13	/-	O
14	64	O
15	,	O
16	and	O
17	single	O
18	point	O
19	mutations	O
20	suggested	O
21	important	O
22	binding	O
23	nucleotides	O
24	between	O
25	-	O
26	79	O
27	/-	O
28	68	O
29	with	O
30	five	O
31	critical	O
32	bases	O
33	between	O
34	-	O
35	74	O
36	/-	O
37	70	O
38	(	O
39	5	O
40	'-	O
41	CTCCT	O
42	-	O
43	3	O
44	').	O
1	We	O
2	demonstrate	O
3	that	O
4	Ddc1p	B
5	interacts	O
6	physically	O
7	in	O
8	vivo	O
9	with	O
10	Mec3p	B
11	,	O
12	and	O
13	this	O
14	interaction	O
15	requires	O
16	Rad17p	B
17	.	O
1	Deleting	O
2	SNF1	B
3	repressed	O
4	meiosis	O
5	at	O
6	the	O
7	same	O
8	three	O
9	steps	O
10	that	O
11	were	O
12	inhibited	O
13	by	O
14	glucose	O
15	,	O
16	suggesting	O
17	that	O
18	glucose	O
19	blocks	O
20	meiosis	O
21	by	O
22	inhibiting	O
23	Snf1	B
24	.	O
1	Here	O
2	we	O
3	investigate	O
4	the	O
5	role	O
6	of	O
7	c	B
8	-	I
9	Cbl	I
10	in	O
11	development	O
12	and	O
13	homeostasis	O
14	in	O
15	mice	O
16	by	O
17	targeted	O
18	disruption	O
19	of	O
20	the	O
21	c	B
22	-	I
23	Cbl	I
24	locus	I
25	.	O
26	c	B
27	-	I
28	Cbl	I
29	-	O
30	deficient	O
31	mice	O
32	were	O
33	viable	O
34	,	O
35	fertile	O
36	,	O
37	and	O
38	outwardly	O
39	normal	O
40	in	O
41	appearance	O
42	.	O
1	METHODS	O
2	:	O
3	Fibrotic	O
4	changes	O
5	involving	O
6	bone	O
7	marrow	O
8	were	O
9	evaluated	O
10	histologically	O
11	semiquantitatively	O
12	using	O
13	reticulin	B
14	fiber	O
15	impregnation	O
16	(	O
17	method	O
18	of	O
19	Gomori	O
20	).	O
1	At	O
2	the	O
3	same	O
4	time	O
5	,	O
6	the	O
7	results	O
8	indicate	O
9	that	O
10	p53	B
11	plays	O
12	a	O
13	defensive	O
14	role	O
15	against	O
16	HBV	O
17	by	O
18	transcriptionally	O
19	repressing	O
20	the	O
21	HBV	B
22	core	I
23	promoter	I
24	through	O
25	liver	B
26	-	I
27	specific	I
28	enhancer	I
29	II	I
30	and	O
31	HBx	B
32	is	O
33	required	O
34	to	O
35	counteract	O
36	this	O
37	inhibitory	O
38	function	O
39	of	O
40	p53	B
41	.	O
1	The	O
2	aim	O
3	of	O
4	the	O
5	study	O
6	was	O
7	to	O
8	correlate	O
9	the	O
10	responsiveness	O
11	to	O
12	bronchoprovocation	O
13	with	O
14	methacholine	O
15	in	O
16	subjects	O
17	a	O
18	with	O
19	allergic	O
20	rhinitis	O
21	during	O
22	and	O
23	out	O
24	of	O
25	the	O
26	pollen	O
27	season	O
28	with	O
29	total	O
30	serum	O
31	IgE	B
32	and	O
33	blood	O
34	eosinophils	O
35	.	O
1	Mutating	O
2	a	O
3	potential	O
4	cleavage	O
5	site	O
6	located	O
7	N	O
8	-	O
9	terminal	O
10	to	O
11	the	O
12	protease	O
13	domain	O
14	,	O
15	Gln2526	O
16	-	O
17	Asp2527	O
18	,	O
19	diminished	O
20	processing	O
21	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	describe	O
7	a	O
8	mammalian	O
9	cell	O
10	-	O
11	free	O
12	transcription	O
13	system	O
14	reconstituted	O
15	with	O
16	only	O
17	recombinant	O
18	proteins	O
19	and	O
20	epitope	O
21	-	O
22	tagged	O
23	multiprotein	O
24	complexes	O
25	.	O
1	A	O
2	prerequisite	O
3	for	O
4	the	O
5	synthesis	O
6	of	O
7	sialylated	O
8	glycoconjugates	O
9	is	O
10	the	O
11	activated	O
12	sugar	O
13	-	O
14	nucleotide	O
15	cytidine	O
16	5	O
17	'-	O
18	monophosphate	O
19	N	O
20	-	O
21	acetylneuraminic	O
22	acid	O
23	(	O
24	CMP	O
25	-	O
26	Neu5Ac	O
27	),	O
28	which	O
29	provides	O
30	a	O
31	substrate	O
32	for	O
33	Golgi	B
34	sialyltransferases	I
35	.	O
1	Human	B
2	ULK1	I
3	,	O
4	a	O
5	novel	O
6	serine	B
7	/	I
8	threonine	I
9	kinase	I
10	related	O
11	to	O
12	UNC	B
13	-	I
14	51	I
15	kinase	I
16	of	O
17	Caenorhabditis	O
18	elegans	O
19	:	O
20	cDNA	O
21	cloning	O
22	,	O
23	expression	O
24	,	O
25	and	O
26	chromosomal	O
27	assignment	O
28	.	O
1	CONCLUSIONS	O
2	:	O
3	Significant	O
4	elevations	O
5	of	O
6	IL	B
7	-	I
8	1alpha	I
9	and	O
10	IL	B
11	-	I
12	1beta	I
13	occur	O
14	in	O
15	patients	O
16	with	O
17	bacterial	O
18	cystitis	O
19	and	O
20	microscopic	O
21	hematuria	O
22	.	O
1	In	O
2	experiments	O
3	with	O
4	the	O
5	D1	O
6	antagonist	O
7	SCH	O
8	23390	O
9	,	O
10	buprenorphine	O
11	-	O
12	induced	O
13	depression	O
14	was	O
15	consistently	O
16	blocked	O
17	,	O
18	but	O
19	facilitation	O
20	was	O
21	unaffected	O
22	.	O
1	E2F	B
2	-	I
3	6	I
4	shares	O
5	significant	O
6	homology	O
7	with	O
8	E2Fs	B
9	1	I
10	-	I
11	5	I
12	,	O
13	especially	O
14	within	O
15	the	O
16	DNA	O
17	binding	O
18	,	O
19	heterodimerization	O
20	and	O
21	marked	O
22	box	O
23	domains	O
24	.	O
1	The	O
2	IE13	O
3	.	O
4	1	O
5	cell	O
6	line	O
7	was	O
8	able	O
9	to	O
10	complement	O
11	a	O
12	recombinant	O
13	virus	O
14	in	O
15	which	O
16	both	O
17	copies	O
18	of	O
19	the	O
20	IE	B
21	gene	I
22	were	O
23	replaced	O
24	by	O
25	insertion	O
26	of	O
27	the	O
28	Escherichia	B
29	coli	I
30	lacZ	I
31	gene	I
32	.	O
1	The	O
2	yeast	B
3	MMS2	I
4	gene	I
5	was	O
6	cloned	O
7	by	O
8	its	O
9	ability	O
10	to	O
11	complement	O
12	the	O
13	methyl	O
14	methanesulfonate	O
15	sensitivity	O
16	of	O
17	the	O
18	mms2	B
19	-	I
20	1	I
21	mutant	I
22	and	O
23	was	O
24	later	O
25	shown	O
26	to	O
27	be	O
28	involved	O
29	in	O
30	DNA	O
31	post	O
32	-	O
33	replication	O
34	repair	O
35	.	O
1	Anesthesia	O
2	with	O
3	M	O
4	/	O
5	K	O
6	was	O
7	reversed	O
8	after	O
9	41	O
10	.	O
11	6	O
12	min	O
13	of	O
14	immobilization	O
15	with	O
16	atipamezole	O
17	.	O
1	The	O
2	purpose	O
3	of	O
4	this	O
5	article	O
6	is	O
7	to	O
8	discuss	O
9	the	O
10	factors	O
11	involved	O
12	in	O
13	the	O
14	selection	O
15	of	O
16	antibodies	O
17	,	O
18	radionuclides	O
19	and	O
20	labeling	O
21	methods	O
22	in	O
23	the	O
24	development	O
25	of	O
26	radioimmunotherapy	O
27	(	O
28	RIT	O
29	)	O
30	for	O
31	non	O
32	-	O
33	Hodgkin	O
34	'	O
35	s	O
36	lymphoma	O
37	(	O
38	NHL	O
39	)	O
40	from	O
41	a	O
42	single	O
43	clinical	O
44	study	O
45	site	O
46	through	O
47	multicenter	O
48	trials	O
49	and	O
50	commercialization	O
51	.	O
1	Identification	O
2	of	O
3	a	O
4	proline	O
5	-	O
6	rich	O
7	sequence	O
8	in	O
9	the	O
10	CD2	B
11	cytoplasmic	I
12	domain	I
13	critical	O
14	for	O
15	regulation	O
16	of	O
17	integrin	B
18	-	O
19	mediated	O
20	adhesion	O
21	and	O
22	activation	O
23	of	O
24	phosphoinositide	B
25	3	I
26	-	I
27	kinase	I
28	.	O
1	Tctex	B
2	-	I
3	1	I
4	binding	O
5	required	O
6	the	O
7	first	O
8	19	O
9	amino	O
10	acids	O
11	of	O
12	Fyn	B
13	and	O
14	integrity	O
15	of	O
16	two	O
17	lysine	O
18	residues	O
19	within	O
20	this	O
21	sequence	O
22	that	O
23	were	O
24	previously	O
25	shown	O
26	to	O
27	be	O
28	important	O
29	for	O
30	Fyn	B
31	interactions	O
32	with	O
33	the	O
34	immunoreceptor	O
35	tyrosine	O
36	-	O
37	based	O
38	activation	O
39	motifs	O
40	(	O
41	ITAMs	O
42	)	O
43	of	O
44	lymphocyte	B
45	Ag	I
46	receptors	I
47	.	O
1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	GluR2	B
6	gene	I
7	:	O
8	neural	O
9	-	O
10	specific	O
11	expression	O
12	,	O
13	multiple	O
14	promoters	O
15	,	O
16	and	O
17	regulatory	O
18	elements	O
19	.	O
1	Tumor	B
2	necrosis	I
3	factor	I
4	signaling	O
5	to	O
6	stress	B
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	(	O
12	SAPK	B
13	)/	O
14	Jun	B
15	NH2	I
16	-	I
17	terminal	I
18	kinase	I
19	(	O
20	JNK	B
21	)	O
22	and	O
23	p38	B
24	.	O
1	Overexpression	O
2	of	O
3	MDR1	B
4	has	O
5	been	O
6	demonstrated	O
7	in	O
8	many	O
9	cancers	O
10	,	O
11	both	O
12	in	O
13	patient	O
14	tumors	O
15	and	O
16	in	O
17	cell	O
18	lines	O
19	selected	O
20	with	O
21	a	O
22	variety	O
23	of	O
24	chemotherapeutic	O
25	agents	O
26	.	O
1	BACKGROUND	O
2	:	O
3	It	O
4	is	O
5	generally	O
6	accepted	O
7	that	O
8	smoking	O
9	increases	O
10	blood	O
11	pressure	O
12	and	O
13	inhibits	O
14	muscle	O
15	sympathetic	O
16	nerve	O
17	activity	O
18	(	O
19	SNA	O
20	).	O
1	RXR	B
2	-	I
3	gamma	I
4	expression	O
5	produced	O
6	significant	O
7	reduction	O
8	in	O
9	levels	O
10	of	O
11	RA	O
12	-	O
13	responsive	O
14	genes	O
15	including	O
16	the	O
17	cyclin	B
18	-	I
19	dependent	I
20	kinase	I
21	inhibitors	O
22	p21Cip1	B
23	/	O
24	WAF1	B
25	and	O
26	p27Kip1	B
27	,	O
28	resulting	O
29	in	O
30	increased	O
31	cdc2	B
32	and	O
33	cdk2	B
34	kinase	I
35	activity	O
36	and	O
37	RB	B
38	phosphorylation	O
39	.	O
1	During	O
2	the	O
3	CR	O
4	/	O
5	PP	O
6	diet	O
7	only	O
8	the	O
9	HS	O
10	subjects	O
11	did	O
12	not	O
13	show	O
14	the	O
15	stress	O
16	-	O
17	induced	O
18	rise	O
19	in	O
20	depression	O
21	,	O
22	decline	O
23	in	O
24	vigour	O
25	and	O
26	cortisol	O
27	elevation	O
28	that	O
29	they	O
30	showed	O
31	after	O
32	the	O
33	PR	O
34	/	O
35	CP	O
36	diet	O
37	.	O
1	Seventy	O
2	-	O
3	five	O
4	percent	O
5	of	O
6	children	O
7	who	O
8	received	O
9	a	O
10	second	O
11	transplant	O
12	for	O
13	HCV	O
14	hepatitis	O
15	had	O
16	early	O
17	histologic	O
18	recurrence	O
19	that	O
20	led	O
21	to	O
22	liver	O
23	failure	O
24	and	O
25	death	O
26	.	O
1	The	O
2	micturition	O
3	pressure	O
4	was	O
5	significantly	O
6	decreased	O
7	only	O
8	after	O
9	injection	O
10	with	O
11	BUP	O
12	-	O
13	4	O
14	in	O
15	both	O
16	normal	O
17	and	O
18	obstructed	O
19	rats	O
20	.	O
1	Tyrosine	O
2	phosphorylated	O
3	STATs	B
4	dimerize	O
5	and	O
6	translocate	O
7	into	O
8	the	O
9	nucleus	O
10	to	O
11	activate	O
12	specific	O
13	genes	O
14	.	O
1	The	O
2	CBF1	B
3	site	I
4	within	O
5	HS2	O
6	resides	O
7	near	O
8	sites	O
9	for	O
10	hematopoietic	O
11	regulators	O
12	such	O
13	as	O
14	GATA	B
15	-	I
16	1	I
17	,	O
18	NF	B
19	-	I
20	E2	I
21	,	O
22	and	O
23	TAL1	B
24	.	O
1	Studies	O
2	using	O
3	the	O
4	yeast	O
5	two	O
6	-	O
7	hybrid	O
8	system	O
9	also	O
10	did	O
11	not	O
12	provide	O
13	evidence	O
14	for	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	VDR	B
20	-	O
21	TR	B
22	protein	O
23	-	O
24	protein	O
25	interaction	O
26	.	O
1	This	O
2	sequence	O
3	,	O
4	Thr	O
5	-	O
6	Gly	O
7	-	O
8	X	O
9	-	O
10	X	O
11	-	O
12	Gly	O
13	-	O
14	Asp	O
15	-	O
16	Gly	O
17	-	O
18	Lys	O
19	-	O
20	Ile	O
21	-	O
22	Phe	O
23	,	O
24	forms	O
25	part	O
26	of	O
27	the	O
28	B	O
29	-	O
30	loop	O
31	and	O
32	is	O
33	conserved	O
34	in	O
35	a	O
36	wide	O
37	variety	O
38	of	O
39	organisms	O
40	that	O
41	include	O
42	bacteria	O
43	,	O
44	algae	O
45	and	O
46	archeabacteria	O
47	.	O
1	To	O
2	improve	O
3	test	O
4	efficiency	O
5	,	O
6	we	O
7	modified	O
8	our	O
9	previously	O
10	introduced	O
11	contrast	O
12	/	O
13	color	O
14	card	O
15	test	O
16	by	O
17	including	O
18	a	O
19	patterned	O
20	test	O
21	stimulus	O
22	and	O
23	reducing	O
24	the	O
25	number	O
26	of	O
27	stimuli	O
28	in	O
29	both	O
30	experimental	O
31	phases	O
32	.	O
1	Second	O
2	,	O
3	the	O
4	wild	B
5	-	I
6	type	I
7	m8	I
8	3	I
9	'	I
10	UTR	I
11	strongly	O
12	reduces	O
13	accumulation	O
14	of	O
15	heterologous	O
16	transcripts	O
17	in	O
18	vivo	O
19	,	O
20	an	O
21	activity	O
22	that	O
23	requires	O
24	its	O
25	K	O
26	box	O
27	sequences	O
28	.	O
1	The	O
2	effect	O
3	of	O
4	independent	O
5	predictors	O
6	on	O
7	survival	O
8	was	O
9	examined	O
10	in	O
11	a	O
12	Cox	O
13	regression	O
14	model	O
15	with	O
16	adjustment	O
17	for	O
18	existing	O
19	illnesses	O
20	.	O
1	Effects	O
2	of	O
3	rhG	B
4	-	I
5	CSF	I
6	on	O
7	neutrophil	O
8	functions	O
9	and	O
10	survival	O
11	in	O
12	sepsis	O
13	induced	O
14	diabetic	O
15	rats	O
16	.	O
1	Whereas	O
2	,	O
3	in	O
4	the	O
5	single	O
6	-	O
7	chambered	O
8	body	O
9	box	O
10	,	O
11	PenH	O
12	units	O
13	(	O
14	Enhanced	O
15	Pause	O
16	)	O
17	reflect	O
18	""""	O
19	effort	O
20	of	O
21	breathing	O
22	"."""	O
23	This	O
24	is	O
25	measured	O
26	as	O
27	the	O
28	pause	O
29	between	O
30	inspiration	O
31	and	O
32	expiration	O
33	.	O
1	Wild	O
2	-	O
3	type	O
4	and	O
5	mutant	O
6	MyoD	B
7	were	O
8	introduced	O
9	into	O
10	cells	O
11	using	O
12	an	O
13	E1	B
14	,	O
15	E3	B
16	-	O
17	deleted	O
18	adenoviral	O
19	vector	O
20	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	Thr115	O
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	MyoD	B
16	function	O
17	under	O
18	conditions	O
19	of	O
20	high	O
21	mitogenesis	O
22	.	O
1	The	O
2	primers	O
3	were	O
4	degenerate	O
5	sets	O
6	of	O
7	oligonucleotides	O
8	derived	O
9	from	O
10	known	O
11	amino	O
12	acid	O
13	sequences	O
14	of	O
15	the	O
16	PBAN	B
17	precursor	I
18	.	O
1	The	O
2	presence	O
3	of	O
4	PDZ	B
5	and	O
6	SAM	O
7	domains	O
8	in	O
9	the	O
10	KS5	B
11	protein	I
12	suggests	O
13	that	O
14	it	O
15	may	O
16	act	O
17	as	O
18	a	O
19	molecular	O
20	adaptor	O
21	,	O
22	promoting	O
23	and	O
24	relaying	O
25	information	O
26	in	O
27	a	O
28	signal	O
29	transduction	O
30	pathway	O
31	.	O
1	Pseudocontact	O
2	shifts	O
3	arise	O
4	from	O
5	the	O
6	isotropic	O
7	reorientational	O
8	average	O
9	of	O
10	the	O
11	dipolar	O
12	coupling	O
13	between	O
14	unpaired	O
15	electron	O
16	and	O
17	nuclei	O
18	,	O
19	in	O
20	the	O
21	presence	O
22	of	O
23	magnetic	O
24	susceptibility	O
25	anisotropy	O
26	.	O
1	The	O
2	GEF	B
3	and	O
4	GAP	B
5	activities	O
6	for	O
7	Ypt1p	B
8	localize	O
9	to	O
10	particulate	O
11	cellular	O
12	fractions	O
13	.	O
1	Collectively	O
2	,	O
3	this	O
4	study	O
5	emphasizes	O
6	a	O
7	critical	O
8	role	O
9	of	O
10	Phox2a	B
11	as	O
12	well	O
13	as	O
14	its	O
15	functional	O
16	synergism	O
17	with	O
18	other	O
19	transcription	O
20	factors	O
21	(	O
22	e	O
23	.	O
24	g	O
25	.,	O
26	CREB	B
27	,	O
28	AP2	B
29	,	O
30	and	O
31	Sp1	B
32	)	O
33	in	O
34	transcriptional	O
35	activation	O
36	of	O
37	the	O
38	DBH	B
39	gene	I
40	.	O
1	The	O
2	levels	O
3	of	O
4	transactivation	O
5	are	O
6	correlated	O
7	with	O
8	the	O
9	respective	O
10	binding	O
11	affinities	O
12	of	O
13	the	O
14	response	O
15	elements	O
16	(	O
17	IRper	O
18	-	O
19	1	O
20	>	O
21	DR	O
22	-	O
23	4	O
24	>	O
25	IRhsp	O
26	-	O
27	1	O
28	).	O
1	J	O
2	.	O
1	This	O
2	domain	O
3	,	O
4	although	O
5	adjacent	O
6	to	O
7	the	O
8	5	O
9	'	O
10	edge	O
11	of	O
12	the	O
13	SD	O
14	sequence	O
15	,	O
16	does	O
17	not	O
18	inhibit	O
19	ribosome	O
20	binding	O
21	as	O
22	long	O
23	as	O
24	the	O
25	single	O
26	-	O
27	stranded	O
28	region	O
29	of	O
30	domain	O
31	3	O
32	is	O
33	present	O
34	.	O
1	Forskolin	O
2	significantly	O
3	enhanced	O
4	heregulin	B
5	-	O
6	stimulated	O
7	expression	O
8	of	O
9	cyclin	B
10	D	I
11	and	O
12	phosphorylation	O
13	of	O
14	the	O
15	retinoblastoma	B
16	gene	I
17	product	I
18	.	O
1	Multivariate	O
2	Cox	O
3	survival	O
4	analysis	O
5	identified	O
6	baseline	O
7	EF	O
8	<	O
9	or	O
10	=	O
11	30	O
12	%,	O
13	presence	O
14	of	O
15	significant	O
16	mitral	O
17	regurgitation	O
18	(>	O
19	2	O
20	+)	O
21	before	O
22	ablation	O
23	,	O
24	and	O
25	failure	O
26	to	O
27	exhibit	O
28	improved	O
29	cardiac	O
30	performance	O
31	by	O
32	1	O
33	month	O
34	after	O
35	ablation	O
36	as	O
37	the	O
38	only	O
39	independent	O
40	predictors	O
41	of	O
42	death	O
43	.	O
1	Glycogen	O
2	synthesis	O
3	and	O
4	catabolism	O
5	,	O
6	gluconeogenesis	O
7	,	O
8	glycolysis	O
9	,	O
10	motility	O
11	,	O
12	cell	O
13	surface	O
14	properties	O
15	and	O
16	adherence	O
17	are	O
18	modulated	O
19	by	O
20	csrA	B
21	in	I
22	Escherichia	I
23	coli	I
24	,	O
25	while	O
26	the	O
27	production	O
28	of	O
29	several	O
30	secreted	O
31	virulence	O
32	factors	O
33	,	O
34	the	O
35	plant	O
36	hypersensitive	O
37	response	O
38	elicitor	O
39	HrpN	B
40	(	O
41	Ecc	B
42	)	O
43	and	O
44	,	O
45	potentially	O
46	,	O
47	other	O
48	secondary	O
49	metabolites	O
50	are	O
51	regulated	O
52	by	O
53	rsmA	B
54	in	I
55	Erwinia	I
56	carotovora	I
57	.	O
1	The	O
2	cwg2	B
3	-	I
4	1	I
5	mutation	I
6	was	O
7	identified	O
8	as	O
9	a	O
10	guanine	O
11	to	O
12	adenine	O
13	substitution	O
14	at	O
15	nucleotide	O
16	604	O
17	of	O
18	the	O
19	coding	O
20	region	O
21	,	O
22	originating	O
23	the	O
24	change	O
25	A202T	O
26	in	O
27	the	O
28	cwg2p	B
29	.	O
1	Deletion	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	essential	O
7	domain	O
8	of	O
9	this	O
10	promoter	O
11	,	O
12	termed	O
13	the	O
14	ORF5	B
15	/	I
16	deltaX	I
17	transcript	I
18	promoter	I
19	,	O
20	mapped	O
21	to	O
22	nucleotides	O
23	1525	O
24	-	O
25	1625	O
26	.	O
1	Handling	O
2	on	O
3	PND	O
4	9	O
5	did	O
6	not	O
7	result	O
8	in	O
9	elevated	O
10	CORT	O
11	levels	O
12	in	O
13	any	O
14	of	O
15	the	O
16	groups	O
17	.	O
1	Thus	O
2	,	O
3	IRF	B
4	-	I
5	7	I
6	exhibits	O
7	functional	O
8	similarity	O
9	to	O
10	IRF	B
11	-	I
12	3	I
13	;	O
14	however	O
15	,	O
16	the	O
17	preferential	O
18	expression	O
19	of	O
20	IRF	B
21	-	I
22	7	I
23	in	O
24	lymphoid	O
25	cells	O
26	(	O
27	the	O
28	cell	O
29	type	O
30	that	O
31	expresses	O
32	IFNA	B
33	)	O
34	suggests	O
35	that	O
36	IRF	B
37	-	I
38	7	I
39	may	O
40	play	O
41	a	O
42	critical	O
43	role	O
44	in	O
45	regulating	O
46	the	O
47	IFNA	B
48	gene	I
49	expression	O
50	.	O
1	CKII	B
2	as	O
3	a	O
4	CD44	B
5	-	I
6	associated	I
7	serine	I
8	kinase	I
9	therefore	O
10	may	O
11	serve	O
12	as	O
13	an	O
14	important	O
15	molecule	O
16	in	O
17	a	O
18	signaling	O
19	cascade	O
20	that	O
21	produces	O
22	a	O
23	variety	O
24	of	O
25	cellular	O
26	responses	O
27	in	O
28	MDA231	O
29	breast	O
30	cancer	O
31	cells	O
32	.	O
1	Additionally	O
2	in	O
3	seven	O
4	subjects	O
5	adrenaline	O
6	(	O
7	A	O
8	)	O
9	and	O
10	noradrenaline	O
11	(	O
12	NA	O
13	)	O
14	concentrations	O
15	were	O
16	determined	O
17	.	O
1	Gng3lg	B
2	transcripts	I
3	are	O
4	expressed	O
5	in	O
6	a	O
7	variety	O
8	of	O
9	tissues	O
10	including	O
11	both	O
12	brain	O
13	and	O
14	testes	O
15	.	O
1	Inhibition	O
2	of	O
3	the	O
4	apolipoprotein	B
5	B	I
6	mRNA	I
7	editing	O
8	enzyme	O
9	-	O
10	complex	O
11	by	O
12	hnRNP	B
13	C1	I
14	protein	I
15	and	O
16	40S	B
17	hnRNP	I
18	complexes	I
19	.	O
1	However	O
2	the	O
3	sequence	O
4	surrounding	O
5	the	O
6	transcription	O
7	start	O
8	site	O
9	CTCA	O
10	(+	O
11	1	O
12	)	O
13	TTCC	O
14	was	O
15	similar	O
16	to	O
17	the	O
18	consensus	O
19	CTCA	O
20	(+	O
21	1	O
22	)	O
23	NTCT	O
24	(	O
25	N	O
26	is	O
27	any	O
28	nucleoside	O
29	)	O
30	for	O
31	an	O
32	initiator	O
33	element	O
34	found	O
35	in	O
36	terminal	B
37	deoxynucleotidyltransferase	I
38	and	O
39	a	O
40	number	O
41	of	O
42	other	O
43	highly	O
44	regulated	O
45	genes	O
46	.	O
1	An	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assay	O
6	was	O
7	performed	O
8	to	O
9	characterize	O
10	the	O
11	binding	O
12	property	O
13	of	O
14	TR2	B
15	and	O
16	its	O
17	truncated	O
18	isoform	O
19	.	O
1	We	O
2	propose	O
3	that	O
4	two	O
5	pathways	O
6	regulate	O
7	Stat5	B
8	serine	O
9	phosphorylation	O
10	,	O
11	one	O
12	that	O
13	is	O
14	prolactin	B
15	-	O
16	activated	O
17	and	O
18	PD98059	O
19	-	O
20	resistant	O
21	and	O
22	one	O
23	that	O
24	is	O
25	constitutively	O
26	active	O
27	and	O
28	PD98059	O
29	-	O
30	sensitive	O
31	and	O
32	preferentially	O
33	targets	O
34	Stat5a	B
35	.	O
1	The	O
2	various	O
3	available	O
4	data	O
5	strongly	O
6	suggesting	O
7	an	O
8	environmental	O
9	toxic	O
10	origin	O
11	for	O
12	the	O
13	""""	O
14	sperm	O
15	fall	O
16	""""	O
17	will	O
18	be	O
19	presented	O
20	as	O
21	well	O
22	as	O
23	the	O
24	most	O
25	frequently	O
26	suspected	O
27	class	O
28	of	O
29	substances	O
30	,	O
31	the	O
32	xenoestrogens	O
33	.	O
1	These	O
2	data	O
3	may	O
4	also	O
5	aid	O
6	in	O
7	the	O
8	localization	O
9	of	O
10	other	O
11	disease	O
12	loci	O
13	mapped	O
14	to	O
15	this	O
16	region	O
17	,	O
18	including	O
19	the	O
20	gene	O
21	for	O
22	tricho	O
23	-	O
24	dento	O
25	-	O
26	osseous	O
27	syndrome	O
28	and	O
29	a	O
30	murine	O
31	locus	O
32	for	O
33	susceptibility	O
34	to	O
35	ozone	O
36	-	O
37	induced	O
38	acute	O
39	lung	O
40	injury	O
41	.	O
1	Rather	O
2	,	O
3	usp	B
4	is	O
5	required	O
6	in	O
7	late	O
8	third	O
9	instar	O
10	larvae	O
11	for	O
12	appropriate	O
13	developmental	O
14	and	O
15	transcriptional	O
16	responses	O
17	to	O
18	the	O
19	ecdysone	O
20	pulse	O
21	that	O
22	triggers	O
23	puparium	O
24	formation	O
25	.	O
1	An	O
2	intact	O
3	neurovascular	O
4	supply	O
5	is	O
6	essential	O
7	for	O
8	the	O
9	viability	O
10	of	O
11	a	O
12	muscle	O
13	flap	O
14	.	O
1	Fatal	O
2	apneusis	O
3	was	O
4	observed	O
5	under	O
6	following	O
7	conditions	O
8	:	O
9	(	O
10	1	O
11	)	O
12	Persistent	O
13	apnea	O
14	was	O
15	produced	O
16	after	O
17	a	O
18	single	O
19	KA	O
20	microinjection	O
21	in	O
22	one	O
23	side	O
24	of	O
25	the	O
26	VRG	O
27	-	O
28	Apa	O
29	(	O
30	5	O
31	animals	O
32	).	O
1	The	O
2	human	B
3	2	I
4	',	I
5	5	I
6	'-	I
7	oligoadenylate	I
8	(	I
9	2	I
10	-	I
11	5A	I
12	)	I
13	synthetases	I
14	are	O
15	members	O
16	of	O
17	a	O
18	family	O
19	interferon	B
20	(	O
21	IFN	B
22	)-	O
23	inducible	O
24	anti	B
25	-	I
26	viral	I
27	proteins	I
28	.	O
1	These	O
2	striations	O
3	were	O
4	caused	O
5	by	O
6	contact	O
7	between	O
8	the	O
9	sharp	O
10	edge	O
11	of	O
12	the	O
13	upper	O
14	canine	O
15	and	O
16	the	O
17	P3	O
18	during	O
19	honing	O
20	(	O
21	canine	O
22	/	O
23	premolar	O
24	complex	O
25	).	O
1	In	O
2	vitro	O
3	protein	O
4	retention	O
5	experiments	O
6	in	O
7	which	O
8	Hsp90	B
9	heterocomplexes	I
10	were	O
11	precipitated	O
12	resulted	O
13	in	O
14	coprecipitation	O
15	of	O
16	Cns1	B
17	.	O
1	These	O
2	cognitive	O
3	deficits	O
4	were	O
5	prevented	O
6	in	O
7	animals	O
8	treated	O
9	with	O
10	MK	O
11	-	O
12	801	O
13	during	O
14	SE	O
15	.	O
1	A	O
2	synergistic	O
3	effect	O
4	on	O
5	HCK	B
6	promoter	I
7	activity	O
8	was	O
9	observed	O
10	at	O
11	high	O
12	concentrations	O
13	of	O
14	Sp1	B
15	.	O
1	This	O
2	core	O
3	sequence	O
4	,	O
5	along	O
6	with	O
7	additional	O
8	nonspecific	O
9	downstream	O
10	nucleotides	O
11	,	O
12	is	O
13	sufficient	O
14	for	O
15	partial	O
16	suppression	O
17	of	O
18	spliceosome	O
19	assembly	O
20	and	O
21	splicing	O
22	of	O
23	BPV	O
24	-	O
25	1	O
26	pre	O
27	-	O
28	mRNAs	O
29	.	O
1	Familial	O
2	autoimmune	O
3	hepatitis	O
4	and	O
5	C4	B
6	deficiency	O
1	Since	O
2	glutathione	B
3	peroxidase	I
4	(	O
5	GPX	B
6	)	O
7	and	O
8	superoxide	B
9	dismutase	I
10	(	O
11	SOD	B
12	)	O
13	play	O
14	a	O
15	significant	O
16	role	O
17	in	O
18	erythrocyte	O
19	antioxidative	O
20	defence	O
21	,	O
22	it	O
23	is	O
24	very	O
25	important	O
26	to	O
27	determine	O
28	their	O
29	activity	O
30	in	O
31	occupationally	O
32	exposed	O
33	workers	O
34	.	O
1	We	O
2	evaluated	O
3	regional	O
4	right	O
5	ventricular	O
6	wall	O
7	motion	O
8	during	O
9	systole	O
10	in	O
11	patients	O
12	with	O
13	surgically	O
14	repaired	O
15	tetralogy	O
16	of	O
17	Fallot	O
18	(	O
19	TOF	O
20	)	O
21	using	O
22	color	O
23	kinesis	O
24	imaging	O
25	.	O
1	Thus	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	an	O
7	activation	O
8	target	O
9	of	O
10	a	O
11	human	O
12	activator	O
13	,	O
14	Oct	B
15	-	I
16	1	I
17	,	O
18	within	O
19	its	O
20	cognate	O
21	basal	O
22	transcription	O
23	complex	O
24	.	O
1	During	O
2	early	O
3	neurogenesis	O
4	,	O
5	Vnd	B
6	protein	I
7	is	O
8	restricted	O
9	to	O
10	ventral	O
11	column	O
12	neuroectoderm	O
13	and	O
14	neuroblasts	O
15	;	O
16	later	O
17	it	O
18	is	O
19	detected	O
20	in	O
21	a	O
22	complex	O
23	pattern	O
24	of	O
25	neurons	O
26	.	O
1	The	O
2	exodomain	O
3	alone	O
4	has	O
5	the	O
6	high	O
7	affinity	O
8	hormone	O
9	binding	O
10	site	O
11	but	O
12	is	O
13	not	O
14	capable	O
15	of	O
16	generating	O
17	hormonal	O
18	signal	O
19	.	O
1	We	O
2	report	O
3	here	O
4	that	O
5	,	O
6	for	O
7	a	O
8	constant	O
9	amount	O
10	of	O
11	transfected	O
12	DNA	O
13	,	O
14	the	O
15	level	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	(	O
20	CAT	B
21	)	O
22	mRNA	O
23	is	O
24	increased	O
25	in	O
26	Vpr	B
27	-	O
28	expressing	O
29	cells	O
30	using	O
31	either	O
32	HIV	O
33	-	O
34	1	O
35	or	O
36	a	O
37	murine	O
38	leukemia	B
39	virus	I
40	(	I
41	MLV	I
42	)	I
43	SL3	I
44	-	I
45	3	I
46	LTR	I
47	-	O
48	CAT	B
49	reporter	O
50	construct	O
51	.	O
1	The	O
2	decrease	O
3	of	O
4	TNF	B
5	receptors	I
6	by	O
7	IL	B
8	-	I
9	4	I
10	was	O
11	accompanied	O
12	by	O
13	down	O
14	-	O
15	regulation	O
16	of	O
17	TNF	B
18	-	O
19	induced	O
20	activities	O
21	,	O
22	including	O
23	cytotoxicity	O
24	,	O
25	caspase	B
26	-	I
27	3	I
28	activation	O
29	,	O
30	NF	B
31	-	I
32	kappaB	I
33	and	O
34	AP	B
35	-	I
36	1	I
37	activation	O
38	,	O
39	and	O
40	c	B
41	-	I
42	Jun	I
43	N	I
44	-	I
45	terminal	I
46	kinase	I
47	induction	O
48	.	O
1	The	O
2	method	O
3	also	O
4	eliminates	O
5	tagging	O
6	of	O
7	venous	O
8	spins	O
9	and	O
10	concern	O
11	about	O
12	asymmetric	O
13	magnetization	O
14	transfer	O
15	effects	O
16	.	O
1	In	O
2	this	O
3	study	O
4	we	O
5	provide	O
6	evidence	O
7	that	O
8	B	B
9	-	I
10	Myb	I
11	is	O
12	a	O
13	direct	O
14	physiological	O
15	target	O
16	for	O
17	cyclin	B
18	A	I
19	/	O
20	Cdk2	B
21	.	O
1	Neither	O
2	Ha	B
3	-	I
4	Ras	I
5	(	O
6	G12V	O
7	,	O
8	T35S	O
9	)	O
10	(	O
11	Ha	B
12	-	I
13	RasV12S35	I
14	),	O
15	which	O
16	activates	O
17	the	O
18	Rafl	B
19	signaling	O
20	pathway	O
21	,	O
22	nor	O
23	Ha	B
24	-	I
25	Ras	I
26	(	I
27	G12V	I
28	,	I
29	E37G	I
30	)	I
31	(	O
32	Ha	B
33	-	I
34	RasV12G37	I
35	),	O
36	which	O
37	stimulates	O
38	the	O
39	RalGDS	B
40	pathway	O
41	,	O
42	did	O
43	not	O
44	have	O
45	significant	O
46	effects	O
47	on	O
48	factor	O
49	-	O
50	withdrawal	O
51	apoptosis	O
52	of	O
53	myeloid	O
54	cells	O
55	.	O
1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	human	B
7	cyclin	I
8	,	O
9	cyclin	B
10	E2	I
11	,	O
12	that	O
13	contains	O
14	significant	O
15	homology	O
16	to	O
17	cyclin	B
18	E	I
19	.	O
1	Collagen	B
2	was	O
3	extracted	O
4	from	O
5	the	O
6	skin	O
7	,	O
8	and	O
9	the	O
10	lack	O
11	of	O
12	type	B
13	III	I
14	collagen	I
15	was	O
16	determined	O
17	by	O
18	means	O
19	of	O
20	sodium	O
21	dodecyl	O
22	sulfate	O
23	-	O
24	polyacrylamide	O
25	gel	O
26	electrophoresis	O
27	(	O
28	SDS	O
29	-	O
30	PAGE	O
31	).	O
1	RESULTS	O
2	:	O
3	During	O
4	the	O
5	7	O
6	-	O
7	year	O
8	period	O
9	,	O
10	10	O
11	,	O
12	331	O
13	symptomatic	O
14	duodenal	O
15	ulcer	O
16	diseases	O
17	were	O
18	diagnosed	O
19	.	O
1	The	O
2	tip	O
3	of	O
4	the	O
5	button	O
6	caused	O
7	a	O
8	perforation	O
9	of	O
10	the	O
11	posterior	O
12	stomach	O
13	wall	O
14	,	O
15	leading	O
16	to	O
17	death	O
18	.	O
1	Jembrana	O
2	disease	O
3	virus	O
4	(	O
5	JDV	O
6	)	O
7	is	O
8	a	O
9	newly	O
10	identified	O
11	bovine	O
12	lentivirus	O
13	that	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	bovine	O
20	immunodeficiency	O
21	virus	O
22	(	O
23	BIV	O
24	).	O
1	Nhp2p	B
2	is	O
3	a	O
4	highly	O
5	basic	O
6	protein	O
7	that	O
8	belongs	O
9	to	O
10	a	O
11	family	O
12	of	O
13	putative	O
14	RNA	O
15	-	O
16	binding	O
17	proteins	O
18	.	O
1	E	O
2	.,	O
3	Scott	O
4	,	O
5	J	O
6	.	O
1	Another	O
2	ORF	O
3	,	O
4	dda	B
5	.	I
6	2	I
7	located	O
8	between	O
9	modA	B
10	and	O
11	dda	B
12	,	O
13	shares	O
14	sequence	O
15	similarity	O
16	with	O
17	sigma70	B
18	,	O
19	and	O
20	we	O
21	call	O
22	it	O
23	srd	B
24	.	O
1	Ethylene	O
2	is	O
3	involved	O
4	in	O
5	endosperm	O
6	rupture	O
7	and	O
8	high	O
9	-	O
10	level	O
11	betaGLU	B
12	I	I
13	expression	O
14	;	O
15	but	O
16	,	O
17	it	O
18	does	O
19	not	O
20	affect	O
21	the	O
22	spatial	O
23	and	O
24	temporal	O
25	pattern	O
26	of	O
27	betaGLU	B
28	I	I
29	expression	O
30	.	O
1	The	O
2	divergence	O
3	in	O
4	primary	O
5	structure	O
6	between	O
7	the	O
8	sheep	O
9	CRF1	B
10	and	O
11	the	O
12	other	O
13	mammalian	B
14	CRF1s	I
15	is	O
16	primarily	O
17	localized	O
18	to	O
19	the	O
20	extracellular	O
21	amino	O
22	terminal	O
23	domain	O
24	of	O
25	the	O
26	receptor	O
27	(	O
28	18	O
29	of	O
30	22	O
31	divergent	O
32	residues	O
33	,	O
34	ovine	O
35	vs	O
36	human	B
37	CRF1	I
38	).	O
1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	indicate	O
7	that	O
8	the	O
9	FCR1	B
10	gene	I
11	behaves	O
12	as	O
13	a	O
14	negative	O
15	regulator	O
16	of	O
17	drug	O
18	resistance	O
19	in	O
20	C	O
21	.	O
22	albicans	O
23	and	O
24	constitute	O
25	the	O
26	first	O
27	evidence	O
28	that	O
29	FCZ	O
30	resistance	O
31	can	O
32	result	O
33	from	O
34	the	O
35	inactivation	O
36	of	O
37	a	O
38	regulatory	O
39	factor	O
40	such	O
41	as	O
42	Fcr1p	B
43	.	O
1	These	O
2	findings	O
3	suggest	O
4	that	O
5	late	O
6	MYO	O
7	/	O
8	M	O
9	is	O
10	more	O
11	useful	O
12	than	O
13	washout	O
14	rate	O
15	to	O
16	assess	O
17	the	O
18	effect	O
19	of	O
20	treatment	O
21	on	O
22	heart	O
23	failure	O
24	due	O
25	to	O
26	DCM	O
27	.	O
1	CONCLUSIONS	O
2	:	O
3	Pretreatment	O
4	with	O
5	OCs	O
6	prior	O
7	to	O
8	pituitary	O
9	suppression	O
10	in	O
11	the	O
12	early	O
13	follicular	O
14	phase	O
15	decreases	O
16	ovarian	O
17	cyst	O
18	formation	O
19	,	O
20	without	O
21	an	O
22	apparent	O
23	effect	O
24	on	O
25	subsequent	O
26	follicular	O
27	recruitment	O
28	or	O
29	pregnancy	O
30	rates	O
31	.	O
1	CONCLUSION	O
2	:	O
3	Our	O
4	study	O
5	shows	O
6	that	O
7	(	O
8	1	O
9	)	O
10	total	O
11	body	O
12	BMD	O
13	and	O
14	femoral	O
15	neck	O
16	BMD	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	study	O
23	group	O
24	that	O
25	performed	O
26	weight	O
27	-	O
28	bearing	O
29	exercises	O
30	than	O
31	in	O
32	control	O
33	subjects	O
34	,	O
35	(	O
36	2	O
37	)	O
38	swimming	O
39	exercise	O
40	had	O
41	no	O
42	effect	O
43	on	O
44	BMD	O
45	,	O
46	and	O
47	(	O
48	3	O
49	)	O
50	although	O
51	swimming	O
52	is	O
53	not	O
54	a	O
55	bone	O
56	-	O
57	building	O
58	exercise	O
59	,	O
60	it	O
61	can	O
62	significantly	O
63	improve	O
64	shoulder	O
65	,	O
66	back	O
67	,	O
68	and	O
69	grip	O
70	muscle	O
71	strength	O
72	.	O
1	Lead	O
2	fixation	O
3	in	O
4	dogs	O
5	achieved	O
6	with	O
7	RF	O
8	energy	O
9	.	O
1	The	O
2	percutaneous	O
3	absorption	O
4	of	O
5	clindamycin	O
6	was	O
7	studied	O
8	in	O
9	healthy	O
10	male	O
11	volunteers	O
12	,	O
13	comparing	O
14	two	O
15	investigative	O
16	clindamycin	O
17	(%	O
18	w	O
19	/	O
20	v	O
21	)/	O
22	tretinoin	O
23	(	O
24	0	O
25	.	O
26	025	O
27	%	O
28	w	O
29	/	O
30	v	O
31	)	O
32	gels	O
33	,	O
34	containing	O
35	clindamycin	O
36	phosphate	O
37	ester	O
38	and	O
39	clindamycin	O
40	HCl	O
41	,	O
42	respectively	O
43	,	O
44	relative	O
45	to	O
46	a	O
47	clindamycin	O
48	phosphate	O
49	lotion	O
50	(	O
51	1	O
52	%	O
53	clindamycin	O
54	;	O
55	Dalacin	O
56	T	O
57	).	O
1	The	O
2	human	O
3	pathogenic	O
4	bacterium	O
5	group	O
6	A	O
7	Streptococcus	O
8	produces	O
9	an	O
10	extracellular	O
11	cysteine	B
12	protease	I
13	[	O
14	streptococcal	B
15	pyrogenic	I
16	exotoxin	I
17	B	I
18	(	O
19	SpeB	B
20	)]	O
21	that	O
22	is	O
23	a	O
24	critical	O
25	virulence	O
26	factor	O
27	for	O
28	invasive	O
29	disease	O
30	episodes	O
31	.	O
1	Plasma	O
2	CCK	B
3	levels	O
4	were	O
5	determined	O
6	at	O
7	regular	O
8	intervals	O
9	.	O
1	The	O
2	active	O
3	site	O
4	includes	O
5	the	O
6	acidic	O
7	triad	O
8	Asp53	O
9	(	O
10	the	O
11	site	O
12	of	O
13	phosphorylation	O
14	),	O
15	Asp10	O
16	and	O
17	Glu9	O
18	.	O
1	Consistent	O
2	with	O
3	these	O
4	findings	O
5	,	O
6	relatively	O
7	weak	O
8	transcriptional	O
9	silencing	O
10	by	O
11	the	O
12	native	O
13	VDR	B
14	was	O
15	observed	O
16	using	O
17	the	O
18	osteopontin	B
19	VDRE	O
20	.	O
1	In	O
2	PAV	O
3	-	O
4	3	O
5	,	O
6	the	O
7	E1A	B
8	region	I
9	is	O
10	located	O
11	between	O
12	1	O
13	.	O
14	5	O
15	and	O
16	3	O
17	.	O
18	8	O
19	map	O
20	units	O
21	.	O
1	MPO	B
2	was	O
3	labeled	O
4	with	O
5	1	O
6	mCi	O
7	125I	O
8	by	O
9	a	O
10	technique	O
11	of	O
12	self	O
13	-	O
14	labeling	O
15	in	O
16	the	O
17	presence	O
18	of	O
19	10	O
20	(-	O
21	4	O
22	)	O
23	M	O
24	hydrogen	O
25	peroxide	O
26	.	O
1	Therefore	O
2	,	O
3	in	O
4	order	O
5	to	O
6	search	O
7	for	O
8	the	O
9	latent	O
10	genes	O
11	,	O
12	we	O
13	used	O
14	allotype	O
15	-	O
16	specific	O
17	oligonucleotides	O
18	for	O
19	b5	O
20	,	O
21	b6	O
22	and	O
23	b9	O
24	to	O
25	probe	O
26	DNAs	O
27	from	O
28	both	O
29	normal	O
30	and	O
31	T	O
32	.	O
33	brucei	O
34	-	O
35	infected	O
36	rabbits	O
37	by	O
38	Southern	O
39	blotting	O
40	.	O
1	TRAF2	B
2	is	O
3	known	O
4	to	O
5	associate	O
6	with	O
7	TRADD	B
8	,	O
9	and	O
10	expression	O
11	of	O
12	a	O
13	dominant	O
14	-	O
15	negative	O
16	N	O
17	-	O
18	terminal	O
19	deletion	O
20	TRAF2	B
21	mutant	I
22	was	O
23	found	O
24	to	O
25	partially	O
26	inhibit	O
27	LMP1	B
28	-	O
29	induced	O
30	JNK	B
31	activation	O
32	in	O
33	293	O
34	cells	O
35	.	O
1	These	O
2	data	O
3	further	O
4	define	O
5	a	O
6	role	O
7	for	O
8	TRADD	B
9	and	O
10	TRAF2	B
11	in	O
12	JNK	B
13	activation	O
14	and	O
15	confirm	O
16	that	O
17	LMP1	B
18	utilizes	O
19	signalling	O
20	mechanisms	O
21	used	O
22	by	O
23	the	O
24	TNF	B
25	receptor	I
26	/	O
27	CD40	B
28	family	O
29	to	O
30	elicit	O
31	its	O
32	pleiotropic	O
33	activities	O
34	.	O
1	In	O
2	contrast	O
3	,	O
4	transiently	O
5	transfected	O
6	cells	O
7	expressing	O
8	EBNA	B
9	-	I
10	3	I
11	revealed	O
12	a	O
13	sixfold	O
14	increase	O
15	in	O
16	EBNA	B
17	-	I
18	3	I
19	protein	I
20	expression	O
21	from	O
22	the	O
23	genomic	O
24	EBNA	B
25	-	I
26	3	I
27	gene	I
28	compared	O
29	to	O
30	EBNA	B
31	-	I
32	3	I
33	cDNA	I
34	.	O
1	Folded	O
2	tissue	O
3	and	O
4	crimped	O
5	collagen	B
6	fibers	O
7	in	O
8	the	O
9	tunica	O
10	albuginea	O
11	permit	O
12	its	O
13	expansion	O
14	during	O
15	erection	O
16	.	O
1	Number	O
2	of	O
3	patients	O
4	infected	O
5	with	O
6	nontuberculous	O
7	mycobacteria	O
8	(	O
9	NTM	O
10	)	O
11	is	O
12	increasing	O
13	world	O
14	-	O
15	wide	O
16	in	O
17	recent	O
18	years	O
19	.	O
1	Immunological	O
2	testing	O
3	was	O
4	performed	O
5	on	O
6	all	O
7	brewery	O
8	workers	O
9	and	O
10	some	O
11	control	O
12	volunteers	O
13	using	O
14	skin	O
15	prick	O
16	testing	O
17	with	O
18	hops	O
19	,	O
20	barley	O
21	,	O
22	and	O
23	yeast	O
24	antigens	O
25	as	O
26	well	O
27	as	O
28	other	O
29	nonoccupational	O
30	allergens	O
31	,	O
32	and	O
33	by	O
34	determining	O
35	total	O
36	serum	B
37	IgE	I
38	levels	O
39	.	O
1	The	O
2	transcriptional	O
3	activity	O
4	of	O
5	PPARgamma	B
6	is	O
7	positively	O
8	modulated	O
9	by	O
10	ligand	O
11	binding	O
12	and	O
13	negatively	O
14	regulated	O
15	by	O
16	phosphorylation	O
17	mediated	O
18	by	O
19	the	O
20	MEK	B
21	/	O
22	ERK	B
23	signaling	O
24	pathway	O
25	.	O
1	To	O
2	search	O
3	for	O
4	transcriptional	O
5	regulators	O
6	,	O
7	we	O
8	used	O
9	a	O
10	fragment	O
11	of	O
12	the	O
13	SpHE	B
14	promoter	I
15	containing	O
16	several	O
17	individual	O
18	elements	O
19	instead	O
20	of	O
21	the	O
22	conventional	O
23	bait	O
24	that	O
25	contains	O
26	a	O
27	multimerized	O
28	cis	O
29	element	O
30	.	O
1	Nip7p	B
2	-	O
3	depleted	O
4	cells	O
5	exhibited	O
6	the	O
7	same	O
8	defects	O
9	as	O
10	Nop8p	B
11	-	O
12	depleted	O
13	cells	O
14	,	O
15	except	O
16	that	O
17	they	O
18	accumulated	O
19	27S	B
20	precursors	I
21	.	O
1	We	O
2	show	O
3	that	O
4	the	O
5	Sm	B
6	-	I
7	binding	I
8	site	I
9	and	O
10	stem	O
11	-	O
12	loop	O
13	III	O
14	structures	O
15	are	O
16	necessary	O
17	for	O
18	correct	O
19	3	O
20	'-	O
21	end	O
22	formation	O
23	.	O
1	Conserved	O
2	and	O
3	distinct	O
4	roles	O
5	of	O
6	kreisler	B
7	in	O
8	regulation	O
9	of	O
10	the	O
11	paralogous	O
12	Hoxa3	B
13	and	O
14	Hoxb3	B
15	genes	I
16	.	O
1	Autoionization	O
2	rates	O
3	and	O
4	energy	O
5	levels	O
6	of	O
7	triplet	O
8	nf	O
9	,	O
10	v	O
11	=	O
12	1	O
13	Rydberg	O
14	states	O
15	of	O
16	H2	O
17	.	O
1	Next	O
2	,	O
3	to	O
4	identify	O
5	regions	O
6	of	O
7	the	O
8	promoter	O
9	involved	O
10	,	O
11	we	O
12	examined	O
13	a	O
14	series	O
15	of	O
16	tenascin	B
17	-	I
18	C	I
19	promoter	I
20	constructs	I
21	with	O
22	5	O
23	'	O
24	deletions	O
25	and	O
26	showed	O
27	that	O
28	denatured	O
29	collagen	B
30	-	I
31	dependent	I
32	promoter	I
33	activity	O
34	was	O
35	retained	O
36	by	O
37	a	O
38	122	O
39	-	O
40	base	O
41	pair	O
42	element	O
43	,	O
44	located	O
45	-	O
46	43	O
47	to	O
48	-	O
49	165	O
50	bp	O
51	upstream	O
52	of	O
53	the	O
54	RNA	O
55	start	O
56	site	O
57	.	O
1	Moreover	O
2	,	O
3	this	O
4	enhancement	O
5	of	O
6	transcriptional	O
7	activation	O
8	by	O
9	COUP	B
10	-	I
11	TFI	I
12	requires	O
13	specifically	O
14	the	O
15	AF	O
16	-	O
17	1	O
18	transactivation	O
19	function	O
20	of	O
21	ER	B
22	and	O
23	can	O
24	be	O
25	observed	O
26	in	O
27	the	O
28	presence	O
29	of	O
30	E2	O
31	or	O
32	4	O
33	-	O
34	hydroxytamoxifen	O
35	but	O
36	not	O
37	ICI	O
38	164384	O
39	.	O
1	Recombinant	B
2	Ffh	I
3	has	O
4	a	O
5	melting	O
6	point	O
7	of	O
8	tm	O
9	=	O
10	89	O
11	degreesC	O
12	.	O
1	The	O
2	RNA	B
3	polymerase	I
4	III	I
5	-	I
6	recruiting	I
7	factor	I
8	TFIIIB	I
9	induces	O
10	a	O
11	DNA	O
12	bend	O
13	between	O
14	the	O
15	TATA	O
16	box	O
17	and	O
18	the	O
19	transcriptional	O
20	start	O
21	site	O
22	.	O
1	The	O
2	sequence	O
3	up	O
4	to	O
5	-	O
6	267	O
7	bp	O
8	relative	O
9	to	O
10	the	O
11	transcription	O
12	start	O
13	site	O
14	was	O
15	sufficient	O
16	to	O
17	enhance	O
18	reporter	O
19	gene	O
20	expression	O
21	depending	O
22	on	O
23	the	O
24	mesodermal	O
25	differentiation	O
26	of	O
27	P19	O
28	cells	O
29	.	O
1	Chem	O
2	.	O
1	However	O
2	,	O
3	C3	B
4	toxin	I
5	alone	O
6	or	O
7	in	O
8	combination	O
9	with	O
10	growth	O
11	factors	O
12	did	O
13	not	O
14	stimulate	O
15	AP	B
16	-	I
17	1	I
18	:	O
19	Luc	B
20	activity	O
21	and	O
22	actually	O
23	antagonized	O
24	the	O
25	synergistic	O
26	activation	O
27	of	O
28	AP	B
29	-	I
30	1	I
31	:	O
32	Luc	B
33	observed	O
34	in	O
35	response	O
36	to	O
37	co	O
38	-	O
39	stimulation	O
40	with	O
41	growth	O
42	factors	O
43	and	O
44	Ro	O
45	-	O
46	31	O
47	-	O
48	8220	O
49	.	O
1	The	O
2	RMRI	O
3	was	O
4	tested	O
5	for	O
6	interrater	O
7	reliability	O
8	using	O
9	three	O
10	simulated	O
11	and	O
12	10	O
13	actual	O
14	patients	O
15	.	O
1	The	O
2	starting	O
3	point	O
4	is	O
5	the	O
6	consideration	O
7	that	O
8	the	O
9	conceptions	O
10	underlying	O
11	the	O
12	ICIDH	O
13	are	O
14	not	O
15	suitable	O
16	to	O
17	serve	O
18	as	O
19	a	O
20	mainstay	O
21	of	O
22	a	O
23	model	O
24	for	O
25	diagnostics	O
26	in	O
27	rehabilitation	O
28	because	O
29	they	O
30	do	O
31	not	O
32	reflect	O
33	essential	O
34	characteristics	O
35	of	O
36	the	O
37	diagnostic	O
38	process	O
39	which	O
40	is	O
41	the	O
42	basis	O
43	for	O
44	intervention	O
45	.	O
1	Pokeweed	B
2	antiviral	I
3	protein	I
4	(	O
5	PAP	B
6	)	O
7	from	O
8	Phytolacca	O
9	americana	O
10	is	O
11	a	O
12	highly	O
13	specific	O
14	N	B
15	-	I
16	glycosidase	I
17	removing	O
18	adenine	O
19	residues	O
20	(	O
21	A4324	O
22	in	O
23	28S	B
24	rRNA	I
25	and	O
26	A2660	O
27	in	O
28	23S	B
29	rRNA	I
30	)	O
31	from	O
32	intact	O
33	ribosomes	O
34	of	O
35	both	O
36	eukaryotes	O
37	and	O
38	prokaryotes	O
39	.	O
1	The	O
2	3	O
3	.	O
4	3	O
5	-	O
6	fold	O
7	higher	O
8	expression	O
9	in	O
10	the	O
11	fetal	O
12	heart	O
13	than	O
14	in	O
15	the	O
16	adult	O
17	heart	O
18	suggests	O
19	that	O
20	HFHZ	B
21	mRNA	I
22	is	O
23	downregulated	O
24	in	O
25	the	O
26	process	O
27	of	O
28	development	O
29	.	O
1	To	O
2	date	O
3	,	O
4	two	O
5	such	O
6	proteins	O
7	,	O
8	PLZF	B
9	and	O
10	LAZ	B
11	-	I
12	3	I
13	/	O
14	BCL	B
15	-	I
16	6	I
17	,	O
18	have	O
19	been	O
20	implicated	O
21	in	O
22	oncogenesis	O
23	.	O
1	Overexpression	O
2	of	O
3	POG1	B
4	inhibits	O
5	alpha	B
6	-	I
7	factor	I
8	-	O
9	induced	O
10	G1	O
11	arrest	O
12	and	O
13	transcriptional	O
14	repression	O
15	of	O
16	the	O
17	CLN1	B
18	and	O
19	CLN2	B
20	genes	I
21	.	O
1	Competitionsupershift	O
2	EMSA	O
3	assays	O
4	revealed	O
5	that	O
6	multiple	O
7	proteins	O
8	were	O
9	involved	O
10	in	O
11	bandshift	O
12	complex	O
13	formation	O
14	with	O
15	KCS	B
16	,	O
17	one	O
18	of	O
19	which	O
20	was	O
21	identified	O
22	as	O
23	factor	O
24	Sp1	O
25	.	O
1	Neither	O
2	the	O
3	p42	B
4	/	I
5	44	I
6	nor	O
7	the	O
8	JNK	B
9	pathway	O
10	was	O
11	involved	O
12	in	O
13	the	O
14	action	O
15	of	O
16	IL	B
17	-	I
18	1beta	I
19	.	O
1	IFN	B
2	-	I
3	gamma	I
4	was	O
5	elevated	O
6	during	O
7	active	O
8	TB	O
9	when	O
10	compared	O
11	with	O
12	healthy	O
13	controls	O
14	,	O
15	declining	O
16	during	O
17	and	O
18	after	O
19	treatment	O
20	.	O
1	Bound	O
2	-	O
3	exciton	O
4	transfer	O
5	and	O
6	photoluminescence	O
7	undulation	O
8	spectra	O
9	for	O
10	acceptors	O
11	in	O
12	ZnTe	O
13	.	O
1	Envelope	O
2	-	O
3	function	O
4	matching	O
5	conditions	O
6	for	O
7	GaAs	O
8	/(	O
9	Al	O
10	,	O
11	Ga	O
12	)	O
13	As	O
14	heterojunctions	O
15	.	O
1	The	O
2	history	O
3	of	O
4	exposure	O
5	and	O
6	carboxyhemoglobin	B
7	levels	O
8	should	O
9	alert	O
10	the	O
11	physician	O
12	to	O
13	this	O
14	diagnosis	O
15	.	O
1	Model	O
2	of	O
3	spatiotemporal	O
4	dynamics	O
5	of	O
6	stick	O
7	-	O
8	slip	O
9	motion	O
10	.	O
1	Microstructure	O
2	and	O
3	conductivity	O
4	of	O
5	hierarchical	O
6	laminate	O
7	composites	O
8	.	O
1	The	O
2	lytic	O
3	cycle	O
4	of	O
5	KSHV	O
6	,	O
7	probably	O
8	under	O
9	the	O
10	initial	O
11	control	O
12	of	O
13	the	O
14	KSHV	B
15	/	I
16	Rta	I
17	gene	I
18	,	O
19	may	O
20	directly	O
21	contribute	O
22	to	O
23	tumor	O
24	pathogenesis	O
25	.	O
1	Electronic	O
2	structure	O
3	of	O
4	a	O
5	buried	O
6	NiSi2	O
7	or	O
8	CoSi2	O
9	layer	O
10	in	O
11	bulk	O
12	Si	O
13	.	O
1	However	O
2	,	O
3	deletions	O
4	of	O
5	the	O
6	C	O
7	terminal	O
8	11	O
9	or	O
10	14	O
11	amino	O
12	acids	O
13	had	O
14	more	O
15	substantial	O
16	effects	O
17	.	O
1	Its	O
2	early	O
3	lesions	O
4	were	O
5	characterized	O
6	by	O
7	angiomatosis	O
8	,	O
9	vasculopathy	O
10	,	O
11	and	O
12	proliferation	O
13	of	O
14	synoviocytes	O
15	and	O
16	fibroblasts	O
17	.	O
1	Recombination	O
2	and	O
3	transcription	O
4	of	O
5	the	O
6	endogenous	B
7	Ig	I
8	heavy	I
9	chain	I
10	locus	I
11	is	O
12	effected	O
13	by	O
14	the	O
15	Ig	B
16	heavy	I
17	chain	I
18	intronic	I
19	enhancer	I
20	core	I
21	region	I
22	in	O
23	the	O
24	absence	O
25	of	O
26	the	O
27	matrix	O
28	attachment	O
29	regions	O
30	.	O
1	Two	O
2	of	O
3	these	O
4	motifs	O
5	are	O
6	part	O
7	of	O
8	a	O
9	highly	O
10	conserved	O
11	and	O
12	inducible	O
13	dyad	O
14	symmetry	O
15	element	O
16	shown	O
17	previously	O
18	to	O
19	control	O
20	a	O
21	remote	O
22	IL	B
23	-	I
24	2	I
25	enhancer	I
26	and	O
27	the	O
28	CD18	B
29	promoter	I
30	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	potent	O
6	splicing	O
7	enhancer	O
8	sequence	O
9	isolated	O
10	in	O
11	the	O
12	selection	O
13	specifically	O
14	binds	O
15	a	O
16	20	B
17	-	I
18	kDa	I
19	SR	I
20	protein	I
21	.	O
1	Elimination	O
2	of	O
3	ETH1	B
4	in	O
5	apn1	B
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	reversion	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	prototrophy	O
32	,	O
33	respectively	O
34	.	O
1	Three	O
2	mog	B
3	-	I
4	1	I
5	alleles	I
6	possess	O
7	premature	O
8	stop	O
9	codons	O
10	and	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	null	O
16	alleles	O
17	,	O
18	and	O
19	one	O
20	is	O
21	a	O
22	missense	O
23	mutation	O
24	and	O
25	is	O
26	likely	O
27	to	O
28	retain	O
29	residual	O
30	activity	O
31	.	O
32	mog	B
33	-	I
34	1	I
35	mRNA	I
36	is	O
37	expressed	O
38	in	O
39	both	O
40	germ	O
41	line	O
42	and	O
43	somatic	O
44	tissues	O
45	and	O
46	appears	O
47	to	O
48	be	O
49	ubiquitous	O
50	.	O
1	The	O
2	therapy	O
3	with	O
4	a	O
5	H2	B
6	-	I
7	receptor	I
8	antagonist	O
9	is	O
10	less	O
11	effective	O
12	than	O
13	the	O
14	triple	O
15	therapies	O
16	with	O
17	omeprazole	O
18	or	O
19	lansoprazole	O
20	.	O
1	In	O
2	addition	O
3	,	O
4	in	O
5	vitro	O
6	mutagenesis	O
7	of	O
8	both	O
9	Engrailed	B
10	and	O
11	Pbx1	B
12	sites	I
13	indicated	O
14	that	O
15	other	O
16	unidentified	O
17	sites	O
18	are	O
19	responsible	O
20	for	O
21	the	O
22	transcriptional	O
23	enhancement	O
24	observed	O
25	with	O
26	the	O
27	intronic	O
28	fragment	O
29	.	O
1	Several	O
2	secondary	O
3	structure	O
4	elements	O
5	were	O
6	identified	O
7	.	O
1	Here	O
2	,	O
3	we	O
4	evidence	O
5	that	O
6	the	O
7	developmental	O
8	functions	O
9	of	O
10	the	O
11	family	O
12	of	O
13	transcription	O
14	factors	O
15	characterized	O
16	by	O
17	the	O
18	POU	B
19	DNA	I
20	binding	I
21	motif	I
22	exerts	O
23	roles	O
24	in	O
25	mammalian	O
26	development	O
27	.	O
1	The	O
2	other	O
3	is	O
4	located	O
5	at	O
6	-	O
7	1335	O
8	,	O
9	outside	O
10	this	O
11	highly	O
12	conserved	O
13	region	O
14	.	O
1	Depth	O
2	-	O
3	controlled	O
4	grazing	O
5	-	O
6	incidence	O
7	diffraction	O
8	of	O
9	synchrotron	O
10	x	O
11	radiation	O
12	.	O
1	Structure	O
2	determination	O
3	of	O
4	an	O
5	adsorbate	O
6	-	O
7	induced	O
8	multilayer	O
9	reconstruction	O
10	:	O
11	(	O
12	1	O
13	x	O
14	2	O
15	)-	O
16	H	O
17	/	O
18	Ni	O
19	(	O
20	110	O
21	).	O
1	High	O
2	-	O
3	pressure	O
4	effects	O
5	on	O
6	ultrafast	O
7	-	O
8	relaxation	O
9	kinetics	O
10	of	O
11	excitons	O
12	in	O
13	polydiacetylene	O
14	4BCMU	O
15	.	O
1	Current	O
2	world	O
3	literature	O
4	.	O
1	Mapping	O
2	of	O
3	the	O
4	human	B
5	Voltage	I
6	-	I
7	Dependent	I
8	Anion	I
9	Channel	I
10	isoforms	I
11	1	I
12	and	I
13	2	I
14	reconsidered	O
15	.	O
1	Band	O
2	structure	O
3	effects	O
4	of	O
5	transport	O
6	properties	O
7	in	O
8	icosahedral	O
9	quasicrystals	O
10	.	O
1	Acoustic	O
2	transmission	O
3	spectra	O
4	in	O
5	the	O
6	Penrose	O
7	lattice	O
8	.	O
1	The	O
2	SH2	B
3	domain	I
4	-	I
5	containing	I
6	inositol	I
7	5	I
8	'-	I
9	phosphatase	I
10	(	O
11	SHIP	B
12	)	O
13	recruits	O
14	the	O
15	p85	B
16	subunit	I
17	of	O
18	phosphoinositide	B
19	3	I
20	-	I
21	kinase	I
22	during	O
23	FcgammaRIIb1	B
24	-	O
25	mediated	O
26	inhibition	O
27	of	O
28	B	B
29	cell	I
30	receptor	I
31	signaling	O
32	.	O
1	We	O
2	show	O
3	that	O
4	the	O
5	mouse	O
6	genome	O
7	contains	O
8	four	O
9	copies	O
10	of	O
11	the	O
12	ubc	B
13	-	I
14	9	I
15	gene	I
16	.	O
1	Interestingly	O
2	,	O
3	Csx	B
4	/	O
5	Nkx2	B
6	.	O
1	The	O
2	costs	O
3	were	O
4	DM	O
5	11	O
6	,	O
7	562	O
8	for	O
9	a	O
10	PE	O
11	,	O
12	DM	O
13	12	O
14	,	O
15	477	O
16	for	O
17	a	O
18	VR	O
19	and	O
20	DM	O
21	7	O
22	,	O
23	532	O
24	for	O
25	a	O
26	MR	O
27	.	O
1	We	O
2	now	O
3	provide	O
4	evidence	O
5	for	O
6	physical	O
7	and	O
8	functional	O
9	interaction	O
10	between	O
11	Doa4	B
12	and	O
13	the	O
14	proteasome	O
15	.	O
1	The	O
2	rate	O
3	of	O
4	resectability	O
5	is	O
6	low	O
7	and	O
8	5	O
9	-	O
10	year	O
11	survival	O
12	is	O
13	very	O
14	poor	O
15	.	O
1	In	O
2	order	O
3	to	O
4	better	O
5	characterize	O
6	the	O
7	distribution	O
8	of	O
9	ML	O
10	and	O
11	MAP	O
12	estimates	O
13	under	O
14	these	O
15	conditions	O
16	,	O
17	we	O
18	derive	O
19	a	O
20	point	O
21	approximation	O
22	to	O
23	density	O
24	values	O
25	of	O
26	the	O
27	conditional	O
28	distribution	O
29	of	O
30	such	O
31	estimates	O
32	.	O
1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	are	O
7	consistent	O
8	with	O
9	the	O
10	possibility	O
11	that	O
12	p202	B
13	protein	I
14	contributes	O
15	to	O
16	the	O
17	cell	O
18	growth	O
19	retardation	O
20	activity	O
21	of	O
22	the	O
23	IFNs	B
24	,	O
25	at	O
26	least	O
27	in	O
28	part	O
29	,	O
30	by	O
31	modulating	O
32	p21	B
33	protein	I
34	levels	O
35	.	O
1	Human	B
2	neuronal	I
3	Elav	I
4	-	I
5	like	I
6	proteins	I
7	contain	O
8	three	O
9	RNP	O
10	-	O
11	type	O
12	RNA	O
13	recognition	O
14	motifs	O
15	(	O
16	RRMs	O
17	).	O
1	MDS1	B
2	/	O
3	EVI1	B
4	,	O
5	located	O
6	on	O
7	chromosome	O
8	3	O
9	band	O
10	q26	O
11	,	O
12	encodes	O
13	a	O
14	zinc	B
15	-	I
16	finger	I
17	DNA	I
18	-	I
19	binding	I
20	transcription	I
21	activator	I
22	not	O
23	detected	O
24	in	O
25	normal	O
26	hematopoietic	O
27	cells	O
28	but	O
29	expressed	O
30	in	O
31	several	O
32	normal	O
33	tissues	O
34	.	O
1	In	O
2	contrast	O
3	,	O
4	deletion	O
5	of	O
6	the	O
7	upstream	O
8	portion	O
9	of	O
10	the	O
11	delta	O
12	promoter	O
13	led	O
14	to	O
15	a	O
16	10	O
17	fold	O
18	decrease	O
19	in	O
20	expression	O
21	.	O
1	Conformational	O
2	studies	O
3	combining	O
4	secondary	O
5	structure	O
6	predictions	O
7	,	O
8	CD	O
9	and	O
10	NMR	O
11	spectroscopy	O
12	together	O
13	with	O
14	ELISA	O
15	assays	O
16	,	O
17	showed	O
18	that	O
19	the	O
20	greater	O
21	is	O
22	the	O
23	propensity	O
24	of	O
25	the	O
26	epitope	O
27	for	O
28	helix	O
29	formation	O
30	the	O
31	higher	O
32	is	O
33	the	O
34	recognition	O
35	by	O
36	anti	B
37	-	I
38	K159	I
39	.	O
1	Topoisomerase	B
2	II	I
3	is	O
4	a	O
5	major	O
6	target	O
7	of	O
8	the	O
9	protein	B
10	kinase	I
11	casein	I
12	kinase	I
13	2	I
14	(	O
15	PK	B
16	CK2	I
17	)	O
18	in	O
19	vivo	O
20	.	O
1	In	O
2	contrast	O
3	,	O
4	no	O
5	change	O
6	was	O
7	detected	O
8	in	O
9	the	O
10	phenotype	O
11	of	O
12	'	O
13	unstressed	O
14	'	O
15	clones	O
16	,	O
17	with	O
18	respect	O
19	to	O
20	any	O
21	of	O
22	the	O
23	following	O
24	parameters	O
25	:	O
26	proliferation	O
27	rate	O
28	in	O
29	monolayer	O
30	,	O
31	serum	O
32	-	O
33	dependence	O
34	for	O
35	proliferation	O
36	or	O
37	survival	O
38	,	O
39	tumorigenicity	O
40	,	O
41	cellular	O
42	morphology	O
43	,	O
44	or	O
45	tissue	O
46	-	O
47	specific	O
48	differentiation	O
49	markers	O
50	.	O
1	UPMC	O
2	is	O
3	not	O
4	the	O
5	only	O
6	organization	O
7	pursuing	O
8	controlled	O
9	NHBC	O
10	organ	O
11	procurement	O
12	,	O
13	however	O
14	.	O
1	These	O
2	results	O
3	suggest	O
4	KCC3	B
5	is	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	KCC	B
12	family	I
13	that	O
14	is	O
15	under	O
16	distinct	O
17	regulation	O
18	from	O
19	KCC1	B
20	.	O
1	A	O
2	list	O
3	of	O
4	12	O
5	names	O
6	for	O
7	the	O
8	disease	O
9	and	O
10	37	O
11	diagnostic	O
12	criteria	O
13	were	O
14	proposed	O
15	to	O
16	a	O
17	Consensus	O
18	Panel	O
19	of	O
20	12	O
21	Italian	O
22	experts	O
23	who	O
24	ranked	O
25	them	O
26	in	O
27	order	O
28	so	O
29	as	O
30	to	O
31	identify	O
32	a	O
33	core	O
34	set	O
35	of	O
36	criteria	O
37	.	O
1	Methanesulfonyl	O
2	fluoride	O
3	(	O
4	MSF	O
5	):	O
6	a	O
7	double	O
8	-	O
9	blind	O
10	,	O
11	placebo	O
12	-	O
13	controlled	O
14	study	O
15	of	O
16	safety	O
17	and	O
18	efficacy	O
19	in	O
20	the	O
21	treatment	O
22	of	O
23	senile	O
24	dementia	O
25	of	O
26	the	O
27	Alzheimer	O
28	type	O
29	.	O
1	One	O
2	such	O
3	element	O
4	,	O
5	1P	O
6	,	O
7	was	O
8	employed	O
9	to	O
10	clone	O
11	from	O
12	a	O
13	rat	O
14	pituitary	O
15	cDNA	O
16	expression	O
17	library	O
18	a	O
19	novel	O
20	417	B
21	-	I
22	amino	I
23	acid	I
24	WD	I
25	protein	I
26	,	O
27	designated	O
28	PREB	B
29	(	I
30	PRL	I
31	regulatory	I
32	element	I
33	binding	I
34	)	I
35	protein	I
36	.	O
1	However	O
2	,	O
3	F	B
4	-	I
5	SRC	I
6	-	I
7	1	I
8	mutant	I
9	lacking	O
10	CBP	B
11	-	I
12	interacting	I
13	domain	I
14	still	O
15	preserved	O
16	enhancing	O
17	activity	O
18	.	O
1	The	O
2	catalytic	O
3	site	O
4	has	O
5	an	O
6	S1	O
7	pocket	O
8	lined	O
9	with	O
10	conserved	O
11	hydrophobic	O
12	residues	O
13	to	O
14	accommodate	O
15	the	O
16	pyroglutamyl	O
17	residue	O
18	.	O
1	Analysis	O
2	of	O
3	lacZ	B
4	transcriptional	I
5	fusions	I
6	shows	O
7	that	O
8	the	O
9	KdgR	B
10	-	I
11	binding	I
12	sites	I
13	negatively	O
14	affect	O
15	the	O
16	expression	O
17	of	O
18	rsmB	B
19	.	O
1	In	O
2	the	O
3	cell	O
4	-	O
5	free	O
6	import	O
7	assay	O
8	,	O
9	beta	B
10	-	I
11	catenin	I
12	rapidly	O
13	migrates	O
14	into	O
15	the	O
16	nucleus	O
17	without	O
18	the	O
19	exogenous	O
20	addition	O
21	of	O
22	cytosol	O
23	,	O
24	Ran	B
25	,	O
26	or	O
27	ATP	O
28	/	O
29	GTP	O
30	.	O
1	When	O
2	tethered	O
3	to	O
4	a	O
5	heterologous	O
6	DNA	O
7	-	O
8	binding	O
9	domain	O
10	,	O
11	PSU1	B
12	can	O
13	activate	O
14	transcription	O
15	on	O
16	its	O
17	own	O
18	.	O
1	The	O
2	eukaryotic	O
3	cell	O
4	cycle	O
5	is	O
6	governed	O
7	in	O
8	part	O
9	by	O
10	the	O
11	periodic	O
12	transcription	O
13	of	O
14	cyclin	B
15	genes	I
16	,	O
17	whose	O
18	protein	O
19	products	O
20	associate	O
21	with	O
22	and	O
23	positively	O
24	regulate	O
25	the	O
26	cyclin	B
27	-	I
28	dependent	I
29	kinases	I
30	.	O
1	The	O
2	Fyn	B
3	NH2	I
4	terminus	I
5	was	O
6	necessary	O
7	but	O
8	not	O
9	sufficient	O
10	for	O
11	interaction	O
12	with	O
13	zeta	O
14	and	O
15	both	O
16	Fyn	B
17	kinase	I
18	and	O
19	SH2	B
20	domains	I
21	were	O
22	required	O
23	,	O
24	directing	O
25	phosphorylation	O
26	of	O
27	zeta	B
28	ITAM	I
29	tyrosines	O
30	and	O
31	binding	O
32	to	O
33	zeta	B
34	ITAM	I
35	phosphotyrosines	O
36	.	O
1	We	O
2	show	O
3	here	O
4	that	O
5	,	O
6	despite	O
7	their	O
8	structural	O
9	and	O
10	functional	O
11	similarities	O
12	,	O
13	the	O
14	pop1	B
15	and	O
16	pop2	B
17	genes	I
18	fail	O
19	to	O
20	complement	O
21	each	O
22	other	O
23	'	O
24	s	O
25	deletion	O
26	phenotypes	O
27	,	O
28	indicating	O
29	that	O
30	they	O
31	perform	O
32	non	O
33	-	O
34	redundant	O
35	,	O
36	but	O
37	potentially	O
38	interdependent	O
39	,	O
40	functions	O
41	in	O
42	proteolysis	O
43	.	O
1	Acute	O
2	pancreatitis	O
3	as	O
4	a	O
5	complication	O
6	of	O
7	polyarteritis	O
8	nodosa	O
9	.	O
1	Initial	O
2	control	O
3	of	O
4	bleeding	O
5	is	O
6	similar	O
7	,	O
8	but	O
9	eradication	O
10	is	O
11	achieved	O
12	in	O
13	fewer	O
14	sessions	O
15	with	O
16	EVL	O
17	.	O
1	The	O
2	binding	O
3	of	O
4	PH	B
5	domains	I
6	to	O
7	Gbetagamma	B
8	was	O
9	inhibited	O
10	by	O
11	preincubation	O
12	of	O
13	Gbetagamma	B
14	with	O
15	the	O
16	GDP	O
17	-	O
18	bound	O
19	but	O
20	not	O
21	the	O
22	GTP	O
23	-	O
24	bound	O
25	form	O
26	of	O
27	Gialpha	B
28	.	O
1	Receptor	B
2	protein	I
3	tyrosine	I
4	phosphatases	I
5	(	O
6	RPTPs	B
7	)	O
8	comprise	O
9	a	O
10	family	O
11	of	O
12	proteins	O
13	that	O
14	feature	O
15	intracellular	O
16	phosphatase	O
17	domains	O
18	and	O
19	an	O
20	ectodomain	O
21	with	O
22	putative	O
23	ligand	O
24	-	O
25	binding	O
26	motifs	O
27	.	O
1	We	O
2	show	O
3	that	O
4	other	O
5	cdc33	B
6	mutants	I
7	also	O
8	arrest	O
9	in	O
10	G1	O
11	.	O
1	A	O
2	cdc33	B
3	-	I
4	1	I
5	strain	O
6	expressing	O
7	either	O
8	stable	O
9	Cln3p	B
10	(	O
11	Cln3	B
12	-	I
13	1p	I
14	)	O
15	or	O
16	a	O
17	hybrid	O
18	UBI4	B
19	5	I
20	'-	I
21	CLN3	I
22	mRNA	O
23	,	O
24	whose	O
25	translation	O
26	displays	O
27	decreased	O
28	dependence	O
29	on	O
30	eIF4E	B
31	,	O
32	arrested	O
33	randomly	O
34	in	O
35	the	O
36	cell	O
37	cycle	O
38	.	O
1	The	O
2	gene	O
3	structure	O
4	of	O
5	Elk1	B
6	spans	O
7	15	O
8	.	O
9	2	O
10	kb	O
11	and	O
12	consists	O
13	of	O
14	seven	O
15	exons	O
16	and	O
17	six	O
18	introns	O
19	.	O
1	Sequence	O
2	analysis	O
3	suggests	O
4	that	O
5	TtrA	B
6	contains	O
7	a	O
8	molybdopterin	O
9	guanine	O
10	dinucleotide	O
11	cofactor	O
12	and	O
13	a	O
14	[	O
15	4Fe	O
16	-	O
17	4S	O
18	]	O
19	cluster	O
20	,	O
21	that	O
22	TtrB	B
23	binds	O
24	four	O
25	[	O
26	4Fe	O
27	-	O
28	4S	O
29	]	O
30	clusters	O
31	,	O
32	and	O
33	that	O
34	TtrC	B
35	is	O
36	an	O
37	integral	O
38	membrane	O
39	protein	O
40	containing	O
41	a	O
42	quinol	O
43	oxidation	O
44	site	O
45	.	O
1	Predictors	O
2	of	O
3	success	O
4	in	O
5	pharmacy	O
6	school	O
7	:	O
8	PCAT	O
9	vs	O
10	.	O
11	other	O
12	admission	O
13	criteria	O
14	.	O
1	Canadian	O
2	survey	O
3	reveals	O
4	widespread	O
5	dissatisfaction	O
6	among	O
7	physicians	O
8	.	O
1	Online	O
2	LATCH	O
3	demonstrates	O
4	a	O
5	shift	O
6	in	O
7	identification	O
8	of	O
9	the	O
10	library	O
11	as	O
12	an	O
13	isolated	O
14	unit	O
15	to	O
16	an	O
17	interactive	O
18	resource	O
19	center	O
20	.	O
1	An	O
2	end	O
3	-	O
4	to	O
5	-	O
6	end	O
7	pancreaticojejunostomy	O
8	using	O
9	a	O
10	mechanical	O
11	purse	O
12	-	O
13	string	O
14	device	O
15	.	O
1	Insulin	B
2	stimulation	O
3	promoted	O
4	the	O
5	association	O
6	of	O
7	mIRS3	B
8	with	O
9	p85	B
10	,	O
11	SHP2	B
12	,	O
13	Nck	B
14	,	O
15	and	O
16	Shc	B
17	.	O
1	In	O
2	the	O
3	case	O
4	of	O
5	the	O
6	unspliceable	O
7	intron	O
8	,	O
9	repression	O
10	of	O
11	luciferase	B
12	expression	O
13	likely	O
14	involved	O
15	two	O
16	AUF1	B
17	-	I
18	binding	I
19	sequences	I
20	,	O
21	since	O
22	luciferase	B
23	expression	O
24	was	O
25	increased	O
26	by	O
27	deletion	O
28	of	O
29	these	O
30	sites	O
31	.	O
1	Thus	O
2	,	O
3	VDR	B
4	acts	O
5	selectively	O
6	on	O
7	the	O
8	two	O
9	components	O
10	required	O
11	for	O
12	activation	O
13	of	O
14	this	O
15	promoter	O
16	/	O
17	enhancer	O
18	:	O
19	it	O
20	competes	O
21	with	O
22	NFAT1	B
23	for	O
24	binding	O
25	to	O
26	the	O
27	composite	O
28	site	O
29	,	O
30	positioning	O
31	itself	O
32	adjacent	O
33	to	O
34	Jun	B
35	-	O
36	Fos	B
37	on	O
38	the	O
39	DNA	O
40	.	O
1	The	O
2	RanQ69L	B
3	preincubation	O
4	leads	O
5	to	O
6	accumulation	O
7	of	O
8	CRM1	B
9	at	O
10	the	O
11	cytoplasmic	O
12	periphery	O
13	of	O
14	the	O
15	nuclear	O
16	pore	O
17	complex	O
18	(	O
19	NPC	O
20	)	O
21	in	O
22	association	O
23	with	O
24	the	O
25	p62	B
26	complex	I
27	and	O
28	Can	B
29	/	O
30	Nup214	B
31	.	O
1	The	O
2	hTERT	B
3	gene	I
4	encompasses	O
5	more	O
6	than	O
7	37kb	O
8	and	O
9	consists	O
10	of	O
11	16	O
12	exons	O
13	.	O
1	This	O
2	repression	O
3	was	O
4	reversed	O
5	agonists	O
6	of	O
7	either	O
8	receptor	O
9	demonstrating	O
10	a	O
11	functional	O
12	interaction	O
13	between	O
14	NCoR	B
15	and	O
16	PPARalpha	B
17	.	O
18	RXRalpha	B
19	heterodimeric	O
20	complexes	O
21	in	O
22	mammalian	O
23	cells	O
24	.	O
1	CDK4	B
2	kinase	I
3	activities	O
4	were	O
5	unaffected	O
6	,	O
7	as	O
8	were	O
9	the	O
10	levels	O
11	of	O
12	the	O
13	CDK	B
14	inhibitor	O
15	p21Cip1	B
16	present	O
17	in	O
18	cyclin	B
19	E	I
20	immunocomplexes	I
21	.	O
1	Nevertheless	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	the	O
7	entire	O
8	three	O
9	-	O
10	component	O
11	yeast	O
12	capping	O
13	apparatus	O
14	,	O
15	consisting	O
16	of	O
17	RNA	B
18	5	I
19	'-	I
20	triphosphatase	I
21	(	O
22	Cet1p	B
23	),	O
24	RNA	B
25	guanylyltransferase	I
26	(	O
27	Ceg1p	B
28	),	O
29	and	O
30	Abd1p	B
31	could	O
32	be	O
33	replaced	O
34	in	O
35	vivo	O
36	by	O
37	the	O
38	two	O
39	-	O
40	component	O
41	mammalian	O
42	apparatus	O
43	consisting	O
44	of	O
45	a	O
46	bifunctional	O
47	triphosphatase	B
48	-	I
49	guanylyltransferase	I
50	Mce1p	I
51	and	O
52	the	O
53	methyltransferase	B
54	Hcm1	I
55	(	I
56	121	I
57	-	I
58	476	I
59	)	I
60	p	I
61	.	O
1	The	O
2	IC50	O
3	values	O
4	for	O
5	rat	O
6	and	O
7	dog	O
8	urinary	O
9	bladder	O
10	were	O
11	3	O
12	.	O
13	9	O
14	x	O
15	10	O
16	(-	O
17	6	O
18	)	O
19	M	O
20	and	O
21	3	O
22	.	O
23	8	O
24	x	O
25	10	O
26	(-	O
27	6	O
28	)	O
29	M	O
30	,	O
31	respectively	O
32	.	O
1	MutY	B
2	is	O
3	an	O
4	adenine	B
5	-	I
6	DNA	I
7	glycosylase	I
8	with	O
9	specificity	O
10	for	O
11	mismatches	O
12	involving	O
13	8	O
14	-	O
15	oxoguanine	O
16	(	O
17	oG	O
18	.	O
19	A	O
20	)	O
21	or	O
22	guanine	O
23	(	O
24	G	O
25	.	O
26	A	O
27	).	O
1	Nevertheless	O
2	,	O
3	they	O
4	are	O
5	functionally	O
6	distinct	O
7	in	O
8	that	O
9	FcalphaRI	B
10	binds	O
11	human	B
12	IgA	I
13	(	O
14	hIgA	B
15	)	O
16	but	O
17	not	O
18	bovine	B
19	IgG2	I
20	(	O
21	bIgG2	B
22	),	O
23	whereas	O
24	bFcgamma2R	B
25	binds	O
26	bIgG2	B
27	but	O
28	not	O
29	hIgA	B
30	.	O
1	In	O
2	a	O
3	heterologous	O
4	transcriptional	O
5	system	O
6	in	O
7	which	O
8	the	O
9	upstream	O
10	regions	O
11	of	O
12	oIFNtau	B
13	were	O
14	inserted	O
15	in	O
16	front	O
17	of	O
18	simian	B
19	virus	I
20	40	I
21	(	I
22	SV40	I
23	)	I
24	promoter	I
25	,	O
26	the	O
27	regions	O
28	between	O
29	bases	O
30	-	O
31	654	O
32	and	O
33	-	O
34	555	O
35	were	O
36	determined	O
37	as	O
38	being	O
39	the	O
40	enhancer	O
41	region	O
42	required	O
43	for	O
44	oIFNtau	B
45	-	O
46	SV40	O
47	-	O
48	CAT	B
49	transactivation	O
50	.	O
1	In	O
2	addition	O
3	,	O
4	we	O
5	show	O
6	that	O
7	the	O
8	expression	O
9	of	O
10	individual	O
11	members	O
12	of	O
13	one	O
14	subfamily	O
15	of	O
16	KRAB	B
17	zinc	I
18	finger	I
19	genes	I
20	is	O
21	restricted	O
22	to	O
23	specific	O
24	hematopoietic	O
25	cell	O
26	lineages	O
27	.	O
1	Both	O
2	carbachol	O
3	(	O
4	100	O
5	microM	O
6	)	O
7	and	O
8	EGF	B
9	(	O
10	10	O
11	nM	O
12	)	O
13	induced	O
14	Ras	B
15	activation	O
16	.	O
1	With	O
2	exon	O
3	trapping	O
4	,	O
5	we	O
6	could	O
7	isolate	O
8	five	O
9	potential	O
10	exons	O
11	from	O
12	the	O
13	YAC	O
14	946E12	O
15	that	O
16	spans	O
17	the	O
18	region	O
19	,	O
20	four	O
21	of	O
22	which	O
23	could	O
24	be	O
25	placed	O
26	in	O
27	the	O
28	contig	O
29	in	O
30	the	O
31	vicinity	O
32	of	O
33	the	O
34	breakpoints	O
35	.	O
1	Campomelic	O
2	dysplasia	O
3	translocation	O
4	breakpoints	O
5	are	O
6	scattered	O
7	over	O
8	1	O
9	Mb	O
10	proximal	O
11	to	O
12	SOX9	B
13	:	O
14	evidence	O
15	for	O
16	an	O
17	extended	O
18	control	O
19	region	O
20	.	O
1	A	O
2	coiled	O
3	-	O
4	coil	O
5	domain	O
6	,	O
7	conserved	O
8	within	O
9	each	O
10	encoded	O
11	protein	O
12	,	O
13	serves	O
14	as	O
15	a	O
16	potential	O
17	interaction	O
18	motif	O
19	for	O
20	FLI	B
21	LRR	I
22	.	O
1	Severe	O
2	hemolysis	O
3	resulted	O
4	in	O
5	statistically	O
6	significant	O
7	changes	O
8	in	O
9	the	O
10	mean	O
11	values	O
12	of	O
13	the	O
14	above	O
15	analytes	O
16	in	O
17	addition	O
18	to	O
19	the	O
20	following	O
21	increases	O
22	:	O
23	alanine	B
24	aminotransferase	I
25	,	O
26	calcium	O
27	,	O
28	and	O
29	serum	B
30	globulins	I
31	(	O
32	P	O
33	<	O
34	0	O
35	.	O
36	001	O
37	)	O
38	and	O
39	albumin	B
40	and	O
41	total	O
42	protein	O
43	(	O
44	P	O
45	<	O
46	0	O
47	.	O
48	01	O
49	).	O
1	CONCLUSIONS	O
2	:	O
3	Turbutest	O
4	is	O
5	a	O
6	valuable	O
7	tool	O
8	in	O
9	asthmatic	O
10	patients	O
11	'	O
12	training	O
13	,	O
14	allowing	O
15	identification	O
16	and	O
17	improvement	O
18	of	O
19	an	O
20	inadequate	O
21	inhalation	O
22	technique	O
23	with	O
24	Turbuhaler	O
25	.	O
1	SRFDelta5	B
2	acts	O
3	as	O
4	a	O
5	naturally	O
6	occurring	O
7	dominant	O
8	negative	O
9	regulatory	O
10	mutant	O
11	that	O
12	blocks	O
13	SRF	B
14	-	O
15	dependent	O
16	skeletal	B
17	alpha	I
18	-	I
19	actin	I
20	,	O
21	cardiac	B
22	alpha	I
23	-	I
24	actin	I
25	,	O
26	smooth	B
27	alpha	I
28	-	I
29	actin	I
30	,	O
31	SM22alpha	B
32	,	O
33	and	O
34	SRF	B
35	promoter	O
36	-	O
37	luciferase	B
38	reporter	O
39	activities	O
40	.	O
1	In	O
2	serum	O
3	-	O
4	free	O
5	media	O
6	,	O
7	p50E4F	B
8	accelerated	O
9	E1A	B
10	-	O
11	induced	O
12	apoptosis	O
13	.	O
1	Progression	O
2	after	O
3	first	O
4	-	O
5	line	O
6	chemotherapy	O
7	was	O
8	associated	O
9	with	O
10	significantly	O
11	worse	O
12	survival	O
13	for	O
14	patients	O
15	with	O
16	metastasis	O
17	.	O
1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	investigate	O
9	the	O
10	spontaneous	O
11	reports	O
12	of	O
13	suspected	O
14	adverse	O
15	drug	O
16	reactions	O
17	,	O
18	observed	O
19	in	O
20	elderly	O
21	patients	O
22	(	O
23	over	O
24	65	O
25	years	O
26	of	O
27	age	O
28	)	O
29	in	O
30	Sicily	O
31	(	O
32	Italy	O
33	)	O
34	during	O
35	the	O
36	period	O
37	from	O
38	1	O
39	January	O
40	1995	O
41	to	O
42	31	O
43	December	O
44	1997	O
45	.	O
1	Consistent	O
2	with	O
3	this	O
4	possibility	O
5	,	O
6	a	O
7	non	O
8	-	O
9	MBD	B
10	region	O
11	of	O
12	Bin1	B
13	was	O
14	sufficient	O
15	to	O
16	recruit	O
17	a	O
18	repression	O
19	function	O
20	to	O
21	DNA	O
22	that	O
23	was	O
24	unrelated	O
25	to	O
26	histone	B
27	deacetylase	I
28	.	O
1	TCR	B
2	alpha	I
3	(	O
4	TCRA	B
5	)	O
6	expression	O
7	was	O
8	examined	O
9	in	O
10	RNA	O
11	samples	O
12	from	O
13	PBMC	O
14	and	O
15	isolated	O
16	populations	O
17	of	O
18	CD4	O
19	+,	O
20	CD8	O
21	+,	O
22	and	O
23	DN	O
24	T	O
25	cells	O
26	from	O
27	15	O
28	healthy	O
29	individuals	O
30	.	O
1	Similar	O
2	results	O
3	were	O
4	obtained	O
5	with	O
6	xylitol	O
7	,	O
8	an	O
9	activator	O
10	of	O
11	the	O
12	pentose	O
13	phosphate	O
14	pathway	O
15	.	O
1	The	O
2	high	B
3	density	I
4	lipoprotein	I
5	(	I
6	HDL	I
7	)	I
8	receptor	I
9	mediates	O
10	the	O
11	uptake	O
12	of	O
13	cholesterol	O
14	and	O
15	cholesteryl	O
16	esters	O
17	,	O
18	substrates	O
19	for	O
20	steroidogenesis	O
21	,	O
22	from	O
23	an	O
24	HDL	B
25	particle	O
26	in	O
27	the	O
28	adrenal	O
29	gland	O
30	and	O
31	gonads	O
32	.	O
1	Lung	O
2	mesenchyme	O
3	serves	O
4	as	O
5	a	O
6	'	O
7	compleat	O
8	'	O
9	inducer	O
10	of	O
11	lung	O
12	morphogenesis	O
13	by	O
14	secreting	O
15	soluble	O
16	peptide	O
17	growth	O
18	factors	O
19	.	O
1	Neurospora	O
2	crassa	O
3	CYT	B
4	-	I
5	18	I
6	,	O
7	can	O
8	rescue	O
9	the	O
10	exonic	O
11	trap	O
12	and	O
13	intron	O
14	mutants	O
15	which	O
16	cause	O
17	a	O
18	structural	O
19	defect	O
20	.	O
1	This	O
2	is	O
3	predicted	O
4	to	O
5	encode	O
6	a	O
7	315	O
8	-	O
9	residue	O
10	protein	O
11	containing	O
12	seven	O
13	hydrophobic	O
14	helical	O
15	regions	O
16	and	O
17	a	O
18	17	O
19	amino	O
20	acid	O
21	motif	O
22	characteristic	O
23	of	O
24	the	O
25	R7G	B
26	family	I
27	of	O
28	G	B
29	-	I
30	protein	I
31	coupled	I
32	membrane	I
33	-	I
34	bound	I
35	receptors	I
36	.	O
1	The	O
2	results	O
3	of	O
4	these	O
5	analyses	O
6	indicate	O
7	that	O
8	the	O
9	proteinase	O
10	cleaves	O
11	at	O
12	amino	O
13	acid	O
14	residues	O
15	E960	O
16	-	O
17	A961	O
18	,	O
19	E1071	O
20	-	O
21	S1072	O
22	,	O
23	E1345	O
24	-	O
25	T1346	O
26	,	O
27	and	O
28	E1419	O
29	-	O
30	G1420	O
31	;	O
32	however	O
33	,	O
34	the	O
35	cleavage	O
36	efficiency	O
37	is	O
38	varied	O
39	.	O
1	SM	B
2	is	O
3	also	O
4	shown	O
5	to	O
6	be	O
7	associated	O
8	in	O
9	vivo	O
10	with	O
11	other	O
12	components	O
13	of	O
14	the	O
15	CRM	B
16	1	I
17	export	O
18	pathway	O
19	,	O
20	including	O
21	the	O
22	small	B
23	GTPase	I
24	Ran	I
25	and	O
26	the	O
27	nucleoporin	O
28	CAN	B
29	/	O
30	Nup214	B
31	.	O
1	A	O
2	13	O
3	-	O
4	bp	O
5	cis	O
6	-	O
7	regulatory	O
8	element	O
9	in	O
10	the	O
11	LTR	O
12	promoter	O
13	of	O
14	the	O
15	tobacco	B
16	retrotransposon	I
17	Tto1	I
18	is	O
19	involved	O
20	in	O
21	responsiveness	O
22	to	O
23	tissue	O
24	culture	O
25	,	O
26	wounding	O
27	,	O
28	methyl	O
29	jasmonate	O
30	and	O
31	fungal	O
32	elicitors	O
33	.	O
1	Classical	O
2	ligand	O
3	-	O
4	activated	O
5	nuclear	O
6	receptors	O
7	(	O
8	e	O
9	.	O
10	g	O
11	.	O
12	thyroid	B
13	hormone	I
14	receptor	I
15	,	O
16	retinoic	B
17	acid	I
18	receptor	I
19	),	O
20	orphan	B
21	nuclear	I
22	receptors	I
23	(	O
24	e	O
25	.	O
26	g	O
27	.	O
1	Expression	O
2	of	O
3	GlcNAc	B
4	-	I
5	TI	I
6	mRNA	I
7	in	O
8	tobacco	O
9	leaves	O
10	was	O
11	detected	O
12	using	O
13	RT	O
14	-	O
15	PCR	O
16	.	O
1	Activation	O
2	of	O
3	ERK1	B
4	/	I
5	2	I
6	is	O
7	correlated	O
8	with	O
9	induction	O
10	of	O
11	the	O
12	immediate	B
13	-	I
14	early	I
15	response	I
16	genes	I
17	.	O
1	We	O
2	have	O
3	isolated	O
4	three	O
5	mutant	O
6	alleles	O
7	of	O
8	CDC4	B
9	(	O
10	cdc4	B
11	-	I
12	10	I
13	,	O
14	cdc4	B
15	-	I
16	11	I
17	,	O
18	and	O
19	cdc4	B
20	-	I
21	16	I
22	)	O
23	which	O
24	suppress	O
25	the	O
26	nuclear	O
27	division	O
28	defect	O
29	of	O
30	cdc20	B
31	-	I
32	1	I
33	cells	O
34	.	O
1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	the	O
5	cAMP	B
6	-	I
7	dependent	I
8	kinases	I
9	(	O
10	PKAs	B
11	)	O
12	promote	O
13	cytoplasmic	O
14	growth	O
15	and	O
16	modulate	O
17	the	O
18	growth	O
19	-	O
20	regulated	O
21	mechanism	O
22	triggering	O
23	the	O
24	begin	O
25	of	O
26	DNA	O
27	synthesis	O
28	.	O
1	A	O
2	recombinant	O
3	derivative	O
4	harboring	O
5	the	O
6	pMJ101	O
7	replication	O
8	region	O
9	proved	O
10	to	O
11	be	O
12	compatible	O
13	with	O
14	pJM1	O
15	,	O
16	a	O
17	plasmid	O
18	containing	O
19	the	O
20	iron	O
21	acquisition	O
22	system	O
23	required	O
24	for	O
25	the	O
26	virulence	O
27	of	O
28	V	O
29	.	O
30	anguillarum	O
31	775	O
32	,	O
33	another	O
34	important	O
35	pathogen	O
36	that	O
37	causes	O
38	vibriosis	O
39	.	O
1	Expression	O
2	of	O
3	various	O
4	FAK	B
5	mutants	I
6	in	O
7	the	O
8	FAK	B
9	-	O
10	cells	O
11	showed	O
12	that	O
13	FAK	B
14	kinase	I
15	activity	O
16	,	O
17	the	O
18	Tyr	B
19	-	I
20	397	I
21	/	I
22	SH2	I
23	domain	I
24	binding	I
25	site	I
26	,	O
27	and	O
28	the	O
29	first	O
30	proline	O
31	-	O
32	rich	O
33	SH3	B
34	binding	I
35	region	I
36	in	O
37	the	O
38	FAK	B
39	C	I
40	-	I
41	terminal	I
42	domain	I
43	were	O
44	individually	O
45	needed	O
46	to	O
47	promote	O
48	full	O
49	FAK	B
50	-	O
51	mediated	O
52	FAK	B
53	-	O
54	cell	O
55	migration	O
56	to	O
57	FN	B
58	whereas	O
59	direct	O
60	paxillin	B
61	binding	O
62	to	O
63	FAK	B
64	was	O
65	not	O
66	required	O
67	.	O
1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	demonstrate	O
7	that	O
8	the	O
9	RP	B
10	,	O
11	like	O
12	the	O
13	20S	B
14	proteasome	I
15	,	O
16	is	O
17	functionally	O
18	and	O
19	structurally	O
20	conserved	O
21	among	O
22	eukaryotes	O
23	and	O
24	indicate	O
25	that	O
26	the	O
27	plant	B
28	RPT	I
29	subunits	I
30	,	O
31	like	O
32	their	O
33	yeast	O
34	counterparts	O
35	,	O
36	have	O
37	non	O
38	-	O
39	redundant	O
40	functions	O
41	.	O
1	In	O
2	addition	O
3	to	O
4	its	O
5	elongation	O
6	activity	O
7	,	O
8	ELL	B
9	contains	O
10	a	O
11	novel	O
12	type	O
13	of	O
14	RNA	B
15	polymerase	I
16	II	I
17	interaction	I
18	domain	I
19	that	O
20	is	O
21	capable	O
22	of	O
23	repressing	O
24	polymerase	O
25	activity	O
26	in	O
27	promoter	O
28	-	O
29	specific	O
30	transcription	O
31	.	O
1	The	O
2	in	O
3	vitro	O
4	relaxivity	O
5	of	O
6	the	O
7	complex	O
8	is	O
9	16	O
10	.	O
11	24	O
12	s	O
13	(-	O
14	1	O
15	)	O
16	mM	O
17	(-	O
18	1	O
19	).	O
1	Repair	O
2	of	O
3	double	O
4	-	O
5	strand	O
6	breaks	O
7	(	O
8	DSBs	O
9	)	O
10	in	O
11	chromosomal	O
12	DNA	O
13	by	O
14	nonhomologous	O
15	end	O
16	-	O
17	joining	O
18	(	O
19	NHEJ	O
20	)	O
21	is	O
22	not	O
23	well	O
24	characterized	O
25	in	O
26	the	O
27	yeast	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O
1	Among	O
2	mucus	O
3	-	O
4	secreting	O
5	cells	O
6	,	O
7	the	O
8	gastric	O
9	gland	O
10	mucous	O
11	cells	O
12	,	O
13	Brunner	O
14	'	O
15	s	O
16	glands	O
17	,	O
18	accessory	O
19	glands	O
20	of	O
21	pancreaticobiliary	O
22	tract	O
23	,	O
24	and	O
25	pancreatic	O
26	ducts	O
27	exhibiting	O
28	gastric	O
29	metaplasia	O
30	are	O
31	unique	O
32	in	O
33	that	O
34	they	O
35	express	O
36	class	B
37	III	I
38	mucin	I
39	identified	O
40	by	O
41	paradoxical	O
42	Con	B
43	A	I
44	staining	O
45	composed	O
46	of	O
47	periodate	O
48	oxidation	O
49	,	O
50	sodium	O
51	borohydride	O
52	reduction	O
53	,	O
54	Con	B
55	A	I
56	,	O
57	and	O
58	horseradish	B
59	peroxidase	I
60	reaction	O
61	.	O
1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	-	I
7	1	I
8	(	I
9	HIV	I
10	-	I
11	1	I
12	)	I
13	Tat	I
14	protein	I
15	regulates	O
16	transcription	O
17	by	O
18	stimulating	O
19	RNA	B
20	polymerase	I
21	processivity	O
22	.	O
1	Analysis	O
2	of	O
3	cell	O
4	cycle	O
5	proteins	O
6	showed	O
7	that	O
8	24	O
9	h	O
10	of	O
11	lovastatin	O
12	treatment	O
13	in	O
14	the	O
15	control	O
16	cells	O
17	caused	O
18	an	O
19	elevation	O
20	in	O
21	the	O
22	levels	O
23	of	O
24	the	O
25	cyclin	B
26	-	I
27	dependent	I
28	kinase	I
29	inhibitor	O
30	p27	B
31	(	O
32	kip1	B
33	),	O
34	inhibition	O
35	of	O
36	both	O
37	cyclin	B
38	E	I
39	-	I
40	and	I
41	cyclin	I
42	A	I
43	-	I
44	dependent	I
45	kinase	I
46	activity	O
47	,	O
48	and	O
49	decreased	O
50	levels	O
51	of	O
52	hyperphosphorylated	O
53	retinoblastoma	B
54	protein	I
55	(	O
56	pRb	B
57	).	O
1	Oligonucleotide	O
2	probes	O
3	corresponding	O
4	to	O
5	wild	O
6	-	O
7	type	O
8	and	O
9	mutant	O
10	EpRE	O
11	sequences	O
12	were	O
13	used	O
14	in	O
15	gel	O
16	-	O
17	shift	O
18	and	O
19	super	O
20	-	O
21	shift	O
22	analyses	O
23	to	O
24	identify	O
25	proteins	O
26	binding	O
27	.	O
1	BACKGROUND	O
2	:	O
3	Chronic	O
4	alcohol	O
5	consumption	O
6	has	O
7	been	O
8	demonstrated	O
9	to	O
10	be	O
11	deleterious	O
12	to	O
13	bone	O
14	health	O
15	.	O
1	Interestingly	O
2	,	O
3	following	O
4	induction	O
5	of	O
6	stress	O
7	by	O
8	heat	O
9	shock	O
10	,	O
11	high	O
12	salt	O
13	,	O
14	or	O
15	ethanol	O
16	,	O
17	conditions	O
18	under	O
19	which	O
20	most	O
21	mRNA	O
22	export	O
23	is	O
24	blocked	O
25	,	O
26	Npl3p	B
27	is	O
28	still	O
29	exported	O
30	from	O
31	the	O
32	nucleus	O
33	.	O
1	In	O
2	summary	O
3	,	O
4	the	O
5	no	O
6	-	O
7	adverse	O
8	-	O
9	effect	O
10	-	O
11	level	O
12	for	O
13	this	O
14	study	O
15	was	O
16	determined	O
17	to	O
18	be	O
19	1000	O
20	ppm	O
21	,	O
22	based	O
23	on	O
24	decreased	O
25	weight	O
26	gain	O
27	in	O
28	female	O
29	rats	O
30	,	O
31	and	O
32	on	O
33	slight	O
34	organ	O
35	weight	O
36	changes	O
37	in	O
38	both	O
39	sexes	O
40	at	O
41	3000	O
42	ppm	O
43	.	O
1	PDGF	B
2	A	I
3	-	I
4	chain	I
5	levels	O
6	increase	O
7	in	O
8	cultured	O
9	vascular	O
10	smooth	O
11	muscle	O
12	cells	O
13	(	O
14	SMCs	O
15	)	O
16	exposed	O
17	to	O
18	ATII	B
19	.	O
1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	whether	O
6	administration	O
7	of	O
8	misoprostol	O
9	prevents	O
10	gastric	O
11	hemorrhage	O
12	in	O
13	healthy	O
14	dogs	O
15	treated	O
16	with	O
17	high	O
18	doses	O
19	of	O
20	methylprednisolone	O
21	sodium	O
22	succinate	O
23	(	O
24	MPSS	O
25	).	O
1	These	O
2	cells	O
3	were	O
4	able	O
5	to	O
6	present	O
7	influenza	O
8	virus	O
9	particles	O
10	to	O
11	HLA	B
12	-	I
13	DR1	I
14	-	O
15	restricted	O
16	T	O
17	cell	O
18	clones	O
19	.	O
1	It	O
2	applies	O
3	Udry	O
4	'	O
5	s	O
6	biosocial	O
7	perspective	O
8	,	O
9	which	O
10	attempts	O
11	to	O
12	reconcile	O
13	the	O
14	biological	O
15	and	O
16	sociological	O
17	models	O
18	of	O
19	premarital	O
20	sexual	O
21	and	O
22	reproductive	O
23	behaviour	O
24	.	O
1	Previous	O
2	experimental	O
3	evidence	O
4	had	O
5	indicated	O
6	that	O
7	Reg1	B
8	might	O
9	target	O
10	Glc7	B
11	to	O
12	nuclear	O
13	substrates	O
14	such	O
15	as	O
16	the	O
17	Snf1	B
18	kinase	I
19	complex	I
20	.	O
1	Independent	O
2	protrudor	O
3	muscle	O
4	stimulation	O
5	increased	O
6	VI	O
7	,	O
8	max	O
9	(	O
10	peak	O
11	increase	O
12	61	O
13	%,	O
14	P	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	did	O
21	not	O
22	change	O
23	Pcrit	O
24	,	O
25	and	O
26	decreased	O
27	Rn	O
28	(	O
29	peak	O
30	decrease	O
31	of	O
32	41	O
33	%,	O
34	P	O
35	<	O
36	0	O
37	.	O
38	05	O
39	).	O
1	The	O
2	human	B
3	RAD30B	I
4	and	O
5	mouse	B
6	Rad30b	I
7	mRNA	I
8	transcripts	I
9	,	O
10	like	O
11	many	O
12	repair	O
13	proteins	O
14	,	O
15	are	O
16	highly	O
17	expressed	O
18	in	O
19	the	O
20	testis	O
21	.	O
1	After	O
2	10	O
3	months	O
4	of	O
5	treatment	O
6	with	O
7	the	O
8	conjugated	O
9	estrogen	O
10	,	O
11	both	O
12	his	O
13	height	O
14	and	O
15	weight	O
16	showed	O
17	improvement	O
18	,	O
19	while	O
20	his	O
21	bone	O
22	mineral	O
23	density	O
24	and	O
25	bone	O
26	age	O
27	were	O
28	increased	O
29	.	O
1	(	O
2	1998	O
3	)	O
4	FASEB	O
5	J	O
6	.	O
1	The	O
2	intron	O
3	RNA	O
4	consists	O
5	of	O
6	2492	O
7	nucleotides	O
8	which	O
9	can	O
10	be	O
11	folded	O
12	into	O
13	a	O
14	secondary	O
15	structure	O
16	with	O
17	all	O
18	the	O
19	expected	O
20	sequence	O
21	motifs	O
22	of	O
23	subgroup	O
24	-	O
25	IIA1	O
26	introns	O
27	(	O
28	Michel	O
29	et	O
30	al	O
31	.	O
1	The	O
2	intron	O
3	is	O
4	capable	O
5	of	O
6	splicing	O
7	despite	O
8	the	O
9	fact	O
10	that	O
11	both	O
12	the	O
13	EBS1	B
14	/	O
15	IBS1	B
16	and	O
17	the	O
18	EBS2	B
19	/	O
20	IBS2	B
21	sequence	O
22	motifs	O
23	,	O
24	thought	O
25	to	O
26	be	O
27	necessary	O
28	for	O
29	correct	O
30	splicing	O
31	,	O
32	extend	O
33	over	O
34	5	O
35	instead	O
36	of	O
37	6	O
38	bp	O
39	.	O
1	Like	O
2	DNA	O
3	binding	O
4	,	O
5	transcriptional	O
6	enhancement	O
7	required	O
8	amino	O
9	-	O
10	terminally	O
11	located	O
12	basic	O
13	amino	O
14	acid	O
15	residues	O
16	but	O
17	not	O
18	the	O
19	carboxyl	O
20	-	O
21	terminal	O
22	portion	O
23	of	O
24	Hap46	B
25	known	O
26	to	O
27	participate	O
28	in	O
29	hsp70	B
30	interaction	O
31	.	O
1	We	O
2	have	O
3	tested	O
4	the	O
5	function	O
6	of	O
7	two	O
8	potential	O
9	NF	B
10	-	I
11	kappaB	I
12	-	I
13	like	I
14	sites	I
15	present	O
16	in	O
17	the	O
18	PAI	B
19	-	I
20	2	I
21	proximal	I
22	promoter	I
23	for	O
24	responsiveness	O
25	to	O
26	TNFalpha	B
27	using	O
28	chloramphenicol	B
29	acetyl	I
30	transferase	I
31	reporter	I
32	gene	I
33	deletion	O
34	and	O
35	mutation	O
36	analyses	O
37	.	O
1	N	O
2	-	O
3	terminal	O
4	sequence	O
5	analysis	O
6	and	O
7	NMR	O
8	measurements	O
9	revealed	O
10	that	O
11	this	O
12	fragment	O
13	originates	O
14	from	O
15	the	O
16	C	O
17	-	O
18	terminal	O
19	80	O
20	residues	O
21	of	O
22	MBF1	B
23	and	O
24	form	O
25	a	O
26	well	O
27	structured	O
28	C	O
29	-	O
30	terminal	O
31	domain	O
32	of	O
33	MBF1	B
34	,	O
35	MBF1CTD	B
36	.	O
1	The	O
2	nucleosomal	O
3	response	O
4	associated	O
5	with	O
6	immediate	B
7	-	I
8	early	I
9	gene	I
10	induction	O
11	is	O
12	mediated	O
13	via	O
14	alternative	O
15	MAP	B
16	kinase	I
17	cascades	I
18	:	O
19	MSK1	B
20	as	O
21	a	O
22	potential	O
23	histone	B
24	H3	I
25	/	O
26	HMG	B
27	-	I
28	14	I
29	kinase	O
30	.	O
1	272	O
2	,	O
3	1904	O
4	].	O
1	Null	O
2	alleles	O
3	of	O
4	SAS4	B
5	and	O
6	SAS5	B
7	bypassed	O
8	the	O
9	role	O
10	of	O
11	the	O
12	Abf1p	B
13	binding	I
14	site	I
15	of	O
16	the	O
17	HMR	B
18	-	I
19	E	I
20	silencer	I
21	but	O
22	not	O
23	the	O
24	role	O
25	of	O
26	the	O
27	ACS	B
28	or	O
29	Rap1p	B
30	binding	I
31	site	I
32	.	O
1	Recent	O
2	molecular	O
3	analysis	O
4	has	O
5	revealed	O
6	that	O
7	the	O
8	S	B
9	locus	I
10	is	O
11	highly	O
12	polymorphic	O
13	and	O
14	contains	O
15	several	O
16	genes	O
17	,	O
18	i	O
19	.	O
20	e	O
21	.,	O
22	SLG	B
23	,	O
24	SRK	B
25	,	O
26	the	O
27	as	O
28	-	O
29	yet	O
30	-	O
31	unidentified	O
32	pollen	O
33	S	O
34	gene	O
35	(	O
36	s	O
37	),	O
38	and	O
39	other	O
40	linked	O
41	genes	O
42	.	O
1	RESULTS	O
2	:	O
3	256	O
4	Periods	O
5	of	O
6	TTP	O
7	or	O
8	PUNP	O
9	were	O
10	reported	O
11	by	O
12	men	O
13	and	O
14	174	O
15	by	O
16	women	O
17	.	O
1	The	O
2	N	O
3	terminus	O
4	of	O
5	beta	O
6	(	O
7	95	O
8	kDa	O
9	)	O
10	corresponds	O
11	to	O
12	alpha	O
13	with	O
14	the	O
15	integrase	B
16	domain	I
17	attached	O
18	to	O
19	the	O
20	C	O
21	terminus	O
22	(	O
23	32	O
24	kDa	O
25	).	O
1	Skn	B
2	-	I
3	1a	I
4	lacking	O
5	the	O
6	C	O
7	-	O
8	terminal	O
9	region	O
10	completely	O
11	lost	O
12	transactivation	O
13	ability	O
14	,	O
15	irrespective	O
16	of	O
17	the	O
18	promoter	O
19	tested	O
20	,	O
21	and	O
22	was	O
23	able	O
24	to	O
25	block	O
26	transactivation	O
27	by	O
28	normal	O
29	Skn	B
30	-	I
31	1a	I
32	in	O
33	competition	O
34	assays	O
35	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	a	O
6	novel	O
7	isoform	O
8	of	O
9	Rapl	B
10	GTPase	I
11	-	I
12	activating	I
13	protein	I
14	,	O
15	called	O
16	rap1GAPII	B
17	,	O
18	binds	O
19	specifically	O
20	to	O
21	the	O
22	alpha	O
23	-	O
24	subunits	O
25	of	O
26	the	O
27	G	B
28	(	I
29	i	I
30	)	I
31	family	I
32	of	O
33	heterotrimeric	B
34	G	I
35	-	I
36	proteins	I
37	.	O
1	The	O
2	B	O
3	-	O
4	oligomer	O
5	of	O
6	pertussis	B
7	toxin	I
8	deactivates	O
9	CC	B
10	chemokine	I
11	receptor	I
12	5	I
13	and	O
14	blocks	O
15	entry	O
16	of	O
17	M	O
18	-	O
19	tropic	O
20	HIV	O
21	-	O
22	1	O
23	strains	O
24	.	O
1	TRAF2	B
2	is	O
3	a	O
4	potent	O
5	activator	O
6	of	O
7	a	O
8	95	B
9	-	I
10	kDa	I
11	serine	I
12	/	I
13	threonine	I
14	kinase	I
15	termed	O
16	germinal	B
17	center	I
18	kinase	I
19	related	I
20	(	O
21	GCKR	B
22	,	O
23	also	O
24	referred	O
25	to	O
26	as	O
27	KHS1	B
28	),	O
29	which	O
30	signals	O
31	activation	O
32	of	O
33	the	O
34	SAPK	B
35	pathway	O
36	.	O
1	Cytokine	O
2	-	O
3	induced	O
4	NF	B
5	-	I
6	kappa	I
7	B	I
8	DNA	O
9	binding	O
10	activity	O
11	,	O
12	RelA	B
13	nuclear	O
14	translocation	O
15	,	O
16	I	B
17	kappa	I
18	B	I
19	alpha	I
20	degradation	O
21	,	O
22	I	B
23	kappa	I
24	B	I
25	serine	O
26	32	O
27	phosphorylation	O
28	,	O
29	and	O
30	I	B
31	kappa	I
32	B	I
33	kinase	I
34	(	O
35	IKK	B
36	)	O
37	activity	O
38	were	O
39	blocked	O
40	by	O
41	curcumin	O
42	treatment	O
43	.	O
1	A	O
2	portion	O
3	of	O
4	p193	B
5	is	O
6	nuclear	O
7	and	O
8	localizes	O
9	to	O
10	the	O
11	mitotic	O
12	spindle	O
13	.	O
1	OBJECTIVE	O
2	:	O
3	1998	O
4	Surveillance	O
5	,	O
6	Epidemiology	O
7	,	O
8	and	O
9	End	O
10	Results	O
11	(	O
12	SEER	O
13	)	O
14	data	O
15	estimate	O
16	an	O
17	83	O
18	.	O
19	1	O
20	%	O
21	5	O
22	-	O
23	year	O
24	survival	O
25	rate	O
26	for	O
27	corpus	O
28	uteri	O
29	adenocarcinoma	O
30	FIGO	O
31	stage	O
32	II	O
33	.	O
1	Furthermore	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	transcription	O
7	from	O
8	the	O
9	MMTV	B
10	5	I
11	'	I
12	LTR	I
13	is	O
14	highly	O
15	active	O
16	in	O
17	the	O
18	absence	O
19	of	O
20	Stat5a	B
21	,	O
22	a	O
23	transcription	O
24	factor	O
25	that	O
26	had	O
27	been	O
28	shown	O
29	previously	O
30	to	O
31	be	O
32	required	O
33	for	O
34	transcription	O
35	from	O
36	the	O
37	MMTV	B
38	LTR	I
39	.	O
1	Galoyan	O
2	has	O
3	summarized	O
4	the	O
5	results	O
6	of	O
7	his	O
8	discovery	O
9	of	O
10	cardioactive	O
11	neurohormones	O
12	.	O
1	Two	O
2	patients	O
3	with	O
4	recurrent	O
5	tumors	O
6	had	O
7	high	O
8	S	O
9	-	O
10	phase	O
11	fractions	O
12	both	O
13	on	O
14	the	O
15	first	O
16	resected	O
17	specimens	O
18	and	O
19	at	O
20	the	O
21	time	O
22	of	O
23	the	O
24	second	O
25	operation	O
26	.	O
1	Clinical	O
2	differentiation	O
3	of	O
4	patients	O
5	with	O
6	mild	O
7	diplegic	O
8	cerebral	O
9	palsy	O
10	(	O
11	CP	O
12	)	O
13	and	O
14	idiopathic	O
15	toe	O
16	walking	O
17	(	O
18	ITW	O
19	)	O
20	can	O
21	be	O
22	difficult	O
23	.	O
1	Sputum	B
2	IL	I
3	-	I
4	8	I
5	and	O
6	MPO	B
7	were	O
8	significantly	O
9	increased	O
10	after	O
11	BPT	O
12	in	O
13	both	O
14	TDI	O
15	-	O
16	and	O
17	grain	O
18	dust	O
19	-	O
20	asthma	O
21	(	O
22	P	O
23	<	O
24	0	O
25	.	O
26	05	O
27	).	O
1	Here	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	kinase	O
7	-	O
8	dead	O
9	but	O
10	not	O
11	wild	O
12	-	O
13	type	O
14	forms	O
15	of	O
16	Fyn	B
17	,	O
18	Lck	B
19	,	O
20	and	O
21	ZAP	B
22	-	I
23	70	I
24	block	O
25	70Z	O
26	Cbl	B
27	-	O
28	mediated	O
29	NFAT	B
30	activation	O
31	.	O
1	These	O
2	results	O
3	show	O
4	that	O
5	targeting	O
6	of	O
7	Ras	B
8	-	O
9	GAP	B
10	could	O
11	represent	O
12	a	O
13	novel	O
14	anticancer	O
15	approach	O
16	.	O
1	In	O
2	another	O
3	study	O
4	,	O
5	intravenous	O
6	administration	O
7	of	O
8	devazepide	O
9	,	O
10	a	O
11	specific	O
12	cholecystokinin	B
13	-	I
14	A	I
15	receptor	I
16	antagonist	O
17	,	O
18	at	O
19	a	O
20	dose	O
21	of	O
22	0	O
23	.	O
24	1	O
25	mg	O
26	/	O
27	kg	O
28	/	O
29	hr	O
30	was	O
31	begun	O
32	15	O
33	min	O
34	before	O
35	postprandial	O
36	saline	O
37	intake	O
38	and	O
39	continued	O
40	for	O
41	1	O
42	hr	O
43	.	O
1	Structural	O
2	changes	O
3	in	O
4	the	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	Ca2	O
10	+-	O
11	bound	O
12	rat	B
13	S100B	I
14	(	O
15	beta	B
16	beta	I
17	)	O
18	upon	O
19	binding	O
20	to	O
21	a	O
22	peptide	O
23	derived	O
24	from	O
25	the	O
26	C	O
27	-	O
28	terminal	O
29	regulatory	O
30	domain	O
31	of	O
32	p53	B
33	.	O
1	The	O
2	solution	O
3	structure	O
4	of	O
5	the	O
6	adduct	O
7	derived	O
8	from	O
9	the	O
10	covalent	O
11	bonding	O
12	of	O
13	the	O
14	fjord	O
15	region	O
16	(+)-(	O
17	11S	O
18	,	O
19	12R	O
20	,	O
21	13R	O
22	,	O
23	14S	O
24	)	O
25	stereoisomer	O
26	of	O
27	anti	O
28	-	O
29	11	O
30	,	O
31	12	O
32	-	O
33	dihydroxy	O
34	-	O
35	13	O
36	,	O
37	14	O
38	-	O
39	epoxy	O
40	-	O
41	11	O
42	,	O
43	12	O
44	,	O
45	13	O
46	,	O
47	14	O
48	-	O
49	tetrahydrobenzo	O
50	[	O
51	g	O
52	]	O
53	chrysene	O
54	,	O
55	(+)-	O
56	anti	O
57	-	O
58	B	O
59	[	O
60	g	O
61	]	O
62	CDE	O
63	,	O
64	to	O
65	the	O
66	exocyclic	O
67	N	O
68	(	O
69	6	O
70	)	O
71	amino	O
72	group	O
73	of	O
74	the	O
75	adenine	O
76	residue	O
77	dA6	O
78	,	O
79	(	O
80	designated	O
81	(+)-	O
82	trans	O
83	-	O
84	anti	O
85	-(	O
86	B	O
87	[	O
88	g	O
89	]	O
90	C	O
91	)	O
92	dA6	O
93	),	O
94	positioned	O
95	opposite	O
96	a	O
97	thymine	O
98	residue	O
99	dT17	O
100	in	O
101	the	O
102	DNA	O
103	sequence	O
104	context	O
105	d	O
106	(	O
107	C1	O
108	-	O
109	T2	O
110	-	O
111	C3	O
112	-	O
113	T4	O
114	-	O
115	C5	O
116	-(	O
117	B	O
118	[	O
119	g	O
120	]	O
121	C	O
122	)	O
123	A6	O
124	-	O
125	C7	O
126	-	O
127	T8	O
128	-	O
129	T9	O
130	-	O
131	C10	O
132	-	O
133	C11	O
134	).	O
135	d	O
136	(	O
137	G12	O
138	-	O
139	G13	O
140	-	O
141	A14	O
142	-	O
143	A15	O
144	-	O
145	G16	O
146	-	O
147	T17	O
148	-	O
149	G18	O
150	-	O
151	A19	O
152	-	O
153	G20	O
154	++	O
155	+-	O
156	A21	O
157	-	O
158	G22	O
159	)	O
160	(	O
161	designated	O
162	(	O
163	B	O
164	[	O
165	g	O
166	]	O
167	C	O
168	)	O
169	dA	O
170	.	O
171	dT	O
172	11	O
173	-	O
174	mer	O
175	duplex	O
176	),	O
177	has	O
178	been	O
179	studied	O
180	using	O
181	structural	O
182	information	O
183	derived	O
184	from	O
185	NMR	O
186	data	O
187	in	O
188	combination	O
189	with	O
190	molecular	O
191	dynamics	O
192	(	O
193	MD	O
194	)	O
195	calculations	O
196	.	O
1	Differential	O
2	expression	O
3	was	O
4	confirmed	O
5	by	O
6	Northern	O
7	blot	O
8	analysis	O
9	employing	O
10	multiple	O
11	normal	O
12	and	O
13	tumor	O
14	cell	O
15	lines	O
16	.	O
1	High	O
2	-	O
3	affinity	O
4	binding	O
5	sites	O
6	for	O
7	both	O
8	GR	B
9	and	O
10	AP	B
11	-	I
12	1	I
13	nucleoproteins	I
14	were	O
15	identified	O
16	at	O
17	adjacent	O
18	elements	O
19	within	O
20	the	O
21	nGRE	O
22	.	O
1	ESS	O
2	type	O
3	1	O
4	,	O
5	with	O
6	FT3	O
7	low	O
8	and	O
9	FT4	O
10	and	O
11	TSH	B
12	normal	O
13	,	O
14	is	O
15	the	O
16	most	O
17	frequent	O
18	form	O
19	.	O
1	RNase	B
2	MRP	I
3	is	O
4	a	O
5	ribonucleoprotein	O
6	endoribonuclease	O
7	that	O
8	has	O
9	been	O
10	shown	O
11	to	O
12	have	O
13	roles	O
14	in	O
15	both	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	and	O
20	nuclear	B
21	5	I
22	.	I
23	8S	I
24	rRNA	I
25	processing	O
26	.	O
1	The	O
2	backbone	O
3	dynamics	O
4	of	O
5	residues	O
6	located	O
7	in	O
8	the	O
9	folded	O
10	part	O
11	of	O
12	CRP2	B
13	(	O
14	LIM2	B
15	)	O
16	R122A	B
17	have	O
18	been	O
19	characterized	O
20	by	O
21	proton	O
22	-	O
23	detected	O
24	(	O
25	15	O
26	)	O
27	N	O
28	NMR	O
29	spectroscopy	O
30	.	O
1	One	O
2	form	O
3	of	O
4	the	O
5	SBEI	B
6	gene	I
7	transcript	I
8	in	O
9	12	O
10	-	O
11	day	O
12	old	O
13	kernels	O
14	contained	O
15	the	O
16	exon	O
17	I	O
18	+	O
19	II	O
20	+	O
21	III	O
22	combination	O
23	at	O
24	the	O
25	5	O
26	'	O
27	end	O
28	,	O
29	whereas	O
30	other	O
31	forms	O
32	differed	O
33	by	O
34	inclusion	O
35	of	O
36	intron	O
37	1	O
38	or	O
39	exclusion	O
40	of	O
41	exon	O
42	II	O
43	sequences	O
44	.	O
1	16	O
2	percent	O
3	,	O
4	P	O
5	<	O
6	0	O
7	.	O
8	001	O
9	),	O
10	and	O
11	sustained	O
12	normalization	O
13	of	O
14	serum	B
15	alanine	I
16	aminotransferase	I
17	levels	O
18	(	O
19	41	O
20	percent	O
21	vs	O
22	.	O
1	Its	O
2	C	O
3	-	O
4	terminal	O
5	catalytic	O
6	domain	O
7	was	O
8	found	O
9	to	O
10	be	O
11	highly	O
12	conserved	O
13	in	O
14	the	O
15	homologues	O
16	p140	B
17	(	O
18	ras	B
19	-	O
20	GRF	B
21	)	O
22	and	O
23	Sos	B
24	.	O
1	In	O
2	contrast	O
3	to	O
4	previously	O
5	characterized	O
6	proteophosphoglycans	O
7	,	O
8	the	O
9	ppg1	B
10	gene	O
11	product	O
12	is	O
13	predominantly	O
14	membrane	O
15	-	O
16	associated	O
17	and	O
18	it	O
19	is	O
20	expressed	O
21	on	O
22	the	O
23	promastigote	O
24	cell	O
25	surface	O
26	.	O
1	Twelve	O
2	patients	O
3	without	O
4	abnormalities	O
5	in	O
6	the	O
7	PTT	O
8	are	O
9	assumed	O
10	to	O
11	harbor	O
12	missense	O
13	mutations	O
14	,	O
15	probably	O
16	in	O
17	TSC2	B
18	.	O
1	The	O
2	relative	O
3	importance	O
4	of	O
5	these	O
6	two	O
7	mechanisms	O
8	differed	O
9	in	O
10	a	O
11	response	O
12	element	O
13	-	O
14	specific	O
15	manner	O
16	.	O
1	After	O
2	14	O
3	d	O
4	of	O
5	overfeeding	O
6	,	O
7	hepatic	O
8	PL	O
9	profiles	O
10	were	O
11	identical	O
12	in	O
13	the	O
14	two	O
15	breeds	O
16	and	O
17	similar	O
18	to	O
19	that	O
20	in	O
21	control	O
22	livers	O
23	;	O
24	choline	O
25	-	O
26	containing	O
27	PL	O
28	accounted	O
29	for	O
30	95	O
31	%	O
32	of	O
33	total	O
34	PL	O
35	.	O
1	C	O
2	-	O
3	SP	O
4	duration	O
5	was	O
6	significantly	O
7	reduced	O
8	in	O
9	ALS	O
10	patients	O
11	compared	O
12	to	O
13	controls	O
14	at	O
15	low	O
16	stimulation	O
17	intensity	O
18	corresponding	O
19	to	O
20	an	O
21	MEP	O
22	threshold	O
23	increased	O
24	by	O
25	15	O
26	%.	O
1	The	O
2	tumorigenic	O
3	E1A	B
4	+	O
5	cHa	B
6	-	I
7	ras	I
8	cells	O
9	are	O
10	characterized	O
11	by	O
12	high	O
13	and	O
14	constitutive	O
15	DNA	O
16	binding	O
17	activities	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	,	O
23	in	O
24	contrast	O
25	to	O
26	nontransformed	O
27	cells	O
28	and	O
29	the	O
30	E1A	B
31	cells	O
32	.	O
1	The	O
2	NF	B
3	-	I
4	kappaB	I
5	responsive	O
6	reporter	O
7	construct	O
8	,	O
9	(	O
10	PRDII	O
11	)(	O
12	4	O
13	)-	O
14	CAT	B
15	,	O
16	was	O
17	used	O
18	to	O
19	explore	O
20	transcription	O
21	resulting	O
22	from	O
23	NF	B
24	-	I
25	kappaB	I
26	activated	O
27	by	O
28	Tat	B
29	.	O
1	The	O
2	core	O
3	of	O
4	this	O
5	enhancer	O
6	contains	O
7	two	O
8	evolutionarily	O
9	conserved	O
10	binding	O
11	sites	O
12	for	O
13	the	O
14	homeodomain	B
15	protein	I
16	Tinman	I
17	(	O
18	Tin	B
19	),	O
20	expressed	O
21	in	O
22	developing	O
23	cardiac	O
24	,	O
25	somatic	O
26	,	O
27	and	O
28	visceral	O
29	muscle	O
30	lineages	O
31	.	O
1	We	O
2	recommend	O
3	that	O
4	paracervical	O
5	block	O
6	with	O
7	lignocaine	O
8	should	O
9	be	O
10	used	O
11	in	O
12	conjunction	O
13	with	O
14	i	O
15	.	O
16	v	O
17	.	O
18	sedation	O
19	/	O
20	analgesia	O
21	during	O
22	egg	O
23	collection	O
24	performed	O
25	through	O
26	the	O
27	transvaginal	O
28	route	O
29	under	O
30	ultrasound	O
31	guidance	O
32	(	O
33	TUGOR	O
34	)	O
35	to	O
36	reduce	O
37	the	O
38	pain	O
39	of	O
40	the	O
41	procedure	O
42	.	O
1	Similar	O
2	mechanisms	O
3	leading	O
4	to	O
5	deregulation	O
6	of	O
7	Tcf	B
8	target	I
9	gene	I
10	activity	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	involved	O
16	in	O
17	melanoma	O
18	and	O
19	other	O
20	forms	O
21	of	O
22	cancer	O
23	.	O
1	LHbeta	B
2	is	O
3	expressed	O
4	in	O
5	pituitary	O
6	gonadotrope	O
7	cells	O
8	and	O
9	CGbeta	B
10	is	O
11	expressed	O
12	in	O
13	placental	O
14	trophoblast	O
15	cells	O
16	.	O
1	The	O
2	more	O
3	traditional	O
4	SERMS	O
5	,	O
6	clomiphene	O
7	citrate	O
8	and	O
9	tamoxifen	O
10	,	O
11	will	O
12	be	O
13	reviewed	O
14	along	O
15	with	O
16	such	O
17	modern	O
18	drugs	O
19	as	O
20	raloxifene	O
21	and	O
22	faslodex	O
23	,	O
24	with	O
25	emphasis	O
26	upon	O
27	their	O
28	actions	O
29	on	O
30	breast	O
31	,	O
32	uterus	O
33	,	O
34	bone	O
35	and	O
36	lipids	O
37	.	O
1	This	O
2	organization	O
3	suggests	O
4	that	O
5	duplication	O
6	events	O
7	that	O
8	have	O
9	generated	O
10	the	O
11	primate	O
12	FUT3	B
13	-	O
14	FUT5	B
15	-	O
16	FUT6	B
17	cluster	O
18	might	O
19	have	O
20	occurred	O
21	through	O
22	a	O
23	long	O
24	-	O
25	interspersed	O
26	-	O
27	nuclear	O
28	-	O
29	element	O
30	-	O
31	based	O
32	mechanism	O
33	of	O
34	unequal	O
35	crossing	O
36	over	O
37	,	O
38	as	O
39	described	O
40	for	O
41	the	O
42	globin	B
43	cluster	I
44	.	O
1	An	O
2	analysis	O
3	of	O
4	sequence	O
5	of	O
6	the	O
7	mutant	B
8	recN	I
9	gene	I
10	revealed	O
11	a	O
12	G	O
13	:	O
14	C	O
15	to	O
16	T	O
17	:	O
18	A	O
19	transversion	O
20	near	O
21	the	O
22	3	O
23	'	O
24	end	O
25	of	O
26	the	O
27	coding	O
28	region	O
29	.	O
1	The	O
2	amino	O
3	-	O
4	terminal	O
5	half	O
6	of	O
7	1a	B
8	is	O
9	a	O
10	distant	O
11	homolog	B
12	of	I
13	alphavirus	I
14	nonstructural	I
15	protein	I
16	nsP1	I
17	,	O
18	which	O
19	has	O
20	been	O
21	implicated	O
22	in	O
23	capping	O
24	viral	O
25	RNAs	O
26	.	O
1	We	O
2	have	O
3	cloned	O
4	a	O
5	novel	O
6	100	O
7	-	O
8	kDa	O
9	mammalian	O
10	protein	O
11	,	O
12	which	O
13	was	O
14	recognized	O
15	by	O
16	an	O
17	anti	O
18	-	O
19	peptide	O
20	antibody	O
21	against	O
22	an	O
23	epitope	O
24	-	O
25	containing	O
26	nuclear	O
27	localization	O
28	signal	O
29	of	O
30	NF	B
31	-	I
32	kappaB	I
33	p65	I
34	subunit	I
35	.	O
1	These	O
2	mutants	O
3	all	O
4	failed	O
5	to	O
6	interact	O
7	with	O
8	the	O
9	TraR	B
10	fusion	I
11	in	O
12	the	O
13	two	O
14	-	O
15	hybrid	O
16	system	O
17	.	O
1	FISH	O
2	using	O
3	a	O
4	whole	O
5	chromosome	O
6	4	O
7	paint	O
8	demonstrated	O
9	multiple	O
10	rearrangements	O
11	involving	O
12	chromosome	O
13	4	O
14	in	O
15	MCF	O
16	-	O
17	7	O
18	AdVp3000	O
19	and	O
20	MCF	O
21	-	O
22	7	O
23	MX	O
24	,	O
25	while	O
26	S1	O
27	-	O
28	M1	O
29	-	O
30	80	O
31	contained	O
32	only	O
33	a	O
34	simple	O
35	reciprocal	O
36	translocation	O
37	.	O
1	The	O
2	elm1	B
3	kinase	I
4	functions	O
5	in	O
6	a	O
7	mitotic	O
8	signaling	O
9	network	O
10	in	O
11	budding	O
12	yeast	O
13	.	O
1	The	O
2	proliferation	O
3	-	O
4	specific	O
5	HNF	B
6	-	I
7	3	I
8	/	O
9	fork	B
10	head	I
11	homolog	I
12	-	I
13	11B	I
14	protein	O
15	(	O
16	HFH	B
17	-	I
18	11B	I
19	;	O
20	also	O
21	known	O
22	as	O
23	Trident	B
24	and	O
25	Win	B
26	)	O
27	is	O
28	a	O
29	family	O
30	member	O
31	of	O
32	the	O
33	winged	B
34	helix	I
35	/	O
36	fork	B
37	head	I
38	transcription	O
39	factors	O
40	and	O
41	in	O
42	regenerating	O
43	liver	O
44	its	O
45	expression	O
46	is	O
47	reactivated	O
48	prior	O
49	to	O
50	hepatocyte	O
51	entry	O
52	into	O
53	DNA	O
54	replication	O
55	(	O
56	S	O
57	phase	O
58	).	O
1	Cytoprotection	O
2	with	O
3	amifostine	O
4	in	O
5	radiotherapy	O
6	or	O
7	radio	O
8	-	O
9	chemotherapy	O
10	of	O
11	head	O
12	and	O
13	neck	O
14	tumors	O
1	Patients	O
2	with	O
3	types	O
4	I	O
5	and	O
6	III	O
7	MPGN	O
8	did	O
9	not	O
10	differ	O
11	in	O
12	age	O
13	at	O
14	apparent	O
15	onset	O
16	,	O
17	age	O
18	at	O
19	diagnosis	O
20	,	O
21	or	O
22	interval	O
23	from	O
24	apparent	O
25	onset	O
26	of	O
27	symptoms	O
28	to	O
29	diagnosis	O
30	(	O
31	biopsy	O
32	).	O
1	Residual	O
2	urinary	O
3	abnormalities	O
4	were	O
5	significantly	O
6	more	O
7	frequent	O
8	in	O
9	patients	O
10	with	O
11	type	O
12	III	O
13	than	O
14	type	O
15	I	O
16	MPGN	O
17	.	O
1	We	O
2	describe	O
3	here	O
4	a	O
5	Drosophila	B
6	melanogaster	I
7	FAK	I
8	homologue	I
9	,	O
10	DFak56	B
11	,	O
12	which	O
13	maps	O
14	to	O
15	band	O
16	56D	O
17	on	O
18	the	O
19	right	O
20	arm	O
21	of	O
22	the	O
23	second	O
24	chromosome	O
25	.	O
1	In	O
2	addition	O
3	,	O
4	narZ	B
5	expression	O
6	was	O
7	induced	O
8	approximately	O
9	20	O
10	-	O
11	fold	O
12	intracellularly	O
13	in	O
14	Madin	O
15	-	O
16	Darby	O
17	canine	O
18	kidney	O
19	epithelial	O
20	cells	O
21	and	O
22	16	O
23	-	O
24	fold	O
25	in	O
26	intracellular	O
27	salts	O
28	medium	O
29	,	O
30	which	O
31	is	O
32	believed	O
33	to	O
34	mimic	O
35	the	O
36	intracellular	O
37	milieu	O
38	.	O
1	However	O
2	,	O
3	mechanisms	O
4	underlying	O
5	HIV	O
6	-	O
7	1	O
8	gene	O
9	expression	O
10	in	O
11	the	O
12	CNS	O
13	are	O
14	poorly	O
15	understood	O
16	.	O
1	Is	O
2	radical	O
3	trachelectomy	O
4	a	O
5	safe	O
6	alternative	O
7	to	O
8	radical	O
9	hysterectomy	O
10	for	O
11	patients	O
12	with	O
13	stage	O
14	IA	O
15	-	O
16	B	O
17	carcinoma	O
18	of	O
19	the	O
20	cervix	O
21	?	O
22	BACKGROUND	O
23	:	O
24	The	O
25	prognosis	O
26	associated	O
27	with	O
28	lymph	O
29	node	O
30	negative	O
31	,	O
32	early	O
33	stage	O
34	carcinoma	O
35	of	O
36	the	O
37	cervix	O
38	is	O
39	excellent	O
40	,	O
41	with	O
42	5	O
43	-	O
44	year	O
45	survival	O
46	rates	O
47	greater	O
48	than	O
49	90	O
50	%.	O
1	Higher	O
2	CYP3A23	B
3	basal	O
4	activity	O
5	appears	O
6	to	O
7	be	O
8	due	O
9	to	O
10	an	O
11	E	O
12	-	O
13	box	O
14	in	O
15	3A23SiteA	B
16	that	O
17	interacts	O
18	with	O
19	USF1	B
20	,	O
21	a	O
22	ubiquitous	O
23	bHLH	B
24	/	I
25	leucine	I
26	zipper	I
27	transcription	I
28	factor	I
29	.	O
1	The	O
2	first	O
3	one	O
4	is	O
5	a	O
6	TPA	O
7	-	O
8	responsive	O
9	element	O
10	that	O
11	controls	O
12	the	O
13	base	O
14	-	O
15	line	O
16	ST3	B
17	promoter	I
18	activity	O
19	but	O
20	is	O
21	not	O
22	required	O
23	for	O
24	its	O
25	activation	O
26	.	O
1	The	O
2	rhabdomyosarcoma	O
3	R1H	O
4	growing	O
5	on	O
6	the	O
7	right	O
8	flank	O
9	of	O
10	male	O
11	WAG	O
12	/	O
13	Rij	O
14	rats	O
15	was	O
16	clamped	O
17	for	O
18	2	O
19	or	O
20	4	O
21	h	O
22	at	O
23	20	O
24	degrees	O
25	C	O
26	or	O
27	37	O
28	degrees	O
29	C	O
30	.	O
1	Overexpression	O
2	of	O
3	CDP	B
4	/	O
5	cut	B
6	in	O
7	ROS	O
8	17	O
9	/	O
10	2	O
11	.	O
12	8	O
13	osteosarcoma	O
14	cells	O
15	results	O
16	in	O
17	repression	O
18	of	O
19	OC	B
20	promoter	I
21	activity	O
22	;	O
23	this	O
24	repression	O
25	is	O
26	abrogated	O
27	by	O
28	mutating	O
29	OC	B
30	box	I
31	I	I
32	.	O
1	Both	O
2	domains	O
3	were	O
4	required	O
5	for	O
6	specific	O
7	DNA	O
8	binding	O
9	to	O
10	the	O
11	beta	B
12	-	I
13	retinoic	I
14	acid	I
15	receptor	I
16	element	I
17	,	O
18	producing	O
19	a	O
20	DNase	B
21	I	I
22	footprint	O
23	covering	O
24	predominantly	O
25	one	O
26	strand	O
27	.	O
1	Sak	B
2	kinase	I
3	gene	O
4	structure	O
5	and	O
6	transcriptional	O
7	regulation	O
8	.	O
1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	wild	B
7	-	I
8	type	I
9	SAGA	I
10	inhibits	O
11	TBP	B
12	binding	O
13	to	O
14	the	O
15	HIS3	B
16	promoter	I
17	in	O
18	vitro	O
19	,	O
20	while	O
21	SAGA	B
22	lacking	O
23	Spt3	B
24	or	O
25	Spt8	B
26	is	O
27	not	O
28	inhibitory	O
29	.	O
1	Particularly	O
2	striking	O
3	was	O
4	the	O
5	conservation	O
6	of	O
7	an	O
8	AP	B
9	-	I
10	4	I
11	binding	I
12	site	I
13	within	O
14	100	O
15	nucleotides	O
16	upstream	O
17	of	O
18	the	O
19	transcription	O
20	initiation	O
21	site	O
22	in	O
23	both	O
24	Aal	B
25	-	O
26	rpL34	B
27	and	O
28	Aal	B
29	-	O
30	rpL8	B
31	genes	O
32	.	O
1	Statins	B
2	:	O
3	lower	O
4	lipids	O
5	and	O
6	better	O
7	bones	O
8	?	O
9	Although	O
10	statins	O
11	are	O
12	widely	O
13	used	O
14	as	O
15	cholesterol	O
16	-	O
17	lowering	O
18	drugs	O
19	,	O
20	a	O
21	recent	O
22	study	O
23	suggests	O
24	that	O
25	these	O
26	compounds	O
27	have	O
28	anabolic	O
29	effects	O
30	on	O
31	bone	O
32	and	O
33	could	O
34	be	O
35	developed	O
36	into	O
37	new	O
38	treatments	O
39	for	O
40	common	O
41	metabolic	O
42	bone	O
43	diseases	O
44	such	O
45	as	O
46	osteoporosis	O
1	Cloning	O
2	and	O
3	sequencing	O
4	of	O
5	the	O
6	upstream	O
7	region	O
8	of	O
9	pepX	B
10	revealed	O
11	the	O
12	presence	O
13	of	O
14	two	O
15	ORFs	O
16	of	O
17	360	O
18	and	O
19	1	O
20	,	O
21	338	O
22	bp	O
23	that	O
24	were	O
25	shown	O
26	to	O
27	be	O
28	able	O
29	to	O
30	encode	O
31	proteins	O
32	with	O
33	high	O
34	homology	O
35	to	O
36	GlnR	B
37	and	O
38	GlnA	B
39	proteins	I
40	,	O
41	respectively	O
42	.	O
1	In	O
2	the	O
3	BF	O
4	ECT	O
5	group	O
6	the	O
7	-	O
8	age	O
9	based	O
10	dose	O
11	would	O
12	have	O
13	been	O
14	similarly	O
15	dependent	O
16	on	O
17	the	O
18	initial	O
19	seizure	O
20	threshold	O
21	level	O
22	.	O
1	Histological	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	neuronal	O
7	loss	O
8	in	O
9	the	O
10	DHED	O
11	-	O
12	treated	O
13	group	O
14	was	O
15	notably	O
16	reduced	O
17	in	O
18	the	O
19	hippocampal	O
20	area	O
21	(	O
22	CA1	O
23	)	O
24	of	O
25	ischemic	O
26	rats	O
27	and	O
28	in	O
29	the	O
30	dentate	O
31	gyrus	O
32	and	O
33	hippocampal	O
34	area	O
35	(	O
36	CA1	O
37	and	O
38	CA3	O
39	)	O
40	of	O
41	EC	O
42	-	O
43	lesioned	O
44	rats	O
45	compared	O
46	with	O
47	the	O
48	nontreated	O
49	group	O
50	.	O
1	Preimmune	B
2	IgG	I
3	,	O
4	anti	B
5	-	I
6	GalT	I
7	Fab	I
8	fragments	I
9	,	O
10	irrelevant	O
11	polymers	O
12	and	O
13	monomeric	O
14	N	O
15	-	O
16	acetylglucosamine	O
17	had	O
18	no	O
19	effect	O
20	.	O
1	Studies	O
2	of	O
3	MPO	B
4	gene	I
5	regulation	O
6	can	O
7	help	O
8	to	O
9	elucidate	O
10	the	O
11	mechanism	O
12	of	O
13	normal	O
14	and	O
15	abnormal	O
16	myeloid	O
17	differentiation	O
18	.	O
1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	P19	O
6	cells	O
7	revealed	O
8	that	O
9	expression	O
10	of	O
11	NDRF	B
12	/	O
13	NeuroD2	B
14	increased	O
15	the	O
16	transactivation	O
17	of	O
18	the	O
19	rat	B
20	insulin	I
21	promoter	I
22	element	I
23	3	I
24	(	O
25	RIPE3	B
26	)	O
27	enhancer	O
28	up	O
29	to	O
30	approximately	O
31	12	O
32	-	O
33	fold	O
34	and	O
35	that	O
36	co	O
37	-	O
38	expression	O
39	of	O
40	catalytically	O
41	active	O
42	form	O
43	of	O
44	PKN	B
45	,	O
46	but	O
47	not	O
48	kinase	O
49	-	O
50	deficient	O
51	derivative	O
52	,	O
53	resulted	O
54	in	O
55	a	O
56	further	O
57	threefold	O
58	increase	O
59	of	O
60	NDRF	B
61	/	O
62	NeuroD2	B
63	-	O
64	mediated	O
65	transcription	O
66	.	O
1	Alignment	O
2	of	O
3	the	O
4	cervical	O
5	spine	O
6	,	O
7	vertebral	O
8	abnormalities	O
9	,	O
10	and	O
11	disc	O
12	changes	O
13	also	O
14	were	O
15	evaluated	O
16	.	O
1	The	O
2	concomitant	O
3	interaction	O
4	of	O
5	mSTI1	B
6	with	O
7	hsp70	B
8	and	O
9	hsp90	B
10	at	O
11	its	O
12	N	O
13	-	O
14	and	O
15	C	O
16	-	O
17	termini	O
18	respectively	O
19	is	O
20	mediated	O
21	by	O
22	the	O
23	tetratricopeptide	O
24	repeat	O
25	(	O
26	TPR	O
27	)	O
28	motifs	O
29	in	O
30	these	O
31	regions	O
32	.	O
1	Sequence	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	upstream	O
11	to	O
12	the	O
13	ATG	O
14	codon	O
15	did	O
16	not	O
17	contain	O
18	a	O
19	conventional	O
20	TATA	O
21	box	O
22	.	O
1	The	O
2	three	O
3	isoforms	O
4	purified	O
5	with	O
6	anti	B
7	-	I
8	FLAG	I
9	antibody	I
10	affinity	O
11	column	O
12	transferred	O
13	sulfate	O
14	to	O
15	heparan	O
16	sulfate	O
17	and	O
18	heparin	O
19	but	O
20	not	O
21	to	O
22	other	O
23	glycosaminoglycans	O
24	.	O
1	BACKGROUND	O
2	:	O
3	Left	O
4	ventricular	O
5	hypertrophy	O
6	is	O
7	a	O
8	heterogeneous	O
9	disorder	O
10	with	O
11	distinct	O
12	morphologies	O
13	.	O
1	Isolation	O
2	of	O
3	cDNAs	B
4	encoding	I
5	gibbon	I
6	and	I
7	monkey	I
8	platelet	I
9	and	I
10	T	I
11	cell	I
12	activation	I
13	antigen	I
14	1	I
15	(	O
16	PTA1	B
17	).	O
1	Two	O
2	estrogen	B
3	receptor	I
4	(	O
5	ER	B
6	)	O
7	isoforms	O
8	with	O
9	different	O
10	estrogen	O
11	dependencies	O
12	are	O
13	generated	O
14	from	O
15	the	O
16	trout	B
17	ER	I
18	gene	I
19	.	O
1	Induction	O
2	was	O
3	reversed	O
4	by	O
5	coexpression	O
6	of	O
7	A	B
8	-	I
9	Fos	I
10	,	O
11	a	O
12	dominant	O
13	negative	O
14	to	O
15	AP	B
16	-	I
17	1	I
18	.	O
1	Electron	O
2	microscopic	O
3	and	O
4	enzymatic	O
5	analyses	O
6	revealed	O
7	that	O
8	the	O
9	A118	O
10	genome	O
11	is	O
12	a	O
13	linear	O
14	,	O
15	circularly	O
16	permuted	O
17	,	O
18	terminally	O
19	redundant	O
20	collection	O
21	of	O
22	double	O
23	-	O
24	stranded	O
25	DNA	O
26	molecules	O
27	.	O
1	Another	O
2	long	O
3	insertion	O
4	in	O
5	the	O
6	cathepsin	B
7	X	I
8	amino	I
9	acid	I
10	sequence	I
11	forms	O
12	a	O
13	beta	O
14	-	O
15	hairpin	O
16	pointing	O
17	away	O
18	from	O
19	the	O
20	active	O
21	site	O
22	.	O
1	Zebrafish	O
2	cyclops	B
3	(	O
4	cyc	B
5	)	O
6	encodes	O
7	a	O
8	Transforming	B
9	Growth	I
10	Factor	I
11	beta	I
12	(	O
13	TGFbeta	B
14	)	O
15	signaling	O
16	factor	O
17	closely	O
18	related	O
19	to	O
20	mouse	O
21	Nodal	B
22	.	O
1	The	O
2	two	O
3	-	O
4	hybrid	O
5	assay	O
6	was	O
7	then	O
8	performed	O
9	using	O
10	full	O
11	-	O
12	length	O
13	genes	O
14	of	O
15	CI	B
16	,	O
17	HC	B
18	-	I
19	Pro	I
20	,	O
21	P1	B
22	,	O
23	P3	B
24	,	O
25	and	O
26	CP	B
27	,	O
28	but	O
29	no	O
30	heterologous	O
31	interactions	O
32	were	O
33	detected	O
34	.	O
1	Productive	O
2	growth	O
3	of	O
4	phage	O
5	P22	O
6	in	O
7	wild	O
8	-	O
9	type	O
10	Salmonella	O
11	typhimurium	O
12	correlates	O
13	with	O
14	the	O
15	presence	O
16	of	O
17	Abc2	B
18	,	O
19	but	O
20	is	O
21	independent	O
22	of	O
23	the	O
24	absolute	O
25	level	O
26	of	O
27	ATP	B
28	-	I
29	dependent	I
30	nuclease	I
31	activity	O
32	,	O
33	suggesting	O
34	a	O
35	qualitative	O
36	change	O
37	in	O
38	the	O
39	nature	O
40	of	O
41	Abc2	B
42	-	O
43	modified	O
44	RecBCD	B
45	nuclease	I
46	activity	O
47	relative	O
48	to	O
49	the	O
50	native	O
51	enzyme	O
52	.	O
1	Multiple	O
2	mitogen	B
3	-	I
4	activated	I
5	protein	I
6	kinase	I
7	signaling	O
8	pathways	O
9	connect	O
10	the	O
11	cot	B
12	oncoprotein	I
13	to	O
14	the	O
15	c	B
16	-	I
17	jun	I
18	promoter	I
19	and	O
20	to	O
21	cellular	O
22	transformation	O
23	.	O
1	4	O
2	.	O
1	In	O
2	the	O
3	present	O
4	study	O
5	we	O
6	have	O
7	investigated	O
8	the	O
9	regulatory	O
10	mechanism	O
11	for	O
12	CD95L	B
13	expression	O
14	.	O
1	BCR	B
2	cross	O
3	-	O
4	linking	O
5	also	O
6	led	O
7	to	O
8	increased	O
9	MAPK	B
10	-	O
11	activated	O
12	protein	B
13	kinase	I
14	-	I
15	2	I
16	activity	O
17	,	O
18	an	O
19	enzyme	O
20	that	O
21	lies	O
22	immediately	O
23	downstream	O
24	from	O
25	p38	B
26	MAPK	I
27	;	O
28	MAPK	B
29	-	O
30	activated	O
31	protein	B
32	kinase	I
33	-	I
34	2	I
35	immune	O
36	complexes	O
37	phosphorylated	O
38	a	O
39	peptide	O
40	substrate	O
41	containing	O
42	the	O
43	CREB	B
44	serine	I
45	133	I
46	phosphoacceptor	I
47	motif	I
48	.	O
1	Second	O
2	,	O
3	when	O
4	the	O
5	NBF1	B
6	+	I
7	R	I
8	protein	I
9	,	O
10	the	O
11	NBF2	B
12	protein	I
13	,	O
14	and	O
15	a	O
16	mixture	O
17	of	O
18	the	O
19	two	O
20	proteins	O
21	were	O
22	folded	O
23	separately	O
24	and	O
25	analyzed	O
26	by	O
27	molecular	O
28	sieve	O
29	chomatography	O
30	,	O
31	the	O
32	mixture	O
33	was	O
34	found	O
35	to	O
36	elute	O
37	prior	O
38	to	O
39	either	O
40	NBF1	B
41	+	I
42	R	I
43	or	O
44	NBF2	B
45	.	O
1	Sulfhydryl	O
2	titration	O
3	with	O
4	iodoacetamide	O
5	,	O
6	monitored	O
7	by	O
8	quantitating	O
9	the	O
10	residual	O
11	thiols	O
12	after	O
13	reaction	O
14	with	O
15	a	O
16	maleimide	O
17	derivative	O
18	of	O
19	biotin	O
20	,	O
21	revealed	O
22	a	O
23	striking	O
24	difference	O
25	in	O
26	the	O
27	apparent	O
28	pK	O
29	(	O
30	a	O
31	)	O
32	values	O
33	of	O
34	the	O
35	cysteines	O
36	at	O
37	the	O
38	two	O
39	splice	O
40	junctions	O
41	.	O
1	Forty	O
2	4	O
3	-	O
4	month	O
5	old	O
6	SD	O
7	female	O
8	rats	O
9	were	O
10	randomly	O
11	divided	O
12	into	O
13	four	O
14	groups	O
15	,	O
16	namely	O
17	sham	O
18	operation	O
19	,	O
20	bilateral	O
21	ovariectomy	O
22	,	O
23	ovariectomy	O
24	plus	O
25	supplementary	O
26	ethinyl	O
27	estradiol	O
28	(	O
29	0	O
30	.	O
31	2	O
32	microgram	O
33	/	O
34	100	O
35	g	O
36	B	O
37	.	O
1	The	O
2	interaction	O
3	between	O
4	U	O
5	(	O
6	L	O
7	)	O
8	3	O
9	.	O
1	The	O
2	requirement	O
3	of	O
4	3	O
5	'	O
6	complementarity	O
7	for	O
8	a	O
9	ligation	O
10	reaction	O
11	is	O
12	reaffirmed	O
13	by	O
14	results	O
15	from	O
16	1	O
17	nt	O
18	insertions	O
19	on	O
20	either	O
21	the	O
22	3	O
23	'-	O
24	or	O
25	5	O
26	'-	O
27	side	O
28	of	O
29	the	O
30	nick	O
31	.	O
1	First	O
2	,	O
3	human	O
4	erythroid	O
5	K562	O
6	cells	O
7	stably	O
8	integrated	O
9	with	O
10	various	O
11	HS	B
12	-	I
13	40	I
14	mutants	I
15	cis	O
16	linked	O
17	to	O
18	a	O
19	human	B
20	alpha	I
21	-	I
22	globin	I
23	promoter	I
24	-	O
25	growth	B
26	hormone	I
27	hybrid	O
28	gene	O
29	were	O
30	analyzed	O
31	by	O
32	genomic	O
33	footprinting	O
34	and	O
35	expression	O
36	analysis	O
37	.	O
1	Finally	O
2	,	O
3	the	O
4	mechanism	O
5	of	O
6	ASK1	B
7	activation	O
8	involves	O
9	,	O
10	in	O
11	part	O
12	,	O
13	homo	O
14	-	O
15	oligomerization	O
16	.	O
1	The	O
2	regional	O
3	blockade	O
4	of	O
5	H1R	B
6	was	O
7	observed	O
8	mainly	O
9	in	O
10	the	O
11	frontal	O
12	,	O
13	temporal	O
14	and	O
15	anterior	O
16	cingulate	O
17	cortices	O
18	,	O
19	and	O
20	the	O
21	intravenous	O
22	administration	O
23	of	O
24	d	O
25	-	O
26	chlorpheniramine	O
27	as	O
28	a	O
29	therapeutic	O
30	dose	O
31	(	O
32	2	O
33	mg	O
34	)	O
35	blocked	O
36	over	O
37	60	O
38	%	O
39	of	O
40	H1R	B
41	in	O
42	the	O
43	frontal	O
44	cortices	O
45	.	O
1	KFC	B
2	,	O
3	a	O
4	Ste20	B
5	-	I
6	like	I
7	kinase	I
8	with	O
9	mitogenic	O
10	potential	O
11	and	O
12	capability	O
13	to	O
14	activate	O
15	the	O
16	SAPK	B
17	/	O
18	JNK	B
19	pathway	O
20	.	O
1	Reaction	O
2	time	O
3	(	O
4	RT	O
5	)	O
6	and	O
7	P300	O
8	were	O
9	collected	O
10	simultaneously	O
11	.	O
1	RESULTS	O
2	:	O
3	In	O
4	this	O
5	group	O
6	of	O
7	patients	O
8	,	O
9	male	O
10	gender	O
11	(	O
12	P	O
13	=	O
14	0	O
15	.	O
1	Selective	O
2	visual	O
3	attention	O
4	involves	O
5	dynamic	O
6	interplay	O
7	between	O
8	attentional	O
9	control	O
10	systems	O
11	and	O
12	sensory	O
13	brain	O
14	structures	O
15	.	O
1	In	O
2	order	O
3	to	O
4	gain	O
5	deeper	O
6	insight	O
7	into	O
8	the	O
9	role	O
10	of	O
11	the	O
12	amino	O
13	-	O
14	terminal	O
15	domain	O
16	of	O
17	the	O
18	p24	B
19	(	O
20	CA	B
21	)	O
22	protein	O
23	during	O
24	viral	O
25	replication	O
26	,	O
27	eight	O
28	highly	O
29	conserved	O
30	proline	O
31	residues	O
32	known	O
33	to	O
34	promote	O
35	turns	O
36	and	O
37	to	O
38	terminate	O
39	alpha	O
40	-	O
41	helices	O
42	within	O
43	the	O
44	p24	B
45	tertiary	O
46	structure	O
47	were	O
48	replaced	O
49	by	O
50	a	O
51	leucine	O
52	residue	O
53	(	O
54	P	O
55	-	O
56	position	O
57	-	O
58	L	O
59	).	O
1	PURPOSE	O
2	:	O
3	A	O
4	two	O
5	-	O
6	generation	O
7	consanguineous	O
8	Pakistani	O
9	family	O
10	with	O
11	autosomal	O
12	recessive	O
13	Leber	O
14	congenital	O
15	amaurosis	O
16	(	O
17	LCA	O
18	,	O
19	MIM	O
20	204	O
21	,	O
22	000	O
23	)	O
24	and	O
25	keratoconus	O
26	was	O
27	identified	O
28	.	O
1	Inactivation	O
2	of	O
3	Ulp2	B
4	also	O
5	suppresses	O
6	several	O
7	ulp1	B
8	(	I
9	ts	I
10	)	I
11	defects	O
12	,	O
13	and	O
14	the	O
15	double	O
16	mutant	O
17	accumulates	O
18	far	O
19	fewer	O
20	Smt3	B
21	-	I
22	protein	I
23	conjugates	O
24	than	O
25	either	O
26	single	O
27	mutant	O
28	.	O
1	Cyclin	B
2	A	I
3	expression	O
4	is	O
5	repressed	O
6	in	O
7	quiescent	O
8	cells	O
9	by	O
10	E2F	B
11	acting	O
12	in	O
13	conjunction	O
14	with	O
15	its	O
16	pocket	O
17	protein	O
18	partners	O
19	Rb	B
20	,	O
21	p107	B
22	,	O
23	and	O
24	p130	B
25	;	O
26	however	O
27	,	O
28	v	B
29	-	I
30	Jun	I
31	overrides	O
32	this	O
33	control	O
34	,	O
35	causing	O
36	phosphorylated	O
37	Rb	B
38	and	O
39	proliferation	O
40	-	O
41	specific	O
42	E2F	B
43	-	O
44	p107	B
45	complexes	O
46	to	O
47	persist	O
48	after	O
49	mitogen	O
50	withdrawal	O
51	.	O
1	CONCLUSION	O
2	:	O
3	A	O
4	valve	O
5	-	O
6	like	O
7	mechanism	O
8	formed	O
9	by	O
10	the	O
11	capsulorhexis	O
12	rim	O
13	partially	O
14	adhered	O
15	to	O
16	the	O
17	IOL	O
18	optic	O
19	can	O
20	occur	O
21	postoperatively	O
22	.	O
1	3	O
2	'	O
3	RNA	O
4	boundary	O
5	experiments	O
6	indicate	O
7	that	O
8	the	O
9	5	O
10	'	O
11	structure	O
12	reduces	O
13	the	O
14	number	O
15	of	O
16	(	O
17	G	O
18	/	O
19	U	O
20	)	O
21	AG	O
22	repeats	O
23	required	O
24	for	O
25	stable	O
26	TRAP	B
27	-	O
28	trp	B
29	leader	O
30	RNA	O
31	association	O
32	.	O
1	Gene	O
2	silencing	O
3	associated	O
4	with	O
5	repeated	O
6	DNA	O
7	sequences	O
8	has	O
9	been	O
10	reported	O
11	for	O
12	many	O
13	eukaryotes	O
14	,	O
15	including	O
16	plants	O
17	.	O
1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	the	O
12	response	O
13	rates	O
14	and	O
15	toxicity	O
16	of	O
17	two	O
18	regimens	O
19	containing	O
20	granulocyte	B
21	-	I
22	macrophage	I
23	-	I
24	colony	I
25	stimulating	I
26	factor	I
27	(	O
28	GM	B
29	-	I
30	CSF	I
31	)	O
32	in	O
33	combination	O
34	with	O
35	interleukin	B
36	-	I
37	2	I
38	(	O
39	IL	B
40	-	I
41	2	I
42	)	O
43	in	O
44	the	O
45	treatment	O
46	of	O
47	patients	O
48	with	O
49	metastatic	O
50	renal	O
51	cell	O
52	carcinoma	O
53	.	O
1	Depleted	O
2	and	O
3	enriched	O
4	U3O8	O
5	standard	O
6	reference	O
7	materials	O
8	were	O
9	used	O
10	to	O
11	calibrate	O
12	the	O
13	system	O
14	.	O
1	Here	O
2	we	O
3	describe	O
4	the	O
5	cloning	O
6	,	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	pattern	O
12	,	O
13	and	O
14	functional	O
15	characterization	O
16	of	O
17	two	O
18	novel	O
19	TEF	B
20	-	I
21	1	I
22	isoforms	I
23	,	O
24	TEF	B
25	-	I
26	1beta	I
27	and	O
28	TEF	B
29	-	I
30	1gamma	I
31	.	O
1	Regulation	O
2	of	O
3	urokinase	B
4	plasminogen	I
5	activator	I
6	gene	I
7	transcription	O
8	in	O
9	the	O
10	RAW264	O
11	murine	O
12	macrophage	O
13	cell	O
14	line	O
15	by	O
16	macrophage	B
17	colony	I
18	-	I
19	stimulating	I
20	factor	I
21	(	O
22	CSF	B
23	-	I
24	1	I
25	)	O
26	is	O
27	dependent	O
28	upon	O
29	the	O
30	level	O
31	of	O
32	cell	O
33	-	O
34	surface	O
35	receptor	O
36	.	O
1	Molecule	O
2	(	O
3	s	O
4	)	O
5	secreted	O
6	by	O
7	neuronal	O
8	cultures	O
9	contribute	O
10	to	O
11	this	O
12	induction	O
13	of	O
14	GLT	B
15	-	I
16	1	I
17	,	O
18	but	O
19	little	O
20	is	O
21	known	O
22	about	O
23	the	O
24	signaling	O
25	pathways	O
26	mediating	O
27	this	O
28	regulation	O
29	.	O
1	Importantly	O
2	,	O
3	concomitant	O
4	expression	O
5	of	O
6	constitutive	O
7	activated	O
8	Raf	B
9	and	O
10	V12N38	B
11	Ras	I
12	results	O
13	in	O
14	almost	O
15	complete	O
16	loss	O
17	of	O
18	TTF	B
19	-	I
20	1	I
21	activity	O
22	.	O
1	They	O
2	share	O
3	many	O
4	downstream	O
5	targets	O
6	,	O
7	including	O
8	remodeling	O
9	of	O
10	the	O
11	actin	B
12	cytoskeleton	O
13	,	O
14	activation	O
15	of	O
16	p70	B
17	(	I
18	S6	I
19	)	I
20	kinase	I
21	and	O
22	c	B
23	-	I
24	jun	I
25	N	I
26	-	I
27	terminal	I
28	kinase	I
29	(	O
30	JNK	B
31	),	O
32	and	O
33	regulation	O
34	of	O
35	transcription	O
36	and	O
37	cell	O
38	proliferation	O
39	.	O
1	Based	O
2	on	O
3	these	O
4	data	O
5	,	O
6	we	O
7	conclude	O
8	that	O
9	transcription	O
10	of	O
11	prgX	B
12	is	O
13	initiated	O
14	from	O
15	the	O
16	Qa	B
17	promoter	I
18	in	O
19	prgQ	B
20	,	O
21	and	O
22	PrgX	B
23	autoregulates	O
24	its	O
25	transcription	O
26	either	O
27	by	O
28	mediating	O
29	transcriptional	O
30	readthrough	O
31	or	O
32	increasing	O
33	mRNA	O
34	stability	O
35	.	O
1	It	O
2	was	O
3	established	O
4	that	O
5	intrathecal	O
6	or	O
7	intraperitoneal	O
8	PTFL	O
9	,	O
10	elevated	O
11	the	O
12	nociceptive	O
13	threshold	O
14	for	O
15	mechanical	O
16	stimuli	O
17	in	O
18	the	O
19	formalin	O
20	test	O
21	in	O
22	rats	O
23	.	O
1	Electrophile	O
2	Response	O
3	Elements	O
4	(	O
5	EpREs	O
6	),	O
7	located	O
8	in	O
9	5	O
10	'-	O
11	flanking	O
12	sequences	O
13	of	O
14	both	O
15	the	O
16	GCSh	B
17	and	O
18	GCSl	B
19	subunit	I
20	genes	I
21	,	O
22	are	O
23	hypothesized	O
24	to	O
25	at	O
26	least	O
27	partially	O
28	mediate	O
29	gene	O
30	induction	O
31	following	O
32	xenobiotic	O
33	exposure	O
34	.	O
1	The	O
2	cell	O
3	cycle	O
4	and	O
5	transcriptional	O
6	defects	O
7	caused	O
8	by	O
9	taf17	B
10	(	O
11	slm7	B
12	-	I
13	1	I
14	)	O
15	are	O
16	consistent	O
17	with	O
18	the	O
19	role	O
20	of	O
21	TAF	B
22	(	I
23	II	I
24	)	I
25	s	I
26	as	O
27	modulators	O
28	of	O
29	transcriptional	O
30	activation	O
31	and	O
32	may	O
33	reflect	O
34	a	O
35	role	O
36	for	O
37	TAF17	B
38	in	O
39	regulating	O
40	activation	O
41	by	O
42	SBF	B
43	and	O
44	MBF	B
45	.	O
1	The	O
2	recombinant	O
3	enzymes	O
4	exist	O
5	as	O
6	monomers	O
7	.	O
1	A	O
2	pathway	O
3	for	O
4	regulation	O
5	of	O
6	B	B
7	lymphocyte	I
8	antigen	I
9	receptor	I
10	-	O
11	induced	O
12	calcium	O
13	flux	O
14	.	O
1	Bites	O
2	by	O
3	two	O
4	species	O
5	of	O
6	adders	O
7	(	O
8	Vipera	O
9	aspis	O
10	and	O
11	Vipera	O
12	berus	O
13	)	O
14	can	O
15	lead	O
16	to	O
17	extensive	O
18	swelling	O
19	with	O
20	multiorgan	O
21	failure	O
22	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	transcription	O
6	of	O
7	c	B
8	-	I
9	IAP2	I
10	promoter	I
11	was	O
12	strongly	O
13	up	O
14	-	O
15	regulated	O
16	when	O
17	CD40	B
18	or	O
19	Epstein	B
20	-	I
21	Barr	I
22	virus	I
23	latent	I
24	membrane	I
25	protein	I
26	1	I
27	was	O
28	overexpressed	O
29	.	O
1	CONCLUSION	O
2	:	O
3	Treatment	O
4	of	O
5	sepsis	O
6	with	O
7	the	O
8	platelet	B
9	-	I
10	activating	I
11	factor	I
12	antagonist	O
13	BB	O
14	-	O
15	882	O
16	offers	O
17	no	O
18	advantage	O
19	over	O
20	placebo	O
21	on	O
22	survival	O
23	,	O
24	hemodynamic	O
25	status	O
26	,	O
27	respiratory	O
28	function	O
29	,	O
30	or	O
31	organ	O
32	failure	O
33	scores	O
34	.	O
1	Recently	O
2	,	O
3	a	O
4	mutation	O
5	in	O
6	the	O
7	amino	O
8	-	O
9	terminus	O
10	of	O
11	IB1	B
12	was	O
13	associated	O
14	with	O
15	diabetes	O
16	.	O
1	On	O
2	the	O
3	basis	O
4	of	O
5	size	O
6	,	O
7	the	O
8	CRS	O
9	sequence	O
10	to	O
11	which	O
12	it	O
13	binds	O
14	,	O
15	and	O
16	its	O
17	tentative	O
18	identification	O
19	as	O
20	a	O
21	zinc	B
22	finger	I
23	protein	I
24	,	O
25	Adx	B
26	factor	I
27	has	O
28	been	O
29	identified	O
30	as	O
31	a	O
32	Kruppel	B
33	-	I
34	like	I
35	zinc	I
36	finger	I
37	protein	I
38	(	O
39	a	O
40	mouse	B
41	ZBP	I
42	-	I
43	89	I
44	homologue	I
45	).	O
1	Integrin	B
2	adhesion	I
3	receptors	I
4	transduce	O
5	signals	O
6	that	O
7	control	O
8	complex	O
9	cell	O
10	functions	O
11	which	O
12	require	O
13	the	O
14	regulation	O
15	of	O
16	gene	O
17	expression	O
18	,	O
19	such	O
20	as	O
21	proliferation	O
22	,	O
23	differentiation	O
24	and	O
25	survival	O
26	.	O
1	As	O
2	an	O
3	extension	O
4	of	O
5	our	O
6	structural	O
7	characterization	O
8	of	O
9	the	O
10	exon	O
11	-	O
12	intron	O
13	organization	O
14	of	O
15	the	O
16	mouse	B
17	Pkr	I
18	gene	I
19	,	O
20	we	O
21	now	O
22	have	O
23	isolated	O
24	and	O
25	characterized	O
26	the	O
27	mouse	B
28	Pkr	I
29	promoter	I
30	region	I
31	required	O
32	for	O
33	IFN	B
34	-	O
35	inducible	O
36	transcription	O
37	.	O
1	The	O
2	clinical	O
3	stage	O
4	was	O
5	I	O
6	(	O
7	T1N0M0	O
8	),	O
9	and	O
10	S2	O
11	sleeve	O
12	segmentectomy	O
13	with	O
14	lymph	O
15	node	O
16	dissection	O
17	(	O
18	R	O
19	2	O
20	b	O
21	)	O
22	was	O
23	performed	O
24	.	O
1	Viral	O
2	cell	O
3	-	O
4	to	O
5	-	O
6	cell	O
7	movement	O
8	of	O
9	PVX	B
10	CP	I
11	mutant	I
12	was	O
13	complemented	O
14	in	O
15	Nicotiana	O
16	tabacum	O
17	cv	O
18	.	O
1	Induction	O
2	of	O
3	CD86	B
4	expression	O
5	by	O
6	stimulation	O
7	of	O
8	U937	O
9	cells	O
10	with	O
11	IFN	B
12	-	I
13	gamma	I
14	revealed	O
15	the	O
16	presence	O
17	of	O
18	two	O
19	functional	O
20	GAS	B
21	(	O
22	gamma	B
23	-	I
24	interferon	I
25	activation	I
26	site	I
27	)	O
28	elements	O
29	.	O
1	IgM	B
2	and	O
3	IgG	B
4	anti	I
5	A	I
6	and	O
7	anti	B
8	B	I
9	antibody	I
10	status	O
11	of	O
12	100	O
13	antenatal	O
14	O	O
15	group	O
16	mothers	O
17	(	O
18	who	O
19	had	O
20	non	O
21	O	O
22	group	O
23	husbands	O
24	)	O
25	were	O
26	studied	O
27	.	O
1	In	O
2	an	O
3	attempt	O
4	to	O
5	understand	O
6	Wee1	B
7	regulation	O
8	during	O
9	cell	O
10	cycle	O
11	,	O
12	yeast	O
13	two	O
14	-	O
15	hybrid	O
16	screening	O
17	was	O
18	used	O
19	to	O
20	identify	O
21	Wee1	O
22	-	O
23	binding	O
24	protein	O
25	(	O
26	s	O
27	).	O
1	Retroviral	O
2	transduction	O
3	of	O
4	T	B
5	/	I
6	T	I
7	(	I
8	L	I
9	)	I
10	causes	O
11	a	O
12	rapidly	O
13	fatal	O
14	myeloproliferative	O
15	disease	O
16	in	O
17	a	O
18	murine	O
19	bone	O
20	marrow	O
21	transplant	O
22	(	O
23	BMT	O
24	)	O
25	model	O
26	,	O
27	whereas	O
28	T	B
29	/	I
30	T	I
31	(	I
32	F	I
33	)	I
34	causes	O
35	a	O
36	long	O
37	-	O
38	latency	O
39	,	O
40	pre	O
41	-	O
42	B	O
43	-	O
44	cell	O
45	lymphoblastic	O
46	lymphoma	O
47	.	O
1	Results	O
2	from	O
3	transient	O
4	assays	O
5	using	O
6	these	O
7	mutants	O
8	showed	O
9	that	O
10	the	O
11	DE1	O
12	received	O
13	signals	O
14	from	O
15	phytochromes	B
16	A	I
17	and	I
18	B	I
19	,	O
20	demonstrating	O
21	that	O
22	this	O
23	element	O
24	is	O
25	indeed	O
26	a	O
27	light	O
28	-	O
29	responsive	O
30	element	O
31	.	O
1	We	O
2	report	O
3	here	O
4	on	O
5	the	O
6	molecular	O
7	nature	O
8	of	O
9	an	O
10	EMS	O
11	-	O
12	induced	O
13	mutant	O
14	,	O
15	mn1	B
16	-	I
17	89	I
18	,	O
19	a	O
20	leaky	O
21	semidominant	O
22	allele	O
23	of	O
24	the	O
25	Miniature1	B
26	(	O
27	Mn1	B
28	)	O
29	seed	O
30	locus	O
31	that	O
32	encodes	O
33	a	O
34	seed	B
35	-	I
36	specific	I
37	cell	I
38	wall	I
39	invertase	I
40	,	O
41	INCW2	B
42	.	O
1	Slap	B
2	negatively	O
3	regulates	O
4	Src	B
5	mitogenic	O
6	function	O
7	but	O
8	does	O
9	not	O
10	revert	O
11	Src	B
12	-	O
13	induced	O
14	cell	O
15	morphology	O
16	changes	O
17	.	O
1	In	O
2	DNase	B
3	I	I
4	footprinting	O
5	protection	O
6	analysis	O
7	,	O
8	both	O
9	SFRE	B
10	and	O
11	ERE	O
12	regions	O
13	were	O
14	protected	O
15	by	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	-	O
21	ERRalpha1	B
22	fusion	O
23	protein	O
24	.	O
1	Two	O
2	additional	O
3	cis	O
4	-	O
5	acting	O
6	sequences	O
7	,	O
8	conserved	O
9	in	O
10	both	O
11	the	O
12	region	O
13	1	O
14	and	O
15	3	O
16	promoters	O
17	,	O
18	were	O
19	identified	O
20	,	O
21	suggesting	O
22	a	O
23	role	O
24	for	O
25	these	O
26	sequences	O
27	in	O
28	the	O
29	coordinate	O
30	regulation	O
31	of	O
32	transcription	O
33	from	O
34	these	O
35	promoters	O
36	.	O
1	Marrow	O
2	dysplasia	O
3	is	O
4	a	O
5	major	O
6	characteristic	O
7	of	O
8	patients	O
9	with	O
10	myelodysplastic	O
11	syndrome	O
12	(	O
13	MDS	O
14	),	O
15	along	O
16	with	O
17	marrow	O
18	blastosis	O
19	,	O
20	cytopenia	O
21	and	O
22	cytogenetic	O
23	anomalies	O
24	.	O
1	How	O
2	plants	O
3	respond	O
4	to	O
5	attack	O
6	by	O
7	the	O
8	range	O
9	of	O
10	herbivores	O
11	and	O
12	pathogens	O
13	that	O
14	confront	O
15	them	O
16	in	O
17	the	O
18	field	O
19	is	O
20	the	O
21	subject	O
22	of	O
23	considerable	O
24	research	O
25	by	O
26	both	O
27	molecular	O
28	biologists	O
29	and	O
30	ecologists	O
31	.	O
1	However	O
2	,	O
3	the	O
4	element	O
5	proximal	O
6	to	O
7	the	O
8	transcription	O
9	start	O
10	site	O
11	is	O
12	dependent	O
13	on	O
14	the	O
15	SRE	O
16	-	O
17	1	O
18	.	O
1	Antibodies	O
2	raised	O
3	against	O
4	a	O
5	C	O
6	-	O
7	terminal	O
8	portion	O
9	of	O
10	Sec31A	B
11	co	O
12	-	O
13	precipitate	O
14	Sec13	B
15	and	O
16	inhibit	O
17	ER	O
18	-	O
19	Golgi	O
20	transport	O
21	of	O
22	temperature	O
23	-	O
24	arrested	O
25	vesicular	O
26	stomatitis	B
27	G	I
28	protein	I
29	in	O
30	a	O
31	semi	O
32	-	O
33	intact	O
34	cell	O
35	assay	O
36	.	O
1	Because	O
2	the	O
3	mutant	O
4	defective	O
5	in	O
6	DNA	O
7	binding	O
8	also	O
9	fails	O
10	to	O
11	stimulate	O
12	Abf1	B
13	ARS1	O
14	DNA	O
15	-	O
16	binding	O
17	activity	O
18	,	O
19	our	O
20	results	O
21	suggest	O
22	that	O
23	Cdc6	B
24	DNA	O
25	-	O
26	binding	O
27	activity	O
28	may	O
29	play	O
30	a	O
31	pivotal	O
32	role	O
33	in	O
34	the	O
35	initiation	O
36	of	O
37	DNA	O
38	replication	O
39	.	O
1	Finally	O
2	,	O
3	Cas	B
4	existed	O
5	mainly	O
6	in	O
7	cytosol	O
8	and	O
9	membrane	O
10	cytoskeleton	O
11	fractions	O
12	in	O
13	the	O
14	resting	O
15	state	O
16	,	O
17	and	O
18	remained	O
19	unchanged	O
20	during	O
21	platelet	O
22	aggregation	O
23	,	O
24	when	O
25	FAK	B
26	translocated	O
27	to	O
28	the	O
29	cytoskeletal	O
30	fraction	O
31	.	O
1	The	O
2	Siglecs	B
3	are	O
4	a	O
5	subfamily	O
6	of	O
7	I	B
8	-	I
9	type	I
10	lectins	I
11	(	O
12	immunoglobulin	B
13	superfamily	I
14	proteins	I
15	that	O
16	bind	O
17	sugars	O
18	)	O
19	that	O
20	specifically	O
21	recognize	O
22	sialic	O
23	acids	O
24	.	O
1	PATIENTS	O
2	OR	O
3	OTHER	O
4	PARTICIPANTS	O
5	:	O
6	Twenty	O
7	children	O
8	met	O
9	the	O
10	criteria	O
11	for	O
12	being	O
13	learning	O
14	disabled	O
15	.	O
1	In	O
2	the	O
3	study	O
4	on	O
5	PCI	B
6	mRNA	I
7	expression	O
8	in	O
9	the	O
10	reproductive	O
11	organs	O
12	,	O
13	we	O
14	first	O
15	cloned	O
16	rat	B
17	PCI	I
18	cDNA	I
19	and	O
20	then	O
21	evaluated	O
22	the	O
23	effect	O
24	of	O
25	androgen	O
26	on	O
27	the	O
28	PCI	B
29	mRNA	I
30	expression	O
31	.	O
1	Our	O
2	analysis	O
3	of	O
4	nonsense	O
5	mutations	O
6	indicates	O
7	that	O
8	the	O
9	C	O
10	terminus	O
11	of	O
12	eIF2Bepsilon	B
13	(	I
14	residues	I
15	518	I
16	to	I
17	712	I
18	)	I
19	is	O
20	required	O
21	for	O
22	both	O
23	catalytic	O
24	activity	O
25	and	O
26	interaction	O
27	with	O
28	eIF2	B
29	.	O
1	D5	B
2	/	I
3	D1	I
4	(	I
5	CT	I
6	)	I
7	or	O
8	D5	B
9	/	I
10	D1D	I
11	(	I
12	CT	I
13	)	I
14	tail	O
15	substitution	O
16	mutants	O
17	displayed	O
18	a	O
19	rank	O
20	order	O
21	of	O
22	potency	O
23	and	O
24	agonist	O
25	affinities	O
26	virtually	O
27	mimicking	O
28	wild	B
29	-	I
30	type	I
31	(	I
32	wt	I
33	)	I
34	D1	I
35	receptors	I
36	,	O
37	as	O
38	indexed	O
39	by	O
40	both	O
41	ligand	O
42	binding	O
43	and	O
44	dopamine	O
45	-	O
46	stimulated	O
47	cAMP	O
48	accumulation	O
49	assays	O
50	,	O
51	and	O
52	,	O
53	similar	O
54	to	O
55	wt	O
56	D1	B
57	receptors	I
58	,	O
59	did	O
60	not	O
61	exhibit	O
62	receptor	O
63	constitutive	O
64	activity	O
65	or	O
66	responsiveness	O
67	to	O
68	inverse	O
69	agonists	O
70	.	O
1	The	O
2	immune	O
3	system	O
4	is	O
5	closely	O
6	integrated	O
7	with	O
8	the	O
9	neuroendocrine	O
10	system	O
11	,	O
12	and	O
13	infection	O
14	-	O
15	induced	O
16	increases	O
17	in	O
18	cytokines	O
19	such	O
20	as	O
21	IL	B
22	-	I
23	1	I
24	,	O
25	IL	B
26	-	I
27	6	I
28	and	O
29	TNF	B
30	have	O
31	numerous	O
32	effects	O
33	on	O
34	the	O
35	central	O
36	nervous	O
37	system	O
38	.	O
1	C	O
2	.	O
3	elegans	O
4	KLP	B
5	-	I
6	11	I
7	/	O
8	OSM	B
9	-	I
10	3	I
11	/	O
12	KAP	B
13	-	I
14	1	I
15	:	O
16	orthologs	O
17	of	O
18	the	O
19	sea	B
20	urchin	I
21	kinesin	I
22	-	I
23	II	I
24	,	O
25	and	O
26	mouse	O
27	KIF3A	B
28	/	O
29	KIFB	B
30	/	O
31	KAP3	B
32	kinesin	I
33	complexes	O
34	.	O
1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	effacement	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	practical	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	preferred	O
20	in	O
21	that	O
22	prediction	O
23	.	O
1	Here	O
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	TAFII250	B
8	,	O
9	the	O
10	largest	O
11	subunit	O
12	of	O
13	TFIID	B
14	,	O
15	contains	O
16	two	O
17	tandem	O
18	bromodomain	O
19	modules	O
20	that	O
21	bind	O
22	selectively	O
23	to	O
24	multiply	O
25	acetylated	O
26	histone	B
27	H4	I
28	peptides	I
29	.	O
1	Endostatin	O
2	treatment	O
3	for	O
4	10	O
5	minutes	O
6	or	O
7	24	O
8	hours	O
9	induced	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	Shb	B
14	and	O
15	formation	O
16	of	O
17	multiprotein	O
18	complexes	O
19	.	O
1	The	O
2	transcript	O
3	was	O
4	initially	O
5	identified	O
6	as	O
7	a	O
8	partial	O
9	cDNA	O
10	sequence	O
11	in	O
12	the	O
13	course	O
14	of	O
15	constructing	O
16	a	O
17	transcript	O
18	map	O
19	of	O
20	the	O
21	region	O
22	between	O
23	markers	O
24	D11S1765	B
25	and	O
26	uteroglobin	B
27	known	O
28	to	O
29	encompass	O
30	the	O
31	gene	O
32	causing	O
33	Best	O
34	disease	O
35	.	O
1	Iodine	O
2	deficiency	O
3	disorders	O
4	in	O
5	Bangladesh	O
6	.	O
1	The	O
2	network	O
3	evolution	O
4	was	O
5	interpreted	O
6	by	O
7	an	O
8	approach	O
9	based	O
10	on	O
11	the	O
12	Flory	O
13	model	O
14	.	O
1	CONCLUSION	O
2	:	O
3	Our	O
4	findings	O
5	suggest	O
6	that	O
7	endometriosis	O
8	increases	O
9	soluble	O
10	CD23	B
11	levels	O
12	,	O
13	which	O
14	can	O
15	be	O
16	suppressed	O
17	with	O
18	either	O
19	danazol	O
20	or	O
21	leuprolide	O
22	acetate	O
23	injection	O
24	.	O
1	Consistent	O
2	with	O
3	our	O
4	model	O
5	,	O
6	CTCF	B
7	binding	O
8	is	O
9	abolished	O
10	by	O
11	DNA	O
12	methylation	O
13	.	O
1	The	O
2	experimentally	O
3	mapped	O
4	regions	O
5	of	O
6	RPB5	B
7	involved	O
8	in	O
9	these	O
10	interactions	O
11	correspond	O
12	to	O
13	distinct	O
14	and	O
15	surface	O
16	-	O
17	exposed	O
18	alpha	O
19	-	O
20	helical	O
21	structures	O
22	.	O
1	The	O
2	model	O
3	indicates	O
4	that	O
5	a	O
6	0	O
7	.	O
8	076	O
9	%	O
10	reduction	O
11	in	O
12	cigarette	O
13	consumption	O
14	is	O
15	associated	O
16	with	O
17	the	O
18	availability	O
19	of	O
20	nicotine	O
21	patches	O
22	after	O
23	1992	O
24	.	O
1	The	O
2	cellular	O
3	part	O
4	of	O
5	the	O
6	third	O
7	chimeric	O
8	clone	O
9	shows	O
10	significant	O
11	homology	O
12	to	O
13	an	O
14	exon	O
15	of	O
16	the	O
17	human	B
18	tyrosine	I
19	phosphatase	I
20	1	I
21	gene	I
22	,	O
23	although	O
24	oriented	O
25	in	O
26	the	O
27	antisense	O
28	direction	O
29	compared	O
30	to	O
31	the	O
32	adjacent	O
33	LTR	O
34	.	O
1	RESULTS	O
2	:	O
3	Fournier	O
4	'	O
5	s	O
6	gangrene	O
7	occurs	O
8	worldwide	O
9	.	O
1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	prostate	O
9	carcinomas	O
10	with	O
11	the	O
12	Ras	B
13	/	O
14	MAPK	B
15	pathway	O
16	activation	O
17	might	O
18	have	O
19	a	O
20	selective	O
21	growth	O
22	advantage	O
23	by	O
24	autocrine	O
25	TGF	B
26	-	I
27	beta1	I
28	production	O
29	.	O
1	It	O
2	brings	O
3	about	O
4	fatigue	O
5	,	O
6	negative	O
7	moods	O
8	,	O
9	and	O
10	impaired	O
11	health	O
12	,	O
13	sleep	O
14	,	O
15	safety	O
16	,	O
17	and	O
18	working	O
19	capacity	O
20	.	O
1	During	O
2	surgery	O
3	bone	O
4	cysts	O
5	were	O
6	excised	O
7	and	O
8	filled	O
9	by	O
10	bone	O
11	grafts	O
12	.	O
1	Characterization	O
2	of	O
3	polymorphic	O
4	TNRs	O
5	in	O
6	novel	O
7	and	O
8	even	O
9	known	O
10	genes	O
11	expressed	O
12	in	O
13	human	O
14	spinal	O
15	cord	O
16	is	O
17	likely	O
18	to	O
19	help	O
20	in	O
21	the	O
22	identification	O
23	of	O
24	new	O
25	candidates	O
26	for	O
27	genes	O
28	involved	O
29	in	O
30	neurodegenerative	O
31	disorders	O
32	.	O
1	Using	O
2	adenoviral	O
3	transfer	O
4	of	O
5	IkappaBalpha	B
6	(	O
7	IkappaBalpha	B
8	overexpression	O
9	),	O
10	the	O
11	production	O
12	of	O
13	TNF	B
14	-	I
15	alpha	I
16	induced	O
17	by	O
18	whole	O
19	GBS	O
20	was	O
21	inhibited	O
22	by	O
23	only	O
24	20	O
25	%.	O
1	The	O
2	effect	O
3	of	O
4	acute	O
5	,	O
6	mid	O
7	-	O
8	cervical	O
9	spinal	O
10	cord	O
11	lesions	O
12	on	O
13	neuronal	O
14	and	O
15	reflex	O
16	activity	O
17	evoked	O
18	by	O
19	the	O
20	noxious	O
21	visceral	O
22	stimulus	O
23	,	O
24	colorectal	O
25	distension	O
26	(	O
27	CRD	O
28	;	O
29	80	O
30	mmHg	O
31	,	O
32	20	O
33	s	O
34	),	O
35	was	O
36	determined	O
37	in	O
38	halothane	O
39	-	O
40	anesthetized	O
41	rats	O
42	.	O
1	Phd	B
2	antibody	O
3	-	O
4	immunoreactive	O
5	peptides	O
6	are	O
7	seen	O
8	in	O
9	light	O
10	-	O
11	adapted	O
12	mouse	O
13	retinal	O
14	cytosolic	O
15	and	O
16	nuclear	O
17	extracts	O
18	.	O
1	In	O
2	contrast	O
3	to	O
4	the	O
5	morphological	O
6	criteria	O
7	,	O
8	the	O
9	few	O
10	data	O
11	available	O
12	from	O
13	recent	O
14	studies	O
15	at	O
16	the	O
17	genetic	O
18	level	O
19	have	O
20	suggested	O
21	that	O
22	EPVs	O
23	infecting	O
24	different	O
25	insect	O
26	orders	O
27	are	O
28	phylogenetically	O
29	distant	O
30	.	O
1	The	O
2	administration	O
3	of	O
4	the	O
5	GnRH	B
6	agonist	O
7	reduced	O
8	the	O
9	bone	O
10	mineral	O
11	density	O
12	in	O
13	the	O
14	whole	O
15	femur	O
16	to	O
17	91	O
18	.	O
19	0	O
20	%	O
21	of	O
22	that	O
23	in	O
24	the	O
25	control	O
26	group	O
27	.	O
1	Prevention	O
2	,	O
3	differential	O
4	diagnosis	O
5	and	O
6	therapy	O
7	of	O
8	travel	O
9	diarrhea	O
1	As	O
2	with	O
3	VP16	B
4	,	O
5	the	O
6	transactivation	O
7	function	O
8	of	O
9	Luman	B
10	is	O
11	also	O
12	regulated	O
13	by	O
14	HCF	B
15	.	O
1	When	O
2	the	O
3	LCx	O
4	was	O
5	partially	O
6	occluded	O
7	,	O
8	mild	O
9	PM	O
10	-	O
11	induced	O
12	tachycardia	O
13	resulted	O
14	in	O
15	decreased	O
16	AoP	O
17	(	O
18	P	O
19	=	O
20	0	O
21	.	O
22	045	O
23	)	O
24	as	O
25	well	O
26	as	O
27	in	O
28	decreased	O
29	SV	O
30	(	O
31	P	O
32	=	O
33	0	O
34	.	O
35	048	O
36	);	O
37	the	O
38	LVEDP	O
39	remained	O
40	high	O
41	(	O
42	P	O
43	=	O
44	0	O
45	.	O
46	002	O
47	).	O
1	Furthermore	O
2	,	O
3	as	O
4	in	O
5	the	O
6	human	O
7	gene	O
8	,	O
9	the	O
10	3	O
11	'	O
12	end	O
13	of	O
14	the	O
15	Cacna1f	B
16	gene	I
17	maps	O
18	within	O
19	5	O
20	kb	O
21	of	O
22	the	O
23	5	O
24	'	O
25	end	O
26	of	O
27	the	O
28	mouse	B
29	synaptophysin	I
30	gene	I
31	in	O
32	a	O
33	region	O
34	orthologous	O
35	to	O
36	Xp11	O
37	.	O
38	23	O
39	.	O
1	CONCLUSION	O
2	:	O
3	The	O
4	alpha2	O
5	-	O
6	adrenergic	O
7	antagonist	O
8	idazoxan	O
9	increases	O
10	glucose	O
11	-	O
12	induced	O
13	sympathetic	O
14	activity	O
15	but	O
16	not	O
17	energy	O
18	expenditure	O
19	in	O
20	obese	O
21	subjects	O
22	.	O
1	Testing	O
2	for	O
3	serum	B
4	IgM	I
5	binding	O
6	to	O
7	GM1	O
8	ganglioside	O
9	in	O
10	clinical	O
11	practice	O
12	.	O
1	Objective	O
2	responses	O
3	also	O
4	occurred	O
5	in	O
6	studies	O
7	that	O
8	explored	O
9	sequential	O
10	use	O
11	of	O
12	exemestane	O
13	after	O
14	failure	O
15	of	O
16	aminoglutethimide	O
17	(	O
18	26	O
19	%	O
20	with	O
21	exemestane	O
22	200	O
23	mg	O
24	/	O
25	day	O
26	)	O
27	or	O
28	other	O
29	nonsteroidal	O
30	aromatase	B
31	inhibitors	O
32	(	O
33	6	O
34	.	O
35	6	O
36	%	O
37	with	O
38	exemestane	O
39	25	O
40	mg	O
41	/	O
42	day	O
43	).	O
1	The	O
2	duration	O
3	of	O
4	reactive	O
5	hyperemia	O
6	decreased	O
7	with	O
8	aging	O
9	,	O
10	but	O
11	the	O
12	difference	O
13	between	O
14	males	O
15	and	O
16	females	O
17	was	O
18	not	O
19	significant	O
20	at	O
21	any	O
22	age	O
23	.	O
1	Acquired	O
2	bile	O
3	duct	O
4	blockage	O
5	:	O
6	entry	O
7	of	O
8	hepatobiliary	O
9	agent	O
10	into	O
11	an	O
12	intrahepatic	O
13	abscess	O
14	.	O
1	ACE	B
2	-	I
3	2	I
4	has	O
5	a	O
6	hydrophobic	O
7	C	O
8	terminus	O
9	of	O
10	H	O
11	type	O
12	.	O
1	The	O
2	first	O
3	symptoms	O
4	of	O
5	enzootic	O
6	calcinosis	O
7	were	O
8	noted	O
9	in	O
10	March	O
11	1998	O
12	,	O
13	when	O
14	some	O
15	of	O
16	the	O
17	cows	O
18	developed	O
19	locomotor	O
20	abnormalities	O
21	.	O
1	The	O
2	unfolded	O
3	protein	O
4	response	O
5	regulates	O
6	multiple	O
7	aspects	O
8	of	O
9	secretory	O
10	and	O
11	membrane	O
12	protein	O
13	biogenesis	O
14	and	O
15	endoplasmic	O
16	reticulum	O
17	quality	O
18	control	O
19	.	O
1	The	O
2	effect	O
3	of	O
4	water	O
5	deprivation	O
6	for	O
7	19	O
8	h	O
9	on	O
10	renal	O
11	Na	O
12	excretion	O
13	of	O
14	conscious	O
15	adrenalectomized	O
16	(	O
17	ADX	O
18	)	O
19	sheep	O
20	maintained	O
21	on	O
22	a	O
23	constant	O
24	intravenous	O
25	infusion	O
26	of	O
27	aldosterone	O
28	and	O
29	cortisol	O
30	(	O
31	ADX	O
32	-	O
33	constant	O
34	steroid	O
35	sheep	O
36	)	O
37	was	O
38	investigated	O
39	.	O
1	Antithrombin	B
2	III	I
3	deficiency	O
4	:	O
5	when	O
6	substitute	O
7	,	O
8	when	O
9	heparin	O
10	?	O
11	Thrombosis	O
12	ABC	O
13	,	O
14	3	O
15	:	O
16	The	O
17	role	O
18	of	O
19	antithrombin	B
20	III	I
1	In	O
2	a	O
3	gel	O
4	retardation	O
5	assay	O
6	using	O
7	HepG2	O
8	nuclear	O
9	extracts	O
10	,	O
11	the	O
12	5	O
13	'	O
14	flanking	O
15	sequence	O
16	from	O
17	-	O
18	74	O
19	to	O
20	-	O
21	46	O
22	showed	O
23	a	O
24	shifted	O
25	band	O
26	.	O
1	Since	O
2	the	O
3	RINX	B
4	gene	I
5	is	O
6	likely	O
7	an	O
8	ortholog	O
9	of	O
10	the	O
11	goldfish	B
12	Vsx1	I
13	gene	I
14	,	O
15	it	O
16	has	O
17	been	O
18	named	O
19	VSX1	B
20	by	O
21	the	O
22	Human	O
23	Gene	O
24	Nomenclature	O
25	Committee	O
26	.	O
1	The	O
2	two	O
3	main	O
4	experimental	O
5	variables	O
6	were	O
7	the	O
8	attended	O
9	hemifield	O
10	(	O
11	left	O
12	or	O
13	right	O
14	)	O
15	and	O
16	the	O
17	proportion	O
18	of	O
19	trials	O
20	requiring	O
21	a	O
22	shift	O
23	within	O
24	that	O
25	hemifield	O
26	(	O
27	20	O
28	%	O
29	or	O
30	80	O
31	%).	O
1	G	O
2	-	O
3	DNA	O
4	is	O
5	a	O
6	four	O
7	-	O
8	stranded	O
9	DNA	O
10	structure	O
11	with	O
12	diverse	O
13	putative	O
14	biological	O
15	roles	O
16	.	O
1	Six	O
2	distinct	O
3	Ets	B
4	mRNAs	I
5	were	O
6	identified	O
7	:	O
8	Ets2	B
9	,	O
10	Fli1	B
11	,	O
12	GABPalpha	B
13	,	O
14	SAP1	B
15	,	O
16	Elk1	B
17	,	O
18	and	O
19	PE1	B
20	.	O
1	Wnt	B
2	-	I
3	1	I
4	overexpression	O
5	in	O
6	mammary	O
7	epithelial	O
8	cells	O
9	induced	O
10	cyclin	B
11	D1	I
12	mRNA	I
13	and	O
14	targeted	O
15	overexpression	O
16	of	O
17	Wnt	B
18	-	I
19	1	I
20	in	O
21	the	O
22	mammary	O
23	gland	O
24	of	O
25	transgenic	O
26	mice	O
27	increased	O
28	both	O
29	ILK	B
30	activity	O
31	and	O
32	cyclin	B
33	D1	I
34	levels	O
35	.	O
1	This	O
2	enabled	O
3	the	O
4	formation	O
5	of	O
6	stem	O
7	-	O
8	loop	O
9	templates	O
10	with	O
11	the	O
12	fusion	O
13	point	O
14	of	O
15	the	O
16	chimeric	O
17	transcript	O
18	in	O
19	the	O
20	loop	O
21	and	O
22	the	O
23	use	O
24	of	O
25	MLL	B
26	primers	O
27	in	O
28	two	O
29	-	O
30	sided	O
31	PCR	O
32	.	O
1	CONCLUSION	O
2	:	O
3	The	O
4	authors	O
5	emphasize	O
6	that	O
7	the	O
8	initial	O
9	management	O
10	of	O
11	primary	O
12	STS	O
13	should	O
14	be	O
15	adequate	O
16	and	O
17	suggest	O
18	that	O
19	safty	O
20	margin	O
21	of	O
22	>	O
23	or	O
24	=	O
25	2	O
26	cm	O
27	should	O
28	be	O
29	adhered	O
30	to	O
31	.	O
1	Activation	O
2	was	O
3	biphasic	O
4	;	O
5	peaking	O
6	at	O
7	5	O
8	-	O
9	10	O
10	min	O
11	and	O
12	24	O
13	h	O
14	after	O
15	treatment	O
16	.	O
1	We	O
2	recently	O
3	reported	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	PL	B
10	scramblase	I
11	of	O
12	human	O
13	(	O
14	HuPLSCR1	B
15	)	O
16	and	O
17	mouse	O
18	origin	O
19	,	O
20	respectively	O
21	.	O
1	Using	O
2	an	O
3	oligomer	O
4	duplex	O
5	5	O
6	'-	O
7	A	O
8	(	O
9	GGGTTA	O
10	)(	O
11	5	O
12	)-	O
13	3	O
14	'/	O
15	5	O
16	'-(	O
17	TAACCC	O
18	)(	O
19	5	O
20	)	O
21	T	O
22	-	O
23	3	O
24	'	O
25	as	O
26	a	O
27	template	O
28	-	O
29	primer	O
30	,	O
31	we	O
32	show	O
33	that	O
34	both	O
35	the	O
36	Klenow	B
37	fragment	I
38	of	I
39	Escherichia	I
40	coli	I
41	DNA	I
42	polymerase	I
43	I	I
44	and	O
45	HIV	B
46	reverse	I
47	transcriptase	I
48	could	O
49	expand	O
50	telomere	O
51	DNA	O
52	sequences	O
53	as	O
54	well	O
55	,	O
56	giving	O
57	products	O
58	greater	O
59	than	O
60	the	O
61	size	O
62	of	O
63	the	O
64	template	O
65	DNA	O
66	.	O
1	Despite	O
2	these	O
3	limitations	O
4	the	O
5	CHIME	O
6	monitor	O
7	provides	O
8	an	O
9	opportunity	O
10	to	O
11	record	O
12	physiological	O
13	data	O
14	previously	O
15	unavailable	O
16	in	O
17	the	O
18	home	O
19	.	O
1	TB	O
2	bone	O
3	area	O
4	(	O
5	p	O
6	<	O
7	0	O
8	.	O
9	001	O
10	),	O
11	height	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	01	O
18	),	O
19	years	O
20	in	O
21	present	O
22	colony	O
23	(	O
24	p	O
25	=	O
26	0	O
27	.	O
28	03	O
29	),	O
30	and	O
31	menses	O
32	(	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	)	O
39	predicted	O
40	TB	O
41	BMC	O
42	.	O
1	CREST	O
2	syndrome	O
3	;	O
4	a	O
5	changing	O
6	clinical	O
7	significance	O
1	Troglitazone	O
2	also	O
3	induced	O
4	an	O
5	endogenous	B
6	PPARgamma	I
7	target	I
8	gene	I
9	in	O
10	T24	O
11	cells	O
12	,	O
13	adipocyte	B
14	-	I
15	type	I
16	fatty	I
17	acid	I
18	binding	I
19	protein	I
20	(	O
21	A	B
22	-	I
23	FABP	I
24	),	O
25	the	O
26	expression	O
27	of	O
28	which	O
29	correlates	O
30	with	O
31	bladder	O
32	cancer	O
33	differentiation	O
34	.	O
1	Eukaryotic	B
2	translation	I
3	initiation	I
4	factor	I
5	4GI	I
6	is	O
7	a	O
8	cellular	O
9	target	O
10	for	O
11	NS1	B
12	protein	I
13	,	O
14	a	O
15	translational	O
16	activator	O
17	of	O
18	influenza	O
19	virus	O
20	.	O
1	To	O
2	facilitate	O
3	manipulation	O
4	of	O
5	large	O
6	genomic	O
7	sequences	O
8	,	O
9	we	O
10	developed	O
11	a	O
12	method	O
13	of	O
14	converting	O
15	Escherichia	O
16	coli	O
17	P1	O
18	artificial	O
19	chromosomes	O
20	(	O
21	PACs	O
22	)	O
23	into	O
24	yeast	O
25	artificial	O
26	chromosomes	O
27	(	O
28	YACs	O
29	).	O
1	This	O
2	suggests	O
3	that	O
4	cardiovascular	O
5	magnetic	O
6	resonance	O
7	is	O
8	the	O
9	preferred	O
10	technique	O
11	for	O
12	volume	O
13	and	O
14	ejection	O
15	fraction	O
16	estimation	O
17	in	O
18	heart	O
19	failure	O
20	patients	O
21	,	O
22	because	O
23	of	O
24	its	O
25	3D	O
26	approach	O
27	for	O
28	non	O
29	-	O
30	symmetric	O
31	ventricles	O
32	and	O
33	superior	O
34	image	O
35	quality	O
36	.	O
1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	Tax	B
7	I	I
8	increased	O
9	the	O
10	extent	O
11	and	O
12	altered	O
13	the	O
14	profile	O
15	of	O
16	proteins	O
17	binding	O
18	TRE	B
19	-	I
20	2	I
21	in	O
22	vivo	O
23	.	O
1	PLUS	O
2	-	O
3	3	O
4	is	O
5	a	O
6	new	O
7	Swedish	O
8	protocol	O
9	of	O
10	natural	O
11	speech	O
12	in	O
13	3	O
14	-	O
15	year	O
16	-	O
17	old	O
18	children	O
19	.	O
1	Once	O
2	HIT	O
3	II	O
4	is	O
5	suspected	O
6	,	O
7	heparin	O
8	(	O
9	and	O
10	low	O
11	-	O
12	molecular	O
13	-	O
14	weight	O
15	heparins	O
16	)	O
17	should	O
18	be	O
19	stopped	O
20	immediately	O
21	.	O
1	Platelet	O
2	counts	O
3	and	O
4	function	O
5	as	O
6	well	O
7	as	O
8	fibrinogen	B
9	and	O
10	von	B
11	Willebrand	I
12	factor	I
13	(	O
14	vWF	B
15	)	O
16	levels	O
17	were	O
18	determined	O
19	in	O
20	each	O
21	sample	O
22	.	O
1	The	O
2	manifestations	O
3	often	O
4	include	O
5	a	O
6	moderate	O
7	thrombocytopenia	O
8	and	O
9	,	O
10	less	O
11	commonly	O
12	,	O
13	hemolysis	O
14	.	O
1	Picture	O
2	the	O
3	smell	O
4	.	O
1	Indirect	O
2	plasma	O
3	parameters	O
4	such	O
5	as	O
6	vitamin	O
7	E	O
8	,	O
9	thiol	O
10	and	O
11	uric	O
12	acid	O
13	levels	O
14	were	O
15	also	O
16	quantified	O
17	.	O
1	It	O
2	was	O
3	found	O
4	that	O
5	increase	O
6	in	O
7	the	O
8	RH	O
9	level	O
10	boosts	O
11	the	O
12	current	O
13	values	O
14	by	O
15	2	O
16	-	O
17	3	O
18	orders	O
19	of	O
20	magnitude	O
21	;	O
22	contrariwise	O
23	,	O
24	the	O
25	voltage	O
26	values	O
27	rise	O
28	by	O
29	about	O
30	three	O
31	times	O
32	with	O
33	drop	O
34	in	O
35	the	O
36	RH	O
37	.	O
1	In	O
2	patients	O
3	with	O
4	type	O
5	II	O
6	tumors	O
7	,	O
8	the	O
9	pattern	O
10	of	O
11	lymphatic	O
12	spread	O
13	was	O
14	primarily	O
15	directed	O
16	toward	O
17	the	O
18	paracardial	O
19	,	O
20	lesser	O
21	curvature	O
22	,	O
23	and	O
24	left	O
25	gastric	O
26	artery	O
27	nodes	O
28	;	O
29	esophagectomy	O
30	offered	O
31	no	O
32	survival	O
33	benefit	O
34	over	O
35	extended	O
36	gastrectomy	O
37	in	O
38	these	O
39	patients	O
40	.	O
1	We	O
2	show	O
3	here	O
4	that	O
5	this	O
6	difference	O
7	is	O
8	due	O
9	to	O
10	the	O
11	presence	O
12	of	O
13	a	O
14	Mot3	B
15	binding	I
16	site	I
17	in	O
18	OpA	B
19	.	O
1	The	O
2	article	O
3	deals	O
4	with	O
5	the	O
6	diagnosing	O
7	and	O
8	correction	O
9	of	O
10	reversible	O
11	ischemia	O
12	of	O
13	the	O
14	intestine	O
15	.	O
1	This	O
2	slope	O
3	was	O
4	further	O
5	significantly	O
6	decreased	O
7	at	O
8	5	O
9	min	O
10	ischemia	O
11	(-	O
12	26	O
13	.	O
14	5	O
15	+/-	O
16	8	O
17	.	O
18	8	O
19	microm	O
20	/	O
21	mmHg	O
22	)	O
23	but	O
24	returned	O
25	toward	O
26	control	O
27	values	O
28	in	O
29	short	O
30	-	O
31	term	O
32	hibernating	O
33	myocardium	O
34	at	O
35	90	O
36	min	O
37	ischemia	O
38	(-	O
39	17	O
40	.	O
41	2	O
42	+/-	O
43	6	O
44	.	O
45	6	O
46	microm	O
47	/	O
48	mmHg	O
49	).	O
1	We	O
2	have	O
3	recently	O
4	discovered	O
5	that	O
6	CCAAAT	B
7	/	I
8	enhancer	I
9	-	I
10	binding	I
11	protein	I
12	-	I
13	beta	I
14	(	O
15	C	B
16	/	I
17	EBP	I
18	-	I
19	beta	I
20	)	O
21	induces	O
22	gene	O
23	transcription	O
24	through	O
25	a	O
26	novel	O
27	IFN	B
28	response	I
29	element	I
30	called	O
31	the	O
32	gamma	B
33	-	I
34	IFN	I
35	-	I
36	activated	I
37	transcriptional	I
38	element	I
1	The	O
2	Spo0F	B
3	residues	I
4	making	O
5	up	O
6	the	O
7	hydrophobic	O
8	patch	O
9	are	O
10	very	O
11	similar	O
12	in	O
13	all	O
14	response	O
15	regulators	O
16	suggesting	O
17	that	O
18	the	O
19	binding	O
20	is	O
21	initiated	O
22	through	O
23	the	O
24	same	O
25	residues	O
26	in	O
27	all	O
28	interacting	O
29	response	O
30	regulator	O
31	-	O
32	kinase	O
33	pairs	O
34	.	O
1	Quantitative	O
2	evaluation	O
3	of	O
4	magneto	O
5	-	O
6	optical	O
7	parameters	O
8	is	O
9	necessary	O
10	in	O
11	order	O
12	to	O
13	apply	O
14	scanning	O
15	near	O
16	-	O
17	field	O
18	optical	O
19	microscope	O
20	(	O
21	SNOM	O
22	)	O
23	technology	O
24	to	O
25	the	O
26	study	O
27	of	O
28	magnetism	O
29	on	O
30	the	O
31	mesoscopic	O
32	scale	O
33	.	O
1	While	O
2	mutations	O
3	in	O
4	K	B
5	-	I
6	Rev	I
7	that	O
8	inactivate	O
9	any	O
10	one	O
11	of	O
12	these	O
13	properties	O
14	also	O
15	blocked	O
16	K	B
17	-	I
18	Rev	I
19	-	O
20	dependent	O
21	nuclear	O
22	RNA	O
23	export	O
24	,	O
25	several	O
26	K	B
27	-	I
28	Rev	I
29	mutants	I
30	were	O
31	comparable	O
32	to	O
33	wild	O
34	type	O
35	when	O
36	assayed	O
37	for	O
38	any	O
39	of	O
40	these	O
41	individual	O
42	activities	O
43	yet	O
44	nevertheless	O
45	defective	O
46	for	O
47	RNA	O
48	export	O
49	.	O
1	LMP	B
2	-	I
3	1	I
4	is	O
5	targeted	O
6	to	O
7	the	O
8	plasma	O
9	membrane	O
10	,	O
11	where	O
12	it	O
13	binds	O
14	TRAF	B
15	,	O
16	TRADD	B
17	,	O
18	and	O
19	JAK	B
20	molecules	I
21	to	O
22	activate	O
23	NF	B
24	-	I
25	kappaB	I
26	-,	O
27	AP	B
28	-	I
29	1	I
30	-,	O
31	and	O
32	STAT	B
33	-	O
34	dependent	O
35	pathways	O
36	as	O
37	does	O
38	CD40	B
39	.	O
1	Phylogenetic	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	ToLCV	O
7	isolates	O
8	from	O
9	Bangalore	O
10	constitute	O
11	a	O
12	group	O
13	of	O
14	viruses	O
15	separated	O
16	from	O
17	those	O
18	of	O
19	Northern	O
20	India	O
21	.	O
1	The	O
2	product	O
3	of	O
4	rat	B
5	gene	I
6	33	I
7	was	O
8	identified	O
9	as	O
10	an	O
11	ErbB	B
12	-	I
13	2	I
14	-	I
15	interacting	I
16	protein	I
17	in	O
18	a	O
19	two	O
20	-	O
21	hybrid	O
22	screen	O
23	employing	O
24	the	O
25	ErbB	B
26	-	I
27	2	I
28	juxtamembrane	I
29	and	I
30	kinase	I
31	domains	I
32	as	O
33	bait	O
34	.	O
1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	relationship	O
7	between	O
8	blood	O
9	flow	O
10	in	O
11	the	O
12	tumor	O
13	assessed	O
14	by	O
15	color	O
16	Doppler	O
17	ultrasound	O
18	,	O
19	microvessel	O
20	density	O
21	,	O
22	and	O
23	vascular	B
24	endothelial	I
25	growth	I
26	factor	I
27	levels	O
28	in	O
29	endometrial	O
30	carcinoma	O
31	.	O
1	Src	B
2	activation	O
3	induced	O
4	by	O
5	FGF1	B
6	was	O
7	blocked	O
8	by	O
9	the	O
10	SH2	B
11	domain	I
12	of	O
13	Src	B
14	and	O
15	PP2	B
16	,	O
17	a	O
18	specific	O
19	inhibitor	O
20	of	O
21	Src	B
22	.	O
1	Multiple	O
2	transcription	O
3	start	O
4	sites	O
5	were	O
6	revealed	O
7	by	O
8	primer	O
9	extension	O
10	analysis	O
11	of	O
12	the	O
13	mouse	O
14	gene	O
15	,	O
16	and	O
17	transfection	O
18	constructs	O
19	containing	O
20	the	O
21	prospective	O
22	promoter	O
23	generated	O
24	transcriptional	O
25	activity	O
26	comparable	O
27	to	O
28	that	O
29	of	O
30	the	O
31	SV40	B
32	promoter	I
33	.	O
1	To	O
2	determine	O
3	whether	O
4	interaction	O
5	of	O
6	arsenite	O
7	with	O
8	the	O
9	hormone	O
10	-	O
11	binding	O
12	domain	O
13	results	O
14	in	O
15	receptor	O
16	activation	O
17	,	O
18	COS	O
19	-	O
20	1	O
21	cells	O
22	were	O
23	transiently	O
24	cotransfected	O
25	with	O
26	the	O
27	chimeric	B
28	receptors	I
29	GAL	I
30	-	I
31	ER	I
32	,	O
33	which	O
34	contains	O
35	the	O
36	hormone	O
37	-	O
38	binding	O
39	domain	O
40	of	O
41	ERalpha	B
42	and	O
43	the	O
44	DNA	O
45	-	O
46	binding	O
47	domain	O
48	of	O
49	the	O
50	transcription	O
51	factor	O
52	GAL4	B
53	,	O
54	and	O
55	a	O
56	GAL4	B
57	-	O
58	responsive	O
59	CAT	B
60	reporter	I
61	gene	I
62	.	O
1	We	O
2	have	O
3	mutated	O
4	to	O
5	cysteine	O
6	,	O
7	one	O
8	at	O
9	a	O
10	time	O
11	,	O
12	21	O
13	consecutive	O
14	residues	O
15	in	O
16	the	O
17	fourth	O
18	TMS	O
19	(	O
20	TM4	O
21	).	O
1	Post	O
2	-	O
3	operative	O
4	functional	O
5	outcome	O
6	is	O
7	related	O
8	to	O
9	pre	O
10	-	O
11	operative	O
12	functional	O
13	status	O
14	.	O
1	Altogether	O
2	these	O
3	results	O
4	suggest	O
5	that	O
6	,	O
7	in	O
8	KG1a	O
9	cells	O
10	,	O
11	TNFalpha	B
12	can	O
13	stimulate	O
14	in	O
15	parallel	O
16	PC	B
17	-	I
18	PLC	I
19	and	O
20	PLD	B
21	,	O
22	whose	O
23	lipid	O
24	products	O
25	activate	O
26	in	O
27	turn	O
28	mitogen	B
29	-	I
30	activated	I
31	protein	I
32	kinase	I
33	(	O
34	MAP	B
35	kinase	I
36	)	O
37	and	O
38	NF	B
39	-	I
40	kappaB	I
41	signalling	O
42	respectively	O
43	.	O
1	When	O
2	cotransfected	O
3	in	O
4	fibroblasts	O
5	with	O
6	a	O
7	C	B
8	/	I
9	EBP	I
10	alpha	I
11	expression	O
12	vector	O
13	,	O
14	reporter	O
15	gene	O
16	expression	O
17	increased	O
18	3	O
19	-	O
20	fold	O
21	only	O
22	in	O
23	the	O
24	wild	O
25	-	O
26	type	O
27	constructs	O
28	.	O
1	Polysome	O
2	and	O
3	40S	B
4	ribosome	I
5	fractions	O
6	were	O
7	severely	O
8	decreased	O
9	in	O
10	the	O
11	krr1	B
12	mutant	I
13	and	O
14	Kri1p	B
15	-	O
16	depleted	O
17	cells	O
18	.	O
1	Cam	B
2	kinase	I
3	II	I
4	induces	O
5	in	O
6	vivo	O
7	phosphorylation	O
8	of	O
9	Smad2	B
10	and	O
11	Smad4	B
12	and	O
13	,	O
14	to	O
15	a	O
16	lesser	O
17	extent	O
18	,	O
19	Smad3	B
20	.	O
1	As	O
2	a	O
3	result	O
4	,	O
5	we	O
6	have	O
7	defined	O
8	two	O
9	arginine	O
10	-	O
11	rich	O
12	motifs	O
13	(	O
14	ARM1	O
15	and	O
16	ARM2	O
17	)	O
18	that	O
19	mediate	O
20	the	O
21	RNA	O
22	binding	O
23	activity	O
24	of	O
25	SU	O
26	(	O
27	S	O
28	).	O
1	Both	O
2	the	O
3	Cmax	O
4	and	O
5	AUC	O
6	values	O
7	were	O
8	almost	O
9	doubled	O
10	with	O
11	doubling	O
12	the	O
13	dose	O
14	.	O
1	Transforming	B
2	growth	I
3	factor	I
4	-	I
5	beta1	I
6	(	O
7	TGF	B
8	-	I
9	beta1	I
10	)	O
11	can	O
12	act	O
13	as	O
14	a	O
15	tumor	O
16	suppressor	O
17	or	O
18	a	O
19	tumor	O
20	promoter	O
21	depending	O
22	on	O
23	the	O
24	characteristics	O
25	of	O
26	the	O
27	malignant	O
28	cell	O
29	.	O
1	Escalation	O
2	to	O
3	180	O
4	mg	O
5	/	O
6	m2	O
7	was	O
8	to	O
9	be	O
10	carried	O
11	out	O
12	if	O
13	white	O
14	blood	O
15	cell	O
16	nadir	O
17	count	O
18	was	O
19	>	O
20	2	O
21	.	O
22	0	O
23	x	O
24	10	O
25	(	O
26	9	O
27	)/	O
28	l	O
29	and	O
30	platelet	O
31	nadir	O
32	count	O
33	was	O
34	>	O
35	75	O
36	x	O
37	10	O
38	(	O
39	9	O
40	)/	O
41	l	O
42	.	O
1	Together	O
2	,	O
3	these	O
4	results	O
5	indicate	O
6	that	O
7	IL	B
8	-	I
9	1	I
10	beta	I
11	induces	O
12	VEGF	B
13	gene	I
14	expression	O
15	at	O
16	both	O
17	transcriptional	O
18	and	O
19	post	O
20	-	O
21	transcriptional	O
22	levels	O
23	,	O
24	and	O
25	IL	B
26	-	I
27	1	I
28	beta	I
29	evokes	O
30	p38	B
31	MAPK	O
32	and	O
33	JNK	B
34	signalings	O
35	,	O
36	which	O
37	in	O
38	turn	O
39	stimulate	O
40	the	O
41	transcription	O
42	of	O
43	the	O
44	VEGF	B
45	gene	I
46	through	O
47	Sp1	B
48	-	I
49	binding	I
50	sites	I
51	.	O
1	Using	O
2	purified	O
3	recombinant	B
4	HMG	I
5	I	I
6	,	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	high	O
12	-	O
13	affinity	O
14	binding	O
15	sites	O
16	which	O
17	overlap	O
18	important	O
19	transcription	O
20	factor	O
21	binding	O
22	sites	O
23	.	O
1	High	B
2	-	I
3	mobility	I
4	-	I
5	group	I
6	protein	I
7	I	I
8	can	O
9	modulate	O
10	binding	O
11	of	O
12	transcription	O
13	factors	O
14	to	O
15	the	O
16	U5	B
17	region	I
18	of	O
19	the	O
20	human	B
21	immunodeficiency	I
22	virus	I
23	type	I
24	1	I
25	proviral	I
26	promoter	I
27	.	O
1	5	O
2	'-	O
3	RACE	O
4	analysis	O
5	suggested	O
6	a	O
7	single	O
8	transcription	O
9	initiation	O
10	site	O
11	187	O
12	bp	O
13	upstream	O
14	from	O
15	the	O
16	translational	O
17	start	O
18	site	O
19	.	O
1	LMP2A	B
2	enhances	O
3	Lyn	B
4	and	O
5	Syk	B
6	ubiquitination	O
7	in	O
8	vivo	O
9	in	O
10	a	O
11	fashion	O
12	that	O
13	depends	O
14	on	O
15	the	O
16	activity	O
17	of	O
18	Nedd4	B
19	family	O
20	members	O
21	and	O
22	correlates	O
23	with	O
24	destabilization	O
25	of	O
26	the	O
27	Lyn	B
28	tyrosine	I
29	kinase	I
30	.	O
1	Further	O
2	,	O
3	Tax	B
4	-	O
5	mediated	O
6	apoptosis	O
7	was	O
8	effectively	O
9	prevented	O
10	by	O
11	ectopic	O
12	expression	O
13	of	O
14	the	O
15	p300	B
16	coactivator	I
17	.	O
1	Fisher	O
2	'	O
3	s	O
4	exact	O
5	test	O
6	or	O
7	Pearson	O
8	'	O
9	s	O
10	chi2	O
11	test	O
12	were	O
13	used	O
14	for	O
15	statistical	O
16	analysis	O
17	.	O
1	These	O
2	results	O
3	provide	O
4	direct	O
5	evidence	O
6	for	O
7	differential	O
8	susceptibility	O
9	to	O
10	endonuclease	O
11	-	O
12	mediated	O
13	mRNA	O
14	decay	O
15	resulting	O
16	from	O
17	the	O
18	differential	O
19	affinity	O
20	of	O
21	a	O
22	RNA	O
23	-	O
24	binding	O
25	protein	O
26	for	O
27	cis	O
28	-	O
29	acting	O
30	stability	O
31	determinants	O
32	.	O
1	Expression	O
2	of	O
3	a	O
4	hybrid	O
5	protein	O
6	containing	O
7	the	O
8	cytoplasmic	O
9	C	O
10	-	O
11	terminal	O
12	half	O
13	of	O
14	UhpB	B
15	fused	O
16	to	O
17	glutathione	B
18	S	I
19	-	I
20	transferase	I
21	(	O
22	GST	B
23	)	O
24	also	O
25	interfered	O
26	with	O
27	Uhp	B
28	signaling	O
29	.	O
1	CONCLUSIONS	O
2	:	O
3	The	O
4	surgical	O
5	or	O
6	multimodality	O
7	treatment	O
8	of	O
9	MSGT	O
10	has	O
11	provided	O
12	a	O
13	good	O
14	locoregional	O
15	control	O
16	(	O
17	78	O
18	%)	O
19	and	O
20	68	O
21	%	O
22	10	O
23	-	O
24	year	O
25	survival	O
26	in	O
27	a	O
28	series	O
29	of	O
30	patients	O
31	treated	O
32	at	O
33	the	O
34	oncology	O
35	department	O
36	of	O
37	a	O
38	general	O
39	hospital	O
40	in	O
41	Quito	O
42	,	O
43	Ecuador	O
44	.	O
1	MED1	B
2	has	O
3	a	O
4	weak	O
5	glycosylase	B
6	activity	O
7	on	O
8	the	O
9	mutagenic	O
10	adduct	O
11	3	O
12	,	O
13	N	O
14	(	O
15	4	O
16	)-	O
17	ethenocytosine	O
18	,	O
19	a	O
20	metabolite	O
21	of	O
22	vinyl	O
23	chloride	O
24	and	O
25	ethyl	O
26	carbamate	O
27	.	O
1	There	O
2	were	O
3	no	O
4	instances	O
5	of	O
6	major	O
7	flap	O
8	necrosis	O
9	although	O
10	two	O
11	flaps	O
12	showed	O
13	tip	O
14	ischaemia	O
15	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	XAB1	B
6	is	O
7	a	O
8	novel	O
9	cytoplasmic	B
10	GTPase	I
11	involved	O
12	in	O
13	nuclear	O
14	localization	O
15	of	O
16	XPA	B
17	.	O
1	Bacteriol	O
2	.	O
1	Terminal	B
2	deoxynucleotidyl	I
3	transferase	I
4	-	O
5	mediated	O
6	nick	O
7	end	O
8	labeling	O
9	assays	O
10	revealed	O
11	that	O
12	hormonal	O
13	activation	O
14	of	O
15	the	O
16	PAX3	B
17	repressors	I
18	induced	O
19	extensive	O
20	apoptosis	O
21	that	O
22	correlated	O
23	with	O
24	down	O
25	-	O
26	regulation	O
27	of	O
28	BCL	B
29	-	I
30	X	I
31	(	I
32	L	I
33	)	I
34	expression	O
35	.	O
1	Thus	O
2	,	O
3	IHHNV	O
4	is	O
5	closely	O
6	related	O
7	to	O
8	densoviruses	O
9	of	O
10	the	O
11	genus	O
12	Brevidensovirus	O
13	in	O
14	the	O
15	family	O
16	Parvoviridae	O
17	,	O
18	and	O
19	we	O
20	therefore	O
21	propose	O
22	to	O
23	rename	O
24	this	O
25	virus	O
26	Penaeus	O
27	stylirostris	O
28	densovirus	O
29	(	O
30	PstDNV	O
31	).	O
1	Stress	B
2	-	I
3	activated	I
4	protein	I
5	kinase	I
6	1	I
7	(	O
8	SAPK1	B
9	),	O
10	also	O
11	called	O
12	c	B
13	-	I
14	Jun	I
15	N	I
16	-	I
17	terminal	I
18	kinase	I
19	(	O
20	JNK	B
21	),	O
22	becomes	O
23	activated	O
24	in	O
25	vivo	O
26	in	O
27	response	O
28	to	O
29	pro	O
30	-	O
31	inflammatory	O
32	cytokines	O
33	or	O
34	cellular	O
35	stresses	O
36	.	O
1	Combined	O
2	intravenous	O
3	and	O
4	intra	O
5	-	O
6	arterial	O
7	recombinant	O
8	tissue	B
9	plasminogen	I
10	activator	I
11	in	O
12	acute	O
13	ischemic	O
14	stroke	O
15	.	O
1	Botulinum	B
2	toxin	I
3	A	I
4	in	O
5	the	O
6	treatment	O
7	of	O
8	hemiplegic	O
9	spastic	O
10	foot	O
11	drop	O
12	--	O
13	clinical	O
14	and	O
15	functional	O
16	outcomes	O
17	.	O
1	Inhibition	O
2	of	O
3	RNA2	B
4	translation	O
5	was	O
6	selective	O
7	,	O
8	with	O
9	no	O
10	effect	O
11	on	O
12	general	O
13	cellular	O
14	translation	O
15	or	O
16	translation	O
17	of	O
18	BMV	O
19	RNA1	B
20	-	O
21	encoded	O
22	replication	B
23	factor	I
24	1a	I
25	,	O
26	and	O
27	was	O
28	independent	O
29	of	O
30	p20	B
31	,	O
32	a	O
33	cellular	O
34	antagonist	O
35	of	O
36	DED1	B
37	function	O
38	in	O
39	translation	O
40	.	O
1	There	O
2	was	O
3	a	O
4	weak	O
5	significant	O
6	correlation	O
7	between	O
8	TGF	B
9	beta	I
10	1	I
11	levels	O
12	and	O
13	normal	O
14	cell	O
15	radiosensitivity	O
16	(	O
17	lymphocyte	O
18	SF2	O
19	).	O
1	Interestingly	O
2	,	O
3	this	O
4	mutant	O
5	cell	O
6	line	O
7	lacks	O
8	expression	O
9	of	O
10	the	O
11	IKK	B
12	regulatory	I
13	protein	I
14	,	O
15	IKKgamma	B
16	.	O
1	In	O
2	addition	O
3	,	O
4	we	O
5	identified	O
6	a	O
7	novel	O
8	type	O
9	of	O
10	inhibitory	O
11	domain	O
12	in	O
13	the	O
14	N	O
15	-	O
16	terminal	O
17	60	O
18	amino	O
19	acids	O
20	of	O
21	IRF	B
22	-	I
23	1	I
24	which	O
25	strongly	O
26	inhibits	O
27	its	O
28	transcriptional	O
29	activity	O
30	.	O
1	Simultaneous	O
2	determination	O
3	of	O
4	theophylline	O
5	and	O
6	its	O
7	metabolites	O
8	by	O
9	HPLC	O
10	]	O
11	A	O
12	high	O
13	performance	O
14	liquid	O
15	chromatography	O
16	(	O
17	HPLC	O
18	)	O
19	method	O
20	has	O
21	been	O
22	developed	O
23	for	O
24	the	O
25	simultaneous	O
26	determination	O
27	of	O
28	theophylline	O
29	and	O
30	its	O
31	metabolites	O
32	,	O
33	with	O
34	caffeine	O
35	and	O
36	its	O
37	metabolites	O
38	.	O
1	CONCLUSION	O
2	:	O
3	SPT	O
4	is	O
5	more	O
6	useful	O
7	than	O
8	WST	O
9	in	O
10	differentiating	O
11	patients	O
12	predisposed	O
13	to	O
14	aspiration	O
15	.	O
1	Nevertheless	O
2	,	O
3	protein	B
4	kinase	I
5	A	I
6	stimulation	O
7	induces	O
8	CREMalpha	B
9	to	O
10	activate	O
11	the	O
12	complex	O
13	native	O
14	promoter	O
15	in	O
16	the	O
17	phosphoenolpyruvate	B
18	carboxykinase	I
19	(	O
20	PEPCK	B
21	)	O
22	gene	O
23	.	O
1	Thyrotoxicosis	O
2	due	O
3	to	O
4	amiodarone	O
5	is	O
6	difficult	O
7	to	O
8	treat	O
9	and	O
10	is	O
11	further	O
12	complicated	O
13	by	O
14	the	O
15	pro	O
16	-	O
17	arrhythmic	O
18	potential	O
19	of	O
20	thyrotoxicosis	O
21	and	O
22	the	O
23	fading	O
24	antiarrhythmic	O
25	effect	O
26	after	O
27	amiodarone	O
28	withdrawal	O
29	.	O
1	Oncogenic	O
2	signalling	O
3	by	O
4	E2F1	B
5	has	O
6	recently	O
7	been	O
8	linked	O
9	to	O
10	stabilization	O
11	and	O
12	activation	O
13	of	O
14	the	O
15	tumour	O
16	suppressor	O
17	p53	B
18	(	O
19	refs	O
20	1	O
21	,	O
22	3	O
23	,	O
24	4	O
25	).	O
1	Children	O
2	with	O
3	ADD	O
4	showed	O
5	an	O
6	attenuated	O
7	frontal	O
8	CNV	O
9	-	O
10	1	O
11	amplitude	O
12	and	O
13	a	O
14	trend	O
15	towards	O
16	increased	O
17	CNV	O
18	-	O
19	1	O
20	and	O
21	CNV	O
22	-	O
23	2	O
24	occipital	O
25	amplitudes	O
26	.	O
1	Furthermore	O
2	,	O
3	transfection	O
4	of	O
5	cells	O
6	with	O
7	the	O
8	spacer	O
9	-	O
10	RING	O
11	domain	O
12	alone	O
13	suppressed	O
14	the	O
15	antiapoptotic	O
16	function	O
17	of	O
18	the	O
19	N	O
20	-	O
21	terminal	O
22	BIR	B
23	domain	O
24	of	O
25	c	B
26	-	I
27	IAP1	I
28	and	O
29	induced	O
30	apoptosis	O
31	.	O
1	Ang	B
2	II	I
3	-	O
4	induced	O
5	fibronectin	B
6	mRNA	O
7	was	O
8	not	O
9	affected	O
10	by	O
11	PKC	B
12	inhibitors	O
13	or	O
14	PKC	B
15	depletion	O
16	,	O
17	whereas	O
18	specific	O
19	inhibition	O
20	of	O
21	EGF	B
22	-	I
23	R	I
24	function	O
25	by	O
26	a	O
27	dominant	B
28	negative	I
29	EGF	I
30	-	I
31	R	I
32	mutant	I
33	and	O
34	tyrphostin	O
35	AG1478	O
36	abolished	O
37	induction	O
38	of	O
39	fibronectin	B
40	mRNA	I
41	.	O
1	T	O
2	cells	O
3	express	O
4	two	O
5	isoforms	O
6	of	O
7	S6k1	B
8	:	O
9	a	O
10	70	O
11	kDa	O
12	cytoplasmic	O
13	kinase	O
14	and	O
15	an	O
16	85	O
17	kDa	O
18	isoform	O
19	that	O
20	has	O
21	a	O
22	classic	O
23	nuclear	O
24	localisation	O
25	.	O
1	These	O
2	results	O
3	also	O
4	suggest	O
5	the	O
6	involvement	O
7	of	O
8	additional	O
9	elements	O
10	in	O
11	the	O
12	UPR	O
13	.	O
1	Regulation	O
2	of	O
3	RhoA	B
4	is	O
5	required	O
6	to	O
7	maintain	O
8	adhesion	O
9	in	O
10	stationary	O
11	cells	O
12	,	O
13	but	O
14	is	O
15	also	O
16	critical	O
17	for	O
18	cell	O
19	spreading	O
20	and	O
21	migration	O
22	[	O
23	3	O
24	].	O
1	Here	O
2	we	O
3	show	O
4	in	O
5	mouse	O
6	fibroblasts	O
7	stably	O
8	transformed	O
9	by	O
10	v	B
11	-	I
12	Src	I
13	that	O
14	mRNA	O
15	and	O
16	protein	O
17	levels	O
18	of	O
19	p21	B
20	(	O
21	WAF1	B
22	/	O
23	CIP1	B
24	),	O
25	cyclin	B
26	D1	I
27	,	O
28	and	O
29	cyclin	B
30	E	I
31	are	O
32	elevated	O
33	.	O
1	These	O
2	cells	O
3	produced	O
4	P2Y	B
5	(	I
6	11	I
7	)	I
8	mRNA	I
9	during	O
10	culture	O
11	.	O
1	Coexpression	O
2	studies	O
3	indicate	O
4	that	O
5	insulin	B
6	and	O
7	PKB	B
8	suppress	O
9	transactivation	O
10	by	O
11	C	B
12	/	I
13	EBPbeta	I
14	,	O
15	but	O
16	not	O
17	C	B
18	/	I
19	EBPalpha	I
20	,	O
21	and	O
22	that	O
23	N	O
24	-	O
25	terminal	O
26	transactivation	O
27	domains	O
28	in	O
29	C	B
30	/	I
31	EBPbeta	I
32	are	O
33	required	O
34	.	O
1	Among	O
2	eight	O
3	graminaceous	O
4	species	O
5	tested	O
6	,	O
7	Ids3	B
8	expression	O
9	was	O
10	observed	O
11	only	O
12	in	O
13	Fe	O
14	-	O
15	deficient	O
16	roots	O
17	of	O
18	H	O
19	.	O
20	vulgare	O
21	and	O
22	Secale	O
23	cereale	O
24	.	O
25	which	O
26	not	O
27	only	O
28	secrete	O
29	2	O
30	'-	O
31	deoxymugineic	O
32	acid	O
33	(	O
34	DMA	O
35	),	O
36	but	O
37	also	O
38	mugineic	O
39	acid	O
40	(	O
41	MA	O
42	)	O
43	and	O
44	3	O
45	-	O
46	epihydroxymugineic	O
47	acid	O
48	(	O
49	epiHMA	O
50	,	O
51	H	O
52	.	O
53	vulgare	O
54	),	O
55	and	O
56	3	O
57	-	O
58	hydroxymugineic	O
59	acid	O
60	(	O
61	HMA	O
62	,	O
63	S	O
64	.	O
65	cereale	O
66	).	O
1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Percentage	O
6	change	O
7	in	O
8	the	O
9	apnea	O
10	-	O
11	hypopnea	O
12	index	O
13	(	O
14	AHI	O
15	;	O
16	apnea	O
17	events	O
18	+	O
19	hypopnea	O
20	events	O
21	per	O
22	hour	O
23	of	O
24	sleep	O
25	)	O
26	and	O
27	odds	O
28	of	O
29	developing	O
30	moderate	O
31	-	O
32	to	O
33	-	O
34	severe	O
35	SDB	O
36	(	O
37	defined	O
38	by	O
39	an	O
40	AHI	O
41	>	O
42	or	O
43	=	O
44	15	O
45	events	O
46	per	O
47	hour	O
48	of	O
49	sleep	O
50	),	O
51	with	O
52	respect	O
53	to	O
54	change	O
55	in	O
56	weight	O
57	.	O
1	Patients	O
2	underwent	O
3	pretreatment	O
4	cystoscopy	O
5	and	O
6	detailed	O
7	tumor	O
8	mapping	O
9	,	O
10	and	O
11	were	O
12	treated	O
13	with	O
14	75	O
15	mg	O
16	.	O
17	/	O
18	m	O
19	.	O
20	2	O
21	cisplatin	O
22	on	O
23	day	O
24	1	O
25	and	O
26	1	O
27	gm	O
28	./	O
29	m	O
30	.	O
31	2	O
32	daily	O
33	,	O
34	5	O
35	-	O
36	fluorouracil	O
37	on	O
38	days	O
39	1	O
40	to	O
41	4	O
42	and	O
43	definitive	O
44	radiotherapy	O
45	.	O
1	Increased	O
2	levels	O
3	of	O
4	anticardiolipin	B
5	immunoglobulin	I
6	G	I
7	may	O
8	also	O
9	cause	O
10	bleeding	O
11	.	O
1	PM	O
2	12	O
3	or	O
4	18	O
5	mg	O
6	/	O
7	kg	O
8	daily	O
9	plus	O
10	a	O
11	standard	O
12	dose	O
13	of	O
14	SB	O
15	for	O
16	21	O
17	days	O
18	was	O
19	statistically	O
20	more	O
21	effective	O
22	than	O
23	SB	O
24	in	O
25	producing	O
26	a	O
27	final	O
28	cure	O
29	for	O
30	patients	O
31	with	O
32	VL	O
33	in	O
34	Bihar	O
35	,	O
36	India	O
37	.	O
1	In	O
2	a	O
3	prospective	O
4	,	O
5	multicentre	O
6	trial	O
7	the	O
8	efficacy	O
9	of	O
10	an	O
11	Vitex	O
12	agnus	O
13	castus	O
14	L	O
15	extract	O
16	Ze	O
17	440	O
18	was	O
19	investigated	O
20	in	O
21	50	O
22	patients	O
23	with	O
24	pre	O
25	-	O
26	menstrual	O
27	syndrome	O
28	(	O
29	PMS	O
30	).	O
1	Effects	O
2	of	O
3	Trypanosoma	O
4	vivax	O
5	on	O
6	pregnancy	O
7	of	O
8	Yankasa	O
9	sheep	O
10	and	O
11	the	O
12	results	O
13	of	O
14	homidum	O
15	chloride	O
16	chemotherapy	O
17	.	O
1	NF	B
2	kappa	I
3	B	I
4	was	O
5	activated	O
6	to	O
7	a	O
8	much	O
9	greater	O
10	extent	O
11	by	O
12	roscovitine	O
13	in	O
14	the	O
15	WT	O
16	cells	O
17	than	O
18	in	O
19	Y8	O
20	cells	O
21	.	O
1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	tissue	O
7	-	O
8	restricted	O
9	transcription	O
10	factors	O
11	including	O
12	PU	B
13	.	I
14	1	I
15	and	O
16	PU	B
17	.	I
18	1	I
19	interaction	I
20	partner	I
21	(	O
22	PIP	B
23	)	O
24	function	O
25	synergistically	O
26	with	O
27	c	B
28	-	I
29	Fos	I
30	plus	O
31	c	B
32	-	I
33	Jun	I
34	to	O
35	stimulate	O
36	the	O
37	kappaE3	B
38	'-	I
39	enhancer	I
40	in	O
41	3T3	O
42	cells	O
43	.	O
1	An	O
2	int6	B
3	deletion	I
4	(	O
5	int6Delta	B
6	)	O
7	mutant	O
8	was	O
9	viable	O
10	but	O
11	grew	O
12	slowly	O
13	in	O
14	minimal	O
15	medium	O
16	.	O
1	We	O
2	produced	O
3	transgenic	O
4	plants	O
5	expressing	O
6	the	O
7	antisense	B
8	Arabidopsis	I
9	HD	I
10	(	O
11	AtHD1	B
12	)	O
13	gene	O
14	.	O
1	3	O
2	.	O
3	04	O
4	+/-	O
5	1	O
6	.	O
7	2	O
8	,	O
9	P	O
10	<	O
11	0	O
12	.	O
13	0001	O
14	),	O
15	large	O
16	accelerations	O
17	/	O
18	30	O
19	min	O
20	(	O
21	1	O
22	.	O
23	46	O
24	+/-	O
25	1	O
26	.	O
27	96	O
28	vs	O
29	.	O
1	PFK	B
2	-	I
3	A	I
4	mRNA	O
5	was	O
6	more	O
7	abundantly	O
8	expressed	O
9	in	O
10	all	O
11	tissues	O
12	than	O
13	were	O
14	the	O
15	PFK	B
16	-	I
17	B	I
18	and	O
19	PFK	B
20	-	I
21	C	I
22	genes	I
23	.	O
1	[	O
2	18F	O
3	](+)-	O
4	4	O
5	-	O
6	fluorobenzyltrozamicol	O
7	(	O
8	FBT	O
9	),	O
10	which	O
11	selectively	O
12	binds	O
13	to	O
14	the	O
15	vesicular	O
16	acetylcholine	B
17	transporter	I
18	in	O
19	the	O
20	presynaptic	O
21	cholinergic	O
22	neuron	O
23	,	O
24	has	O
25	previously	O
26	been	O
27	shown	O
28	to	O
29	be	O
30	a	O
31	useful	O
32	ligand	O
33	for	O
34	the	O
35	study	O
36	of	O
37	cholinergic	O
38	terminal	O
39	density	O
40	in	O
41	the	O
42	basal	O
43	ganglia	O
44	with	O
45	PET	O
46	.	O
1	The	O
2	molecular	O
3	associations	O
4	dictating	O
5	INCENP	B
6	behavior	O
7	during	O
8	mitosis	O
9	are	O
10	currently	O
11	unknown	O
12	.	O
1	Nuclease	O
2	probing	O
3	and	O
4	structure	O
5	-	O
6	directed	O
7	mutagenesis	O
8	revealed	O
9	that	O
10	the	O
11	105	O
12	-	O
13	nt	O
14	TE	O
15	(	O
16	TE105	O
17	)	O
18	forms	O
19	a	O
20	cruciform	O
21	secondary	O
22	structure	O
23	containing	O
24	four	O
25	helices	O
26	connected	O
27	by	O
28	single	O
29	-	O
30	stranded	O
31	regions	O
32	.	O
